<SEC-DOCUMENT>0001193125-18-275420.txt : 20180917
<SEC-HEADER>0001193125-18-275420.hdr.sgml : 20180917
<ACCEPTANCE-DATETIME>20180917172111
ACCESSION NUMBER:		0001193125-18-275420
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		35
FILED AS OF DATE:		20180917
DATE AS OF CHANGE:		20180917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Equillium, Inc.
		CENTRAL INDEX KEY:			0001746466
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				821554746
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-227387
		FILM NUMBER:		181074166

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 108
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(858) 412-5302

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 108
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d582934ds1.htm
<DESCRIPTION>S-1
<TEXT>
<HTML><HEAD>
<TITLE>S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on September 17, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12.5pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:12.5pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>Equillium, Inc. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>(Exact Name of Registrant
as Specified in Its Charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">20-3828755</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>2223 Avenida de la Playa, Suite 108 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>La Jolla, CA 92037 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>858-412-5302 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Daniel M. Bradbury </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Chief Executive Officer
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Equillium, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>2223 Avenida de
la Playa, Suite 108 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>La Jolla, CA 92037 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>858-412-5302 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Name, Address, Including Zip
Code, and Telephone Number, Including Area Code, of Agent for Service) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Thomas A. Coll, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Karen E. Anderson, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Wade W. Andrews,
Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>4401 Eastgate
Mall</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>San Diego, California 92121</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">550-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Cheston J. Larson, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Matthew T. Bush, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Anthony A. Gostanian,
Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>12670 High Bluff Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>San Diego,
California 92130</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">523-5400</FONT></B></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">As soon as practicable after the effective date of this registration statement. </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has not elected to use the extended transition period for
complying with any new or revised financial accounting standards provided in Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title of each class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>securities to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>offering&nbsp;price<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>registration&nbsp;fee<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Common Stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$86,250,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$10,739</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under
the Securities Act. Includes the offering price of shares that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum offering price. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a
further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#c21128"><B>The information in this prospectus is not complete and may be changed. We may not sell these
securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where
the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#c21128">SUBJECT TO COMPLETION, DATED SEPTEMBER 17, 2018 </FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g29h41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This is the
initial public offering of Equillium, Inc. We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. Prior to this offering, there has been no public market for our
common stock. We estimate that the initial public offering price of our common stock will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have applied to list our common stock on The Nasdaq
Global Market under the symbol &#147;EQ.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of
2012 and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our
common stock involves a high degree of risk. See &#147;<A HREF="#toc582934_2">Risk Factors</A>&#148; beginning on page 10. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial Public Offering Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting Discounts and Commissions<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds to Equillium (before expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have agreed to reimburse the underwriters for certain expenses. See &#147;Underwriting.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted the
underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock from us at the
initial public offering price less the underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters expect to deliver the shares of common stock to purchasers on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2018 through the book-entry facilities of The Depository Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Joint Book-Running Managers </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Leerink&nbsp;Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Stifel</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_5">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_6">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_8">SELECTED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_10">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_12">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_13">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_14">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_15">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_16">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_17">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT STYLE="white-space:nowrap">NON-U.S.
</FONT> HOLDERS OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_18">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_19">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_20">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_21">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><A HREF="#toc582934_22">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or
in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus
is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its
date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (25 days after the commencement of this
offering), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&#146; obligation to deliver a
prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This prospectus includes statistical and other industry and
market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained
from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">For investors outside the United States: we
have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside
the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights information contained in other parts of this prospectus. Because it is only a summary, it does not contain all of the information that you
should consider before investing in shares of our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. You should read the entire
prospectus carefully, especially &#147;Risk Factors&#148; and our financial statements and the related notes, before deciding to buy shares of our common stock. Unless the context requires otherwise, references in this prospectus to
&#147;Equillium,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Equillium, Inc. </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>OVERVIEW </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory,
disorders with high unmet medical need. Our initial product candidate, EQ001 (itolizumab), is a clinical-stage, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> monoclonal antibody that selectively
targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T&nbsp;cells, or T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB>&nbsp;cells. Activated T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff&nbsp;</SUB>cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular,
ophthalmic and dermatologic disorders. Therefore, we believe EQ001 may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g46k96.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We are focusing our initial development efforts on EQ001 for the treatment of the diseases underlined in bold and are
evaluating additional T cell driven indications for future development. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pipeline is focused on developing EQ001 as a potentially <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class,</FONT></FONT> disease modifying treatment for multiple severe immuno-inflammatory disorders. We plan to initiate a Phase 1b/2 clinical trial of EQ001 for the treatment of
acute graft-versus-host disease, or aGVHD, in early 2019, and expect top-line data from the Phase 1b part of this trial within 12 months of initiation. Our Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or
FDA, for aGVHD was accepted in July 2018. Additionally, in the first half of 2019, we plan to commence a Phase 2 clinical trial of EQ001 for the treatment of chronic graft-versus-host disease, or cGVHD, initiate a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial for the treatment of severe asthma and select one or more additional indications for future development. The following chart summarizes our initial development plans for
EQ001.<B> </B> </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g04t71.jpg" ALT="LOGO">
 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The Phase 1 clinical trial was conducted by Biocon, our collaboration partner, in Australia. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have an ongoing translational biology program to assess the therapeutic utility of EQ001 in additional indications where the CD6 pathway and activated T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells play an important role in disease pathogenesis. Our selection of additional indications is driven by our analysis of the scientific, translational, clinical and commercial rationale for
advancing EQ001 into further development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired U.S. and Canadian rights to itolizumab in May 2017, pursuant to a collaboration and license agreement with
Biocon SA (subsequently assigned to Biocon Limited, or together, Biocon). Following completion of a Phase 3 clinical trial conducted outside of North America, itolizumab was approved in India for the treatment of moderate to severe plaque psoriasis
and is marketed by Biocon as ALZUMAb. Today, India is the only jurisdiction where ALZUMAb is approved or marketed. EQ001 has been evaluated in one Phase 1 clinical trial to date, conducted by Biocon, and is not approved for commercial sale in the
United States or Canada. Our partnership with Biocon includes an exclusive supply agreement for clinical and commercial drug product of EQ001. Biocon currently manufactures EQ001 at commercial scale in a facility regulated by the FDA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have assembled an accomplished team that includes veterans in drug discovery, development and commercialization. Notably, our Chief Executive Officer is Daniel
Bradbury, who has over 30 years of experience bringing novel medicines to market. Mr.&nbsp;Bradbury was the President, Chief Executive Officer and Director of Amylin Pharmaceuticals, Inc., where during his 18 year tenure he oversaw the development
and launch of three <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicines, which ultimately led to the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Understanding the Basis of Our Approach: The Role of CD6 in Autoimmunity </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
role of the immune system is to defend the body against foreign organisms and cells, including cancerous cells, and in doing so must distinguish accurately between self- and <FONT STYLE="white-space:nowrap">non-self</FONT> entities, a process called
tolerance. Autoimmunity is an immune response directed against the body&#146;s own healthy cells and tissues, and is the underlying process in many inflammatory diseases. Autoimmunity results from a loss of tolerance caused in part by an imbalance
in the relationship between regulatory T cells, or T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB>&nbsp;cells, and T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB>&nbsp;cells. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CD6 is a novel, tightly-regulated, co-stimulatory receptor that plays an integral role in modulating T cell activation, proliferation, differentiation and trafficking.
CD6 serves as a key checkpoint in regulating T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells that are central to autoimmune responses. Preclinical and clinical studies have shown that blockade of CD6
<FONT STYLE="white-space:nowrap">co-stimulation</FONT> leads to selective inhibition of pathogenic T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell activity and trafficking, while preserving the important regulatory function of T<SUB
STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells. Such studies and new insights into the underlying biology highlight CD6 as a resurgent target for the treatment of multiple immuno-inflammatory diseases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Modulation of T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> Cell Activity with EQ001 </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">EQ001 is a humanized antibody that selectively binds to human CD6 and inhibits the interaction of CD6 with its ligand ALCAM, preventing
<FONT STYLE="white-space:nowrap">co-stimulation,</FONT> and thereby reducing T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell activity and trafficking. Preclinical </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
studies of EQ001 have shown that blockade of CD6 leads to a reduction in T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell proliferation and downregulation of several important
intracellular pathways that contribute to T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell development. Critically, CD6 blockade leads to the downregulation of important cellular pathways that control inflammation, including STAT3
and ROR<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>t. The downregulation of these pathways is accompanied by decreased secretion of the <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cytokines <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>,
<FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>, <FONT STYLE="white-space:nowrap">IL-6</FONT> and <FONT STYLE="white-space:nowrap">IL-17.</FONT>
Additionally, inhibiting the binding of ALCAM to CD6, either by <FONT STYLE="white-space:nowrap">anti-CD6</FONT> monoclonal antibodies or by deletion of the gene expressing CD6, modulates lymphocyte trafficking and results in reduced T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell infiltration into inflamed tissues. Based on its broad multi-modal mechanism, we believe EQ001 has the potential to treat multiple immuno-inflammatory diseases including those that are
resistant or refractory to existing therapies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Planned Initial Clinical Indications </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to initially develop EQ001 for the treatment of aGVHD, cGVHD, severe asthma and at least one additional indication. We expect to initiate a Phase 1b/2 clinical
trial of EQ001 in patients with aGVHD in early 2019 and a Phase 2 clinical trial of EQ001 in patients with cGVHD in the first half of 2019. We also plan to initiate a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial in severe asthma in the first half of 2019. We continue to evaluate additional indications for future development and plan to select a
fourth indication in the first half of 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Strategy </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our goal is to
become a leading, fully-integrated biotechnology company focused on therapies for severe immuno-inflammatory disorders. To achieve our goal, we intend to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Advance EQ001 through clinical development for aGVHD and cGVHD.</B> Based on our deep and proprietary understanding of
the CD6 pathway, our translational research and prior clinical studies targeting CD6, we are initially focused on aGVHD and cGVHD as our initial indications for the clinical development of EQ001. We plan to initiate a Phase 1b/2 clinical trial of
EQ001 as a front-line therapy concomitant with steroids in patients with aGVHD in early 2019 and expect <FONT STYLE="white-space:nowrap">top-line</FONT> data from the Phase 1b part of this trial within 12 months of initiation. In this trial we will
assess safety, overall response rate, survival, steroid taper and incidence of cGVHD. In addition, we plan to initiate a Phase 2 clinical trial of EQ001 in patients with cGVHD in the first half of 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Develop EQ001 for the treatment of severe asthma.</B> We believe that the unique mechanism of action of EQ001 has the
potential to treat severe asthma patients characterized by an immunophenotype of low T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 and high T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 and who consequently have a poor
response to high dose inhaled and/or oral steroids. There are a sizeable number of these patients who are underserved by currently available therapies and for which there are no FDA-approved biologic or other targeted treatments. We plan to initiate
a proof-of-concept clinical trial of EQ001 in patients with severe asthma in the first half of 2019. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Expand clinical development of EQ001 into additional indications based on our translational biology program. </B>We
will<B> </B>continue to conduct studies in animal models and human tissue, as well as EQ001 clinical trials, to help inform the selection of additional indications for further development. In the first half of 2019, we intend to select a fourth
indication for future EQ001 development. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Opportunistically expand our pipeline of product candidates.</B> We will leverage the collective talent within our
organization to opportunistically acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other high-value therapeutic programs that may complement our core strategy or have the potential for synergistic therapeutic benefit in combination with
EQ001. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Build a commercial infrastructure.</B> If approved, we intend to commercialize EQ001 ourselves in indications that can
be efficiently targeted using a specialty sales force, such as aGVHD and cGVHD. For other indications, we intend to commercialize EQ001 either independently or through collaborations with other parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RISKS ASSOCIATED WITH OUR BUSINESS </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business and our
ability to implement our business strategy are subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148; immediately following this prospectus summary. You should
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
read these risks before you invest in our common stock. We may be unable, for many reasons, including those that are beyond our control, to implement our business strategy. In particular, risks
associated with our business include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have a very limited operating history and have never generated any revenues. We expect to incur significant losses for
the foreseeable future and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We are highly dependent on the success of our product candidate, EQ001, which is in early stage clinical development, and
we may not be able to successfully obtain regulatory or marketing approval for, or successfully commercialize, this product candidate in any of the indications for which we plan to develop it. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we fail to comply with U.S. export control and economic sanctions, our business, financial condition and prospects may
be materially and adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">EQ001 is a monoclonal antibody that selectively targets CD6, a target for which there are no FDA-approved therapies. This
makes it difficult to predict the timing and costs of clinical development for EQ001. We do not know whether our approach in targeting CD6 will allow us to develop any products of commercial value. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Even if this offering is successful, we will need to obtain substantial additional funding to complete the development and
any commercialization of EQ001. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our research and development programs or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We are very early in our development efforts. We have not yet begun our first clinical trial to evaluate EQ001 in patients
and, as a company, we have limited experience in this area. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have licensed EQ001 from Biocon pursuant to an exclusive license agreement which rights are conditioned upon us meeting
certain development and commercialization milestones and on making significant milestone payments in connection with regulatory approval and commercial milestones as well as royalty payments. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The development and commercialization of biopharmaceutical products are subject to extensive regulation, and we may not
obtain regulatory approvals for EQ001 in any of the indications for which we plan to develop it, or any future product candidates, on a timely basis or at all. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any delays in the commencement or completion, or termination or suspension, of our planned or future clinical trials could
result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Adverse side effects or other safety risks associated with EQ001 could delay or preclude approval, cause us to suspend or
discontinue clinical trials, abandon further development, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The manufacture of biologics is complex and Biocon, our third-party manufacturer, may encounter difficulties in
production. If Biocon encounters such difficulties, our ability to provide supply of EQ001 for clinical trials, our ability to obtain marketing approval, or our ability to obtain commercial supply of our products, if approved, could be delayed or
stopped. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies, and
these third parties may not perform satisfactorily. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products more
quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we are unable to obtain or protect intellectual property rights covering our product candidates, or if the scope of the
intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and we may not be able to compete effectively in our market. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">There has been no prior public market for our common stock, the stock price of our common stock may be volatile or may
decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CORPORATE AND OTHER INFORMATION </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were originally
incorporated as Attenuate Biopharmaceuticals, Inc. in Delaware in March 2017 and subsequently changed our name to Equillium, Inc. in May 2017. Our principal executive offices are located at 2223 Avenida de la Playa, Suite 108, La Jolla, CA 92037,
and our telephone number is 858-412-5302. Our corporate website address is www.equilliumbio.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus
is an inactive textual reference only. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience,
trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or TM symbols, but such references are not intended to
indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#146; trade names or trademarks to imply a relationship
with, or endorsement or sponsorship of us by, any other companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>IMPLICATIONS OF BEING AN EMERGING GROWTH COMPANY </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act, as amended, or JOBS Act, enacted in April 2012. An
&#147;emerging growth company&#148; may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">being permitted to present only two years of audited financial statements and only two years of related Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of
2002, as amended, or Sarbanes-Oxley; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration
statements; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute
payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will
remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at least
$1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior
June 30th and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to
take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity
interests. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with the adoption of new or
revised accounting standards. We have elected to avail ourselves of this exemption. Therefore, we may not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth
companies, which may make comparison of our financials to those of other public companies more difficult. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Option to purchase additional shares </P></TD>
<TD>The underwriters have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering to fund research and development of EQ001 and for working capital and other general corporate purposes, including costs and expenses associated with being a public company. See &#147;Use of
Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of certain of the factors to consider carefully before deciding to purchase any shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Proposed Nasdaq Global Market symbol </P></TD>
<TD>&#147;EQ&#148; </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding as of June&nbsp;30, 2018, including 31,055 shares of restricted common stock which are subject to a right of
repurchase by us as of June&nbsp;30, 2018 and after giving effect to (i)&nbsp;the conversion of $9.4&nbsp;million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the
completion of this offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 and (ii)&nbsp;the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock upon completion of this offering to Biocon, pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and excludes: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">12,423 shares of common stock issuable upon the exercise of outstanding stock options as of June&nbsp;30, 2018, each at an
exercise price of $0.35 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future
issuance under our 2018 equity incentive plan, or the 2018 Plan, which will become effective upon the execution and delivery of the underwriting agreement for this offering
(including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under our 2017 equity incentive plan, or the 2017 Plan, which shares will be added to the shares
reserved under the 2018 Plan upon its effectiveness); and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future
issuance under our 2018 employee stock purchase plan, or the ESPP, which will become effective upon the execution and delivery of the underwriting agreement for this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the conversion of $9.4&nbsp;million of aggregate principal amount, plus accrued interest thereon, of convertible
promissory notes which will automatically convert upon the completion of this offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock based on an
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the
occurrence of the conversion on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on
the cover page of this prospectus); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no exercise by the underwriters of their option to purchase up to a total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws
immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT> stock split of our common stock to be effected prior to the
completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) would decrease the number of shares of our common stock
issued on conversion of our convertible promissory notes and issued to Biocon (and therefore the number of shares to be outstanding after this offering)
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. A $1.00 decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase the number of shares of our common stock
issued on conversion of our convertible promissory notes and issued to Biocon (and therefore the number of shares to be outstanding after this offering)
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares<B>. </B>Because the closing date of this offering will occur
after&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, the convertible promissory notes will continue to accrue interest at a rate of 6% per annum and additional shares of our common stock will
be issued upon conversion of this additional accrued interest. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following summary statement of operations data for the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017 is derived from our audited financial
statements appearing elsewhere in this prospectus. The summary statements of operations data for the period March&nbsp;16, 2017 (inception) through June&nbsp;30, 2017 and the six months ended June&nbsp;30, 2018 and the balance sheet data as of
June&nbsp;30, 2018 are derived from our unaudited interim financial statements included elsewhere in this prospectus. In our opinion, these unaudited financial statements have been prepared on a basis consistent with our audited financial statements
and contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such financial data. You should read these data together with our financial statements and related notes appearing elsewhere in
this prospectus and the information in &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not necessarily indicative of the
results to be expected in the future, and our operating results for the interim periods are not necessarily indicative of the results that may be expected for any other interim periods or any future year. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD<BR>MARCH&nbsp;16,<BR>2017<BR>(INCEPTION)<BR>THROUGH<BR>DECEMBER&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD<BR>MARCH&nbsp;16,<BR>2017<BR>(INCEPTION)<BR>THROUGH <BR>JUNE&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS<BR>ENDED <BR>JUNE 30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">801,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,202,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">958,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,712,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">988,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,161,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,712,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(988,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,161,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,342,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share, basic and diluted <SUP STYLE="font-size:85%; vertical-align:top">(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average shares of common stock outstanding, basic and diluted <SUP
STYLE="font-size:85%; vertical-align:top">(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted (unaudited)&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted average shares of common stock outstanding, basic and diluted (unaudited) <SUP
STYLE="font-size:85%; vertical-align:top">(2) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note&nbsp;2 to our financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate the basic and diluted net loss per common share and the number of shares used in the
computation of the per share amounts. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">The calculations for the unaudited pro forma net loss per common share, basic and diluted, and the pro forma weighted
average shares of common stock outstanding, basic and diluted, assume (i)&nbsp;the conversion of $9.4&nbsp;million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon
the completion of this offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2018, and (ii)&nbsp;the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus). </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF JUNE&nbsp;30, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED <SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,626,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,788,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,728,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible promissory notes, including related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,517,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,604,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,593,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pro forma amounts reflect (i)&nbsp;the conversion of $9.4&nbsp;million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion
of this offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2018 and (ii)&nbsp;the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus). </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pro forma as adjusted amounts reflect the pro forma adjustments described in footnote (1)&nbsp;above, as well as the sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A $1.00 increase (decrease) in the assumed initial public offering price would increase (decrease) each of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the number of shares offered by us as stated on the cover page of this prospectus remain unchanged and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a one million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase
(decrease) each of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) remains the same, and after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our common stock is speculative and involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks
described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. If any of the following risks occur, our business, financial
condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. This prospectus
also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described
below. See &#147;Information Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business and to the Development and Regulatory Approval of
EQ001 </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have a very limited operating history and have never generated any revenues. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an early-stage biotechnology company with a very limited operating history that may make it difficult to evaluate the success of our business to date and to
assess our future viability. We were incorporated in March 2017 and our operations, to date, have been limited to organizing and staffing our company, business planning, raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> rights to
EQ001, conducting preclinical research, filing our initial IND and preparing to commence clinical development of EQ001. We have not yet demonstrated an ability to successfully complete any clinical trials and have never completed the development of
any product candidate, and we have never generated any revenue from product sales or otherwise. Consequently, we have no meaningful operations upon which to evaluate our business, and predictions about our future success or viability may not be as
accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing biopharmaceutical products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We
expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Investment in biopharmaceutical product
development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. We have never generated any revenues,
and we cannot estimate with precision the extent of our future losses. For the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017 and six months ended June&nbsp;30, 2018, our net losses were $2.3&nbsp;million and
$3.3&nbsp;million, respectively. As of December&nbsp;31, 2017, and June&nbsp;30, 2018, we had an accumulated deficit of $2.3&nbsp;million and $5.6&nbsp;million, respectively. We expect to incur increasing levels of operating losses for the
foreseeable future as we execute our plan to continue our research and development activities, including the planned clinical development of EQ001, and as we incur the additional costs of operating as a public company. In addition, if we obtain
regulatory approval for EQ001, we expect to incur increased sales and marketing expenses. As a result, we expect to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future. These losses have
had and will continue to have an adverse effect on our financial position and working capital. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To become and remain profitable, we must develop and eventually
commercialize a product with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of EQ001, obtaining marketing approval for EQ001,
manufacturing, marketing and selling EQ001 if we obtain marketing approval, and satisfying post-marketing requirements, if any. We may never succeed in these activities and, even if we succeed in obtaining approval for and commercializing EQ001, we
may never generate revenues that are significant enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. Furthermore,
because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we do
achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we may continue to incur substantial research and development and other expenditures to develop and market additional product
candidates. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline
in the value of our company could also cause you to lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our independent registered public accounting firm has expressed substantial doubt about our ability to continue
as a going concern. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our auditors have issued a going concern opinion on our financial statements as of December&nbsp;31, 2017 and for the period from
March&nbsp;16, 2017 (inception) to December&nbsp;31, 2017, expressing substantial doubt that we can continue as an ongoing business due to insufficient capital for us to fund our operations. Our financial statements do not include any adjustments
that may result from the outcome of this uncertainty. If we are unable to successfully complete this offering, we will need to create and implement alternate financing or operational plans to continue as a going concern, and investors or other
financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are highly dependent on the success of
our product candidate, EQ001, which is in early stage clinical development, and we may not be able to successfully obtain regulatory or marketing approval for, or successfully commercialize, this product candidate in any of the indications for which
we plan to develop it. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future success will depend almost entirely on our ability to successfully develop, obtain regulatory approval for and then
successfully commercialize EQ001, in any of the indications for which we initially plan to develop it, including aGVHD, cGVHD and severe asthma, which may never occur. We have no product candidates in our pipeline other than EQ001. We currently
generate no revenues from sales of any biopharmaceutical products or otherwise, and we may never be able to develop or commercialize a marketable biopharmaceutical product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before we can market and sell EQ001 in the United States, we will need to manage research and development activities, commence and complete clinical trials, obtain
necessary regulatory approvals from the FDA and build a commercial organization or enter into a marketing collaboration with a third party, among other things. We cannot assure you that we will be able to successfully complete the necessary clinical
trials and/or obtain regulatory approval and develop sufficient commercial capabilities for EQ001. We have not submitted a Biologics License Application, or BLA, to the FDA for any product candidate. Further, EQ001 may not receive regulatory
approval even if it is successful in clinical trials. If we do not receive regulatory approvals, our business, prospects, financial condition and results of operations will be adversely affected. Even if we obtain regulatory approval, we may never
generate significant revenues from any commercial sales of EQ001. If EQ001 is approved and we fail to successfully commercialize it, we may be unable to generate sufficient revenues to sustain and grow our business, and our business, prospects,
financial condition and results of operations will be adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with U.S. export control and economic sanctions, our business,
financial condition and prospects may be materially and adversely affected. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our products are subject to U.S. export control laws and regulations, including
the U.S. Export Administration Regulations and economic and trade sanctions regulations administered by the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control, or OFAC. Our company must comply with these laws and regulations.
The antibody sequence for both EQ001 and ALZUMAb is derived from Cuban-origin intellectual property and thus we believe this to be a pharmaceutical of Cuban origin. We currently rely on a general license issued by OFAC under the Cuban Assets Control
Regulations, or CACR, relating to Cuban-origin pharmaceuticals to import and conduct clinical trials relating to EQ001. Although we believe our activities for EQ001 qualify for, and are authorized under, the OFAC general license and we have
maintained compliance with the general license requirements, OFAC has not confirmed the applicability of the general license to EQ001. In the absence of the OFAC general license, all of our development and potential commercialization activities for
EQ001 would be prohibited under the CACR, and we would be required to request a specific license from OFAC authorizing such activities, which OFAC could deny. We have submitted to OFAC a request for interpretive guidance confirming the applicability
of the general license, or in its absence, a specific license authorization from OFAC. We have simultaneously requested that OFAC treat our submission as a voluntary disclosure if OFAC concludes that our determination that the general license
applies to EQ001 was in error. If OFAC concludes that the general license applies to EQ001, there can be no assurance that the general license will not be revoked or modified by OFAC, or that we will remain in compliance with these or other export
laws and regulations. If OFAC determines that the general license does not apply, and OFAC then denies our request for a specific license, we will be unable to deal in, or otherwise commercialize, EQ001. In that case, we would be required to cease
operations related to EQ001 which would materially and adversely affect our financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
condition and business prospects. In addition, in the absence of the general or specific license, the transfer, sale and/or purchase of our securities could be prohibited, and the ownership or
possession of our securities could be subject to an affirmative OFAC reporting requirement relating to blocked property. We and certain of our employees could also be subject to substantial civil or criminal penalties. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>EQ001 is a monoclonal antibody that selectively targets CD6, a target for which there are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapies. This
makes it difficult to predict the timing and costs of clinical development for EQ001. We do not know whether our approach in targeting CD6 will allow us to develop any products of commercial value. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have concentrated our research and development approach on targeting CD6, and our future success depends on the successful development of this therapeutic approach
to the diseases we are targeting for treatment. To date, there are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs that target CD6, and while there are a number of independent studies clinically validating CD6 as a target, other than
our partner Biocon, CD6 has not traditionally been a pathway targeted by other biopharmaceutical companies. The regulatory approval process for novel product candidates such as EQ001 can be more expensive and take longer than for other, better known
or extensively studied therapeutic approaches. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring EQ001 to market could decrease our ability to generate sufficient revenue to maintain our
business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if this offering is successful, we will need to obtain substantial additional funding to complete the development and any commercialization of
EQ001. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our research and development programs or other operations. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect our expenses to increase substantially during the next few years. The development of biotechnology product candidates is capital intensive. As EQ001 enters
and advances through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory and quality capabilities. In addition, if we obtain marketing approval for EQ001, we expect to incur
significant commercialization expenses for marketing, sales, manufacturing and distribution. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2018, we had $6.6&nbsp;million in cash and cash equivalents. Based on our current operating plan, we believe that the net proceeds from this
offering, together with our existing cash and cash equivalents, will enable us to fund our operations for at least the next 24 months. In particular, we expect that the net proceeds from this offering will allow us to fund a Phase 1b/2 clinical
trial of EQ001 for aGVHD, a Phase 2 clinical trial of EQ001 for cGVHD and a proof-of-concept clinical trial of EQ001 for severe asthma. However, changing circumstances or inaccurate estimates by us may cause us to use capital significantly faster
than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. For example, our planned clinical trials for EQ001 may encounter technical, enrollment or other issues that could
cause our development costs to increase more than we expect. Even with the expected net proceeds from this offering, we will not have sufficient funds to complete the clinical development of EQ001 through regulatory approval, and we will need to
raise substantial additional capital to complete the development and commercialization of EQ001. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future capital requirements will depend on many factors,
including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress, timing, costs and results of our planned clinical trials for EQ001; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and scope of indications we decide to pursue for EQ001 development; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost, timing and outcome of regulatory review of any BLA we may submit for EQ001; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs and timing of manufacturing for EQOO1, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property
rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including
personnel to support the development of EQ001; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost associated with commercializing EQ001, if approved for commercial sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for sale for at least the next several years,
if ever. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional
capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise capital when needed or on attractive terms, we would be forced to
delay, reduce or eliminate our research and development programs or other operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are very early in our development efforts. We have not yet begun our
first clinical trial to evaluate EQ001 in patients and, as a company, we have limited experience in this area. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While Biocon has evaluated EQ001 in a Phase
1 clinical trial, we expect to initiate our first clinical trial of EQ001 in patients with aGVHD in early 2019. We have one active IND with the FDA for EQ001 in the aGVHD indication. Because of our limited interaction with the FDA, we may not learn
of certain information or data that the FDA may request until future interactions. In part because of our limited infrastructure, experience conducting clinical trials as a company and regulatory interactions, we cannot be certain that our clinical
trials will be initiated on time, that our planned clinical trials will be completed on time, if at all, or that our planned development programs would be acceptable to the FDA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adverse safety and toxicology findings may emerge as we conduct clinical trials. In addition, success in early clinical trials does not mean that later clinical trials
will be successful, because later-stage clinical trials may be conducted in broader patient populations and involve different study designs. For example, although EQ001 and ALZUMAb share the same primary monoclonal antibody sequence, they are
manufactured in different cell lines and thus could be considered different biopharmaceutical products. Therefore, results seen in clinical trials of ALZUMAb conducted by Biocon may not be predictive of the results of our clinical trials of EQ001.
Furthermore, our future clinical trials will need to demonstrate sufficient safety and efficacy in larger patient populations for approval by the FDA. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier
clinical trials have shown promising results, and we cannot be certain that we will not face similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have
believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. In addition, only a small percentage of biologics under development result
in the submission of a BLA to the FDA and even fewer are approved for commercialization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to generate product revenues, which we do not expect will
occur for at least the next several years, if ever, will depend heavily on our ability to successfully complete the above activities and any other activities required for the successful development and eventual commercialization of EQ001. The
success of EQ001 will further depend on factors such as: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of our planned clinical trials and preclinical studies with favorable results; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acceptance of INDs by the FDA for our future clinical trials in additional indications such as cGVHD and asthma, as
applicable; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">timely and successful enrollment in, and completion of, clinical trials with favorable results; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">demonstrating safety, efficacy and acceptable risk-benefit profile of EQ001 to the satisfaction of the FDA;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">receipt of marketing approvals from the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintaining arrangements with Biocon, our third-party manufacturer, for cell lines and drug product clinical supply and,
if and when approved, for commercial supply of EQ001; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing sales, marketing and distribution capabilities and launching commercial sale of EQ001, if and when approved
in one or more indications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acceptance of EQ001, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effectively competing with other therapies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for
EQ001; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintaining a continued acceptable safety profile of EQ001, following approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not achieve one or more of these factors in a timely manner, we could experience significant delays or an inability to successfully obtain marketing approval
and commercialize EQ001, which would materially harm our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have licensed EQ001 from Biocon pursuant to an exclusive license agreement, which
rights are conditioned upon us meeting certain development and commercialization milestones and on making significant milestone payments in connection with regulatory approval and commercial milestones as well as royalty payments. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are party to an exclusive license agreement with Biocon, pursuant to which we acquired an exclusive license in the United States and Canada to develop, make, have
made, use, sell, have sold, offer for sale, import and otherwise exploit EQ001 and any pharmaceutical composition or preparation containing or comprising EQ001. We are obligated, under this agreement, to use commercially reasonable efforts to
achieve certain development, regulatory, commercialization and funding milestones within specified timeframes in order to retain all of the licensed rights. Certain of such milestones are largely outside of our control. Further, we are obligated to
make certain cash milestone payments to Biocon upon completion of certain development and commercial milestones and are required to make certain cash royalty payments upon our achievement of target levels of revenue from sales of EQ001, if approved.
Though we believe that the royalty rates and milestone payments are reasonable in light of our business plan, we will require large amounts of capital to satisfy these obligations. We may become obligated to make a milestone payment when we do not
have the cash on hand to make such payment, which could require us to delay our clinical trials, curtail our operations, scale back our commercialization and marketing efforts or seek funds to meet these obligations on terms unfavorable to us. In
addition, if we are unable to make any payment when due or, if we fail to use commercially reasonable efforts to achieve the development, regulatory, commercial and funding milestones within the timeframes required by the license agreement, Biocon
may have the right to limit the scope of our license or terminate the agreement and all of our rights to develop and commercialize EQ001. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have only
licensed the rights to EQ001 in the United States and Canada. Any adverse developments that occur during any clinical trials conducted by third parties in other jurisdictions may affect our ability to obtain regulatory approval or commercialize
EQ001. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biocon and its partner, over which we have no control, have the rights to develop and commercialize itolizumab in geographies outside of the United
States and Canada. Itolizumab is approved in India for the treatment of moderate to severe plaque psoriasis and is marketed by Biocon as ALZUMAb. In addition, a conditional approval for itolizumab was granted to Centro de Immunologia Molecular, Cuba
in May 2014. This approval is subject to completion of a Phase 3 clinical trial in Cuban patients. Two clinical trials are currently open in Cuba. If serious adverse events occur with patients using ALZUMAb or during any clinical trials of
itolizumab conducted by third parties, the FDA may delay, limit or deny approval of EQ001 or require us to conduct additional clinical trials as a condition to marketing approval, which would increase our costs. If we receive FDA approval for EQ001
and a new and serious safety issue is identified in connection with use of ALZUMAb or in clinical trials of itolizumab conducted by third parties, the FDA may withdraw their approval of the product or otherwise restrict our ability to market and
sell EQ001. In addition, treating physicians may be less willing to administer our product due to concerns over such adverse events, which would limit our ability to commercialize EQ001. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The development and commercialization of biopharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals for EQ001 in
any of the indications for which we plan to develop it, or any future product candidates, on a timely basis or at all. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical development,
manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other
possible activities relating to EQ001, currently our only product candidate, as well as any other product candidate that we may develop in the future, are subject to extensive regulation. Marketing approval of biologics in the United States requires
the submission of a BLA to the FDA and we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the BLA for that product. A BLA must be supported by extensive clinical and
preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing and controls. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FDA approval of a BLA is not guaranteed, and the
review and approval process is an expensive and uncertain process that may take several years. The FDA also has substantial discretion in the approval process. The number and types of preclinical studies and clinical trials that will be required for
BLA approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to treat and the regulations applicable to any particular product candidate. Despite the time and expense associated with
preclinical studies and clinical trials, failure can occur at any stage. The results of preclinical and early clinical trials of EQ001 or any future product candidates may not be predictive of the results of our later-stage clinical trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trial failure may result from a multitude of factors including flaws in trial design, dose selection, placebo effect, patient enrollment criteria and failure
to demonstrate favorable safety or efficacy traits, and failure in clinical trials can occur at any stage. Companies in the biopharmaceutical industry frequently suffer setbacks in the advancement of clinical trials due to lack of efficacy or
adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data
obtained from clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA could delay, limit or deny approval of a product candidate for many reasons, including because they: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may not deem our product candidate to be adequately safe and effective; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may not agree that the data collected from clinical trials are acceptable or sufficient to support the submission of a BLA
or other submission or to obtain regulatory approval, and may impose requirements for additional preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may determine that adverse events experienced by participants in our clinical trials represents an unacceptable level of
risk; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may determine that population studied in the clinical trial may not be sufficiently broad or representative to assure
safety in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may not accept clinical data from trials, which are conducted at clinical facilities or in countries where the standard of
care is potentially different from that of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may disagree regarding the formulation, labeling and/or the specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may not approve the manufacturing processes or facilities associated with our product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may change approval policies or adopt new regulations; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">may not accept a submission due to, among other reasons, the content or formatting of the submission.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, public concern regarding the safety of biopharmaceutical products could delay or limit our ability to obtain regulatory approval,
result in the inclusion of unfavorable information in our labeling, or require us to undertake other activities that may entail additional costs. We have not obtained FDA approval for any product. This lack of experience may impede our ability to
obtain FDA approval in a timely manner, if at all, for EQ001. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we experience delays in obtaining approval or if we fail to obtain approval of EQ001, our
commercial prospects will be harmed and our ability to generate revenues will be materially impaired which would adversely affect our business, prospects, financial condition and results of operations.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any delays in the commencement or completion, or termination or suspension, of our planned or future clinical trials could result in increased costs to us, delay
or limit our ability to generate revenue and adversely affect our commercial prospects. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any delays in the commencement or completion, or termination or
suspension, of our planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. Before we can initiate clinical trials of EQ001 in any distinct
indication, we must submit the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
results of preclinical studies to the FDA along with other information, including information about EQ001 chemistry, manufacturing and controls and our proposed clinical trial protocol, as part
of an IND or similar regulatory filing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining marketing approval from the FDA for the sale of EQ001 in any indication, we must conduct extensive
clinical studies to demonstrate the safety and efficacy of EQ001. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we expect to rely in part on preclinical, clinical and quality data generated by our partner,
Biocon, as well as contract research organizations, or CROs, and other third parties for regulatory submissions for EQ001. While we have or will have agreements governing these third parties&#146; services, we have limited influence over their
actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed
and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. To date, we have only submitted an IND for clinical trials of EQ001 for the treatment of aGVHD, and we will
need to submit an IND for acceptance by the FDA prior to initiating any clinical trials in the United States in other indications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may require us to
conduct additional preclinical studies for EQ001 or any future product candidate before it allows us to initiate clinical trials under any IND, which may lead to additional delays and increase the costs of our preclinical development programs. Any
such delays in the commencement or completion of our planned or future clinical trials could significantly affect our product development costs. We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The
commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA disagreeing as to the design or implementation of our clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining FDA authorizations to commence a trial or reaching a consensus with the FDA on trial design;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to
extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining approval from one or more institutional review boards, or IRBs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of
additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes to clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of combination therapies for
use in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subjects choosing an alternative treatment, or participating in competing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">lack of adequate funding to continue the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subjects experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA to temporarily or
permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any changes to our manufacturing process that may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing
our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">us, or our third-party contractors not performing data collection or analysis in a timely or accurate manner or improperly
disclosing data prematurely or otherwise in violation of a clinical trial protocol; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory
authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are
being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory
requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from
using a pharmaceutical, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend
clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of our scientific advisors or consultants who receive compensation from us are likely to be investigators for our future clinical trials. Under certain
circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of
the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our
marketing applications by the FDA and may ultimately lead to the denial of marketing approval of EQ001 in one or more indications. If we experience delays in the completion of, or termination of, any clinical trial of EQ001, the commercial prospects
of EQ001 will be harmed, and our ability to generate product revenues will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to
commence product sales and generate revenues which may harm our business, financial condition, results of operations and prospects significantly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we
experience delays or difficulties in enrolling patients in our planned clinical trials, our receipt of necessary regulatory approval could be delayed or prevented. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not be able to initiate or continue our planned clinical trials for EQ001 if we are unable to identify and enroll a sufficient number of eligible patients to
participate in these trials as required by the FDA. The first indication that we are pursuing, aGVHD, is an acute and life threatening condition which may make it difficult to enroll patients in clinical trials. In addition, some of our competitors
may have ongoing clinical trials for product candidates that would treat the same indications as EQ001, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#146; product
candidates. This is acutely relevant for our development of EQ001 for the treatment of patients with severe asthma, a disease for which there is significant competition for clinical trial subjects. Patient enrollment is also affected by other
factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to recruit clinical trial investigators of appropriate competencies and experience; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">invasive procedures required to obtain evidence of the product candidate&#146;s performance during the clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">availability and efficacy of approved medications for the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">eligibility criteria defined in the protocol for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">perceived risks and benefits; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reluctance of physicians to encourage patient participation in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">proximity and availability of clinical trial sites for prospective patients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or
may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs, which would cause the value of our company to decline and limit our ability to obtain additional
financing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Adverse side effects or other safety risks associated with EQ001 could delay or preclude approval, cause us to suspend or discontinue clinical
trials, abandon further development, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with EQ001 in our planned clinical trials. In
the Phase 1 clinical trial of EQ001 conducted by Biocon in healthy subjects, there were no serious adverse events, dose limiting toxicities, or study drug discontinuations reported. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biocon has completed three clinical studies of ALZUMAb in India in patients with rheumatoid arthritis and chronic plaque psoriasis, with a total of 333 patients exposed
to ALZUMAb to date at dose levels ranging from 0.2 mg/kg to 1.6 mg/kg. An additional 35 patients have received itolizumab in clinical trials conducted in Cuba. In Biocon&#146;s Phase&nbsp;3 clinical trial, infusion-related reactions and related
events were the main adverse events attributed to itolizumab. There were five serious adverse events reported including exfoliative dermatitis (widespread redness and peeling of the skin), erythrodermic (severe) psoriasis, infusion-related reaction,
adjustment disorder with anxiety, and bacterial arthritis. There has been limited market experience of ALZUMAb in patients since the date of market authorization in India in December 2012. Since the date of market authorization and as of the current
<FONT STYLE="white-space:nowrap">cut-off</FONT> date of August&nbsp;10, 2017 for the most recent Periodic Safety Update Report, ALZUMAb has accrued approximately 275&nbsp;patient-years of use. Post-market safety surveillance has demonstrated 27
adverse event reports in that time period, of which four have been noted as serious, including infusion reaction, type&nbsp;1 hypersensitivity, diarrhea and urticaria (hives). The majority of reactions have involved the dermatologic standard of care
and include rash, acne, urticaria, increased pruritus (itching) and increased psoriasis. Although EQ001 and ALZUMAb share the same primary monoclonal antibody sequence, they are manufactured in different cell lines and thus could be considered
different biopharmaceutical products. Therefore, clinical results seen with ALZUMAb may have no bearing on results, including adverse events, that may be seen with EQ001. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects
caused by EQ001 could result in the delay, suspension or termination of clinical trials by us or the FDA for a number of reasons. Additionally, a material percentage of patients in our GVHD clinical trials will die from GVHD, possibly as a result of
EQ001, which could impact development of EQ001. If we elect or are required to delay, suspend or terminate any clinical trial, the commercial prospects of EQ001 will be harmed and our ability to generate product revenues from this product candidate
will be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of EQ001. Any of these occurrences may harm our business, prospects, financial condition and results of operations
significantly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, if EQ001 is associated with undesirable side effects in clinical trials or has characteristics that are unexpected, we may elect to
abandon or limit its development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial
expectations for EQ001, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Many biologics that initially showed promise in early stage testing have later been found to cause side effects that
prevented further development. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It
is possible that as we test EQ001 in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of EQ001 becomes more widespread following any regulatory approval, illnesses, injuries, discomforts and
other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any,
such findings may harm our business, financial condition, results of operations and prospects significantly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if EQ001 receives marketing approval, and we or others later identify undesirable side effects caused by
EQ001, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may withdraw approval of EQ001; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be required to recall a product or change the way EQ001 is administered to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may require additional warnings on the label, such as a &#147;black box&#148; warning or a
contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining
the risks of such side effects for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional restrictions may be imposed on the marketing or promotion of the particular product or the manufacturing
processes for the product or any component thereof; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">EQ001 could become less competitive; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these events could prevent us from achieving or maintaining market acceptance of EQ001, if approved, and could significantly harm our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time
may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may publicly disclose preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and
the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our
analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or
considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the
preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials
that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final
data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock after this offering. See the description of risks under the heading
&#147;Risks Related to our Common Stock and this Offering&#148; for more disclosure related to the risks of volatility in our stock price. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, others,
including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses, or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the
approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically
extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant
with respect to future decisions, conclusions, views, activities or otherwise regarding a particular biopharmaceutical product, biopharmaceutical product candidate or our business. If the topline data that we report differ from actual results, or if
others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, EQ001 or any future product candidates may be harmed, which could harm our business, operating results, prospects
or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A Phase 1 clinical trial for EQ001 was recently conducted by Biocon in Australia, and we may conduct additional
clinical trials of EQ001 outside of the United States. However, the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the fourth quarter of 2017, Biocon completed a Phase 1 clinical trial of EQ001 in healthy subjects in Australia to assess the safety and tolerability of the
subcutaneous version of EQ001. The trial also included a separate stage to compare the pharmacokinetics of the intravenous administration of EQ001 to ALZUMAb and determine the absolute bioavailability of subcutaneous EQ001 SC, but this stage was
terminated early due to the occurrence of an initial decrease in lymphocyte counts and the occurrence of transient lymphopenia in the healthy subjects. We submitted this data to the FDA as part of our IND submission for the conduct of clinical
trials for the treatment of aGVHD. However, it is possible that the FDA will not authorize us to proceed with clinical studies in connection with any future IND submissions in other indications that have different patient populations, and we may be
required to conduct additional Phase 1 clinical trials, which would be costly and time consuming, and delay aspects of our development plan, which could harm our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although the FDA may accept data from clinical trials conducted entirely outside the United States and not under an IND, acceptance of such study data is generally
subject to certain conditions. For example, the FDA requires the clinical trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such
inspection necessary. In addition, when studies are conducted only at sites outside of the United States, the FDA generally does not provide advance comment on the clinical protocols for the studies, and therefore there is an additional potential
risk that the FDA could determine that the study design or protocol for a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial was inadequate, which would likely require us to conduct additional clinical trials. Conducting clinical trials
outside the United States also exposes us to additional risks, including risks associated with: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">foreign exchange fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cultural differences in medical practice and clinical research; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">diminished protection of intellectual property in some countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to expand our pipeline by identifying additional indications for which to test EQ001 in the future. We may expend our
limited resources to pursue a particular indication for EQ001 and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our translational biology program may initially show promise in identifying additional indications for which EQ001 may have therapeutic benefit, yet this may fail to
yield additional clinical development opportunities for EQ001 for a number of reasons, including, EQ001 may, on further study, be shown to have harmful side effects, limited to no efficacy or other characteristics that indicate that it is unlikely
to receive marketing approval and achieve market acceptance in such additional indications. Research programs to identify additional indications for EQ001 require substantial technical, financial and human resources. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus EQ001 development on the potential treatment
of certain indications. As a result, we may forego or delay pursuit of opportunities with other indications or for any future product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to
fail to capitalize on viable commercial products or profitable market opportunities. Our spending on EQ001 for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target
market for EQ001&nbsp;or any future product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to
retain sole development and commercialization rights to such product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive regulatory approval for EQ001 or any future product candidates, we will be subject to
ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, EQ001 and any future product candidates, if approved, could be subject to labeling and other restrictions and market
withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any
regulatory approvals that we receive for EQ001 or any future product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for
potentially costly post-marketing testing, including Phase&nbsp;4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the FDA approves any product candidate, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and record keeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions
of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product,
including adverse events of unanticipated severity or frequency, undesirable side effects caused by the product, problems encountered by our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements,
either before or after product approval, may result in, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to include additional warnings on the label; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to create a medication guide outlining the risks to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of the product from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">voluntary or mandatory product recalls; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to change the way the product is administered or for us to conduct additional clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic
partners, or suspension or revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil or criminal penalties; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">harm to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally if any product candidate receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of the therapy outweigh its
risks, which may include, among other things, a medication guide outlining the risks for distribution to patients and a communication plan to health care practitioners. Any of these events could prevent us from achieving or maintaining market
acceptance of the product or the particular product candidate at issue and could significantly harm our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if we have any product candidate approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing
regulatory review. The FDA strictly regulates the promotional claims that may be made about biopharmaceutical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#146;s
approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT>
uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for
alleged improper promotion and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which
specified promotional conduct is changed or curtailed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent,
limit or delay regulatory approval of EQ001 or any future product candidates. We cannot predict the likelihood, nature or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing
requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would
adversely affect our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if EQ001 receives marketing approval in any indication, it may
fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial success. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If EQ001 receives marketing approval in any one or more indication, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare
payors and others in the medical community. If EQ001 does not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of EQ001, if approved for
commercial sale in any indication, will depend on a number of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">efficacy and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to offer EQ001 for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential product liability claims; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of market introduction of EQ001 as well as competitive biopharmaceutical products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effectiveness of our or any of our potential future sales and marketing strategies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">unfavorable publicity relating to EQ001; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sufficient third-party payor coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of patients to pay all, or a portion of,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prevalence and severity of any side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant
resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell EQ001, we may not be able to generate product revenue. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If EQ001 ultimately receives regulatory approval, we may not be
able to effectively market and distribute it. We may have to seek collaborators or invest significant amounts of financial and management resources to develop internal sales, distribution and marketing capabilities, some of which will be committed
prior to any confirmation that EQ001 will be approved, if at all. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial
terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute EQ001 ourselves. We likely will have little control over
such third parties, and any of them may fail to devote the necessary resources and attention to sell and market EQ001 effectively. Even if we determine to perform sales, marketing and distribution functions ourselves, we could face a number of
additional related risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not be able to attract and build an effective marketing department or sales force; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of establishing a marketing department or sales force may exceed our available financial resources and the
revenue generated by EQ001; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our direct sales and marketing efforts may not be successful. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing products
more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The development and commercialization of new products is highly competitive. We compete in the segments of the pharmaceutical, biotechnology and other related markets
that develop drugs and biologics for the treatment of immuno-inflammatory diseases. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less
severe side effects, are more convenient or are less expensive than any products that we may develop, or that would render any products that we may develop obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Our competitors also may
obtain marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other products in the same class as EQ001 have already been approved or are further along in development. Currently-marketed treatments for cGVHD include AbbVie
Inc.&#146;s Imbruvica (ibrutinib), a BTK inhibitor previously approved for the treatment of chronic lymphocytic leukemia and other cancers. Further, we are aware of both private and public companies with development programs in GVHD, including
AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, CSL Behring LLC, Incyte Corporation, Jazz Pharmaceuticals plc, Kadmon Holdings, Inc., Kalytera Therapeutics, Inc., Kamada Ltd., Mesoblast Limited, Novartis AG, Prometheus
Laboratories Inc. and Xenikos B.V. Major, currently marketed asthma therapies include several biologic therapies that specifically target IgE or T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-associated cytokines including products
developed by AbbVie Inc., Amgen Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Roche Holding AG and Teva Pharmaceutical Industries Limited, and we are aware of several companies with
development programs in this indication including, AbbVie Inc., Amgen Inc., AnaptysBio, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG and Sanofi-Aventis U.S.
LLC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our competitors, such as large pharmaceutical and biotechnology companies like Amgen Inc. and Bristol-Myers Squibb Company have longer operating
histories and significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. In
addition, these larger companies may be able to use their greater market power to obtain more favorable distribution and sales-related agreements with third parties, which could give them a competitive advantage over us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, as more product candidates within a particular class of biopharmaceutical products proceed through clinical development to regulatory review and approval, the
amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for product candidates in those classes will likely need to show a risk benefit profile that is
competitive with or more favorable than those products and product candidates in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those
products or product candidates, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product
revenues and financial condition would be materially and adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result
in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and subject enrollment for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, EQ001 or any future programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The key competitive factors affecting the success of EQ001 are likely to be its efficacy, safety,
convenience and availability of reimbursement. If we are not successful in developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be
materially harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>EQ001 and any future product candidates for which we intend to seek approval as biologic products may face
competition sooner than anticipated. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Patient Protection and Affordable Care Act, or Affordable Care Act, signed into law on March&nbsp;23, 2010,
includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an
<FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first
licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT>
period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own preclinical data and data from adequate and
well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to
uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period
of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially
creating the opportunity for biosimilar competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a
biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend
on a number of marketplace and regulatory factors that are still developing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the U.S. market opportunities for EQ001 are smaller than we believe they are,
our revenue may be adversely affected and our business may suffer. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We only have the rights to EQ001 for the United States and Canada and we are focused on
the development of EQ001 for immuno-inflammatory diseases, with an initial intention to develop it for the treatment of aGVHD, cGVHD and severe asthma. Our projections of addressable patient populations in the United States and Canada that have the
potential to benefit from treatment with EQ001 are based on estimates and may prove to be incorrect. If any of our estimates are inaccurate, the market opportunities for EQ001 could be significantly diminished and have an adverse material impact on
our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unsuccessful in our efforts to obtain orphan drug designations from the FDA for EQ001 or may not ultimately realize the potential
benefits of orphan drug designation. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to seek orphan drug designation for EQ001 in eligible indications. The FDA grants orphan designation to
drugs that are intended to treat rare diseases with fewer than 200,000 patients in the United States or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug. Orphan drugs do not
require prescription drug user fees with a marketing application, may qualify the drug development sponsor for certain tax credits, and may be eligible for a market exclusivity period of seven years (with certain exceptions). However, orphan drug
designation neither shortens the development time nor regulatory review time of a product candidate nor gives the candidate any advantage in the regulatory review or approval process. If we are unable to secure orphan drug designation in eligible
indications, our regulatory and commercial prospects may be negatively impacted. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we obtain orphan drug designations and are awarded marketing exclusivity,
the FDA can still approve another drug containing the same active ingredient and used for the same orphan indication if it determines that a subsequent drug is safer, more effective or makes a major contribution to patient care, and orphan
exclusivity can be lost if the orphan drug manufacturer is unable to assure that a sufficient quantity of the orphan drug is available to meet the needs of patients with the rare disease or condition. Orphan drug exclusivity may also be lost if the
FDA later determines that the initial request for designation was materially defective. In addition, orphan drug exclusivity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
does not prevent the FDA from approving competing drugs for the same or similar indication containing a different active ingredient. If orphan drug exclusivity is lost and we were unable to
successfully enforce any remaining patents covering our eligible product candidates, we could be subject to biosimilar competition earlier than we anticipate. In addition, if a subsequent drug is approved for marketing for the same or a similar
indication as EQ001, we may face increased competition and lose market share regardless of orphan drug exclusivity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Manufacturing and Our
Reliance on Third Parties </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The manufacture of biologics is complex and Biocon, our third-party manufacturer, may encounter difficulties in production. If
Biocon encounters such difficulties, our ability to provide supply of EQ001 for clinical trials, our ability to obtain marketing approval, or our ability to obtain commercial supply of our products, if approved, could be delayed or stopped.
</I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have no experience in biologic manufacturing and do not own or operate, and we do not expect to own or operate, facilities for product manufacturing,
storage and distribution, or testing. We are completely dependent on Biocon to fulfill our clinical and commercial supply of EQ001.&nbsp;In May 2017, we entered into an exclusive clinical supply agreement with Biocon and have agreed to enter into an
exclusive commercial supply agreement with Biocon in the future. Biocon manufactures EQ001 at its FDA regulated facility in Bangalore, India.&nbsp;However the process of manufacturing biologics is complex, highly-regulated and subject to multiple
risks. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics
and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions and higher costs. If microbial, viral or other
contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials, result in higher costs of drug
product and adversely harm our business. Moreover, if the FDA determines that our manufacturer is not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny BLA approval until the deficiencies are corrected or
we replace the manufacturer in our BLA with a manufacturer that is in compliance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, there are risks associated with large scale manufacturing for
clinical trials or commercial scale including, among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues, compliance with cGMPs, lot consistency and
timely availability of raw materials. Even if we obtain regulatory approval for EQ001 or any future product candidates, there is no assurance that Biocon or other potential manufacturers will be able to manufacture the approved product to
specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to
produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Scaling up a biologic manufacturing process is a difficult and uncertain task, and Biocon may not have the necessary capabilities to complete the implementation and
development process of further scaling up production, transferring production to other sites, or managing its production capacity to timely meet product demand. If Biocon is unable to meet our manufacturing requirements, it has the discretion to
outsource manufacturing to a third party and the joint steering committee may determine to shift manufacturing to a third party. However, transfer of the manufacturing of biologic products to a new contract manufacturer can be lengthy and involve
significant additional costs. Even if we are able to adequately validate and <FONT STYLE="white-space:nowrap">scale-up</FONT> the manufacturing process for EQ001 with a contract manufacturer, we will still need to negotiate with such contract
manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us, if at all. In addition, Biocon has certain rights to reacquire exclusive manufacturing rights for EQ001, even after
a third party has been engaged following shortfalls by Biocon, which will may make it difficult and expensive to engage any third party manufacturer for EQ001 other than Biocon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We rely, and intend to continue to rely, on third parties to conduct our clinical trials and perform some of
our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, our development programs may be delayed or
subject to increased costs or we may be unable to obtain regulatory approval, each of which may have an adverse effect on our business, financial condition, results of operations and prospects. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have the ability to independently conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we will be dependent on third
parties to conduct our planned clinical trials of EQ001 and preclinical studies, and any future preclinical studies and clinical trials of any other product candidates. The timing of the initiation and completion of these trials will therefore be
partially controlled by such third parties and may result in delays to our development programs. Specifically, we expect CROs, clinical investigators and consultants to play a significant role in the conduct of these trials and the subsequent
collection and analysis of data. However, we will not be able to control all aspects of their activities. Nevertheless, we are responsible for ensuring that each clinical trial is conducted in accordance with the applicable protocol and legal,
regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines
enforced by the FDA, for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our
CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA may require us to perform additional clinical trials before approving our marketing
applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing
approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and
resources to our development activities or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard
manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If our clinical trial site terminates for any reason, we may experience
the loss of <FONT STYLE="white-space:nowrap">follow-up</FONT> information on subjects enrolled in such clinical trial unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In
addition, clinical trial investigators for our clinical trial may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any
related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial
site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA. Any such delay or rejection could prevent us from commercializing
EQ001 or any future product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors for
whom they may also be conducting clinical trials or other biopharmaceutical product development activities that could harm our competitive position. If these third parties do not successfully carry out their contractual duties, meet expected
deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for EQ001 or any future product candidates and will not
be able to, or may be delayed in our efforts to, successfully commercialize our products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive marketing approval, we may not be able to
successfully commercialize EQ001 due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell EQ001 or any future product candidates profitably. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining coverage and adequate reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could
require us to provide supporting scientific, clinical and cost effectiveness data for the use of EQ001 or other future products to the payor. There may be significant delays in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA. Moreover, eligibility for
coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement
levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on
reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or
private payors, by any future laws limiting pharmaceutical prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Third-party payors often rely upon Medicare coverage
policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Decisions regarding the extent of coverage and amount of
reimbursement to be provided for any product candidates that we develop will be made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis. One payor&#146;s determination to provide coverage for a
drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor&#146;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be
approved. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a product is:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be sure that coverage or reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the
level of reimbursement will be. Obtaining adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a
physician. Similarly, because our product candidates are physician-administered injectables, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may be reimbursed for providing the
treatment or procedure in which our product is used. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse
effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reimbursement may impact the
demand for, and the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT
STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy and on what tier of its list of
covered drugs, or formulary, it will be placed. The position on a payor&#146;s formulary, generally determines the <FONT STYLE="white-space:nowrap">co-payment</FONT> that a patient will need to make to obtain the therapy and can strongly influence
the adoption of such therapy by patients and physicians. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs
associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement
is critical to new product acceptance. Coverage decisions may depend upon clinical and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to experience pricing pressures in connection with the sale of EQ001 or any future product candidates due to the trend toward managed healthcare, the
increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has
become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform
initiative may result in additional downward pressure on the price that we may receive for any approved product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our reliance on third parties requires us to
share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we rely on third parties to research and develop and to manufacture EQ001, we must share trade secrets with them. We seek to protect our proprietary technology
in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research
or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third
parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in
violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s independent discovery of our trade secrets or other unauthorized use
or disclosure would impair our competitive position and may have a material adverse effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, these agreements typically restrict the
ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that
we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development
or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our
third-party collaborators. A competitor&#146;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may wish to acquire rights to future assets through <FONT STYLE="white-space:nowrap">in-licensing</FONT> or may attempt to form collaborations in the future
with respect to future product candidates, but may not be able to do so, which may cause us to alter or delay our development and commercialization plans. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The development and potential commercialization of EQ001 and any future product candidates will require substantial additional capital to fund expenses. We may, in the
future, decide to collaborate with biotechnology companies for the development and potential commercialization of product candidates. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts
to establish a strategic partnership or other alternative arrangements for any product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view such product candidates
as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future
success of that product candidate to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions
of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the design or results of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the likelihood of approval by the FDA or comparable foreign regulatory authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential market for the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs and complexities of manufacturing and delivering such product candidate to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential of competing products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the existence of uncertainty with respect to our ownership of technology or other rights, which can exist if there is a
challenge to such ownership without regard to the merits of the challenge; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">industry and market conditions generally. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a
collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators. Collaborations are
complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and
changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product
candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake
development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which
may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our future product candidates or bring them to market and generate product revenue. Even if we are successful in our
efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development approval of a product candidate is delayed, the safety of a
product candidate is questioned or sales of an approved product candidate are unsatisfactory. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to obtain or protect intellectual property rights covering our product candidates, or if the scope of the intellectual property protection is not
sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and we may not be able to compete effectively in our market. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends in significant part on our and Biocon&#146;s ability to establish, maintain and protect patents and other intellectual property rights with respect
to our proprietary technologies, research programs, and product candidates, including EQ001 and operate without infringing the intellectual property rights of others. The patent prosecution process is expensive and time-consuming, and we and our
current or future licensors, licensees or partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current and future
licensors, licensees or partners will fail to identify patentable aspects of our research or inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Although we enter
into confidentiality agreements with parties who have access to patentable aspects of our research and development programs, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants,
independent contractors, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection on technology
relating to our research programs. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license
to third parties and are reliant on our licensors, licensees or partners. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our current or future
licensors, licensees or partners fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or partners are not fully cooperative or disagree with
us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. There may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of
much litigation, resulting in court decisions, including Supreme Court decisions, that have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to
the same extent as the laws of the United States, allowing foreign competitors a better opportunity to create, develop and market competing product candidates, or vice versa. We cannot be certain that the claims in our pending patent applications
directed to our product candidates such as EQ001 and others, as well as technologies relating to our research programs, will be considered patentable by the United States Patent and Trademark Office, or USPTO, or by patent offices in foreign
countries. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. As a result, the issuance, scope,
validity, enforceability and commercial value of our and our current or future licensors&#146;, licensees&#146; or partners&#146; patent rights are highly uncertain. Our and our licensors&#146;, licensees&#146; or partners&#146; pending and future
patent applications may not result in patents being issued, which protect our technology or products, in whole or in part, or their intended uses, methods of manufacture or formulations, or which effectively prevent others from commercializing
competitive technologies and products. The patent examination process may require us or our licensors, licensees or partners to narrow the scope of the claims of our or our licensors&#146;, licensees&#146; or partners&#146; pending and future patent
applications, which may limit the scope of patent protection that may be obtained. In the past, we have not always been able to obtain the full scope of patent protection we have initially sought in our patent applications, and as described above
and as is typical for most biotechnology patent prosecution, we have been required to narrow or eliminate patent claims as part of the patent prosecution process. In addition, some patent applications that we or our licensors have filed have not
resulted in issued patents because we or our licensors have abandoned those patent applications as changes in business and/or legal strategies dictated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot
assure you that all of the potentially relevant prior art&#151;information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention&#151;relating to our patents and patent
applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application, and we may be subject to a third party <FONT STYLE="white-space:nowrap">pre-issuance</FONT>
submission of prior art to the USPTO. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may an initiate litigation or opposition, interference,
<FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such
patents, which may result in the patent claims being narrowed or invalidated, may allow third parties to commercialize our product candidates and compete directly with us, without payment to us, or limit the duration of the patent protection of our
technology and products. The legal threshold for initiating such proceedings may be low, so that even proceedings with a low probability of success might be initiated. In addition, if the breadth or strength of protection provided by our patents and
patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Our and our licensors&#146;, licensees&#146; or
partners&#146; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the
technology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until
issued, we cannot be certain that we or our licensors were the first to file any patent application related to our research programs and product candidates such as EQ001. Even where we have a valid and enforceable patent, we may not be able to
exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the
United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is
limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are not able to obtain patent term extension in the United States under the Hatch-Waxman Act and in
foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for EQ001 or any other product candidates that we may identify, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before
or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek
extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act, which permits a
patent term extension of up to five years beyond the expiration of the patent. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review
process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing
it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However the applicable authorities, including the FDA and USPTO, in the United States, and any
equivalent foreign regulatory authority, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our
competitors may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of future protection for our proprietary rights is uncertain, and we cannot predict: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if and when patents may issue based on our patent applications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of protection of any patent issuing based on our patent applications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether the claims of any patent issuing based on our patent applications will provide protection against competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether any of the patents we own or license will be found to ultimately be valid and enforceable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether or not third parties will find ways to invalidate or circumvent our patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent
applications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether the patents of others will not have an adverse effect on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether we will develop additional proprietary technologies or products that are separately patentable
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which
will be costly whether we win or lose; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether the patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> will result in issued
patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We depend on
intellectual property licensed from Biocon and termination of our license could result in the loss of significant rights, which would harm our business. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
currently <FONT STYLE="white-space:nowrap">in-license</FONT> certain intellectual property that is important to our business from Biocon and, in the future, we may enter into additional agreements that provide us with licenses to valuable
intellectual property or technology. We rely to some extent on Biocon to file patent applications and to otherwise protect the intellectual property we license from them. We have limited control over these activities or any other intellectual
property that may be related to our <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. For example, we cannot be certain that such activities by Biocon have been or will be conducted in compliance with applicable laws and
regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which Biocon initiates an infringement proceeding against a third-party infringer of the intellectual
property rights, or defend certain of the intellectual property that is licensed to us. It is possible that our licensor&#146;s infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be subject to a reservation of rights by
one or more third parties. Further, our existing license with Biocon imposes, and future agreements may also impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations,
we may be required to pay damages and our licensor may have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed intellectual property and our competitors or other third
parties might be able to gain access to technologies and products that are identical to ours. Our business would suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to
enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any current or
future licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our
licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#146;s rights. Disputes may also
arise between us and our licensor regarding intellectual property subject to a license agreement, including those relating to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not
subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to
our development and commercialization of our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the allocation of ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and by us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, intellectual property or technology license
agreements, including our existing agreements, are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we
believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our
business, financial condition, results of operations, and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to
successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which
are described below. If we or our licensor fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because our
programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights. We may be unable
to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing
and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider
attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party
intellectual property rights on terms that would allow us to make an appropriate return on our investment. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future
products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we
successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>In the future, we may need to obtain additional licenses of third-party technology that may not be available to
us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time we may be required to license technologies relating to our therapeutic research programs from additional third parties to further develop or
commercialize our product candidates such as EQ001 and/or others. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not
be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously
harm our business and operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our
ability to develop and commercialize our products. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any future collaborations that we enter into may not be successful. The success of our collaboration
arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew
development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts
resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly
with our products or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient
resources to or otherwise not perform satisfactorily in carrying out these activities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or
proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or
commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable current or future products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our products that
results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator&#146;s sales and marketing activities or other operations may not be in compliance with applicable laws
resulting in civil or criminal proceedings. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance,
scope or expiration of a third party patent, which might adversely affect our ability to develop and market our products. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot assure you that our
operations do not, or will not in the future, infringe existing or future patents. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of
relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the United States and abroad that is relevant to our therapeutic research programs or necessary
for the commercialization of our product candidates such as EQ001 and/or others in any jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third
parties, and there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of EQ001 that we may identify. Our competitors in both the
United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents
that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the
United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will
not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or
applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. As such,
there may be applications of others now pending or recently revived patents of which we are unaware, potentially relating to our research programs and product candidates such as EQ001 and others, or their intended uses. These applications may later
result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#146;s prosecution history. Our
interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third party
patent or may incorrectly predict whether a third party&#146;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be
incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot provide any assurances that third party patents do not exist which might be enforced against our current technology, including our research programs, product
candidates, which include EQ001 and others, their respective methods of use, manufacture and formulations thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an
obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are sued for infringing
intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell EQ001 and other potential future product candidates without infringing
the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims,
with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel
from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it
could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales,
marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more
effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a
material adverse effect on our ability to compete in the marketplace. We cannot assure you that our operations do not, or will not in the future, infringe existing or future patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries,
and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. Our competitors in both the United States and abroad, many of which have
substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise
interfere with our ability to make, use and sell our product candidates. Third parties may assert infringement claims against us based on existing or future intellectual property rights. The pharmaceutical and biotechnology industries have produced
a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the
interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims
are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of
validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could
have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. Furthermore, because of the substantial amount of discovery required in connection
with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are found to infringe a third party&#146;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or
commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing
product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our
competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement
could prevent us from commercializing our product candidates or force us to cease some of our business operations, and could divert the time and attention of our technical personnel and management, cause development delays, and/or require us to
develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be possible on a cost-effective basis, which could materially harm our business. Claims that we have misappropriated the confidential information or trade
secrets of third parties could have a similar negative impact on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce our patents or other
intellectual property, which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors may infringe our patents, trademarks, copyrights or other
intellectual property that relate to our current and future product candidates, including EQ001 and others, their respective methods of use, manufacture and formulations thereof. To counter infringement or unauthorized use, we or our licensor may be
required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we or our licensor assert against perceived infringers could provoke these
parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace, and the outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a
patent that we own or have licensed is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is
upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome
in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or
competitive products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be
necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. For
example, an unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially
reasonable terms or at all, or if a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and,
even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to
continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring EQ001 or other product candidates that we may identify to market. Any of
these occurrences could adversely affect our competitive business position, results of operations business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have
asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which
may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by
disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a
material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are
concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent relating to our research programs and
product candidates, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the
best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or
solution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information
of third parties. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We employ individuals who previously worked with other companies, including our competitors or potential competitors. We could in the
future be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of current or former employers or competitors.
Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we
may become subject to claims that we caused an individual to breach the terms of his or her <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, or that we or these
individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a current or former employer or competitor. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to
management and other employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, including EQ001,
if such technologies or features are found to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
incorporate or be derived from the trade secrets or other proprietary information of the current or former employers. Moreover, any such litigation or the threat thereof may adversely affect our
reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and
financial condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect our product candidates. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual
property, particularly patents relating to our research programs and product candidates. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and
inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or USPTO rules and regulations could increase the uncertainties and costs. Recent patent reform legislation in the United States and
other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September&nbsp;16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement
or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and
cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO
administered post-grant proceedings, including post-grant review, <I>inter partes </I>review, and derivation proceedings. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which,
assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However, the
Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. Supreme Court has ruled on several patent cases
in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the
relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing
patents and patents that we might obtain in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting and defending all current and future patents in all countries throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the
United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or
other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent
protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it
difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to
third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Proceedings to enforce our
patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in
any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with
various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these
requirements. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to
be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are
situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT>
events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and
failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our research programs and product candidates such as EQ001 and others as well as their respective methods of use,
manufacture and formulations thereof, our competitive position would be adversely affected, as, for example, competitors might be able to enter the market earlier than would otherwise have been the case. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may rely on trade secret and proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> which can be difficult to trace and enforce and, if we are unable to
protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to seeking patents for some of our
technology and product candidates, we may also rely on trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position with respect to our
research programs and product candidates. Elements of our product candidates, including processes for their preparation and manufacture, may involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not
covered by patents, and thus for these aspects we may consider trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the
employees of third parties with whom we share our facilities or third party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a
cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We require our employees to enter into written employment agreements
containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with whom we share facilities enter into written agreements that include confidentiality
and intellectual property obligations to protect each party&#146;s property, potential trade secrets, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> and information. We further seek to protect our potential trade secrets, proprietary <FONT
STYLE="white-space:nowrap">know-how,</FONT> and information in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who are given access to them, such as our corporate
collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention
assignment obligations. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that
competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Moreover, despite these efforts, any of these parties may breach the agreements and disclose our
proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our
proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
aspects of our products that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the
outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Trade secrets may
be independently developed by others in a manner that could prevent legal recourse by us. Trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of
personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators, licensors, suppliers, third-party
contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. Because from time to time we expect to rely on third parties in the development, manufacture, and
distribution of our products and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that
such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of our trade secrets were to be lawfully obtained or independently
developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or
other third party, our competitive position would be harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become subject to claims challenging the inventorship or ownership of our patents and
other intellectual property. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We or our licensor may be subject to claims that former employees, consultants, independent contractors, collaborators or
other third parties have an interest in our patents or other intellectual property as an owner, <FONT STYLE="white-space:nowrap">co-owner,</FONT> inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper
inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign
laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding <FONT
STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to
clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use,
valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and
other employees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patent rights are of limited duration. In the United States, the natural expiration of a patent is generally 20 years after its first effective <FONT
STYLE="white-space:nowrap">non-provisional</FONT> filing date. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after
such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. A patent term extension
based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the
period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing
the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy
applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened
and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently do not own any registered trademarks. Our current or future
trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop
using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those
rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel
registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may
not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and
trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the
patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued
patent or pending patent application that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of
our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal
challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then
use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are highly dependent on the services of our key personnel. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are
highly dependent on the services of our key personnel, Daniel M. Bradbury, who serves as our Chief Executive Officer, Bruce D. Steel, who serves as our President and Chief Business Officer, Krishna R. Polu, M.D., who serves as our Chief Medical
Officer, and Stephen Connelly, Ph.D., who serves as our Chief Scientific Officer. Although we have entered into agreements with them regarding their employment, they are not for a specific term and each of them may terminate their employment with us
at any time, though we are not aware of any present intention of either of these individuals to leave us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter
difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2018, we had seven full-time employees. As we advance EQ001
into clinical development, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, quality, regulatory affairs and, if EQ001 or any future product
candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identify, recruit integrate, maintain and motivate additional qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identify and lease additional facilities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manage our development efforts effectively, including the initiation and conduct of clinical trials for EQ001 and any
future product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">improve our operational, financial and management controls, reporting systems and procedures. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future financial performance and our ability to develop, manufacture and commercialize EQ001 and any future product candidates will depend, in part, on our ability
to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a substantial amount of time, to managing these growth activities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain third party contract organizations, advisors and consultants to
provide certain services, including assuming substantial responsibilities for the conduct of our planned clinical trials and the manufacture of EQ001 and any future product candidates. We cannot assure you that the services of such third party
contract organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the
quality or accuracy of the services provided by our vendors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of our product candidates or
otherwise advance our business. We cannot assure you that we will be able to properly manage our existing vendors or consultants or find other competent outside vendors and consultants on economically reasonable terms, or at all. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not able to effectively expand our organization by leasing additional facilities, hiring new employees and expanding our groups of consultants and
contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize EQ001 and any future product candidates and, accordingly, may not achieve our research, development and commercialization goals. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our industry has experienced a high rate of turnover in recent years. Our ability to compete in the highly competitive biopharmaceuticals industry depends upon our
ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing and management skills and experience. We conduct our operations in the Greater San Diego Area and the San Francisco
Bay Area, regions that are home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. We may not be able to attract or retain qualified personnel in the
future due to the intense competition for a limited number of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we compete have greater financial and other resources, different risk
profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors may limit our ability to
continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize EQ001 or any future product candidates and to grow our business and operations as currently contemplated. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial partners
may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial
partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i)&nbsp;FDA laws and regulations or those of comparable foreign regulatory authorities,
including those laws that require the reporting of true, complete and accurate information, (ii)&nbsp;manufacturing standards, (iii)&nbsp;federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency
reporting requirements, and other healthcare laws and regulations in the United States and abroad, (iv)&nbsp;sexual harassment and other workplace misconduct, or (v)&nbsp;laws that require the true, complete and accurate reporting of financial
information or data. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We intend to adopt a code of
conduct applicable to all of our employees prior to completion of this offering, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with
these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of
significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare, Medicaid and other federal healthcare programs, contractual
damages, reputational harm, diminished profits and future earnings, additional integrity reporting and oversight obligations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our
business and our results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our internal information technology systems, or those of our third-party CROs or other contractors or consultants,
may fail or suffer security breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our development programs, compromise sensitive information related to our business or prevent us from accessing
critical information, potentially exposing us to liability or otherwise adversely affecting our business. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are increasingly dependent upon information
technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information
and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage
a number of third party contractors who have access to our confidential information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the implementation of security measures, given their size and
complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are potentially vulnerable to breakdown or
other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees,
contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information),
which may compromise our system infrastructure or lead to data leakage. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or
proprietary information, we could incur liability and reputational damage and the further development and commercialization of EQ001 or any future product candidates could be delayed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we have not experienced any such system failure, accident or security breach to date, we cannot assure you that our data protection efforts and our investment in
information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if
such an event were to occur and cause </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
interruptions in our operations, it could result in a material disruption of our programs and the development of EQ001 or any future product candidates could be delayed. In addition, the loss of
clinical trial data for EQ001 or any future product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal
information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other
intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of
personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject
us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational
damages that could potentially have an adverse effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Failure to comply with health and data protection laws and regulations could lead to
government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and any potential collaborators may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy
and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer
protection laws (e.g., Section&nbsp;5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we
may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the federal Health Insurance Portability and Accountability Act
of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose
individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of May&nbsp;25,
2018, the General Data Protection Regulation, or GDPR, has replaced the Data Protection Directive with respect to the processing of personal data in the European Union. The GDPR imposes several stringent requirements for controllers and processors
of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data
breach notifications, limitations on retention and secondary use of information, increased requirements pertaining to health data and pseudonymised (i.e., <FONT STYLE="white-space:nowrap">key-coded)</FONT> data and additional obligations when we
contract third party processors in connection with the processing of the personal data. The GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of genetic, biometric or health data,
which could limit our ability to use and share personal data or could cause our costs could increase, and harm our business and financial condition. Failure to comply with the requirements of GDPR and the applicable national data protection laws of
the European Union member states may result in fines of up to <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other
administrative penalties. To comply with the new data protection rules imposed by GDPR we may be required to put in place additional mechanisms ensuring compliance. This may be onerous and adversely affect our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">European data protection law also imposes strict rules on the transfer of personal data out of the European Union, including to the
United States. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. In addition, these rules are constantly under scrutiny. For
example, following a decision of the Court of Justice of the European Union in October 2015, transferring personal data to U.S. companies that had certified as members of the U.S. Safe Harbor Scheme was declared invalid. In July 2016 the European
Commission adopted the <FONT STYLE="white-space:nowrap">U.S.-EU</FONT> Privacy Shield Framework which replaces the Safe Harbor Scheme. However, this Framework is under review and there is currently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
litigation challenging other E.U. mechanisms for adequate data transfers (i.e., the standard contractual clauses). It is uncertain whether the Privacy Shield Framework and/or the standard
contractual clauses will be similarly invalidated by the European courts. We rely on a mixture of mechanisms to transfer personal data from our E.U. business to the United States, and could be impacted by changes in law as a result of a future
review of these transfer mechanisms by European regulators under the GDPR, as well as current challenges to these mechanisms in the European courts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, the
United Kingdom&#146;s vote in favor of exiting the European Union, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear whether the United Kingdom will
enact data protection legislation equivalent to the GDPR and how data transfers to and from the United Kingdom will be regulated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Compliance with U.S. and
international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain
jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and
could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our
ability to use and disclose the information. Claims that we have violated individuals&#146; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and
time-consuming to defend and could result in adverse publicity that could harm our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We or the third parties upon whom we depend may be adversely
affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our headquarters and main research facility are located in the Greater San Diego Area, which in the past has experienced severe earthquakes and fires. If these
earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases,
impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or
third party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our
supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our
ability to conduct our clinical trials, our development plans and business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. federal income tax reform could adversely affect us. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;22, 2017, President Trump signed into law new legislation that significantly revises the Internal Revenue Code of 1986, as amended. The newly enacted
federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense
to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses generated after December&nbsp;31, 2017 to 80% of current year taxable income and elimination of net operating loss carrybacks,
one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of
deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. We do not expect this tax legislation to have a material impact to our current projection of minimal cash taxes for the near future.
However, we continue to examine the impact that this tax legislation may have on our business in the longer term. Accordingly, notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain
and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law. The impact of this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
tax legislation on holders of our common stock is also uncertain and could be adverse. We urge prospective investors to consult with their legal and tax advisors with respect to this legislation
and the potential tax consequences of investing in or holding our common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Product liability lawsuits against us could cause us to incur substantial
liabilities and could limit our commercialization of any product candidates that we may develop. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We face an inherent risk of product liability exposure
related to the testing of EQ001 and any future product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that
EQ001 or any future product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delay or termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">decreased demand for any product candidates or products that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of clinical trial subjects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">significant costs to defend the related litigation and diversion of management&#146;s time and our resources;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">substantial monetary awards to study subjects or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product recalls, withdrawals or labeling, or marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">loss of revenue; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently have product liability insurance but intend to obtain it before we initiate our first clinical trials. However, the amount of insurance that we
obtain may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as EQ001 and any future product candidates advance through clinical trials and if we successfully commercialize
any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict
and may have a significant adverse effect on our business and results of operations. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been, and continue to be, several legislative and
regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product
candidates for which we obtain marketing approval. Among policy makers and payors in the United States there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality
and/or expanding access and the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act,
substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act, among other things: (i)&nbsp;introduced a new average manufacturer
price definition for drugs and biologics that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies; (ii)&nbsp;increased the minimum Medicaid rebates owed by manufacturers under the
Medicaid Drug Rebate Program and expanded rebate liability from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> Medicaid utilization to include the utilization of Medicaid managed care organizations as
well; (iii)&nbsp;established a branded prescription drug fee that pharmaceutical manufacturers of branded prescription drugs must pay to the federal government; (iv)&nbsp;expanded the list of covered entities eligible to participate in the 340B drug
pricing program by adding new entities to the program; (v)&nbsp;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts (which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
through subsequent legislative amendments, will be increased to 70% from 50% starting in 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap
period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; (vi)&nbsp;extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed
care organizations; (vii)&nbsp;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, including individuals with income at or below 133% of the federal
poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; (viii)&nbsp;created a licensure framework for follow-on biologic products; and (ix)&nbsp;established a Center for Medicare and Medicaid Innovation at the
Centers for Medicare and Medicaid Services (CMS) to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since its
enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the Affordable Care Act. For example, the
Tax Cuts and Jobs Act of 2017 was enacted, which includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; Since the enactment of the Tax Cuts and Jobs Act of 2017, there have been additional amendments
to certain provisions of the Affordable Care Act, and we expect the current Trump administration and Congress will likely continue to seek to modify, repeal or otherwise invalidate all, or certain provisions of, the Affordable Care Act. It is
uncertain the extent to which any such changes may impact our business or financial condition. Congress may consider other legislation to repeal and replace elements of the Affordable Care Act. We continue to evaluate the effect that the Affordable
Care Act and its possible repeal and replacement has on our business. It is uncertain the extent to which any such changes may impact our business or financial condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to
providers of 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and will remain in effect through 2027, unless additional Congressional action is taken. In January 2013, the American Taxpayer
Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our
products and, accordingly, the results of our financial operations. Also, there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which have resulted in
several Congressional inquiries and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration&#146;s budget proposal for fiscal year 2019 contains further drug price
control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some
states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. Further, the Trump administration released a &#147;Blueprint,&#148; or plan, to lower
drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list
price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some of these measures and, at the same,
is immediately implementing others under its existing authority. While some proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will
continue to seek new legislative and/or administrative measures to control drug costs. Most recently, the Trump administration released a &#147;Blueprint,&#148; or plan, to reduce the cost of drugs. The Trump administration&#146;s Blueprint contains
certain measures that the U.S. Department of Health and Human Services is already working to implement. At the state level, individual states in the United States are increasingly active in passing legislation and implementing regulations designed
to control pharmaceutical and biological product pricing, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to
encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that these and other healthcare reform measures that may be adopted in the future, may
result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result
in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing
approval is obtained. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will be subject to applicable foreign, federal and state fraud and abuse, transparency, government price reporting, and other
healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Healthcare
providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any future product candidates for which we obtain marketing approval. Our arrangements with
<FONT STYLE="white-space:nowrap">third-party</FONT> payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may affect the business or financial arrangements and relationships through
which we would market, sell and distribute our products. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and
regulations pertaining to fraud and abuse and patients&#146; rights are and will be applicable to our business. The laws that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully
soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service
reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has also been
interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other the other hand. There are a number of statutory exceptions and regulatory safe harbors
protecting some common activities from prosecution. Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act such that a person or entity no longer needs to have actual knowledge of the statute or
specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false
or fraudulent claim for purposes of the federal False Claims Act, or FCA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the FCA, which imposes significant
penalties and can be enforced by private citizens through civil qui tam actions, prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment or
approval by the federal government, including federal health care programs, such as Medicare and Medicaid, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or knowingly
making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a
false or fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. In
addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. Criminal prosecution is also possible
for making or presenting a false, fictitious or fraudulent claim to the federal government. Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety
of alleged promotional and marketing activities, such as providing free product to customers with the expectation that </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
the customers would bill federal programs for the product, providing consulting fees and other benefits to physicians to induce them to prescribe products, engaging in promotion for <FONT
STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses, and submitting inflated best price information to the Medicaid Rebate Program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any
healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully
falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, in connection with the delivery of or payment for healthcare benefits, items or services. Like the
Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in
order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, as amended by HITECH and its implementing regulations, which imposes privacy, security and breach reporting
obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers and their respective business associates that perform
services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state
attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the U.S. federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of
drugs, biologics and medical devices; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Public Health Service Act, which prohibits, among other things, the introduction of a biological product into
interstate commerce without an approved BLA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal transparency requirements under the Physician Payments Sunshine Act, created under the Affordable Care Act,
which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to annually report to HHS information related to
payments and other transfers of value provided to physicians and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#146;s immediate family members;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may
impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by any <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">state and foreign laws that require pharmaceutical companies to implement compliance programs and comply with the
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; track and report gifts, compensation and other remuneration provided to physicians, other health care
providers, and certain health care entities; and/or ensure the registration and compliance of sales and medical personnel. In addition, we may be subject to federal, state and foreign laws that govern the privacy and security of health information
or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal
information, many of which differ from each other in significant ways and often are not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of
EQ001 and any future product candidates, if approved. Because of the complex and <FONT STYLE="white-space:nowrap">far-reaching</FONT> nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be
restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
providers who may influence the ordering of and use of EQ001 or any future product candidates, if approved, to be in violation of applicable laws. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement
bodies have recently increased their scrutiny of interactions between healthcare companies, healthcare providers and other third parties, including charitable foundations, which has led to a number of investigations, prosecutions, convictions and
settlements in the healthcare industry. It is possible that governmental authorities may conclude that our business practices, including our consulting arrangements with physicians, some of whom receive stock options as compensation for services
provided, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. Responding to investigations can be time and resource-consuming and can divert management&#146;s attention from
the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ensuring that our business
arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. If our operations are found to be in violation of any of these laws or any other current or future governmental laws and regulations that
may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual
damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or
entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to certain U.S. and certain foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can
face serious consequences for violations. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and
regulations, collectively, Trade Laws, prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting,
or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment,
the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or
government-affiliated hospitals, universities, and other organizations. We also expect our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase over time. We expect to rely on third parties for research, preclinical studies, and
clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly
authorize or have prior knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax
reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Requirements associated with being a public company will
increase our costs significantly, as well as divert significant company resources and management attention. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of this offering, we will
be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or the other rules and regulations of the Securities and Exchange Commission, or the SEC, or any securities exchange relating to public
companies. Sarbanes-Oxley, as well as rules subsequently adopted by the SEC, and The Nasdaq Global Market to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and
maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
regulations in these areas, such as mandatory &#147;say on pay&#148; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current
political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we
operate our business in ways we cannot currently anticipate. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management. We cannot assure you that we will
satisfy our obligations as a public company on a timely basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect the rules and regulations applicable to public companies to substantially increase our
legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on
our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or
services. In addition, as a public company, it may be more difficult or more costly for us to obtain certain types of insurance, including directors&#146; and officers&#146; liability insurance, and we may be forced to accept reduced policy limits
and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our board of directors, our board
committees or as executive officers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or
penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, and the third parties with whom we share our
facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our
operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of
these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us
or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of
hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or
disposal of biological, hazardous or radioactive materials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may incur substantial costs in order to comply with current or future environmental,
health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to our Common Stock and this Offering </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>There has been no
prior public market for our common stock, the stock price of our common stock may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price.
</I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There has been no public market for our common stock prior to this offering. The initial public offering price for our common stock will be determined
through negotiations between the underwriters and us and may vary from the market price of our common stock following this offering. If you purchase shares of our common stock in this offering, you may not be able to resell those shares at or above
the initial public offering price. An active or liquid market in our common stock may not develop upon the completion of this offering or, if it does develop, it may not be sustainable. The market price of our common stock may fluctuate
significantly in response to numerous factors, many of which are beyond our control, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our operating performance and the performance of other similar companies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to enroll subjects in our ongoing and planned clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">results from our planned clinical trials and future clinical trials with our current and future product candidates or of
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes
in recommendations by securities analysts that elect to follow our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of expenses related to future product candidates or clinical development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to achieve product development goals in the timeframe we announce; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements of clinical trial results, regulatory developments, acquisitions, strategic alliances or significant
agreements by us or by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success or failure of our efforts to acquire, license or develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the economy as a whole and market conditions in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the expiration of market standoff or contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size of our market float; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any other factors discussed in this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities
of many life sciences companies. Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class action
litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our
business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations
or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we can generate substantial product revenues, we
expect to finance our cash needs through a combination of equity offerings, debt financings, collaboration and license agreements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your
ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we raise
funds through collaboration and license agreements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be
favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop
and market product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Substantial amounts of our outstanding shares may be sold into
the market when <FONT STYLE="white-space:nowrap">lock-up</FONT> or market standoff periods end. If there are substantial sales of shares of our common stock, the price of our common stock could decline. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant
stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. After this offering, we will have outstanding shares of our common stock, based on the number of shares
outstanding as of June&nbsp;30, 2018. All of the shares of common stock sold in this offering will be available for sale in the public market. Substantially all of our outstanding shares of common stock are currently restricted from resale as a
result of market standoff and <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
as more fully described in &#147;Shares Eligible for Future Sale.&#148; These shares will become available to be sold 181 days after the date of this prospectus. Shares held by directors,
executive officers and other affiliates will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the Securities Act, and various vesting agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After our initial public offering, certain of our stockholders will have rights, subject to some conditions, to require us to file registration statements covering
their shares or to include their shares in registration statements that we may file for ourselves or our stockholders, subject to market standoff and lockup agreements. We also intend to register shares of common stock that we have issued and may
issue under our employee equity incentive plans. Once we register these shares, they will be able to be sold freely in the public market upon issuance, subject to existing market standoff or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements. Jefferies LLC and Leerink Partners LLC may, in their discretion, permit our stockholders to sell shares prior to the expiration of the restrictive provisions contained in those <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public market
or the perception in the market that the holders of a large number of shares intend to sell their shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If you purchase shares of our common stock in this
offering, you will experience substantial and immediate dilution. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase shares of our common stock in this offering, you will experience
substantial and immediate dilution in the pro forma net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share as of June&nbsp;30, 2018, based on an assumed initial
public offering price of our common stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range on the cover page of this prospectus, because the price that you
pay will be substantially greater than the pro forma net tangible book value per share of the common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the initial public
offering price when they purchased their shares of our capital stock. You will experience additional dilution upon exercise of options to purchase common stock under our equity incentive plans, upon vesting of options to purchase common stock under
our equity incentive plans, if we issue restricted stock to our employees under our equity incentive plans or if we otherwise issue additional shares of our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will have broad discretion in the use of the net proceeds of this offering and may not use them effectively or in ways that increase the value of our share
price. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot specify with any certainty the particular uses of the net proceeds that we will receive from this offering, but we currently expect such
uses will include funding research and development of EQ001 and working capital and other general corporate purposes, including the additional costs associated with being a public company. We will have broad discretion in the application of the net
proceeds, including working capital and other general corporate purposes, and you and other stockholders may disagree with how we spend or invest these proceeds. The failure by our management to apply these funds effectively could adversely affect
our business and financial condition. Pending their use, we may invest the net proceeds from our initial public offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our
investors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and
trading volume could decline. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts
publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us,
the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely
decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and
procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the
control system are met. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of
simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be
circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may
occur and not be detected. In addition, we do not have a risk management program or processes or procedures for identifying and addressing risks to our business in other areas. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an &#147;emerging growth company,&#148; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make
our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012,
as amended, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to hold a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation
or obtain stockholder approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, as an &#147;emerging growth company&#148;
the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. We have elected to use this extended transition period under the
JOBS Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common
stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We
will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at least
$1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior
June 30th and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not intend to pay dividends for the foreseeable future. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have never declared nor paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
dividends in the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Consequently, stockholders must rely on sales of their common
stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The concentration of our stock
ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based upon shares outstanding as of June&nbsp;30, 2018, our executive officers, directors and the holders of more than 5% of our outstanding common stock, in the
aggregate, beneficially owned approximately 98.9% of our common stock, and upon the completion of this offering, that same group, in the aggregate, will beneficially own approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our common stock, assuming that
these holders do not purchase any shares in this offering, no exercise by the underwriters of their option to purchase additional shares, no exercise of outstanding options or warrants and after giving effect to the issuance of shares in this
offering. As a result, these stockholders, acting together, will have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate
actions might be taken even if other stockholders, including those who purchase shares in this offering, oppose them. This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other
stockholders may view as beneficial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws
that will be in effect at the completion of this offering could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the
completion of this offering, respectively, may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for
their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of
incorporation and amended and restated bylaws: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and
privileges as they may designate (including the right to approve an acquisition or other change in our control); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that the authorized number of directors may be changed only by resolution of the board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of
the holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of all of our then outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by
the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">divide our board of directors into three classes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of
stockholders and not be taken by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for
election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock
entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive
Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&nbsp;any
derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the Delaware General
Corporation Law or our certificate of incorporation or bylaws, or (iv)&nbsp;any action asserting a claim against us governed by the internal affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights,
preferences and privileges thereto, would require approval by the holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of our then-outstanding common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, as a Delaware corporation, we are subject to Section&nbsp;203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in
particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of
incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These
and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate
actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and
limit opportunities for you to realize value in a corporate transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For information regarding these and other provisions, see &#147;Description of Capital
Stock.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for
substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action
or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws or any action
asserting a claim against us that is governed by the internal affairs doctrine. This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees and may discourage these types of lawsuits. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an
action, we may incur additional costs associated with resolving such action in other jurisdictions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We could be subject to securities class action
litigation. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of
management&#146;s attention and resources, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled &#147;Prospectus Summary,&#148;
&#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business.&#148; These statements relate to future events or to our future financial performance and involve
known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements. Forward-looking statements include, but are not limited to, statements about: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our plans to research, develop and commercialize EQ001 and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain regulatory approval of EQ001 in any of the indications for which we plan to develop it;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain funding for our operations, including funding necessary to commence and complete the clinical trials
of EQ001; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success, cost, and timing of our product development activities, including our planned clinical trials of EQ001;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size of the markets for our product candidates, and our ability to serve those markets; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to successfully commercialize EQ001; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rate and degree of market acceptance of EQ001; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future
collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory developments in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the performance of our third-party service providers, including Biocon and other suppliers and manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the safety, efficacy and market success of competing therapies that are or become available; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to attract and retain collaborators with development, regulatory and commercialization expertise;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our use of the proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional
financing; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection for EQ001 and our ability
to operate our business without infringing on the intellectual property rights of others. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some cases, you can identify these statements by
terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expects,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;should,&#148; &#147;will,&#148; &#147;would&#148; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. These forward-looking statements reflect our management&#146;s beliefs and views
with respect to future events and are based on estimates and assumptions as of the date of this prospectus and are subject to risks and uncertainties. In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and
opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or
incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not
to unduly rely upon these statements. We discuss many of the risks associated with the forward-looking statements in this prospectus in greater detail under the heading &#147;Risk Factors.&#148; Moreover, we operate in a very competitive and rapidly
changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should carefully read this prospectus and the documents that we reference in this prospectus and have filed as
exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in
this prospectus by these cautionary statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to
update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that we will receive net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
(or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters&#146; option to purchase additional shares is exercised in full) from the sale of the shares of common
stock offered by us in this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the
cover page of this prospectus), and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00
increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this
prospectus) would increase (decrease) the net proceeds to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by
us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a one million share increase (decrease) in the
number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) remains the same,
and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The principal purposes of this offering are to
obtain additional capital to support our operations, to create a public market for our common stock and to facilitate our future access to the public equity markets. We anticipate that we will use the net proceeds of this offering as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $50.0&nbsp;million to fund research and development of EQ001; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the remainder for working capital and other general corporate purposes, including the additional costs associated with
being a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also use a portion of the net proceeds from this offering to <FONT STYLE="white-space:nowrap">in-license,</FONT>
acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current plans, commitments or obligations to do so. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
believe that the net proceeds from this offering and our existing cash and cash equivalents, together with interest thereon, will be sufficient to fund our currently planned operations for at least the next 24 months, although there can be no
assurance in that regard. In particular, we expect that the net proceeds from this offering will allow us to fund a Phase 1b/2 clinical trial of EQ001 for aGVHD, a Phase 2 clinical trial of EQ001 for cGVHD and a proof-of-concept clinical trial of
EQ001 for severe asthma. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition.
As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering, or the amounts that we will actually spend on the uses set forth above. The
amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including the progress, cost and results of our preclinical and clinical development programs, our ability to obtain additional financing, and other
factors described under &#147;Risk Factors&#148; in this prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs. We may find it necessary or advisable to use the net proceeds for other purposes, and our
management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending their use, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments,
certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our
operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our
board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant, and subject
to the restrictions contained in any future financing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and our capitalization as of June&nbsp;30, 2018 as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma basis to reflect (1)&nbsp;the conversion of $9.4&nbsp;million of aggregate principal amount, plus accrued
interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
our common stock based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this
prospectus), and assuming the occurrence of the conversion on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, (2) the issuance by us
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such
issuance, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this
prospectus), and (3)&nbsp;the filing of our amended and restated certificate of incorporation immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma as adjusted basis to give further effect to our issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pro forma and pro forma as adjusted information below is illustrative only, and
our cash and cash equivalents and capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in
conjunction with our financial statements and the related notes included in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section and other financial information
contained in this prospectus. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF JUNE&nbsp;30, 2018</B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO</B><br><B>FORMA</B><br><B>AS<BR>ADJUSTED<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,626,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible promissory notes, including related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,517,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.0001 par value; 5,000,000 shares authorized at June&nbsp;30, 2018 (unaudited);</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">1,273,291 shares issued and outstanding as of June&nbsp;30, 2018, which includes 31,055 shares of
restricted common stock subject to a right of repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,604,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,593,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,924,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range
set forth on the cover page of this prospectus) would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and
total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains
the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of one million shares in the number of shares offered by us at the assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) each of
cash and cash equivalents, additional paid-in capital, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) would decrease the number of shares of our common stock
issued on conversion of our convertible promissory notes and issued to Biocon (and therefore the number of shares to be outstanding after this offering)
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. A $1.00 decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase the number of shares of our common stock
issued on conversion of our convertible promissory notes and issued to Biocon (and therefore the number of shares to be outstanding after this offering)
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares<B>. </B>Because the closing date of this offering will occur
after&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, the convertible promissory notes will continue to accrue interest at a rate of 6% per annum and additional shares of our common stock will
be issued upon conversion of this additional accrued interest. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares in the table above excludes, as of June&nbsp;30, 2018: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">12,423 shares of common stock issuable upon the exercise of outstanding options as of June&nbsp;30, 2018, each at an
exercise price of $0.35 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future
issuance under our 2018 Plan which will become effective upon the execution and delivery of the underwriting agreement for this offering (including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock reserved for issuance under our 2017 Plan which shares will be added to the shares reserved under the 2018 Plan upon its effectiveness); and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for issuance
under the ESPP, which will become effective upon the execution and delivery of the underwriting agreement for this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_7"></A>DILUTION </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
June&nbsp;30, 2018, we had a historical net tangible book deficit of $(5.6) million, or $(4.39) per share of common stock. Our historical net tangible book deficit per share represents the amount of our total tangible assets less total liabilities,
divided by the total number of shares of common stock outstanding (including 31,055 shares of restricted common stock which are subject to a right of repurchase by us as of June&nbsp;30, 2018) at June&nbsp;30, 2018. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving effect to the (i)&nbsp;conversion of $9.4&nbsp;million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which
will automatically convert upon the completion of this offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock based on an assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the
conversion on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, and (ii)&nbsp;the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), our pro forma net tangible book value as of June&nbsp;30,
2018 is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving further effect to the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that we
are offering at the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), and
after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2018 is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This amount
represents an immediate increase in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and an immediate dilution in pro forma
net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors participating in this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public
offering price per share paid by new investors. The following table illustrates this dilution: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Historical net tangible book deficit per share at June&nbsp;30, 2018, before giving effect to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma increase in historical net tangible book value per share attributable to conversion of
convertible promissory notes and issuance of shares of common stock pursuant to anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value per share at June&nbsp;30, 2018, before giving effect to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in pro forma net tangible book value per share attributable to investors participating in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) the pro forma as adjusted net
tangible book value per share after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and dilution in pro forma net tangible book value per share to new investors by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An increase of one million shares in the number of shares offered by us, as set forth on the cover page of this
prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and decrease the dilution to
investors participating in this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial public offering price remains the same, and after
deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. Similarly, a decrease of one million shares in the number of shares offered by us, as set forth on the cover page of this prospectus,
would decrease the pro forma as adjusted net tangible book value per share after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and increase the dilution to investors
participating in this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial public offering price remains the same, and after deducting
the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise their option to purchase
additional shares of our common stock in full in this offering, the pro forma as adjusted net tangible book value after the offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution per share to new
investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, in each case assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes on a pro forma as adjusted basis as of June&nbsp;30, 2018, the number of shares of common stock purchased or to be purchased from us, the
total consideration paid or to be paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The calculation below is based on
the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), before
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. As the table below shows, investors participating in this offering will pay an average price per share substantially higher than our
existing stockholders paid. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL&nbsp;CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AVERAGE<BR>PRICE&nbsp;PER<BR>SHARE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) total consideration paid by new
investors, total consideration paid by all stockholders and the average price per share paid by all stockholders by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively, assuming the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, a one million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease)
the total consideration paid by investors participating in this offering, total consideration paid by all stockholders and the average price per share paid by all stockholders by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively, assuming the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) remains the same, and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing tables and calculations exclude: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">12,423 shares of common stock issuable upon the exercise of outstanding options as of June&nbsp;30, 2018, each at an
exercise price of $0.35 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future
issuance under our 2018 Plan which will become effective upon the execution and delivery of the underwriting agreement for this offering (including shares of common stock reserved for issuance under our 2017 Plan which shares will be added to the
shares reserved under the 2018 Plan upon its effectiveness); and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under
the ESPP, which will become effective upon the execution and delivery of the underwriting agreement for this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may choose to raise
additional capital through the sale of equity or convertible debt securities due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent we issue
additional shares of common stock or other equity or convertible debt securities in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_8"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following selected statement of operations data for the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017 and the balance sheet data as of
December&nbsp;31, 2017 are derived from our audited financial statements appearing elsewhere in this prospectus. The selected statement of operations data for the period March&nbsp;16, 2017 (inception) through June&nbsp;30, 2017 and the six months
ended June&nbsp;30, 2018 and the balance sheet data as of June&nbsp;30, 2018 have been derived from our unaudited financial statements included elsewhere in this prospectus. In our opinion, these unaudited financial statements have been prepared on
a basis consistent with our audited financial statements and contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such financial data.<SUP STYLE="font-size:85%; vertical-align:top">
</SUP>You should read these data together with our financial statements and related notes appearing elsewhere in this prospectus and the information in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations.&#148; Our historical results are not necessarily indicative of the results to be expected in the future, and our operating results for the interim periods are not necessarily indicative of the results that may be expected for any other
interim periods or any future year. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD<BR>MARCH&nbsp;16,<BR>2017<BR>(INCEPTION)<BR>THROUGH</B><br><B>DECEMBER&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERIOD<BR>MARCH&nbsp;16,<BR>2017<BR>(INCEPTION)<BR>THROUGH</B><br><B>JUNE&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS<BR>ENDED</B><br><B>JUNE 30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">801,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,202,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">958,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,712,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">988,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,161,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,712,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(988,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,161,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,342,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share, basic and diluted <SUP STYLE="font-size:85%; vertical-align:top">(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average shares of common stock outstanding, basic and diluted <SUP
STYLE="font-size:85%; vertical-align:top">(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted (unaudited)
<SUP STYLE="font-size:85%; vertical-align:top">(2) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted average shares of common stock outstanding, basic and diluted (unaudited) <SUP
STYLE="font-size:85%; vertical-align:top">(2) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note&nbsp;2 to our financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate the basic and diluted net loss per common share and the number of shares used in the
computation of the per share amounts. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The calculations for the unaudited pro forma net loss per common share, basic and diluted, and the pro forma weighted average shares of common stock outstanding, basic and diluted, assume (i)&nbsp;the conversion of
$9.4&nbsp;million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2018, and (ii)&nbsp;the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF<BR>DECEMBER&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF<BR>JUNE&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,103,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,626,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,580,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,788,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,151,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,728,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible promissory notes, including related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,058,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,517,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,604,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,252,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,593,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following discussion and analysis should be read in conjunction with &#147;Selected Financial Data&#148; and our financial
statements and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs, plans and expectations that involve risks,
uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking
statements as a result of several factors, including those set forth under &#147;Risk Factors&#148; and elsewhere in this prospectus. You should carefully read the &#147;Risk Factors&#148; section of this prospectus to gain an understanding of the
important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a biotechnology company leveraging deep understanding of
immunobiology to develop products for severe immuno-inflammatory disorders with high unmet medical need. Our initial product candidate, EQ001, is a clinical-stage,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells. Activated T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic
autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe EQ001 may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pipeline is focused on developing EQ001 as a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class,</FONT></FONT> disease
modifying treatment for multiple severe immuno-inflammatory disorders. We plan to initiate a Phase 1b/2 clinical trial of EQ001 for the treatment of aGVHD in early 2019, and expect top-line data from the Phase 1b part of this trial within 12 months
of initiation. Our IND with the FDA for aGVHD was accepted in July 2018. Additionally, in the first half of 2019, we plan to commence a Phase&nbsp;2 clinical trial of EQ001 for the treatment of cGVHD, initiate a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial for the treatment of severe asthma and select one or more additional indications for future development. In May 2017, we acquired U.S. and Canadian rights to itolizumab from
Biocon. Itolizumab is approved in India for the treatment of moderate to severe plaque psoriasis and is marketed by Biocon as ALZUMAb. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception,
substantially all of our efforts have been focused on organizing and staffing our company, business planning, raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> rights to EQ001, conducting preclinical research, filing our initial
IND and preparing to commence clinical development of EQ001. We have not generated any revenue from product sales or otherwise. From inception through June&nbsp;30, 2018, we have raised gross proceeds of $9.4&nbsp;million from the issuance of
convertible promissory notes to fund our operations. We have incurred losses since our inception. Our net losses were $2.3&nbsp;million for the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017, and $1.0&nbsp;million and
$3.3&nbsp;million for the period March&nbsp;16, 2017 (inception) through June&nbsp;30, 2017 and the six months ended June&nbsp;30, 2018, respectively. As of December&nbsp;31, 2017 and June&nbsp;30, 2018, we had an accumulated deficit of
$2.3&nbsp;million and $5.6&nbsp;million, respectively. Substantially all of our operating losses resulted from expenses incurred in connection with our research and preclinical activities and general and administrative costs associated with our
operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to continue to incur significant expenses and increasing losses into the foreseeable future. We anticipate our expenses will increase
substantially as we continue our research and development activities, including the planned clinical development of EQ001, seek regulatory approval for and potentially commercialize any approved product candidates, hire additional personnel, protect
our intellectual property, and incur additional costs associated with being a public company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not expect to generate any revenues from product sales unless
and until we successfully complete development and obtain regulatory approval for EQ001 or any future product candidate, which will not be for at least the next several years, if ever. Accordingly, until such time as we can generate significant
revenue from sales of our product candidates, if ever, we expect to finance our cash needs through a combination of equity offerings, debt financings, and collaboration and license agreements. However, we may not be able to secure additional
financing or enter into such other arrangements in a timely manner or on favorable terms, if at all. Our failure to raise capital or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, reduce or terminate our research and development programs or
other operations, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Financial Overview
</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently have no products approved for sale,
and we have not generated any revenues to date. In the future, we may generate revenue from collaboration or license agreements we may enter into with respect to our product candidates, as well as product sales from any approved product, which
approval we do not expect to occur for at least the next several years, if ever. Our ability to generate product revenues will depend on the successful development and eventual commercialization of EQ001 and any future product candidates. If we fail
to complete the development of EQ001 or any future product candidates in a timely manner, or to obtain regulatory approval for our product candidates, our ability to generate future revenue and our results of operations and financial position would
be materially adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses primarily consist of costs associated with our research and preclinical activities, and clinical development of EQ001. Our research
and development expenses include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">salaries and related overhead expenses, which include stock-based compensation and benefits, for personnel in research and
development functions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">external research and development expenses incurred under arrangements with third parties, such as consultants and
advisors for research and development; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to <FONT STYLE="white-space:nowrap">in-licensing</FONT> rights to EQ001 from Biocon; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs of services performed by third parties, such as contract research organizations, or CROs, that conduct research and
development and preclinical activities on our behalf; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to preparing and filing an IND with the FDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expense research and development costs as incurred. From our inception through June&nbsp;30, 2018, we have incurred $2.5&nbsp;million in research and development
expenses. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our direct research and development expenses consist principally of external costs, such as fees paid to CROs and consultants in connection with our preclinical and
clinical development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of EQ001
and potentially expand the number of indications for which we are developing EQ001. The successful development of EQ001 is highly uncertain. At this time, due to the inherently unpredictable nature of preclinical and clinical development, we cannot
reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of EQ001 or the period, if any, in which material net cash inflows from EQ001 may commence. Clinical development
timelines, the probability of success, and development costs can differ materially from expectations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Completion of clinical trials may take several years or more,
and the length of time generally varies according to the type, complexity, novelty, and intended use of a product candidate. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during
clinical development, including, among others: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">per patient clinical trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of clinical trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of sites included in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the length of time required to enroll suitable patients; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of patients that participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients in our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the duration of patient <FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential additional safety monitoring or other studies requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and complexity of procedures, analyses and tests performed during our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of procuring drug product for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the phase of development of the product candidate; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efficacy and safety profile of the product candidate. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General and Administrative Expenses </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative
expenses consist primarily of salaries and other related costs, including stock-based compensation and benefits, and consulting fees for executive, finance, and accounting functions. Other significant costs include legal fees relating to patent and
corporate matters, insurance, travel and facility costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that our general and administrative expenses will increase in future periods, reflecting an
expanding infrastructure and increased professional fees associated with being a public company. In addition, if we obtain regulatory approval for any product candidate, we expect to incur expenses associated with building the infrastructure to
commercialize such product. However, we do not expect to receive any such regulatory approval for at least the next several years, if ever. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Expense
</I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest expense consists of interest on our convertible promissory notes. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Change in Fair Value of Biocon Anti-Dilution Right </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have committed
to issue to Biocon additional shares of common stock to maintain Biocon&#146;s ownership interest at 19.5% of our fully-diluted capitalization until we have received aggregate cumulative gross proceeds from sales of equity securities of
$15&nbsp;million, or the Biocon Anti-Dilution Right. The Biocon Anti-Dilution Right has been classified as a liability in the accompanying balance sheet. The Biocon Anti-Dilution Right is recorded at fair value using the Precedent Transaction
Method. The fair value of the Biocon Anti-Dilution Right is <FONT STYLE="white-space:nowrap">re-measured</FONT> at each financial reporting period with any changes in fair value being recognized as a component of other income (expense). The Biocon
Anti-Dilution Right will be satisfied in full upon the issuance of additional shares of common stock to Biocon in connection with the completion of this initial public offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Period March&nbsp;16, 2017
(Inception) Through June&nbsp;30, 2017 and the Six Months Ended June&nbsp;30, 2018 </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our results of operations for the period
March&nbsp;16, 2017 (inception) through June&nbsp;30, 2017 and the six months ended June&nbsp;30, 2018: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD<BR>MARCH&nbsp;16,&nbsp;2017<BR>(INCEPTION)<BR>THROUGH<BR>JUNE&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS<BR>ENDED<BR>JUNE&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PERIOD-TO-PERIOD</FONT></FONT><BR>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">801,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,202,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">401,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">958,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">771,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,101,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were $0.8&nbsp;million and $1.2&nbsp;million for the period ended June&nbsp;30, 2017 and the six months ended June&nbsp;30, 2018,
respectively. The $0.4&nbsp;million increase in research and development expenses during this period was primarily due to an increase in costs related to our translational research and the filing of our IND. The increase in research and development
expense included consulting expenses of $0.5&nbsp;million, $0.4&nbsp;million of expenses related to preclinical research, salary expenses of $0.3&nbsp;million, and other expenses of $0.1&nbsp;million, offset by a decrease in license expense of
$0.9&nbsp;million under our collaboration and license agreement with Biocon, or the Biocon License. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $0.2&nbsp;million and $1.0&nbsp;million for the period ended June&nbsp;30, 2017 and the six months ended June&nbsp;30, 2018,
respectively. The $0.8&nbsp;million increase in general and administrative expenses during this period was related to a $0.4&nbsp;million increase in salary expenses, a $0.3&nbsp;million increase in consulting expenses, and a $0.1&nbsp;million
increase in other general and administrative expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Interest Expense </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest expense was $7,069 for the period ended June&nbsp;30, 2017 compared to $1.1&nbsp;million for the six months ended June&nbsp;30, 2018. Interest expense
consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense, including accretion of debt premium and issuance costs in relation to our outstanding convertible promissory notes. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Change in Fair Value of Biocon Anti-Dilution Right </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Change in fair value of
the Biocon Anti-Dilution Right was $18,887 and $0.1&nbsp;million for the period ended June&nbsp;30, 2017 and the six months ended June&nbsp;30, 2018, respectively. The increase in change in fair value of the Biocon Anti-Dilution Right primarily
reflects the increase in the likelihood that the right will be settled. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Period March&nbsp;16, 2017 (Inception) Through December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our results of operations for the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD</B><br><B>MARCH&nbsp;16,&nbsp;2017</B><br><B>(INCEPTION)</B><br><B>THROUGH</B><br><B>DECEMBER&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research
and development expenses were $1.3&nbsp;million for the period ended December&nbsp;31, 2017. Research and development expenses included $0.8&nbsp;million to acquire the rights under the Biocon License, $0.3&nbsp;million in salary and consulting
expenses and $0.2&nbsp;million related to translational research activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $0.4&nbsp;million for the period ended December&nbsp;31, 2017. General and administrative expenses included $0.2&nbsp;million
in legal fees, $0.1&nbsp;million in consulting expenses, and $0.1&nbsp;million in overhead and other expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Interest Expense </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest expense was $0.4&nbsp;million for the period ended December&nbsp;31, 2017. Interest expense consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT>
interest expense, including accretion of debt premium and issuance costs in relation to our convertible promissory notes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Change in Fair Value of Biocon
Anti-Dilution Right </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Change in fair value of the Biocon Anti-Dilution Right was $0.2&nbsp;million for the period ended December&nbsp;31, 2017. The change in
fair value of the Biocon Anti-Dilution Right primarily reflects the increase in the likelihood that the right will be settled. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources
</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From inception through June&nbsp;30,
2018, we have raised gross proceeds of $9.4&nbsp;million from the issuance of convertible promissory notes to fund our operations. The convertible promissory notes accrue interest at a rate of 6% per year, mature two years from their issuance and
automatically convert into equity securities sold pursuant to a qualified financing transaction from which we receive total gross proceeds of not less than $15.0&nbsp;million at a conversion price equal to 90% of the per share price paid by
investors for such securities if the closing of the financing occurs on or prior to the six month anniversary of the issuance of convertible promissory notes, or at a conversion price equal to 80% of the per share price paid by investors for such
securities if the closing of the financing occurs after the six month anniversary of the issuance of convertible promissory notes. If we consummate a change in control prior to the conversion or repayment in full of the convertible promissory notes,
we shall pay each holder in cash in an amount equal to the outstanding principal amount of the convertible promissory note plus any unpaid accrued interest on the original principal plus 1.0 times the outstanding principal amount of the note. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2018, we had $6.6&nbsp;million in cash and cash equivalents. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding Requirements </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect our expenses to increase
substantially in connection with our ongoing activities, particularly as we advance clinical development of EQ001. In addition, we expect to incur additional costs associated with operating as a public company following the completion of this
offering. We expect that our primary uses of capital will be third-party clinical research and development services, manufacturing, clinical trial costs, legal and other regulatory compliance expenses, compensation and related expenses, and general
overhead costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our currently
planned operations for at least the next 24 months. In particular, we expect that the net proceeds from this offering will allow us to fund a Phase 1b/2 clinical trial of EQ001 for aGVHD, a Phase 2 clinical trial of EQ001 for cGVHD and a
proof-of-concept clinical trial of EQ001 for severe asthma. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Furthermore, our operating plans may change, and we may
need additional funds sooner than planned. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress in these trials is uncertain. Because the outcome of these efforts is uncertain, we cannot
estimate the actual amounts necessary to successfully complete the development and commercialization of EQ001 or whether, or when, we may achieve profitability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future capital requirements will depend on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress, timing, costs and results of our planned clinical trials for EQ001; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and scope of indications we decide to pursue for EQ001 development; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost, timing and outcome of regulatory review of any BLA we may submit for EQ001; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs and timing of manufacturing for EQOO1, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property
rights and defending intellectual property-related claims; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including
personnel to support the development of EQ001; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost associated with commercializing EQ001, if approved for commercial sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time as we can generate substantial product revenues, if ever, we expect to finance our cash needs through a combination of equity offerings, debt
financings, and collaboration and license agreements. The sale of additional equity or convertible debt could result in additional dilution to our stockholders and the terms of these securities may include liquidation or other preferences that
adversely affect the rights of our existing common stockholders. The incurrence of debt financing would result in debt service obligations and the governing documents would likely include operating and financing covenants that would restrict our
operations. If we raise additional funds through collaboration or license agreements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may
not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or other
operations. Any of these actions could have a material effect on our business, financial condition and results of operations. We have experienced net losses and negative cash flows from operating activities since our inception and expect to continue
to incur net losses into the foreseeable future. We had an accumulated deficit of $2.3&nbsp;million and $5.6&nbsp;million at December&nbsp;31, 2017 and June&nbsp;30, 2018, respectively. We expect operating losses and negative cash flows to continue
for at least the next several years as we continue to incur costs related to the development of EQ001. We have prepared cash flow forecasts which indicate that based on our expected operating losses and negative cash flows, there is substantial
doubt about our ability to continue as a going concern without raising additional capital within 12 months after the date that the financial statements for the six months ended June&nbsp;30, 2018, are issued. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the cash flow from operating, investing and financing activities for the period March&nbsp;16,&nbsp;2017 (inception) through
December&nbsp;31, 2017 and the period March&nbsp;16,&nbsp;2017 (inception) through June&nbsp;30, 2017 and the six months ended June&nbsp;30, 2018: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD<BR>MARCH&nbsp;16,&nbsp;2017<BR>(INCEPTION)<BR>THROUGH<BR>DECEMBER&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD<BR>MARCH&nbsp;16,&nbsp;2017<BR>(INCEPTION)<BR>THROUGH<BR>JUNE&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX&nbsp;MONTHS<BR>ENDED<BR>JUNE&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(662,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(183,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,057,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,767,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,103,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">816,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(477,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Period March 16, 2017 (Inception) Through June&nbsp;30, 2017 and the Six Months Ended June&nbsp;30, 2018
</I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities was
$0.2&nbsp;million during the period ended June&nbsp;30, 2017 as compared to $2.1&nbsp;million during the six months ended June&nbsp;30, 2018. The increase in cash used in operating activities of $1.9&nbsp;million was primarily the result of the
increase in operating expenses in 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net
cash used in investing activities was $0 and $21,823 during the period ended June&nbsp;30, 2017 and the six months ended June&nbsp;30, 2018, respectively. The increase in cash used in investing activities of $21,823 was the result of the purchase of
property and equipment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing Activities </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by
financing activities was $1.0&nbsp;million during the period ended June&nbsp;30, 2017 as compared to $1.6&nbsp;million during the six months ended June&nbsp;30, 2018. The increase in cash provided by financing activities of $0.6&nbsp;million was the
result of an increase in convertible promissory notes issued in 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Period March&nbsp;16, 2017 (Inception) Through December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities was
$0.7&nbsp;million during the period ended December&nbsp;31, 2017. The cash used in operating activities was primarily the result of wages, consulting fees, legal fees, and preclinical research expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities was $2,199
during the period ended December&nbsp;31, 2017. The cash used in investing activities was the result of the purchase of property and equipment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing
Activities </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities was $7.8&nbsp;million during the period ended December&nbsp;31, 2017. The cash provided by financing
activities was the result of the issuance of convertible promissory notes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following summarizes our significant contractual obligations as of June&nbsp;30, 2018: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENT DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>CONTRACTUAL OBLIGATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN&nbsp;1<BR>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3</FONT> YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5</FONT><BR>YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AFTER&nbsp;5<BR>YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">214,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">156,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Principal under convertible notes payable, excluding accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,407,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,407,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest payable on convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,958,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,900,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have payment obligations under the Biocon License that are contingent upon future events such as our achievement of specified development and commercial
milestones and are required to make certain cash royalty payments upon our achievement of target levels of revenue from sales of EQ001, if approved. As of June&nbsp;30, 2018, we were unable to estimate the timing or likelihood of achieving the
milestones or making future product sales and, therefore, any related payments are not included in the table above. For additional information regarding the Biocon License, including our payment obligations thereunder, see Note 5 to our financial
statements appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We enter into agreements in the normal course of business with vendors for research studies and other services
and products for operating purposes. We have not included these payments in the table of contractual obligations above since the contracts are cancelable at any time by us, generally upon written notice to the vendor, and therefore we believe that
our <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations under these agreements are not material. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined under
SEC rules, and similarly did not and do not have any holdings in variable interest entities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Critical Accounting Policies and Significant Judgement and
Estimates </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets,
liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on
various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are more fully described in Note 2 to
our financial statements appearing elsewhere in this prospectus, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accrued Research and Development Expense </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are required to estimate
our expenses resulting from obligations under contracts with vendors, consultants and CROs, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from
contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. We reflect research and development expenses in our financial statements by matching those
expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities. We
determine accrual estimates through review of the underlying contracts along with preparation of financial models taking into account discussions with research and other key personnel as to the progress of studies, or other services being conducted.
During the course of a study, we adjust our rate of expense recognition if actual results differ from our estimates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we do not expect our estimates to be
materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low
in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based Compensation Expense </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense
represents the cost of the grant date fair value of employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line
basis. We estimate the fair value of stock option grants using the Black-Scholes option-pricing model. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Black-Scholes option-pricing model requires the use of
subjective assumptions, including the risk- free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the fair value of the underlying common stock on the date of grant. See Note 7
to our financial statements included elsewhere in this prospectus for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options
granted during the six months ended June&nbsp;30, 2018. No stock options were granted during the period ended December&nbsp;31, 2017. Total employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> stock-based compensation expense related to
unvested stock option grants not yet recognized as of December&nbsp;31, 2017 and June&nbsp;30, 2018 was $0 and $10,343, respectively, and the weighted-average period over which these grants are expected to vest is 0.0 and 3.73 years, respectively.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Determination of the Fair Value of Common Stock </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations using the Black-Scholes
option pricing model. Because our common stock is not currently publicly traded, the fair value of the common stock underlying our stock-based awards has been determined on each grant date by our board of directors, with input from management,
considering our most recently available third-party valuation of common shares. All options to purchase shares of our common stock are intended to be granted with an exercise price per share no less than the fair value per share of our common stock
underlying those options on the date of grant, based on the information known to us on the date of grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our determination of the value of our common stock was
performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants, or AICPA, Audit and Accounting Practice Aid Series: <I>Valuation of Privately Held Company Equity Securities Issued as
Compensation</I>, or the AICPA Practice Aid. In addition, our board of directors considered various objective and subjective factors to determine the fair value of our common stock, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">valuations of our common stock performed by independent third-party valuation specialists; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the anticipated capital structure that will directly impact the value of the currently outstanding securities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our results of operations and financial position; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the status of our research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the composition of, and changes to, our management team and board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the lack of liquidity of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">external market conditions affecting the life sciences and biotechnology industry sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. and global economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering, or
IPO, or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the market value and volatility of comparable companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The AICPA Practice Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various
methodologies for allocating the value of an enterprise to its common stock. The cost approach establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional or economic
obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective of our company&#146;s future operations, discounting to the present value with an
appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the AICPA Practice Aid, we considered the various methods for allocating the enterprise value to determine the fair value of our common stock at the
valuation date. Under the option pricing method, or OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The value of the common stock is
inferred by analyzing these options. The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available
to us, as well as the economic and control rights of each share class. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have utilized the precedent transaction method to value our common stock which
derives the implied equity value for one type of equity security from a contemporaneous transaction involving another type of equity security. We determined the precedent transaction method was the most appropriate method given the early stage of
our company. The OPM was then used to allocate the enterprise value to our common stock as it was determined to be the most reliable given the expectation of various potential liquidity outcomes and the difficulty of selecting and supporting
appropriate exit values given our stage of development and financial position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are significant judgments and estimates inherent in the determination of the fair value of our common stock.
These judgments and estimates include assumptions regarding our future operating performance, the time to completing an IPO or other liquidity event and the determination of the appropriate valuation methods. If we had made different assumptions,
our stock-based compensation expense, net loss and net loss per common share could have been significantly different. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the closing of this offering, the
fair value of our common stock will be equal to the closing price of our common stock as reported on the date of the grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), the intrinsic value of stock options outstanding as of
June&nbsp;30, 2018 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, of which $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million would relate to stock options that were vested and unvested, respectively, at that date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Biocon Anti-Dilution Right </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We classify the Biocon Anti-Dilution
Right as a liability on our balance sheets, as an obligation exists to issue a variable number of shares and that obligation is not indexed to our own stock. The Biocon Anti-Dilution Right was initially recorded at fair value on date of grant and is
subsequently remeasured to fair value at each balance sheet date. The Biocon Anti-Dilution Right is estimated at fair value using the Precedent Transaction Method. The Precedent Transaction Method was applied to solve for our enterprise value under
two scenarios: with the Biocon Anti-Dilution Right and without the Biocon Anti-Dilution Right. The resulting difference in the enterprise value under these two scenarios is the estimated fair value of the Biocon Anti-Dilution Right. The estimates
used to determine our enterprise value are based, in part, on subjective assumptions and could differ materially in the future. Fluctuations in the fair value of the Biocon Anti-Dilution Right are impacted by unobservable inputs, most significantly
our estimated fair value and probability of achieving different financing scenarios. If we do not receive proceeds from an equity financing, the fair value of the Biocon Anti-Dilution Right would be zero. Alternatively, if an equity financing
results in gross proceeds of $15.0&nbsp;million or greater, the fair value of the Biocon Anti-Dilution Right could be as high as $3.6&nbsp;million. Changes in our estimated fair value and the probability of achieving different financing scenarios
can have a significant impact on the fair value of the Biocon Anti-Dilution Right. Changes in fair value of the Biocon Anti-Dilution Right are reported in Other expense (income) in the statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Information </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net Operating Loss and Research and Development Tax
Credit Carryforwards </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2017, we had federal and California tax net operating loss carryforwards of $0.9&nbsp;million and
$0.9&nbsp;million, respectively, which begin to expire in 2037 and 2037, respectively, unless previously utilized. As of December&nbsp;31, 2017, we also had federal and California research and development tax credit carryforwards of $23,355 and
$14,344, respectively. The federal research and development tax credit carryforwards will begin to expire in 2037. The California research and development tax credit carryforwards are available indefinitely. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Utilization of the net operating losses and credits may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal
Revenue Code of 1986, as amended. The annual limitation may result in the expiration of our net operating losses and credits before we can use them. We have recorded a valuation allowance on all of our deferred tax assets, including our deferred tax
assets related to our net operating loss and research and development tax credit carryforwards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2017, the Tax Cuts and Jobs Act, or the 2017 Tax Act,
was enacted. The 2017 Tax Act includes a number of changes to existing U.S. tax laws that impact us, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December&nbsp;31, 2017. The 2017 Tax
Act also provides for the acceleration of depreciation for certain assets placed in service after September&nbsp;27, 2017 as well as prospective changes beginning in 2018, including limitations on the deductibility of interest and capitalization of
research and development expenditures. We measure deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. Accordingly, our deferred tax
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
assets and liabilities were remeasured to reflect the reduction in the U.S. corporate income tax rate from 35% to 21%, resulting in a $198,687 increase in tax expense for the period ended
December&nbsp;31, 2017 and a corresponding $198,687 decrease in net deferred tax assets as of December&nbsp;31, 2017. The impact was offset by our valuation allowance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See Note 2 to our financial statements
included elsewhere in this prospectus for information concerning recent accounting pronouncements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures About Market Risk
</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our cash and cash equivalents and short-term investments as of June&nbsp;30, 2018 consisted of cash and money market funds. We are exposed to market risk
related to fluctuations in interest rates and market prices. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of
the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition and/or results of operation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our convertible promissory notes bear interest at a fixed rate and therefore have minimal exposure to changes in interest rates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal Control Over Financial Reporting </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Section&nbsp;404(a) of
the Sarbanes-Oxley Act of 2002, as amended, commencing the year following our first annual report required to be filed with the SEC, our management will be required to report on the effectiveness of our internal control over financial reporting. To
comply with the requirements of being a reporting company under the Securities Exchange Act of 1934, as amended, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting
and finance staff, as well as potentially upgrade our information technology systems. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a biotechnology company leveraging deep understanding of
immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, EQ001 (itolizumab), is a clinical-stage, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T&nbsp;cells, or T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff</SUB>&nbsp;cells. Activated T<SUB STYLE="font-size:85%; vertical-align:bottom">eff&nbsp;</SUB>cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant
science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe EQ001 may have broad therapeutic utility in treating a large and diverse set of severe
immuno-inflammatory diseases. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g46k96.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We are focusing our initial development efforts on EQ001 for the treatment of the diseases underlined in bold and are
evaluating additional T cell driven indications for future development. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pipeline is focused on developing EQ001 as a potentially <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class,</FONT></FONT> disease modifying treatment for multiple severe immuno-inflammatory disorders. We plan to initiate a Phase&nbsp;1b/2 clinical trial of EQ001 for the treatment
of acute graft-versus-host disease, or aGVHD, in early 2019, and expect top-line data from the Phase 1b part of this trial within 12 months of initiation. Our Investigational New Drug application, or IND, with the U.S. Food and Drug Administration,
or FDA, for aGVHD was accepted in July 2018. Additionally, in the first half of 2019, we plan to commence a Phase&nbsp;2 clinical trial of EQ001 for the treatment of chronic graft-versus-host disease, or cGVHD, initiate a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial for the treatment of severe asthma and select one or more additional indications for future development. The following chart summarizes our
initial development plans for EQ001.<B> </B> </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g04t71.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The Phase&nbsp;1 clinical trial was conducted by Biocon, our collaboration partner, in Australia. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have an ongoing translational biology program to assess the therapeutic utility of EQ001 in additional indications
where the CD6 pathway and activated T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells play an important role in disease pathogenesis. Our selection of additional indications is driven by our analysis of the scientific,
translational, clinical and commercial rationale for advancing EQ001 into further development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired U.S. and Canadian rights to itolizumab in May 2017,
pursuant to a collaboration and license agreement with Biocon SA (subsequently assigned to Biocon Limited, or together, Biocon). Following completion of a Phase 3 clinical trial conducted outside of North America, itolizumab was approved in India
for the treatment of moderate to severe plaque psoriasis and is marketed by Biocon as ALZUMAb. Today, India is the only jurisdiction where ALZUMAb is approved or marketed. EQ001 has been evaluated in one Phase 1 clinical trial to date, conducted by
Biocon, and is not approved for commercial sale in the United States or Canada. Our partnership with Biocon includes an exclusive supply agreement for clinical and commercial drug product of EQ001. Biocon currently manufactures EQ001 at commercial
scale in a facility regulated by the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have assembled an accomplished team that includes veterans in drug discovery, development and commercialization.
Notably, our Chief Executive Officer is Daniel Bradbury, who has over 30 years of experience bringing novel medicines to market. Mr.&nbsp;Bradbury was the President, Chief Executive Officer and Director of Amylin Pharmaceuticals, Inc., where during
his 18 year tenure he oversaw the development and launch of three <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicines, which ultimately led to the acquisition of Amylin Pharmaceuticals, Inc. by
Bristol-Myers Squibb. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Strategy </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our goal is to become a leading,
fully-integrated biotechnology company focused on therapies for severe immuno-inflammatory disorders. To achieve our goal, we intend to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Advance EQ001 through clinical development for aGVHD and cGVHD.</B> Based on our deep and proprietary understanding of
the CD6 pathway, our translational research, and prior clinical studies targeting CD6, we are initially focused on aGVHD and cGVHD as our initial indications for the clinical development of EQ001. We plan to initiate a Phase 1b/2 clinical trial of
EQ001 as a front-line therapy concomitant with steroids in patients with aGVHD in early 2019 and expect <FONT STYLE="white-space:nowrap">top-line</FONT> data from the Phase 1b part of this trial within 12 months of initiation. In this trial we will
assess safety, overall response rate, survival, steroid taper and incidence of cGVHD. In addition, we plan to initiate a Phase 2 clinical trial of EQ001 in patients with cGVHD in the first half of 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Develop EQ001 for the treatment of severe asthma.</B> We believe that the unique mechanism of action of EQ001 has the
potential to treat severe asthma patients characterized by an immunophenotype of low T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 and high T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 and who consequently have a poor
response to high dose inhaled and/or oral steroids. There are a sizeable number of these patients who are underserved by currently available therapies and for which there are no FDA-approved biologic or other targeted treatments. We plan to initiate
a proof-of-concept clinical trial of EQ001 in patients with severe asthma in the first half of 2019. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Expand clinical development of EQ001 into additional indications based on our translational biology program. </B>We
will<B> </B>continue to conduct studies in animal models and human tissue, as well as EQ001 clinical trials, to help inform the selection of additional indications for further development. In the first half of 2019, we intend to select a fourth
indication for future EQ001 development. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Opportunistically expand our pipeline of product candidates.</B> We will leverage the collective talent within our
organization to opportunistically acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other high-value therapeutic programs that may complement our core strategy or have the potential for synergistic therapeutic benefit in combination with
EQ001. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Build a commercial infrastructure.</B> If approved, we intend to commercialize EQ001 ourselves in indications that can
be efficiently targeted using a specialty sales force, such as aGVHD and cGVHD. For other indications, we intend to commercialize EQ001 either independently or through collaborations with other parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Understanding the Basis of Our Approach: The Role of CD6 in Autoimmunity </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The role of the immune system is to defend the body against foreign organisms and cells, including cancerous cells, and in doing so must distinguish accurately between
self- and <FONT STYLE="white-space:nowrap">non-self</FONT> entities, a process called tolerance. Autoimmunity is an immune response directed against the body&#146;s own healthy cells and tissues, and is the underlying process in many inflammatory
diseases. Autoimmunity results from a loss of tolerance caused in part by an imbalance in the relationship between T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> and regulatory T cells, or T<SUB
STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells, see <B>Figure 1</B>. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g61c22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:5%; font-size:7.5pt; font-family:ARIAL"><B>Figure 1: Autoimmunity is a balancing act. </B>T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells
play an important role in preventing T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells targeting of self-antigens that can lead to autoimmunity and tissue destruction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immune checkpoints are critical regulators of immune activation pathways and can be either <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> (activating) or <FONT
STYLE="white-space:nowrap">co-inhibitory</FONT> (inhibiting). These pathways are crucial for maintaining immune balance and preventing autoimmunity. Immune checkpoints have been targeted for the treatment of cancers, where blockade of <FONT
STYLE="white-space:nowrap">co-inhibitory</FONT> signals results in an increased immune response against tumor cells, and such approaches have resulted in the approval of several novel therapeutics. We believe
<FONT STYLE="white-space:nowrap">co-stimulatory</FONT> checkpoints are attractive drug targets for the treatment of immuno-inflammatory diseases and more recently they have become a focus of development in immuno-inflammation. However, identifying
checkpoints that allow for the selective modulation of T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell activity while preserving T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cell activity in order to promote
tolerance has proven challenging. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CD6 is a novel, tightly-regulated, <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> receptor that plays an integral role in
modulating T cell activation, proliferation, differentiation and trafficking. CD6 serves as a key checkpoint in regulating T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells that are central to autoimmune responses. Preclinical and
clinical studies have shown that blockade of CD6 <FONT STYLE="white-space:nowrap">co-stimulation</FONT> leads to selective inhibition of pathogenic T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell activity and trafficking, while
preserving the important regulatory function of T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells. Such studies and new insights into the underlying biology highlight CD6 as a resurgent target for the treatment of multiple
immuno-inflammatory diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CD6 is predominantly expressed on T helper cells, or T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB> cells, and regulates
T cell responses. Once activated, na&iuml;ve T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB> cells become T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells and carry out specialized immune functions depending on their
specific phenotype such as T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>1, T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 and T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells. The expression levels of CD6
are increased on T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells and are associated with autoreactivity in cells, leading to autoimmunity. Conversely, the lack of expression of CD6 on T<SUB
STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells suggests that CD6 is not required for their regulatory function. See<B> Figure 2.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g13p56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 2: CD6, a novel, tightly-regulated, co-stimulatory checkpoint central to autoimmunity.</B> The expression
levels of CD6 are increased on T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells such as T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>1, T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 and T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells and are associated with autoreactivity. Conversely, the lack of expression of CD6 on T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells suggests that CD6 is not required
for their regulatory function. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Activated leukocyte cell adhesion molecule, or ALCAM, is a ligand of CD6 that is expressed on hematopoietic tissues such as
antigen-presenting cells, where it is important for immune synapse formation and optimal <FONT STYLE="white-space:nowrap">co-stimulation.</FONT> Binding of ALCAM to <FONT STYLE="white-space:nowrap">domain-3</FONT> of CD6 leads to the downstream
activation of several mitogen activated protein kinase, or MAPK, pathways related to T cell activation, proliferation, differentiation and survival. See<B> Figure 3</B>. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Studies have shown that <FONT STYLE="white-space:nowrap">co-stimulation</FONT> of CD6 by ALCAM enhances T cell activation and resulted in a five-fold increase in <FONT
STYLE="white-space:nowrap">IL-2</FONT> receptor mediated T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell proliferation. Moreover, CD6 <FONT STYLE="white-space:nowrap">co-stimulation</FONT> promotes a preferentially <FONT
STYLE="white-space:nowrap">pro-inflammatory</FONT> response and increased secretion of T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cytokines <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>, <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> and <FONT STYLE="white-space:nowrap">IL-6</FONT> .
Additionally, CD6 <FONT STYLE="white-space:nowrap">co-stimulation</FONT> leads to increased expression and activation of validated targets for the treatment of immuno-inflammatory disease, including signal transducer and activator of transcription
3, or STAT3, and retinoid acid-related orphan receptor, or ROR<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>t, the master transcriptional regulator of
T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells. This results in increased expression of <FONT STYLE="white-space:nowrap">IL-23R</FONT> and high levels of <FONT STYLE="white-space:nowrap">IL-17,</FONT> both markers of pathogenic T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cell activity and resistance to steroid treatment, which is a first-line therapy in many immuno-inflammatory diseases. T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells play an
especially important role in autoimmunity: T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 and T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells are reciprocally regulated and thus an increase in T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells and associated cytokines leads to suppression of T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cell activity and loss of tolerance. Studies have shown that <FONT
STYLE="white-space:nowrap">co-stimulation</FONT> through CD6 is superior to CD28 <FONT STYLE="white-space:nowrap">co-stimulation</FONT> in driving T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cell development and thus represents an
attractive target for the treatment of immuno-inflammatory diseases, especially those resistant or refractory to steroid treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ALCAM is also expressed on <FONT
STYLE="white-space:nowrap">non-hematopoietic</FONT> tissues such as the vascular endothelium, blood-brain barrier, skin, lung and gut, where it selectively facilitates the trafficking of T cells expressing CD6. Studies have shown that, in the
presence of the <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokine <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>, the expression of ALCAM is
increased on a number of cell types, suggesting an important dual role for CD6 and ALCAM in autoimmune responses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g62o26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 3: CD6 <FONT STYLE="white-space:nowrap">co-stimulation</FONT> drives pathogenic T cell development and
activity. </B><FONT STYLE="white-space:nowrap">(1)&nbsp;Co-stimulation</FONT> occurs through the binding of ALCAM to <FONT STYLE="white-space:nowrap">domain-3</FONT> of CD6, (2) leading to synergistic activation resulting in a five-fold increase in <FONT
STYLE="white-space:nowrap">IL-2</FONT> receptor mediated T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell proliferation. <FONT STYLE="white-space:nowrap">(3)&nbsp;Co-stimulation</FONT> through CD6 promotes a <FONT
STYLE="white-space:nowrap">pro-inflammatory</FONT> response including the activation of pSTAT3 and ROR<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>t resulting in increased expression of <FONT
STYLE="white-space:nowrap">IL-23R</FONT> and pathogenic secretion of several <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines. (4)&nbsp;ALCAM expressed on tissues such as the skin, lung and gut, selectively facilitates the
trafficking of T cells expressing CD6. (5) T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells and associated cytokines suppress T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cell activity leading to a high T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17:T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> ratio. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Modulation of T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff</SUB> Cell Activity with EQ001 </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">EQ001 is a humanized antibody that selectively binds to human CD6 and inhibits
the interaction of CD6 with its ligand ALCAM, preventing <FONT STYLE="white-space:nowrap">co-stimulation,</FONT> and thereby reducing T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell activity and trafficking. Preclinical studies of
EQ001 have shown that blockade of CD6 leads to a reduction in T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell proliferation and downregulation of several important pathways that contribute to T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell development. Critically, CD6 blockade leads to the downregulation of important cellular pathways that control inflammation, including STAT3 and ROR<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>t. The downregulation of these pathways is accompanied by decreased secretion of the <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB>
cytokines <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>, <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>, <FONT STYLE="white-space:nowrap">IL-6</FONT> and <FONT STYLE="white-space:nowrap">IL-17.</FONT> See<B> Figure 4</B>. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g58p01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 4: Blockade of CD6 reduces T cell activation, proliferation and differentiation.</B> <FONT
STYLE="white-space:nowrap">(A-C)</FONT> Human peripheral blood mononuclear cells, or PBMC, were stimulated in T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 polarizing conditions in the presence of EQ001 or a control antibody. On
Day&nbsp;3 post-stimulation, EQ001 reduced the percentage of activated T cells, shown in panel A, and the percentage of proliferating T cells, shown </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL">
in panel B. EQ001 also reduced levels of pSTAT3, a T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 signature transcription factor, shown in panel C. (D and E) PBMC cells were <FONT
STYLE="white-space:nowrap">re-stimulated</FONT> with <FONT STYLE="white-space:nowrap">PMA-Ionomycin</FONT> for five hours and analyzed for expression of intracellular cytokine <FONT STYLE="white-space:nowrap">IL-17A</FONT> and another T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 signature transcription factor ROR<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>t. Day&nbsp;6 representative histogram of ROR<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>t is shown in panel D and the corresponding dot plots of ROR<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>t and
<FONT STYLE="white-space:nowrap">IL-17A</FONT> gated on lymphocyte scatter and CD3 expressing T cells are shown in panel E. (F)&nbsp;Splenocytes were isolated from mice treated with anti-CD6D1, a mouse surrogate
<FONT STYLE="white-space:nowrap">anti-CD6</FONT> antibody, or a control antibody and stimulated <I>ex vivo</I>. <FONT STYLE="white-space:nowrap">Anti-CD6D1</FONT> treatment resulted in a substantially reduced response to stimulation and the
splenocytes secreted lower levels of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> T cell cytokines IL-17A, <FONT STYLE="white-space:nowrap">IL-6,</FONT>
IFN-<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> and TNF-<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>, shown in panel F. *p&lt;0.05. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, inhibiting the binding of ALCAM to CD6, either by <FONT STYLE="white-space:nowrap">anti-CD6</FONT> monoclonal antibodies or by deletion of the gene
expressing CD6, modulates lymphocyte trafficking and results in reduced T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell infiltration into inflamed tissues. Based on its broad multi-modal mechanism, we believe EQ001 has the
potential to treat multiple immuno-inflammatory diseases including those that are resistant or refractory to existing therapies. See<B> Figure 5</B>. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g33e76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 5: Blockade of CD6 by EQ001 inhibits
T</B><B><SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB></B><B> cell activation, proliferation, differentiation and trafficking. </B>(1)&nbsp;EQ001 selectively binds to domain-1 of CD6 and inhibits the interaction of ALCAM, preventing <FONT
STYLE="white-space:nowrap">co-stimulation</FONT> (2)&nbsp;and thereby reducing T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cell proliferation. (3)&nbsp;Blockade of CD6 downregulates pSTAT and ROR<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>t resulting in reduced expression of <FONT STYLE="white-space:nowrap">IL-23R</FONT> and secretion of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cytokines <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>,
<FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>, <FONT STYLE="white-space:nowrap">IL-6</FONT> and <FONT STYLE="white-space:nowrap">IL-17.</FONT>
(4)&nbsp;Additionally, inhibiting the binding of ALCAM to CD6, reduces lymphocyte trafficking into inflamed tissues. (5)&nbsp;Reduction of T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells inhibiting T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells restores immune balance and promotes tolerance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Experimental Evidence for Targeting CD6 in
Immuno-Inflammation </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are leveraging our deep understanding of immunobiology and translational biology program to assess the importance of CD6 in disease
pathogenesis and therapeutic utility of CD6 blockade using well-characterized model systems and human tissues. As a leader in the field of CD6 immunobiology, our objective is to inform selection of indications in specific disease areas that&nbsp;are
likely to respond to CD6 targeting by EQ001.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The role of CD6 in pathogenic T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB>&nbsp;cell development has
been independently validated<I> in vivo</I> both genetically and pharmacologically in experimental models of immuno-inflammation, as summarized in <B>Table&nbsp;1</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Table 1: Published, independent studies supporting the role of CD6 in immuno-inflammatory diseases. </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="40%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>ANIMAL MODEL/INDICATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>METHOD</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>RESULTS&nbsp;&amp; CONCLUSIONS</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Experimental Autoimmune Uveitis</B></P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Zhang et al. 2018</I></B></P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Journal of Autoimmunity</I></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">CD6-/-</FONT> mouse&#134;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased retinal inflammation (80% reduction in the mean histopathological scores)*</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased autoreactive T cell responses
(&gt;70% reduction in T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>1 and T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cytokine production)*</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">Mouse&nbsp;anti-CD6D1**</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased retinal inflammation (80% reduction in the mean histopathological scores)*</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased T cell infiltration in the eyes
(79% reduction in infiltrating T cell numbers)*</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Experimental <FONT STYLE="white-space:nowrap">OVA-induced</FONT> Asthma</B></P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Kim et al. 2018</I></B></P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>The Journal of Translational Immunology</I></B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">ALCAM-/- mouse&#134;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2<SUB
STYLE="font-size:85%; vertical-align:bottom"> </SUB>cell responses*</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased T cell trafficking into the
lung</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">Mouse anti-CD6D1**</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased T cell proliferation*</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Experimental Autoimmune Encephalomyelitis</B></P> <P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Multiple Sclerosis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis</B></P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Li et al. 2017</I></B></P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Proceedings of the National Academy of Sciences</I></B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">CD6-/-</FONT> mouse&#134;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased clinical disease scores*</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased pathogenic T cell responses
(significant reduction in T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>1 and T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cytokine production)*</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Blocked pathogenic T cell infiltration into
the CNS</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Mouse anti-CD6D1**</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased clinical disease scores*</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>1 and T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cell responses*</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased inflammation and demyelination in
the CNS</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Imiquimod-induced
Psoriasis</B></P> <P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Consuegra-Fernandez et al. 2017</I></B></P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Cellular and Molecular Immunology</I></B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT
STYLE="white-space:nowrap">CD6-/-</FONT> mouse&#134;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased skin inflammation (epidermal thickness)*</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased
<FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines*</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cell differentiation <I>in vitro*</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="middle" ROWSPAN="2"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Experimental OVA-induced Allergy</B></P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Kim et al., 2018</I></B></P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Clinical &amp; Experimental Immunology</I></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">ALCAM-/-</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased pro-inflammatory T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2&nbsp;cell responses*</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased disturbance of intestinal
tissue</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 cytokines (IL-4, IL-5 and <FONT STYLE="white-space:nowrap">IL-13)</FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">anti-mouse CD6</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-2.25em; font-size:8pt; font-family:ARIAL"><FONT
STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT>&#8195;&#8194;Decreased T cell proliferation*</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><FONT STYLE="white-space:nowrap">CD6-/-</FONT> is a mouse with a homozygous null gene deletion of CD6. ALCAM -/- is a
mouse with a homozygous null gene deletion of ALCAM. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents a statistically significant result (p&lt;0.05). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Mouse surrogate anti-CD6 antibody. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to these published studies,&nbsp;we have demonstrated the activity of EQ001 (or anti-CD6D1, its mouse surrogate
<FONT STYLE="white-space:nowrap">anti-CD6</FONT> antibody) in a number of disease models. Described below are findings from studies in models of several key immuno-inflammatory disease areas, including GVHD, inflammatory bowel disease and
neuroinflammation, which illustrate blockade of CD6 inhibiting pathogenic T cell activity.&nbsp;We believe the results of these published studies and our internal translational program support our approach in targeting CD6 in the treatment of
immuno-inflammation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Treatment with EQ001 Attenuates GVHD</I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">GVHD is a multisystem disease commonly associated with hematopoietic stem cell transplants in which transplanted donor lymphocytes attack host tissues. GVHD is
predominantly driven by T cells that express high levels of CD6. Prior clinical studies have implicated cells expressing CD6 in the development of GVHD, suggesting that CD6 is a highly relevant target to this disease.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Hu-PBMC-NSG</FONT></FONT> model is a humanized xenograft mouse model of GVHD generated by
injection of human peripheral blood mononuclear cells, or <FONT STYLE="white-space:nowrap">Hu-PBMC,</FONT> into an NSG mouse, which is an immunodeficient mouse. In this well-characterized, gold standard model, disease is aggressively driven by a
human T cell response against host tissue.&nbsp;The severity of disease is assessed by survival, weight loss, prevalence of human cells in peripheral blood and trafficking of human cells into tissues. EQ001 can be assessed in this model because
human T cells are present. In the model, we tested a high dose of EQ001 (300<FONT STYLE="font-family:Times New Roman">&#956;</FONT>g/dose), a low dose of EQ001 (60<FONT STYLE="font-family:Times New Roman">&#956;</FONT>g), and as comparator controls,
two <FONT STYLE="white-space:nowrap">CTLA4-Ig</FONT> based modulators of CD28 <FONT STYLE="white-space:nowrap">co-stimulation,</FONT> Nulojix (belatacept) and Orencia (abatacept), which are both <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
drugs that also target activated T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB>&nbsp;cells. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Treatment with both high and low dose EQ001 resulted in
no deaths by Day 35 compared to the 90% mortality seen in vehicle treated control animals. <B></B>See<B>&nbsp;Figure 6.</B> This is a direct result of inhibition of human T cell proliferation and infiltration into tissues. Animals treated with EQ001
demonstrated a profound reduction in human T cells at Days&nbsp;10 and 35 with a prevalence of 0.2% (both days), whereas vehicle treated animals exhibit a prevalence of 17.5% human T cells by Day&nbsp;10. The ability of EQ001 to prevent T cell
establishment compared highly favorably to both Nulojix and Orencia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g28r56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 6: Treatment with EQ001 attenuates GVHD. </B>(A)&nbsp;Kaplan-Meier survival curve of mice treated with either
EQ001, Nulojix, Orencia or vehicle prior to injection with human PBMCs. Mice treated with EQ001 experienced 100% survival. (B and C) Proportion of human T cells detected in the periphery was statistically significantly lower in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Hu-NSG-PBMC</FONT></FONT> mice treated with EQ001 vs. vehicle control at Day 10 (B) and remains low at Day 35 (C). (E and F) CD3 staining in lung tissue shows infiltration of T cells. No
statistically significant presence of T cells was detected in the lungs of mice treated with EQ001. ****p&lt;0.0001 and **p&lt;0.01. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Treatment with <FONT
STYLE="white-space:nowrap">Anti-CD6</FONT> Antibody Inhibits Inflammatory Bowel Disease</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Inflammatory bowel disease, or&nbsp;IBD,&nbsp;such as&nbsp;Crohn&#146;s
disease and&nbsp;ulcerative colitis, is&nbsp;characterized by chronic inflammation resulting from persistent activation of&nbsp;immune cells in the gut.&nbsp;Activated&nbsp;T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB>&nbsp;cells,
such as T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17, which express CD6, are associated with IBD and its severity.&nbsp;Data from human genetic studies have demonstrated an association between CD6 and the development and severity of
IBD. Inhibition of T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells, such as T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells, have been shown to reduce IBD disease severity and progression, confirming the
relevance of the CD6 pathway in this disease.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">The&nbsp;2,4,6-trinitrobenzenesulfonic</FONT> acid,&nbsp;or&nbsp;TNBS,&nbsp;model is
a&nbsp;standard&nbsp;model of IBD that is driven by&nbsp;T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>1&nbsp;and&nbsp;T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cell responses. Exposure to TNBS leads to inflammation,
diarrhea, tissue destruction and shortening of the colon. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
this model, we tested blockade of CD6 using anti-CD6D1, which binds to the same CD6 domain-1 in mice that EQ001 binds on human CD6. As comparator controls, separate groups of mice were treated
with either <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-12p40</FONT></FONT> (a therapeutic mechanism of action similar to&nbsp;Stelara, an FDA-approved therapy for Crohn&#146;s disease), dexamethasone or vehicle.
Blockade of&nbsp;CD6 inhibits the&nbsp;TNBS-induced&nbsp;immune response&nbsp;as&nbsp;exhibited by&nbsp;decreases&nbsp;in serum and tissue <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines,&nbsp;see<B>&nbsp;Figure 7</B>.&nbsp;This
is accompanied by&nbsp;statistically significant decreases in&nbsp;inflammation-mediated&nbsp;colon shrinkage,&nbsp;histological measures of&nbsp;necrosis,&nbsp;edema and mucosal inflammation,&nbsp;and diarrhea/loose stool.&nbsp;The results
of&nbsp;anti-CD6D1 treatment&nbsp;were&nbsp;comparable to&nbsp;high <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dose&nbsp;anti-IL-12p40&nbsp;treatment,</FONT></FONT> another inhibitor of&nbsp;the&nbsp;T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>1 and T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cell pathways. Results of this model are relevant not only to IBD but also other immuno-inflammatory gut conditions,
including&nbsp;GVHD. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g00h84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 7: Treatment with anti-CD6D1 inhibits inflammatory bowel disease.</B> (A and B) Anti-CD6D1 treatment
decreased disease scores as measured by (A)&nbsp;a reduction in body weight loss and (B)&nbsp;the statistically significant reduction of colon weight to length ratio compared to vehicle control. (C)&nbsp;CD6 blockade decreased serum <FONT
STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines. (D and E) Tissue pathology scores were statistically significantly improved by anti-CD6D1 treatment. Red line denotes width of colon mucosa, delineating mucosal hyperplasia (tissue
thickening). Hyperplasia was greatest in vehicle animals and was reduced in anti-CD6D1, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-12p40</FONT></FONT> and dexamethasone treated animals. (F and G) Anti-CD6D1 treatment
reduced trafficking of T cells into the colon, as demonstrated by CD3, a pan T cell marker. ****p&lt;0.0001, ***p&lt;0.001, **p&lt;0.01 and *p&lt;0.05. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Treatment with <FONT STYLE="white-space:nowrap">Anti-CD6</FONT> Antibody Reduces Neuroinflammation</B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CD6 is overexpressed on activated T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells isolated from multiple sclerosis patients and has been implicated
in the pathogenesis of neuroinflammation. On the vascular endothelium of the blood-brain-barrier, ALCAM is upregulated by
<FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>, providing a potential mechanism for the entry of T&nbsp;cells expressing CD6 into the central nervous
system, or CNS. Increased levels of CD6 are correlated to increased infiltration of T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells into the CNS and the development of neuroinflammation.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Experimental autoimmune encephalomyelitis, or EAE,&nbsp;is a well-established mouse model of neuroinflammation that is commonly used to study disorders such as multiple
sclerosis and neuromyelitis optica. In this model, an autoimmune response leads to T cell infiltration across the blood-brain barrier and into the tissues of the CNS (including spinal cord and optic nerve). Mice with EAE exhibit muscle weakness
progressing to paralysis due to increasing neuronal damage. Blockade of CD6 by anti-CD6D1 results in reduced disease severity as demonstrated by statistically significant improvements in disease model scores (i.e., less weakness and
paralysis),&nbsp;decreased autoimmune T cell activity and decreased T cell trafficking, resulting in decreased demyelination of the spinal cord, see<B> Figure 8</B>. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g35c23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 8: Treatment with anti-CD6D1 attenuates neuroinflammation.</B> (A)&nbsp;Antagonism of the CD6 pathway during
EAE induction results in statistically significant decreases in disease model scores. (B)&nbsp;Isolated T cells stimulated <I>ex vivo</I> exhibit a substantially reduced response to stimulation, secreting lower levels of important T cell cytokines <FONT
STYLE="white-space:nowrap">IL-17A,</FONT> <FONT STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>, and <FONT
STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>. (C) Amelioration of EAE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL">
is supported by decreased cellular trafficking into the spinal cord and reduced demyelination. Anti-CD6D1 treated animals appear similar to normal, disease-free animals. *p&lt;0.01. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Itolizumab: Clinically Validated in the Treatment of Immuno-Inflammatory Diseases </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Itolizumab has shown activity in clinical trials in patients with rheumatoid arthritis and psoriasis. Itolizumab has been approved for the treatment of moderate to
severe plaque psoriasis in India and is marketed by Biocon under the brand name ALZUMAb. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Psoriasis is a chronic immuno-inflammatory disease characterized by
inflammation and aberrant hyperproliferation of keratinocytes. The pathogenesis of psoriasis is complex and numerous components of the immune system play a role, including T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells and
associated cytokines, most notably <FONT STYLE="white-space:nowrap">IL-17.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biocon has completed three clinical studies of ALZUMAb in India in patients with
rheumatoid arthritis and chronic plaque psoriasis, with a total of 333 patients exposed to ALZUMAb at dose levels ranging from 0.2 mg/kg to 1.6 mg/kg.&nbsp;An overview of these clinical studies is presented in <B>Table 2</B>. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><B>Table 2: Overview of the Biocon clinical development program of itolizumab </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>PHASE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>STUDY NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>PATIENTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DOSE LEVELS<BR>(MG/KG)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DURATION</B><br><B>(WEEKS)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>INDICATION</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CLG007/BIO004/<BR>RA/CD6/2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.2, 0.4, and 0.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Rheumatoid arthritis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T1hAb-CT1-001-07</FONT></FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.4, 0.8, and 1.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chronic plaque psoriasis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T1hAb-CT3-002-09</FONT></FONT></FONT> (TREAT-PLAQ)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">223</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.4 and 1.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chronic plaque psoriasis</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the clinical trials described above, 35 patients have received itolizumab in prior clinical trials conducted in Cuba for the treatment of rheumatoid
arthritis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Phase 3 TREAT-PLAQ trial was a randomized, double-blind, placebo controlled, <FONT STYLE="white-space:nowrap">multi-arm,</FONT> multi-dose, <FONT
STYLE="white-space:nowrap">one-way</FONT> crossover design studying 223 psoriasis patients. Results from this trial demonstrated that ALZUMAb had a favorable safety and tolerability profile and durable efficacy as measured by psoriasis area and
severity index, or PASI. The primary end point was the proportion of patients with at least 75% improvement in PASI score, or PASI 75, at Week 12. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In Arm A patients received ALZUMAb at 0.4 mg/kg weekly for the first four weeks, then 1.6 mg/kg every two weeks until
Week 12; in Arm B patients received ALZUMAb at 1.6 mg/kg every two weeks until Week 12. At Week 12 only 2.3% of patients receiving placebo achieved PASI 75 compared to 27.0% and 36.4% of patients achieving PASI 75 by Week 12 in Arms A (p value =
0.0172) and B (p value = 0.0043), respectively. At Week 12, patients in the placebo arm crossed over to treatment with ALZUMAb. Following Week 28, patients that responded to ALZUMAb (those that reached PASI 75) were re-randomized to one of two
groups, either cessation of drug (n =40) or maintenance therapy (n = 39, with 1.6mg/kg of drug given every 3 weeks). Prior ALZUMAb treatment produced a durable effect in patients that were no longer given drug, with 53% of patients maintaining PASI
75 and 75% at PASI 50.&nbsp;67% of patients that continued ALZUMAb treatment had maintained PASI 75 scores, while 85% maintained PASI 50. Histologically, skin biopsy data show that treatment with ALZUMAb statistically significantly reduces the
trafficking of T cells in to the dermis and this is consistent with observed reduced severity of disease and therapeutic mechanism. See<B> Figure 9</B>. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g46t15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure&nbsp;9: ALZUMAb, an approved treatment for psoriasis in India.</B> (A)&nbsp;The proportion of patients who
achieved a PASI&nbsp;75 response at each visit until Week&nbsp;28. (B)&nbsp;Treatment with ALZUMAb statistically significantly reduces the trafficking of T&nbsp;cells into the dermis. Compared to Visit&nbsp;1, at Visit&nbsp;16 there were
statistically significantly fewer T cells in the dermis, as shown by CD3 labeling, a pan T&nbsp;cell marker. (C)&nbsp;Histogram shows the mean T cell count in the dermis was statistically significantly reduced in Week&nbsp;12 and Week&nbsp;28,
compared to Week&nbsp;0, which was consistent with the observed reduced severity of disease. ****p&lt;0.0001. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underlying pathophysiology of different
immuno-inflammatory diseases can vary substantially, and therefore drugs that operate by different mechanisms can demonstrate diverging levels of efficacy in each condition. For example, the PASI 75 scores achieved at three months by subjects
treated with ALZUMAb (36%) in its pivotal trial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
in psoriasis were in line with Enbrel (46-47%), an effective psoriasis drug, but they were less than the newly approved
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-17</FONT></FONT> agents such as Cosentyx (66-82%). We believe the explanation for this result is that while T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells
play a role in psoriasis, there are also <FONT STYLE="white-space:nowrap">non-T&nbsp;cell</FONT> mediators that contribute to disease pathogenesis, suggesting that psoriasis may not be an ideal indication for this therapeutic approach. Based on
published clinical trial data from multiple studies that were not conducted on a head-to-head basis, it appears that ALZUMAb has demonstrated superior PASI&nbsp;75 scores in psoriasis compared to modulation of CD28
<FONT STYLE="white-space:nowrap">co-stimulation</FONT> using Orencia (16.4%), which is approved for the treatment of psoriatic and rheumatoid arthritis. Also, a recent meta-analysis comparing efficacy across trials indicated that Orencia
demonstrated superior efficacy in ACR&nbsp;50 scores, a common clinical test for determining improvement in a person&#146;s rheumatoid arthritis, than Cosentyx in certain populations of psoriatic arthritis patients. These observations illustrate the
importance of matching disease pathology and therapeutic mechanism in order to optimize therapeutic benefit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ALZUMAb was well tolerated by the patients in the
Phase 3 TREAT-PLAQ trial, with infusion reactions and related events, which are expected for an antibody infusion, as the main adverse events, or AEs, attributed to ALZUMAb. The incidence of infusion reactions dropped sharply after the first few
infusions. ALZUMAb did not appear to increase the rate of infections compared to placebo, and the incidence of severe adverse events, or SAEs, was low (a total of five SAEs were reported). SAEs included exfoliative dermatitis (widespread redness and
peeling of the skin), erythrodermic (severe) psoriasis, infusion-related reaction, adjustment disorder with anxiety, and bacterial arthritis. No SAEs led to discontinuation or reduction of drug dosage. See <B>Table&nbsp;3</B> for a summary of
adverse events seen during the Phase&nbsp;3 trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><B>Table 3. Adverse events that occurred in &gt;5% of subjects in either ALZUMAb treatment arm, placebo arm, or
overall in the trial. </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Weeks <FONT STYLE="white-space:nowrap">1-12</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>ALZUMAb</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(n =
180)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">n(%)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Placebo</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(n =
43)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">n(%)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" ALIGN="center">Any Adverse Event</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">72 (40.0%)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20 (46.5%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" ALIGN="center">Infusion Reaction (acute)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">33 (18.3%)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (2.3%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" ALIGN="center">Infection</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6 (3.3%)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4 (9.3%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" ALIGN="center">Pruritus (itching)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 (2.8%)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 (7.0%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Weeks <FONT STYLE="white-space:nowrap">13-52</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>ALZUMAb</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(n = 223)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">n(%)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" ALIGN="center">Any Adverse Event</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">111 (49.8%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" ALIGN="center">Infusion Reaction (acute)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">38 (17.0%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" ALIGN="center">Pyrexia (fever)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">19 (8.5%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" ALIGN="center">Infection</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">17 (7.6%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" ALIGN="center">Pruritus</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">12 (5.4%)</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An examination of lymphocyte counts in the study noted an initially mild decrease in the mean absolute lymphocyte count in the two ALZUMab treatment arms during the
placebo controlled portion of the study (weeks 1-12). These observed changes were not associated with an increase in infection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g63c88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 10: Mean ALC Values (+/- Standard Deviation) vs Time.</B> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since approval and as of the current cut-off date of August&nbsp;10, 2017 for the most recent Periodic Safety Update Report, ALZUMAb has accrued approximately
275&nbsp;patient-years of use. Post-market safety surveillance has demonstrated 27&nbsp;AE reports in that time period, of which four have been noted as serious, including infusion reaction, type&nbsp;1 hypersensitivity, diarrhea and urticaria. The
overall safety profile is favorable and has remained largely unchanged from the time of approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>EQ001 Product Development </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ALZUMAb is produced in an NS0 cell line and is currently available only in an intravenous, or IV, formulation. EQ001 contains the identical monoclonal antibody sequence
produced in a Chinese hamster ovary, or CHO, cell line and is available in IV and subcutaneous injection, or SC, formulations. CHO cell lines are the industry-standard antibody therapeutic production system. EQ001 is manufactured by Biocon at
commercial scale in an FDA regulated manufacturing facility. We have received a &#147;study may proceed&#148; letter from the FDA in response to our IND submission, which contained data from Biocon demonstrating biocomparability of EQ001 and ALZUMAb
using industry-standard physico-chemical and biofunctional characterization methods. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g55w46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>EQ001 Phase 1 Clinical Trial in Healthy Subjects </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biocon conducted a Phase 1 clinical trial of EQ001 in 37 healthy subjects that was completed in Australia in the fourth quarter of 2017. The study was conducted in two
stages, with the first stage designed to assess the safety, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
tolerability, pharmacokinetics, or PK, pharmacodynamics, or PD, and immunogenicity of ascending single doses of EQ001 SC, and the second stage designed to compare the PK of EQ001 IV to ALZUMAb
and determine the absolute bioavailability of EQ001 SC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stage 1 was a randomized, double-blind, placebo controlled, ascending single dose evaluation of EQ001 SC. <FONT
STYLE="white-space:nowrap">Thirty-two</FONT> subjects completed Stage 1: 24 subjects (six per cohort) were administered EQ001 SC in single doses of 0.8 mg/kg, 1.6mg/kg, 2.4 mg/kg, or 3.2 mg/kg, and eight subjects were administered placebo. Serum
concentrations of EQ001 were measurable at Day 57, and the mean half-life ranged from 532 hours to 616 hours across dose cohorts. The PK for exposure following EQ001 SC administration were dose proportional, with the peak serum concentration
generally achieved within 168 hours after dosing for most subjects. Saturation of CD6 receptors by EQ001 was seen at all dose levels. During Stage 1, a transient decrease in T cells expressing CD4, and to a lesser extent CD8, here observed, as well
as a <FONT STYLE="white-space:nowrap">two-</FONT> to three-times increase in the proportion of T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The administration of single doses of EQ001 SC in Stage 1 was found to be well tolerated, with a low incidence (2/24) of low titer anti-drug antibodies. There were no
SAEs, dose limiting toxicities, or DLTs, or study drug discontinuations reported. No clinically meaningful changes in physical examinations or vital signs was observed, whereas transient decreases in lymphocyte counts without clinical consequences
were seen in 11/24 (46%) subjects. There were five subjects who experienced grade 3 treatment emergent adverse events, or TEAEs, of lymphocyte count decreases (two subjects each in the 1.6 mg/kg and 3.2 mg/kg dose cohorts and one subject in the 2.4
mg/kg dose cohort). Mild to moderate injection site reactions were observed in 15/24 (63%) of the patients. The other most common TEAEs with EQ001 SC were headache in 7/24 (29%), urticaria (hives) in 4/24 (17%), and pyrexia (fever) in 3/24 (13%) of
the subjects. In general, observed AEs were transient, mild to moderate in severity, were not dose dependent, and most were consistent with those observed in prior clinical experience with ALZUMAb. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stage 2 was a comparability study of the PK of EQ001&nbsp;IV, and ALZUMAb, and the absolute bioavailability of EQ001 SC. The trial featured a randomized, single-blind,
parallel group design for the comparability component, and an open-label design for the absolute bioavailability component. Seven subjects enrolled in the study and received single doses of 0.4 mg/kg (one subject each EQ001 SC, EQ001 IV, ALZUMAb,
and placebo) and 0.8 mg/kg (one subject each EQ001 SC, EQ001 IV, and ALZUMAb); five subjects completed the study, and one subject each that received EQ001 IV and ALZUMAb in the 0.8 mg/kg group discontinued dosing early due to AEs (one subject
experienced persistent cough and dizziness; one subject experienced nausea). The infusion of single doses of both EQ001 IV and ALZUMAb was associated with the development of transient, reversible, grade 2 to 3 decreases in lymphocyte counts in the
healthy subjects. As a result, Stage 2 of the trial was terminated early following the enrollment of seven subjects, yielding limited overall safety data and insufficient PK data for evaluation. There were no SAEs reported. No other clinically
meaningful abnormalities or trends were noted in clinical chemistry, hematology, and urinalysis parameters. Similar to Stage 1, a transient decrease in T cells expressing CD4, and to a lesser extent CD8, a
<FONT STYLE="white-space:nowrap">two-</FONT> to three-times increase in the proportion of T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells, and saturation of CD6 receptors were observed across EQ001 and ALZUMAb cohorts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While similar decreases in lymphocyte counts have not been reported with ALZUMAb previously, the timing of hematologic assessments in prior clinical studies may not
have occurred at sufficiently early time-points to detect this transient response. Additionally, ALZUMAb had previously only been dosed in patients with active autoimmune disease and not healthy subjects. Importantly, the magnitude and kinetics of
lymphocyte decreases were similar for EQ001 IV and ALZUMAb in Stage 2, while administration of EQ001 SC demonstrated milder decreases in lymphocyte counts, which would be expected based on the different PK properties of SC versus IV formulations.
Furthermore, ALZUMAb had been well tolerated with demonstrated safety and clinical activity in three clinical studies in India in patients with rheumatoid arthritis and chronic plaque psoriasis, with a total of 333 patients exposed to ALZUMAb to
date in clinical trials at doses ranging from 0.2 mg/kg to 1.6 mg/kg over a period of four years. Therefore, we believe the transient decreases in lymphocyte counts seen in the Phase 1 clinical trial in healthy subjects represents a PD property of
both EQ001 and ALZUMAb that will be monitored going forward, and the results of the Phase 1 clinical trial support the advancement of EQ001 SC and IV into further clinical development in patients with immuno-inflammatory disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Planned Initial Clinical Indications </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to initially develop EQ001 for the treatment of aGVHD, cGVHD, severe asthma and at least one additional indication. We expect to initiate a Phase 1b/2 clinical
trial of EQ001 in patients with aGVHD in early 2019 and a Phase 2 clinical trial of EQ001 in patients with cGVHD in the first half of 2019. We also plan to initiate a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial in severe asthma in the first half of 2019. We continue to evaluate additional indications for future development and plan to select a
fourth indication in the first half of 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Graft-Versus-Host Disease Market Overview </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">aGVHD and cGVHD are multisystem disorders that are common complications of allogeneic hematopoietic stem cell transplants, or allo-HSCT, caused by the transplanted
immune system recognizing and attacking the recipient&#146;s body. GVHD is the leading cause of <FONT STYLE="white-space:nowrap">non-relapse</FONT> mortality in patients receiving an allo-HSCT. The risk of GVHD limits the number and type of patients
receiving HSCT and we believe that a therapy that can attenuate GVHD risk could significantly expand the patient population eligible for allo-HSCT. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to
the Center for International Blood&nbsp;&amp; Marrow Transplant Research, there were more than 8,500 allo-HSCT&#146;s performed in the United States in 2016 and the number of procedures has grown at an average annual growth rate of approximately 4%
since 2007. Approximately 50% of HSCT recipients develop GVHD. HSCT recipients are at risk of developing either or both aGVHD and cGVHD with approximately <FONT STYLE="white-space:nowrap">30-70%</FONT> of HSCT recipients developing aGVHD, 50% of
which will get cGVHD, and another <FONT STYLE="white-space:nowrap">30-70%</FONT> developing cGVHD independent of aGVHD. Five year survival for patients that respond to first-line treatment with corticosteroids has been reported to be as low as 53%
while steroid refractory aGVHD mortality has been reported to be as high as 95%. We estimate that the incidence of aGVHD in 2018 is up to 5,000 patients and the total prevalence of GVHD could be up to 25,000 patients. We estimate that by the year
2025, the annual incidence of aGVHD will be up to 6,000 patients and the total prevalence of GVHD could be up to 35,000 patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rationale for EQ001 for the
Treatment of GVHD </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third-party clinical experience with targeting CD6 in GVHD </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical evidence to support the rationale of treating GVHD with EQ001 comes from previously-reported third-party clinical experience with CD6 expressing T cell
depletion in patients receiving bone marrow transplants for hematologic malignancies where it has been demonstrated that using an <FONT STYLE="white-space:nowrap">anti-CD6</FONT> monoclonal antibody to deplete T&nbsp;cells from donor bone marrow or
lymphocyte infusions has the potential to prevent aGVHD. In a study evaluating the clinical effects of selective <I>in vitro </I>CD6 expressing <FONT STYLE="white-space:nowrap">T-cell</FONT> depletion of donor allogeneic bone marrow using a
monoclonal antibody to CD6 and rabbit complement, Soiffer et al. reported that <I>in vitro</I> <FONT STYLE="white-space:nowrap">T-cell</FONT> depletion with an <FONT STYLE="white-space:nowrap">anti-CD6</FONT> monoclonal antibody effectively reduced
the incidence of both acute and chronic GVHD after allogeneic bone marrow transplant without compromising engraftment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subsequent studies further confirmed the
feasibility of CD6 expressing T&nbsp;cell depletion in patients undergoing allogeneic bone marrow transplantation from human leukocyte antigen identical related and unrelated donors. In these studies, CD6 expressing depletion of the donor stem cell
product was the sole method for GVHD prophylaxis. The low incidence of aGVHD reported in patients receiving allogeneic bone marrow treated with <FONT STYLE="white-space:nowrap">anti-CD6</FONT> monoclonal antibodies was attributed to the early
appearance of a population of peripheral CD3 expressing T&nbsp;lymphocytes with a <FONT STYLE="white-space:nowrap">CD6-negative</FONT> phenotype, which showed diminished reactivity to allogeneic stimulation in mixed lymphocyte reaction assays.
Although the above described approach is one of <I>ex vivo</I> CD6 expressing T&nbsp;cell depletion, we believe that it further supports the role of CD6 expressing T&nbsp;cells in aGVHD pathogenesis and validates CD6 as a potentially important
target for modulation for the treatment of GVHD. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>EQ001 selectively targets GVHD pathogenesis </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is a high unmet medical need for a safe, effective and targeted treatment in GVHD. We believe EQ001 has the potential to be a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for both aGVHD and cGVHD based on its ability to target the underlying biology of GVHD in a highly selective way. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is well established that T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells, driven by pSTAT3 signaling, play a role in the pathogenesis of both
aGVHD and cGVHD, and studies have shown that pSTAT3 was significantly increased in T&nbsp;cells of GVHD patients. In aGVHD, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
additional studies have reported that T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells and <FONT STYLE="white-space:nowrap">IL-17</FONT> serum levels were significantly elevated
in patients at onset compared with HSCT patients without aGVHD. As the disease progresses, T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells traffic from the peripheral blood into GVHD target tissues where they trigger damage.
Furthermore, the expansion of T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells in the early phase of aGVHD plays a role in the transition to cGVHD. In GVHD patients, studies have shown a high T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17:T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> ratio suggesting a loss of tolerance. Notably the increased number of circulating
T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells was accompanied by a decrease in T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells, suggesting a loss of T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB>
cell regulation. Such regulatory mechanisms are crucial for eliminating alloreactive T cell activity, thus preventing sustained autoimmune responses and tissue destruction in GVHD. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe EQ001 can selectively target elements of the underlying pathogenesis of both aGVHD and cGVHD by: a)&nbsp;inhibiting T<SUB
STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells proliferation; b)&nbsp;downregulating the STAT3 pathway associated with development of pathogenic T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells driving GVHD
pathogenesis; c)&nbsp;inhibiting trafficking of T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> cells into GVHD target tissues preventing further inflammation and organ damage; and d)&nbsp;reducing the T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17:T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> ratio associated with the development of GVHD and thereby promoting tolerance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Development Plan in GVHD </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to initiate a Phase 1b/2
multicenter clinical trial in approximately 84 patients in order to evaluate the safety, tolerability, PK and clinical activity of EQ001&nbsp;IV in newly diagnosed aGVHD patients in early 2019 and expect
<FONT STYLE="white-space:nowrap">top-line</FONT> data from the Phase 1b part of the trial within 12 months of initiation. All patients will be administered EQ001 as a front-line therapy concomitant with steroid use upon first presentation of aGVHD.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Phase 1b part of the trial will be an open-label, cohort based, dose escalation study that will enroll up to 24 adult patients in successive cohorts of three
to six patients treated with multiple doses of EQ001&nbsp;IV. The primary objective of this part of the trial will be to assess the safety and tolerability of EQ001 and to determine the optimal dose. Secondary objectives include assessing
pharmacological activity of EQ001. Once an optimal dose is determined, and if the observed safety, tolerability, and pharmacological activity of EQ001 warrants, we will commence the Phase 2 part of the trial. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Phase 2 part of the trial will be a randomized, double-blind, placebo-controlled study that will enroll up to 60 additional patients, randomized in a 2:1 ratio with
40 patients on active treatment of EQ001 and 20 patients on placebo. The primary objective of the Phase 2 part of the trial will be to assess the clinical activity of EQ001 and secondary objectives include further characterizing safety and
tolerability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also plan to initiate a Phase 2 clinical trial of EQ001 for the treatment of cGVHD in the first half of 2019 under our existing IND. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Severe Asthma Market Overview </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Asthma is a heterogeneous disease
characterized by both allergic (T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 driven) and autoimmune mechanisms (T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 driven), leading to chronic airway inflammation. Asthma is
now recognized as a disease with two predominant subtypes categorized by the degree of T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-associated inflammation present in the airways. One subtype of asthma, often characterized as allergic
asthma, includes patients with high levels of T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-associated inflammation, or T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-high,</FONT> in the
airways, often accompanied by high levels of eosinophils, and production of immunoglobulin E, or IgE. We estimate that <FONT STYLE="white-space:nowrap">40-50%</FONT> of the poorly controlled severe asthma population fall within the T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-high</FONT> subtype. These T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-high patients often respond to treatment with steroids and recently
approved biologic therapies which target IgE or T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-cytokines.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Another subtype of asthma is characterized by low levels of T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-associated inflammation, or T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-low,</FONT> in the airways. These T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-low patients typically do not respond to treatment with
corticosteroids or recently approved biologic therapies, have more severe disease, and have low levels of eosinophils. We estimate that 50&#150;60% of the poorly controlled severe asthma population fall within the T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-low</FONT> subtype. A portion of T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-low patients have airway inflammation caused by T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cytokines such as IL-17. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on publicly available sources, we estimate that asthma impacts approximately
26&nbsp;million individuals. Of these, 5&#150;10%, or approximately 1.3&#150;2.6&nbsp;million individuals, suffer from severe disease, and approximately half of these patients are poorly controlled with the current standard of care. We estimate that
50&#150;60% of poorly controlled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patients do not respond to therapies targeting T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-driven</FONT> disease. Notably, these patients account
for most asthma-related treatment costs and economic burden. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rationale for EQ001 for Severe Asthma </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Current therapies for severe asthma and their limitations </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mild-to-moderate</FONT></FONT> asthma accompanied by T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-high</FONT> inflammation respond well to
currently available treatments, including inhaled corticosteroids, or ICS, and long-acting beta agonists. Patients with T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-low</FONT> or severe disease are
often not adequately controlled by these therapies, resulting in a large unmet need. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recently, several biologic therapies that specifically target IgE or T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-associated cytokines have been approved by the FDA for the treatment of moderate to severe asthma. While these therapies have proven effective for
T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-high</FONT> inflammation they have had a minimal impact in patients with T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT
STYLE="white-space:nowrap">2-low</FONT> inflammation. Genentech Inc.&#146;s Xolair, or omalizumab, is an <FONT STYLE="white-space:nowrap">anti-IgE</FONT> approved for the treatment of moderate to severe persistent allergic asthma that is not
controlled by ICS. Other recently approved biologic therapies that are directed against <FONT STYLE="white-space:nowrap">IL-5</FONT> or the <FONT STYLE="white-space:nowrap">IL-5</FONT> receptor, which together mediate eosinophil development and
inflammation of the airways, include mepolizumab (marketed under the name Nucala by GlaxoSmithKline plc), reslizumab (marketed under the name CINQAIR by Teva Pharmaceutical Industries Limited) and benralizumab (marketed under the name Fasenra by
AstraZeneca plc). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC have filed a BLA for the approval of Dupixent (dupilimab), an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-4</FONT></FONT> receptor antibody, for the treatment of moderate to severe asthma. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>EQ001 for
T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB><FONT STYLE="white-space:nowrap">2-low</FONT> inflammation in asthma pathogenesis </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is a high
unmet medical need for a safe, effective and targeted treatment for patients with severe asthma. We believe that the unique mechanism of action of EQ001 has the potential to treat severe asthma patients characterized by an immunophenotype of low T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 and high T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 and who consequently have a poor response to high dose inhaled and/or oral steroids. There are a sizeable number of these
patients who are underserved by currently available therapies and for which there are no FDA-approved biologic or other targeted treatments. Studies have shown that T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 and T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells are reciprocally regulated. More specifically, T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 cytokines can negatively regulate T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cytokine expression which means that T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-high patients cannot also be T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17-high
patients. As a result, if a drug only downregulates T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 associated inflammation, then a T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-high patient may experience increased
inflammation caused by T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells, and vice versa. We believe that targeting both T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 cytokines and T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cytokines, such as IL-17, may maximize therapeutic efficacy for T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-low patients with inflammation caused by T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cytokines by avoiding a potential increase in inflammation caused by T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells. By selectively targeting elements of the underlying
pathogenesis of severe asthma by inhibiting proliferation of both T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 and T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells and associated cytokines driving T<SUB
STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-low inflammation, EQ001 has the potential opportunity to provide a meaningful benefit to severe asthma patients. <B>See Figure 11.</B> </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g31y00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 11: T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 cells expressing CD6 drive severe refractory
asthma.</B> Current approved therapeutic approaches target downstream signaling of T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-associated inflammation and are largely ineffective in patients with low levels of eosinophils. We believe
the upstream mechanism of EQ001 can uniquely address both the T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2 and T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>17 inflammation driving severe refractory asthma pathogenesis.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Translational research program supporting EQ001 in severe asthma </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:3%; font-size:9.5pt; font-family:ARIAL">To further validate the use of EQ001 in severe asthma, we have an ongoing translational research program assessing the role of CD6 in severe asthma,
specifically in T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-low asthma. Preliminary findings derived from analysis of gene expression datasets support the presence of increased CD6, CD4 T cells, and ALCAM in the lungs of severe
asthma patients. Gene expression in cells collected from the lungs of non-asthma, steroid-sensitive moderate asthma, and steroid-insensitive severe asthma patients, suggest that CD6 is significantly elevated in severe asthma, likely due to increases
in CD4 T cells as supported by higher CD4 gene expression. In a separate set of patients, analysis of gene expression in lung tissue suggests higher expression of the CD6 ligand ALCAM within the airway of patients who have died from asthma. See
<B>Figure&nbsp;12</B>. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g13f61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:8pt; font-family:ARIAL"><B>Figure 12: CD6 is upregulated in cells collected from lungs of severe asthma patients.</B> (A and B) Analysis of
gene expression in cells collected from lungs of healthy non-asthma, moderate asthma and severe asthma patients as part of two multi-center prospective observational studies (Study of the Mechanisms of Asthma (MAST; NCT00595153); Bronchoscopic
Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) study) shows higher levels of (A) CD6 expression and (B) CD4 expression in severe asthma, indicating the presence of CD6 in severe asthma and the presence of CD4 T
cells. (C) Gene expression in smooth airway muscle from lung tissue of fatal asthmatic patients suggest elevation of ALCAM. <I>***p&lt;0.001, *p&lt;0.05.</I> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Development Plan in Asthma </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to file an IND and initiate a
proof-of-concept clinical trial of EQ001 for the treatment of severe asthma in the first half of 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Partnerships </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Collaboration and License Agreement with Biocon </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2017, we
entered into a collaboration and license agreement with Biocon, or the Biocon License, pursuant to which Biocon granted us an exclusive license in the United States and Canada, or the Equillium Territory, to develop, make, have made, use, sell, have
sold, offer for sale, import and otherwise exploit EQ001 and any pharmaceutical composition or preparation containing or comprising EQ001, or collectively, a Biocon Product, that uses Biocon technology or Biocon
<FONT STYLE="white-space:nowrap">know-how.</FONT> However, unless we achieve certain regulatory and development milestones within a specific time period, the licensed rights, other than development rights, are limited to the field of orphan
indications. We also have the right to sublicense through multiple tiers to third parties, provided such sublicenses comply with the terms of the Biocon License and we provide Biocon a copy of each sublicense agreement within 30 days of execution.
Under the Biocon License, we granted back to Biocon a license to use our technology and <FONT STYLE="white-space:nowrap">know-how</FONT> related to EQ001 and Biocon Products in certain countries outside of the Equillium Territory. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In consideration of the rights granted to us by Biocon, we issued Biocon shares of our common stock equal to 19.5% of our outstanding shares at the time of the
execution of the Biocon License. Biocon also has certain anti-dilution rights which are described in &#147;Description of Capital Stock&nbsp;&#151; Anti-Dilution Rights.&#148; In addition, we are obligated to pay Biocon up to an aggregate of
$30&nbsp;million in regulatory milestone payments upon the achievement of certain regulatory approvals and up to an aggregate of $565&nbsp;million in sales milestone payments upon the achievement of </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
first commercial sale of product and specified levels of product sales. We are also required to pay quarterly tiered royalties based on a percentage from the
<FONT STYLE="white-space:nowrap">mid-single</FONT> digits to sub-teen double digits of net sales of Biocon Products, subject to adjustments in certain circumstances. Biocon is also required to pay us royalties at comparable percentages for sales of
EQ001 outside of the Equillium Territory if the approvals in such geographies included or referenced our data, including data from certain of our clinical trials, subject to adjustments in certain circumstances. Under the Biocon License, net sales
are calculated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and are subject to adjustments, including whether the Biocon Product is sold in the form of a combination product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Biocon License will continue until the expiration of all royalty obligations, unless terminated earlier. Our royalty obligations expire on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of ten years from the first
commercial sale of such Biocon Product in such country, the expiration of regulatory exclusivity, and the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Biocon patent covering such
Biocon Product in such country. We may terminate the Biocon License unilaterally, with or without reason, upon 120&nbsp;days&#146; prior written notice and either party may terminate the Biocon License in the event of the other party&#146;s material
breach of the Biocon License that remains uncured for 90&nbsp;days after receipt of notice from the <FONT STYLE="white-space:nowrap">non-breaching</FONT> party. Upon termination by us unilaterally or by Biocon for our material breach, Biocon will
retain its license to use our intellectual property related to EQ001 and Biocon Products in certain countries outside the Equillium Territory, and we also will grant Biocon a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, and a right
of first negotiation to an exclusive license, to use our intellectual property related to EQ001 and Biocon Products in the Equillium Territory. Further, we are subject to certain diligence obligations related to development, commercialization and
funding activities and if we fail to comply with these obligations Biocon may, in certain circumstances, terminate the Biocon License and, in certain other circumstances, such failure may result in the permitted field of use for licensed Biocon
Products being limited to orphan indications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Supply Agreement with Biocon </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2017, in connection with the Biocon License, we entered into a clinical supply agreement, or the Biocon Supply Agreement, with Biocon, pursuant to which Biocon
agreed to be our exclusive supplier of EQ001 clinical drug product for up to three concurrent orphan drug clinical indications at no cost until our first U.S. regulatory approval and all other clinical drug product at cost. The Biocon Supply
Agreement will remain in effect until the expiration or termination of the Biocon License. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the United States and
internationally for our product candidate, novel biological discoveries, epitopes, new therapeutic approaches and potential indications, and other inventions that are important to our business. For our product candidates, generally we initially
pursue patent protection covering compositions of matter, antibody sequence diversity, epitopes, functional activity and methods of use. Throughout the development of our product candidates, we will seek to identify additional means of obtaining
patent protection that would potentially enhance commercial success, including through additional methods of use and biomarker and companion diagnostic related claims. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2018, our patent portfolio related to EQ001 included patents and patent applications exclusively licensed from Biocon in the United States and
Canada, as well as a pending U.S. provisional patent application that we own. The terms of the Biocon License are discussed above in &#147;Business&#151;Partnerships&#151;Collaboration and License Agreement with Biocon and Clinical Supply Agreement
with Biocon.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specifically, as of June&nbsp;30, 2018, our licensed rights from Biocon related to EQ001 include four issued patents in the United States, two
issued patents in Canada, three pending patent applications in the United States, one pending patent application in Canada, and two pending international applications filed under the Patent Cooperation Treaty, or PCT. Our issued U.S. patents are
expected to expire in 2028 (absent any patent term extension for regulatory delays) and include claims directed to the antibody sequence of EQ001 and methods of formulating and using EQ001 alone or in combination with other agents to treat various
T&nbsp;cell mediated diseases and disorders including GVHD and transplant rejection. Our issued Canadian patents are expected to expire between 2027 and 2030. Patents that may issue from our pending
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications are expected to expire between 2027 and 2037, absent any patent term adjustments or extensions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, Equillium owns one pending U.S. provisional patent application related to methods of using EQ001 to
treat severe asthma. If granted, this patent is expected to expire in 2039, absent any patent term adjustments or extensions. Provisional applications for patents were designed to provide a lower-cost first patent filing in the United States.
Corresponding <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications must be filed not later than 12 months after the provisional application filing date. The corresponding <FONT STYLE="white-space:nowrap">non-provisional</FONT>
application benefits in that the priority date(s) of the patent application is/are the earlier provisional application filing date(s), and the patent term of the finally issued patent is calculated from the later
<FONT STYLE="white-space:nowrap">non-provisional</FONT> application filing date. This system allows us to obtain an early priority date, add material to the patent application(s) during the priority year, obtain a later start to the patent term and
to delay prosecution costs, which may be useful in the event that we decide not to pursue examination in an application. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We file U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> applications and PCT applications that claim the benefit of the priority date of earlier filed provisional applications, when applicable. The PCT system allows a single application to be filed within
12 months of the original priority date of the patent application, and to designate all of the 152 PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The
PCT searching authority performs a patentability search and issues a <FONT STYLE="white-space:nowrap">non-binding</FONT> patentability opinion which can be used to evaluate the chances of success for the national applications in foreign countries
prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications. At the end of the period of 2 1/2 years from
the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases by filing through a regional patent organization, such as the European
Patent Organization. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial savings where applications are abandoned within the first 2 1/2 years of
filing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to prosecute the pending applications that we own and <FONT STYLE="white-space:nowrap">in-license</FONT> and to pursue patent issuance and
protection in key commercial markets where we expect significant product sales may occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With the enactment of the Biologics Price Competition and Innovation Act
of 2009, or BPCIA, an abbreviated pathway for the approval of biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics,
including the possible designation of a biosimilar as interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original
branded product is approved under a BLA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific
and factual questions. We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty and
<FONT STYLE="white-space:nowrap">non-obviousness</FONT> of the invention, and the ability to satisfy the enablement requirement of the patent laws. In addition, the coverage claimed in a patent application can be significantly reduced before the
patent is issued, and its scope can be reinterpreted after issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our product candidates. We cannot predict whether the patent applications we are currently
pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by
third parties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success will also depend in part on not infringing the proprietary rights of third parties. In addition, we have licensed rights
under proprietary technologies of third parties to develop, manufacture and commercialize specific aspects of our products and services. It is uncertain whether the issuance of any third party patent would require us to alter our development or
commercial strategies, alter our processes, obtain licenses or cease certain activities. The expiration of patents or patent applications licensed from third parties or our breach of any license agreements or failure to obtain a license to
proprietary rights that we may require to develop or commercialize our future technology may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have
rights, we may have to participate in interference proceedings in the United States Patent and Trademark Office, or USPTO, to determine priority of invention. For a more comprehensive discussion of the risks related to our intellectual property,
please see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term of individual patents depends upon the legal term of the patents in the countries in which they are
obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-</FONT> provisional patent application related to the patent. A U.S. patent also may be accorded a PTA
under certain circumstances to compensate for delays in obtaining the patent from the USPTO. In some instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest date of filing a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application related to the U.S. patent. In addition, in the United States, the term of a U.S. patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may also be
eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the
expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of
product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when
our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is
no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also rely on trade secrets relating to product candidates and seek to protect and maintain the confidentiality of proprietary information to protect aspects of our
business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and
consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets, including through breaches of such agreements with our employees and consultants.
Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific partners, sponsored researchers and other advisors to execute confidentiality agreements upon the
commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the
individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of
employment with us or from the employee&#146;s use of our confidential information are our exclusive property. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are characterized by continuing technological advancement and significant competition. While we believe that our product
candidates, technology, knowledge, experience and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and
private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect
our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. The level of generic competition and the availability of reimbursement from government and other third-party payors will also
significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors
establishing a strong market position before we are able to enter the market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of the companies against which we may compete have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove
to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specifically, there are several companies developing or marketing treatments that may be approved for the same
indications and/or diseases as our lead product candidate EQ001. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Graft-Versus-Host Disease </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Corticosteroids, or steroids, remain the first-line of therapy for both aGVHD and cGVHD. There are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
therapies for the treatment of aGVHD, and second-line therapy consists of <FONT STYLE="white-space:nowrap">off-label</FONT> immunosuppressives for which the therapeutic benefit has not been established. Additionally, there is only one approved
therapy for cGVHD, Imbruvica (ibrutinib), approved for cGVHD after failure of one or more lines of therapy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we are aware of a number of companies with
development programs in aGVHD and cGVHD, including AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, CSL Behring LLC, Jazz Pharmaceuticals plc, Kadmon Holdings, Inc., Kalytera Therapeutics, Inc., Kamada Ltd., Mesoblast Limited,
Novartis AG, Prometheus Laboratories Inc. and Xenikos B.V. Incyte Corporation is developing both Jakafi (ruxolitinib), for steroid-refractory aGVHD as well as cGVHD, and itacitinib, a JAK1 inhibitor, for first-line treatment of aGVHD, currently in
Phase 3 clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Severe Asthma </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Several biologic
therapies that specifically target IgE or T<SUB STYLE="font-size:85%; vertical-align:bottom">h</SUB>2-associated cytokines have been approved by the FDA for the treatment of asthma including products developed by AbbVie Inc., Amgen Inc., AstraZeneca
plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Roche Holding AG and Teva Pharmaceutical Industries Limited. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition,
Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC have filed a BLA for the approval of Dupixent (dupilimab), an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-4</FONT></FONT> receptor antibody, for the treatment
of moderate to severe asthma. We are also aware of several companies with development programs in this indication including, AbbVie Inc., Amgen Inc., AnaptysBio, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG,
Regeneron Pharmaceuticals, Inc., Roche Holding AG and Sanofi-Aventis U.S. LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We intend to build a commercial infrastructure to
support sales of&nbsp;EQ001&nbsp;in the United States. We expect to manage sales, marketing and distribution through internal resources and third-party relationships. While we may commit significant financial and management resources to commercial
activities, we will also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not own or operate manufacturing facilities for the production of EQ001 or any future product candidates, nor do we have plans to develop our own manufacturing
operations in the foreseeable future. We currently rely on Biocon, our third-party contract manufacturer, pursuant to the Biocon License and Biocon Supply Agreement, for all our required raw materials, drug substance and drug product needs for
preclinical research, clinical trials and commercial supply of EQ001. If EQ001 is approved, we have agreed to enter into a separate exclusive supply agreement with Biocon in the future. Biocon currently manufactures EQ001 at its FDA regulated
facility in Bangalore, India. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to any future product candidates, we expect to rely on third-party contract manufacturers for all our required raw
materials, drug substance and drug product needs for preclinical research, clinical trials and commercial supply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation and Product Approval
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the
research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various
preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the FDA regulates biologics under both the Federal Food, Drug and Cosmetic Act, or FDCA, and the Public Health Services Act, or PHSA, and their
implementing regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s current Good
Laboratory Practices, or GLP, regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually
or when significant changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial
is commenced; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the
proposed biologic product candidate for its intended purpose; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials that includes
substantial evidence of safety, purity and potency from results of nonclinical testing and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing
facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s continued safety, purity and potency, and
of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA review and approval, or licensure, of the BLA to permit commercial marketing of the product for particular indications
for use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical and Clinical Development </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer
an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and <I>in vitro</I> studies assessing the
toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product candidate; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational
product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises
safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission
of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials involve the administration of the investigational product
to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are
conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each
successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial
and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding
that the subjects are being exposed to an unacceptable health risk or that the trial is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring
board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for
subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1&#151;The investigational product is initially introduced into healthy human subjects or patients with the target
disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism, distribution and elimination of the investigational product in humans, the side effects associated with increasing doses, and, if
possible, to gain early evidence on effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2&#151;The investigational product is administered to a limited patient population with a specified disease or
condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and
more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3&#151;The investigational product is administered to an expanded patient population to further evaluate dosage, to
provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of
the investigational product and to provide an adequate basis for product approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some cases, the FDA may require, or companies may
voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <FONT STYLE="white-space:nowrap">so-</FONT> called Phase 4 studies may be made a condition to approval of the BLA.
Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in
commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity,
strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate
does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>BLA Submission, Review and Approval </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical
studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment of
a substantial application user fee to FDA, unless a waiver or exemption applies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once a BLA has been submitted, the FDA&#146;s goal is to review standard
applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process
is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed,
packed, or held meets standards designed to assure the product&#146;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will
typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure
compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information.
Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA
may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the
deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required
inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for
additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor
safety or efficacy of a product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail
limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety
strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or
elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate
controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches
the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further marketing of the product based on
the results of these post-marketing studies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any marketing application for a biologic submitted to the FDA for approval may be eligible for FDA programs intended to expedite the FDA review and approval process,
such as priority review, fast track designation, breakthrough therapy and accelerated approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A product is eligible for priority review if it has the potential
to provide safe and effective therapy where no satisfactory alternative therapy exists or to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products
containing new molecular entities, priority review designation means the FDA&#146;s goal is to take action on the marketing application within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date (compared with ten months
under standard review). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat
a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety
factors. Fast track designation provides opportunities for frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the BLA for a fast track product on a rolling basis
before the complete application is submitted, if the sponsor and FDA agree on a schedule for the submission of the application sections, and the sponsor pays any required user fees upon submission of the first section of the BLA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, passed in July 2012, a sponsor can request designation of a
product candidate as a &#147;breakthrough therapy.&#148; A breakthrough </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and
preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review
of an application for approval of a breakthrough therapy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening
diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than
irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or
lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible
morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing
of the commercial launch of the product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets
the conditions for qualification or decide that the time period for FDA review and approval will not be shortened. Furthermore, priority review, fast track designation, breakthrough therapy designation, and accelerated approval do not change the
standards for approval but may expedite the development or approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition
that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or
biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan designation must be requested before submitting a BLA. After the FDA grants orphan designation, the generic identity
of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to
orphan exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority
to the product with orphan drug exclusivity . Orphan exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other
benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A designated orphan product may not receive
orphan exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for
designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any products manufactured or distributed
by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to quality control and quality assurance, record-keeping, reporting of adverse experiences, periodic
reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval.
There also are continuing user fee requirements, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with
the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party
manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any
deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to
maintain compliance with cGMP and other aspects of regulatory compliance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may withdraw approval if compliance with regulatory requirements and standards is
not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to
comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or
other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of a product, mandated modification of promotional materials or issuance of
corrective information, issuance by FDA or other regulatory authorities of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product, or complete
withdrawal of the product from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, warning or untitled letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of
existing product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention, or refusal of the FDA to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions, consent decrees or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity
and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT>
uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses
that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties. Physicians may believe that
such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict
manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Biosimilars and Reference
Product Exclusivity </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the
ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents
outlining its approach to the review and approval of biosimilars. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biosimilarity, which requires that there be no clinically meaningful differences between the
biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference
product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive
use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the
abbreviated approval pathway that are still being worked out by the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA
until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was
first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that
applicant&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as
interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the <FONT
STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact,
implementation, and impact of the BPCIA is subject to significant uncertainty. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other U.S. Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, our current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including but
not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, or HHS (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and
Service Administration), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, our clinical research, sales, marketing and scientific/educational grant programs may
have to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as
amended, as applicable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable, in
whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between
therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions
and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor.
Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under
a statutory exception or regulatory safe harbor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or Affordable Care Act, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to
violate it in order to have committed a violation. In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the federal False Claims Act, or FCA (discussed below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal false claims and civil monetary penalty laws, including the FCA, which imposes significant penalties and
can be enforced by private citizens through civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal
government, including federal healthcare programs, such as Medicare and Medicaid, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or knowingly
making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. For instance,
historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies
have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, <FONT STYLE="white-space:nowrap">off-label,</FONT> and thus generally
<FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and
willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit
program, including private third-party payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any
materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare
fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also, many states have similar, and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and
other state programs, or, in several states, apply regardless of the payor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be subject to data privacy and security regulations by both the federal
government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the privacy,
security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates, independent contractors, or agents of covered
entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties
directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal
civil actions. In addition, many state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted</FONT>
by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may develop products that, once approved, may be administered
by a physician. Under currently applicable U.S. law, certain products not usually self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the
federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services and supplies, including certain biopharmaceutical products, that are medically necessary to treat a beneficiary&#146;s health
condition. As a condition of receiving Medicare Part B reimbursement for a manufacturer&#146;s eligible drugs, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug Rebate Program and the
340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching funds for
the manufacturer&#146;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that participate in the program. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and
best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors
and by any future relaxation of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. It is difficult to predict how Medicare coverage and reimbursement
policies will be applied to our products in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare
program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the federal Physician Payments Sunshine Act, or the Sunshine Act, within the Affordable Care Act, and its implementing regulations, require
that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report annually to CMS information
related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report
annually certain ownership and investment interests held by physicians and their immediate family members. Failure to report accurately could result in penalties. In addition, many states also govern the reporting of payments or other transfers of
value, many of which differ from each other in significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted,</FONT> and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and
biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements
on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the
distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing,
pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology
companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ensuring business arrangements with third parties comply with applicable healthcare laws and regulations is a costly endeavor. If our operations are found to be in
violation of any of the federal and state healthcare laws described above or any other current or future governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative
penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name
of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject
to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our
ability to operate our business and our results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Coverage, Pricing and Reimbursement </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. In the United States
and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such
products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. Adequate coverage and reimbursement from governmental healthcare programs,
such as Medicare and Medicaid in the United States, and commercial payors are critical to new product acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to commercialize any products
successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.
Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which therapeutics they will pay for and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a
therapeutic is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of
reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement may impact the demand for, or the price of, any product for which we
obtain regulatory approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third-party payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of
medical products, therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded drugs and drugs
administered under the supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA
approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could
require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance
that coverage and adequate reimbursement will be obtained. A payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for
a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in
product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Different pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the price of biopharmaceutical products through their
pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed
once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently
available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being
erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to
provide adequate coverage and reimbursement. In addition, emphasis on managed care, the increasing influence of health maintenance organizations, and additional legislative changes in the United States has increased, and we expect will continue to
increase, the pressure on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. Coverage
policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and
reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the
healthcare system that could prevent or delay marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy
makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the
pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, the
Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to
those otherwise described above, are the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and
biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive
to January&nbsp;1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts, which through subsequent legislative amendments, will be increased to 70%, starting in 2019, off negotiated prices of applicable brand drugs to
eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#146; outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in
Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage
to additional individuals beginning in 2014 and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expansion of the entities eligible for discounts under the 340B Drug Discount Program; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical
effectiveness research, along with funding for such research; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expansion of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute, new government
investigative powers, and enhanced penalties for noncompliance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs
that are inhaled, infused, instilled, implanted, or injected; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to report certain financial arrangements with physicians and teaching hospitals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to
physicians; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery
models to lower Medicare and Medicaid spending; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a licensure framework for follow on biologic products. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to certain aspects of the Affordable
Care Act. Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December 2017, Congress repealed the tax penalty
for an individual&#146;s failure to maintain Affordable Care <FONT STYLE="white-space:nowrap">Act-mandated</FONT> health insurance as part of a tax reform bill. Further, on January&nbsp;22, 2018, President Trump signed a continuing resolution on
appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care <FONT STYLE="white-space:nowrap">Act-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on
certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share,&nbsp;and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices.
Moreover, the Bipartisan Budget Act of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
2018, or the BBA, among other things, amends the Affordable Care Act, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the
&#147;donut hole.&#148; More recently, in July 2018, CMS announced that it is suspending further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk
adjustment program pending the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Congress is continuing to consider legislation that would alter other aspects of the Affordable Care Act.
The ultimate content, timing or effect of any healthcare reform legislation on the U.S. healthcare industry is unclear. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that the Affordable Care Act,
if substantially maintained in its current form, will continue to result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from
Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain
profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall
financial condition and ability to develop product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further legislation or regulation could be passed that could harm our business, financial condition
and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things,
created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal
years 2012 through 2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on
April&nbsp;1, 2013 and will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to
several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there
have been several recent U.S. Congressional inquiries and proposed federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between
pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#146;s budget proposal for fiscal year 2019 contains further drug price control measures
that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate
drug prices under Medicaid, and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. Further, the Trump administration released a &#147;Blueprint,&#148; or plan, to lower drug prices and reduce
out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products,
and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some of these measures and, at the same, is immediately
implementing others under its existing authority. While some proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new
legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control biopharmaceutical product pricing,
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Foreign Corrupt Practices Act </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value,
directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also
obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international
subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Regulation </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the
Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by,
our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable
environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Regulations </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also subject to numerous federal, state and
local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such
laws and regulations now or in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
June&nbsp;30, 2018, we employed seven employees, all of whom are full-time and engaged in research and development activities, operations, finance, business development and administration. Two of our employees hold doctorate degrees (Ph.D., M.D. or
PharmD.). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Research and Development </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have invested $1.3&nbsp;million
and $1.2&nbsp;million in research and development for the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017 and the six months ended June&nbsp;30, 2018, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Property and Facilities </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We lease approximately 1,750&nbsp;square feet of
space for our current headquarters in La Jolla, California under an agreement that expires in February 2022. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be
available in the future on commercially reasonable terms. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of
litigation and claims cannot be predicted with certainty, as of the date of this prospectus, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be
reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information about our executive officers and directors as of August&nbsp;30, 2018. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>POSITION(S)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Daniel M. Bradbury</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Executive Officer and Chairman of the Board of Directors</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bruce D. Steel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">President, Chief Business Officer and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Connelly, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Scientific Officer and Director</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jason A. Keyes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Krishna R. Polu, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Medical Officer</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martha J. Demski<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bala S. Manian, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Charles McDermott<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mark Pruzanski, M.D.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">(3)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and corporate governance committee. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Daniel M. Bradbury</I></B> has served as our Chief Executive Officer since June 2018 and as a member and the chairman of our board of directors since March 2017.
Mr.&nbsp;Bradbury is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Equillium and served as our President from March 2017 until June 2018. Mr.&nbsp;Bradbury is the founder and has served as the managing member of BioBrit, LLC, a life
sciences consulting and investment firm, since September 2012. Mr.&nbsp;Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from March 2007 until
Amylin&#146;s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr.&nbsp;Bradbury worked in marketing and sales for 10 years at SmithKline Beecham Pharmaceuticals, a privately-held pharmaceutical company. Mr.&nbsp;Bradbury
serves on the board of directors of numerous private companies and the following publicly-held companies: Biocon Limited, Corcept Therapeutics Incorporated, Geron Corporation and Intercept Pharmaceuticals, Inc. Mr. Bradbury previously served on the
board of directors of BioMed Realty Trust, Inc., a publicly-held real estate investment trust company, from 2013 to 2016; Illumina, Inc., a publicly-held biotechnology company, from 2004 to 2017; and Syngene International Ltd., a publicly-held
science research company, from 2015 to 2016. Mr.&nbsp;Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors believes that Mr.&nbsp;Bradbury&#146;s experience as our Chief Executive Officer and his other executive and board experience qualify him to
serve on our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Bruce D. Steel</I></B> has served as our President and as our Chief Business Officer since June 2018 and as a member of our
board of directors since March 2017. Mr.&nbsp;Steel is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Equillium. Mr.&nbsp;Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed
Realty, LP, since 2010. From 2008 to 2010, Mr.&nbsp;Steel served as the Chief Business Officer at Anaphore, Inc., a privately-held pharmaceutical company. Prior to that, Mr. Steel was <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief
Executive Officer of Rincon Pharmaceuticals, Inc., a genetic engineering biotechnology company, from 2005 until its acquisition in 2008. Mr.&nbsp;Steel also previously served as the Head of Corporate Development at Ambit Biosciences Corporation from
2002 to 2005. Mr. Steel previously served on the board of directors of Zosano Pharma Corporation, a publicly-held biopharmaceutical company, from 2012 to 2017. Mr.&nbsp;Steel serves on the board of directors of the following privately-held
companies: Breathe Technologies, Inc. and Aegea Medical, Inc. Mr.&nbsp;Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the
designation of Chartered Financial Analyst. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors believes that Mr.&nbsp;Steel&#146;s experience in founding, managing and building companies and
investment experience qualify him to serve on our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stephen Connelly, Ph.D. </I></B>has served as our Chief Scientific Officer since
January 2018 and as a member of our board of directors since March 2017. Dr.&nbsp;Connelly is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Equillium and served as a consultant from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
March 2017 until January 2018. Dr.&nbsp;Connelly has served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, since March 2016. From March 2014 to March 2016,
Dr.&nbsp;Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publicly-held biotechnology company. Prior to that, Dr.&nbsp;Connelly was a Senior Scientist at The Scripps Research Institute from
March 2012 to March 2014, where he worked on multiple drug discovery projects spanning different therapeutic areas. Dr.&nbsp;Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific
papers and patents. Dr.&nbsp;Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors believes that Dr.&nbsp;Connelly&#146;s scientific and research expertise qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Jason A. Keyes</I></B> has served as our Chief Financial Officer since March 2018. From January 2013 to February 2018, Mr.&nbsp;Keyes held positions of increasing
responsibility at Orexigen Therapeutics, Inc., a publicly-held pharmaceutical company which filed a voluntary petition for Chapter 11 bankruptcy in March 2018, most recently as Executive Vice President and Chief Financial Officer. Mr.&nbsp;Keyes
held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from August 2007 until January 2013, most recently as Senior Director of Finance. Prior to joining Amylin, Mr.&nbsp;Keyes held
positions of increasing responsibility in finance and corporate strategy at Amgen Inc., a publicly-held biopharmaceutical company, and Baxter Healthcare Corporation, a publicly-held healthcare company. Mr.&nbsp;Keyes is also a licensed professional
engineer and has six years of experience in the environmental engineering industry. Mr.&nbsp;Keyes received his B.S. and M.S. degrees in Civil Engineering from Stanford University and an M.B.A. from the Anderson School at the University of
California, Los Angeles. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Krishna R. Polu, M.D.</I></B> has served as our Chief Medical Officer since August 2018. From February 2018 to August 2018,
Dr.&nbsp;Polu served as Interim Chief Executive Officer of Scout Bio, Inc., a privately-held biotechnology company. Dr.&nbsp;Polu founded Expedition Therapeutics, Inc., a privately-held search company, in June 2017 and served as its Chief Executive
Officer from June 2017 until August 2018. Dr.&nbsp;Polu also served as an Entrepreneur-in-Residence at Frazier Healthcare Partners, an investment firm, from February 2017 until August 2018. Prior to that, Dr.&nbsp;Polu served as the Chief Medical
Officer of Raptor Pharmaceutical Corp., a publicly-held biopharmaceutical company, from January 2015 to December 2016. Dr.&nbsp;Polu also previously served as the Chief Medical Officer of CytomX Therapeutics, Inc., a privately-held biotechnology
company, from March 2013 to June 2014. From July 2009 to March 2013, Dr.&nbsp;Polu served as Vice President of Clinical Development at Affymax, Inc., a publicly-held biopharmaceutical company. Prior to Affymax, Inc., Dr.&nbsp;Polu served as the
Executive Director, Global Development of Amgen Inc., a publicly-held biotechnology company, from November 2007 to July 2009. Dr.&nbsp;Polu holds a B.A. in Human Biology from Stanford University and a M.D. from University of Texas Health Science
Center, San Antonio. Dr.&nbsp;Polu also completed an internal medicine internship and residency at the University of Colorado as well as clinical and research fellowships in nephrology and transplant at Harvard Medical School in a joint program with
Brigham and Women&#146;s Hospital and Massachusetts General Hospital. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Martha J. Demski</I></B> has served as a member of our board of directors since September 2018. From August 2011 to May 2017, Ms.&nbsp;Demski served as Senior
Vice President and Chief Financial Officer of Ajinomoto Althea, Inc. (formerly Althea Technologies, Inc.), a privately-held fully-integrated contract development and manufacturing organization. From July 2008 to December 2010, Ms.&nbsp;Demski served
as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center, a non-profit corporation that was engaged in biomedical research prior to voluntarily filing for Chapter&nbsp;11 bankruptcy in 2009. Previously,
Ms.&nbsp;Demski served as Vice President and Chief Financial Officer of Vical Incorporated, a publicly-held biopharmaceutical company, from December 1988 to June 2004. Ms.&nbsp;Demski currently serves as the chair of the board of directors of
Chimerix, Inc., a publicly-held biopharmaceutical company, and on the board of directors, as the chair of the audit committee and as a member of the compensation and finance committees, of Adamas Pharmaceuticals, Inc., a publicly-held biotechnology
company. Prior to 2018, Ms.&nbsp;Demski was a member of the board of directors, chair of the audit committee and member of the compensation committee, nominating and governance committee, and operating committee of Neothetics, Inc., a publicly-held
biotechnology company. Ms.&nbsp;Demski is a National Association of Corporate Directors Board Governance Fellow. In 2017, she received the Director of the Year in Corporate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Governance award by the Corporate Directors Forum. Additionally, Ms.&nbsp;Demski has over 13&nbsp;years of banking experience with Bank of America and U.S. Trust. Ms.&nbsp;Demski earned a B.A.
from Michigan State University and M.B.A. from The University of Chicago Booth School of Business with concentrations in accounting and finance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of
directors believes that Ms.&nbsp;Demski&#146;s more than 30&nbsp;years&#146; experience in the fields of finance and biotechnology as well as her experience as a member of various boards of directors qualify her to serve on our board of directors.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Bala S. Manian, Ph.D.</I></B> has served as a member of our board of directors since May 2017. Dr.&nbsp;Manian has served on the board of directors of
Syngene International Ltd., a publicly-held contract research and manufacturing organization based in India, since June 2015. Dr.&nbsp;Manian has served as Chief Executive Officer and chairman of the board of directors of ReaMatrix, Inc., a
privately-held biotechnology company, since 2004. Dr.&nbsp;Manian has served as Executive Chairman of LeukoDx Inc., a privately-held biotechnology company, since May 2017. Dr.&nbsp;Manian founded and served as chairman of the board of directors of
Lumisys Incorporated, a publicly-held medical systems company, from 1987 to 1994, of Molecular Dynamics, Inc., a publicly-held genetic discovery and analysis company, from 1987 to 1994, and of Biometric Imaging, Inc., a privately-held biotechnology
company, from 1993 to 1998. Dr.&nbsp;Manian also <FONT STYLE="white-space:nowrap">co-founded</FONT> Quantum Dot Corporation and SurroMed Inc. Dr.&nbsp;Manian received a B.S. in Physics from Loyola College, Chennai, a postgraduate level Diploma in
Instrumentation from the Madras Institute of Technology, Chennai, an M.S. in Applied Optics from the University of Rochester, and a Ph.D. in Mechanical Engineering from Purdue University. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors believes that Dr.&nbsp;Manian&#146;s experience in founding, managing and building companies and scientific and research experience qualify him
to serve on our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Charles McDermott</I></B><B></B> has served as a member of our board of directors since September 2018. From September
2017 to May 2018, Mr.&nbsp;McDermott served as President and Chief Business Officer of Impact Biomedicines, Inc., a privately-held biotechnology company. Prior to that, Mr.&nbsp;McDermott served as President and Chief Business Officer of Kala
Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from June 2015 to August 2017. Previously, he served as Interim President and Chief Business Officer of Kala from October 2014 to June 2015 and as Executive Vice President of Business
Development of Kala from June 2013 to October 2014. Prior to joining Kala, Mr.&nbsp;McDermott served first as Director and then Vice President of Business Development, Eye Care and Drug Delivery at Allergan plc, a publicly-held global pharmaceutical
company, where he worked from April 2005 to May 2013. Prior to joining Allergan, Mr.&nbsp;McDermott held a variety of business development positions at deCODE Genetics, Inc. (now DGI Resolutions, Inc.), a privately-held biopharmaceutical company,
from January 2001 to March 2005. Prior to deCODE Genetics, Mr.&nbsp;McDermott was a research scientist in the angiogenesis pharmacology group at Agouron Pharmaceuticals, Inc. Mr.&nbsp;McDermott currently serves on the board of directors of Primmune
Therapeutics, Inc., a privately-held biotechnology company. Mr.&nbsp;McDermott holds an M.B.A. from the University of San Diego, an M.A. in Molecular, Cellular and Developmental Biology from the University of California at Santa Barbara, a B.S. in
Biochemistry and Molecular Biology from the University of California Santa Cruz and a Certificate in Clinical Trial Design and Management from the University of California San Diego Extension. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors believes that Mr.&nbsp;McDermott&#146;s biopharmaceutical and executive experience qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Mark Pruzanski, M.D.</I></B>&nbsp;has served as a member of our board of directors since September 2018. Dr.&nbsp;Pruzanski is a co-founder and has served as
President and Chief Executive Officer and as a member of the board of directors of Intercept Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, since 2002. Dr.&nbsp;Pruzanski has over 20 years of experience in life sciences company
management, venture capital and strategic consulting. Prior to co-founding Intercept, Dr.&nbsp;Pruzanski was a venture partner at Apple Tree Partners, an early stage life sciences venture capital firm that he co-founded, and an
entrepreneur-in-residence at Oak Investment Partners, a venture capital firm. Dr.&nbsp;Pruzanski is a co-author of a number of scientific publications and is named as an inventor on several patents. Dr.&nbsp;Pruzanski currently serves on the boards
of the Emerging Companies Section of the Biotechnology Innovation Organization, a biotechnology-focused trade association, and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security.
Dr.&nbsp;Pruzanski received his M.D. from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C.,
and a bachelor&#146;s degree from McGill University in Montreal, Canada. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors believes that Dr.&nbsp;Pruzanski&#146;s experience in founding,
managing and building life sciences companies as well as his venture capital experience qualify him to serve on our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition
</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business and affairs are organized under the direction of our board of directors, which currently consists of seven members. The primary responsibilities
of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and on an ad hoc basis as required. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has determined that all of our directors, other than Mr.&nbsp;Bradbury, Dr.&nbsp;Connelly and Mr.&nbsp;Steel, are independent directors, as
defined by Rule&nbsp;5605(a)(2) of The Nasdaq Listing Rules. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the terms of our amended and restated certificate of incorporation and amended and
restated bylaws, which will become effective immediately prior to and upon the completion of this offering, respectively, we will divide our board of directors into three classes, as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Class&nbsp;I, which will consist of Dr.&nbsp;Connelly and Dr.&nbsp;Manian, whose terms will expire at our annual meeting
of stockholders to be held in 2019; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Class&nbsp;II, which will consist of Mr.&nbsp;McDermott and Mr.&nbsp;Steel, whose terms will expire at our annual meeting
of stockholders to be held in 2020; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Class&nbsp;III, which will consist of Mr.&nbsp;Bradbury, Ms.&nbsp;Demski and Dr.&nbsp;Pruzanski, whose terms will expire
at our annual meeting of stockholders to be held in 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At each annual meeting of stockholders to be held after the initial classification, the
successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. The authorized size of our board of directors is currently seven members.
The authorized number of directors may be changed only by resolution of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed between the three classes so that, as nearly as
possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. This classification of our board of directors may have the effect of delaying or preventing changes in our control or management. Our directors
may be removed for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of our voting stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Leadership
Structure </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors is currently chaired by Mr.&nbsp;Bradbury who has authority, among other things, to call and preside over board of directors
meetings, to set meeting agendas and to determine materials to be distributed to the board of directors. Accordingly, the Chairman has substantial ability to shape the work of the board of directors. We have a separate chair for each committee of
our board of directors. The chair of each committee is expected to report annually to our board of directors on the activities of their committee in fulfilling their responsibilities as detailed in their respective charters or specify any
shortcomings should that be the case. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our board of directors has
appointed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to serve as our lead independent director upon the closing of this offering. As lead independent
director,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will preside over periodic meetings of our independent directors, serve as a liaison between our Chairman and the independent directors and
perform such additional duties as set forth in our bylaws and as our board of directors may otherwise determine and delegate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of the Board in Risk Oversight
</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The audit committee of our board of directors is primarily responsible for overseeing our risk management processes on behalf of our board of directors. Going
forward, we expect that the audit committee will receive reports from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
management at least quarterly regarding our assessment of risks. In addition, the audit committee reports regularly to our board of directors, which also considers our risk profile. The audit
committee and our board of directors focus on the most significant risks we face and our general risk management strategies. While our board of directors oversees our risk management, management is responsible for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> risk management processes. Our board of directors expects management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies
and processes for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and to effectively implement risk management strategies adopted by the audit committee and our board of directors. We believe
this division of responsibilities is the most effective approach for addressing the risks we face and that our board of directors&#146; leadership structure, which also emphasizes the independence of our board of directors in its oversight of its
business and affairs, supports this approach. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee
</I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee consists of Ms.&nbsp;Demski, Dr.&nbsp;Manian and Mr.&nbsp;McDermott. Our board of directors has determined that each of the members of
our audit committee satisfies The Nasdaq Stock Market and SEC independence requirements. Ms.&nbsp;Demski serves as the chair of our audit committee. The functions of this committee include, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain
our existing independent auditors or engage new independent auditors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving the engagement of our independent auditors to perform audit services and any permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">monitoring the rotation of partners of our independent auditors on our engagement team as required by law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may
reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and discussing the statements and reports with our independent auditors and management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, with our independent auditors and management, significant issues that arise regarding accounting principles and
financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing with management and our independent auditors any earnings announcements and other public announcements regarding
material developments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial
controls, accounting or auditing matters and other matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing the report that the SEC requires in our annual proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and providing oversight of any related-person transactions in accordance with our related person transaction
policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of business conduct and ethics; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk
assessment and risk management are implemented; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing on a periodic basis our investment policy; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and evaluating on an annual basis the performance of the audit committee and the audit committee charter.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has determined that Ms. Demski qualifies as an audit committee financial expert within the meaning of SEC regulations and
meets the financial sophistication requirements of the Nasdaq Listing Rules. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
making this determination, our board has considered Ms. Demski&#146;s prior experience, business acumen and independence. Both our independent registered public accounting firm and management
periodically meet privately with our audit committee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that the composition and functioning of our audit committee complies with all applicable
requirements of Sarbanes-Oxley, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee consists of Ms.
Demski and Dr. Manian. Dr. Manian serves as the chair of our compensation committee. Our board of directors has determined that each of the members of our compensation committee is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as
defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and satisfies The Nasdaq Stock Market independence requirements. The functions of this committee include, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of directors
regarding) our overall compensation strategy and policies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to the full board of directors regarding the compensation and other terms of
employment of our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding)
performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding)
the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating risks associated with our compensation policies and practices and assessing whether risks arising from our
compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to the full board of directors regarding the type and amount of compensation to be
paid or awarded to our <FONT STYLE="white-space:nowrap">non-employee</FONT> board members; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing policies with respect to votes by our stockholders to approve executive compensation as required by
Section&nbsp;14A of the Exchange Act and determining our recommendations regarding the frequency of advisory votes on executive compensation, to the extent required by law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by
Section&nbsp;10C of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">administering our equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing policies with respect to equity compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our compensation
policy and strategy in achieving expected benefits to us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to the full board of directors regarding the terms of any employment agreements,
severance arrangements, change in control protections and any other compensatory arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing with management and approving our disclosures under the caption &#147;Compensation Discussion and Analysis&#148;
in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing the report that the SEC requires in our annual proxy statement; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing on an annual basis the performance of the compensation committee and the compensation committee
charter. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that the composition and functioning of our compensation committee complies with all applicable requirements of
Sarbanes-Oxley, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our nominating and corporate governance committee consists of Mr. McDermott and Dr. Pruzanski. Mr. McDermott serves as the chair of our nominating and corporate
governance committee. Our board of directors has determined that each of the members of this committee satisfies the Nasdaq Stock Market independence requirements. The functions of this committee include, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying, reviewing and evaluating candidates to serve on our board of directors consistent with criteria approved by
our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">determining the minimum qualifications for service on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating director performance on the board and applicable committees of the board and determining whether continued
service on our board is appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating, nominating and recommending individuals for membership on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating nominations by stockholders of candidates for election to our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">considering and assessing the independence of members of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing a set of corporate governance policies and principles, including a code of business conduct and ethics,
periodically reviewing and assessing these policies and principles and their application and recommending to our board of directors any changes to such policies and principles; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">considering questions of possible conflicts of interest of directors as such questions arise; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing on an annual basis the performance of the nominating and corporate governance committee and the
nominating and corporate governance committee charter. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that the composition and functioning of our nominating and corporate governance
committee complies with all applicable requirements of Sarbanes-Oxley, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">None of our
current or former executive officers serve as a member of the compensation committee. None of our officers serve, or have served during the last completed fiscal year, on the board of directors or compensation committee, or other committee serving
an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. Prior to establishing the compensation committee, our full board of directors
made decisions relating to compensation of our officers. For a description of transactions between us and members of our compensation committee and affiliates of such members, please see &#147;Certain Relationships and Related Party
Transactions.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted
a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or person performing similar
functions. Following this offering, a current copy of the code will be available on the Corporate Governance section of our website, www.equilliumbio.com. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitation of Liability and Indemnification </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated
certificate of incorporation, which will become effective immediately prior to the completion of this offering, limits the liability of directors to the maximum extent permitted by Delaware law. Delaware law allows a corporation to eliminate the
personal liability of directors of a corporation to the corporation and its stockholders for monetary damages for breach of their fiduciary duties as directors, except for liability for any: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">breach of his or her duty of loyalty to the corporation or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the
Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, does not eliminate a
director&#146;s duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, will remain available under Delaware law. These limitations also do
not affect a director&#146;s responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Our amended and restated bylaws, which will become effective upon the completion of this offering, provide that
we will indemnify our directors and executive officers and may indemnify other officers, employees and other agents, to the fullest extent permitted by law. Our amended and restated bylaws, which will become effective upon the completion of this
offering, also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding and also permit us to secure insurance on behalf of any officer, director, employee or
other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained a policy of directors&#146; and
officers&#146; liability insurance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered, and intend to continue to enter, into separate indemnification agreements with our directors and executive
officers, in addition to the indemnification provided for in our amended and restated bylaws. These agreements, among other things, will require us to indemnify our directors and executive officers for certain expenses, including attorneys&#146;
fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or any other company or enterprise to which the person
provides services at our request. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage
stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our
stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and these indemnification agreements are
necessary to attract and retain qualified persons as directors and officers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise disclosed under the heading &#147;Legal Proceedings&#148; in the
&#147;Business&#148; section of this prospectus, at present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any
threatened litigation or proceeding that may result in a claim for indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_12"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to our limited operations in 2017, we did not have an executive or board compensation program and we did not pay any executive compensation or issue any stock-based
compensation to any executive or board member in 2017.&nbsp;Daniel M. Bradbury, our Chief Executive Officer, was our only executive officer during 2017 and accordingly is our only named executive officer for the period March&nbsp;16, 2017
(inception) through December&nbsp;31, 2017. During 2017, Mr.&nbsp;Bradbury served as our President. Our other current executive officers commenced employment with us during 2018. We have included information in the following narrative regarding our
named executive officer and other current executive officers&#146; 2018 compensation where it may be helpful to an understanding of our compensation program. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Mr.&nbsp;Bradbury did not receive any
compensation from us for services in any capacity during the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Annual Base Salary </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than with respect to Mr.&nbsp;Bradbury, the base salary of our executive officers is generally determined and approved in connection with the commencement of
employment of the executive, by our board of directors. As of December&nbsp;31, 2017, Mr.&nbsp;Bradbury did not receive an annual base salary. Effective June&nbsp;1, 2018, in connection with his offer letter, the board of directors approved an
annual base salary for Mr.&nbsp;Bradbury of $400,000. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Bonus Compensation </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Mr.&nbsp;Bradbury was not entitled to and did not receive any bonus payments during 2017. Our board of directors or compensation committee may approve bonuses in the
future for our executives based on individual performance, company performance or as otherwise determined appropriate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beginning in 2018, pursuant to his offer
letter, Mr.&nbsp;Bradbury is entitled to an annual discretionary performance-based bonus. Mr.&nbsp;Bradbury&#146;s offer letter is described under &#147;&#151;Agreements with Executive Officers.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity-Based Incentive Awards </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our equity-based incentive awards are designed
to align our interests and those of our stockholders with those of our employees and consultants, including our executive officers. The board of directors is responsible for approving equity grants. As of the date of this prospectus, we have not
granted any equity awards to Mr. Bradbury. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2018, we granted stock options to each of Mr.&nbsp;Keyes and Dr. Polu, which are described in the section entitled
&#147;&#151;Agreements with Executive Officers.&#148; Following this offering, we expect to use stock options or other stock awards as an incentive for long-term compensation to our executive officers at such times as our board of directors
determines appropriate. Other than our founders, our executive officers generally are awarded an initial grant in the form of a stock option in connection with their commencement of employment with us. Additional grants may occur periodically in
order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this
offering, we have granted all stock options pursuant to our 2017 Plan. Following this offering, we expect to grant equity incentive awards under the terms of our 2018 Plan. The terms of the 2017 Plan and the 2018 Plan are described below under
&#147;&#151;Equity Benefit Plans.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All options are granted with an exercise price per share that is no less than the fair market value of our common stock on
the date of grant of such award. Our stock option awards generally vest over a four-year period subject to continued service and may be subject to acceleration of vesting and exercisability under certain termination and change in control events.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Executive Officers </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreement with Mr. Bradbury </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We did not maintain an agreement with
Mr.&nbsp;Bradbury governing his services to us during 2017. In June 2018, we entered into an offer letter with Mr.&nbsp;Bradbury, which governs the terms of his employment with us. Under the terms of the offer letter, Mr.&nbsp;Bradbury is entitled
to an annual base salary of $400,000 and is eligible to receive an annual performance-based bonus opportunity at a target amount of 35% of his base salary, based on the attainment of individual and corporate objectives to be determined and approved
by us. The payment and amount of the annual bonus will be in our sole discretion. The offer letter also provides for severance benefits described below under &#147;&#151;Potential Payments and Benefits upon Termination or Change in Control.&#148; In
addition, Mr.&nbsp;Bradbury is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreement with Mr.&nbsp;Steel </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2018, we entered into an offer
letter with Mr.&nbsp;Steel, our President and Chief Business Officer, which governs the terms of his employment with us. Under the terms of the offer letter, Mr.&nbsp;Steel is entitled to an annual base salary of $375,000 and is eligible for an
annual performance-based bonus opportunity at a target amount of 35% of his base salary, based on the attainment of individual and corporate objectives to be determined and approved by us. The payment and amount of the annual bonus will be in our
sole discretion. The offer letter also provides for severance benefits described below under &#147;&#151;Potential Payments and Benefits upon Termination or Change in Control.&#148; In addition, Mr.&nbsp;Steel is eligible to participate in the
employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreement with Dr. Connelly </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2018, we entered into an offer letter Dr.&nbsp;Connelly, our Chief Scientific Officer, which governs the terms of his employment with us, and which was
amended and restated in June 2018. Under the terms of his offer letter, Dr.&nbsp;Connelly is currently entitled to an annual base salary of $300,000 and is eligible for an annual performance-based bonus opportunity at a target amount of 35% of his
base salary, based on the attainment of individual and corporate objectives to be determined and approved by us. The payment and amount of the annual bonus will be in our sole discretion. The offer letter also provides for severance benefits
described below under &#147;&#151;Potential Payments and Benefits upon Termination or Change in Control.&#148; In addition, Dr.&nbsp;Connelly is eligible to participate in the employee benefit plans generally available to our employees, and is
subject to customary confidentiality covenants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreement with Mr.&nbsp;Keyes </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2018, we entered into an offer letter with Mr.&nbsp;Keyes, our Chief Financial Officer, which governs the terms of his employment with us. Under the terms of
the offer letter, Mr.&nbsp;Keyes is entitled to an annual base salary of $290,000 and is eligible for an annual performance-based bonus opportunity at a target amount of 30% of his base salary, based on the attainment of individual and corporate
objectives to be determined and approved by us. The payment and amount of the annual bonus will be in our sole discretion. The offer letter also provides for severance benefits described below under &#147;&#151;Potential Payments and Benefits upon
Termination or Change in Control.&#148; In addition, Mr.&nbsp;Keyes is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offer letter also contemplates the grant to Mr.&nbsp;Keyes of a stock option, which was granted to Mr.&nbsp;Keyes on June&nbsp;6, 2018. The option provides that
Mr.&nbsp;Keyes may purchase up to 17,253 shares of our common stock at an exercise price of $0.35 per share, which vests as to 25% of the shares on April&nbsp;1, 2019 with the balance of shares vesting in approximately equal monthly installments
over the remaining 36 months, subject to Mr.&nbsp;Keyes&#146; continued service with us, subject to full acceleration of all of the shares in the event Mr.&nbsp;Keyes is terminated by us without cause or resigns for good reason within 12 months
after a change in control. In June 2018, Mr.&nbsp;Keyes early exercised his option in full and we issued him 17,253 shares of common stock, all of which are restricted shares subject to the vesting schedule described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreement with Dr. Polu </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August 1, 2018, we entered into an offer letter with Dr. Polu, our Chief Medical Officer, which governs the terms of his employment with us. Under the terms of the
offer letter, Dr. Polu is entitled to an annual base salary of $375,000 and is eligible for an annual performance-based bonus opportunity at a target amount of 30% of his base salary, based on the attainment of individual and corporate objectives to
be determined and approved by us. The payment and amount of the annual bonus will be in our sole discretion. The offer letter also provides for severance benefits described below under &#147;&#151;Potential Payments and Benefits upon Termination or
Change in Control.&#148; In addition, Dr. Polu is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants. The offer letter also contemplates that Dr. Polu
will, at our discretion, be reimbursed for up to $50,000 per year, subject to adjustment based on our business needs, to commute to our offices in La Jolla. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
offer letter also contemplates the grant to Dr. Polu of a stock option, which was granted to Dr. Polu on August&nbsp;16, 2018. The option provides that Dr. Polu may purchase up to 24,155 shares of our common stock at an exercise price of $28.39 per
share, which vests as to 25% of the shares on September&nbsp;1, 2019 with the balance of shares vesting in approximately equal monthly installments over the remaining 36 months, subject to Dr. Polu&#146;s continued service with us, subject to full
acceleration of all of the shares in the event Dr. Polu is terminated by us without cause or resigns for good reason within 12 months after a change in control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Potential Payments and Benefits upon Termination or Change in Control </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each
of our executive officer&#146;s employment is at will and may be terminated by us at any time. Regardless of the manner in which an executive officer&#146;s service terminates, such executive officer is entitled to receive any and all accrued but
unpaid amounts earned during his or her term of service, including unpaid salary and unused vacation, as applicable. In addition, the offer letter agreements with each of Messrs. Bradbury, Steel, and Keyes and Drs.&nbsp;Connelly and Polu each
provide that, if we terminate such executive&#146;s employment without cause, the executive is entitled to receive (i)&nbsp;continuation of the applicable executive officer&#146;s then-current base salary for six months and (ii)&nbsp;payment of the
premiums for group health insurance COBRA continuance coverage for six months or, if earlier, until the date on which the executive becomes eligible to receive comparable benefits from another employer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, if we terminate the executive&#146;s employment without cause within one month prior to, or 12 months following, certain change of control and asset sale
transactions, the executive is entitled to receive (i)&nbsp;continuation of the applicable executive officer&#146;s then-current base salary for 12 months, (ii)&nbsp;an amount equal to the applicable executive&#146;s target annual bonus and
(iii)&nbsp;payment of the premiums for group health insurance COBRA continuance coverage for 12 months or, if earlier, until the date on which the executive becomes eligible to receive comparable benefits from another employer. In each case, the
severance benefits are conditioned upon the execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a general release of claims by the applicable executive in a form provided by us. Mr.&nbsp;Keyes and Dr.&nbsp;Polu are also entitled
to vesting acceleration upon their respective terminations in connection with a change in control pursuant to the terms of their stock options granted on June&nbsp;6, 2018 and August 16, 2018, respectively, as described above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Mr.&nbsp;Bradbury does not hold any unexercised options, stock that has not vested or equity incentive plan awards that were outstanding as of December&nbsp;31, 2017.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We did not engage in any repricings or other modifications or cancellations to our named executive officer&#146;s outstanding equity awards during the period
March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Perquisites, Health, Welfare and Retirement Benefits </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our named executive officer and other executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our
medical, dental, group term life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of our other employees. In addition, we provide a 401(k) plan to our employees, including our named executive
officer, as discussed in the section below entitled &#147;&#151;401(k) Plan.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We generally do not provide perquisites or personal benefits to our named executive officer and other executive
officers, except in limited circumstances. We do, however, pay the premiums for medical, dental, group term life, disability and accidental death and dismemberment insurance for all of our employees, including our named executive officer. Our board
of directors may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best interests. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>401(k) Plan
</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain a defined contribution employee retirement plan, or 401(k) plan, for our employees. Our named executive officer and other executive officers are
eligible to participate in the 401(k) plan on the same basis as our other employees. The 401(k) plan is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> plan under Section&nbsp;401(k) of the U.S. Internal Revenue Code
of 1986, as amended, or the Code. The 401(k) plan provides that each participant may contribute up to the lesser of 100% of his or her compensation or the statutory limit, which is $18,000 and $18,500 for calendar years 2017 and 2018, respectively.
Participants that are 50 years or older can also make <FONT STYLE="white-space:nowrap">&#147;catch-up&#148;</FONT> contributions, which in calendar years 2017 and 2018 may be up to an additional $6,000 above the statutory limit. We currently do not
make matching contributions into the 401(k) plan on behalf of participants. Participant contributions are held and invested, pursuant to the participant&#146;s instructions, by the plan&#146;s trustee. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nonqualified Deferred Compensation </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not maintain nonqualified defined
contribution plans or other nonqualified deferred compensation plans. Our board of directors may elect to provide our officers and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the
future, if it determines that doing so is in our best interests. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Equity Benefit Plans </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The principal features of our equity plans are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which are
filed as exhibits to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2018 Plan </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors adopted our 2018 Plan in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2018 and our
stockholders approved our 2018 Plan in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2018. Our 2018 Plan is a successor to and continuation of our 2017 Plan. No stock awards may be granted under the
2018 Plan until the date of the underwriting agreement related to this offering. Once the 2018 Plan is effective, no further grants will be made under the 2017 Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock awards. </I>Our 2018 Plan provides for the grant of incentive stock options, or ISOs, within the meaning of Section&nbsp;422 of the Code, to employees,
including employees of any parent or subsidiary, and for the grant of nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other
forms of stock awards to employees, directors and consultants, including employees and consultants of our affiliates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized shares.</I> Initially, the
maximum number of shares of our common stock that may be issued under our 2018 Plan after it becomes effective will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, which is the sum of (1)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new shares, plus (2)&nbsp;the number of shares (not to exceed
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares)&nbsp;(i) that remain available for the issuance of awards under our 2017 Plan at the time our 2018 Plan becomes effective, and (ii)&nbsp;any
shares subject to outstanding stock options or other stock awards that were granted under our 2017 Plan that terminate or expire prior to exercise or settlement; are forfeited because of the failure to vest; or are reacquired or withheld (or not
issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares of our common stock reserved for issuance under our 2018 Plan will automatically increase on January&nbsp;1 of each calendar year,
starting on January&nbsp;1, 2019 (assuming the 2018 Plan becomes effective in 2018) through January&nbsp;1, 2028, in an amount equal to &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our capital stock outstanding on the last day of the
calendar month before the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of shares of our common stock that may be issued on the exercise of ISOs under our 2018 Plan is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares subject to stock awards granted under our 2018 Plan that expire or terminate without being exercised in full
or that are paid out in cash rather than in shares do not reduce the number of shares available for issuance under our 2018 Plan. If any shares of common stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by us
for any reason, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the 2018 Plan. Any shares reacquired in satisfaction of tax withholding obligations or as consideration for the
exercise or purchase price of a stock award will again become available for issuance under the 2018 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan administration.</I> Our board of directors, or a
duly authorized committee of our board of directors, will administer our 2018 Plan and is referred to as the &#147;plan administrator&#148; herein. Our board of directors may also delegate to one or more of our officers the authority to
(1)&nbsp;designate employees (other than officers) to receive specified stock awards and (2)&nbsp;determine the number of shares subject to such stock awards. Under our 2018 Plan, our board of directors has the authority to determine award
recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value, and the provisions of each stock award, including the period of exercisability and the vesting schedule applicable to a stock award. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the 2018 Plan, the board of directors also generally has the authority to effect, with the consent of any adversely affected participant, (A)&nbsp;the reduction
of the exercise, purchase, or strike price of any outstanding award; (B)&nbsp;the cancellation of any outstanding award and the grant in substitution therefore of other awards, cash, or other consideration; or (C)&nbsp;any other action that is
treated as a repricing under generally accepted accounting principles. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock options.</I> ISOs and NSOs are granted under stock option agreements adopted by the
plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2018 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market
value of our common stock on the date of grant. Options granted under the 2018 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The plan administrator determines the term of stock options granted under the 2018 Plan, up to a maximum of 10 years. Unless the terms of an optionholder&#146;s stock
option agreement provide otherwise, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than disability, death, or cause, the optionholder may generally exercise any vested options for a period
of three months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#146;s service relationship with
us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date
of death. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event
of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include
(1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of our common stock previously owned by the optionholder, (4)&nbsp;a net exercise of the option if it is an NSO, or
(5)&nbsp;other legal consideration approved by the plan administrator. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless the plan administrator provides otherwise, options generally are not transferable
except by will or the laws of descent and distribution. Subject to approval of the plan administrator or a duly authorized officer in each case, (i)&nbsp;an option may be transferred pursuant to a domestic relations order, official marital
settlement agreement, or other divorce or separation instrument and (ii)&nbsp;an optionholder may designate a beneficiary who may exercise the option following the optionholder&#146;s death. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax limitations on ISOs. </I>The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the
first time by an award holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time
of the grant, owns or is deemed to own stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
possessing more than 10% of our total combined voting power or that of any of our affiliates unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock
subject to the option on the date of grant, and (2)&nbsp;the term of the ISO does not exceed five years from the date of grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted stock unit
awards.</I> Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be
acceptable to our board of directors and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form
of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award
agreement, restricted stock unit awards that have not vested will be forfeited once the participant&#146;s continuous service ends for any reason. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted
stock awards.</I> Restricted stock awards are granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past or future
services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting
and forfeiture terms. If a participant&#146;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service
with us through a forfeiture condition or a repurchase right. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock appreciation rights.</I> Stock appreciation rights are granted under stock appreciation
right agreements adopted by the plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the
date of grant. A stock appreciation right granted under the 2018 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The plan administrator determines the term of stock appreciation rights granted under the 2018 Plan, up to a maximum of 10 years. If a participant&#146;s service
relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service.
This period may be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If a participant&#146;s service
relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation
right for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the
termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Performance awards. </I>The
2018 Plan permits the grant of performance-based stock and cash awards. Our compensation committee may structure awards so that the stock or cash will be issued or paid only following the achievement of certain
<FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The performance goals that may be selected
include one or more of the following: (i)&nbsp;sales; (ii)&nbsp;revenues; (iii)&nbsp;assets; (iv) expenses; (v)&nbsp;market penetration or expansion; (vi)&nbsp;earnings from operations; (vii)&nbsp;earnings before or after deduction for all or any
portion of interest, taxes, depreciation, amortization, incentives, service fees or extraordinary or special items, whether or not on a continuing operations or an aggregate or per share basis; (viii)&nbsp;net income or net income per common share
(basic or diluted); (ix) return on equity, investment, capital or assets; (x)&nbsp;one or more operating ratios; (xi)&nbsp;borrowing levels, leverage ratios or credit rating; (xii)&nbsp;market share; (xiii)&nbsp;capital expenditures; (xiv)&nbsp;cash
flow, free cash flow, cash flow return on investment, or net cash provided by operations; (xv)&nbsp;stock price, dividends or total stockholder return; (xvi)&nbsp;development of new technologies or products; (xvii)&nbsp;sales of particular products
or services; (xviii)&nbsp;economic value created or added; (xix)&nbsp;operating margin or profit margin; (xx)&nbsp;customer acquisition or retention; (xxi)&nbsp;raising or refinancing of capital; (xxii)&nbsp;successful hiring of key individuals;
(xxiii)&nbsp;resolution of significant litigation; (xxiv)&nbsp;acquisitions and divestitures (in whole or in part); (xxv) joint ventures and strategic alliances; (xxvi)&nbsp;spin-offs, <FONT STYLE="white-space:nowrap">split-ups</FONT> and the like;
(xxvii)&nbsp;reorganizations; (xxviii)&nbsp;recapitalizations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
restructurings, financings (issuance of debt or equity) or refinancings; (xxix)&nbsp;or strategic business criteria, consisting of one or more objectives based on the following goals: achievement
of timely development, design management or enrollment, meeting specified market penetration or value added, payor acceptance, patient adherence, peer reviewed publications, issuance of new patents, establishment of or securing of licenses to
intellectual property, product development or introduction (including, without limitation, any clinical trial accomplishments, regulatory or other filings, approvals or milestones, discovery of novel products, maintenance of multiple products in
pipeline, product launch or other product development milestones), geographic business expansion, cost targets, cost reductions or savings, customer satisfaction, operating efficiency, acquisition or retention, employee satisfaction, information
technology, corporate development (including, without limitation, licenses, innovation, research or establishment of third-party collaborations), manufacturing or process development, legal compliance or risk reduction, patent application or
issuance goals, or goals relating to acquisitions, divestitures or other business combinations (in whole or in part), joint ventures or strategic alliances; and (xxx)&nbsp;other measures of performance selected by the board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be
either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Our board of directors is authorized at any time in its sole discretion, to adjust or modify the calculation of a
performance goal for such performance period in order to prevent the dilution or enlargement of the rights of participants, (a)&nbsp;in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or
development; (b)&nbsp;in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting us, or our financial statements in response to, or in anticipation of, changes in applicable laws, regulations, accounting principles,
or business conditions; or (c)&nbsp;in view of the board of director&#146;s assessment of our business strategy, performance of comparable organizations, economic and business conditions, and any other circumstances deemed relevant. Specifically,
the board of directors is authorized to make adjustment in the method of calculating attainment of performance goals and objectives for a performance period as follows: (i)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures;
(ii)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; and (iii)&nbsp;to exclude the effect of any change in the outstanding
shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar
corporate change, or any distributions to common stockholders other than regular cash dividends. In addition, the board of directors is authorized to make adjustment in the method of calculating attainment of performance goals and objectives for a
performance period as follows: (i)&nbsp;to exclude restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects, as applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated net sales and
operating earnings; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting standards required by the Financial Accounting Standards Board; (iv)&nbsp;to exclude the effects of any items that are &#147;unusual&#148; in nature or
occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (v)&nbsp;to exclude the effects to any statutory adjustments to corporate tax rates; and (vi)&nbsp;to make other appropriate adjustments selected by the
board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other stock awards</I>. The plan administrator may grant other awards based in whole or in part by reference to our common stock. The plan
administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to capital structure</I>. In the
event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under
the 2018 Plan, (2)&nbsp;the class and maximum number of shares by which the share reserve may increase automatically each year, (3)&nbsp;the class and maximum number of shares that may be issued on the exercise of ISOs, (4) the class(es) and maximum
number of securities that may be awarded to any non-employee director, and (5) the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Corporate transactions</I>. Our 2018 Plan provides that in the event of certain specified significant corporate transactions (or a change in control, as defined
below), unless otherwise provided in an award agreement or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
written agreement between us and the award holder, the plan administrator may take one or more of the following actions with respect to such stock awards: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">arrange for the assumption, continuation, or substitution of a stock award by a successor corporation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">arrange for the assignment of any reacquisition or repurchase rights held by us to a successor corporation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">accelerate the vesting, in whole or in part, of the stock award and provide for its termination if not exercised (if
applicable) at or before the effective time of the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cancel or arrange for the cancellation of the stock award, to the extent not vested or not exercised before the effective
time of the transaction, in exchange for a cash payment, if any; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">make a payment equal to the excess, if any, of (A)&nbsp;the value of the property the participant would have received on
exercise of the award immediately before the effective time of the transaction, over (B)&nbsp;any exercise price payable by the participant in connection with the exercise. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The plan administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to take the same actions with
respect to all participants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the 2018 Plan, a corporate transaction is generally the consummation of: (1)&nbsp;a sale of all or substantially all of our
assets, (2)&nbsp;the sale or disposition of more than 50% of our outstanding securities, (3)&nbsp;a merger or consolidation where we do not survive the transaction, or (4)&nbsp;a merger or consolidation where we do survive the transaction but the
shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Change
in control. </I>In the event of a change in control, the plan administrator may take any of the above-mentioned actions. Awards granted under the 2018 Plan may be subject to additional acceleration of vesting and exercisability upon or after a
change in control as may be provided in the applicable stock award agreement or in any other written agreement between us or any affiliate and the participant, but in the absence of such provision, no such acceleration will automatically occur.
Under the 2018 Plan, a change in control is generally (1)&nbsp;the acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock, (2)&nbsp;a merger, consolidation or similar transaction in which our
stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the same proportions as their ownership
immediately prior to such transaction, (3)&nbsp;a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders
in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction, (4)&nbsp;a complete dissolution or liquidation of the company, or (5)&nbsp;when a majority of our board of directors
becomes comprised of individuals who were not serving on our board of directors on the date of the underwriting agreement related to this offering, or the incumbent board, or whose nomination, appointment, or election was not approved by a majority
of the incumbent board still in office. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan amendment or termination</I>. Our board of directors has the authority to amend, suspend, or terminate our 2018
Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted
after the tenth anniversary of the date our board of directors adopts our 2018 Plan. No stock awards may be granted under our 2018 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2017 Plan </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors and our stockholders approved our 2017
Plan in December 2017. As of June&nbsp;30, 2018, there were 106,971 shares remaining available for the future grant of stock awards under our 2017 Plan. As of June&nbsp;30, 2018, there were outstanding stock options covering a total of 12,423 shares
of our common stock that were granted under our 2017 Plan. We expect that any shares remaining available for issuance under the 2017 will become available for issuance under the 2018 Plan in connection with this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock awards. </I>Our 2017 Plan provides for the grant of ISOs within the meaning of Section&nbsp;422 of the Code to employees, including employees of any parent or
subsidiary, and for the grant of NSOs, stock appreciation rights, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
restricted stock, restricted stock units and other forms of stock awards to employees, directors and consultants, including employees and consultants of our affiliates. To date, we have only
granted stock options under the 2017 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized shares.</I> Subject to certain capitalization adjustments, the aggregate number of shares of common stock
that may be issued pursuant to stock awards under the 2017 Plan will not exceed 138,026 shares. The maximum number of shares of our common stock that may be issued pursuant to the exercise of ISOs under our 2017 Plan is 414,078 shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares subject to stock awards granted under our 2017 Plan that expire or otherwise terminate without being exercised in full or that are settled in cash rather than in
shares do not reduce or otherwise offset the number of shares available for issuance under our 2017 Plan. Additionally, if any shares issued pursuant to a stock award are forfeited back to or repurchased because of the failure to meet a contingency
or condition required to vest, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the 2017 Plan. This includes shares used to pay the exercise price of a stock award or to satisfy the tax
withholding obligations related to a stock award. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan administration.</I> Our board of directors, or a duly authorized committee of our board of directors to
which the board delegates its administrative authority, will administer our 2017 Plan and is referred to as the &#147;plan administrator&#148; herein. The plan administrator may also delegate to one or more of our officers the authority to
(1)&nbsp;designate employees (other than officers) to receive specified options and stock appreciation rights (and to the extent permitted by applicable law, other stock awards) and (2)&nbsp;determine the number of shares subject to such stock
awards; provided, however, that the board resolutions regarding such delegation must specify the total number of shares that may be subject to awards granted by such officer, and provided further, that no officer may grant an award under the 2017
Plan to himself or herself. Under our 2017 Plan, the plan administrator has the authority to, among other things, determine award recipients, dates of grant, the numbers and types of stock awards to be granted, the applicable fair market value and
the provisions of each stock award, including the period of their exercisability and the vesting schedule applicable to a stock award, to construe and interpret the 2017 Plan and awards granted thereunder (and to establish, amend and revoke any
rules and regulations for the administration of the 2017 Plan and any such awards), or to accelerate awards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the 2017 Plan, the plan administrator also
generally has the authority to effect, with the consent of any adversely affected participant, (A)&nbsp;the reduction of the exercise, purchase, or strike price of any outstanding award; (B)&nbsp;the cancellation of any outstanding award and the
grant in substitution therefor of other awards, cash, or other consideration; or (C)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock options.</I> ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price
for stock options, within the terms and conditions of the 2017 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant (or 110% of the fair market
value for certain major stockholders). Options granted under the 2017 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The plan administrator determines the term of stock options granted under the 2017 Plan, up to a maximum of 10 years (or five years, for certain major stockholders). If
an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of up to three months following the
cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws or our insider trading policy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation
of service, the optionholder or a beneficiary may generally exercise any vested options for a period of up to 18 months following the date of death. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to
disability, the optionholder may generally exercise any vested options for a period of up to 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. In no event
may an option be exercised beyond the expiration of its term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be
determined by the plan administrator and may include (1)&nbsp;cash, check, bank draft or money order payable to us, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of our common stock previously owned by the optionholder,
(4)&nbsp;a net exercise of the option if it is an NSO, (5)&nbsp;a deferred payment arrangement, or (6)&nbsp;other legal consideration approved by the plan administrator. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless the plan administrator provides otherwise, options generally are not transferable except by will or the laws of descent and distribution. Subject to approval of
the plan administrator or a duly authorized officer in each case, (i)&nbsp;an option may be transferred pursuant to a domestic relations order, official marital settlement agreement, or other divorce or separation instrument and (ii)&nbsp;an
optionholder may designate a beneficiary who may exercise the option following the optionholder&#146;s death. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax limitations on ISOs. </I>The aggregate fair
market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions
thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our
affiliates unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2)&nbsp;the term of the ISO does not exceed five years from the date of grant. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted stock unit awards.</I> Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the plan administrator. Restricted
stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit awards may be settled by cash, delivery of stock, a
combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares
covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock unit awards that have not vested will be forfeited once the participant&#146;s continuous service ends for any reason. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted stock awards.</I> Restricted stock awards are granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award
may be awarded in consideration for cash, check, bank draft or money order, past or future services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The plan
administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#146;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock
held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to capital structure</I>. In the event of a &#147;capitalization adjustment,&#148; the board of directors, in its discretion, will make appropriate and
proportionate adjustments to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2017 Plan, (2)&nbsp;the class and maximum number of shares that may be issued on the exercise of ISOs, and (3)&nbsp;the class and number of
shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. For purposes of the 2017 Plan, &#147;capitalization adjustment&#148; generally means any change that is made in (or other events occurring
with respect to) our common stock subject to the 2017 Plan or any award without the receipt of consideration by us through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than
cash, large <FONT STYLE="white-space:nowrap">non-recurring</FONT> cash dividend, stock split, reverse stock split, liquidating dividend, combination or exchange of shares, change in corporate structure, or other similar equity restructuring
transaction (within the meaning of Statement of Financial Accounting Standards Board ASC Topic&nbsp;718). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Corporate transactions</I>. Our 2017 Plan provides
that in the event of a &#147;corporate transaction,&#148; unless otherwise provided in an award agreement or other written agreement between us and the award holder, the plan administrator may take one or more of the following actions with respect
to such stock awards: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">arrange for the assumption, continuation, or substitution of a stock award by a surviving or acquiring corporation;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring corporation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">accelerate the vesting, in whole or in part, of the stock award and provide for its termination if not exercised (if
applicable) at or before the effective time of the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cancel or arrange for the cancellation of the stock award, to the extent not exercised before the effective time of the
transaction, in exchange for a payment in such form as may be determined by our board of directors, equal to the excess, if any, of (A)&nbsp;the per share amount (or value of property per share) payable to holders of common stock in connection with
the transaction, over (B)&nbsp;the per share exercise price under the stock award (if any), multiplied by the number of vested shares subject to the stock award; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">make a payment equal to the excess, if any, of (A)&nbsp;the value of the property the participant would have received on
exercise of the award immediately before the effective time of the transaction, over (B)&nbsp;any exercise price payable by the participant in connection with the exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspend the exercise of the stock award, prior to the effective time of the transaction, for such period as our board of
directors determines is necessary to facilitate the negotiation and consummation of the transaction; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if a stock award is eligible for &#147;early exercise,&#148; cancel or arrange for the cancellation of any such
&#147;early exercise&#148; rights upon the transaction, such that following the transaction, such stock award may only be exercised to the extent vested. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The plan administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to treat all participants in the
same manner. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the 2017 Plan, a &#147;corporate transaction&#148; is generally defined as the consummation, in a single transaction or in a series of related
transactions, of: (1)&nbsp;a sale of all or substantially all of our assets, (2)&nbsp;the sale or disposition of more than 50% of our outstanding securities, (3)&nbsp;a merger or consolidation where we do not survive the transaction, or (4)&nbsp;a
merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Change in control. </I><I></I>A stock award may be subject to additional acceleration of vesting and exercisability upon or after a change in control as may be
provided in an applicable award agreement or other written agreement, but in the absence of such provision, no such acceleration will occur<I>. </I>Under the 2017 Plan, a &#147;change in control&#148; is generally defined as (1)&nbsp;certain
acquisitions by a person or company of more than 50% of the combined voting power of our then outstanding stock, (2)&nbsp;a merger, consolidation or similar transaction in which our stockholders immediately before the transaction do not own,
directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the same proportions as their ownership immediately prior to such transaction, or (3)&nbsp;a sale,
lease, exclusive license or other disposition of all or substantially all of our consolidated assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders in substantially the same proportions as
their ownership of our outstanding voting securities immediately prior to such transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan amendment or termination</I>. Our board of directors has the
authority to amend, suspend, or terminate our 2017 Plan, provided that such action does not impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our
stockholders. Unless terminated sooner, the 2017 Plan will automatically terminate on December&nbsp;10, 2027. No stock awards may be granted under our 2017 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2018 Employee Stock Purchase Plan </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors adopted,
and our stockholders approved, our ESPP in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2018. The ESPP will become effective immediately prior to and contingent upon the date of the underwriting
agreement related to this offering. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that
of our affiliates. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code for U.S. employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Share reserve</I>. Following this offering, the ESPP authorizes the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of
our common stock reserved for issuance will automatically increase on January&nbsp;1 of each calendar year, beginning on January&nbsp;1, 2019 (assuming the ESPP becomes effective in 2018) through January&nbsp;1, 2028, by the lesser of (1)
&nbsp;&nbsp;&nbsp;&nbsp; % of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of the automatic increase, and
(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares; provided that before the date of any such increase, our board of directors may determine that such increase will be less than the amount set
forth in clauses (1)&nbsp;and (2). As of the date hereof, no shares of our common stock have been purchased under the ESPP. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Administration</I>. Our board of
directors administers the ESPP and may delegate its authority to administer the ESPP to our compensation committee. The ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares
of our common stock on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months, and may
specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering under the ESPP may be terminated
under certain circumstances. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Payroll deductions</I>. Generally, all regular employees, including executive officers, employed by us or by any of our designated
affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to&nbsp;&nbsp;&nbsp;&nbsp;% of their earnings (as defined in the ESPP) for the purchase of our common stock under the ESPP. Unless otherwise
determined by our board of directors, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is at least the lesser of (1) 85% of the fair market value of a share of our common stock on the
first date of an offering, or (2) 85% of the fair market value of a share of our common stock on the date of purchase. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Limitations</I>. Employees may have to
satisfy one or more of the following service requirements before participating in the ESPP, as determined by our board of directors, including: (1)&nbsp;being customarily employed for more than 20 hours per week, (2)&nbsp;being customarily employed
for more than five months per calendar year, or (3)&nbsp;continuous employment with us or one of our affiliates for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of
our common stock based on the fair market value per share of our common stock at the beginning of an offering for each calendar year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights
under the ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value under Section&nbsp;424(d) of the Code. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to capital structure</I>. In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar
transaction, the board of directors will make appropriate adjustments to: (1)&nbsp;the class(es) and maximum number of shares reserved under the ESPP, (2)&nbsp;the class(es) and maximum number of shares by which the share reserve may increase
automatically each year, (3)&nbsp;the class(es) and number of shares subject to and purchase price applicable to outstanding offerings and purchase rights, and (4)&nbsp;the class(es) and number of shares that are subject to purchase limits under
ongoing offerings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Corporate transactions</I>. In the event of certain significant corporate transactions, any then-outstanding rights to purchase our stock
under the ESPP may be assumed, continued, or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue, or substitute for such purchase
rights, then the participants&#146; accumulated payroll contributions will be used to purchase shares of our common stock within 10 business days before such corporate transaction, and such purchase rights will terminate immediately. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the ESPP, a corporate transaction is generally the consummation of: (1)&nbsp;a sale of all or substantially all of our assets, (2)&nbsp;the sale or disposition of
more than 50% of our outstanding securities, (3)&nbsp;a merger or consolidation where we do not survive the transaction, and (4)&nbsp;a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding
immediately before such transaction are converted or exchanged into other property by virtue of the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>ESPP amendment or termination</I>. Our board of directors has the authority to amend or terminate our ESPP,
provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by
applicable law or listing requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Historically, we have not paid or awarded any cash compensation to any of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on our board of
directors. In addition, we have not paid equity compensation to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on our board of directors, except as set forth below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017, we did not pay or award any compensation to any of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on our board and none of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors were granted or held outstanding stock or option awards. The following table sets
forth in summary form information concerning the compensation that we paid or awarded during the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017 to each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who
served at any time during 2017. Ms.&nbsp;Demski, Mr.&nbsp;McDermott and Dr.&nbsp;Pruzanski were not members of our board of directors in 2017 and are not included in the table. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL&nbsp;OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Connelly, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bala S. Manian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bruce D. Steel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents fees paid to Dr.&nbsp;Connelly for his consulting services to us during 2017. Dr.&nbsp;Connelly provided scientific and business-related consulting services to us from October 2017 through December 2017
pursuant to a consulting agreement with us effective as of October&nbsp;16, 2017, which terminated in connection with his commencement as our Chief Scientific Officer in January 2018. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;6, 2018, we granted Dr.&nbsp;Manian an option to purchase 2,761 shares of common stock at an exercise price of $0.35 per share. Dr.&nbsp;Manian&#146;s
option vests in 48&nbsp;successive equal monthly installments beginning on June&nbsp;6, 2018, subject to Dr.&nbsp;Manian&#146;s continued service with us. In July 2018, Dr.&nbsp;Manian early exercised his option in full and we issued him 2,761
shares of common stock, which are restricted shares subject to the vesting schedule described in the preceding sentence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;13, 2018, we granted
each of Ms.&nbsp;Demski and Mr.&nbsp;McDermott an option to purchase 2,761 shares of common stock at an exercise price of $33.32 per share. Each such option vests in 48 successive equal monthly installments beginning on September&nbsp;13, 2018,
subject to Ms.&nbsp;Demski&#146;s and Mr.&nbsp;McDermott&#146;s respective continued service with us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;14, 2018, we granted Dr.&nbsp;Pruzanski an
option to purchase 2,761 shares of common stock at an exercise price of $33.32 per share. Such option vests in 48 successive equal monthly installments beginning on September&nbsp;14, 2018, subject to Dr.&nbsp;Pruzanski&#146;s continued service with
us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have reimbursed and expect to continue to reimburse all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their travel, lodging and
other reasonable expenses incurred in attending meetings of our board of directors and committees of our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Director Compensation Policy </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors adopted a new compensation policy in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that will
become effective upon the execution and delivery of the underwriting agreement for this offering and will be applicable to all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. This compensation policy provides that each such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director will receive the following compensation for service on our board of directors: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an annual cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an additional cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to the chairman of the board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an additional cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to the lead independent director of the board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an additional annual cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for service as a member of the audit committee, compensation committee and the nominating and corporate governance committee, respectively;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an additional annual cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for service as chairman of the audit committee, compensation committee and the nominating and corporate governance committee, respectively;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an initial option grant to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock for each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who first joins our board of directors, on the
date of commencement of service on the board, vesting over a three year period following the grant date; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an annual option grant to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock for each <FONT STYLE="white-space:nowrap">non-employee</FONT> director serving on the board of directors on the date
of our annual stockholder meeting, vesting one year following the grant date. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of the option grants described above will vest and become
exercisable subject to the director&#146;s continuous service to us, provided that each option will vest in full upon a change in control (as defined in the 2018 Plan). The term of each option will be 10 years, subject to earlier termination as
provided in the 2018 Plan, except that the post-termination exercise period will be for 12 months from the date of termination, if such termination is other than for death, disability or cause. The options will be granted under our 2018 Plan, the
terms of which are described in more detail above under &#147;&#151;Equity Benefit Plans&#151;2018 Plan.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following includes a summary of transactions since March&nbsp;16, 2017, our inception, to which we have been a party, in which the amount involved in the
transaction exceeded $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have
a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#147;Executive And Director Compensation.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Convertible Promissory Note Financing </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From May 2017 to June 2018, we issued
and sold to investors convertible promissory notes in the aggregate principal amount of approximately $9.4&nbsp;million. The convertible promissory notes carry an interest rate of 6% per annum. The participants in this convertible promissory note
financing included the following executive officers and members of our board of directors, or entities affiliated with them. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>PARTICIPANTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE&nbsp;PRINCIPAL<BR>AMOUNT OF NOTES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Daniel M. Bradbury</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">512,165.00</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP>&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bruce D. Steel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">512,164.00</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP>&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of convertible promissory notes held by (i)&nbsp;BioBrit, LLC, or BioBrit, in the principal amount of $409,732.00 (which convertible promissory note was originally issued in May 2017 in principal amount of
$400,000.00 and was amended and restated in October 2017 in principal amount of $409,732.00, which amount includes accrued interest from May 2017 to October 2017), or the BioBrit Note, and (ii)&nbsp;The Bradbury Family 2009 Irrevocable Trust dated
September&nbsp;1, 2009, or Bradbury Trust, in the principal amount of $102,433.00 (which convertible promissory note was originally issued in May 2017 in principal amount of $100,000.00 and was amended and restated in October 2017 in principal
amount of $102,433.00, which amount includes accrued interest from May 2017 to October 2017), or the Bradbury Trust Note. Mr.&nbsp;Bradbury, is the managing member of BioBrit. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Such convertible promissory note, or the Steel Note, was originally issued in May 2017 in principal amount of $500,000.00 and was amended and restated in October 2017 in principal amount of $512,164.00, which amount
includes accrued interest from May 2017 to October 2017. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The BioBrit Note, the Bradbury Note and the Steel Note will automatically convert upon the
completion of this offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, respectively, each based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into offer letters with Mr.&nbsp;Bradbury, Mr.&nbsp;Steel, Dr.&nbsp;Connelly, Mr.&nbsp;Keyes and Dr.&nbsp;Polu, each of which is described in the
section titled &#147;Executive and Director Compensation.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Biocon Agreements </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2017, we entered into the Biocon License and the Biocon Supply Agreement with Biocon, one of our 5% stockholders. Such agreements are described in
&#147;Business&#151;Partnerships&#151;Collaboration and License Agreement with Biocon&#148; and &#147;Business&#151;Partnerships&#151;Clinical Supply Agreement with Biocon.&#148; In connection with the Biocon License, we entered into a Common Stock
Purchase Agreement with Biocon, pursuant to which we issued 242,236&nbsp;shares of our common stock as consideration under the Biocon License. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with
the completion of this offering, we will issue to Biocon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock pursuant to certain anti-dilution rights that will be satisfied in full
upon such issuance, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus). Such anti-dilution rights are
described in &#147;Description of Capital Stock&#151;Anti-Dilution Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investor Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
May 2017, we entered into an investor rights agreement and voting agreement with Biocon and certain other of our stockholders containing, among other things, voting rights, information rights, <FONT STYLE="white-space:nowrap">pre-emptive</FONT>
rights, <FONT STYLE="white-space:nowrap">co-sale</FONT> rights, anti-dilution rights and potential future registration rights. These rights will terminate upon the closing of this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered, and intend to continue to enter,
into separate indemnification agreements with each of our directors and executive officers, as described in &#147;Management&#151;Limitation of Liability and Indemnification.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies and Procedures for Transactions with Related Persons </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have
adopted a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of &#147;related-person transactions.&#148; For purposes of our policy only, a
&#147;related-person transaction&#148; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#147;related person&#148; are participants involving an amount that
exceeds $120,000. Transactions involving compensation for services provided to us as an employee, consultant or director are not considered related-person transactions under this policy. A related person is any executive officer, director, nominee
to become a director or a holder of more than five percent of our common stock, including any of their immediate family members and affiliates, including entities owned or controlled by such persons. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the proposed related-person
transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our board of directors) for review. The presentation must include a description of, among other things, all of the
parties thereto, the direct and indirect interests of the related persons, the purpose of the transaction, the material facts, the benefits of the transaction to us and whether any alternative transactions are available, an assessment of whether the
terms are comparable to the terms available from unrelated third parties and management&#146;s recommendation. To identify related-person transactions in advance, we rely on information supplied by our executive officers, directors and certain
significant stockholders. In considering related-person transactions, our audit committee or another independent body of our board of directors takes into account the relevant available facts and circumstances including, but not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the impact on a director&#146;s independence in the event the related person is a director, immediate family member of a
director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms of the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the terms available to or from, as the case may be, unrelated third parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval. All of the
transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information regarding beneficial ownership of our capital stock by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The percentage ownership information under the column entitled &#147;Before Offering&#148; is based on 1,285,714 shares of common stock outstanding as of
August&nbsp;30, 2018. The percentage ownership information under the column entitled &#147;After Offering&#148; is based on the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock in this offering and takes into account (i)&nbsp;the conversion of $9.4&nbsp;million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this
offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 and (ii)&nbsp;the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information with respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of our common stock. We have
determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In
addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable on or before October&nbsp;29, 2018, which is 60 days after August&nbsp;30, 2018.
These shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of
computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to
applicable community property laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise noted below, the address for each person or entity listed in the table is c/o Equillium, Inc., 2223 Avenida
de la Playa, Suite 108, La Jolla, CA 92037. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME AND ADDRESS OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF SHARES<BR>BENEFICIALLY OWNED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE&nbsp;OF&nbsp;SHARES<BR>BENEFICIALLY OWNED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BEFORE<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AFTER<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BEFORE<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AFTER<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Biocon SA<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Daniel M. Bradbury<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bruce D. Steel<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Connelly, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martha J. Demski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bala S. Manian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Charles McDermott</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mark Pruzanski, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All current executive officers and directors as a group (9&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,044,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1%. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The number of shares beneficially owned after the offering includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon completion of this
offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus). The address of Biocon SA is c/o BDO SA, Rue de l&#146;Avenir
2, 2800 Del&eacute;mont, Switzerland. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 340,000 shares of common stock held by BioBrit, LLC, or BioBrit, of which Mr.&nbsp;Bradbury is the managing member, and (ii) 85,000 shares of common held by The Bradbury Family 2009 Irrevocable Trust
dated September&nbsp;1, 2009, or Bradbury Trust. The number of shares beneficially owned after the offering includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon
the conversion of a convertible promissory note in the principal amount of (a) $409,732 plus accrued interest held by BioBrit and (b) $102,433.00 plus accrued interest held by Bradbury Trust, each upon the completion of this offering based on an
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the
occurrence of the conversion on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 375,000 shares of common stock held by Bruce D. Steel, as trustee of the Steel Family Revocable Trust dated June&nbsp;5, 2002, and (ii) 50,000 shares of common held by Kevin N. Steel, as trustee of the
Sierra Kathleen Steel Trust of January&nbsp;1, 2005. The number of shares beneficially owned after the offering includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable
upon the conversion of a convertible promissory note in the principal amount of $512,164 plus accrued interest held by Bruce D. Steel upon the completion of this offering based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;the shares described in Notes&nbsp;(2) and (3) above, (ii)&nbsp;17,253 shares of common stock held by The Keyes Trust Dated September&nbsp;10, 2004 and beneficially owned by Jason A. Keyes, our
Chief Financial Officer, all of which are subject to a right of repurchase by us as of August&nbsp;30, 2018 and 24,155 shares of common stock that Krishna R. Polu, M.D., our Chief Medical Officer, has the right to acquire from us within 60 days of
August 30, 2018 pursuant to the exercise of stock options. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon filing of our amended and restated certificate of incorporation and the completion of this offering, our authorized capital stock will consist of 200,000,000
shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the completion of this offering will be undesignated. The following is a summary
of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the completion of
this offering, respectively, and of the Delaware General Corporation Law. This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed
as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law. As of the date of this prospectus, we have not issued any shares of preferred stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Outstanding Shares </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2018, there were 1,273,291 shares of common stock issued and outstanding (including 31,055 shares of restricted common stock which are subject to a
right of repurchase by us as of June&nbsp;30, 2018) held of record by 12 stockholders. Based on the number of shares of common stock outstanding as of June&nbsp;30, 2018, and assuming (1)&nbsp;the conversion of $9.4&nbsp;million of aggregate
principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, (2) the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and (3)&nbsp;the issuance by us
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering, there will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding upon the completion of this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2018, there were 12,423 shares of common stock subject to outstanding options under our 2017 Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our common stock is entitled to one vote for each share held
of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any
election of directors can elect all of the directors standing for election. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be
declared from time to time by our board of directors out of legally available funds. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> holders of our common stock will be entitled to share ratably in the
net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rights and Preferences </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the closing of this offering,
no holders of our common stock will have preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock
that we may designate and issue in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fully Paid and Nonassessable </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stockholder Registration Rights </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of our capital stock do not have
the right to require us to register with the SEC any such shares of capital stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Dilution Rights </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to that certain Investors&#146; Rights Agreement, dated May&nbsp;22, 2017, by and among us and certain of our stockholders listed therein, in the event we
issue certain equity securities, in connection with such issuances we are obligated to issue to Biocon additional shares of our common stock in order to maintain Biocon&#146;s ownership interest at 19.5% of our outstanding shares. Such anti-dilution
rights terminate at such time we have received aggregate cumulative gross proceeds from sales of equity securities equal to $15,000,000 and will terminate in connection with this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Delaware Anti-Takeover Law </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to Section&nbsp;203 of the
Delaware General Corporation Law, or Section&nbsp;203. Section&nbsp;203 generally prohibits a public Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years
following the time that such stockholder became an interested stockholder, unless: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">prior to such time the board of directors of the corporation approved either the business combination or the transaction
which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested
stockholder) those shares owned (1)&nbsp;by persons who are directors and also officers and (2)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will
be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual
or special meeting of stockholders, and not by written consent, by the affirmative vote of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the
corporation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share
of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, Section&nbsp;203 defines an interested stockholder as any entity or person
beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the
completion of this offering, respectively, may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for
their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of
incorporation and amended and restated bylaws: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and
privileges as they may designate (including the right to approve an acquisition or other change in our control); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that the authorized number of directors may be changed only by resolution of the board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of
the holders of at least 66-2/3% of the voting power of all of our then outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by
the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">divide our board of directors into three classes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of
stockholders and not be taken by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for
election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock
entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive
Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&nbsp;any
derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii)&nbsp;any action asserting a claim against us
arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws, and (iv)&nbsp;any action asserting a claim against us governed by the internal affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights,
preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>The Nasdaq Global Market
Listing </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have applied for listing of our common stock on The Nasdaq Global Market under the symbol &#147;EQ.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent and registrar&#146;s address is 6201
15th Avenue, Brooklyn, New York 11219. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of common stock in the public market could
adversely affect prevailing market prices. Furthermore, since only a limited number of shares will be available for sale shortly after this offering because of contractual and legal restrictions on resale described below, sales of substantial
amounts of common stock in the public market after the restrictions lapse could adversely affect the prevailing market price for our common stock as well as our ability to raise equity capital in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the number of shares of common stock outstanding as of June&nbsp;30, 2018, upon the completion of this offering and assuming (1)&nbsp;the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stock</FONT></FONT> split of all outstanding shares of our capital stock, (2)&nbsp;the
conversion of $9.4&nbsp;million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, (3) the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, (4)&nbsp;no exercise of the underwriters&#146; option to purchase additional shares of common stock and
(5)&nbsp;no exercise of outstanding options, an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be outstanding. All of the shares sold in this offering will be
freely tradable in the public market without restriction or further registration under the Securities Act, unless held by an affiliate of ours. Except as set forth below, the remaining shares of common stock outstanding after this offering will be
restricted as a result of securities laws or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. In addition, any shares sold in this offering to entities affiliated with our existing stockholders and directors will be subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements. These remaining shares will generally become available for sale in the public market as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no restricted shares will be eligible for immediate sale upon the completion of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;restricted shares
will be eligible for sale under Rule 144 or Rule 701 upon expiration of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements 180 days after the date of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the remainder of the restricted shares will be eligible for sale from time to time thereafter upon expiration of their
respective holding periods under Rule 144, as described below. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule 144 as currently in effect, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, any
person who is not an affiliate of ours and has held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell shares without restriction, provided current public information
about us is available. In addition, under Rule 144, any person who is not an affiliate of ours and has held their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to
sell an unlimited number of shares immediately upon the completion of this offering without regard to whether current public information about us is available. Beginning 90 days after the effective date of the registration statement of which this
prospectus is a part, a person who is an affiliate of ours and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to sell a number
of restricted shares within any three-month period that does not exceed the greater of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1% of the number of shares of our common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks preceding
the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of restricted shares under Rule 144 held by our affiliates are also subject to
requirements regarding the manner of sale, notice and the availability of current public information about us. Rule 144 also provides that affiliates relying on Rule 144 to sell shares of our common stock that are not restricted shares must
nonetheless comply with the same restrictions applicable to restricted shares, other than the holding period requirement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding the availability of Rule 144, the holders of substantially all of our restricted shares have entered
into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and their restricted shares will become eligible for sale at the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Rule 701, shares of our common stock acquired upon the
exercise of currently outstanding options or pursuant to other rights granted under our stock plans may be resold by: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons other than affiliates, beginning 90 days after the effective date of the registration statement of which this
prospectus is a part, subject only to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> provisions of Rule 144; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a
part, subject to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> and volume limitations, current public information and filing requirements of Rule 144, in each case, without compliance with the <FONT
STYLE="white-space:nowrap">six-month</FONT> holding period requirement of Rule 144. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2018, options to purchase a total of
12,423 shares of common stock were outstanding, of which 805 were vested. Of the total number of shares of our common stock issuable under these options, substantially all are subject to contractual <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements with us or the underwriters described below under &#147;Underwriting&#148; and will become eligible for sale at the expiration of those agreements unless held by an affiliate of ours. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, along with
our directors, executive officers and substantially all of our other stockholders and optionholders, have agreed that for a period of 180 days, after the date of this prospectus, except with the prior written consent of Jefferies LLC and Leerink
Partners LLC and subject to specified exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or
otherwise dispose of or transfer, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, or enter into any swap or other arrangement that transfers to another, in whole or in part,
directly or indirectly, any of the economic consequences of ownership of the common stock. Jefferies LLC and Leerink Partners LLC have advised us that it has no current intent or arrangement to release any of the shares subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After this
offering, certain of our employees, including our executive officers and/or directors, may enter into written trading plans that are intended to comply with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act. Sales under
these trading plans would not be permitted until the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements relating to the offering described above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of our capital stock do not have any rights
with respect to the registration of their shares under the Securities Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to file with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act covering the shares of common stock
reserved for issuance under the 2017 Plan, the 2018 Plan and the ESPP. The registration statement is expected to be filed and become effective as soon as practicable after the completion of this offering. Accordingly, shares registered under the
registration statement will be available for sale in the open market following its effective date, subject to Rule 144 volume limitations and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_17"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TO <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following summary describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our common stock acquired in this
offering by <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below). This discussion does not address all aspects of U.S. federal income taxes that may be relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders in
light of their particular circumstances, nor does it address any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences or U.S. federal tax consequences other than income taxes (such as U.S. federal estate or gift tax
consequences). Rules different from those described below may apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are subject to special treatment under the Code such as financial institutions, insurance companies, <FONT
STYLE="white-space:nowrap">tax-exempt</FONT> organizations, <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans, broker-dealers and traders in securities, commodities or currencies, government organizations, certain foreign
citizens or long-term residents of the United States, &#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; corporations that accumulate earnings to avoid U.S. federal income tax, persons that hold our common
stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;synthetic security,&#148; integrated investment or other risk reduction strategy, holders deemed to sell our common stock under the constructive
sale provisions of the Code, holders who hold or receive our common stock pursuant to the exercise of employee stock options or otherwise as compensation, holders who are subject to the alternative minimum tax or the federal Medicare contribution
tax on net investment income, persons who have a functional currency other than the U.S. dollar, accrual method taxpayers subject to special tax accounting rules under Section&nbsp;451(b) of the Code, partnerships and other pass-through entities,
and investors in such pass-through entities or entities that are treated as disregarded entities for U.S. federal income tax purposes (regardless of their places of organization or formation). Such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. Furthermore, the discussion below is based upon the provisions of the Code, and U.S. Treasury
regulations, published administrative pronouncements, rulings and judicial decisions thereunder as of the date hereof. Such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax
consequences different from those discussed below. We have not requested a ruling from the U.S. Internal Revenue Service, or IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance
that the IRS will agree with such statements and conclusions. This discussion assumes that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of
the Code (generally, property held for investment). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion is for general information only and is not tax advice for any <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders under their particular circumstances. Persons considering the purchase of our common stock pursuant to this offering should consult their own tax advisors concerning the U.S. federal income tax and
other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences arising under the laws of any other taxing jurisdiction, including any state, local and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences and any U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences. In addition, significant changes in U.S. federal income tax laws were recently enacted. You should
also consult with your tax advisor with respect to such changes in U.S. tax law as well as potential conforming changes in state tax laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this
discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is, for U.S. federal income tax purposes, a beneficial owner of common stock that is not a U.S. Holder. A &#147;U.S. Holder&#148; means a beneficial owner of our
common stock that is for U.S. federal income tax purposes (a)&nbsp;an individual who is a citizen or resident of the United States, (b)&nbsp;a corporation or other entity treated as a corporation that is created or organized in or under the laws of
the United States, any state thereof or the District of Columbia, (c)&nbsp;an estate the income of which is subject to U.S. federal income taxation regardless of its source or (d)&nbsp;a trust if it (1)&nbsp;is subject to the primary supervision of
a court within the United States and one or more U.S. persons have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.
Also, partnerships and their partners, or other entities that are treated as partnerships for U.S. federal income tax purposes and their equity holders (regardless of their place of organization or formation) and entities that are treated as
disregarded entities for U.S. federal income tax purposes (regardless of their place of organization or formation) are not addressed by this discussion and are, therefore, not considered to be <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
for the purposes of this discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion below regarding backup withholding and foreign accounts, distributions, if any, made on our common stock to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will constitute dividends for U.S. tax purposes to the extent made out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) and
will be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. To obtain a reduced rate of withholding under a treaty, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally
will be required to provide us with a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the
case of entities), or other appropriate form, certifying the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s entitlement to benefits under that treaty. This certification must be provided to us or our paying agent prior to the payment
of dividends and must be updated periodically. In the case of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is an entity, U.S. Treasury regulations and the relevant tax treaty provide rules to determine whether, for purposes of
determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds stock through a financial institution
or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#146;s agent will then be required to provide such certification to us or our paying agent, either directly
or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, you should consult with your own tax advisor to determine if you are able to obtain a refund or credit if any excess
amount is withheld by timely filing an appropriate claim for a refund with the IRS. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We generally are not required to withhold tax on dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable
income tax treaty, are attributable to a permanent establishment that such holder maintains in the United States) if a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are so connected, is
furnished to us (or, if stock is held through a financial institution or other agent, to such agent). In general, such effectively connected dividends will be subject to U.S. federal income tax, on a net income basis at the regular graduated rates
applicable to U.S. residents, unless a specific treaty exemption applies. A corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder receiving effectively connected dividends may also be subject to an additional &#147;branch profits
tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s effectively connected
earnings and profits, subject to certain adjustments. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will first reduce the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted basis in our common stock as a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital, but not below zero, and then any excess will be treated as gain and taxed in the
same manner as gain realized from a sale or other disposition of common stock as described in the next section. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion below regarding backup withholding and foreign accounts, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally should not be
subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&nbsp;the gain is effectively connected with a trade or business of such holder in the United States (and, if required by
an applicable income tax treaty, is attributable to a permanent establishment that such holder maintains in the United States), (b) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual and is present in the
United States or 183 or more days in the taxable year of the disposition and certain other conditions are met, or (c)&nbsp;we are or have been a &#147;United States real property holding corporation,&#148; or a USRPHC, within the meaning of Code
Section&nbsp;897(c)(2) at any time within the shorter of the five-year period preceding such disposition or such holder&#146;s holding period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you are a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in clause (a)&nbsp;above, you will be required to pay tax on the net gain derived from the sale at regular graduated U.S. federal income tax rates, unless a specific treaty exemption
applies, and corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders described in clause (a)&nbsp;above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax
treaty. If you are an individual <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in clause (b)&nbsp;above, you will be required to pay a flat 30% tax on the gain derived from the sale, which gain may be offset by U.S. source
capital losses (even though you are not considered a resident of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the United States), provided you have timely filed U.S. federal income tax returns with respect to such losses. With respect to clause (c)&nbsp;above, in general, we would be a USRPHC if
interests in U.S. real property constituted (by fair market value) at least half of our assets. We believe that we are not, and do not anticipate becoming, a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair
market value of our U.S. real property interests relative to the fair market value of our other assets, there can be no assurance that we will not become a USRPHC in the future. Even if we are treated as a USRPHC, gain realized by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, directly, indirectly and
constructively, no more than 5% of our common stock at all times within the shorter of (a)&nbsp;the five-year period preceding the disposition or (b)&nbsp;the holder&#146;s holding period and (2)&nbsp;our common stock is regularly traded on an
established securities market within the meaning of applicable U.S. Treasury regulations. There can be no assurance that our common stock will continue to qualify as regularly traded on an established securities market. If any gain on your
disposition of our common stock is taxable because we are a USRPHC and your ownership of our common stock exceeds 5%, you will be taxed on such disposition generally in the manner applicable to U.S. persons and in addition, a purchaser of your
common stock may be required to withhold tax with respect to that obligation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting Requirements and Backup Withholding </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, we or certain financial middlemen must report information to the IRS with respect to any dividends we pay on our common stock (even if payments are not
subject to withholding) including the amount of any such dividends, the name and address of the recipient, and the amount, if any, of tax withheld. A similar report is sent to the holder to whom any such dividends are paid. Pursuant to tax treaties
or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#146;s country of residence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Dividends paid by us (or our
paying agents) to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject to U.S. backup withholding. U.S. backup withholding generally will not apply to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder who provides a
properly executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (in the case of individuals), IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities) or IRS Form <FONT
STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if the payor has actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt
recipient. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under current U.S. federal income tax law, U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a
disposition of our common stock effected within the United States or through certain U.S.-related brokers, unless the holder provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals), IRS Form <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities) or IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. Generally, U.S. information reporting and
backup withholding requirements will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder where the transaction is effected outside the United States through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker. Information reporting and backup withholding requirements may, however, apply to a payment of disposition proceeds if the broker
has actual knowledge, or reason to know, that the holder is, in fact, a U.S. person. For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner similar to U.S. brokers.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. If backup withholding is applied to you, you should consult with your own tax advisor to
determine if you are able to obtain a tax refund or credit with respect to the amount withheld. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Foreign Accounts </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A U.S. federal withholding tax of 30% may apply to dividends and the gross proceeds of a disposition of our common stock paid to a foreign financial institution (as
specifically defined by applicable rules), including when the foreign financial institution holds our common stock on behalf of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, unless such institution enters into an agreement with the U.S.
government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which may include certain equity holders of such institution, as well as
certain account holders that are foreign entities with U.S. owners). Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
States governing these withholding and reporting requirements may be subject to different rules. This U.S. federal withholding tax of 30% will also apply to dividends on and the gross proceeds of
a disposition of our common stock paid to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect
U.S. owners or provides information regarding direct and indirect U.S. owners of the entity. The withholding tax described above will not apply if the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign
entity otherwise qualifies for an exemption from these rules. Under certain circumstances, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder might be eligible for refunds or credits of such taxes. Holders are encouraged to consult with their
own tax advisors regarding the possible implications of these rules on their investment in our common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The withholding provisions described above generally
apply to payments of dividends, and will apply to payments of gross proceeds from a sale or other disposition of common stock after December&nbsp;31, 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">EACH
PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT AND PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX
CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> OR U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement, dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; among us and Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, as the representatives of the underwriters named
below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of shares of common stock shown
opposite its name below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of
their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable
laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the
liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the cover page of
this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. The underwriters may allow, and certain dealers
may reallow, a discount from the concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock to certain brokers and dealers. After the offering, the initial public offering price, concession and
reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses,
to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION&nbsp;TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Determination of Offering Price </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our common stock will be determined
by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe
to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We offer no assurances that
the initial public offering price will correspond to the price at which the common stock will trade in the public market subsequent to the offering or that an active trading market for the common stock will develop and continue after the offering.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to apply to have our common stock listed on The
Nasdaq Global Market under the symbol &#147;EQ.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If
you purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this
prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the
underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us at
the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a
number of additional shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table above.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No
Sales of Similar Securities </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and holders of all or substantially all our outstanding capital stock and other securities have agreed,
subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act, or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities
exchangeable or exercisable for or convertible into shares of common stock hereafter owned either of record or beneficially, or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus
without the prior written consent of Jefferies LLC and Leerink Partners LLC. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the common stock on and including the 180<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC and Leerink Partners LLC may, in their sole discretion and
at any time or from time to time before the termination of the <FONT STYLE="white-space:nowrap">180-day</FONT> period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no
existing agreements between the underwriters and any of our shareholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale of shares prior to the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
underwriters have advised us that they, pursuant to Regulation M under the Exchange Act, and certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the
imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing
short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an
amount not greater than the underwriters&#146; option to purchase additional shares of our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of
our common stock or purchasing shares of our common stock in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase
in the open market as compared to the price at which they may purchase shares through the option to purchase additional shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are
sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common
stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase
transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a
result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member
in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may
have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our common stock on The Nasdaq Global Market in accordance with Rule&nbsp;103 of
Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of
the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus in electronic format may be made
available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation
for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site
maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and Relationships </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriter and certain of its
affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. The underwriter and certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates,
for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriter and certain of
its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their
customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates.&nbsp;&nbsp;&nbsp;&nbsp;If the underwriters or their respective affiliates have a lending relationship with us, they
routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of
credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common
stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such
securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTICE TO HOLDERS </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Australia </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged
with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You confirm and warrant that you are either: </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have
provided an accountant&#146;s certificate to the Company which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a person associated with the Company under Section&nbsp;708(12) of the Corporations Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You warrant and agree that you will not offer any of
the securities issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the
Corporations Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Canada </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Resale
Restrictions </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of our shares in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private
placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares of common stock in Canada must be made
under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities
regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Representations of Canadian Purchasers </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing our shares of common stock in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the
purchase confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is entitled under applicable provincial securities laws to purchase the shares without the benefit of a
prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;</FONT><I>Prospectus Exemptions</I>, </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;</FONT><I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where required by law, the purchaser is purchasing as principal and not as agent, and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conflicts of Interest </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that
the underwriters proposing to sell into Canada are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;</FONT><I>Underwriting Conflicts</I> from having to
provide certain conflict of interest disclosure in this document. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Statutory Rights of Action </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any
amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Enforcement of Legal Rights </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers
as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and
the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons
outside of Canada. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation and Eligibility for Investment </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers of our shares of common stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the share in
their particular circumstances and about the eligibility of the shares for investment by the purchaser under relevant Canadian legislation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Economic
Area </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each member state of the European Economic Area which has implemented the Prospectus Directive, each, a Relevant Member State, an offer to
the public of any common shares which are the subject of the offering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
contemplated by this prospectus supplement and the accompanying prospectus may not be made in that Relevant Member State except that an offer to the public in that Relevant Member State of any
common shares may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to any legal entity which is a &#147;qualified investor&#148; as defined in the Prospectus Directive;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending
Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the underwriters or the underwriters nominated
by us for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of common shares shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive or
supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer common shares to the
public&#148; in relation to the common shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the common shares to be offered so as to enable an investor to
decide to purchase or subscribe to the common shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression &#147;Prospectus Directive&#148;
means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression
&#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Hong Kong </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business
is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong, or SFO, and any rules made under that Ordinance; or in other
circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong, or CO, or which do not constitute an offer or invitation to the public for the purpose of the CO or the
SFO. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or
the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been
registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each
person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and
that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Israel </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel
Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law and
(ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members
of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under
the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to
it. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Japan </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been and will not be registered under
the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended), or FIEL, and the Initial Purchaser will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident
of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or
indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial
guidelines of Japan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Singapore </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been and will
not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities
may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional
investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the
conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and
interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the notes pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Switzerland </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The securities may not
be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards
for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated
trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus nor any other offering or marketing material relating to the offering, the Company or the
securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority
FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the
CISA does not extend to acquirers of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>United Kingdom </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This
prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii)&nbsp;high net worth entities falling within Article 49(2)(a) to (d)&nbsp;of the Order and other persons to
whom it may lawfully be communicated (each such person being referred to as a &#147;relevant person&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus and its contents are confidential and
should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or
any of its contents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Cooley LLP, San Diego, California. The underwriters are being
represented by Latham&nbsp;&amp; Watkins LLP, San Diego, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements of Equillium, Inc. as of December&nbsp;31, 2017 and for the period from March&nbsp;16, 2017 (inception) to December&nbsp;31, 2017 have been
included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the
December&nbsp;31, 2017 financial statements contains an explanatory paragraph that states that the Company&#146;s recurring losses from operations and net capital deficiency raise substantial doubt about the entity&#146;s ability to continue as a
going concern. The financial statements do not include any adjustments that might result from the outcome of that uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc582934_21"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act, with respect to the shares of common
stock being offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, we refer you
to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract
or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You can read our SEC
filings, including the registration statement, over the Internet at the SEC&#146;s website at www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street NE, Washington, D.C. 20549.
You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street N.E., Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing us at
2223 Avenida de la Playa, Suite 108, La Jolla, CA 92037 or telephoning us at (858) 412-5302. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, we will be subject to the
information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for inspection and copying at the public
reference room and website of the SEC referred to above. We also maintain a website at www.equilliumbio.com, at which, following the completion of this offering, you may access these materials free of charge as soon as reasonably practicable after
they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fintoc"></A><A NAME="toc582934_22"></A>EQUILLIUM, INC. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Index to Financial Statements </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin582934_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin582934_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin582934_3">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin582934_4">Statements of Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin582934_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin582934_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin582934_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equillium, Inc.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying
balance sheet of Equillium, Inc. (the Company) as of December&nbsp;31, 2017, the related statements of operations and comprehensive loss, stockholders&#146; deficit, and cash flows for the period from March&nbsp;16, 2017 (inception) to
December&nbsp;31, 2017, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2017, and the
results of its operations and its cash flows for the period from inception to December&nbsp;31, 2017, in conformity with U.S.&nbsp;generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Going Concern </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability
to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements are the responsibility of the
Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks
of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a
reasonable basis for our opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ KPMG LLP </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the
Company&#146;s auditor since 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">August&nbsp;3, 2018
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin582934_2"></A>EQUILLIUM, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30,</B><br><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma</B><br><B>JUNE&nbsp;30,</B><br><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,103,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,626,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,149,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,706,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,151,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,728,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities and stockholders&#146; (deficit) equity</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:9.5pt; font-family:ARIAL"><B>&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">346,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">917,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long term convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,994,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,355,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term convertible promissory notes, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,064,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">878,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,403,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,321,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.0001 par value; 5,000,000 shares authorized at December&nbsp;31, 2017 and June&nbsp;30,
2018 (unaudited); 1,242,236 and 1,273,291 shares issued as of December&nbsp;31, 2017 and June&nbsp;30, 2018 (unaudited), respectively; and 1,242,236 and 1,273,291 shares outstanding as of December&nbsp;31, 2017 and June&nbsp;30, 2018 (unaudited),
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,604,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,252,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,593,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities and stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,151,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,728,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin582934_3"></A>EQUILLIUM, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statements of Operations and Comprehensive Loss </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE<BR>PERIOD<BR>MARCH&nbsp;16,<BR>2017<BR>(INCEPTION)<BR>THROUGH</B><br><B>DECEMBER&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE<BR>PERIOD<BR>MARCH&nbsp;16,<BR>2017<BR>(INCEPTION)<BR>THROUGH<BR>JUNE&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS<BR>ENDED</B><br><B>JUNE&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">801,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,202,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">958,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,712,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">988,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,161,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,712,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(988,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,161,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expense (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,342,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted-average common shares outstanding, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin582934_4"></A>EQUILLIUM, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statements of Stockholders&#146; Deficit </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN</FONT></B><br><B>CAPITAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>STOCKHOLDERS&#146;</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance at March&nbsp;16, 2017 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of founders&#146; stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of common stock to Biocon at $0.04 per share for license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,252,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of common stock, net of liability (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,342,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,342,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance at June&nbsp;30, 2018 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,273,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,604,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,593,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes </P> <P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin582934_5"></A>EQUILLIUM, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statements of Cash Flows </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD<BR>MARCH&nbsp;16,&nbsp;2017<BR>(INCEPTION)&nbsp;THROUGH</B><br><B>DECEMBER&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD<BR>MARCH&nbsp;16,&nbsp;2017<BR>(INCEPTION)&nbsp;THROUGH</B><br><B>JUNE&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX&nbsp;MONTHS&nbsp;ENDED<BR>JUNE&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,342,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> research license expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,813</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(662,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,057,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of convertible promissory notes, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,767,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,599,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of convertible promissory notes, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of unvested common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,767,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,103,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">816,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(477,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,103,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,103,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">816,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,626,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Supplemental disclosures of noncash activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of common stock to Biocon for license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><A NAME="fin582934_6"></A>1. Organization and Basis of Presentation </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Description of Business </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company was incorporated in the state of
Delaware on March&nbsp;16, 2017, under the name Attenuate Biopharmaceuticals, Inc. On May&nbsp;18, 2017, the Company changed its name to Equillium, Inc. (&#147;the Company&#148;). The Company is engaged in the research and development of products
for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has devoted substantially all of its efforts on
organizing and staffing our company, business planning, raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> rights to EQ001, conducting preclinical research, filing our initial IND and preparing to commence clinical development of
EQ001. In addition, the Company has a limited operating history, has not generated revenues from its principal operations, and the sales and income potential of its business is unproven. The accompanying financial statements have been prepared
assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on
the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity
</I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into
the foreseeable future. The Company had an accumulated deficit of $2.3&nbsp;million and $5.6&nbsp;million at December&nbsp;31, 2017 and June&nbsp;30, 2018 (unaudited), respectively. In 2017, the Company used $0.7&nbsp;million in cash for operations.
For the six month period ended June&nbsp;30, 2018 (unaudited), the Company used $2.1&nbsp;million in cash for operations. At December&nbsp;31, 2017 and June&nbsp;30, 2018 (unaudited), the Company had cash and cash equivalents of $7.1&nbsp;million
and $6.6&nbsp;million, respectively. Management expects operating losses and negative cash flows to continue for at least the next several years as the Company continues to incur costs related to the development of EQ001. Management has prepared
cash flow forecasts which indicate that based on the Company&#146;s expected operating losses and negative cash flows, there is substantial doubt about the Company&#146;s ability to continue as a going concern without raising additional capital
within 12&nbsp;months after the date that the financial statements for the period March&nbsp;16, 2017 (inception) through December&nbsp;31, 2017 are issued. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company&#146;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management intends to raise additional capital through a combination of equity offerings, debt financings, and collaboration and license
agreements. However, the Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may
experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#146;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar
arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on
attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#146;s ability to achieve the development and commercialization goals would be
adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s financial statements are
prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;). The preparation of the Company&#146;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of
assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#146;s
historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unaudited Interim Financial Information </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying interim balance sheet as of June&nbsp;30, 2018, and the statements of operations and comprehensive loss and cash flows for the period March&nbsp;16,
2017 (inception) through June&nbsp;30, 2017 and the six months ended June&nbsp;30, 2018 and the statement of stockholders&#146; deficit for the six months ended June&nbsp;30, 2018 and the related footnote disclosures are unaudited. These unaudited
interim financial statements have been prepared in accordance with GAAP. The unaudited interim financial statements have been prepared on the same basis as the audited financial statements and reflect, in management&#146;s opinion, all adjustments
of a normal, recurring nature that are necessary for the fair statement of the Company&#146;s financial position as of June&nbsp;30, 2018 and its results of operations and cash flows for the period ended June&nbsp;30, 2017 and the six months ended
June&nbsp;30, 2018. The results for the six months ended June&nbsp;30, 2018 are not necessarily indicative of the results expected for the full fiscal year or any other period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Balance Sheet Information </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro
forma balance sheet information as of June&nbsp;30, 2018 gives effect to the issuance of $9.4&nbsp;million of convertible promissory notes issued in October 2017, November 2017, April 2018, and June 2018 (see Note&nbsp;6) and the automatic
conversion of such notes (including accrued interest thereon) into shares of common stock upon completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range listed on the cover page of this prospectus) and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. The unaudited pro forma balance sheet assumes that the completion of the IPO had occurred as of June&nbsp;30, 2018 and excludes shares of common
stock issued in the offering and any related net proceeds. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash. The Company maintains deposits in federally
insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of
the depository institutions in which those deposits are held. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is required to report all components of comprehensive loss, including net loss, in the financial statements in the period in which they are recognized.
Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources, including unrealized gains and losses on investments and
foreign currency gains and losses. Comprehensive loss is the same as the net loss for the period ended December&nbsp;31, 2017 and six months ended June&nbsp;30, 2018 (unaudited). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value of Financial Instruments </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The carrying amounts of all
prepaid and other current assets, accounts payable, accrued expenses, and debt are considered to be representative of their respective fair values because of the short-term nature of those instruments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment is stated at cost and
depreciated using the straight-line method over the estimated useful lives of the assets (generally two to five years, or the remaining term of the lease). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accrued Research and Development Expense </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is required to
estimate its expenses resulting from its obligations under contracts with vendors, consultants and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject
to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its
financial statements by matching those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical or clinical study as measured by the
timing of various aspects of the study or related activities. The Company determines accrual estimates through review of the underlying contracts along with preparation of financial models taking into account discussions with research and other key
personnel as to the progress of studies, or other services being conducted. During the course of a study, the Company adjusts its rate of expense recognition if actual results differ from its estimates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses include
salaries, benefits, costs to third-party contractors to perform research and development activities, and associated overhead expenses. Research and development costs are expensed as incurred. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent Costs </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company expenses all costs as incurred in
connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statement of operations.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Debt Costs </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company capitalizes related debt issuance costs
and amortizes them over the life of the loan using the effective interest method. Conversion discounts on the Company&#146;s convertible promissory notes based on a future round of financing are recognized as additional interest expense over the
life of the debt using the effective interest method. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred Rent </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company leases. The
Company&#146;s leases for its facilities provide for fixed increases in minimum annual rental payments. The total amount of rental payments due over the lease terms are being charged to rent expense ratably over the life of the leases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Biocon Anti-Dilution Right </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has committed to issue to
Biocon SA (together with Biocon Limited, &#147;Biocon&#148;) additional shares of common stock to maintain Biocon&#146;s ownership interest at 19.5% of the diluted Company shares outstanding (as defined in the License Agreements (as defined below))
until the Company has received aggregate cumulative gross proceeds from sales of equity securities of $15.0&nbsp;million (&#147;Biocon Anti-Dilution Right&#148;). As an obligation exists to issue a variable number of shares and that obligation is
not indexed to the Company&#146;s common stock, the Biocon Anti-Dilution Right has been classified as a liability in the accompanying balance sheet. The Biocon Anti-Dilution Right is recorded at fair value using the Precedent Transaction Method. The
fair value of the Biocon Anti-Dilution Right is <FONT STYLE="white-space:nowrap">re-measured</FONT> at each financial reporting period with any changes in fair value recognized as a component of other expense (income). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense represents
the cost of the grant date fair value of employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of
actual forfeitures during the period. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The exercise price for all stock options granted was at the estimated fair value of the underlying common
stock as determined on the date of grant by the Company&#146;s Board of Directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of
a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes
deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of
existing taxable temporary differences, projected future taxable income, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies, and results of recent operations. If management determines that the Company would be able to realize its
deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2017, and as of June&nbsp;30, 2018, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had
not met the &#147;more likely than not&#148; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company records uncertain tax positions on the basis of a <FONT STYLE="white-space:nowrap">two-step</FONT> process whereby (1)&nbsp;management determines whether it
is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&nbsp;for those tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition
threshold, management recognizes the largest amount of tax benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized
tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share
is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company&#146;s potentially
dilutive securities include outstanding stock options under the Company&#146;s equity incentive plan and have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods
presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#146;s net loss position. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be
anti-dilutive are as follows (in common stock equivalent shares): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD<BR>MARCH&nbsp;16,<BR>2017<BR>(INCEPTION)<BR>THROUGH</B><br><B>DECEMBER&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD<BR>MARCH&nbsp;16,&nbsp;2017<BR>(INCEPTION)<BR>THROUGH</B><br><B>JUNE&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX&nbsp;MONTHS<BR>ENDED</B><br><B>JUNE&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the unaudited pro forma net loss per share: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE PERIOD<BR>MARCH&nbsp;16, 2017<BR>(INCEPTION)<BR>THROUGH</B><br><B>DECEMBER&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS<BR>ENDED<BR>JUNE&nbsp;30,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,261,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,342,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Add:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense on convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,882,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,233,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Add:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma adjustments to reflect assumed conversion of convertible promissory notes into common
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recent Accounting Pronouncements </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
February 2015, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standard Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases (Topic 842), </I>which amends the FASB Accounting Standards
Codification and creates Topic 842, &#147;Leases.&#148; The new topic supersedes Topic 840, &#147;Leases,&#148; and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet
and requires disclosures of key information about leasing arrangements. The guidance is effective for reporting periods beginning after December&nbsp;15, 2018. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> mandates a modified retrospective
transition method. The Company entered into a lease in 2018 and will evaluate the impact of adoption of the ASU on its financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2016, the
FASB issued ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT> <I>Classification of Certain Cash Receipts and Cash Payments</I> <I>(Topic 230)</I>. ASU <FONT STYLE="white-space:nowrap">2016-15</FONT> addresses eight specific cash flow issues with
the objective of reducing the existing diversity in practice for certain cash receipts and cash payments. The standard is effective for annual reporting periods beginning after December&nbsp;15, 2018 and interim periods reporting within fiscal years
beginning after December&nbsp;15, 2019, with early adoption permitted. The Company does not believe the adoption of this guidance will have a material impact on the financial statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT> <I>Improvements to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Share-Based
Payment Accounting (Topic 718)</I>. ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance of share-based payments to employees, with certain
exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date, which may lower their cost and reduce volatility in the income statement. The standard is effective in annual periods beginning
after December&nbsp;15, 2018 including interim periods within that fiscal year, with early adoption permitted but not before the Company adopts <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09,</FONT><I></I><I>&nbsp;Revenue from Contracts with
Customers</I> <I>(Topic 606)</I>. The Company early adopted this guidance as of January&nbsp;1, 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Fair Value Measurements </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability
category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is a market-based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting
guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B>Level</B><B></B><B>&nbsp;1</B>&#151;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical,
unrestricted assets or liabilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B>Level</B><B></B><B>&nbsp;2</B>&#151;Quoted prices for similar assets and liabilities in active markets,
quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B>Level</B><B></B><B>&nbsp;3</B>&#151;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and
unobservable (i.e. supported by little or no market activity). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2017 and June&nbsp;30, 2018, the Company did not have financial assets that are
measured at fair value on a recurring basis. The carrying amounts of the Company&#146;s financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value
due to their short maturities. The Company believes the fair value of its convertible promissory notes approximates its carrying value. None of the Company&#146;s <FONT STYLE="white-space:nowrap">non-financial</FONT> assets or liabilities are
recorded at fair value on a <FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. No transfers between levels have occurred during the periods presented. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company estimated the fair value of its Biocon Anti-Dilution Right (see Note 5) at the time of issuance and remeasures it at each reporting date using the Precedent
Transaction Method. The Precedent Transaction Method was applied to solve for the enterprise value of the Company under two scenarios: with the Biocon Anti-Dilution Right and without the Biocon Anti-Dilution Right. The resulting difference in the
enterprise value under these two scenarios is the estimated fair value of the Biocon Anti-Dilution Right. The estimates used to determine the enterprise value of the Company are based, in part, on subjective assumptions and could differ materially
in the future. Fluctuations in the fair value of the Biocon Anti-Dilution Right are impacted by unobservable inputs, most significantly the estimated fair value of the Company and probability of achieving different financing scenarios. If the
Company does not receive proceeds from an equity financing, the fair value of the Biocon Anti-Dilution Right would be zero. Alternatively, if an equity financing results in gross proceeds of $15.0&nbsp;million or greater, the fair value of the
Biocon Anti-Dilution Right could be as high as $3.6&nbsp;million. Changes in the estimated fair value of the Company and the probability of achieving different financing scenarios can have a significant impact on the fair value of the Biocon
Anti-Dilution Right. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial liabilities measured at fair value on a recurring basis consist of the Biocon Anti-Dilution Right. As of December&nbsp;31, 2017 and
June&nbsp;30, 2018 (unaudited), the carrying amount of the Biocon Anti-Dilution Right was $0.8&nbsp;million and $0.9&nbsp;million, respectively, which approximates fair value and was determined based upon Level&nbsp;3 inputs. As of December&nbsp;31,
2017 and June&nbsp;30, 2018, the Company did not hold any Level&nbsp;1 or Level&nbsp;2 financial liabilities that are recorded at fair value on a recurring basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents activity for the Biocon Anti-Dilution Right measured at fair value using Level&nbsp;3
unobservable inputs as of December&nbsp;31, 2017 and June&nbsp;30, 2018 (unaudited): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FAIR VALUE<BR>MEASUREMENTS<BR>AT REPORTING<BR>DATE USING<BR>SIGNIFICANT<BR>UNOBSERVABLE<BR>INPUTS&nbsp;(LEVEL&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at March&nbsp;16, 2017 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in fair value of Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in fair value of Biocon anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at June&nbsp;30, 2018 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">878,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Accrued Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued expenses consist
of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued payroll and other employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">137,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preclinical studies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">325,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">570,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Collaboration and License Agreement </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
May 2017, the Company entered into a collaboration and license agreement, clinical supply agreement, investor rights agreement, and common stock purchase agreement (collectively &#147;License Agreements&#148;) with Biocon. Pursuant to the License
Agreements, Biocon granted the Company an exclusive license in the United States and Canada (&#147;Company Territory&#148;) to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit EQ001 and any pharmaceutical
composition or preparation containing or comprising EQ001 (&#147;Biocon Product&#148;) that uses Biocon technology or Biocon <FONT STYLE="white-space:nowrap">know-how.</FONT> Pursuant to the License Agreements, Biocon agreed to be the Company&#146;s
exclusive supplier of EQ001 clinical drug product for up to three concurrent orphan drug clinical indications at no cost until the Company&#146;s first U.S. regulatory approval and all other clinical drug product at cost. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In consideration of the rights granted to the Company by Biocon, the Company issued Biocon shares of its common stock equal to 19.5% of its outstanding shares at the
time of the execution of the License Agreements. Biocon also has a Biocon Anti-Dilution Right (see Note 2) which is recorded at fair value using the Precedent Transaction Method (see Note 3) and was determined to be $605,402 at the time of issuance.
As an obligation exists to issue a variable number of shares and such obligation is not indexed to the Company&#146;s common stock, the Biocon Anti-Dilution Right has been classified as a liability in the accompanying balance sheet. The fair value
of the Biocon Anti-Dilution Right is <FONT STYLE="white-space:nowrap">re-measured</FONT> at each financial reporting period with any changes in fair value being recognized as a component of other expense (income). As of December&nbsp;31, 2017, and
June&nbsp;30, 2018 (unaudited), the fair value of the Biocon Anti-Dilution Right was $775,842 and $878,122, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the Company is obligated to
pay Biocon up to an aggregate of $30&nbsp;million in regulatory milestone payments upon the achievement of certain regulatory approvals and up to an aggregate of $565&nbsp;million in sales </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
milestone payments upon the achievement of first commercial sale of product and specified levels of product sales. The Company is also required to pay quarterly tiered royalties based on a
percentage from the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits to sub-teen double-digits of net sales of Biocon Products, subject to adjustments in certain circumstances. Biocon is also required to pay the Company royalties at
comparable percentages for sales of EQ001 outside of the Company Territory if the approvals in such geographies included or referenced the Company&#146;s data. To date, the Company has not made or received payments in connection with the milestones
or royalties within the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Convertible Promissory Notes </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
May 2017, the Company issued $1,000,000 in convertible promissory notes to its founders (&#147;Founder Notes&#148;). The Founder Notes accrued interest at a rate of 6% a year and mature one year from issuance. The Founder Notes are convertible at
the option of the holder upon a Qualified Financing (as defined below). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2017, November 2017, April 2018, and June 2018, the Company entered into note
purchase agreements whereby the Company agreed to issue and investors (the &#147;Noteholders&#148;) agreed to purchase $9,407,474 in convertible promissory notes (the &#147;Convertible Promissory Notes&#148;). As part of the October 2017 Convertible
Promissory Notes, the Founder Notes were amended and restated on terms matching the Convertible Promissory Notes and the then outstanding principal and accrued interest thereunder was included as the principal amount of each such amended and
restated Convertible Promissory Note. The Convertible Promissory Notes accrue interest at a rate of 6% per year and mature two years from their issuance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Convertible Promissory Notes automatically convert into equity securities sold pursuant to a qualified financing (&#147;Qualified Financing&#148;) transaction from which the Company receives total gross proceeds of not less than $15&nbsp;million at
a conversion price equal to 90% of the per share price paid by investors for such securities if the closing of the financing occurs on or prior to the six month anniversary of the issuance of Convertible Promissory Notes or at a conversion price
equal to 80% of the per share price paid by investors for such securities if the closing of the financing occurs after the six month anniversary of the issuance of Convertible Promissory Notes. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recorded interest expense of $379,385 and $1,108,197 using the effective-interest method for the period ending December&nbsp;31, 2017 and the six months
ended June&nbsp;30, 2018 (unaudited), respectively, in relation to stated interest and the estimated discount at which the Convertible Promissory Notes will convert. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of all debt obligations recorded on the balance sheet at December&nbsp;31, 2017 and June&nbsp;30, 2018: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible promissory notes (inclusive of related party)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,807,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,407,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,110,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,058,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,517,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Stockholders&#146; Deficit </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2017,
the Company issued 1,000,000 shares of common stock to founders at a price of $0.0001 per share and 242,236 shares of common stock to Biocon as partial consideration for the License Agreements (Note 5). The shares issued to Biocon were valued at
$0.04 per share, resulting in $9,689 of research license expense. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2017, the Company adopted the 2017 Equity Incentive Plan (the &#147;Plan&#148;). The Plan provides for the grant of incentive stock options, <FONT
STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards. As of December&nbsp;31, 2017 and June&nbsp;30, 2018 (unaudited), the number of
shares reserved under the Plan was 138,026. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There were 138,026 and 94,548 shares available for grant under the Plan as of December&nbsp;31, 2017 and
June&nbsp;30, 2018 (unaudited), respectively. Options granted under the Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their date of grant. The exercise price of each option shall be
determined by the Board of Directors based on the estimated fair value of the Company&#146;s stock on the date of the option grant. The exercise price shall not be less than 100% of the fair market value of the Company&#146;s common stock at the
time the option is granted. Most option grants generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years and early exercise is permitted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A summary of the Company&#146;s stock option activity under the Plan is as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>EXERCISE<BR>PRICE PER<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>REMAINING<BR>CONTRACT<BR>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>INTRINSIC<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at June&nbsp;30, 2018 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested and expected to vest at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested and exercisable at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested and expected to vest at June&nbsp;30, 2018 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested and exercisable at June&nbsp;30, 2018 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the period ended December&nbsp;31, 2017 and six months ended June&nbsp;30, 2018 (unaudited), the total grant date fair value of
vested options was $0 and $0.25, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The weighted-average grant date fair value of employee option grants during the period ended December&nbsp;31, 2017
and the six months ended June&nbsp;30, 2018 (unaudited) was $0 and $0.25 per share, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liability for Early Exercise of Restricted Stock Options
</I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain individuals were granted the ability to early exercise their stock options. The shares of common stock issued from the early exercise of unvested
stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The cash
received, net of par value, in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital as the shares vest. As of December&nbsp;31, 2017 and June&nbsp;30, 2018 (unaudited), there were 0 and 31,055, respectively, shares subject to repurchase by the Company. As of December&nbsp;31, 2017
and June&nbsp;30, 2018 (unaudited), the Company recorded $0 and $10,866, respectively, of liabilities associated with shares issued with repurchase rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognized stock-based compensation expense of $0 for the period ended December&nbsp;31, 2017 and $740 for the six months ended June&nbsp;30, 2018
(unaudited). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock
option grants were as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD&nbsp;MARCH&nbsp;16,<BR>2017 (INCEPTION)<BR>THROUGH DECEMBER&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR&nbsp;THE&nbsp;PERIOD<BR>MARCH&nbsp;16,&nbsp;2017<BR>(INCEPTION)<BR>THROUGH&nbsp;JUNE&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FOR THE SIX<BR>MONTHS&nbsp;ENDED<BR>JUNE&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free rate of interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.86%&nbsp;-&nbsp;2.88%</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.75&nbsp;-&nbsp;6.08&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected stock price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85.56%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Risk-free interest rate. </I>The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were
consistent with the expected term of the Company&#146;s stock options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected volatility. </I>Due to the Company&#146;s limited operating history and lack of
company-specific historical or implied volatility as a private company, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected term. </I>The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the
simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-vesting</FONT></FONT> and the contractual life of the options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected dividend
yield. </I>The expected dividend assumption is based on the Company&#146;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Forfeitures</I>. The Company reduces stock-based compensation expense for actual forfeitures during the period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2017 and June&nbsp;30, 2018 (unaudited), the unrecognized compensation cost related to outstanding employee and nonemployee options was $0 and
$10,343, respectively, and is expected to be recognized as expense over approximately 0 years and 3.73 years, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common Stock Reserved for Future
Issuance </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Common stock reserved for future issuance consists of the following as of December&nbsp;31, 2017 and June&nbsp;30, 2018: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Authorized for future stock awards or options grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Income Taxes </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to our net losses for
the period ended December&nbsp;31, 2017, and since we have a full valuation allowance against deferred tax assets, there was no provision or benefit for income taxes recorded There were no components of current or deferred federal, state or foreign
tax provisions for the period ended December&nbsp;31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reconciliation of the total income tax provision tax rate to the statutory federal income tax rate of 34% for the
period ended December&nbsp;31, 2017 is as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income Taxes at Statutory Rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State Income Tax, Net of Federal Benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Permanent Items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-10.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tax Law Change&#151;Tax Reform</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-8.78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Federal Research Credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in Federal Valuation Allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-14.71</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities
as of December&nbsp;31, 2017 are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">248,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Intangibles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">489,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fixed Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">489,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(489,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization
of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. The
Company has recorded a full valuation allowance of $489,585 as of December&nbsp;31, 2017 as it does not believe it is more likely than not that certain deferred tax assets will be realized primarily due to the generation of <FONT
STYLE="white-space:nowrap">pre-tax</FONT> book losses in its first year, no ability to carryback losses, the lack of feasible <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies, the limited existing taxable temporary differences, and
the subjective nature of forecasting future taxable income into the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company increased its valuation allowance by approximately $489,585 during the
period ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2017, the Company had federal and California tax loss carry forwards of approximately $884,776 and
$893,787, respectively. The federal and state net operating loss carry forwards begin to expire in 2037 and 2037, respectively, if unused. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31,
2017, we had federal and state tax credit carry forwards of approximately $23,355 and $14,344 respectively, after reduction for uncertain tax positions. The Company has not performed a formal research and development credit study with respect to
these credits. The federal credits will begin to expire in 2037, if unused, and the state credits carry forward indefinitely. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Internal Revenue Code
(&#147;IRC&#148;) of 1986, as amended, specifically IRC &#167;382 and IRC &#167;383, the Company&#146;s ability to use net operating loss and R&amp;D tax credit carry forwards (&#147;tax attribute carry forwards&#148;) to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership
change analysis pursuant to IRC Section&nbsp;382. If ownership changes within the meaning of IRC Section&nbsp;382 are identified as having occurred, the amount of remaining tax attribute carry-forwards available to offset future taxable income and
income tax expense in future years may be significantly restricted or eliminated. Further, our deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC
&#167;382. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2017, the Tax Cuts and Jobs Act (the &#147;2017 Tax Act&#148;) was enacted. The 2017 Tax Act includes a number of changes to existing U.S.
tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December&nbsp;31, 2017. The 2017 Tax Act also provides for the acceleration of depreciation for certain
assets placed in service after September&nbsp;27, 2017 as well as prospective changes beginning in 2018, including limitations on the deductibility of interest and capitalization of research and development expenditures. The Company measures
deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. Accordingly, the Company&#146;s deferred tax assets and liabilities were remeasured to
reflect the reduction in the U.S. corporate income tax rate from 35% to 21%, resulting in a $198,687 increase in tax expense for the period ended December&nbsp;31, 2017 and a corresponding $198,687 decrease in net deferred tax assets as of
December&nbsp;31, 2017. The impact was offset by the Company&#146;s valuation allowance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the reconciliation of the unrecognized tax
benefits activity during the years ended December&nbsp;31, 2017: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrecognized Tax Benefits&#151;Beginning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross increases&#151;tax positions in prior period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross decreases&#151;tax positions in prior period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross increase&#151;current-period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross decrease&#151;current-period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Settlements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lapse of statute of limitations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrecognized Tax Benefits&#151;Ending</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unrecognized tax benefit amounts are reflected in the determination of the Company&#146;s deferred tax assets.&nbsp;If recognized,
none of these amounts would affect the Company&#146;s effective tax rate, since it would be offset by an equal corresponding adjustment in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for
uncertain tax benefits within the next 12&nbsp;months. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s policy is to recognize interest and/or penalties related to income tax matters in income
tax expense. The Company had no accrual for interest or penalties on the Company&#146;s balance sheets as of December&nbsp;31, 2017 and has not recognized interest and/or penalties in the Statement of Operations for the period ended
December&nbsp;31, 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All tax years for both federal and state purposes remain open and subject to examination by tax jurisdictions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Related-Party Transactions </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2017, the Company entered into License
Agreements with Biocon, a pharmaceutical company in which the Company&#146;s Chief Executive Officer is on the Board of Directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2017, the Company entered
into Founder Notes with the Company&#146;s Chief Executive Officer and Chief Business Officer in the amounts of $500,000 and $500,000, respectively. These Founder Notes were subsequently amended and restated on terms matching the Convertible
Promissory Notes and the then outstanding principal and accrued interest thereunder was included as the principal amount of each such amended and restated Convertible Promissory Note. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Commitments and Contingencies </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company leases certain office space in San Diego,
California under a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease, with a term through February 2022. Rent expense was $0 and $10,157 for the period ended December&nbsp;31, 2017, and for the six months ended June&nbsp;30,
2018 (unaudited). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The future minimum lease payments required under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> leases as of December&nbsp;31, 2017, are
summarized as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Year Ending December&nbsp;31,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Litigation </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31,
2017 and June&nbsp;30, 2018, there was no litigation against the Company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Subsequent Events </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of the financial statements as of December&nbsp;31, 2017 and the year then ended, the Company has evaluated the subsequent events through
August&nbsp;3, 2018, the date the audited annual financial statements were issued. For the purposes of the unaudited interim condensed financial statements as of June&nbsp;30, 2018 and the six month period then ended, such evaluation of subsequent
events has been performed through August&nbsp;3, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g582934g29h41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRELIMINARY PROSPECTUS
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Joint Book-Running Managers </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies
</B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Leerink Partners </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13. Other
Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by
Equillium, Inc., or the Registrant, in connection with the sale of the common stock being registered. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the FINRA filing fee and The Nasdaq
Global Market listing fee. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$10,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Registrant is incorporated under the laws of the State of Delaware. Section&nbsp;145 of the Delaware General Corporation Law provides that a Delaware corporation
may indemnify any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of
such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation as an officer, director, employee or agent of another
corporation or enterprise. The indemnity may include expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding,
provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#146;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe
that his or her conduct was illegal. A Delaware corporation may indemnify any persons who were, are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the
fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may
include expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he or she reasonably
believed to be in or not opposed to the corporation&#146;s best interests, except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is
successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys&#146; fees) actually and reasonably incurred. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Registrant&#146;s amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the
completion of this offering, respectively, provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware General Corporation Law. Section&nbsp;102(b)(7) of the Delaware General Corporation Law
permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except
for liability for any: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">transaction from which the director derives an improper personal benefit; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">unlawful payment of dividends or redemption of shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">breach of a director&#146;s duty of loyalty to the corporation or its stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Registrant&#146;s amended and restated certificate of incorporation, as currently in effect, includes such a provision, and the Registrant&#146;s amended and
restated certificate of incorporation that will become effective immediately prior to the completion of this offering will include such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding in
advance of its final disposition shall be paid by the Registrant upon delivery to it of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer
is not entitled to be indemnified by the Registrant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;174 of the Delaware General Corporation Law provides, among other things, that a director who
willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved or dissented at the time
may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of
the unlawful acts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted by the Delaware General Corporation Law, the Registrant has entered into indemnity agreements with each of its directors and
executive officers, that require the Registrant to indemnify such persons against any and all costs and expenses (including attorneys&#146;, witness or other professional fees) actually and reasonably incurred by such persons in connection with any
action, suit or proceeding (including derivative actions), whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was a director or officer or is or was acting or serving as an
officer, director, employee or agent of the Registrant or any of its affiliated enterprises. Under these agreements, the Registrant is not required to provide indemnification for certain matters, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">indemnification beyond that permitted by the Delaware General Corporation Law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">indemnification for any proceeding with respect to the unlawful payment of remuneration to the director or officer;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">indemnification for certain proceedings involving a final judgment that the director or officer is required to disgorge
profits from the purchase or sale of the Registrant&#146;s stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">indemnification for proceedings involving a final judgment that the director&#146;s or officer&#146;s conduct was in bad
faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct or a breach of his or her duty of loyalty, but only to the extent of such specific determination; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">indemnification for proceedings or claims brought by an officer or director against us or any of the Registrant&#146;s
directors, officers, employees or agents, except for claims to establish a right of indemnification or proceedings or claims approved by the Registrant&#146;s board of directors or required by law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">indemnification for settlements the director or officer enters into without the Registrant&#146;s consent; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">indemnification in violation of any undertaking required by the Securities Act of 1933, as amended, or the Securities Act,
or in any registration statement filed by the Registrant. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The indemnification agreements also set forth certain procedures that will apply in the
event of a claim for indemnification thereunder. Except as otherwise disclosed under the heading &#147;Legal Proceedings&#148; in the &#147;Business&#148; section of the prospectus included in this registration statement, there is at present no
pending litigation or proceeding involving any of the Registrant&#146;s directors or executive officers as to which indemnification is required or permitted, and the Registrant is not aware of any threatened litigation or proceeding that may result
in a claim for indemnification. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Registrant has an insurance policy in place that covers its officers and directors with respect to certain liabilities,
including liabilities arising under the Securities Act, or otherwise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Registrant plans to enter into an underwriting agreement which provides that the
underwriters are obligated, under some circumstances, to indemnify the Registrant&#146;s directors, officers and controlling persons against specified liabilities, including liabilities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent sales of unregistered securities. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Set forth below is information regarding securities issued and options granted by us since March&nbsp;16, 2017, our inception, that were not registered under the
Securities Act. Also included is the consideration, if any, received by us, for such securities and options and information relating to the Securities Act, or rule of the SEC, under which exemption from registration was claimed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(1) In March 2017, we issued 1,000,000 shares of common stock to our founders and/or entities affiliated with them pursuant to stock purchase agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(2) In May 2017, we issued 242,236 shares of common stock to Biocon SA pursuant to a stock purchase agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(3) From May 2017 to June 2018, we issued convertible promissory notes in an aggregate principal amount of $9.4&nbsp;million to investors pursuant to note purchase
agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(4) From June 2018 to the effective date of this registration statement, we granted stock options under our 2017 equity incentive plan, or the 2017
Plan, to purchase up to an aggregate of 99,381 shares of our common stock to our employees, directors and consultants, at a weighted-average exercise price of $17.70 per share. From June 2018 to the effective date of this registration statement,
43,478 shares of common stock were issued upon the exercise of options granted to certain employees, directors and consultants and the payment of $15,217 to us was made. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offers, sales and issuances of the securities described in paragraphs (1)&nbsp;through (3) were deemed to be exempt from registration under the Securities Act in
reliance on Section&nbsp;4(a)(2) (or Regulation D promulgated thereunder) in that the issuance of securities to the accredited investors did not involve a public offering. The recipients of securities in each of these transactions acquired the
securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these
transactions was an accredited investor under Rule 501 of Regulation D. No underwriters were involved in these transactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offers, sales and issuances of the
securities described in paragraph (4)&nbsp;were deemed to be exempt from registration under the Securities Act in reliance on Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided
under Rule 701. The recipients of such securities were our employees, directors or bona fide consultants and received the securities under the 2017 Plan. Appropriate legends were affixed to the securities issued in these transactions. Each of the
recipients of securities in these transactions had adequate access, through employment, business or other relationships, to information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16.
Exhibits and financial statement schedules. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(a) Exhibits. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The exhibits listed below are filed as part of this registration statement. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>EXHIBIT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DESCRIPTION OF DOCUMENT</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">1.1&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex31.htm">Amended and Restated Certificate of Incorporation, as currently in effect.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex32.htm">Form of Amended and Restated Certificate of Incorporation to become effective immediately prior to the completion of this offering.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.3</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex33.htm">Bylaws, as currently in effect.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.4</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex34.htm">Form of Amended and Restated Bylaws to become effective upon the completion of this offering.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">4.1&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate of the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">5.1&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Cooley LLP.</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><B>EXHIBIT<BR>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DESCRIPTION OF DOCUMENT</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.1+</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex101.htm">Form of Indemnity Agreement by and between the Registrant and its directors and officers.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.2+</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex102.htm">Equillium, Inc. 2017 Equity Incentive Plan and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.3+</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex103.htm">Equillium, Inc. 2018 Equity Incentive Plan and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.4+</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex104.htm">Equillium, Inc. 2018 Employee Stock Purchase Plan.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.5+</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex105.htm">Equillium, Inc. <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.6*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex106.htm">Collaboration and License Agreement, dated May&nbsp;22, 2017, by and between the Registrant and Biocon SA (which was subsequently assigned to Biocon Limited effective March 2018).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.7*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex107.htm">Clinical Supply Agreement, dated May&nbsp;22, 2017, by and between the Registrant and Biocon SA (which was subsequently assigned to Biocon Limited effective March 2018).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.8</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex108.htm">Standard Office Lease, effective as of February&nbsp;1, 2018, by and between the Registrant and La Jolla Shores Plaza, LLC.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.9+</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex109.htm">Offer Letter, dated June&nbsp;1, 2018, by and between the Registrant and Daniel M. Bradbury.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.10+</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex1010.htm">Offer Letter, dated March&nbsp;19, 2018, by and between the Registrant and Jason A. Keyes.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.11+</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex1011.htm">Offer Letter, dated June&nbsp;1, 2018, by and between the Registrant and Bruce D. Steel.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.12+</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex1012.htm">Amended and Restated Offer Letter, dated June&nbsp;7, 2018, by and between the Registrant and Stephen Connelly, Ph.D.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.13</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex1013.htm">Offer Letter, dated August&nbsp;1, 2018, by and between the Registrant and Krishna Polu, M.D.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d582934dex231.htm">Consent of Independent Registered Public Accounting Firm.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.2&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Cooley LLP. Reference is made to Exhibit 5.1.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#ii582934_1">Power of Attorney. Reference is made to the signature page hereto.</A></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">+</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(b) Financial statement schedules. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No financial statement schedules
are provided because the information called for is not required or is shown either in the financial statements or the notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings.
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the Underwriting Agreement certificates in such
denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or
paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a
form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of La Jolla, State of California, on the 17th day of September, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>EQUILLIUM, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Daniel M. Bradbury</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Daniel M. Bradbury</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Chief Executive Officer</I></B></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="ii582934_1"></A>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel M. Bradbury and Jason A. Keyes, and each of them, as his or
her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all
capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing
pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in
and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT>
and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act, this
registration statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Daniel M. Bradbury</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Daniel M. Bradbury</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Chief Executive Officer and<BR>Chairman of the Board of Directors</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">September&nbsp;17,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Jason A. Keyes</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Jason A. Keyes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>(Principal Financial and Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">September&nbsp;17, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Bruce D. Steel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Bruce D. Steel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">President, Chief Business Officer and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Member of the Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">September&nbsp;17, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Stephen Connelly, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Stephen Connelly, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Chief Scientific Officer and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Member of the Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">September&nbsp;17, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Martha J. Demski</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Martha J. Demski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">September&nbsp;17, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Bala S. Manian, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Bala S. Manian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">September&nbsp;17, 2018</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Charles McDermott</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Charles McDermott</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">September&nbsp;17, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Mark Pruzanski, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Mark Pruzanski, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">September&nbsp;17, 2018</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d582934dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE
OF INCORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EQUILLIUM, INC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to
Sections 242 and 245 of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equillium, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware (the
&#147;<B>Corporation</B>&#148;), does hereby certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;The name of this corporation is Equillium,
Inc. The corporation was originally incorporated pursuant to the provisions of the General Corporation Law of the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;) on March&nbsp;16, 2017 under the name Attenuate Biopharmaceuticals,
Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;This Amended and Restated Certificate of Incorporation, which restates and integrates and further
amends the provisions of this Corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law and has been duly approved by the holders of the requisite number of shares
of this corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;The text of the
Certificate of Incorporation is amended and restated to read as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of this Corporation is Equillium, Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>II. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registered
office of the Corporation in the State of Delaware shall be 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, 19808 and the name of the registered agent of the Corporation in the State of Delaware at such address is
Corporation Service Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>III. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General
Corporation Law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IV. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;<U>Capital Stock</U>. The Corporation is authorized to issue only one class of stock, to be designated Common Stock.
The total number of shares of Common Stock authorized is 5,000,000, each having a&nbsp;par value of $0.0001 per share </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting</U>. Each holder of shares of Common Stock shall be
entitled to cast the number of votes equal to the number of shares of Common Stock held by such holder as of the record date for determining stockholders entitled to vote on any matter presented to the stockholders of the Corporation for their
action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments to Holders of Common Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution
or winding up of the Corporation or Deemed Liquidation Event, the remaining assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of shares of Common Stock, pro rata based on the number of
shares held by each such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Definition</U>. Each of the following events shall be considered a &#147;<B>Deemed Liquidation
Event</B>&#148; unless the holders of at least a majority of the outstanding shares of Common Stock elect otherwise by written notice sent to the Corporation at least five days prior to the effective date of any such event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;a merger or consolidation in which </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman">(i) the Corporation is a constituent party or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">(ii) a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or
consolidation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation
outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting
power, of the capital stock of (1)&nbsp;the surviving or resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent
corporation of such surviving or resulting corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the sale, lease, transfer, exclusive license or
other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole (including, without
limitation, the exclusive license under that certain Collaboration and License Agreement dated on or about the date hereof by and between the Corporation and Biocon SA), or the sale or disposition (whether by merger, consolidation or otherwise) of
one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this <U>Section</U><U></U><U>&nbsp;1.2.1</U>, &#147;<B>Affiliate</B>&#148; shall mean, with respect to any holder of shares of Common Stock,
any person, entity or firm which, directly or indirectly, controls, is controlled by or is under common control with such holder, including, without limitation, any entity of which the holder is a partner or member, any partner, officer, director,
member or employee of such holder and any venture capital fund now or hereafter existing of which the holder is a partner or member which is controlled by or under common control with one or more general partners of such holder or shares the same
management company with such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Effecting a Deemed Liquidation Event</U>. The Corporation shall not
have the power to effect a Deemed Liquidation Event referred to in <U>Subsection 1.2.1(a)(</U><U>i</U><U>)</U> unless the agreement or plan of merger or consolidation for such transaction (the &#147;<B>Merger Agreement</B>&#148;) provides that the
consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsection 1.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock
of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or
the acquiring person, firm or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Allocation of Escrow and Contingent Consideration</U>. In
the event of a Deemed Liquidation Event pursuant to <U>Subsection 1.2.1(a)(</U><U>i</U><U>)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the
&#147;<B>Additional Consideration</B>&#148;), such Additional Consideration shall be allocated among, and distributed to, the holders of capital stock of the Corporation in accordance with <U>Subsection 1.1</U>. For the purposes of this
<U>Subsection 1.2.4</U>, consideration placed into escrow or retained as holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional
Consideration. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;The management of the business and the conduct of the affairs of the Corporation shall be vested in its Board of
Directors. The number of directors which shall constitute the whole Board of Directors shall be fixed by the Board of Directors in the manner provided in the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;Directors shall be elected at each annual meeting of stockholders to hold office until the next annual meeting. So
long as it holds shares of Common Stock, Biocon SA, voting as a separate class, shall be entitled to elect one (1)&nbsp;director (the &#147;<B>Biocon Director</B>&#148;) at each meeting of stockholders or pursuant to each consent of the
Corporation&#146;s stockholders for the election of directors, and to remove from office such director in accordance with applicable law and to fill any vacancy caused by the resignation, death or removal of such director. The holders of record of
the shares of Common Stock and of any other class or series of voting stock, exclusively and voting together as a single class, shall be entitled to elect the balance of the total </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of directors of the Corporation, and to remove from office such directors in accordance with applicable law and to fill any vacancy caused by the resignation, death or removal of such
directors. Notwithstanding the foregoing, Biocon SA&#146;s right to elect the Biocon Director under this section shall terminate upon the earlier to occur of: (i)&nbsp;the closing of a firmly underwritten public offering pursuant to an effective <FONT
STYLE="white-space:nowrap">S-1</FONT> or <FONT STYLE="white-space:nowrap">SB-2</FONT> registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock for the account of the Company, or (ii)&nbsp;a
Deemed Liquidation Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;No person entitled to vote at an election for directors may cumulate votes to which
such person is entitled unless required by applicable law at the time of such election. During such time or times that applicable law requires cumulative voting, every stockholder entitled to vote at an election for directors may cumulate such
stockholder&#146;s votes and give one candidate a number of votes equal to the number of directors to be elected multiplied by the number of votes to which such stockholder&#146;s shares are otherwise entitled, or distribute the stockholder&#146;s
votes on the same principle among as many candidates as such stockholder desires. No stockholder, however, shall be entitled to so cumulate such stockholder&#146;s votes unless (i)&nbsp;the names of such candidate or candidates have been placed in
nomination prior to the voting and (ii)&nbsp;the stockholder has given notice at the meeting, prior to the voting, of such stockholder&#146;s intention to cumulate such stockholder&#146;s votes. If any stockholder has given proper notice to cumulate
votes, all stockholders may cumulate their votes for any candidates who have been properly placed in nomination. Under cumulative voting, the candidates receiving the highest number of votes, up to the number of directors to be elected, are elected.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D.&nbsp;&nbsp;&nbsp;&nbsp;Subject to any limitations imposed by applicable law, the Board of Directors or any director may be removed
from office at any time, with or without cause, by the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of capital stock of the Corporation entitled to vote generally at an election of directors;
<I>provided, however</I>, that the Biocon Director may be removed without cause by, and only by, the affirmative vote of the holders entitled to elect such director, given either at a special meeting of such stockholders duly called for that purpose
or pursuant to a written consent of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E.&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors is expressly empowered to adopt, amend
or repeal the Bylaws of the Corporation. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Corporation; <I>provided, however</I>, that, in addition to any vote of the holders of any class or series of stock of the
Corporation required by law or by this Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of the capital stock
of the Corporation entitled to vote generally in the election of directors, voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F.&nbsp;&nbsp;&nbsp;&nbsp;Unless and except to the extent that the bylaws of the Corporation shall so require, the election of directors of
the Corporation need not be by written ballot. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VI. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The liability of the directors for monetary damages for breach of fiduciary duty as a director shall be eliminated to the fullest extent under
applicable law. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by applicable law, the corporation
is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the corporation (and any other persons to which applicable law permits the corporation to provide indemnification) through Bylaw
provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after
approval by the stockholders of this <U>Article VI</U> to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the corporation shall be eliminated or limited to the
fullest extent permitted by applicable law as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;Any repeal or modification of this <U>Article VI</U>
shall only be prospective and shall not affect the rights or protections or increase the liability of any officer or director under this <U>Article VI </U>in effect at the time of the alleged occurrence of any act or omission to act giving rise to
liability or indemnification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VII. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the
manner now or hereafter prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this reservation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VIII. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any notice
required or permitted by the provisions of this Certificate of Incorporation to be given to a holder of shares of Common Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by
electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IX. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation
renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An &#147;<B>Excluded Opportunity</B>&#148; is any matter,
transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or
(ii)&nbsp;any holder of Common Stock or any partner, member, director, stockholder, employee or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, &#147;<B>Covered
Persons</B>&#148;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a
director of the Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>X. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be
the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the corporation, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
owed by any director, officer or other employee of the corporation to the corporation or the corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the corporation, its
directors, officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the corporation, its
directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the
jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or
forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this <U>Article X</U> shall be held to be invalid, illegal or unenforceable as applied to any
person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this <U>Article X</U>
(including, without limitation, each portion of any sentence of this <U>Article X</U> containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of
such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Amended and Restated Certificate of Incorporation has been
executed by a duly authorized officer of this corporation on this 18th day of May, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Daniel M. Bradbury</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Daniel M. Bradbury, President</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>d582934dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Daniel M.
Bradbury hereby certifies that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>ONE:</B> He is the duly elected and acting Chief Executive Officer of Equillium, Inc., a Delaware
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>TWO:</B> The date of filing of said corporation&#146;s original certificate of incorporation with the Delaware Secretary
of State was March&nbsp;16, 2017. Said corporation was originally incorporated under the name Attenuate Biopharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>THREE:</B> The Amended and Restated Certificate of Incorporation of the corporation is hereby amended and restated to read in its entirety
as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
name of this corporation is Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>II. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the registered office of the Company in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New
Castle 19808, and the name of its registered agent at such address is Corporation Service Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>III. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Company is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General
Corporation Law (&#147;<B><I>DGCL</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IV. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The Company is authorized to issue two classes of stock to be designated, respectively, &#147;<B><I>Common Stock</I></B>&#148; and
&#147;<B><I>Preferred Stock</I></B>.&#148; The total number of shares which the Company is authorized to issue is 210,000,000 shares. 200,000,000 shares shall be Common Stock, each having a par value of $0.0001. 10,000,000 shares shall be Preferred
Stock, each having a par value of $0.0001. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> The Preferred Stock may be issued from time to time in one or more series. The Board
of Directors of the Company (the &#147;<B><I>Board of Directors</I></B>&#148;) is hereby expressly authorized to provide for the issue of any or all of the unissued and undesignated shares of the Preferred Stock in one or more series, and to fix the
number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications,
limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any
series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares
constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock may be increased or decreased (but not
below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote thereon, without a separate vote of the holders of the Preferred Stock, or of
any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the
stockholders of the Company for their vote; <I>provided, however</I>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation (this
&#147;<B><I>Certificate of Incorporation</I></B>&#148;) (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the
holders of such affected series of Preferred Stock are entitled, either separately or together as a class with the holders of one or more other such series of Preferred Stock, to vote thereon by law or pursuant to this Certificate of Incorporation
(including any certificate of designation filed with respect to any series of Preferred Stock). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the management of the business and for the conduct of the affairs of the Company, and in further definition, limitation and regulation of
the powers of the Company, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The management of the business and the conduct of the affairs of the Company shall be vested in its Board of Directors. The number of
directors that shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the authorized number of directors constituting the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances,
the directors shall be divided into three classes designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the
time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be
elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the term of office of the Class&nbsp;II directors shall expire and Class&nbsp;II directors shall be elected for a full term
of three years. At the third annual meeting of stockholders following such initial classification, the term of office of the Class&nbsp;III directors shall expire and Class&nbsp;III directors shall be elected for a full term of three years. At each
succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this section, each director shall serve until his or
her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Subject to the rights of any series of Preferred Stock that may be designated from time to time to elect additional directors under
specified circumstances, neither the Board of Directors nor any individual director may be removed without cause. Subject to any limitations imposed by applicable law, any individual director or directors may be removed with cause by the affirmative
vote of the holders of at least 66 2/3%<B> </B>of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors, voting together as a single class. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D.</B> Subject to any limitations imposed by applicable law and subject to the rights of the holders of any series of Preferred Stock that
may be designated from time to time, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors,
shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders and except as otherwise provided by applicable law, be filled only by the affirmative vote of a
majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of
the director for which the vacancy was created or occurred and until such director&#146;s successor shall have been elected and qualified. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E.</B> The Board of Directors is expressly empowered to adopt, amend or repeal the Amended and Restated Bylaws of the Company
(the&nbsp;&#147;<B><I>Bylaws</I></B>&#148;).<B> </B>Any adoption, amendment or repeal of the Bylaws by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders shall also have power to
adopt, amend or repeal the Bylaws; <I>provided, however, </I>that, in addition to any vote of the holders of any class or series of stock of the Company required by law or by this Certificate of Incorporation, such action by stockholders shall
require the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F.</B> The directors of the Company need not be elected by written ballot unless the Bylaws so provide. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>G.</B> No action shall be taken by the stockholders of the Company except at an annual or special meeting of stockholders called in
accordance with the Bylaws. No action shall be taken by the stockholders of the Company by written consent or electronic transmission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>H.</B> Advance notice of stockholder nominations for the election of directors and of business
to be brought by stockholders before any meeting of the stockholders of the Company shall be given in the manner provided in the Bylaws. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VI. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The
liability of a director of the Company for monetary damages shall be eliminated to the fullest extent under applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> To
the fullest extent permitted by applicable law, the Company is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Company (and any other persons to which applicable law permits the Company
to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable
law. If applicable law is amended after approval by the stockholders of this Article VI to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Company shall be
eliminated or limited to the fullest extent permitted by applicable law as so amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Any repeal or modification of this
Article VI shall only be prospective and shall not affect the rights or protections or increase the liability of any director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to
liability or indemnification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VII. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the
fullest extent permitted by law, be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on behalf of the Company;(2) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other
employee of the Company to the Company or the Company&#146;s stockholders; (3)&nbsp;any action asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant to any provision of the DGCL, the
Company&#146;s Certificate of Incorporation or Bylaws; or (4)&nbsp;any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VIII. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The
Company reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, except as provided in Section B of this Article&nbsp;VIII, and all
rights conferred upon the stockholders herein are granted subject to this reservation.<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> Notwithstanding any other
provisions of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the Company required by law or
by this Certificate of Incorporation or any certificate of designation filed with respect to a series </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Preferred Stock that may be designated from time to time, subject to the rights of the holders of any series of Preferred Stock, the affirmative vote of the holders of at least 66 2/3% of the
voting power of all of the <FONT STYLE="white-space:nowrap">then-outstanding</FONT> shares of capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend
or repeal Articles V, VI or VIII of this Certificate of Incorporation.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>FOUR:</B> This Certificate of Incorporation has been duly adopted and approved by the Board of Directors and by written consent of the
stockholders in accordance with Sections 228, 242 and 245 of the DGCL and written notice of such action has been given as provided in section 228 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, Equillium,
Inc. has caused this Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>D<SMALL>ANIEL</SMALL> M. B<SMALL>RADBURY</SMALL></B><SMALL></SMALL></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Chief Executive Officer</I></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>4
<FILENAME>d582934dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(F/K/A
ATTENUATE BIOPHARMACEUTICALS, INC.) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A DELAWARE CORPORATION) </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Registered Office</B>. The registered office of the corporation in the State of
Delaware shall be 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors may from time to time determine or the business of the corporation may require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Offices</B>. The corporation shall also have and maintain an office or
principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Delaware, as the Board of Directors may from time to time determine or the
business of the corporation may require. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE SEAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Corporate Seal</B>. The Board of Directors may adopt a corporate seal. Said
seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Place of Meetings</B>. Meetings of the stockholders of the corporation may be
held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but
may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (&#147;<B><I>DGCL</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Annual Meeting</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for
such other business as may lawfully come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the corporation and
the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders: (i)&nbsp;pursuant to the corporation&#146;s notice of meeting of stockholders; (ii)&nbsp;by or at the direction of the Board of
Directors; or (iii)&nbsp;by any stockholder of the corporation who was a stockholder of record at the time of giving of notice provided for in the following paragraph, who is entitled to vote at the meeting and who complied with the notice
procedures set forth in this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;At an annual meeting of the stockholders, only such business
shall be conducted as shall have been properly brought before the meeting. For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&nbsp;of paragraph (a)&nbsp;of this Section,
(i)&nbsp;the stockholder must have given timely notice thereof in writing to the Secretary of the corporation, (ii)&nbsp;such other business must be a proper matter for stockholder action under the DGCL and applicable law, (iii)&nbsp;if the
stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, has provided the corporation with a Solicitation Notice (as defined in this paragraph), such stockholder or beneficial owner must, in the case of a
proposal, have delivered a proxy statement and form of proxy to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holders of at least the percentage of the corporation&#146;s voting shares required under applicable law to carry any such proposal, or, in the case of a nomination or nominations, have delivered
a proxy statement and form of proxy to holders of a percentage of the corporation&#146;s voting shares reasonably believed by such stockholder or beneficial owner to be sufficient to elect the nominee or nominees proposed to be nominated by such
stockholder, and must, in either case, have included in such materials the Solicitation Notice, and (iv)&nbsp;if no Solicitation Notice relating thereto has been timely provided pursuant to this Section, the stockholder or beneficial owner proposing
such business or nomination must not have solicited a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this Section. To be timely, a stockholder&#146;s notice shall be delivered to the Secretary at the
principal executive offices of the corporation not later than the close of business on the 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day nor earlier than the close of business on the
120<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day prior to the first anniversary of the preceding year&#146;s annual meeting; <I>provided, however</I>, that in the event that the date of the annual meeting is advanced more than 30 days
prior to or delayed by more than 30 days after the anniversary of the preceding year&#146;s annual meeting, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day prior to such annual meeting and not later than the close of business on the later of the 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day prior to such annual meeting or the 10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day following the day on which public announcement of the date of such meeting is first made. In no event shall the public announcement of an adjournment of an annual meeting commence a new time
period for the giving of a stockholder&#146;s notice as described above. Such stockholder&#146;s notice shall set forth: (A)&nbsp;as to each person whom the stockholder proposed to nominate for election or reelection as a director all information
relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as
amended (the &#147;<B><I>1934 Act</I></B>&#148;), and Rule <FONT STYLE="white-space:nowrap">14a-4(d)</FONT> thereunder (including such person&#146;s written consent to being named in the proxy statement as a nominee and to serving as a director if
elected); (B) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material
interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made; and (C)&nbsp;as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal
is made (i)&nbsp;the name and address of such stockholder, as they appear on the corporation&#146;s books, and of such beneficial owner, (ii)&nbsp;the class and number of shares of the corporation that are owned beneficially and of record by such
stockholder and such beneficial owner, and (iii)&nbsp;whether either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in the case of the proposal, at least the percentage of the
corporation&#146;s voting shares required under applicable law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the corporation&#146;s voting shares to elect such nominee or nominees (an
affirmative statement of such intent, a &#147;<B><I>Solicitation Notice</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything in the second sentence of paragraph (b)&nbsp;of this Section to the contrary, in the event that the number of directors to be elected to the Board of Directors of the corporation is increased and there is no public announcement naming all
of the nominees for director or specifying the size of the increased Board of Directors made by the corporation at least 100 days prior to the first anniversary of the preceding year&#146;s annual meeting, a stockholder&#146;s notice required by
this Section shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary at the principal executive offices of the corporation not later than the close
of business on the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the day on which such public announcement is first made by the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Only such persons who are nominated in accordance with the procedures set forth in this Section (or elected
or appointed pursuant to <U>Article IV</U> of these Bylaws) shall be eligible to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the
procedures set forth in this Section. Except as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise provided by law, the Chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made, or
proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws, to declare that such defective proposal or nomination shall not be
presented for stockholder action at the meeting and shall be disregarded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing
provisions of this Section, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholders&#146; meeting, stockholders must provide notice as required by the regulations promulgated
under the 1934 Act. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section, &#147;public announcement&#148; shall mean disclosure in a press release
reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission (the &#147;<B><I>SEC</I></B>&#148;) pursuant to
Section&nbsp;13, 14 or 15(d) of the 1934 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Special Meetings</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of the stockholders of the corporation may be called, for any purpose or purposes, by
(i)&nbsp;the Chairman of the Board of Directors, (ii)&nbsp;the Chief Executive Officer, (iii)&nbsp;the Board of Directors pursuant to a resolution adopted by directors representing a quorum of the Board of Directors or (iv)&nbsp;by the holders of
shares entitled to cast not less than 15% of the votes at the meeting, and shall be held at such place, on such date, and at such time as the Board of Directors shall fix. At any time or times that the corporation is subject to Section&nbsp;2115(b)
of the California General Corporation Law (&#147;<B><I>CGCL</I></B>&#148;), stockholders holding 5% or more of the outstanding shares shall have the right to call a special meeting of stockholders as set forth in Section&nbsp;18(b) of these Bylaws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a special meeting is properly called by any person or persons other than the Board of Directors, the
request shall be in writing, specifying the general nature of the business proposed to be transacted, and shall be delivered personally or sent by certified or registered mail, return receipt requested, or by telegraphic or other facsimile
transmission to the Chairman of the Board of Directors, the Chief Executive Officer, or the Secretary of the corporation. No business may be transacted at such special meeting otherwise than specified in such notice. The Board of Directors shall
determine the time and place of such special meeting, which shall be held not less than 35 nor more than 120 days after the date of the receipt of the request. Upon determination of the time and place of the meeting, the officer receiving the
request shall cause notice to be given to the stockholders entitled to vote, in accordance with the provisions of Section&nbsp;7 of these Bylaws. Nothing contained in this paragraph&nbsp;(b) shall be construed as limiting, fixing, or affecting the
time when a meeting of stockholders called by action of the Board of Directors may be held. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice of Meetings</B>. Except as otherwise provided by law, notice, given in
writing or by electronic transmission, of each meeting of stockholders shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, if
any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at any such meeting.
If mailed, notice is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it appears on the records of the corporation. Notice of the time, place, if any, and purpose of
any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof or by electronic transmission by such person, either before or after such meeting, and will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
waived by any stockholder by his or her attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of
objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all
respects as if due notice thereof had been given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Quorum</B>. At all
meetings of stockholders, except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the
outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of
the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business
until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the
affirmative vote of a majority of shares present in person, by remote communication, if applicable, or represented by proxy duly authorized at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders.
Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy duly
authorized at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by statute, the Certificate of Incorporation or these Bylaws, a
majority of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on
that matter. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present
in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Adjournment and Notice of Adjourned Meetings</B>. Any meeting of stockholders,
whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares present in person, by remote communication, if applicable, or represented by proxy. When a meeting is
adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the time and place, if any, thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may
transact any business that might have been transacted at the original meeting pursuant to the Certificate of Incorporation, these Bylaws or applicable law. If the adjournment is for more than 30 days or if after the adjournment a new record date is
fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Voting Rights</B>. For the purpose of determining those stockholders entitled
to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in <U>Section</U><U></U><U>&nbsp;12</U> of these
Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote or execute consents shall have the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a
proxy granted in accordance with Delaware law. An agent so appointed need not be a stockholder. No proxy shall be voted after three years from its date of creation unless the proxy provides for a longer period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Owners of Stock</B>.
If shares or other securities having voting power stand of record in the names of two or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two or more persons
have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so
provided, their acts with respect to voting (including giving consent pursuant to <U>Section</U><U></U><U>&nbsp;13</U>) shall have the following effect: (a)&nbsp;if only one votes, his or her act binds all; (b)&nbsp;if more than one votes, the act
of the majority so voting binds all; (c)&nbsp;if more than one votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief
as provided in the DGCL, Section&nbsp;217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or <FONT STYLE="white-space:nowrap">even-split</FONT> for the purpose of
subsection&nbsp;(c) shall be a majority or <FONT STYLE="white-space:nowrap">even-split</FONT> in interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>List of Stockholders</B>. The Secretary shall prepare and make, at least 10
days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each
stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with
the notice of the meeting, or during ordinary business hours, at the principal place of business of the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation may take
reasonable steps to ensure that such information is available only to stockholders of the corporation. The list shall be open to examination of any stockholder during the time of the meeting as provided by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Action Without Meeting</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided in the Certificate of Incorporation, any action required by statute to be taken at
any annual or special meeting of the stockholders, or any action that may be taken at any annual or special meeting of the stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent in writing, or by
electronic transmission setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares
entitled to vote thereon were present and voted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Every written consent or electronic transmission shall
bear the date of signature of each stockholder who signs the consent, and no written consent or electronic transmission shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent
delivered to the corporation in the manner herein required, written consents or electronic transmissions signed by a sufficient number of stockholders to take action are delivered to the corporation by delivery to its registered office in the State
of Delaware, its principal place of business or an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to a corporation&#146;s registered office shall be by hand
or by certified or registered mail, return receipt requested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Prompt notice of the taking of the
corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing or by electronic transmission and who, if the action had been taken at a meeting, would have been
entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of stockholders to take action were delivered to the corporation as provided in Section&nbsp;228(c) of the
DGCL. If the action to which the stockholders consent is such as would have required the filing of a certificate under any section of the DGCL if such action had been voted on by stockholders at a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting thereof, then the certificate filed under such section shall state, in lieu of any statement required by such section concerning any vote of stockholders, that written consent has been
given in accordance with Section&nbsp;228 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;An electronic mail, facsimile or other
electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxyholder, shall be deemed to be written, signed and dated for the purposes of this Section, provided that any such electronic mail, facsimile or other
electronic transmission sets forth or is delivered with information from which the corporation can determine (i)&nbsp;that the electronic mail, facsimile or other electronic transmission was transmitted by the stockholder or proxyholder or by a
person or persons authorized to act for the stockholder and (ii)&nbsp;the date on which such stockholder or proxyholder or authorized person or persons transmitted such electronic mail, facsimile or electronic transmission. The date on which such
electronic mail, facsimile or electronic transmission is transmitted shall be deemed to be the date on which such consent was signed. No consent given by electronic mail, facsimile or other electronic transmission shall be deemed to have been
delivered until such consent is reproduced in paper form and until such paper form shall be delivered to the corporation by delivery to its registered office in the state of Delaware, its principal place of business or an officer or agent of the
corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to a corporation&#146;s registered office shall be made by hand or by certified or registered mail, return receipt requested.
Notwithstanding the foregoing limitations on delivery, consents given by electronic mail, facsimile or other electronic transmission may be otherwise delivered to the principal place of business of the corporation or to an officer or agent of the
corporation having custody of the book in which proceedings of meetings of stockholders are recorded if, to the extent and in the manner provided by resolution of the board of directors of the corporation. Any copy, facsimile or other reliable
reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy, facsimile or other reproduction shall be a complete
reproduction of the entire original writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Organization</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;At every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been
appointed or is absent, the Chief Executive Officer, or, if the Chief Executive Officer is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairman.
The Secretary, or, in his or her absence, an Assistant Secretary directed to do so by the Chief Executive Officer, shall act as secretary of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors shall be entitled to make such rules or regulations for the conduct of meetings of
stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and
procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting,
rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other
persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the
polls for balloting on matters that are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the
extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Number and Term of Office</B>. The authorized number of directors of the
corporation shall be fixed by the Board of Directors from time to time and shall be no less than three (3). Directors need not be stockholders unless so required by the Certificate of Incorporation. If for any cause, the directors shall not have
been elected at an annual meeting, they may be elected as soon thereafter as convenient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Powers</B>. The business and affairs of the corporation shall be managed by or
under the direction of the Board of Directors, except as otherwise provided by statute or by the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term of Directors</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the rights of any holders of capital stock to elect additional directors under specified
circumstances, directors shall be elected at each annual meeting of stockholders to serve until his or her successor is duly elected and qualified or until his or her death, resignation or removal. No decrease in the number of directors constituting
the Board of Directors shall shorten the term of any incumbent director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;No person entitled to vote at
an election for directors may cumulate votes to which such person is entitled, unless, at the time of such election, the corporation is subject to Section&nbsp;2115(b) of the CGCL. During such time or times that the corporation is subject to
Section&nbsp;2115(b) of the CGCL, every stockholder entitled to vote at an election for directors may cumulate such stockholder&#146;s votes and give one candidate a number of votes equal to the number of directors to be elected multiplied by the
number of votes to which such stockholder&#146;s shares are otherwise entitled, or distribute the stockholder&#146;s votes on the same principle among as many candidates as such stockholder thinks fit. No stockholder, however, shall be entitled to
so cumulate such stockholder&#146;s votes unless (i)&nbsp;the names of such candidate or candidates have been placed in nomination prior to the voting and (ii)&nbsp;the stockholder has given notice at the meeting, prior to the voting, of such
stockholder&#146;s intention to cumulate such stockholder&#146;s votes. If any stockholder has given proper notice to cumulate votes, all stockholders may cumulate their votes for any candidates who have been properly placed in nomination. Under
cumulative voting, the candidates receiving the highest number of votes, up to the number of directors to be elected, are elected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;18.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Vacancies</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;If the stockholders fail to elect a sufficient number of directors to fill all directorships for which they
are entitled to elect directors, pursuant to the Certificate of Incorporation or these Bylaws, then any directorship not so filled shall remain vacant until such time as the stockholders elect a person to fill such directorship by vote or written
consent in lieu of a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided in the Certificate of Incorporation, and
subject to the rights of any holder of capital stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number
of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by the affirmative vote of a majority of the directors then in office,
even though less than a quorum of the Board of Directors, or by a sole remaining director; <I>provided, however</I>, that whenever the holders of any class or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
classes of stock or series thereof are entitled to elect one or more directors by the provisions of the Certificate of Incorporation or these Bylaws, no such vacancies and newly created
directorships of such class or classes or series may be filled by stockholders of the corporation other than by the stockholders of the corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate
class. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#146;s successor shall have been elected
and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation of any director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;At any time or times that the corporation is subject to Section&nbsp;2115(b) of the CGCL, if, after the
filling of any vacancy, the directors then in office who have been elected by stockholders shall constitute less than a majority of the directors then in office, then </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;any holder or holders of an aggregate of 5% or more of the total number of shares at the time outstanding
having the right to vote for those directors may call a special meeting of stockholders; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;the
Superior Court of the proper county shall, upon application of such stockholder or stockholders, summarily order a special meeting of the stockholders, to be held to elect the entire board, all in accordance with Section&nbsp;305(c) of the CGCL, the
term of office of any director shall terminate upon that election of a successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Resignation</B>. Any director may resign at any time by delivering his or her
notice in writing or by electronic transmission to the Secretary, such resignation to specify whether it will be effective at a particular time, upon receipt by the Secretary or at the pleasure of the Board of Directors. If no such specification is
made, it shall be deemed effective at the pleasure of the Board of Directors. Subject to <U>Section</U><U></U><U>&nbsp;18(b)</U> of these Bylaws, when one or more directors shall resign from the Board of Directors, effective at a future date, a
majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each Director so
chosen shall hold office for the unexpired portion of the term of the Director whose place shall be vacated and until his or her successor shall have been duly elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Removal</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to any limitations imposed by applicable law, the Board of Directors or any director may be removed
from office at any time (i)&nbsp;with cause by the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of capital stock of the corporation entitled to vote generally at an election of directors or
(ii)&nbsp;without cause by the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of capital stock of the corporation, entitled to elect such director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;During such time or times that the corporation is subject to Section&nbsp;2115(b) of the CGCL, the Board of
Directors or any individual director may be removed from office at any time without cause by the affirmative vote of the holders of a majority of the outstanding shares entitled to vote on such removal; <I>provided, however</I>, that unless the
entire Board is removed, no individual director may be removed when the votes cast against such director&#146;s removal, or not consenting in writing to such removal, would be sufficient to elect that director if voted cumulatively at an election at
which the same total number of votes were cast (or, if such action is taken by written consent, all shares entitled to vote were voted) and the entire number of directors authorized at the time of such director&#146;s most recent election were then
being elected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;21.&nbsp;&nbsp;&nbsp;&nbsp;Meetings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Regular Meetings</B>. Unless otherwise restricted by the Certificate of Incorporation, regular meetings
of the Board of Directors may be held at any time or date and at any place within or without the State of Delaware that has been designated by the Board of Directors and publicized among all directors, either orally or in writing, including a
voice-messaging system or other system designated to record and communicate messages, facsimile, or by electronic mail or other electronic means. No further notice shall be required for a regular meeting of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Special Meetings</B>. Unless otherwise restricted by the Certificate of Incorporation, special meetings
of the Board of Directors may be held at any time and place within or without the State of Delaware whenever called by the Chairman of the Board, the Chief Executive Officer (if a director), the President (if a director) or any director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Meetings by Electronic Communications Equipment</B>. Any member of the Board of Directors, or of any
committee thereof, may participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall
constitute presence in person at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice of Special Meetings</B>. Notice of the time
and place of all special meetings of the Board of Directors shall be orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or
by electronic mail or other electronic means, during normal business hours, at least 24 hours before the date and time of the meeting. If notice is sent by US mail, it shall be sent by first class mail, postage prepaid at least three days before the
date of the meeting. Notice of any meeting may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the
express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Waiver of Notice</B>. The transaction of all business at any meeting of the Board of Directors, or any
committee thereof, however called or noticed, or wherever held, shall be as valid as though had at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not
present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;22.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Quorum and Voting</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless the Certificate of Incorporation requires a greater number, a quorum of the Board of Directors shall
consist of a majority of the total number of directors then serving; <I>provided, however</I>, that such number shall never be less than 1/3 of the total number of directors except that when one director is authorized, then one director shall
constitute a quorum. At any meeting, whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than
by announcement at the meeting. If the Certificate of Incorporation provides that one or more directors shall have more or less than one vote per director on any matter, every reference in this Section to a majority or other proportion of the
directors shall refer to a majority or other proportion of the votes of the directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;At each meeting of the Board of Directors at which a
quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;23.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Action Without Meeting</B>. Unless otherwise restricted by the Certificate of
Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may
be, consent thereto in writing or by electronic transmission, and such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the
minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;24.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Fees and Compensation</B>. Directors shall be entitled to such compensation
for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of
Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving
compensation therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;25.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Committees</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Executive Committee</B>. The Board of Directors may appoint an Executive Committee to consist of one or
more members of the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the
management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority in reference to (i)&nbsp;approving or
adopting, or recommending to the stockholders, any action or matter expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&nbsp;adopting, amending or repealing any bylaw of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Committees</B>. The Board of Directors may, from time to time, appoint such other committees as may
be permitted by law. Such other committees appointed by the Board of Directors shall consist of one or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions
creating such committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term</B>. The Board of Directors, subject to any requirements of any outstanding series of Preferred
Stock and the provisions of paragraphs (a)&nbsp;or (b) of this Section may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the
date of his or her death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee
vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member
at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum,
may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Meetings</B>. Unless the Board of Directors shall
otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section&nbsp;shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when
notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place that has been determined from time to time by such
committee, and may be called by any director who is a member of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of notice to members of the Board
of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing at any time before or after the meeting and will be waived by any director by attendance
thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise
provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a
majority of those present at any meeting at which a quorum is present shall be the act of such committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;26.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Organization</B>. At every meeting of the directors, the Chairman of the Board
of Directors, or, if a Chairman has not been appointed or is absent, the Chief Executive Officer (if a director), or if the Chief Executive Officer is not a director or is absent, the President (if a director), or if the President is not a director
or is absent, the most senior Vice President (if a director) or, in the absence of any such person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his or her absence, any
Assistant Secretary directed to do so by the Chief Executive Officer or President, shall act as secretary of the meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;27.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Officers Designated</B>. The officers of the corporation shall include, if and
when designated by the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer, the Treasurer and the Controller, all of whom shall be elected at the annual
organizational meeting of the Board of Directors. The Board of Directors may also appoint one or more Assistant Secretaries, Assistant Treasurers, Assistant Controllers and such other officers and agents with such powers and duties as it shall deem
necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited
therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;28.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Tenure and Duties of Officers</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>General</B>. All officers shall hold office at the pleasure of the Board of Directors and until their
successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any
reason, the vacancy may be filled by the Board of Directors, or by the Chief Executive Officer or other officer if so authorized by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties of Chairman of the Board of Directors</B>. The Chairman of the Board of Directors, when present,
shall preside at all meetings of the stockholders and the Board of Directors. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chairman of the Board of Directors shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors shall
designate from time to time. If there is no Chief Executive Officer and no President, then the Chairman of the Board of Directors shall also serve as the Chief Executive Officer of the corporation and shall have the powers and duties prescribed in
paragraph&nbsp;(c) of this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties of Chief Executive Officer</B>. The Chief Executive
Officer shall preside at all meetings of the stockholders and (if a director) at all meetings of the Board of Directors, unless the Chairman of the Board of Directors has been appointed and is present. The Chief Executive Officer shall be the chief
executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation. The Chief Executive Officer shall perform other duties
commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties of President</B>. In the absence or disability of the Chief Executive Officer or if the office of
Chief Executive Officer is vacant, the President shall preside at all meetings of the stockholders and (if a director) at all meetings of the Board of Directors, unless the Chairman of the Board of Directors has been appointed and is present. If the
office of Chief Executive Officer is vacant, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and
officers of the corporation. The President shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties of Vice Presidents</B>. The Vice Presidents may assume and perform the duties of the President in
the absence or disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the
Board of Directors or the President shall designate from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties of Secretary</B>. The
Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all
meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and
shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. The Chief Executive Officer may direct any Assistant Secretary to assume and perform the duties of the Secretary in the
absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive
Officer shall designate from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties of Chief Financial Officer</B>. The Chief
Financial Officer shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of
Directors or the Chief Executive Officer. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties
commonly incident to his or her office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer shall designate from time to time. The Chief Executive Officer may direct the
Treasurer or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties
commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;29.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Delegation of Authority</B>. The Board of Directors may from time to time
delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;30.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Resignations</B>. Any officer may resign at any time by giving notice in
writing or by electronic transmission notice to the Board of Directors or to the Chief Executive Officer or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is
given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective.
Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;31.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Removal</B>. Any officer may be removed from office at any time, either with
or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written or electronic consent of the directors in office at the time, or by any committee or superior officers upon whom such power
of removal may have been conferred by the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTION OF CORPORATE INSTRUMENTS AND VOTING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF SECURITIES OWNED BY THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;32.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Execution of Corporate Instruments</B>. The Board of Directors may, in its
discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name,
or to enter into contracts on behalf of the corporation, except as otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation. All checks and drafts drawn on banks or other depositaries of funds
to the credit of the corporation or on special accounts of the corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do. Unless authorized or ratified by the Board of Directors or within the agency
power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;33.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Voting of Securities Owned by the Corporation</B>. All stock and other
securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board
of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer, the President, or any Vice President. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES OF
STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;34.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Form and Execution of Certificates</B>. The shares of the
corporation shall be represented by certificates, or shall be uncertificated. Certificates for the shares of stock, if any, of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation shall be in such form as is consistent with the Certificate of Incorporation and applicable law. Every holder of shares of stock in the corporation represented by certificate shall be
entitled to have a certificate signed by or in the name of the corporation by any two authorized officers, including but not limited to the Chief Executive Officer, the President, the Chief Financial Officer, any Vice President, the Treasurer or
Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him or her in the corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar
who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he or she were such
officer, transfer agent, or registrar at the date of issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;35.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Lost
Certificates</B>. A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by
the person claiming the certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or
certificates, or the owner&#146;s legal representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that
may be made against the corporation with respect to the certificate alleged to have been lost, stolen, or destroyed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;36.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Restrictions on Transfer</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp; No holder of any of the shares of stock of the corporation may sell, transfer, assign, pledge, or otherwise
dispose of or encumber any of the shares of stock of the corporation or any right or interest therein, whether voluntarily or by operation of law, or by gift or otherwise (each, a &#147;<B><I>Transfer</I></B>&#148;) without the prior written consent
of the corporation, upon duly authorized action of its Board of Directors.&nbsp;The corporation may withhold consent for any legitimate corporate purpose, as determined by the Board of Directors.&nbsp;&nbsp;&nbsp;&nbsp;Examples of the basis for the
corporation to withhold its consent include, without limitation, (i)&nbsp;if such Transfer to individuals, companies or any other form of entity identified by the corporation as a potential competitor or considered by the corporation to be
unfriendly; or (ii)&nbsp;if such Transfer increases the risk of the corporation having a class of security held of record by 2,000 or more persons, or 500 or more persons who are not accredited investors (as such term is defined by the SEC), as
described in Section&nbsp;12(g) of the 1934 Act and any related regulations, or otherwise requiring the corporation to register any class of securities under the 1934 Act; or (iii)&nbsp;if such Transfer would result in the loss of any federal or
state securities law exemption relied upon by the corporation in connection with the initial issuance of such shares or the issuance of any other securities; or (iv)&nbsp;if such Transfer is facilitated in any manner by any public posting, message
board, trading portal, internet site, or similar method of communication, including without limitation any trading portal or internet site intended to facilitate secondary transfers of securities; or (v)&nbsp;if such Transfer is to be effected in a
brokered transaction; or (vi)&nbsp;if such Transfer represents a Transfer of less than all of the shares then held by the stockholder and its affiliates or is to be made to more than a single transferee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a stockholder desires to Transfer any shares, then the stockholder shall first give written notice
thereof to the corporation. The notice shall name the proposed transferee and state the number of shares to be transferred, the proposed consideration, and all other terms and conditions of the proposed transfer. Any shares proposed to be
transferred to which Transfer the corporation has consented pursuant to paragraph (a)&nbsp;of this Section will first be subject to the corporation&#146;s right of first refusal located in <U>Section</U><U></U><U>&nbsp;37</U> of these Bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;At the option of the corporation, the stockholder shall be
obligated to pay to the corporation a reasonable transfer fee related to the costs and time of the corporation and its legal and other advisors related to any proposed Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Any Transfer, or purported Transfer, of shares not made in strict compliance with this Section shall be null
and void, shall not be recorded on the books of the corporation and shall not be recognized by the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;The foregoing restriction on Transfer shall terminate upon the date securities of the corporation are first
offered to the public pursuant to a registration statement filed with, and declared effective by, the SEC under the Securities Act of 1933, as amended (the &#147;<B><I>1933 Act</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;The certificates representing shares of stock of the corporation shall bear on their face the following
legend so long as the foregoing Transfer restrictions are in effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; margin-right:8%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE
SUBJECT TO A TRANSFER RESTRICTION, AS PROVIDED IN THE BYLAWS OF THE CORPORATION.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;37.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Right of First Refusal</B>. No stockholder shall Transfer any of the shares of
stock of the corporation, except by a Transfer that meets the requirements set forth in this Section&nbsp;37, in addition to any other restrictions or requirements set forth under applicable law or these Bylaws: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;If the stockholder desires to Transfer any of his or her shares of stock, then the stockholder shall first
give written notice thereof to the corporation. The notice shall name the proposed transferee and state the number of shares to be transferred, the proposed consideration, and all other terms and conditions of the proposed transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;For 30 days following receipt of such notice, the corporation shall have the option to purchase up to all
the shares specified in the notice at the price and upon the terms set forth in such notice; <I>provided, however,</I> that, with the consent of the stockholder, the corporation shall have the option to purchase a lesser portion of the shares
specified in said notice at the price and upon the terms set forth therein. In the event of a gift, property settlement or other Transfer in which the proposed transferee is not paying the full price for the shares, and that is not otherwise
exempted from the provisions of this Section, the price shall be deemed to be the fair market value of the stock at such time as determined in good faith by the Board of Directors. In the event the corporation elects to purchase all of the shares
or, with consent of the stockholder, a lesser portion of the shares, it shall give written notice to the transferring stockholder of its election and settlement for said shares shall be made as provided below in paragraph&nbsp;(d) of this Section.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;The corporation may assign its rights hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;In the event the corporation and/or its assignee(s) elect to acquire any of the shares of the transferring
stockholder as specified in said transferring stockholder&#146;s notice, the Secretary of the corporation shall so notify the transferring stockholder and settlement thereof shall be made in cash within 30 days after the Secretary of the corporation
receives said transferring stockholder&#146;s notice; provided that if the terms of payment set forth in said transferring stockholder&#146;s notice were other than cash against delivery, the corporation and/or its assignee(s) shall pay for said
shares on the same terms and conditions set forth in said transferring stockholder&#146;s notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;In the event the corporation and/or its assignees(s) do
not elect to acquire all of the shares specified in the transferring stockholder&#146;s notice, said transferring stockholder may, subject to the corporation&#146;s approval and all other restrictions on Transfer located in Section&nbsp;36 of these
Bylaws, within the <FONT STYLE="white-space:nowrap">60-day</FONT> period following the expiration or waiver of the option rights granted to the corporation and/or its assignees(s) herein, Transfer the shares specified in said transferring
stockholder&#146;s notice that were not acquired by the corporation and/or its assignees(s) as specified in said transferring stockholder&#146;s notice. All shares so sold by said transferring stockholder shall continue to be subject to the
provisions of this Bylaw in the same manner as before said Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;Anything to the contrary contained
herein notwithstanding, the following transactions shall be exempt from the right of first refusal in paragraph (a)&nbsp;of this Section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B>&nbsp;&nbsp;&nbsp;&nbsp;A stockholder&#146;s Transfer of any or all shares held either during such stockholder&#146;s lifetime or
on death by will or intestacy to such stockholder&#146;s immediate family or to any custodian or trustee for the account of such stockholder or such stockholder&#146;s immediate family or to any limited partnership of which the stockholder, members
of such stockholder&#146;s immediate family or any trust for the account of such stockholder or such stockholder&#146;s immediate family will be the general or limited partner(s) of such partnership. &#147;Immediate family&#148; as used herein shall
mean spouse, lineal descendant, father, mother, brother, or sister of the stockholder making such Transfer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B>&nbsp;&nbsp;&nbsp;&nbsp;A stockholder&#146;s bona fide pledge or mortgage of any shares with a commercial lending institution,
provided that any subsequent Transfer of said shares by said institution shall be conducted in the manner set forth in this Bylaw; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(3)</B>&nbsp;&nbsp;&nbsp;&nbsp;A stockholder&#146;s Transfer of any or all of such stockholder&#146;s shares to the corporation or to any
other stockholder of the corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(4)</B>&nbsp;&nbsp;&nbsp;&nbsp;A stockholder&#146;s Transfer of any or all of such
stockholder&#146;s shares to a person who, at the time of such Transfer, is an officer or director of the corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(5)</B>&nbsp;&nbsp;&nbsp;&nbsp;A corporate stockholder&#146;s Transfer of any or all of its shares pursuant to and in accordance with the
terms of any merger, consolidation, reclassification of shares or capital reorganization of the corporate stockholder, or pursuant to a sale of all or substantially all of the stock or assets of a corporate stockholder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(6)</B>&nbsp;&nbsp;&nbsp;&nbsp;A corporate stockholder&#146;s Transfer of any or all of its shares to any or all of its stockholders; or
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(7)</B>&nbsp;&nbsp;&nbsp;&nbsp;A Transfer by a stockholder that is a limited or general partnership to any or all of its partners or
former partners in accordance with partnership interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any such case, the transferee, assignee, or other recipient shall receive
and hold such stock subject to the provisions of this Section and any other restrictions set forth in these Bylaws, and there shall be no further Transfer of such stock except in accord with this Section and the other provisions of these Bylaws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Bylaw may be waived with respect to any Transfer either by the corporation, upon
duly authorized action of its Board of Directors, or by the stockholders, upon the express written consent of the owners of a majority of the voting power of the corporation (excluding the votes represented by those shares to be transferred by the
transferring stockholder).&nbsp;&nbsp;&nbsp;&nbsp;This Bylaw may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended or repealed either by a duly authorized action of the Board of Directors or by the stockholders, upon the express written consent of the owners of a majority of the voting power of the
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;Any Transfer, or purported Transfer, of securities of the corporation shall be null and
void unless the terms, conditions, and provisions of this Bylaw are strictly observed and followed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing right of first refusal shall terminate upon the date securities of the corporation are first offered to the public pursuant to a registration statement filed with, and declared effective by, the SEC under the Securities Act of 1933, as
amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;The certificates representing shares of stock of the corporation that are subject to the right
of first refusal in paragraph (a)&nbsp;of this Section shall bear on their face the following legend so long as the foregoing right of first refusal remains in effect: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; margin-right:8%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL OPTION IN FAVOR OF THE CORPORATION
AND/OR ITS ASSIGNEE(S), AS PROVIDED IN THE BYLAWS OF THE CORPORATION.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>&nbsp;&nbsp;&nbsp;&nbsp;To the extent this Section
conflicts with any written agreements between the corporation and the stockholder attempting to Transfer shares, such agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;38.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Fixing Record Dates</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting
of stockholders or any adjournment thereof, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which
record date shall, subject to applicable law, not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to
vote at a meeting of stockholders shall be at the close of business on the day immediately preceding the day on which notice is given, or if notice is waived, at the close of business on the day immediately preceding the day on which the meeting is
held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however,</I> that the Board of Directors may fix a new record date for the
adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;In order that the corporation may determine the stockholders entitled to consent to
corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which date shall not
be more than 10 days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. Any stockholder of record seeking to have the stockholders authorize or take corporate action by written consent shall, by
written notice to the Secretary, request the Board of Directors to fix a record date. The Board of Directors shall promptly, but in all events within 10 days after the date on which such a request is received, adopt a resolution fixing the record
date. If no record date has been fixed by the Board of Directors within 10 days of the date on which such a request is received, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when
no prior action by the Board of Directors is required by applicable law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the corporation by delivery to its registered
office in the State of Delaware, its principal place of business or an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation&#146;s registered office shall be by hand or by certified or registered mail, return receipt requested. If no record date has been fixed by the Board of Directors and prior action by
the Board of Directors is required by law, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the day on which the Board of Directors adopts the
resolution taking such prior action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;In order that the corporation may determine the stockholders
entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful
action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action.
If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;39.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Registered Stockholders</B>. The corporation shall be entitled to recognize
the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of
any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER
SECURITIES OF THE CORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;40.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Execution of Other Securities</B>. All
bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered in Section&nbsp;34 of these Bylaws), may be signed by the Chairman of the Board of Directors, the Chief Executive Officer, the President or
any Vice President, or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary,
or the Chief Financial Officer or Treasurer or an Assistant Treasurer; <I>provided, however,</I> that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile
signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security
may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant
Treasurer of the corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other
corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such
bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer
of the corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;41.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Declaration of Dividends</B>. Dividends upon the capital stock of the
corporation, subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in
shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;42.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Dividend Reserve</B>. Before payment of any dividend, there may be set aside
out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for
repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or abolish any such reserve in the manner
in which it was created. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FISCAL YEAR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;43.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Fiscal Year</B>. The fiscal year of the corporation shall be fixed by
resolution of the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;44.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification of Directors, Executive Officers, Other Officers, Employees
and Other Agents</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Directors and Executive Officers</B>. The corporation shall indemnify its
directors and executive officers (for the purposes of this Article, &#147;executive officers&#148; shall have the meaning defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> promulgated under the 1934 Act) to the fullest extent not
prohibited by the DGCL or any other applicable law; <I>provided, however,</I> that the corporation may modify the extent of such indemnification by individual contracts with its directors and executive officers; and, <I>provided, further,</I> that
the corporation shall not be required to indemnify any director or executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i)&nbsp;such indemnification is expressly required to be made by law,
(ii)&nbsp;the proceeding was authorized by the Board of Directors of the corporation, (iii)&nbsp;such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the DGCL or any
other applicable law or (iv)&nbsp;such indemnification is required to be made under paragraph (d)&nbsp;of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Officers, Employees and Other Agents</B>. The corporation shall have power to indemnify its other
officers, employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person except executive
officers to such officers or other persons as the Board of Directors shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Expenses</B>.
The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director or executive officer of the corporation, or is or was serving at the request
of the corporation as a director or executive<B> </B>officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred
by any director or executive officer in connection with such proceeding, <I>provided, however</I>, that, if the DGCL requires, an advancement of expenses incurred by a director or officer in his or her capacity as a director or officer (and not in
any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking, by or on behalf of such indemnitee,
to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses under this Section or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph&nbsp;(e) of this Section, no advance shall be made by
the corporation to an executive officer of the corporation (except by reason of the fact that such executive officer is or was a director of the corporation, in which event this paragraph shall not apply) in any action, suit or proceeding, whether
civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i)&nbsp;by a majority vote of a quorum consisting of directors who were not parties to the proceeding, even if not a quorum, or (ii)&nbsp;by a
committee of such directors designated by a majority of such directors, even though less than a quorum, or (iii)&nbsp;if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts
known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Enforcement</B>. Without the necessity of entering into an express contract, all rights
to indemnification and advances to directors and executive officers under this Section shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the corporation and the director or
executive officer. Any right to indemnification or advances granted by this Section to a director or executive officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i)&nbsp;the claim
for indemnification or advances is denied, in whole or in part, or (ii)&nbsp;no disposition of such claim is made within 90 days of request therefor. The claimant in such enforcement action, if successful in whole or in part, shall be entitled to be
paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct that make it
permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. In connection with any claim by an executive officer of the corporation (except in any action, suit or proceeding, whether
civil, criminal, administrative or investigative, by reason of the fact that such executive officer is or was a director of the corporation) for advances, the corporation shall be entitled to raise as a defense as to any such action clear and
convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted
without reasonable cause to believe that his or her conduct was lawful. Neither the failure of the corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement
of such action that indemnification of the claimant is proper in the circumstances because he has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its
Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of
conduct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Non</B><B><FONT STYLE="white-space:nowrap">-Exclusivity</FONT> of Rights</B>. The rights conferred on any
person by this Section shall not be exclusive of any other right that such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested
directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors,
officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL or any other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Survival of Rights</B>. The rights conferred on any person by this Section shall continue as to a person
who has ceased to be a director or executive officer and shall inure to the benefit of the heirs, executors and administrators of such a person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Insurance</B>. To the fullest extent permitted by the DGCL, or any other applicable law, the corporation,
upon approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendments</B>. Any repeal or modification of this Section shall only be prospective and shall not affect
the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Saving Clause</B>. If this Section or any portion hereof shall be invalidated on any ground by any court
of competent jurisdiction, then the corporation shall nevertheless indemnify each director and executive officer to the full extent not prohibited by any applicable portion of this Bylaw that shall not have been invalidated, or by any other
applicable law. If this Section&nbsp;shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and executive officer to the full extent under applicable law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Certain Definitions</B>. For the purposes of this Section, the following definitions shall apply:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B>&nbsp;&nbsp;&nbsp;&nbsp;The term &#147;proceeding&#148; shall be broadly construed and shall include, without limitation, the
investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B>&nbsp;&nbsp;&nbsp;&nbsp;The term &#147;expenses&#148; shall be broadly construed and shall include, without limitation, court
costs, attorneys&#146; fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(3)</B>&nbsp;&nbsp;&nbsp;&nbsp;The term the &#147;corporation&#148; shall include, in addition to the resulting corporation, any
constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger that, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or
agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Section with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its
separate existence had continued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(4)</B>&nbsp;&nbsp;&nbsp;&nbsp;References to a &#147;director,&#148; &#147;executive officer,&#148;
&#147;officer,&#148; &#147;employee,&#148; or &#147;agent&#148; of the corporation shall include, without limitation, situations where such person is serving at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
request of the corporation as, respectively, a director, executive officer, officer, employee, trustee or agent of another corporation, partnership, joint venture, trust or other enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(5)</B>&nbsp;&nbsp;&nbsp;&nbsp;References to &#147;other enterprises&#148; shall include employee benefit plans; references to
&#147;fines&#148; shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &#147;serving at the request of the corporation&#148; shall include any service as a director, officer, employee or
agent of the corporation that imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner
he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#147;not opposed to the best interests of the corporation&#148; as referred to in this Section.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;45.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice to Stockholders</B>. Written notice to stockholders of stockholder meetings shall be given as
provided in <U>Section</U><U></U><U>&nbsp;7</U> of these Bylaws. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required
by law, written notice to stockholders for purposes other than stockholder meetings may be sent by United States mail or nationally recognized overnight courier, or by facsimile, telegraph or telex or by electronic mail or other electronic means.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice to Directors</B>. Any notice required to be given to any director may be given by the method
stated in paragraph&nbsp;(a) of this Section, or as provided for in Section&nbsp;21 of these Bylaws. If such notice is not delivered personally, it shall be sent to such address as such director shall have filed in writing with the Secretary, or, in
the absence of such filing, to the last known post office address of such director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Affidavit of
Mailing</B>. An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected or other agent, specifying the name and address or the names
and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein
contained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Methods of Notice</B>. It shall not be necessary that the same method of giving notice be
employed in respect of all recipients of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice to Person with Whom Communication Is Unlawful</B>. Whenever notice is required to be given, under
any provision of law or of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any
governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting that shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect
as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice to Stockholders Sharing an Address</B>.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>Except as otherwise
prohibited under DGCL, any notice given under the provisions of DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at
that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the corporation within 60 days of having been given notice by the corporation of its intention to
send the single notice. Any consent shall be revocable by the stockholder by written notice to the corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;46.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendments</B>.<B> </B>The Board of Directors is expressly empowered to adopt,
amend or repeal Bylaws of the corporation. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the corporation; <I>provided, however</I>, that, in addition to any vote of the holders of any class or series of stock of the
corporation required by law or by the Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of a majority of the voting power of all of the then-outstanding shares of the capital stock of the
corporation entitled to vote generally in the election of directors, voting together as a single class. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOANS TO OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;47.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Loans to Officers</B>. Except as otherwise prohibited under applicable law,
the corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a Director of the corporation or its
subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be
unsecured, or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or
warranty of the corporation at common law or under any statute. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;48.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Annual Report</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of paragraph&nbsp;(b) of this Section, the Board of Directors shall cause an
annual report to be sent to each stockholder of the corporation not later than 120 days after the close of the corporation&#146;s fiscal year. Such report shall include a balance sheet as of the end of such fiscal year and an income statement and
statement of changes in financial position for such fiscal year, accompanied by any report thereon of independent accountants or, if there is no such report, the certificate of an authorized officer of the corporation that such statements were
prepared without audit from the books and records of the corporation. When there are more than 100 stockholders of record of the corporation&#146;s shares, as determined by Section&nbsp;605 of the CGCL, additional information as required
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by Section&nbsp;1501(b) of the CGCL shall also be contained in such report, provided that if the corporation has a class of securities registered under Section&nbsp;12 of the 1934 Act, the 1934
Act shall take precedence. Such report shall be sent to stockholders at least 15 days prior to the next annual meeting of stockholders after the end of the fiscal year to which it relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;If and so long as there are fewer than 100 holders of record of the corporation&#146;s shares, the
requirement of sending of an annual report to the stockholders of the corporation is hereby expressly waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;49.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Forum</B>. Unless the corporation consents in writing to the selection of an
alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the corporation; (ii)&nbsp;any action asserting a claim of breach of a
fiduciary duty owed by any director, officer or other employee of the corporation to the corporation or the corporation&#146;s stockholders; (iii)&nbsp;any action asserting a claim against the corporation or any director or officer or other employee
of the corporation arising pursuant to any provision of the DGCL, the certificate of incorporation or the Bylaws of the corporation; or (iv)&nbsp;any action asserting a claim against the corporation or any director or officer or other employee of
the corporation governed by the internal affairs doctrine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(F/K/A ATTENUATE BIOPHARMACEUTICALS, INC.) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF SECRETARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I <SMALL>HEREBY</SMALL> <SMALL>CERTIFY</SMALL> <SMALL>THAT</SMALL>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am the duly elected and acting Secretary of <B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B> (F/K/A <B>A<SMALL>TTENUATE</SMALL>
B<SMALL>IOPHARMACEUTICALS</SMALL>, I<SMALL>NC</SMALL>.</B>), a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attached
hereto is a complete and accurate copy of the Bylaws of the Company as duly adopted by the Board of Directors by Unanimous Written Consent dated March 20, 2017 and said Bylaws are presently in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Signed on May 18, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Thomas A. Coll</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>T<SMALL>HOMAS</SMALL> A. C<SMALL>OLL</SMALL></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Secretary</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>5
<FILENAME>d582934dex34.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <B>Registered Office.</B> The registered office of the corporation in the State of Delaware shall be in
the City of Wilmington, County of New Castle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <B>Other Offices.</B> The corporation shall also have
and maintain an office or principal place of business at such place as may be fixed by the corporation&#146;s Board of Directors (the &#147;<B><I>Board of Directors</I></B>&#148;), and may also have offices at such other places, both within and
without the State of Delaware as the Board of Directors may from time to time determine or the business of the corporation may require. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE
SEAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B> <B>Corporate Seal.</B> The Board of Directors may adopt a corporate seal. The corporate
seal shall consist of a die bearing the name of the corporation and the inscription, &#147;Corporate Seal-Delaware.&#148; Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>Place of Meetings.</B> Meetings of the stockholders of the corporation may be held at such place,
either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held
solely by means of remote communication as provided under the Delaware General Corporation Law (the&nbsp;&#147;<B><I>DGCL</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5. Annual Meetings. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as
may properly come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the corporation and the proposal of business
to be considered by the stockholders may be made at an annual meeting of stockholders: (i)&nbsp;pursuant to the corporation&#146;s notice of meeting of stockholders (with respect to business other than nominations); (ii) brought specifically by or
at the direction of the Board of Directors; or (iii)&nbsp;by any stockholder of the corporation who was a stockholder of record at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time of giving the stockholder&#146;s notice provided for in Section&nbsp;5(b) of these Amended and Restated Bylaws (the &#147;<B><I>Bylaws</I></B>&#148;), who is entitled to vote at the meeting
and who complied with the notice procedures set forth in this Section&nbsp;5. For the avoidance of doubt, clause (iii)&nbsp;above shall be the exclusive means for a stockholder to make nominations and submit other business (other than matters
properly included in the corporation&#146;s notice of meeting of stockholders and proxy statement under Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934, as amended, and the rules and regulations
thereunder (the &#147;<B><I>1934 Act</I></B>&#148;)) before an annual meeting of stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> At an annual meeting of the
stockholders, only such business shall be conducted as is a proper matter for stockholder action under Delaware law and as shall have been properly brought before the meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> For nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder
pursuant to clause (iii)&nbsp;of Section&nbsp;5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section&nbsp;5(b)(iii) of these
Bylaws and must update and supplement such written notice on a timely basis as set forth in Section&nbsp;5(c) of these Bylaws. Such stockholder&#146;s notice shall set forth: (A)&nbsp;as to each nominee such stockholder proposes to nominate at the
meeting: (1)&nbsp;the name, age, business address and residence address of such nominee; (2)&nbsp;the principal occupation or employment of such nominee; (3)&nbsp;the class and number of shares of each class of capital stock of the corporation which
are owned of record and beneficially by such nominee; (4)&nbsp;the date or dates on which such shares were acquired and the investment intent of such acquisition; (5)&nbsp;with respect to each nominee for election or
<FONT STYLE="white-space:nowrap">re-election</FONT> to the Board of Directors, include a completed and signed questionnaire, representation and agreement required by Section&nbsp;5(e) of these Bylaws; and (6)&nbsp;such other information concerning
such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved), or that is otherwise required to be
disclosed pursuant to Section&nbsp;14 of the 1934 Act and the rules and regulations promulgated thereunder (including such person&#146;s written consent to being named as a nominee and to serving as a director if elected); and (B)&nbsp;the
information required by Section&nbsp;5(b)(iv) of these Bylaws. The corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as an
independent director of the corporation or that could be material to a reasonable stockholder&#146;s understanding of the independence, or lack thereof, of such proposed nominee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Other than proposals sought to be included in the corporation&#146;s proxy materials pursuant to Rule <FONT
STYLE="white-space:nowrap">14(a)-8</FONT> under the 1934 Act, for business other than nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&nbsp;of
Section&nbsp;5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section&nbsp;5(b)(iii) of these Bylaws, and must update and
supplement such written notice on a timely basis as set forth in Section&nbsp;5(c) of these Bylaws. Such stockholder&#146;s notice shall set forth: (A)&nbsp;as to each matter such stockholder proposes to bring before the meeting, a brief description
of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest (including any anticipated benefit of such business to any Proponent (as defined below) other than solely as
a result of its ownership of the corporation&#146;s capital stock, that is material to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent; and (B)&nbsp;the information required by
Section&nbsp;5(b)(iv) of these Bylaws. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To be timely, the written notice required by Section&nbsp;5(b)(i) or 5(b)(ii) of
these Bylaws must be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day nor earlier than the close of business on
the 120<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day prior to the first anniversary of the preceding year&#146;s annual meeting; <I>provided, however,</I> that, subject to the last sentence of this Section&nbsp;5(b)(iii), in the event
that the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year&#146;s annual meeting, notice by the stockholder to be timely must be so received not earlier than
the close of business on the 120<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day prior to such annual meeting and not later than the close of business on the later of the 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day prior
to such annual meeting or the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the day on which public announcement of the date of such meeting is first made. In no event shall an adjournment or a postponement of an annual
meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#146;s notice as described above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> The written notice required by Section&nbsp;5(b)(i) or 5(b)(ii) of these Bylaws shall also set forth, as of the date of the notice
and as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (each, a &#147;<B><I>Proponent</I></B>&#148; and collectively, the &#147;<B><I>Proponents</I></B>&#148;): (A) the name
and address of each Proponent, as they appear on the corporation&#146;s books; (B)&nbsp;the class, series and number of shares of the corporation that are owned beneficially and of record by each Proponent; (C)&nbsp;a description of any agreement,
arrangement or understanding (whether oral or in writing) with respect to such nomination or proposal between or among any Proponent and any of its affiliates or associates, and any others (including their names) acting in concert, or otherwise
under the agreement, arrangement or understanding, with any of the foregoing; (D)&nbsp;a representation that the Proponents are holders of record or beneficial owners, as the case may be, of shares of the corporation entitled to vote at the meeting
and intend to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice (with respect to a notice under Section&nbsp;5(b)(i) of these Bylaws) or to propose the business that is specified in the notice
(with respect to a notice under Section&nbsp;5(b)(ii) of these Bylaws); (E) a representation as to whether the Proponents intend to deliver a proxy statement and form of proxy to holders of a sufficient number of holders of the corporation&#146;s
voting shares to elect such nominee or nominees (with respect to a notice under Section&nbsp;5(b)(i) of these Bylaws) or to carry such proposal (with respect to a notice under Section&nbsp;5(b)(ii) of these Bylaws); (F) to the extent known by any
Proponent, the name and address of any other stockholder supporting the proposal on the date of such stockholder&#146;s notice; and (G)&nbsp;a description of all Derivative Transactions (as defined below) by each Proponent during the previous 12
month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Sections 5 and 6 of these Bylaws, a &#147;<B><I>Derivative Transaction</I></B>&#148; means any agreement, arrangement, interest or
understanding entered into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(w) the value of which is derived in whole or in part from the value of any class or series of
shares or other securities of the corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(x) which otherwise provides any direct or indirect opportunity to gain or share in any
gain derived from a change in the value of securities of the corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(y) the effect or intent of which is to mitigate loss, manage
risk or benefit of security value or price changes; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(z) which provides the right to vote or increase or decrease the voting power of,
such Proponent, or any of its affiliates or associates, with respect to any securities of the corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which agreement, arrangement, interest or
understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related
fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proponent in the securities of the corporation held by any
general or limited partnership, or any limited liability company, of which such Proponent is, directly or indirectly, a general partner or managing member. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> A stockholder providing written notice required by Section&nbsp;5(b)(i) or (ii)&nbsp;of these Bylaws shall update and supplement
such notice in writing, if necessary, so that the information provided or required to be provided in such notice is true and correct in all material respects as of (i)&nbsp;the record date for the meeting and (ii)&nbsp;the date that is five business
days prior to the meeting and, in the event of any adjournment or postponement thereof, five business days prior to such adjourned or postponed meeting. In the case of an update and supplement pursuant to clause (i)&nbsp;of this Section&nbsp;5(c),
such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than five business days after the record date for the meeting. In the case of an update and supplement pursuant to clause
(ii)&nbsp;of this Section&nbsp;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than two business days prior to the date for the meeting, and, in the event of any
adjournment or postponement thereof, two business days prior to such adjourned or postponed meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Notwithstanding anything
in Section&nbsp;5(b)(iii) of these Bylaws<B> </B>to the contrary, in the event that the number of directors in an Expiring Class (as defined below) is increased and there is no public announcement of the appointment of a director to such class, or,
if no appointment was made, of the vacancy in such class, made by the corporation at least 10 days before the last day a stockholder may deliver a notice of nomination in accordance with<B> </B>Section&nbsp;5(b)(iii) of these Bylaws, a
stockholder&#146;s notice required by this Section&nbsp;5 and which complies with the requirements in Section&nbsp;5(b)(i) of these Bylaws, other than the timing requirements in Section&nbsp;5(b)(iii) of these Bylaws, shall also be considered
timely, but only with respect to nominees for any new positions in such Expiring Class&nbsp;created by such increase, if it shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business
on the 10th day following the day on which such public announcement is first made by the corporation. For purposes of this Section&nbsp;5, an &#147;<B><I>Expiring Class</I></B>&#148; shall mean a class of directors whose term shall expire at the
next annual meeting of stockholders. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> To be eligible to be a nominee for election or
<FONT STYLE="white-space:nowrap">re-election</FONT> as a director of the corporation pursuant to a nomination under clause (iii)&nbsp;of Section&nbsp;5(a) of these Bylaws, such proposed nominee or a person on such proposed nominee&#146;s behalf must
deliver (in accordance with the time periods prescribed for delivery of notice under Section&nbsp;5(b)(iii) or 5(d) of these Bylaws, as applicable) to the Secretary at the principal executive offices of the corporation a written questionnaire with
respect to the background and qualification of such proposed nominee and the background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided by the Secretary upon written request) and a
written representation and agreement (in the form provided by the Secretary upon written request) that such person (i)&nbsp;is not and will not become a party to (A)&nbsp;any agreement, arrangement or understanding with, and has not given any
commitment or assurance to, any person or entity as to how such person, if elected as a director of the corporation, will act or vote on any issue or question (a &#147;<B><I>Voting Commitment</I></B>&#148;) that has not been disclosed to the
corporation in the questionnaire or (B)&nbsp;any Voting Commitment that could limit or interfere with such person&#146;s ability to comply, if elected as a director of the corporation, with such person&#146;s fiduciary duties under applicable law;
(ii)&nbsp;is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with
service or action as a director of the corporation that has not been disclosed therein; and (iii)&nbsp;in such person&#146;s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, would be in
compliance, if elected as a director of the corporation, and will comply with, all applicable publicly disclosed corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the corporation.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> A person shall not be eligible for election or <FONT STYLE="white-space:nowrap">re-election</FONT> as a director unless the
person is nominated either in accordance with clause (ii)&nbsp;of Section&nbsp;5(a) of these Bylaws, or in accordance with clause (iii)&nbsp;of Section&nbsp;5(a) of these Bylaws. Except as otherwise required by law, the chairman of the meeting shall
have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed
nomination or business is not in compliance with these Bylaws, or the Proponent does not act in accordance with the representations in Sections 5(b)(iv)(D) and 5(b)(iv)(E) of these Bylaws, to declare that such proposal or nomination shall not be
presented for stockholder action at the meeting and shall be disregarded, notwithstanding that proxies in respect of such nominations or such business may have been solicited or received. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> Notwithstanding the foregoing provisions of this Section&nbsp;5, in order to include information with respect to a stockholder
proposal in the proxy statement and form of proxy for a stockholders&#146; meeting, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder. Nothing in these Bylaws shall be deemed to
affect any rights of stockholders to request inclusion of proposals in the corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act; <I>provided, however, </I>that any references in these
Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to proposals and/or nominations to be considered pursuant to Section&nbsp;5(a)(iii) of these Bylaws. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> For purposes of Sections&nbsp;5 and 6 of these Bylaws, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>public announcement</I></B>&#148; shall mean disclosure in a press release reported by the Dow Jones News Service,
Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d) of the 1934 Act; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>affiliates</I></B>&#148; and &#147;<B><I>associates</I></B>&#148; shall have the meanings set forth in Rule 405 under
the Securities Act of 1933, as amended (the &#147;<B><I>1933 Act</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6. Special Meetings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Special meetings of the stockholders of the corporation may be called, for any purpose as is a proper matter for stockholder action
under Delaware law, by (i)&nbsp;the Chairman of the Board of Directors, (ii)&nbsp;the Chief Executive Officer, or (iii)&nbsp;the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether
or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board of Directors shall determine the time and place, if any, of such special meeting. Upon determination of the time and
place, if any, of the meeting, the Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance with the provisions of Section&nbsp;7 of these Bylaws. No business may be transacted at such special meeting
otherwise than specified in the notice of meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Nominations of persons for election to the Board of Directors may be made at
a special meeting of stockholders at which directors are to be elected (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the corporation who is a stockholder of record at the time of giving notice provided
for in this paragraph, who shall be entitled to vote at the meeting and who delivers written notice to the Secretary of the corporation setting forth the information required by Section&nbsp;5(b)(i) of these Bylaws. In the event the corporation
calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified
in the corporation&#146;s notice of meeting, if written notice setting forth the information required by Section&nbsp;5(b)(i) of these Bylaws shall be received by the Secretary at the principal executive offices of the corporation not later than the
close of business on the later of the 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day prior to such meeting or the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the day on which public announcement is first
made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. The stockholder shall also update and supplement such information as required under Section&nbsp;5(c) of these Bylaws. In
no event shall an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#146;s notice as described above. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Notwithstanding the foregoing provisions of this Section&nbsp;6, a stockholder must
also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth in this Section&nbsp;6. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request
inclusion of proposals in the corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act; <I>provided, however, </I>that any references in these Bylaws to the 1934 Act or the rules and
regulations thereunder are not intended to and shall not limit the requirements applicable to nominations for the election to the Board of Directors to be considered pursuant to Section&nbsp;6(c) of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B> <B>Notice of Meetings.</B> Except as otherwise provided by law, notice, given in writing or by electronic
transmission, of each meeting of stockholders shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the
case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. If mailed, notice is deemed
given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it appears on the records of the corporation. If sent via electronic transmission, notice is deemed given as of the
sending time recorded at the time of transmission. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person,
either before or after such meeting, and will be waived by any stockholder by his attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting,
at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if
due notice thereof had been given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B> <B>Quorum.</B> At all meetings of stockholders, except where
otherwise provided by statute or by the corporation&#146;s Amended and Restated Certificate of Incorporation (&#147;<B><I>Certificate of Incorporation</I></B>&#148;), or by these Bylaws, the presence, in person, by remote communication, if
applicable, or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be
adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or
convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock
exchange rules, or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by
proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of
the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or classes or series is required,
except where </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person, by remote
communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation or
these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting
shall be the act of such class or classes or series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B> <B>Adjournment and Notice of Adjourned
Meetings.</B> Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares present in person, by remote communication, if applicable, or
represented by proxy at the meeting. When a meeting is adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the time and place, if any, thereof are announced at the meeting at which the adjournment is
taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days or if after the adjournment a new record date is fixed for the adjourned
meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B> <B>Voting Rights.</B> For the purpose of determining those stockholders entitled to vote at any meeting
of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in Section&nbsp;12 of these Bylaws, shall be entitled to vote at any meeting
of stockholders. Every person entitled to vote<B> </B>shall have the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in accordance with Delaware law. An agent so
appointed need not be a stockholder. No proxy shall be voted after three years from its date of creation unless the proxy provides for a longer period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B> <B>Joint Owners of Stock.</B> If shares or other securities having voting power stand of record in the
names of two or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two or more persons have the same fiduciary relationship respecting the same shares, unless
the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect:
(a)&nbsp;if only one votes, his act binds all; (b)&nbsp;if more than one votes, the act of the majority so voting binds all; or (c)&nbsp;if more than one votes, but the vote is evenly split on any particular matter, each faction may vote the
securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the DGCL, Section&nbsp;217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a
majority or even-split for the purpose of clause&nbsp;(c) of this Section&nbsp;11 shall be a majority or even-split in interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>List of Stockholders.</B> The Secretary shall prepare and make, at least 10 days before every meeting
of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, (a)&nbsp;on a reasonably
accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b)&nbsp;during ordinary business hours, at the principal place of business of the corporation. In the
event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. The list shall be open to
examination of any stockholder during the time of the meeting as provided by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.</B> <B>Action Without
Meeting.</B><B> </B>No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws, and no action shall be taken by the stockholders by written consent or electronic
transmission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;14. Organization. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> At every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the
President, or, if the President is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairman. The Secretary, or, in his or her absence, an Assistant
Secretary directed to do so by the President, shall act as secretary of the meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board of Directors of the corporation
shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the
meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including,
without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the
corporation and their duly authorized and constituted proxies and such other persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions
or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders
will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of
parliamentary procedure. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B> <B>Number and Term of Office.</B> The authorized number of directors of the corporation shall be fixed
in accordance with the Certificate of Incorporation. Directors need not be stockholders unless so required by the Certificate of Incorporation. If for any cause, the directors shall not have been elected at an annual meeting, they may be elected as
soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B> <B>Powers.</B> The business and affairs of the corporation
shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B> <B>Classes of Directors. </B><B><I></I></B>Subject to the rights of the holders of any series of
Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, respectively. The Board of Directors is authorized to assign
members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of
the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the term of office of the Class&nbsp;II directors
shall expire and Class&nbsp;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of office of the Class&nbsp;III directors shall expire and
Class&nbsp;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such
annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this Section&nbsp;17, each director shall serve until his or her successor is
duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;18.</B> <B>Vacancies.</B><B> </B>Unless otherwise provided in the Certificate of Incorporation, and subject to
the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the
number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by the affirmative vote of a majority of the directors then in
office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders, <I>provided, however</I>, that whenever the holders of any class or classes of stock or series thereof are entitled to
elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships of such class or classes or series shall, unless the Board of Directors determines by resolution that any such vacancies or
newly created directorships shall be filled by stockholders, be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by a sole remaining director so elected, and not by the stockholders. Any
director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#146;s successor shall have been elected and
qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation of any director. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B> <B>Resignation.</B> Any director may resign at any time by
delivering his or her notice in writing or by electronic transmission to the Secretary, such resignation to specify whether it will be effective at a particular time. If no such specification is made, it shall be deemed effective at the time of
delivery to the Secretary. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or
vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his
successor shall have been duly elected and qualified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;20. Removal. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the rights of any series of Preferred Stock to elect additional directors under specified circumstances,<B> </B>neither
the Board of Directors nor any individual director may be removed without cause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Subject to any limitation imposed by law, any
individual director or directors may be removed with cause by the affirmative vote of the holders of at least 66 2/3% of the voting power of all then outstanding shares of capital stock of the corporation entitled to vote generally at an election of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;21. Meetings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Regular Meetings.</B> Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors
may be held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging
system or other system designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Special Meetings. </B>Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors
may be held at any time and place within or without the State of Delaware whenever called by the Chairman of the Board, the Chief Executive Officer or a majority of the authorized number of directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Meetings by Electronic Communications Equipment. </B>Any member of the Board of Directors, or of any committee thereof, may
participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in
person at such meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Notice of Special Meetings. </B>Notice of the time and place of all special meetings of the Board of
Directors shall be orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means,
during normal business hours, at least 24 hours before the date and time of the meeting. If notice is sent by U.S. mail, it shall be sent by first class mail, charges prepaid, at least three days before the date of the
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting. Notice of any meeting may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except
when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Waiver of Notice. </B>The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however
called or noticed, or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who
did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;22. Quorum and Voting. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Unless the Certificate of Incorporation requires a greater number, and except with respect to questions related to indemnification
arising under Section&nbsp;45 of these Bylaws for which a quorum shall be <FONT STYLE="white-space:nowrap">one-third</FONT> of the exact number of directors fixed from time to time, a quorum of the Board of Directors shall consist of a majority of
the exact number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation; <I>provided, however,</I> at any meeting whether a quorum be present or otherwise, a majority of the directors
present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the
affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;23.</B> <B>Action Without Meeting.</B> Unless otherwise restricted by the Certificate of Incorporation or these
Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in
writing or by electronic transmission, and such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained
in paper form and shall be in electronic form if the minutes are maintained in electronic form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;24.</B>
<B>Fees and Compensation.</B> Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of
attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the
corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;25. Committees. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Executive Committee.</B> The Board of Directors may appoint an Executive Committee to consist of one or more members of the Board
of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and
affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (i)&nbsp;approving or adopting, or recommending to
the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&nbsp;adopting, amending or repealing any Bylaw of the corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Other Committees.</B> The Board of Directors may, from time to time, appoint such other committees as may be permitted by law.
Such other committees appointed by the Board of Directors shall consist of one or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such
committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Term.</B> The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of subsections&nbsp;(a) or (b)&nbsp;of this Section&nbsp;25, may at any time increase or decrease the number of members
of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any
time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate
one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members
thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified
member. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Meetings.</B> Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or
any other committee appointed pursuant to this Section&nbsp;25 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no
further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by any director<B> </B>who is a member
of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings of the
Board of Directors. Notice of any special meeting of any committee may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.
Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the
act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;26.</B> <B>Duties of Chairman of the Board of Directors.</B> The Chairman of the Board of Directors, when
present, shall preside at all meetings of the stockholders and the Board of Directors. The Chairman of the Board of Directors shall perform other duties commonly incident to the office and shall also perform such other duties and have such other
powers, as the Board of Directors shall designate from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;27. Lead Independent Director.</B> The Chairman of
the Board of Directors, or if the Chairman is not an independent director, one of the independent directors, may be designated by the Board of Directors as lead independent director (&#147;<B><I>Lead Independent Director</I></B>&#148;) to serve
until replaced by the Board of Directors. The Lead Independent Director will: with the Chairman of the Board of Directors, establish the agenda for regular Board meetings and serve as chairman of Board of Directors meetings in the absence of the
Chairman of the Board of Directors; establish the agenda for meetings of the independent directors; coordinate with the committee chairs regarding meeting agendas and informational requirements; preside over meetings of the independent directors;
preside over any portions of meetings of the Board of Directors at which the evaluation or compensation of the Chief Executive Officer is presented or discussed; preside over any portions of meetings of the Board of Directors at which the
performance of the Board of Directors is presented or discussed; and perform such other duties as may be established or delegated by the Chairman of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;28.</B> <B>Organization.</B> At every meeting of the directors, the Chairman of the Board of Directors, or, if a
Chairman has not been appointed or is absent, the Lead Independent Director, or if the Lead Independent Director is absent, the Chief Executive Officer (if a director), or, if a Chief Executive Officer is absent, the President (if a director), or if
the President is absent, the most senior Vice President (if a director), or, in the absence of any such person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his
absence, any Assistant Secretary or other officer or director directed to do so by the Chairman, shall act as secretary of the meeting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;29.</B> <B>Officers Designated.</B> The officers of the corporation shall include, if and when
designated by the Board of Directors, the Chairman of the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors may also
appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as
it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or
in the manner designated by the Board of Directors. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;30. Tenure and Duties of Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>General.</B> All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been
duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled
by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Duties of Chief Executive Officer.</B> The Chief Executive Officer shall preside at all meetings
of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors or the Lead Independent Director has been appointed and is present. Unless an officer has been appointed Chief Executive Officer of the
corporation, the President shall be the Chief Executive Officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation. To the
extent that a Chief Executive Officer has been appointed and no President has been appointed, all references in these Bylaws to the President shall be deemed references to the Chief Executive Officer. <B></B>The Chief Executive Officer shall perform
other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Duties of President.</B> The President shall preside at all meetings of the stockholders and at all meetings of the Board of
Directors, unless the Chairman of the Board of Directors, the Lead Independent Director, or the Chief Executive Officer has been appointed and is present. Unless another officer has been appointed Chief Executive Officer of the corporation, the
President shall be the Chief Executive Officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation.<B> </B>The President
shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Duties of Vice Presidents.</B> The Vice Presidents may assume and perform the duties of the President in the absence or
disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors
or the Chief Executive Officer, or, if the Chief Executive Officer has not been appointed or is absent, the President shall designate from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Duties of Secretary.</B> The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall
record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee
thereof requiring notice. The Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall also perform such other </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
duties and have such other powers, as the Board of Directors shall designate from time to time. The President may direct any Assistant Secretary or other officer to assume and perform the duties
of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or
the President shall designate from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Duties of Chief Financial Officer.</B> The Chief Financial Officer shall
keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the
President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to the office and
shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all
references in these Bylaws to the Treasurer shall be deemed references to the Chief Financial Officer. <B></B>The President may direct the Treasurer, if any, or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and
perform the duties of the Chief Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties commonly incident to
the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Duties of Treasurer.</B> Unless another officer has been appointed Chief Financial Officer of the corporation, the Treasurer
shall be the chief financial officer of the corporation and shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form
and as often as required by the Board of Directors or the President, and, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation.<B> </B>The Treasurer shall perform other duties commonly
incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;31.</B> <B>Delegation of Authority.</B> The Board of Directors may from time to time delegate the powers or
duties of any officer to any other officer or agent, notwithstanding any provision hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;32.</B>
<B>Resignations.</B> Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person
or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not
be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;33.</B> <B>Removal.</B> Any officer may be removed from office at
any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or by the Chief Executive Officer
or by other superior officers upon whom such power of removal may have been conferred by the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OWNED BY THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;34.</B> <B>Execution of Corporate Instruments.</B> The Board of Directors may, in its discretion, determine the
method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without limitation, or to
enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation
shall be signed by such person or persons as the Board of Directors shall authorize so to do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless authorized or ratified by the Board
of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any
amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;35.</B> <B>Voting of Securities Owned by the Corporation.</B> All stock and other securities of
other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors,
or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer, the President, or any Vice President. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES OF
STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;36.</B> <B>Form and Execution of Certificates.</B> The shares of the corporation shall be
represented by certificates, or shall be uncertificated if so provided by resolution or resolutions of the Board of Directors. Certificates for the shares of stock of the corporation, if any, shall be in such form<B> </B>as is consistent with the
Certificate of Incorporation and applicable law. Every holder of stock represented by certificate<B> </B>in the corporation shall be entitled to have a certificate signed by or in the name of the corporation by the Chairman of the Board of
Directors, the Chief Executive Officer, or the President or any Vice President and by the Chief Financial Officer, Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the
corporation. Any or all of the signatures on the certificate </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer
agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;37.</B> <B>Lost Certificates.</B> A new certificate or certificates shall be issued in place of any certificate
or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. The corporation may
require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner&#146;s legal representative, to agree to indemnify the corporation in such
manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost, stolen,
or destroyed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;38. Transfers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Transfers of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by
attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes
of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;39. Fixing Record Dates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any
adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable
law, not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be
at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled
to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however,</I> that the Board of Directors may fix a new record date for the adjourned meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or
allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action.
If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;40.</B> <B>Registered Stockholders.</B> The corporation shall be entitled to recognize the exclusive right of a
person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or
not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER SECURITIES OF THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;41.</B> <B>Execution of Other Securities.</B> All bonds, debentures and other corporate securities of the
corporation, other than stock certificates (covered in Section&nbsp;36 of these Bylaws), may be signed by the Chairman of the Board of Directors, the Chief Executive Officer, the President or any Vice President, or such other person as may be
authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an
Assistant Treasurer; <I>provided, however,</I> that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to
which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of
such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may
be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall
appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless
may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;42.</B> <B>Declaration of Dividends.</B> Dividends upon the capital stock of the corporation, subject
to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital
stock, subject to the provisions of the Certificate of Incorporation and applicable law. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;43.</B> <B>Dividend Reserve.</B> Before payment of any dividend,
there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for
equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or abolish
any such reserve in the manner in which it was created. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FISCAL YEAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;44.</B> <B>Fiscal Year.</B> The fiscal year of the corporation shall be fixed by resolution of the Board of
Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;45. Indemnification of Directors, Officers, Employees and Other Agents. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Directors</B><B> </B><B>and Officers</B><B>.</B><B> </B>The corporation shall indemnify its directors and officers to the extent
not prohibited by the DGCL or any other applicable law; <I>provided, however,</I> that the corporation may modify the extent of such indemnification by individual contracts with its directors and officers; and, <I>provided, further,</I> that the
corporation shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless (i)&nbsp;such indemnification is expressly required to be made by law, (ii)&nbsp;the
proceeding was authorized by the Board of Directors of the corporation, (iii)&nbsp;such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the DGCL or any other applicable
law or (iv)&nbsp;such indemnification is required to be made under subsection (d). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Employees and Other Agents.</B> The
corporation shall have power to indemnify its employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any
such person (except for officers) or other persons as the Board of Directors shall determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Expenses.</B> The corporation
shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or
was a director or officer, of the corporation, or is or was serving at the request of the corporation as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the
proceeding, promptly following request therefor, all expenses incurred by any director or officer<B> </B>in connection with such proceeding provided, however, that if the DGCL requires, an advancement of expenses incurred by a director or officer in
his or her capacity as a director or officer<B> </B>(and not in any other capacity in </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking
(hereinafter an &#147;<B><I>undertaking</I></B>&#148;), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter
a &#147;<B><I>final adjudication</I></B>&#148;) that such indemnitee is not entitled to be indemnified for such expenses under this Section&nbsp;45 or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph&nbsp;(e) of this Section&nbsp;45, no advance shall be made by
the corporation to an officer of the corporation (except by reason of the fact that such officer is or was a director of the corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal,
administrative or investigative, if a determination is reasonably and promptly made (i)&nbsp;by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii)&nbsp;by a committee of such directors designated by a
majority vote of such directors, even though less than a quorum, or (iii)&nbsp;if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the
time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Enforcement. </B>Without the necessity of entering into an express contract, all rights to indemnification and advances to
directors and officers under this Section&nbsp;45 shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the corporation and the director or officer. Any right to indemnification or
advances granted by this Section&nbsp;45 to a director or officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i)&nbsp;the claim for indemnification or advances is denied, in whole
or in part, or (ii)&nbsp;no disposition of such claim is made within 90 days of request therefor. To the extent permitted by law, the claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the
expense of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the
DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. In connection with any claim by an officer of the corporation (except in any action, suit or proceeding, whether civil, criminal, administrative
or investigative, by reason of the fact that such officer is or was a director of the corporation) for advances, the corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad
faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct
was lawful. Neither the failure of the corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper
in the circumstances because the director or officer has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal
counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a director
or </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officer to enforce a right to indemnification or to an advancement of expenses hereunder, the burden of proving that the director or officer is not entitled to be indemnified, or to such
advancement of expenses, under this Section&nbsp;45 or otherwise shall be on the corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>
<B><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights. </B>The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute,
provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#146;s official capacity and as to action in another capacity while holding office. The
corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other
applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Survival of Rights. </B>The rights conferred on any person by this Bylaw shall continue as to a person who
has ceased to be a director or officer, or, if applicable, employee or other agent,<B> </B>and shall inure to the benefit of the heirs, executors and administrators of such a person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Insurance. </B>To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon approval by the
Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Section&nbsp;45. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Amendments. </B>Any repeal or modification of this Section&nbsp;45 shall only be prospective and shall not affect the rights
under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Saving Clause. </B>If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction,
then the corporation shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion of this Section&nbsp;45 that shall not have been invalidated, or by any other applicable law. If this
Section&nbsp;45 shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and officer<B> </B>to the full extent under any other applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Certain Definitions. </B>For the purposes of this Bylaw, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The term &#147;<B><I>proceeding</I></B>&#148; shall be broadly construed and shall include, without limitation, the investigation,
preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The term &#147;<B><I>expenses</I></B>&#148; shall be broadly construed and shall include, without limitation, court costs,
attorneys&#146; fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> The term the &#147;<B><I>corporation</I></B>&#148; shall include, in addition to
the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors,
officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Section&nbsp;45 with respect to the resulting or surviving corporation as he would have with respect to such
constituent corporation if its separate existence had continued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> References to a &#147;<B><I>director</I></B>,&#148;
&#147;<B><I>officer</I></B>,&#148; &#147;<B><I>employee</I></B>,&#148; or &#147;<B><I>agent</I></B>&#148; of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as,
respectively, a director, officer, employee, trustee or agent of another corporation, partnership, joint venture, trust or other enterprise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> References to &#147;<B><I>other enterprises</I></B>&#148; shall include employee benefit plans; references to &#147;fines&#148;
shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &#147;<B><I>serving at the request of the corporation</I></B>&#148; shall include any service as a director, officer, employee or agent
of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner such
person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#147;<B><I>not opposed to the best interests of the corporation</I></B>&#148; as referred
to in this Section&nbsp;45. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;46. Notices. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notice to Stockholders. </B>Written notice to stockholders of stockholder meetings shall be given as provided in Section&nbsp;7
of these Bylaws. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by law, written notice to stockholders for
purposes other than stockholder meetings may be sent by U.S. mail or nationally recognized overnight courier, or by facsimile, telegraph or telex or by electronic mail or other electronic means. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Notice to Directors. </B>Any notice required to be given to any director may be given by the method stated in
subsection&nbsp;(a), as otherwise provided in these Bylaws, or by overnight delivery service, facsimile, telex or telegram, except that such notice other than one which is delivered personally shall be sent to such address as such director shall
have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Affidavit of Mailing. </B>An affidavit of mailing, executed by a duly authorized
and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or
directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Methods of Notice. </B>It shall not be necessary that the same method of giving notice be employed in respect of all recipients
of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Notice to Person With Whom Communication is Unlawful. </B>Whenever notice is required to be given, under any provision of law or
of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or
agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had
been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was
given to all persons entitled to receive notice except such persons with whom communication is unlawful. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Notice to
Stockholders Sharing an Address. </B>Except as otherwise prohibited under the DGCL, any notice given under the provisions of the DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to
stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the corporation within 60
days of having been given notice by the corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;47.</B> <B>Amendments.</B> Subject to the limitations set forth in Section&nbsp;45(h) of these Bylaws or the
provisions of the Certificate of Incorporation, the Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. Any adoption, amendment or repeal of the Bylaws of the corporation by the Board of Directors shall
require the approval of a majority of the authorized number of directors. The stockholders also shall have power to adopt, amend or repeal the Bylaws of the corporation; <I>provided, however, </I>that, in addition to any vote of the holders of any
class or series of stock of the corporation required by law or by the Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding
shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOANS TO OFFICERS OR EMPLOYEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;48.</B> <B>Loans to Officers or Employees.</B> Except as otherwise prohibited by applicable law, the corporation
may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a director of the corporation or its subsidiaries, whenever, in
the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner
as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the corporation at
common law or under any statute. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;49.</B> <B>Forum.</B> Unless the corporation consents in writing to the selection of an alternative forum, the
Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the corporation; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any
director, officer or other employee of the corporation to the corporation or the corporation&#146;s stockholders; (iii)&nbsp;any action asserting a claim against the corporation or any director or officer or other employee of the corporation arising
pursuant to any provision of the DGCL, the certificate of incorporation or the Bylaws of the corporation; or (iv)&nbsp;any action asserting a claim against the corporation or any director or officer or other employee of the corporation governed by
the internal affairs doctrine. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>d582934dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> I<SMALL>NDEMNITY</SMALL> A<SMALL>GREEMENT</SMALL> </B>(this &#147;<B><I>Agreement</I></B>&#148;) dated as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, is made by and between
<B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>., </B>a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B>(&#147;<B><I>Indemnitee</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> The Company&#146;s Amended and Restated Bylaws (the &#147;<B><I>Bylaws</I></B>&#148;) require that the Company indemnify its
directors and officers, and empowers the Company to indemnify its<B> </B>employees and other agents, as authorized by the Delaware General Corporation Law, as amended (the &#147;<B><I>Code</I></B>&#148;), under which the Company is organized and
such Bylaws expressly provide that the indemnification provided therein is not exclusive and contemplates that the Company may enter into separate agreements with its directors, officers and other persons to set forth specific indemnification
provisions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Indemnitee does not regard the protection currently provided by applicable law, the Bylaws, the Company&#146;s other
governing documents, and available insurance as adequate under the present circumstances, and the Company has determined that Indemnitee and other directors, officers, employees and agents of the Company may not be willing to serve or continue to
serve in such capacities without additional protection. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D.</B> The Company desires and has requested Indemnitee to serve or continue to
serve as a director, officer, employee or agent of the Company, as the case may be, and has proffered this Agreement to Indemnitee as an additional inducement to serve in such capacity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E.</B> Indemnitee is willing to serve, or to continue to serve, as a director, officer, employee or agent of the Company, as the case may
be, if Indemnitee is furnished the indemnity provided for herein by the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL> T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the mutual covenants and agreements set forth herein,
the parties hereto, intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Definitions</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Agent</B>. For purposes of this Agreement, the term &#147;<B><I>Agent</I></B>&#148; of the Company means any person who:
(i)&nbsp;is or was a director<B>, </B>officer, employee, agent, or other fiduciary of the Company or a subsidiary of the Company; or (ii)&nbsp;is or was serving at the request or for the convenience of, or representing the interests of, the Company
or a subsidiary of the Company, as a director, officer, employee, agent, or other fiduciary of a foreign or domestic corporation, partnership, joint venture, trust or other enterprise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Change in Control</B>. For purposes of this Agreement, a &#147;<B><I>Change in
Control</I></B>&#148; shall be deemed to have occurred if (i)&nbsp;any &#147;person&#148; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;), other than a
trustee or other fiduciary holding securities under an employee benefit plan of the Company or a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the
Company, is or becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, of securities of the Company representing 20% or more of the total voting
power represented by the Company&#146;s then outstanding Voting Securities, (ii)&nbsp;individuals who on the date of this Agreement are members of the Board (the &#147;<B><I>Incumbent Board</I></B>&#148;) cease for any reason to constitute at least
a majority of the members of the Board (<I>provided, however,</I> that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then
still in office, such new member shall be considered as a member of the Incumbent Board), or (iii)&nbsp;the stockholders of the Company approve a merger or consolidation of the Company with any other corporation, other than a merger or consolidation
which would result in the Voting Securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the surviving entity) at least 80% of the total
voting power represented by the Voting Securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of complete liquidation of the Company or an
agreement for the sale or disposition by the Company of (in one transaction or a series of transactions) all or substantially all of the Company&#146;s assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Expenses</B>. For purposes of this Agreement, the term &#147;<B><I>Expenses</I></B>&#148; shall be broadly construed and shall
include, without limitation, all direct and indirect costs of any type or nature whatsoever (including, without limitation, all attorneys&#146;, witness, or other professional fees and related disbursements, and other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of whatever nature, actually and reasonably incurred by Indemnitee in connection with the investigation, defense or appeal of a proceeding or
establishing or enforcing a right to indemnification under this Agreement, the Code or otherwise. The term &#147;<B><I>Expenses</I></B>&#148; shall also include reasonable compensation for time spent by Indemnitee for which he or she is not
compensated by the Company or any subsidiary or third party: (i)&nbsp;for any period during which Indemnitee is not an Agent, in the employment of, or providing services for compensation to, the Company or any subsidiary; and (ii)&nbsp;if the rate
of compensation and estimated time involved is approved by the directors of the Company who are not parties to any action with respect to which Expenses are incurred, for Indemnitee while an Agent of, employed by, or providing services for
compensation to, the Company or any subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Independent Counsel</B>. For purposes of this Agreement, the term
&#147;<B><I>Independent Counsel</I></B>&#148; means a law firm, or a partner (or, if applicable, member) of such a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5)<B></B>&nbsp;years has
been, retained to represent: (i)&nbsp;the Company or Indemnitee in any matter material to either such party, or (ii)&nbsp;any other party to the proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term
&#147;<B><I>Independent Counsel</I></B>&#148; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action
to determine Indemnitee&#146;s rights under this Agreement. The Company will pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and
damages arising out of or relating to this Agreement or its engagement pursuant hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Liabilities</B>. For purposes of this Agreement, the term
&#147;<B><I>Liabilities</I></B>&#148; shall be broadly construed and shall include, without limitation, judgments, damages, deficiencies, liabilities, losses, penalties, excise taxes, fines, assessments and amounts paid in settlement, including any
interest and any federal, state, local or foreign taxes imposed as a result of the actual or deemed receipt of any payment under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Proceedings</B>. For purposes of this Agreement, the term &#147;<B><I>proceeding</I></B>&#148; shall be broadly construed and
shall include, without limitation, any threatened, pending, or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing, or any other
actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature, and whether formal or informal in any case, in which Indemnitee was, is or
will be involved as a party, potential party, <FONT STYLE="white-space:nowrap">non-party</FONT> witness, or otherwise by reason of: (i)&nbsp;the fact that Indemnitee is or was a director or officer of the Company; (ii)&nbsp;the fact that any action
taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee&#146;s part while acting as an Agent; or (iii)&nbsp;the fact that Indemnitee is or was serving at the request of the Company as a
director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan, or other enterprise, and in any such case described above, whether or not serving in any such capacity at the time any liability
or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses may be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a
proceeding, this shall be considered a proceeding under this paragraph. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Subsidiary</B>. For purposes of this Agreement, the
term &#147;<B><I>subsidiary</I></B>&#148; means any corporation, limited liability company, or other entity, of which more than 50% of the outstanding voting securities or equity interests are owned, directly or indirectly, by the Company and one or
more of its subsidiaries, and any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as an Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Voting Securities</B>. For purposes of this Agreement, &#147;<B><I>Voting Securities</I></B>&#148; shall mean any securities of
the Company that vote generally in the election of directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Agreement to Serve</B>. Indemnitee will serve, or continue to
serve, as the case may be, as an Agent, faithfully and to the best of his or her ability, at the will of such entity designated by the Company and at the request of the Company (or under separate agreement, if such agreement exists), in the capacity
Indemnitee currently serves such entity, so long as Indemnitee is duly appointed or elected and qualified in accordance with the applicable provisions of the governance documents of such entity, or until such time as Indemnitee tenders his or her
resignation in writing; provided, however, that nothing contained in this Agreement is intended as an employment agreement between Indemnitee and the Company or any of its subsidiaries or to create any right to continued employment of Indemnitee
with the Company or any of its subsidiaries in any capacity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that it has entered into this Agreement and assumes the obligations
imposed on it hereby, in addition to and separate from its obligations to Indemnitee under the Bylaws, to induce Indemnitee to serve, or continue to serve, as an Agent, and the Company acknowledges that Indemnitee is relying upon this Agreement in
serving as an Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>Indemnification</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Indemnification in Third Party Proceedings</B>. Subject to Section&nbsp;10 below, the Company shall indemnify Indemnitee to the
fullest extent permitted by the Code, as the same may be amended from time to time (but, to the fullest extent of the law, only to the extent that such amendment permits Indemnitee to broader indemnification rights than the Code permitted prior to
adoption of such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any proceeding, other than a proceeding by or in the right of the Company to procure a judgment in its favor, for any and all
Expenses and Liabilities (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses and Liabilities) incurred by Indemnitee in connection with the investigation, defense, settlement or
appeal of such proceeding,<B> </B>if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding had no reasonable cause to
believe that Indemnitee&#146;s conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without
limitation, any indemnification provided by the Certificate of Incorporation of the Company, the Bylaws, vote of its stockholders or disinterested directors, or applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Indemnification in Derivative Actions and Direct Actions by the Company</B>. Subject to Section&nbsp;10 below, the Company shall
indemnify Indemnitee to the fullest extent permitted by the Code, as the same may be amended from time to time (but, fullest extent permitted by applicable law, only to the extent that such amendment permits Indemnitee to broader indemnification
rights than the Code permitted prior to adoption of such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any proceeding by or in the right of the Company to procure a judgment in its favor,
against any and all Expenses actually and reasonably incurred by Indemnitee in connection with the investigation, defense, settlement, or appeal of such proceedings, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to
be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section&nbsp;3(b) in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court
competent jurisdiction to be liable to the Company, unless and only to the extent that the Chancery Court of the State of Delaware or any court in which the proceeding was brought shall determine upon application that, despite the adjudication of
liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>
<B>Indemnification of Expenses of Successful Party</B>. Notwithstanding any other provision of this Agreement, in circumstances where indemnification is not available under Section&nbsp;3(a) or 3(b), as the case may be, to the fullest extent
permitted by law and to the extent that Indemnitee is a party to (or a participant in) any proceeding and has been successful on the merits or otherwise in defense of any proceeding or in defense of any claim, issue or matter therein,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in whole or part, including the dismissal of any action without prejudice, the Company shall indemnify Indemnitee against all Expenses and Liabilities in connection with the investigation,
defense or appeal of such proceeding. If Indemnitee is not wholly successful in such proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such proceeding, the Company shall
indemnify Indemnitee against all Expenses and Liabilities incurred by Indemnitee or on Indemnitee&#146;s behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Partial Indemnification; Witness Indemnification</B>. If Indemnitee is entitled under any provision of this Agreement to
indemnification by the Company for some or a portion of any Expenses and Liabilities incurred by Indemnitee in the investigation, defense, settlement or appeal of a proceeding, but is precluded by applicable law or the specific terms of this
Agreement to indemnification for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. Notwithstanding any other provision of this Agreement, to the fullest extent
permitted by applicable law and to the extent that Indemnitee is, by reason of Indemnitee&#146;s acting as an Agent, a witness or otherwise asked to participate in any proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified
against all Expenses incurred by Indemnitee or on Indemnitee&#146;s behalf in connection therewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Advancement of
Expenses</B>. To the extent not prohibited by law, the Company shall advance the Expenses incurred by Indemnitee in connection with any proceeding, and such advancement shall be made within twenty (20)&nbsp;days after the receipt by the Company of a
statement or statements requesting such advances (which shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to
expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice) and upon request of the Company, an undertaking to repay the advancement of Expenses if and to the extent that it
is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. Advances shall be unsecured, interest free and without regard to
Indemnitee&#146;s ability to repay the Expenses. Advances shall include any and all Expenses incurred by Indemnitee pursuing an action to enforce Indemnitee&#146;s right to indemnification under this Agreement or otherwise and this right of
advancement, including expenses incurred preparing and forwarding statements to the Company to support the advances claimed. Indemnitee acknowledges that the execution and delivery of this Agreement shall constitute an undertaking providing that
Indemnitee shall, to the fullest extent required by law, repay the advance (without interest) if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is
not entitled to be indemnified by the Company. The right to advances under this Section shall continue until final disposition of any proceeding, including any appeal therein. This Section&nbsp;6 shall not apply to any claim made by Indemnitee for
which indemnity is excluded pursuant to Section&nbsp;10(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Notice and Other Indemnification Procedures</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notification of Proceeding</B>. Indemnitee will notify the Company in writing promptly upon being served with any summons,
citation, subpoena, complaint, indictment, information or other document relating to any proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The written notification to the Company shall include
a description of the nature of the proceeding and the facts underlying the proceeding. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or
otherwise and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Request for Indemnification Payments</B>. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company
a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification under the
terms of this Agreement, and shall request payment thereof by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Determination of Right to Indemnification
Payments</B>. Upon written request by Indemnitee for indemnification pursuant to the Section&nbsp;7(b) hereof, a determination with respect to Indemnitee&#146;s entitlement thereto shall be made in the specific case by one of the following four
methods, which shall be at the election of the Board of Directors: (1)&nbsp;by a majority vote of the disinterested directors, even though less than a quorum, (2)&nbsp;by a committee of disinterested directors designated by a majority vote of the
disinterested directors, even though less than a quorum, (3)&nbsp;if there are no disinterested directors or if the disinterested directors so direct, by Independent Counsel in a written opinion to the Board of Directors, a copy of which shall be
delivered to the Indemnitee, or (4)&nbsp;if so directed by the Board of Directors, by the stockholders of the Company; <I>provided, however</I>, that if there has been a Change in Control, then such determination shall be made by Independent Counsel
selected by Indemnitee and approved by the Company (which approval shall not be unreasonably withheld). For purposes hereof, disinterested directors are those members of the board of directors of the Company who are not parties to the action, suit
or proceeding in respect of which indemnification is sought by Indemnitee. Indemnification payments requested by Indemnitee under Section&nbsp;3 hereof shall be made by the Company no later than sixty (60)&nbsp;days after receipt of the written
request of Indemnitee. Claims for advancement of Expenses shall be made under the provisions of Section&nbsp;6 herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
<B>Application for Enforcement</B>. In the event the Company fails to make timely payments as set forth in Sections 6 or 7(b) above, Indemnitee shall have the right to apply to any court of competent jurisdiction for the purpose of enforcing
Indemnitee&#146;s right to indemnification or advancement of Expenses pursuant to this Agreement. In such an enforcement hearing or proceeding, the burden of proof shall be on the Company to prove that indemnification or advancement of Expenses to
Indemnitee is not required under this Agreement or permitted by applicable law. Any determination by the Company (including its Board of Directors, a committee thereof, Independent Counsel) or stockholders of the Company, that Indemnitee is not
entitled to indemnification hereunder, shall not be a defense by the Company to the action nor create any presumption that Indemnitee is not entitled to indemnification or advancement of Expenses hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Indemnification of Certain Expenses</B>. The Company shall indemnify Indemnitee
against all Expenses incurred in connection with any hearing or proceeding under this Section&nbsp;7 unless the Company prevails in such hearing or proceeding on the merits in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>Assumption of Defense</B>. In the event the Company shall be requested by Indemnitee to pay the Expenses of any proceeding, the
Company, if appropriate, shall be entitled to assume the defense of such proceeding, or to participate to the extent permissible in such proceeding, with counsel reasonably acceptable to Indemnitee. Upon assumption of the defense by the Company and
the retention of such counsel by the Company, the Company shall not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that Indemnitee shall have the
right to employ separate counsel in such proceeding at Indemnitee&#146;s sole cost and expense. Notwithstanding the foregoing, if Indemnitee&#146;s counsel delivers a written notice to the Company stating that such counsel has reasonably concluded
that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense or the Company shall not, in fact, have employed counsel or otherwise actively pursued the defense of such proceeding within a reasonable
time, then in any such event the fees and Expenses of Indemnitee&#146;s counsel to defend such proceeding shall be subject to the indemnification and advancement of Expenses provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Insurance. To the extent that the Company maintains an insurance policy or policies providing liability insurance for Agents
(&#147;</B><B><I>D&amp;O Insurance</I></B><B>&#148;), Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such Agent under such policy or policies</B>.
If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has D&amp;O Insurance in effect or otherwise potentially available, the Company shall give prompt notice of the commencement of such proceeding to the
insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such
proceeding in accordance with the terms of such policies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>Exceptions</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Certain Matters</B>. Any provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the
terms of this Agreement to indemnify Indemnitee on account of any proceeding with respect to: (i)&nbsp;remuneration paid to Indemnitee if it is determined by final judgment or other final adjudication that such remuneration was in violation of law
(and, in this respect, both the Company and Indemnitee have been advised that the Securities and Exchange Commission believes that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore,
unenforceable and that claims for indemnification should be submitted to appropriate courts for adjudication, as indicated in Section&nbsp;10(d) below); (ii)&nbsp;a final judgment rendered against Indemnitee for an accounting, disgorgement or
repayment of profits made from the purchase or sale by Indemnitee of securities of the Company against Indemnitee or in connection with a settlement by or on behalf of Indemnitee to the extent it is acknowledged by Indemnitee and the Company that
such amount paid in settlement resulted from Indemnitee&#146;s conduct from which Indemnitee received monetary personal profit, pursuant to the provisions of Section&nbsp;16(b) of the Exchange Act or other provisions of any federal, state or local
statute or rules and regulations thereunder; (iii)&nbsp;a final judgment or other final adjudication </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that Indemnitee&#146;s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct (but only to the extent of such specific determination); or
(iv)&nbsp;on account of conduct that is established by a final judgment as constituting a breach of Indemnitee&#146;s duty of loyalty to the Company or resulting in any personal profit or advantage to which Indemnitee is not legally entitled. For
purposes of the foregoing sentence, a final judgment or other adjudication may be reached in either the underlying proceeding or action in connection with which indemnification is sought or a separate proceeding or action to establish rights and
liabilities under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Claims Initiated by Indemnitee</B>. Any provision herein to the contrary notwithstanding,
the Company shall not be obligated to indemnify or advance Expenses to Indemnitee with respect to proceedings or claims initiated or brought by Indemnitee against the Company or its Agents and not by way of defense, except (i)&nbsp;with respect to
proceedings brought to establish or enforce a right to indemnification or advancement under this Agreement or under any other agreement, provision in the Bylaws or the Certificate of Incorporation or applicable law, or (ii)&nbsp;with respect to any
other proceeding initiated by Indemnitee that is either approved by the Board of Directors or Indemnitee&#146;s participation is required by applicable law. However, indemnification or advancement of Expenses may be provided by the Company in
specific cases if the Board of Directors determines it to be appropriate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Unauthorized Settlements</B>. Any provision herein
to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee under this Agreement for any amounts paid in settlement of a proceeding effected without the Company&#146;s written
consent. Neither the Company nor Indemnitee shall unreasonably withhold consent to any proposed settlement; provided, however, that the Company may in any event decline to consent to (or to otherwise admit or agree to any liability for
indemnification hereunder in respect of) any proposed settlement if the Company is also a party in such proceeding and determines in good faith that such settlement is not in the best interests of the Company and its stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Securities Act Liabilities</B>. Any provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant
to the terms of this Agreement to indemnify Indemnitee or otherwise act in violation of any undertaking appearing in and required by the rules and regulations promulgated under the Securities Act of 1933, as amended (the
&#147;<B><I>Securities</I></B> <B><I>Act</I></B>&#148;), or in any registration statement filed with the SEC under the Securities Act. Indemnitee acknowledges that paragraph (h)&nbsp;of Item 512 of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> currently generally requires the Company to undertake in connection with any registration statement filed under the Securities Act to submit the issue of the enforceability of Indemnitee&#146;s rights
under this Agreement in connection with any liability under the Securities Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any final adjudication of such issue. Indemnitee specifically agrees that any such
undertaking shall supersede the provisions of this Agreement and to be bound by any such undertaking. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Prior Payments </B>Any provision herein to the contrary notwithstanding, the
Company shall not be obligated pursuant to the terms of this Agreement to indemnify or advance Expenses to Indemnitee under this Agreement for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other
indemnity provision, expect with respect to any excess beyond the amount paid under any insurance policy or indemnity policy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B>
<B>Nonexclusivity and Survival of Rights</B>. The provisions for indemnification and advancement of Expenses set forth in this Agreement shall not be deemed exclusive of any other rights which Indemnitee may at any time be entitled under any
provision of applicable law, the Company&#146;s Certificate of Incorporation, the Bylaws or other agreements, both as to action in Indemnitee&#146;s official capacity and Indemnitee&#146;s action as an Agent, in any court in which a proceeding is
brought, and Indemnitee&#146;s rights hereunder shall continue after Indemnitee has ceased acting as an Agent and shall inure to the benefit of the heirs, executors, administrators and assigns of Indemnitee. The obligations and duties of the Company
to Indemnitee under this Agreement shall be binding on the Company and its successors and assigns until terminated in accordance with its terms. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation
or otherwise) to all or substantially all of the business or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession
had taken place. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of
Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her corporate status prior to such amendment, alteration or repeal. To the extent that a change in the Code, whether by statute or judicial
decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company&#146;s Certificate of Incorporation, the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall
enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every
other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, by Indemnitee shall not prevent the concurrent assertion or employment
of any other right or remedy by Indemnitee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Term</B>. This Agreement shall continue until and terminate upon the later of:
(a)&nbsp;five (5) years after the date that Indemnitee shall have ceased to serve as an Agent; or (b)&nbsp;one (1) year after the final termination of any proceeding, including any appeal then pending, in respect to which Indemnitee was granted
rights of indemnification or advancement of Expenses hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No legal action shall be brought and no cause of action shall be asserted
by or in the right of the Company against an Indemnitee or an Indemnitee&#146;s estate, spouse, heirs, executors or personal or legal representatives after the expiration of five (5)&nbsp;years from the date of accrual of such cause of action, and
any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such five-year period; provided, however, that if any shorter period of limitations is otherwise
applicable to such cause of action, such shorter period shall govern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Subrogation</B>. In the event of payment under this Agreement, the Company shall be
subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who, at the request and expense of the Company, shall execute all papers required and shall do everything that may be reasonably necessary to secure such
rights, including the execution of such documents necessary to enable the Company effectively to bring suit to enforce such rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Interpretation of Agreement</B>. It is understood that the parties hereto intend this Agreement to be interpreted and enforced so
as to provide indemnification and advancement of Expenses to Indemnitee to the fullest extent now or hereafter permitted by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Severability</B>. If any provision of this Agreement shall be held to be invalid, illegal or unenforceable for any reason
whatsoever, (a)&nbsp;the validity, legality and enforceability of the remaining provisions of the Agreement (including without limitation, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal or
unenforceable, that are not themselves invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b)&nbsp;to the fullest extent possible, the provisions of this Agreement (including, without limitation, all
portions of any paragraph of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by
the provision held invalid, illegal or unenforceable and to give effect to Section&nbsp;14 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Amendment and Waiver</B>.
No supplement, modification, amendment, or cancellation of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any
other provision hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Notice</B>. Except as
otherwise provided herein, any notice or demand which, by the provisions hereof, is required or which may be given to or served upon the parties hereto shall be in writing and, if by electronic transmission, shall be deemed to have been validly
served, given or delivered when sent, if by overnight delivery, courier or personal delivery, shall be deemed to have been validly served, given or delivered upon actual delivery and, if mailed, shall be deemed to have been validly served, given or
delivered three (3)&nbsp;business days after deposit in the United States mail, as registered or certified mail, with proper postage prepaid and addressed to the party or parties to be notified at the addresses set forth on the signature page of
this Agreement (or such other address(es) as a party may designate for itself by like notice). If to the Company, notices and demands shall be delivered to the attention of the Secretary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Governing Law</B>. This Agreement shall be governed exclusively by and construed according to the laws of the State of Delaware,
as applied to contracts between Delaware residents entered into and to be performed entirely within Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B>
<B>Counterparts</B>. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute but one and the same Agreement. Only one such counterpart
need be produced to evidence the existence of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Headings</B>. The headings of the sections of this Agreement
are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B>Entire Agreement</B>. Subject to Section&nbsp;11 hereof, this Agreement constitutes
the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings and negotiations, written and oral, between the parties with respect to the subject matter of this Agreement;
provided, however, that this Agreement is a supplement to and in furtherance of the Company&#146;s Certificate of Incorporation, the Bylaws, the Code and any other applicable law, and shall not be deemed a substitute therefor, and does not diminish
or abrogate any rights&nbsp;of&nbsp;Indemnitee&nbsp;thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Contribution</B>. To the fullest extent permissible under
applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for
judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in
light of all of the circumstances of such proceeding in order to reflect (i)&nbsp;the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such proceeding; and/or (ii)&nbsp;the
relative fault of the Company and Indemnitee in connection with such event(s) and/or transaction(s). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B>Consent to
Jurisdiction</B>. The Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware
(the &#147;<B><I>Delaware Court</I></B>&#148;), and not in any other state or federal court in the United States of America or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court for
purposes of any action or proceeding arising out of or in connection with this Agreement, (iii)&nbsp;agree to appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, an agent in the State of
Delaware as such party&#146;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware,
(iv)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v)&nbsp;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been
brought in an improper or inconvenient forum. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have entered into this Agreement effective as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>EQUILLIUM, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>INDEMNITEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Signature of Indemnitee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Print or Type Name of Indemnitee</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>7
<FILENAME>d582934dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017
EQUITY INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADOPTED BY THE BOARD OF DIRECTORS: December&nbsp;11, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVED BY THE STOCKHOLDERS: December&nbsp;21, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION DATE: December&nbsp;10, 2027 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. G<SMALL>ENERAL</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Eligible Stock Award Recipients</B>. Employees, Directors and Consultants are eligible to<B> </B>receive Stock
Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Available Stock Awards</B>. The Plan provides for the grant of the following types of Stock Awards:
(i)&nbsp;Incentive Stock Options, (ii)&nbsp;Nonstatutory Stock Options, (iii)&nbsp;Stock Appreciation Rights, (iv)&nbsp;Restricted Stock Awards, (v)&nbsp;Restricted Stock Unit Awards and (vi)&nbsp;Other Stock Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Purpose</B>. The Plan, through the grant of Stock Awards, is intended to help the Company<B> </B>secure and
retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value
of the Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. A<SMALL>DMINISTRATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Administration by the Board</B>. The Board will administer the Plan. The Board may<B> </B>delegate administration
of the Plan to a Committee or Committees, as provided in Section&nbsp;2(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Powers of the Board</B>. The
Board will have the power, subject to, and within the<B> </B>limitations of, the express provisions of the Plan: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> To determine (A)&nbsp;who will be granted Stock Awards; (B)&nbsp;when and how each Stock Award will be granted;
(C)&nbsp;what type of Stock Award will be granted; (D)&nbsp;the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Stock Award;
(E)&nbsp;the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F)&nbsp;the Fair Market Value applicable to a Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and
regulations for administration of the Plan and Stock Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem
necessary or expedient to make the Plan or Stock Award fully effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>To settle all controversies regarding
the Plan and Stock Awards granted under it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> To accelerate, in whole or in part, the time at which a Stock
Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> To suspend or terminate the Plan at any time. Except as otherwise
provided in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not impair a Participant&#146;s rights under the Participant&#146;s then-outstanding Stock Award without the Participant&#146;s written consent except as
provided in subsection (viii)&nbsp;below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)</B> To amend the Plan in any respect the Board deems necessary or
advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section&nbsp;409A of the Code and/or bringing the Plan or Stock Awards granted under the Plan
into compliance with the requirements for Incentive Stock Options or ensuring that they are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section&nbsp;409A of the Code, subject to the limitations, if
any, of applicable law. If required by applicable law or listing requirements, and except as provided in Section&nbsp;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that
(A)&nbsp;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&nbsp;materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C) materially increases the benefits
accruing to Participants under the Plan, (D)&nbsp;materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E)&nbsp;materially extends the term of the Plan, or (F)&nbsp;materially expands the types of
Stock Awards available for issuance under the Plan. Except as otherwise provided in the Plan or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant&#146;s rights under an outstanding Stock Award without the
Participant&#146;s written consent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vii)</B> To submit any amendment to the Plan for stockholder approval, including,
but not limited to, amendments to the Plan intended to satisfy the requirements of Section&nbsp;422 of the Code regarding Incentive Stock Options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(viii)</B> To approve forms of Stock Award Agreements for use under the Plan and to amend the terms of any one or more Stock
Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion;
<I>provided however,</I> that a Participant&#146;s rights under any Stock Award will not be impaired by any such amendment unless (A)&nbsp;the Company requests the consent of the affected Participant, and (B)&nbsp;such Participant consents in
writing. Notwithstanding the foregoing, (1)&nbsp;a Participant&#146;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially
impair the Participant&#146;s rights, and (2)&nbsp;subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards without the affected Participant&#146;s consent (A)&nbsp;to maintain the qualified
status of the Stock Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (B)&nbsp;to change the terms of an Incentive Stock Option, if such change results in impairment of the Stock Award solely because it impairs the qualified
status of the Stock Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (C)&nbsp;to clarify the manner of exemption from, or to bring the Stock Award into compliance with, Section&nbsp;409A of the Code; or (D)&nbsp;to comply with
other applicable laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ix)</B> Generally, to exercise such powers and to perform such acts as the Board deems
necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Stock Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x)</B> To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to
permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws
of the relevant foreign jurisdiction). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(xi)</B> To effect, with the consent of any adversely affected Participant,
(A)&nbsp;the reduction of the exercise, purchase or strike price of any outstanding Stock Award; (B)&nbsp;the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1)&nbsp;Option or SAR, (2)&nbsp;Restricted
Stock Award, (3)&nbsp;Restricted Stock Unit Award, (4)&nbsp;Other Stock Award, (5)&nbsp;cash and/or (6)&nbsp;other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x)&nbsp;covering the same or
a different number of shares of Common Stock as the cancelled Stock Award and (y)&nbsp;granted under the Plan or another equity or compensatory plan of the Company; or (C)&nbsp;any other action that is treated as a repricing under generally accepted
accounting principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Delegation to Committee</B>. The Board may delegate some or all of the administration
of<B> </B>the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been
delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or
subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Board may retain the
authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Delegation to an Officer</B>. The Board may delegate to one or more Officers the<B> </B>authority to do one or
both of the following: (i)&nbsp;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such
Stock Awards, and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; <I>provided,</I> <I>however</I>, that the Board resolutions regarding such delegation will specify the total
number of shares of<I> </I>Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award
Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an
Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section&nbsp;13(t) below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B>
<B>Effect of Board&#146;s Decision</B>. All determinations, interpretations and constructions made<B> </B>by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Share Reserve</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> Subject to Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock
that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed 138,026 shares (the <B><I>&#147;Share Reserve&#148;</I></B>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> For clarity, the Share Reserve in this Section&nbsp;3(a) is a
limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section&nbsp;3(a) does not limit the granting of Stock Awards except as provided in Section&nbsp;7(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Reversion of Shares to the Share Reserve</B>. If a Stock Award or any portion thereof (i) expires or otherwise
terminates without all of the shares covered by such Stock Award having been issued or (ii)&nbsp;is settled in cash (<I>i.e.</I>, the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or
otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to
meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in
satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Incentive Stock Option Limit</B>. Subject to the Share Reserve and Section&nbsp;9(a) relating to<B>
</B>Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be a number of shares of Common Stock equal to three multiplied by the Share Reserve.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Source of Shares</B>. The stock issuable under the Plan will be shares of authorized but<B> </B>unissued or
reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. E<SMALL>LIGIBILITY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Eligibility for Specific Stock Awards</B>. Incentive Stock Options may be granted only to<B> </B>employees of the
Company or a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors
and Consultants; <I>provided, however</I>, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#147;parent&#148; of the Company, as such term is defined in Rule 405, unless
(i)&nbsp;the stock underlying such Stock Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off
transaction), (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section&nbsp;409A of the Code, or (iii)&nbsp;the Company, in consultation with its legal counsel, has determined
that such Stock Awards comply with the distribution requirements of Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Ten
Percent Stockholders</B>. A Ten Percent Stockholder will not be granted an Incentive<B> </B>Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after
the expiration of five years from the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Consultants</B>. A Consultant will not be eligible for
the grant of a Stock Award if, at the<B> </B>time of grant, either the offer or sale of the Company&#146;s securities to such Consultant is not exempt under Rule 701 because of the nature of the services that the Consultant is providing to the
Company, because the Consultant is not a natural person, or because of any other provision of Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule 701 and will satisfy another </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">exemption under the Securities Act as well as comply with the securities laws of all other
relevant jurisdictions<B>.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. P<SMALL>ROVISIONS</SMALL> R<SMALL>ELATING</SMALL> <SMALL>TO</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL>
S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Option or SAR will be in such form and
will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or
certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some
portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical;
<I>provided, however</I>, that each Stock Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Term</B>. Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, no<B> </B>Option or
SAR will be exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Stock Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Exercise Price</B>. Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent<B> </B>Stockholders, the
exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Stock Award is granted. Notwithstanding the foregoing, an Option or SAR may be
granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Stock Award if such Stock Award is granted pursuant to an assumption of or substitution for another option or stock appreciation
right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section&nbsp;409A of the Code and, if applicable, Section&nbsp;424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Purchase Price for Options</B>. The purchase price of Common Stock acquired pursuant to<B> </B>the exercise of an
Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit
all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>by cash, check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the
issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> if an Option is a Nonstatutory Stock Option, by a &#147;net exercise&#148; arrangement pursuant to which the
Company will reduce the number of shares of Common Stock issuable upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; <I>provided, however</I>, that the Company will accept a cash or other
payment from the Pa&#146;rticipant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and
will not be exercisable thereafter to the extent that (A)&nbsp;shares issuable upon exercise are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (B) shares are delivered to the Participant as a result of such exercise, and
(C)&nbsp;shares are withheld to satisfy tax withholding obligations; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> according to a deferred payment or similar
arrangement with the Optionholder; <I>provided, however</I>, that interest will compound at least annually and will be charged at the minimum rate<I> </I>of interest necessary to avoid (A)&nbsp;the imputation of interest income to the Company and
compensation income to the Optionholder under any applicable provisions of the Code, and (B)&nbsp;the classification of the Option as a liability for financial accounting purposes; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)</B> in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Stock
Award Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Exercise and Payment of a SAR</B>. To exercise any outstanding SAR, the Participant<B>
</B>must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an
amount equal to the excess of (A)&nbsp;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR,
and with respect to which the Participant is exercising the SAR on such date, over (B)&nbsp;the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The
appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Award Agreement evidencing such SAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B>Transferability of Options and SARs</B>. The Board may, in its sole discretion, impose<B> </B>such limitations on
the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Restrictions on Transfer</B>. An Option or SAR will not be transferable except by<B> </B>will or by the laws of
descent and distribution (or pursuant to subsections (ii)&nbsp;and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is not
prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> <B>Domestic Relations Orders</B>. Subject to the approval of the Board or a duly<B> </B>authorized Officer, an
Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation
<FONT STYLE="white-space:nowrap">1.421-1(b)(2).</FONT> If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> <B>Beneficiary Designation</B>. Subject to the approval of the Board or a duly<B> </B>authorized Officer, a
Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or
other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#146;s estate will be entitled to exercise the Option or SAR and receive the
Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the
provisions of applicable laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> <B>Vesting Generally</B>. The total number of shares of Common Stock subject to
an Option<B> </B>or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised
(which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section&nbsp;5(f) are subject to any Option or
SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> <B>Termination of Continuous Service</B>. Except as otherwise provided in the applicable<B> </B>Stock Award
Agreement or other agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates (other than for Cause and other than upon the Participant&#146;s death or Disability), the Participant may exercise his or
her Option or SAR (to the extent that the Participant was entitled to exercise such Stock Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i)&nbsp;the date three months following the
termination of the Participant&#146;s Continuous Service (or such longer or shorter period specified in the applicable Stock Award Agreement, which period will not be less than 30 days if necessary to comply with applicable laws unless such
termination is for Cause) and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as
applicable) within the applicable time frame, the Option or SAR will terminate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> <B>Extension of Termination
Date</B>. If the exercise of an Option or SAR following the<B> </B>termination of the Participant&#146;s Continuous Service (other than for Cause and other than upon the Participant&#146;s death or Disability) would be prohibited at any time solely
because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i)&nbsp;the expiration of a total period of time (that need not be
consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#146;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and
(ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. In addition, unless otherwise provided in a Participant&#146;s Stock Award Agreement, if the sale of any Common Stock received upon
exercise of an Option or SAR following the termination of the Participant&#146;s Continuous Service (other than for Cause) would violate the Company&#146;s insider trading policy, then the Option or SAR will terminate on the earlier of (i)&nbsp;the
expiration of the period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#146;s Continuous Service during which the sale of the Common Stock received upon
exercise of the Option or SAR would not be in violation of the Company&#146;s insider trading policy, and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Disability of Participant</B>. Except as otherwise provided in the applicable Stock Award<B> </B>Agreement or
other agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s Disability, the Participant may exercise his or her </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on
the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement, which period will not be less than six months if necessary to comply with applicable
laws unless such termination is for Cause), and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or
SAR within the applicable time frame, the Option or SAR (as applicable) will terminate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> <B>Death of
Participant</B>. Except as otherwise provided in the applicable Stock Award<B> </B>Agreement or other agreement between the Participant and the Company, if (i)&nbsp;a Participant&#146;s Continuous Service terminates as a result of the
Participant&#146;s death, or (ii)&nbsp;the Participant dies within the period (if any) specified in the Stock Award Agreement for exercisability after the termination of the Participant&#146;s Continuous Service (for a reason other than death), then
the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#146;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or
inheritance or by a person designated to exercise the Option or SAR upon the Participant&#146;s death, but only within the period ending on the earlier of (i)&nbsp;the date 18 months following the date of death (or such longer or shorter period
specified in the Stock Award Agreement, which period will not be less than six months if necessary to comply with applicable laws unless such termination is for Cause), and (ii)&nbsp;the expiration of the term of such Option or SAR as set forth in
the Stock Award Agreement. If, after the Participant&#146;s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> <B>Termination for Cause</B>. Except as explicitly provided otherwise in a Participant&#146;s<B> </B>Stock Award
Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#146;s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant&#146;s
termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination of Continuous Service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B>. If an Option or SAR is granted to an Employee
who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following
the date of grant of the Option or SAR (although the Stock Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i)&nbsp;if such <FONT STYLE="white-space:nowrap">non-exempt</FONT> Employee dies
or suffers a Disability, (ii)&nbsp;upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii)&nbsp;upon a Change in Control, or (iv)&nbsp;upon the Participant&#146;s retirement (as such term may be
defined in the Participant&#146;s Stock Award Agreement, in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company&#146;s then current employment policies and guidelines), the vested
portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in
connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a <FONT
STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#146;s regular rate of pay, the provisions of this
Section&nbsp;5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m)</B> <B>Early Exercise of Options</B>. An Option may, but need not,
include a provision whereby<B> </B>the Optionholder may elect at any time before the Optionholder&#146;s Continuous Service terminates to exercise the Option as to any part or all of the shares of Common Stock subject to the Option prior to the full
vesting of the Option. Subject to the &#147;Repurchase Limitation&#148; in Section&nbsp;8(l), any unvested shares of Common Stock so purchased may be subject to a repurchase right in favor of the Company or to any other restriction the Board
determines to be appropriate. Provided that the &#147;Repurchase Limitation&#148; in Section&nbsp;8(l) is not violated, the Company will not be required to exercise its repurchase right until at least six months (or such longer or shorter period of
time required to avoid classification of the Option as a liability for financial accounting purposes) have elapsed following exercise of the Option unless the Board otherwise specifically provides in the Option Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)</B> <B>Right of Repurchase</B>. Subject to the &#147;Repurchase Limitation&#148; in Section&nbsp;8(l), the<B> </B>Option
or SAR may include a provision whereby the Company may elect to repurchase all or any part of the vested shares of Common Stock acquired by the Participant pursuant to the exercise of the Option or SAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o)</B> <B>Right of First Refusal</B>. The Option or SAR may include a provision whereby the<B> </B>Company may elect to
exercise a right of first refusal following receipt of notice from the Participant of the intent to transfer all or any part of the shares of Common Stock received upon the exercise of the Option or SAR. Such right of first refusal will be subject
to the &#147;Repurchase Limitation&#148; in Section&nbsp;8(l). Except as expressly provided in this Section&nbsp;5(o) or in the Stock Award Agreement, such right of first refusal will otherwise comply with any applicable provisions of the bylaws of
the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. P<SMALL>ROVISIONS</SMALL> <SMALL>OF</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> <SMALL>THAN</SMALL>
O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>ARS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Restricted Stock Awards</B>. Each
Restricted Stock Award Agreement will be in such<B> </B>form and will contain such terms and conditions as the Board will deem appropriate. To the extent consistent with the Company&#146;s bylaws, at the Board&#146;s election, shares of Common Stock
underlying a Restricted Stock Award may be (i)&nbsp;held in book entry form subject to the Company&#146;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii)&nbsp;evidenced by a certificate, which certificate
will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be
identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Consideration</B>. A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money
order payable to the Company, (B)&nbsp;past services to the Company or an Affiliate, or (C)&nbsp;any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under
applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> <B>Vesting</B>. Subject to the &#147;Repurchase Limitation&#148; in Section&nbsp;8(l), shares
of<B> </B>Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> <B>Termination of Participant&#146;s Continuous Service</B>. If a Participant&#146;s<B> </B>Continuous Service
terminates, the Company may receive through a forfeiture condition or a repurchase right, any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination of Continuous Service under the terms of
the Restricted Stock Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> <B>Transferability</B>. Rights to acquire shares of Common Stock
under the Restricted<B> </B>Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as
Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> <B>Dividends</B>. A Restricted Stock Award Agreement may provide that any<B> </B>dividends paid on Restricted Stock
will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Restricted Stock Unit Awards</B>. Each Restricted Stock Unit Award Agreement will be<B> </B>in such form and will
contain such terms and conditions as the will Board deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements
need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Consideration</B>. At the time of grant of a Restricted Stock Unit Award, the Board<B> </B>will determine the
consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a
Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> <B>Vesting</B>. At the time of the grant of a Restricted Stock Unit Award, the Board<B> </B>may impose such
restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> <B>Payment</B>. A Restricted Stock Unit Award may be settled by the delivery of<B> </B>shares of Common Stock,
their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> <B>Additional Restrictions</B>. At the time of the grant of a Restricted Stock Unit<B> </B>Award, the Board, as it
deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> <B>Dividend Equivalents</B>. Dividend equivalents may be credited in respect of<B> </B>shares of Common Stock
covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock
covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and
conditions of the underlying Restricted Stock Unit Award Agreement to which they relate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)</B> <B>Termination of
Participant&#146;s Continuous Service</B>. Except as otherwise<B> </B>provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#146;s
termination of Continuous Service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vii)</B> <B>Compliance with Section</B><B></B><B>&nbsp;409A of the
Code</B>. Notwithstanding anything to the<B> </B>contrary set forth herein, any Restricted Stock Unit Award granted under the Plan that is not exempt from the requirements of Section&nbsp;409A of the Code shall contain such provisions so that such
Restricted Stock Unit Award will comply with the requirements of Section&nbsp;409A of the Code. Such restrictions, if any, shall be determined by the Board and contained in the Restricted Stock Unit Award Agreement evidencing such Restricted Stock
Unit Award. For example, such restrictions may include, without limitation, a requirement that any Common Stock that is to be issued in a year following the year in which the Restricted Stock Unit Award vests must be issued in accordance with a
fixed <FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <B>Other Stock Awards</B>. Other forms of Stock
Awards valued in whole or in part by<B> </B>reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value
of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards provided for under Section&nbsp;5 and the preceding provisions of this Section&nbsp;6. Subject to the provisions of the Plan, the Board will have
sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock
Awards and all other terms and conditions of such Other Stock Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMPANY</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Availability of Shares</B>. The Company will keep available at all times the
number of<B> </B>shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B>
<B>Securities Law Compliance</B>. The Company will seek to obtain from each regulatory<B> </B>commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock
upon exercise of the Stock Awards; <I>provided,</I> <I>however, </I>that this undertaking will not require the Company to register under the Securities Act the Plan,<I> </I>any Stock Award or any Common Stock issued or issuable pursuant to any such
Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common
Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a
Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>No Obligation to Notify or Minimize Taxes</B>. The Company will have no duty or<B> </B>obligation to any
Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a
possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. M<SMALL>ISCELLANEOUS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Use of Proceeds from Sales of Common Stock</B>. Proceeds from the sale of shares of<B> </B>Common Stock pursuant
to Stock Awards will constitute general funds of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Corporate Action Constituting Grant of Stock Awards</B>.
Corporate action constituting<B> </B>a grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument,
certificate, or letter evidencing the Stock Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action
constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement or related grant documents as a result of a clerical error in the papering of the Stock
Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Stock Award Agreement or related grant documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Stockholder Rights</B>. No Participant will be deemed to be the holder of, or to have any of<B> </B>the rights of
a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its
terms, and (ii)&nbsp;the issuance of the Common Stock subject to the Stock Award has been entered into the books and records of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>No Employment or Other Service Rights</B>. Nothing in the Plan, any Stock Award<B> </B>Agreement or any other
instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was
granted or will affect the right of the Company or an Affiliate to terminate (i)&nbsp;the employment of an Employee with or without notice and with or without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such
Consultant&#146;s agreement with the Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the
Affiliate is incorporated, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B>Change in Time Commitment</B>. In the event a
Participant&#146;s regular level of time<B> </B>commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the
Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Stock Award to the Participant, the Board has the right in its sole discretion to (x)&nbsp;make a
corresponding reduction in the number of shares subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y)&nbsp;in lieu of or in combination with such a reduction,
extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or extended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> <B>Incentive Stock Option Limitations</B>. To the extent that the aggregate Fair Market<B> </B>Value (determined at
the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other
limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with
such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> <B>Investment Assurances</B>. The Company may require a Participant, as a condition of<B> </B>exercising or
acquiring Common Stock under any Stock Award, (i)&nbsp;to give written assurances satisfactory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to the Company as to the Participant&#146;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is
knowledgeable and experienced in financial and business matters and that the Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii)&nbsp;to give written
assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#146;s own account and not with any present intention of selling or otherwise distributing the Common Stock.
The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A)&nbsp;the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then
currently effective registration statement under the Securities Act, or (B)&nbsp;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then
applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws,
including, but not limited to, legends restricting the transfer of the Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> <B>Withholding
Obligations</B>. Unless prohibited by the terms of a Stock Award Agreement,<B> </B>the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means or by
a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award;
<I>provided, however</I>, that no shares of Common Stock are withheld with a value exceeding the minimum<I> </I>amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a
liability for financial accounting purposes); (iii) withholding cash from a Stock Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to the Participant; or (v)&nbsp;by such other method as may be set forth in the
Stock Award Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Electronic Delivery</B>. Any reference herein to a &#147;written&#148; agreement or
document will<B> </B>include any agreement or document delivered electronically or posted on the Company&#146;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> <B>Deferrals</B>. To the extent permitted by applicable law, the Board, in its sole discretion,<B> </B>may determine
that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.
Deferrals by Participants will be made in accordance with Section&nbsp;409A of the Code. Consistent with Section&nbsp;409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services
to the Company. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#146;s termination of Continuous
Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> <B>Compliance with Section</B><B></B><B>&nbsp;409A of the Code</B>. To the extent that the Board determines<B>
</B>that any Stock Award granted hereunder is subject to Section&nbsp;409A of the Code, the Stock Award Agreement evidencing such Stock Award shall incorporate the terms and conditions necessary to avoid the consequences specified in
Section&nbsp;409A(a)(1) of the Code. To the extent applicable, the Plan and Stock Award Agreements shall be interpreted in accordance with Section&nbsp;409A of the Code. Notwithstanding anything to the contrary in the Plan (and unless the Stock
Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock Award that constitutes &#147;deferred compensation&#148; under Section&nbsp;409A of
the Code is a &#147;specified employee&#148; for purposes of Section&nbsp;409A of the Code, no distribution or payment of any amount that is due because of a &#147;separation from service&#148; (as defined in Section&nbsp;409A of the Code without
regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant&#146;s &#147;separation from service&#148; (as defined in Section&nbsp;409A of the Code without regard to
alternative definitions thereunder) or, if earlier, the date of the Participant&#146;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A of the Code, and any amounts so deferred will be paid in a
lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B> <B>Repurchase Limitation</B>. The terms of any repurchase right will be specified in the<B> </B>Stock Award
Agreement. The repurchase price for vested shares of Common Stock will be the Fair Market Value of the shares of Common Stock on the date of repurchase. The repurchase price for unvested shares of Common Stock will be the lower of (i)&nbsp;the Fair
Market Value of the shares of Common Stock on the date of repurchase or (ii)&nbsp;their original purchase price. However, the Company will not exercise its repurchase right until at least six months (or such longer or shorter period of time
necessary to avoid classification of the Stock Award as a liability for financial accounting purposes) have elapsed following delivery of shares of Common Stock subject to the Stock Award, unless otherwise specifically provided by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. A<SMALL>DJUSTMENTS</SMALL> U<SMALL>PON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL>
C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Capitalization Adjustments</B>. In the event of a
Capitalization Adjustment, the Board will<B> </B>appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii) the class(es) and maximum number of securities
that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;3(c), and (iii)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such
adjustments, and its determination will be final, binding and conclusive. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Dissolution or Liquidation</B>.
Except as otherwise provided in the Stock Award<B> </B>Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not
subject to a forfeiture condition or the Company&#146;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#146;s repurchase rights or
subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, <I>provided,</I> <I>however, </I>that the Board may, in its sole
discretion, cause some or all Stock Awards to become fully<I> </I>vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or
liquidation is completed but contingent on its completion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Corporate Transaction</B>. The following
provisions will apply to Stock Awards in the<B> </B>event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or
unless otherwise expressly provided by the Board at the time of grant of a Stock Award. In the event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions with
respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> arrange for the surviving corporation or acquiring corporation
(or the surviving or acquiring corporation&#146;s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the
stockholders of the Company pursuant to the Corporate Transaction); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> arrange for the assignment of any
reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock
Award may be exercised) to a date prior to the effective time of such Corporate Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective date of the Corporate
Transaction), with such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; <I>provided, however</I>, that the Board may require Participants to complete and deliver to the Company
a<I> </I>notice of exercise before the effective date of a Corporate Transaction, which exercise is contingent upon the effectiveness of such Corporate Transaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with
respect to the Stock Award; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> cancel or arrange for the cancellation of the Stock Award, to the extent not
exercised prior to the effective time of the Corporate Transaction, in exchange for a payment, in such form as may be determined by the Board, equal to the excess, if any, of (A)&nbsp;the per share amount (or value of property per share) payable to
holders of Common Stock in connection with the Corporate Transaction, over (B)&nbsp;the per share exercise price under the applicable Stock Award (if any), multiplied by the number of vested shares subject to the Stock Award. For clarity, this
payment may be $0 if the amount per share (or value of property per share) payable to the holders of Common Stock is equal to or less than exercise price of the Stock Award. Payments under this provision may be delayed to the same extent that
payment of consideration to the holders of Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies. In addition, the Board, in its sole discretion, may condition a
Participant&#146;s right to receive such payment upon the Participant&#146;s delivery of an agreement (x)&nbsp;acknowledging such escrows, earn outs, holdbacks or other contingencies, (y)&nbsp;appointing a representative to act on the
Participant&#146;s behalf following the Corporate Transaction with respect to matters relating to the Corporate Transaction, and/or (z)&nbsp;agreeing to or acknowledging any indemnification obligations required of holders of Common Stock pursuant to
the Corporate Transaction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)</B> make a payment, in such form as may be determined by the Board equal to the excess,
if any, of (A)&nbsp;the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B)&nbsp;any exercise price payable by such holder in
connection with such exercise. For clarity, this payment may be zero ($0) if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the
holders of the Company&#146;s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vii)</B> suspend the exercise of the Awards, prior to the effective time
of the Corporate Transaction, for such period as the Board determines is necessary to facilitate the negotiation and consummation of the Corporate Transaction; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(viii)</B> if an Award is eligible for &#147;early exercise&#148; (i.e., the Award is exercisable prior to vesting for
Restricted Units subject to a repurchase right), cancel or arrange for the cancellation of any such &#147;early exercise&#148; rights upon the Corporate Transaction, such that following the Corporate Transaction, such Award may only be exercised to
the extent vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board need not take the same action or actions with respect to all Stock Awards or portions thereof or with
respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of a Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Change in Control</B>. A Stock Award may be subject to additional acceleration of vesting<B> </B>and
exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence
of such provision, no such acceleration will occur. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. P<SMALL>LAN</SMALL> T<SMALL>ERM</SMALL>; E<SMALL>ARLIER</SMALL> T<SMALL>ERMINATION</SMALL>
<SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B>
<B>Plan Term</B>. The Board may suspend or terminate the Plan at any time. Unless<B> </B>terminated sooner by the Board, the Plan will automatically terminate on the day before the 10th anniversary of the earlier of (i)&nbsp;the date the Plan is
adopted by the Board, or (ii)&nbsp;the date the Plan is approved by the stockholders of the Company. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>No Impairment of Rights</B>. Suspension or termination of the Plan will not impair rights<B> </B>and obligations
under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Plan will become effective on the Effective Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this
Plan, without regard to that state&#146;s conflict of laws rules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>13.</B> <B>D<SMALL>EFINITIONS</SMALL></B><SMALL></SMALL>. As used in
the Plan, the following definitions will apply to the capitalized terms<B> </B>indicated below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B>
&#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any &#147;parent&#148; or &#147;majority-owned subsidiary&#148; of the Company, as such terms are defined in Rule 405. The Board will have the authority to determine the time
or times at which &#147;parent&#148; or &#147;majority-owned subsidiary&#148; status is determined within the foregoing definition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>&#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any
change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in
corporate structure, or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing,
the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B>
&#147;<B><I>Cause</I></B>&#148; will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant,
the occurrence of any of the following events: (i)&nbsp;such Participant&#146;s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii)&nbsp;such
Participant&#146;s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii)&nbsp;such Participant&#146;s intentional, material violation of any contract or agreement between the Participant and the
Company or of any statutory duty owed to the Company; (iv)&nbsp;such Participant&#146;s unauthorized use or disclosure of the Company&#146;s confidential information or trade secrets; or (v)&nbsp;such Participant&#146;s gross misconduct. The
determination that a termination of the Participant&#146;s Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was
terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> &#147;<B><I>Change in Control</I></B>&#148; means the occurrence, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> any Exchange Act Person becomes the Owner, directly
or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the
foregoing, a Change in Control will not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any
affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity
securities or (C)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase
or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the
Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting
securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company
and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing
more than 50% of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">combined outstanding voting power of the surviving Entity in such merger, consolidation or
similar transaction or (B)&nbsp;more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership
of the outstanding voting securities of the Company immediately prior to such transaction; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> there is
consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the
consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of
the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the
foregoing definition or any other provision of this Plan, (A)&nbsp;the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and
(B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Stock Awards subject to such
agreement; <I>provided,</I> <I>however</I>, that if no definition of Change in Control or any analogous term is set forth in such an<I> </I>individual written agreement, the foregoing definition will apply. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable
regulations and guidance thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> &#147;<B><I>Committee</I></B>&#148; means a committee of one or more
Directors to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)
</B>&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)
</B>&#147;<B><I>Company</I></B>&#148; means Equillium, Inc., a Delaware corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B>
&#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of
the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#147;Consultant&#148; for purposes of the Plan.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> &#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an
Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the
Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, will not terminate a Participant&#146;s Continuous Service; <I>provided,
however</I>, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant&#146;s Continuous Service will be considered to have terminated on
the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent
permitted by law, the Board or the chief executive officer of the Company, in that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">party&#146;s sole discretion, may determine whether Continuous Service will be considered
interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their
successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#146;s leave of absence policy, in the written terms
of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B>
&#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the
consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>a sale or other disposition of more than 50% of the
outstanding securities of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> a merger, consolidation or similar transaction following which the
Company is not the surviving corporation; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> a merger, consolidation or similar transaction following which
the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into
other property, whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m) </B>&#147;<B><I>Director</I></B>&#148; means
a member of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)</B> &#147;<B><I>Disability</I></B>&#148; means, with respect to a Participant, the inability
of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of
not less than twelve (12)&nbsp;months as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o)</B> &#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan, which is the earlier of (i)&nbsp;the
date that this Plan is first approved by the Company&#146;s stockholders, and (ii)&nbsp;the date this Plan is adopted by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(p)</B> &#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service solely
as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(q) </B>&#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(r)</B> &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(s)</B> &#147;<B><I>Exchange Act Person</I></B>&#148; means any natural person,
Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; will not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee
benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding
securities pursuant to a registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or
(v)&nbsp;any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more
than 50% of the combined voting power of the Company&#146;s then outstanding securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(t)</B> &#147;<B><I>Fair
Market Value</I></B>&#148; means, as of any date, the value of the Common Stock determined by the Board in compliance with Section&nbsp;409A of the Code or, in the case of an Incentive Stock Option, in compliance with Section&nbsp;422 of the Code.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(u)</B> &#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 of the Plan
that is intended to be, and that qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 of the Plan
that does not qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(w) </B>&#147;<B><I>Officer</I></B>&#148; means any person
designated by the Company as an officer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x)</B> &#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option or a
Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(y)</B> &#147;<B><I>Option
Agreement</I></B>&#148; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(z)</B> &#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is granted pursuant to the Plan or, if
applicable, such other person who holds an outstanding Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(aa)</B> &#147;<B><I>Other Stock Award</I></B>&#148;
means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(bb)</B> &#147;<B><I>Other Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a holder of
an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(cc)</B> &#147;<B><I>Own</I></B>,&#148; &#147;<B><I>Owned</I></B>,&#148; &#147;<B><I>Owner</I></B>,&#148;
&#147;<B><I>Ownership</I></B>&#148; A person or Entity will be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the &#147;Owner&#148; of, or to have acquired &#147;Ownership&#148; of securities if such person or Entity, directly or
indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(dd)</B> &#147;<B><I>Participant</I></B>&#148; means a person to whom a Stock Award is granted pursuant to the Plan or, if
applicable, such other person who holds an outstanding Stock Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ee) </B>&#147;<B><I>Plan</I></B>&#148; means this
2017 Equity Incentive Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ff)</B> &#147;<B><I>Restricted Stock Award</I></B>&#148; means an award
of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(gg)</B>
&#147;<B><I>Restricted Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award
Agreement will be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(hh)</B> &#147;<B><I>Restricted Stock Unit
Award</I></B>&#148; means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> &#147;<B><I>Restricted Stock Unit Award Agreement</I></B>&#148; means a written agreement between the Company and a
holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(jj) </B>&#147;<B><I>Rule 405</I></B>&#148; means Rule 405 promulgated under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(kk) </B>&#147;<B><I>Rule 701</I></B>&#148; means Rule 701 promulgated under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ll) </B>&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(mm)</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148; means a right to receive the
appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(nn)</B>
&#147;<B><I>Stock Appreciation Right Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation
Right Agreement will be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(oo)</B> &#147;<B><I>Stock Award</I></B>&#148;
means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or any Other Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(pp)</B> &#147;<B><I>Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant
evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(qq)</B> &#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more
than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or
might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or
indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(rr)</B> &#147;<B><I>Ten Percent Stockholder</I></B>&#148; means a person
who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>STANDARD FORM</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK
OPTION GRANT NOTICE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2017 EQUITY INCENTIVE PLAN) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL></B><SMALL></SMALL>. (the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2017 Equity
Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;), hereby<B> </B>grants to Optionholder an option to purchase the number of shares of the Company&#146;s Common Stock set forth below. This option is subject to all of the terms and conditions as set
forth in this notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option
Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this notice and the Plan, the terms of the Plan will control. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Optionholder:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date of Grant:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Number of Shares Subject to Option:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exercise Price (Per Share):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Type of Grant:</B> <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#9744;<B></B><B></B><B>
</B>Incentive Stock Option<SUP STYLE="font-size:85%; vertical-align:top">1</SUP><B> </B><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#9744;<B></B><B></B><B> </B>Nonstatutory Stock Option </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Exercise Schedule</B>:<B> </B><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#9744;<B></B><B></B><B> </B>Same as Vesting Schedule
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#9744;<B></B><B></B><B> </B>Early Exercise Permitted </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Vesting&nbsp;Schedule:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<B>Sample of standard vesting. </B><FONT STYLE="white-space:nowrap">One-fourth</FONT><B> (</B>1/4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) of the shares vest one year after the<B> </B>Vesting Commencement Date; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of
the Vesting Commencement Date, subject to Optionholder&#146;s Continuous Service as of each such date.]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Payment:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By one or a combination of the following items (described in the Option Agreement):</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744; By cash, check, bank draft or money order payable to the Company</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744; Pursuant to a Regulation T Program if the shares
are publicly traded</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744; By delivery of
already-owned shares if the shares are publicly traded</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744; If and only to the extent this option is a Nonstatutory Stock Option, and subject to the Company&#146;s consent at the time of
exercise, by a &#147;net exercise&#148; arrangement</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
<I>exercisable</I> for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>STANDARD FORM </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Additional Terms/Acknowledgements:</B> Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice,
the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder further acknowledges that as of
the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises
and/or representations on that subject with the exception of (i)&nbsp;options previously granted and delivered to Optionholder, and (ii)&nbsp;the following agreements only. This Stock Option Grant Notice and any notices, agreements or other
documents related thereto may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been
duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>THER</SMALL>&nbsp;A<SMALL>GREEMENTS</SMALL>:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By accepting this option, you consent to receive such documents by electronic delivery and to participate in
the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>O<SMALL>PTIONHOLDER</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Signature</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL></SMALL>: Option Agreement, 2017 Equity Incentive Plan and Notice of
Exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION AGREEMENT </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>STANDARD FORM</I></B><B> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017
EQUITY INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to your Stock Option Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;) and this Option Agreement,
<B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B>(the &#147;<B><I>Company</I></B>&#148;) has granted you an option under its 2017 Equity Incentive Plan (the<B> </B>&#147;<B><I>Plan</I></B>&#148;) to purchase the number of shares of the
Company&#146;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the &#147;<B><I>Date of
Grant</I></B>&#148;). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the
Plan will have the same definitions as in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The details of your option, in addition to those set forth in the
Grant Notice and the Plan, are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.</B> <B>V<SMALL>ESTING</SMALL></B><SMALL></SMALL>. Your option will vest
as provided in your Grant Notice. Vesting will cease<B> </B>upon the termination of your Continuous Service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.</B>
<B>N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL> <SMALL>AND</SMALL> E<SMALL>XERCISE</SMALL> P<SMALL>RICE</SMALL></B><SMALL></SMALL>. The number of shares of Common Stock<B> </B>subject to your option and your exercise price per share
in your Grant Notice will be adjusted for Capitalization Adjustments. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3. E<SMALL>XERCISE</SMALL>
R<SMALL>ESTRICTION</SMALL> <SMALL>FOR</SMALL> N<SMALL>ON</SMALL>-E<SMALL>XEMPT</SMALL> E<SMALL>MPLOYEES</SMALL></B><SMALL></SMALL>. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended
(that is, a &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employee</I></B>&#148;), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six months of Continuous Service
measured from the Date of Grant, even if you have already been an employee for more than six months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six month
anniversary in the case of (i)&nbsp;your death or disability, (ii)&nbsp;a Corporate Transaction in which your option is not assumed, continued or substituted, (iii)&nbsp;a Change in Control or (iv) your termination of Continuous Service on your
&#147;retirement&#148; (as defined in the Company&#146;s benefit plans). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>4. E<SMALL>XERCISE</SMALL>
P<SMALL>RIOR</SMALL> <SMALL>TO</SMALL> V<SMALL>ESTING</SMALL> (&#147;E<SMALL>ARLY</SMALL> E<SMALL>XERCISE</SMALL></B><SMALL></SMALL>&#148;). If permitted in your Grant Notice (<I>i.e.</I>, the &#147;Exercise Schedule&#148; indicates &#147;Early
Exercise Permitted&#148;) and subject to the provisions of your option, you may elect at any time that is both (i)&nbsp;during the period of your Continuous Service and (ii)&nbsp;during the term of your option, to exercise all or part of your
option, including the unvested portion of your option; <I>provided, however,</I> that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> a partial exercise of
your option will be deemed to cover first vested shares of Common Stock and then the earliest vesting installment of unvested shares of Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> any shares of Common Stock so purchased from installments that have not vested as of the date of exercise will be
subject to the purchase option in favor of the Company as described in the Company&#146;s form of Early Exercise Stock Purchase Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> you will enter into the Company&#146;s form of Early Exercise
Stock Purchase Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> if your option is an Incentive Stock Option, then, to the extent that the aggregate Fair Market Value (determined at
the Date of Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable for the first time by you during any calendar year (under all plans of the Company and its Affiliates)
exceeds $100,000, your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as Nonstatutory Stock Options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>5.</B> <B>M<SMALL>ETHOD</SMALL> <SMALL>OF</SMALL> P<SMALL>AYMENT</SMALL></B><SMALL></SMALL>. You must pay the full amount of
the exercise price for the<B> </B>shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner <B><I>permitted by your Grant Notice,</I></B> which may
include one or more of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Provided that at the time of exercise the Common Stock is publicly
traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable
instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a &#147;broker-assisted exercise&#148;, &#147;same day sale&#148;, or &#147;sell to cover&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by
actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. &#147;Delivery&#148;
for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not
exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#146;s stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a
&#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate
exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the &#147;net exercise&#148; in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and
will not be exercisable thereafter if those shares (i)&nbsp;are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (ii) are delivered to you as a result of such exercise, and (iii)&nbsp;are withheld to satisfy your tax
withholding obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>6. W<SMALL>HOLE</SMALL> S<SMALL>HARES</SMALL></B><SMALL></SMALL>. You may exercise your option
only for whole shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>7.</B> <B>S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL>
C<SMALL>OMPLIANCE</SMALL></B><SMALL></SMALL>. In no event may you exercise your option unless the<B> </B>shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined
that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you
may not exercise your option if the Company determines that such exercise would not be in material compliance with such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. <FONT STYLE="white-space:nowrap">1.401(k)-1(d)(3),</FONT> if applicable). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>8.</B> <B>T<SMALL>ERM</SMALL></B><SMALL></SMALL>. You may not exercise your option before the Date of Grant or after the
expiration<B> </B>of the option&#146;s term. Except as set forth in your Grant Notice, the term of your option expires, subject to the provisions of Section&nbsp;5(h) of the Plan, upon the earliest of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>immediately upon the termination of your Continuous Service for Cause; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> three months after the termination of your Continuous Service for any reason other than Cause, your Disability or
your death (except as otherwise provided in Section&nbsp;8(d) below); <I>provided, however, </I>that if during any part of such three month period your option is not exercisable solely<I> </I>because of the condition set forth in the section above
relating to &#147;Securities Law Compliance,&#148; your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous Service;
<I>provided further,</I> that if (i)&nbsp;you are a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employee, (ii)&nbsp;your Continuous Service terminates within six months after the Date of Grant, and (iii)&nbsp;you have vested in a portion of
your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x)&nbsp;the later of (A)&nbsp;the date that is seven months after the Date of Grant, and (B)&nbsp;the date that is three months
after the termination of your Continuous Service, and (y)&nbsp;the Expiration Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> 12 months after the
termination of your Continuous Service due to your Disability (except as otherwise provided in Section&nbsp;8(d)) below; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> 18 months after your death if you die either during your Continuous Service or within three (3)&nbsp;months after
your Continuous Service terminates for any reason other than Cause; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) </B>the Expiration Date indicated in your Grant
Notice; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) </B>the day before the 10th anniversary of the Date of Grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an
Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your option&#146;s exercise, you must be an employee of the Company or an Affiliate, except in the event
of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you
continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three months after the date your employment with the Company or an Affiliate
terminates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>9. E<SMALL>XERCISE</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so
permits) during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours,
together with such additional documents as the Company may then require <B><U>(including, without limitation, any voting agreement or</U></B> <B><U>other agreement between the Company and certain of its stockholders)</U></B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> By exercising your option you agree that, as a condition to any
exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i)&nbsp;the exercise of your option,
(ii)&nbsp;the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii)&nbsp;the disposition of shares of Common Stock acquired upon such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in
writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the Date of Grant or within one year after such shares of Common Stock are
transferred upon exercise of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> By exercising your option you agree that you will not sell, dispose
of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held
by you, for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule
2711 or NYSE Member Rule 472 or any successor or similar rule<STRIKE>s</STRIKE> or regulation (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;); <I>provided,</I> <I>however</I>, that nothing contained in this
section will prevent the exercise of a repurchase option, if any, in<I> </I>favor of the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. You further agree to execute and deliver such other agreements as may be reasonably
requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to
your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section&nbsp;9(d). The underwriters of the
Company&#146;s stock are intended third party beneficiaries of this Section&nbsp;9(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>10.</B> <B>T<SMALL>RANSFERABILITY</SMALL></B><SMALL></SMALL>. Except as otherwise provided in this Section&nbsp;10, your
option is not<B> </B>transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Certain Trusts</B>. Upon receiving written permission from the Board or its duly<B> </B>authorized designee, you
may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section&nbsp;671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer
and other agreements required by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Domestic Relations Orders</B>. Upon receiving written
permission from the Board<B> </B>or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic
relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation <FONT STYLE="white-space:nowrap">1.421-1(b)(2)</FONT> that contains the information required by the Company to
effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is
contained within the domestic relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Beneficiary Designation</B>. Upon receiving written permission
from the Board or<B> </B>its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your
death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to
exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>11.</B> <B>O<SMALL>PTION</SMALL> <SMALL>NOT</SMALL> <SMALL>A</SMALL> S<SMALL>ERVICE</SMALL>
C<SMALL>ONTRACT</SMALL></B><SMALL></SMALL>. Your option is not an employment or service<B> </B>contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company
or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any
relationship that you might have as a Director or Consultant for the Company or an Affiliate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>12.
W<SMALL>ITHHOLDING</SMALL> O<SMALL>BLIGATIONS</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> At the time you exercise your option,
in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#147;same
day sale&#148; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of
the Company or an Affiliate, if any, which arise in connection with the exercise of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> If this option
is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable
to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such
lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your
option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section&nbsp;83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such
exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock
shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share
withholding procedure shall be your sole responsibility. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> You may not exercise your option unless the tax
withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for
such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>13.</B> <B>T<SMALL>AX</SMALL> C<SMALL>ONSEQUENCES</SMALL></B><SMALL></SMALL>. You hereby agree that the Company does not
have a duty to<B> </B>design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">or Affiliates related to tax liabilities arising from your option or your other
compensation. In particular, you acknowledge that this option is exempt from Section&nbsp;409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#147;fair market value&#148; per share of the
Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. Because the Common Stock is not traded on an established securities market, the Fair Market Value is determined by the Board,
perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will agree with the valuation as determined by the Board, and you will not make any
claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined by the Board is less than the &#147;fair market value&#148; as subsequently
determined by the Internal Revenue Service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>14.</B> <B>N<SMALL>OTICES</SMALL></B><SMALL></SMALL>. Any notices provided
for in your option or the Plan will be given in writing<B> </B>(including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United
States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to
request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or
electronic system established and maintained by the Company or another third party designated by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>15.</B>
<B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL></B><SMALL></SMALL>. Your option is subject to all the provisions of the Plan,<B> </B>the provisions of which are hereby made a part of your option, and is further subject to all
interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will
control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017 EQUITY INCENTIVE PLAN </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Equillium, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2223 Avenida de la Playa </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 108 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Jolla, California 92037 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Date of Exercise:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This constitutes notice to <B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B> (the &#147;<B><I>Company</I></B>&#148;) under
my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the &#147;<B><I>Shares</I></B>&#148;) for the price set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Type of option (check one):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Incentive&nbsp;&#9744;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Nonstatutory&nbsp;&#9744;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stock option dated:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Number of Shares as to which option is exercised:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Certificates to be issued in name of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Total exercise price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cash payment delivered herewith:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulation T Program (cashless exercise<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Value of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Shares
delivered herewith<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By this exercise, I agree (i)&nbsp;to provide such additional documents as you may require
pursuant to the terms of the 2017 Equity Incentive Plan, (ii)&nbsp;to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise
relates to an incentive stock option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant of this option or within
one year after such Shares are issued upon exercise of this option. I further agree that this Notice of Exercise may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of
2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shares must meet the public trading requirements set forth in the option agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shares must meet the public trading requirements set forth in the option. Shares must be valued in
accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I hereby make the following certifications and representations with respect
to the number of Shares listed above, which are being acquired by me for my own account upon exercise of the option as set forth above: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I acknowledge that the Shares have not been registered under the Securities Act of 1933, as amended (the
&#147;<B><I>Securities Act</I></B>&#148;), and are deemed to constitute &#147;restricted securities&#148; under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and represent to the Company that I have no present intention of
distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I further acknowledge and agree that, except for such information as required to be delivered to me by the Company pursuant to
the option or the Plan (if any), I will have no right to receive any information from the Company by virtue of the grant of the option or the purchase of shares of Common Stock through exercise of the option, ownership of such shares of Common
Stock, or as a result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by law, I hereby waive all inspection rights under Section&nbsp;220 of the Delaware General Corporation Law
and all such similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or foreign regulation, that are, or may become, applicable to the Company or the Company&#146;s capital stock
(the &#147;<B><I>Inspection Rights</I></B>&#148;). I hereby covenant and agree never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other
proceeding to pursue or exercise the Inspection Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I further acknowledge that I will not be able to resell the
Shares for at least 90 days after the stock of the Company becomes publicly traded (<I>i.e.,</I> subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934) under Rule 701 and that more restrictive
conditions apply to affiliates of the Company under Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I further acknowledge that all certificates representing
any of the Shares subject to the provisions of the option shall have endorsed thereon appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company&#146;s Certificate of
Incorporation, Bylaws and/or applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I further agree that, if required by the Company (or a
representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for
the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of 180 days following the effective date of a
registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or
regulation) (the &#147;<B><I>Lock- Up</I></B> <B><I>Period</I></B>&#148;). I further agree to execute and deliver such other agreements as may be reasonably requested by<B><I> </I></B>the Company or the underwriters that are consistent with the
foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Name (Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="right">Address&nbsp;of&nbsp;Record:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Equillium, Inc. &#150; Signature Page to Notice of Exercise] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>DOUBLE-TRIGGER FORM </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK
OPTION GRANT NOTICE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2017 EQUITY INCENTIVE PLAN) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL></B><SMALL></SMALL>. (the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2017 Equity
Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;), hereby<B> </B>grants to Optionholder an option to purchase the number of shares of the Company&#146;s Common Stock set forth below. This option is subject to all of the terms and conditions as set
forth in this notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option
Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this notice and the Plan, the terms of the Plan will control. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Optionholder:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date of Grant:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Number of Shares Subject to Option:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exercise Price (Per Share):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Type of Grant:</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B></B>&#9744;<B></B><B></B><B> </B>Incentive
Stock Option<SUP STYLE="font-size:85%; vertical-align:top">1</SUP><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B></B>&#9744;<B></B><B></B><B> </B>Nonstatutory Stock Option </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Exercise Schedule</B>:<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B></B>&#9744;<B></B><B></B><B> </B>Same as Vesting
Schedule&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B></B>&#9744;<B></B><B></B><B> </B>Early Exercise Permitted </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Vesting Schedule</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[<B>Sample of standard vesting. </B><FONT STYLE="white-space:nowrap">One-fourth</FONT><B> (</B>1/4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) of the shares vest one year after the<B> </B>Vesting Commencement Date; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of
the Vesting Commencement Date, subject to Optionholder&#146;s Continuous Service as of each such date <B><U>and the potential vesting acceleration described in Section</U></B><B><U></U></B><B><U>&nbsp;1 of the</U></B> <B><U>Option
Agreement.</U></B>]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Payment:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By one or a combination of the following items (described in the Option Agreement):</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744; By cash, check, bank draft or money order payable
to the Company</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744; Pursuant to a Regulation T
Program if the shares are publicly traded</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744; By
delivery of already-owned shares if the shares are publicly traded</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744; If and only to the extent this option is a Nonstatutory Stock Option, and subject to the Company&#146;s consent at the time of
exercise, by a &#147;net exercise&#148; arrangement</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
<I>exercisable</I> for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>DOUBLE-TRIGGER FORM </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Additional Terms/Acknowledgements: </B>Optionholder acknowledges receipt of, and understands and<B> </B>agrees to, this Stock Option Grant
Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder further acknowledges
that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements,
promises and/or representations on that subject with the exception of (i)&nbsp;options previously granted and delivered to Optionholder, and (ii)&nbsp;the following agreements only. This Stock Option Grant Notice and any notices, agreements or other
documents related thereto may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been
duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>THER</SMALL>&nbsp;A<SMALL>GREEMENTS</SMALL>:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By accepting this option, you consent to receive such documents by electronic delivery and to participate in
the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL></B><SMALL></SMALL>.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>O<SMALL>PTIONHOLDER</SMALL>:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Signature</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL></SMALL>: Option Agreement, 2017 Equity Incentive Plan and Notice of
Exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION AGREEMENT </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>DOUBLE-TRIGGER FORM </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017
EQUITY INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to your Stock Option Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;) and this Option Agreement,
<B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B>(the &#147;<B><I>Company</I></B>&#148;) has granted you an option under its 2017 Equity Incentive Plan (the<B> </B>&#147;<B><I>Plan</I></B>&#148;) to purchase the number of shares of the
Company&#146;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the &#147;<B><I>Date of
Grant</I></B>&#148;). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the
Plan will have the same definitions as in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The details of your option, in addition to those set forth in the
Grant Notice and the Plan, are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.</B> <B>V<SMALL>ESTING</SMALL></B><SMALL></SMALL>. Your option will vest
as provided in your Grant Notice. Vesting will cease<B> </B>upon the termination of your Continuous Service. If a Change in Control occurs and upon or within twelve (12)&nbsp;months after the effective time of such Change in Control, your Continuous
Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to your voluntary termination with Good Reason, then, as of the date of termination of Continuous Service, the vesting and exercisability
of your option will be accelerated in full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> &#147;<B><I>Good Reason</I></B>&#148; means the occurrence of any
of the following events, conditions or actions taken by the Company without Cause and without your written consent: (i)&nbsp;a material reduction of your annual base salary; <I>provided, however</I>, that Good Reason shall not be deemed to have
occurred in the event of a reduction in your annual base salary that is pursuant to a salary reduction program affecting substantially all of the similarly situated employees of the Company and that does not adversely affect you to a greater extent
than other similarly situated employees; (ii)&nbsp;a material reduction in your authority, duties or responsibilities; (iii)&nbsp;a relocation of your principal place of employment with the Company to a place that increases your <FONT
STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles as compared to your then-current principal place of employment immediately prior to such relocation (excluding regular travel in the ordinary course of business);
or (iv)&nbsp;a material breach by the Company of any provision of this Option Agreement or your employment agreement with the Company; <I>provided, however</I>, that in each case above, in order for your resignation to be deemed to have been for
Good Reason, you must first give the Board written notice of the action or omission giving rise to &#147;Good Reason&#148; within thirty (30)&nbsp;days after the first occurrence thereof; the Company must fail to reasonably cure such action or
omission within thirty (30)&nbsp;days after receipt of such notice (the &#147;<B><I>Cure Period</I></B>&#148;), and your resignation from all positions you hold with the Company must be effective not later than thirty (30)&nbsp;days after the
expiration of such Cure Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> If any payment or benefit you would receive from the Company or otherwise in
connection with a change in control of the Company or other similar transaction (&#147;<B><I>Payment</I></B>&#148;) would (1)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (2)&nbsp;but for
this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<B><I>Excise Tax</I></B>&#148;), then such Payment will be equal to the Reduced Amount. The &#147;<B><I>Reduced Amount</I></B>&#148; will be either
(x)&nbsp;the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (y) the largest portion, up to and including the total, of the Payment, whichever amount ((x) or (y)), after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">taking into account all applicable federal, state and local employment taxes, income taxes,
and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding that all or some portion of the
Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction will occur in the manner (the &#147;<B><I>Reduction
Method</I></B>&#148;) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#147;<B><I>Pro</I></B> <B><I>Rata
Reduction Method</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method
would result in any portion of the Payment being subject to taxes pursuant to Section&nbsp;409A of the Code (&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;) that would not otherwise be subject to taxes pursuant to
Section&nbsp;409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows: (A)&nbsp;as a first priority, the modification
shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis; (B)&nbsp;as a second priority, Payments that are contingent on future events (e.g.,
being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C)&nbsp;as a third priority, Payments that are &#147;deferred compensation&#148; within the meaning of Section&nbsp;409A
shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the
effective date of the event described in Section&nbsp;280G(b)(2)(A)(i) of the Code will perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the
individual, entity or group effecting the change in control or similar transaction, the Company will appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company will bear
all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the determinations hereunder will make its
determination with input from you (or your counsel) and provide its calculations, together with detailed supporting documentation, to the Company and you within fifteen (15)&nbsp;calendar days after the date on which your right to a Payment is
triggered (if requested at that time by the Company or you) or such other time as reasonably requested by the Company or you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x)&nbsp;of the first paragraph of
this Section&nbsp;1(b) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to
clause (x)&nbsp;of the first paragraph of this Section&nbsp;1(b) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y)&nbsp;in the first
paragraph of this Section&nbsp;1(b), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.</B> <B>N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL> <SMALL>AND</SMALL> E<SMALL>XERCISE</SMALL>
P<SMALL>RICE</SMALL></B><SMALL></SMALL>. The number of shares of Common Stock<B> </B>subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3. E<SMALL>XERCISE</SMALL> R<SMALL>ESTRICTION</SMALL> <SMALL>FOR</SMALL> N<SMALL>ON</SMALL>-E<SMALL>XEMPT</SMALL>
E<SMALL>MPLOYEES</SMALL></B><SMALL></SMALL>. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT>
Employee</I></B>&#148;), and except as otherwise provided in the Plan, you may not exercise your </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">option until you have completed at least six months of Continuous Service measured from the
Date of Grant, even if you have already been an employee for more than six months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six month anniversary in
the case of (i)&nbsp;your death or disability, (ii)&nbsp;a Corporate Transaction in which your option is not assumed, continued or substituted, (iii)&nbsp;a Change in Control or (iv) your termination of Continuous Service on your
&#147;retirement&#148; (as defined in the Company&#146;s benefit plans). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>4. E<SMALL>XERCISE</SMALL>
P<SMALL>RIOR</SMALL> <SMALL>TO</SMALL> V<SMALL>ESTING</SMALL> (&#147;E<SMALL>ARLY</SMALL> E<SMALL>XERCISE</SMALL>&#148;</B>). If permitted in your Grant Notice (<I>i.e.</I>, the &#147;Exercise Schedule&#148; indicates &#147;Early Exercise
Permitted&#148;) and subject to the provisions of your option, you may elect at any time that is both (i)&nbsp;during the period of your Continuous Service and (ii)&nbsp;during the term of your option, to exercise all or part of your option,
including the unvested portion of your option; <I>provided, however,</I> that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> a partial exercise of your
option will be deemed to cover first vested shares of Common Stock and then the earliest vesting installment of unvested shares of Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> any shares of Common Stock so purchased from installments that have not vested as of the date of exercise will be
subject to the purchase option in favor of the Company as described in the Company&#146;s form of Early Exercise Stock Purchase Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> you will enter into the Company&#146;s form of Early Exercise Stock Purchase Agreement with a vesting schedule that
will result in the same vesting as if no early exercise had occurred; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> if your option is an Incentive Stock
Option, then, to the extent that the aggregate Fair Market Value (determined at the Date of Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable for the first time by
you during any calendar year (under all plans of the Company and its Affiliates) exceeds $100,000, your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as Nonstatutory Stock
Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>5.</B> <B>M<SMALL>ETHOD</SMALL> <SMALL>OF</SMALL> P<SMALL>AYMENT</SMALL></B><SMALL></SMALL>. You must pay the
full amount of the exercise price for the<B> </B>shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner <B><I>permitted by your Grant Notice,</I></B>
which may include one or more of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Provided that at the time of exercise the Common Stock is
publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of
irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a &#147;broker-assisted exercise&#148;, &#147;same day sale&#148;, or &#147;sell to cover&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by
actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. &#147;Delivery&#148;
for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">not exercise your option by delivery to the Company of Common Stock if doing so would
violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#146;s stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a
&#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate
exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the &#147;net exercise&#148; in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and
will not be exercisable thereafter if those shares (i)&nbsp;are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (ii) are delivered to you as a result of such exercise, and (iii)&nbsp;are withheld to satisfy your tax
withholding obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>6. W<SMALL>HOLE</SMALL> S<SMALL>HARES</SMALL></B><SMALL></SMALL>. You may exercise your option
only for whole shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>7.</B> <B>S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL>
C<SMALL>OMPLIANCE</SMALL></B><SMALL></SMALL>. In no event may you exercise your option unless the<B> </B>shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined
that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you
may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. <FONT
STYLE="white-space:nowrap">1.401(k)-1(d)(3),</FONT> if applicable). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>8.</B> <B>T<SMALL>ERM</SMALL></B><SMALL></SMALL>.
You may not exercise your option before the Date of Grant or after the expiration<B> </B>of the option&#146;s term. Except as set forth in your Grant Notice, the term of your option expires, subject to the provisions of Section&nbsp;5(h) of the
Plan, upon the earliest of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>immediately upon the termination of your Continuous Service for
Cause; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> three months after the termination of your Continuous Service for any reason other than Cause, your
Disability or your death (except as otherwise provided in Section&nbsp;8(d) below); <I>provided, however, </I>that if during any part of such three month period your option is not exercisable solely<I> </I>because of the condition set forth in the
section above relating to &#147;Securities Law Compliance,&#148; your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous
Service; <I>provided further,</I> that if (i)&nbsp;you are a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employee, (ii)&nbsp;your Continuous Service terminates within six months after the Date of Grant, and (iii)&nbsp;you have vested in a
portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x)&nbsp;the later of (A)&nbsp;the date that is seven months after the Date of Grant, and (B)&nbsp;the date that is three
months after the termination of your Continuous Service, and (y)&nbsp;the Expiration Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> 12 months after the
termination of your Continuous Service due to your Disability (except as otherwise provided in Section&nbsp;8(d)) below; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> 18 months after your death if you die either during your Continuous Service or within three (3)&nbsp;months after
your Continuous Service terminates for any reason other than Cause; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) </B>the Expiration Date indicated in your Grant
Notice; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) </B>the day before the 10th anniversary of the Date of Grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an
Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your option&#146;s exercise, you must be an employee of the Company or an Affiliate, except in the event
of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you
continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three months after the date your employment with the Company or an Affiliate
terminates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>9. E<SMALL>XERCISE</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so
permits) during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours,
together with such additional documents as the Company may then require <B><U>(including, without limitation, any voting agreement or</U></B> <B><U>other agreement between the Company and certain of its stockholders)</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you
to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i)&nbsp;the exercise of your option, (ii)&nbsp;the lapse of any substantial risk of forfeiture to
which the shares of Common Stock are subject at the time of exercise, or (iii)&nbsp;the disposition of shares of Common Stock acquired upon such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in
writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the Date of Grant or within one year after such shares of Common Stock are
transferred upon exercise of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> By exercising your option you agree that you will not sell, dispose
of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held
by you, for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule
2711 or NYSE Member Rule 472 or any successor or similar rule<STRIKE>s</STRIKE> or regulation (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;); <I>provided,</I> <I>however</I>, that nothing contained in this
section will prevent the exercise of a repurchase option, if any, in<I> </I>favor of the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. You further agree to execute and deliver such other agreements as may be reasonably
requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to
your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section&nbsp;9(d). The underwriters of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Company&#146;s stock are intended third party beneficiaries of this Section&nbsp;9(d) and
will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>10.</B>
<B>T<SMALL>RANSFERABILITY</SMALL></B><SMALL></SMALL>. Except as otherwise provided in this Section&nbsp;10, your option is not<B> </B>transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only
by you. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Certain Trusts</B>. Upon receiving written permission from the Board or its duly<B> </B>authorized
designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section&nbsp;671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter
into transfer and other agreements required by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Domestic Relations Orders</B>. Upon receiving
written permission from the Board<B> </B>or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a
domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation <FONT STYLE="white-space:nowrap">1.421-1(b)(2)</FONT> that contains the information required by the Company
to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is
contained within the domestic relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Beneficiary Designation</B>. Upon receiving written permission from the Board or<B> </B>its duly authorized
designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to
exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on
behalf of your estate, the Common Stock or other consideration resulting from such exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>11.</B>
<B>O<SMALL>PTION</SMALL> <SMALL>NOT</SMALL> <SMALL>A</SMALL> S<SMALL>ERVICE</SMALL> C<SMALL>ONTRACT</SMALL></B><SMALL></SMALL>. Your option is not an employment or service<B> </B>contract, and nothing in your option will be deemed to create in any
way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their
respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>12. W<SMALL>ITHHOLDING</SMALL> O<SMALL>BLIGATIONS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company,
you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#147;same day sale&#148; pursuant to a program developed under Regulation T as
promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with
the exercise of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> If this option is a Nonstatutory Stock Option, then upon your request and subject
to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">exercise of your option a number of whole shares of Common Stock having a Fair Market Value,
determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting
purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and
timely election under Section&nbsp;83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax
withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option
that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are
satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock
from any escrow provided for herein, if applicable, unless such obligations are satisfied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>13.</B>
<B>T<SMALL>AX</SMALL> C<SMALL>ONSEQUENCES</SMALL></B><SMALL></SMALL>. You hereby agree that the Company does not have a duty to<B> </B>design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities.
You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt
from Section&nbsp;409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#147;fair market value&#148; per share of the Common Stock on the Date of Grant and there is no other impermissible
deferral of compensation associated with the option. Because the Common Stock is not traded on an established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by
the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will agree with the valuation as determined by the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or
Affiliates in the event that the Internal Revenue Service asserts that the valuation determined by the Board is less than the &#147;fair market value&#148; as subsequently determined by the Internal Revenue Service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>14.</B> <B>N<SMALL>OTICES</SMALL></B><SMALL></SMALL>. Any notices provided for in your option or the Plan will be given in
writing<B> </B>(including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid, addressed to you at
the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by
electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the
Company or another third party designated by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>15.</B> <B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL>
D<SMALL>OCUMENT</SMALL></B><SMALL></SMALL>. Your option is subject to all the provisions of the Plan,<B> </B>the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and
regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017 EQUITY INCENTIVE PLAN </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Equillium, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2223 Avenida de la Playa </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 108 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Jolla, California 92037 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Date of Exercise:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This constitutes notice to <B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B> (the &#147;<B><I>Company</I></B>&#148;) under
my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the &#147;<B><I>Shares</I></B>&#148;) for the price set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Type of option (check one):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Incentive&nbsp;&#9744;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Nonstatutory&nbsp;&#9744;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stock option dated:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Number of Shares as to which option is exercised:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Certificates to be issued in name of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Total exercise price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cash payment delivered herewith:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulation T Program (cashless exercise<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Value of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Shares
delivered herewith<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U></U>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By this exercise, I agree (i)&nbsp;to provide such additional documents as you may require
pursuant to the terms of the 2017 Equity Incentive Plan, (ii)&nbsp;to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise
relates to an incentive stock option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant of this option or within
one year after such Shares are issued upon exercise of this option. I further agree that this Notice of Exercise may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of
2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shares must meet the public trading requirements set forth in the option agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shares must meet the public trading requirements set forth in the option. Shares must be valued in
accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I hereby make the following certifications and representations with respect
to the number of Shares listed above, which are being acquired by me for my own account upon exercise of the option as set forth above: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I acknowledge that the Shares have not been registered under the Securities Act of 1933, as amended (the
&#147;<B><I>Securities Act</I></B>&#148;), and are deemed to constitute &#147;restricted securities&#148; under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and represent to the Company that I have no present intention of
distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I further acknowledge and agree that, except for such information as required to be delivered to me by the Company pursuant to
the option or the Plan (if any), I will have no right to receive any information from the Company by virtue of the grant of the option or the purchase of shares of Common Stock through exercise of the option, ownership of such shares of Common
Stock, or as a result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by law, I hereby waive all inspection rights under Section&nbsp;220 of the Delaware General Corporation Law
and all such similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or foreign regulation, that are, or may become, applicable to the Company or the Company&#146;s capital stock
(the &#147;<B><I>Inspection Rights</I></B>&#148;). I hereby covenant and agree never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other
proceeding to pursue or exercise the Inspection Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I further acknowledge that I will not be able to resell the
Shares for at least 90 days after the stock of the Company becomes publicly traded (<I>i.e.,</I> subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934) under Rule 701 and that more restrictive
conditions apply to affiliates of the Company under Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I further acknowledge that all certificates representing
any of the Shares subject to the provisions of the option shall have endorsed thereon appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company&#146;s Certificate of
Incorporation, Bylaws and/or applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I further agree that, if required by the Company (or a
representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for
the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of 180 days following the effective date of a
registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or
regulation) (the &#147;<B><I>Lock- Up</I></B> <B><I>Period</I></B>&#148;). I further agree to execute and deliver such other agreements as may be reasonably requested by<B><I> </I></B>the Company or the underwriters that are consistent with the
foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Name (Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="right">Address&nbsp;of&nbsp;Record:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Equillium, Inc. &#150; Signature Page to Notice of Exercise] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>8
<FILENAME>d582934dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IPO
D<SMALL>ATE</SMALL>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
G<SMALL>ENERAL</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Successor to and Continuation of Prior Plan.</B> The Plan is intended as the successor to and
continuation of the Equillium, Inc. 2017 Equity Incentive Plan (the &#147;<B><I>Prior Plan</I></B>&#148;). From and after 12:01 a.m. Pacific Time on the IPO Date, no additional stock awards will be granted under the Prior Plan. All Awards granted on
or after 12:01 a.m. Pacific Time on the IPO Date will be granted under this Plan. All stock awards granted under the Prior Plan will remain subject to the terms of the Prior Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Any shares that would otherwise remain available for future grants under the Prior Plan as of 12:01 a.m. Pacific Time on the IPO
Date (the &#147;<B><I>Prior Plan&#146;s Available Reserve</I></B>&#148;) will cease to be available under the Prior Plan at such time. Instead, that number of shares of Common Stock equal to the Prior Plan&#146;s Available Reserve will be added to
the Share Reserve (as further described in Section&nbsp;3(a) below) and will be immediately available for grants and issuance pursuant to Stock Awards hereunder, up to the maximum number set forth in Section&nbsp;3(a) below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In addition, from and after 12:01 a.m. Pacific Time on the IPO Date, any shares subject, at such time, to outstanding stock awards
granted under the Prior Plan that (i) expire or terminate for any reason prior to exercise or settlement; (ii) are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise return to the Company;
or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award (such shares the &#147;<B><I>Returning Shares</I></B>&#148;)
will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when such shares become Returning Shares, up to the maximum number set forth in Section 3(a) below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Eligible Award Recipients.</B> Employees, Directors and Consultants are eligible to receive Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Available Awards.</B> The Plan provides for the grant of the following types of Awards: (i)&nbsp;Incentive Stock Options,
(ii)&nbsp;Nonstatutory Stock Options, (iii)&nbsp;Stock Appreciation Rights (iv)&nbsp;Restricted Stock Awards, (v)&nbsp;Restricted Stock Unit Awards, (vi)&nbsp;Performance Stock Awards, (vii)&nbsp;Performance Cash Awards, and (viii)&nbsp;Other Stock
Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Purpose.</B> The Plan, through the granting of Awards, is intended to help the Company secure and retain the
services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the
Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. A<SMALL>DMINISTRATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Administration by Board.</B> The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee
or Committees, as provided in Section&nbsp;2(c). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Powers of Board.</B> The Board will have the power, subject to, and within the
limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine (A)&nbsp;who will be granted Awards; (B)&nbsp;when and how
each Award will be granted; (C)&nbsp;what type of Award will be granted; (D)&nbsp;the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the
Award; (E)&nbsp;the number of shares of Common Stock subject to, or the cash value of, an Award; and (F)&nbsp;the Fair Market Value applicable to a Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for
administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement or in the written terms of a Performance Cash Award, in a manner and to the
extent it will deem necessary or expedient to make the Plan or Award fully effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To settle all controversies regarding
the Plan and Awards granted under it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To accelerate, in whole or in part, the time at which an Award may be exercised or vest
(or the time at which cash or shares of Common Stock may be issued in settlement thereof). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To suspend or terminate the Plan at
any time. Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#146;s rights under the Participant&#146;s then-outstanding Award without the Participant&#146;s
written consent except as provided in subsection (viii)&nbsp;below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To amend the Plan in any respect the Board deems necessary
or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section&nbsp;409A of the Code and/or bringing the Plan or Awards granted under the Plan into
compliance with the requirements for Incentive Stock Options or ensuring that they are exempt from or compliant with the requirements for nonqualified deferred compensation under Section&nbsp;409A of the Code, subject to the limitations, if any, of
applicable law. If required by applicable law or listing requirements, and except as provided in Section&nbsp;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that
(A)&nbsp;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&nbsp;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&nbsp;materially increases the benefits
accruing to Participants under the Plan, (D)&nbsp;materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E)&nbsp;materially extends the term of the Plan, or (F)&nbsp;materially expands the types of
Awards available for issuance under the Plan. Except as otherwise provided in the Plan or an Award Agreement, no amendment of the Plan will materially impair a Participant&#146;s rights under an outstanding Award without the Participant&#146;s
written consent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to
the Plan intended to satisfy the requirements of (A)&nbsp;Section&nbsp;422 of the Code regarding incentive stock options or (B)&nbsp;Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not
limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; <I>provided however,</I> that a
Participant&#146;s rights under any Award will not be impaired by any such amendment unless (A)&nbsp;the Company requests the consent of the affected Participant, and (B)&nbsp;such Participant consents in writing. Notwithstanding the foregoing,
(1)&nbsp;a </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant&#146;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially
impair the Participant&#146;s rights, and (2)&nbsp;subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#146;s consent (A)&nbsp;to maintain the qualified
status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (B)&nbsp;to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the
Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (C)&nbsp;to clarify the manner of exemption from, or to bring the Award into compliance with, Section&nbsp;409A of the Code; or (D)&nbsp;to comply with other applicable laws or
listing requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to
promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> To adopt such
procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided
that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(xi)</B> To effect, with the consent of any adversely affected Participant, (A)&nbsp;the reduction of the exercise, purchase or strike price
of any outstanding Stock Award; (B)&nbsp;the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1)&nbsp;Option or SAR, (2)&nbsp;Restricted Stock Award, (3)&nbsp;Restricted Stock Unit Award, (4)&nbsp;Other
Stock Award, (5)&nbsp;cash and/or (6)&nbsp;other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x)&nbsp;covering the same or a different number of shares of Common Stock as the cancelled
Stock Award and (y)&nbsp;granted under the Plan or another equity or compensatory plan of the Company; or (C)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Delegation to Committee. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> <B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of
administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in
the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance.</B> The Committee may consist solely of two or more <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors, in accordance with Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Delegation</B><B> to an Officer</B>. The Board may delegate to one or more Officers the authority to do one or both of the
following (i)&nbsp;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Awards, and
(ii)&nbsp;determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; <I>provided, however</I>, that the Board resolutions </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award
to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority. The
Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section&nbsp;13(w)(iii) below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Effect of Board&#146;s Decision.</B> All determinations, interpretations and constructions made by the Board in good faith will
not be subject to review by any person and will be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL>
<SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Share
Reserve. </B>Subject to Section&nbsp;9(a) relating to Capitalization Adjustments, and the following sentence regarding the annual increase, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards will not exceed
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (the &#147;<B><I>Share Reserve</I></B>&#148;), which number is the sum of (i)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new shares, <I>plus</I> (ii)&nbsp;the number of shares subject to the Prior Plan&#146;s Available Reserve <I>plus</I>
(iii)&nbsp;the number of shares that are Returning Shares, as such shares become available from time to time. In addition, the Share Reserve will automatically increase on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each
year, for a period of not more than ten years, commencing on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the year following the year in which the IPO Date occurs and ending on (and including) January&nbsp;1, 2028, in an
amount equal to &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of Capital Stock outstanding on December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> of a given year to provide that there will be no January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> increase in the Share Reserve for such year or that the increase in the Share
Reserve for such year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For clarity, the Share Reserve in this Section&nbsp;3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant
to the Plan. Accordingly, this Section&nbsp;3(a) does not limit the granting of Stock Awards except as provided in Section&nbsp;7(a). Shares may be issued in connection with a merger or acquisition as permitted by Nasdaq Listing Rule 5635(c) or, if
applicable, NYSE Listed Company Manual Section&nbsp;303A.08, AMEX Company Guide Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Reversion of Shares to the Share Reserve. </B>If a Stock Award or any portion thereof (i)&nbsp;expires or otherwise terminates
without all of the shares covered by such Stock Award having been issued or (ii)&nbsp;is settled in cash (<I>i.e.</I>, the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset)
the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased or reacquired by the Company for any reason, including
because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Plan. Any
shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Incentive Stock Option Limit. </B>Subject to the Share Reserve and
Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Limitation on Grants to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors. </B>The maximum number of shares of
Common Stock subject to Stock Awards granted under the Plan or otherwise during a single calendar year to any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, taken together with any cash fees paid by the Company to such <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director during such calendar year for service on the Board, will not exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in
total value (calculating the value of any such Stock Awards based on the grant date fair value of such Stock Awards for financial reporting purposes), or, with respect to the calendar year in which a
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is first appointed or elected to the Board, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Source of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock,
including shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. E<SMALL>LIGIBILITY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Eligibility for Specific Stock Awards</B>. Incentive Stock Options may be granted only to employees of the Company or a
&#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and
Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#147;parent&#148; of the Company, as such term is defined in Rule 405 of the Securities
Act, unless (i)&nbsp;the stock underlying such Stock Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin
off transaction), (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section&nbsp;409A of the Code, or (iii)&nbsp;the Company, in consultation with its legal counsel, has
determined that such Stock Awards comply with the distribution requirements of Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Ten Percent
Stockholders.</B> A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration
of five years from the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. P<SMALL>ROVISIONS</SMALL> R<SMALL>ELATING</SMALL> <SMALL>TO</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL>
S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option or SAR will be in such form and will contain such
terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will
be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the
Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; <I>provided, however</I>,
that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Term.</B> Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable
after the expiration of ten (10)&nbsp;years from the date of its grant or such shorter period specified in the Award Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Exercise Price.</B> Subject to the provisions of Section&nbsp;4(b) regarding Ten
Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted. Notwithstanding the foregoing, an Option
or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation
right pursuant to a corporate transaction and in a manner consistent with the provisions of Section&nbsp;409A of the Code and, if applicable, Section&nbsp;424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Purchase Price for Options.</B> The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to
the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following
methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> by cash, check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the
stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> if an Option is a Nonstatutory Stock Option, by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce
the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; <I>provided, however</I>, that the Company will accept a cash or other
payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will
not be exercisable thereafter to the extent that (A)&nbsp;shares issuable upon exercise are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (B) shares are delivered to the Participant as a result of such exercise, and
(C)&nbsp;shares are withheld to satisfy tax withholding obligations; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> in any other form of legal consideration that may be
acceptable to the Board and specified in the applicable Award Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Exercise and Payment of a SAR.</B> To exercise any
outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR
will be not greater than an amount equal to the excess of (A)&nbsp;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the
Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B)&nbsp;the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is
exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such
SAR. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Transferability of Options and SARs.</B> The Board may, in its sole discretion,
impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> <B>Restrictions on Transfer</B>. An Option or SAR will not be transferable except by will or by the laws of
descent and distribution (or pursuant to subsections (ii)&nbsp;and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is not
prohibited by applicable tax and securities laws. Except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Domestic Relations Orders</B>. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be
transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(b)(2).</FONT>
If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Beneficiary Designation</B>. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by
delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common
Stock or other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#146;s estate will be entitled to exercise the Option or SAR and
receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with
the provisions of applicable laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Vesting Generally.</B> The total number of shares of Common Stock subject to an Option or
SAR may vest and become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the
satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section&nbsp;5(f) are subject to any Option or SAR provisions governing the
minimum number of shares of Common Stock as to which an Option or SAR may be exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Termination of Continuous
Service.</B> Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates (other than for Cause and other than upon the
Participant&#146;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) within the period of time
ending on the earlier of (i)&nbsp;the date that is three (3)&nbsp;months following the termination of the Participant&#146;s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement, which period will not be
less than thirty (30)&nbsp;days if necessary to comply with applicable laws unless such termination is for Cause) and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous
Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Extension of Termination Date.</B> Except as otherwise provided in the applicable Award Agreement or other written agreement
between the Participant and the Company, if the exercise of an Option or SAR following the termination of the Participant&#146;s Continuous Service (other than for Cause and other than upon the Participant&#146;s death or Disability) would be
prohibited at any time solely because the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i)&nbsp;the expiration of a total
period of time (that need not be consecutive) equal to the applicable post termination exercise period after the termination of the Participant&#146;s Continuous Service during which the exercise of the Option or SAR would not be in violation of
such registration requirements, and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided in a Participant&#146;s Award Agreement, if the sale of any Common
Stock received on exercise of an Option or SAR following the termination of the Participant&#146;s Continuous Service (other than for Cause) would violate the Company&#146;s insider trading policy, then the Option or SAR will terminate on the
earlier of (i)&nbsp;the expiration of a period of months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#146;s Continuous Service during which the sale of the Common
Stock received upon exercise of the Option or SAR would not be in violation of the Company&#146;s insider trading policy, or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> <B>Disability of Participant.</B> Except as otherwise provided in the applicable Award Agreement or other agreement
between the Participant and the Company, if a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled
to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&nbsp;the date twelve (12)&nbsp;months following such termination of Continuous Service (or such
longer or shorter period specified in the Award Agreement, which period will not be less than six (6)&nbsp;months if necessary to comply with applicable laws) and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award
Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Death of Participant.</B> Except as otherwise provided in the applicable Award Agreement or other agreement between the
Participant and the Company, if (i)&nbsp;a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s death, or (ii)&nbsp;the Participant dies within the period (if any) specified in the Award Agreement for exercisability
after the termination of the Participant&#146;s Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the
Participant&#146;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#146;s death, but only within the period ending on the
earlier of (i)&nbsp;the date eighteen (18)&nbsp;months following the date of death (or such longer or shorter period specified in the Award Agreement, which period will not be less than six (6)&nbsp;months if necessary to comply with applicable
laws) and (ii)&nbsp;the expiration of the term of such Option or SAR as set forth in the Award Agreement. If, after the Participant&#146;s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable)
will terminate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Termination for Cause.</B> Except as explicitly provided otherwise in a Participant&#146;s Award Agreement
or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#146;s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant&#146;s termination
of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B>. If an Option or SAR is granted to an Employee who is a <FONT
STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six (6)&nbsp;months following the
date of grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i)&nbsp;if such <FONT STYLE="white-space:nowrap">non-exempt</FONT> Employee dies or suffers
a Disability, (ii)&nbsp;upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substituted, (iii)&nbsp;upon a Change in Control, or (iv)&nbsp;upon the Participant&#146;s retirement (as such term may be defined in the Participant&#146;s Award Agreement, in another agreement
between the Participant and the Company, or, if no such definition, in accordance with the Company&#146;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six&nbsp;(6) months
following the date of grant. The foregoing provision is intended to operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be exempt
from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection
with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#146;s regular rate of pay, the provisions of this Section&nbsp;5(l) will apply to all Stock Awards and are hereby incorporated by
reference into such Stock Award Agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. P<SMALL>ROVISIONS</SMALL> <SMALL>OF</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>WARDS</SMALL>
O<SMALL>THER</SMALL> <SMALL>THAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> SAR<SMALL>S</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Restricted Stock
Awards.</B> Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. To the extent consistent with the Company&#146;s bylaws, at the Board&#146;s election, shares of Common
Stock may be (i)&nbsp;held in book entry form subject to the Company&#146;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii)&nbsp;evidenced by a certificate, which certificate will be held in such form and
manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock
Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Consideration.</B> A Restricted Stock Award may be awarded in consideration for (A)&nbsp;cash, check, bank draft or money order
payable to the Company, (B)&nbsp;past or future services to the Company or an Affiliate, or (C)&nbsp;any other form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Vesting. </B>Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the
Company in accordance with a vesting schedule to be determined by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Termination of Participant&#146;s Continuous
Service.</B> If a Participant&#146;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of
Continuous Service under the terms of the Restricted Stock Award Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Transferability.</B> Rights to acquire shares
of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so
long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B>Dividends. </B>A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the
same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Restricted Stock Unit Awards. </B>Each Restricted Stock Unit Award Agreement will
be in such form and will contain such terms and conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock
Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> <B>Consideration.</B> At the time of grant of a Restricted Stock Unit Award, the Board will determine the
consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a
Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Vesting. </B>At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions
to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Payment</B>. A
Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Additional Restrictions. </B>At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems
appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B>Dividend Equivalents. </B>Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock
Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock
Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying
Restricted Stock Unit Award Agreement to which they relate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> <B>Termination of Participant</B><B>&#146;</B><B>s Continuous
Service. </B>Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement or other written agreement between a Participant and the Company or an Affiliate, such portion of the Restricted Stock Unit Award that has not vested
will be forfeited upon the Participant&#146;s termination of Continuous Service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Performance Awards</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> <B>Performance Stock Awards</B>. A Performance Stock Award is a Stock Award that is payable (including that may be
granted, may vest or may be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the Participant&#146;s completion of a specified period of
Continuous Service. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by
the Board or Committee, in its sole discretion. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board or the Committee may determine that cash may be used in payment of Performance Stock Awards. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Performance Cash Awards</B>. A Performance Cash Award is a cash award that is
payable contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Cash Award may also require the completion of a specified period of Continuous Service. At the time of grant of a Performance Cash Award,
the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Board or
Committee, in its sole discretion. The Board or Committee may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or
such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Board
Discretion</B>. The Board retains the discretion to adjust or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a
Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Stock Award Agreement or the written terms of a Performance Cash Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Other Stock Awards</B>. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common
Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to
Stock Awards provided for under Section&nbsp;5 and the preceding provisions of this Section&nbsp;6. Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at
which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Availability of Shares.</B> The Company will keep available at all times the number of shares of Common Stock reasonably required
to satisfy then-outstanding Stock Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Securities Law Compliance.</B> The Company will seek to obtain from each
regulatory commission or agency having jurisdiction over the Plan, as necessary, such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Stock Awards; <I>provided,
however</I>, that this undertaking will not require the Company to register under the Securities Act or other securities or applicable laws, the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after
reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under
the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an
Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>No Obligation to Notify or Minimize Taxes. </B>The Company will have no duty or obligation to any Participant to advise such
holder as to the tax treatment or time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period
in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. M<SMALL>ISCELLANEOUS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Use of Proceeds from Sales of Common Stock. </B>Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will
constitute general funds of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Corporate Action Constituting Grant of Awards.</B> Corporate action constituting a
grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is
communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price,
vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will
control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Stockholder Rights.</B> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect
to, any shares of Common Stock subject to an Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii)&nbsp;the
issuance of the Common Stock subject to such Award has been entered into the books and records of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>No Employment
or Other Service Rights.</B> Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or
an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i)&nbsp;the employment of an Employee with or without notice and with or without cause, (ii)&nbsp;the
service of a Consultant pursuant to the terms of such Consultant&#146;s agreement with the Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the
corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is domiciled or incorporated, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Change in Time Commitment</B>. In the event a Participant&#146;s regular level of time commitment in the performance of his or
her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an
extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x)&nbsp;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award
that is scheduled to vest or become payable after the date of such change in time commitment, and (y)&nbsp;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such
reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>
<B>Incentive Stock Option Limitations.</B> To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder
during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions
thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option
Agreement(s). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Investment Assurances.</B> The Company may require a Participant, as a condition of
exercising or acquiring Common Stock under any Award, (i)&nbsp;to give written assurances satisfactory to the Company as to the Participant&#146;s knowledge and experience in financial and business matters and/or to employ a purchaser representative
reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that such Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising
the Award; and (ii)&nbsp;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#146;s own account and not with any present intention of selling or
otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A)&nbsp;the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock
Award has been registered under a then currently effective registration statement under the Securities Act, or (B)&nbsp;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the
circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with
applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Withholding
Obligations.</B> Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of
such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; <I>provided,
however, </I>that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for
financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to the Participant; or (v)&nbsp;by such other method as may be set forth in the Award Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Electronic Delivery</B>. Any reference herein to a &#147;written&#148; agreement or document will include any agreement or
document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#146;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Deferrals.</B> To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of
Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants
will be made in accordance with Section&nbsp;409A of the Code. Consistent with Section&nbsp;409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board
is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#146;s termination of Continuous Service, and implement such
other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>
<B>Clawback/Recovery</B>. All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or
association on which the Company&#146;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or
recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of an event constituting Cause. No recovery of compensation under such a
clawback policy will be an event giving rise to a right to voluntary terminate employment upon a &#147;resignation for good reason,&#148; or for a &#147;constructive termination&#148; or any similar term under any plan of or agreement with the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B>Compliance with Section</B><B></B><B>&nbsp;409A of the Code. </B>Unless otherwise expressly provided for in an
Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A of the Code, and, to the extent not so exempt, in
compliance with Section&nbsp;409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A of the Code, the Award Agreement evidencing such Award will incorporate the
terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the
Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes
&#147;deferred compensation&#148; under Section&nbsp;409A of the Code is a &#147;specified employee&#148; for purposes of Section&nbsp;409A of the Code, no distribution or payment of any amount that is due because of a &#147;separation from
service&#148; (as defined in Section&nbsp;409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant&#146;s &#147;separation from
service&#148; or, if earlier, the date of the Participant&#146;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A of the Code, and any amounts so deferred will be paid in a lump sum on the day
after such six month period elapses, with the balance paid thereafter on the original schedule. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL>
C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Capitalization Adjustments</B>. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately
adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii) the class(es) and maximum number of securities by which the share reserve is to increase automatically each year pursuant to
Section&nbsp;3(a), (iii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;3(c), (iv) the class(es) and maximum number of securities that may be awarded to
any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director pursuant to Section&nbsp;3(d), and (v)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such
adjustments, and its determination will be final, binding and conclusive. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Dissolution</B>. Except as otherwise provided in
the Stock Award Agreement, in the event of a Dissolution of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s
right of repurchase) will terminate immediately prior to the completion of such Dissolution, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the
Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service; <I>provided, however,</I> that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no
longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the Dissolution is completed but contingent on its completion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Transaction.</B> The following provisions will apply to Stock Awards in the event of a Transaction unless otherwise provided in
the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the Board at the time of grant of a Stock Award. In the event of a Transaction, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions
with respect to Stock Awards, contingent upon the closing or completion of the Transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> arrange for the surviving
corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to
acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> arrange for the
assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent
company); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock
Award may be exercised) to a date prior to the effective time of such Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective date of the Transaction), with such
Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Transaction; <I>provided, however</I>, that the Board may require Participants to complete and deliver to the Company a notice of exercise before the
effective date of a Transaction, which exercise is contingent upon the effectiveness of such Transaction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> arrange for the
lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock Award; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>
cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider
appropriate; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A)&nbsp;the
value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Transaction, over (B)&nbsp;any exercise price payable by such holder in connection with such exercise. For
clarity, this payment may be $0 if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#146;s Common Stock
in connection with the Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board need not
take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of a Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Change in Control.</B> A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a
Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such
acceleration will automatically occur. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. P<SMALL>LAN</SMALL> T<SMALL>ERM</SMALL>; E<SMALL>ARLIER</SMALL> T<SMALL>ERMINATION</SMALL>
<SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may suspend or
terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of (i)&nbsp;the date the Plan is adopted by the Board (the &#147;<B><I>Adoption Date</I></B>&#148;), or (ii)&nbsp;the date the Plan
is approved by the stockholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.
E<SMALL>XISTENCE</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>; T<SMALL>IMING</SMALL> <SMALL>OF</SMALL> F<SMALL>IRST</SMALL> G<SMALL>RANT</SMALL> <SMALL>OR</SMALL> E<SMALL>XERCISE</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will come into existence on the Adoption Date; <I>provided, however</I>, that no Stock Award may be granted prior to the IPO Date. In
addition, no Stock Award will be exercised (or, in the case of a Restricted Stock Award, Restricted Stock Unit Award, Performance Share Award, or Other Stock Award, no Stock Award will be granted) and no Performance Cash Award will be settled unless
and until the Plan has been approved by the stockholders of the Company, which approval will be within 12 months after the date the Plan is adopted by the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without
regard to that state&#146;s conflict of laws rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>D<SMALL>EFINITIONS</SMALL>. </B>As used in the Plan, the following definitions will
apply to the capitalized terms indicated below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any
&#147;parent&#148; or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is
determined within the foregoing definition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Award</I></B>&#148; means a Stock Award or a Performance Cash Award.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the terms
and conditions of an Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Capital Stock</I></B>&#148; means each and every class of common stock of the Company, regardless of the number of votes
per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur
with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock
dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring
transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company
will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Cause</I></B>&#148;<B><I> </I></B>shall have the meaning
ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events:
(i)&nbsp;such Participant&#146;s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii)&nbsp;such Participant&#146;s attempted commission of, or
participation in, a fraud or act of dishonesty against the Company; (iii)&nbsp;such Participant&#146;s intentional, material violation of </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv)&nbsp;such Participant&#146;s unauthorized use or disclosure of the
Company&#146;s confidential information or trade secrets; or (v)&nbsp;such Participant&#146;s gross misconduct. The determination that a termination of the Participant&#146;s Continuous Service is either for Cause or without Cause shall be made by
the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant shall have no effect upon any
determination of the rights or obligations of the Company or such Participant for any other purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Change in
Control</I></B>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the
combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A)&nbsp;on account of the
acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s
securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, (C)&nbsp;on account of the acquisition of securities of the Company by any
individual who is, on the IPO Date, either an executive officer or a Director (either, an &#147;<B><I>IPO Investor</I></B>&#148;) and/or any entity in which an IPO Investor has a direct or indirect interest (whether in the form of voting rights or
participation in profits or capital contributions) of more than 50% (collectively, the &#147;<B><I>IPO Entities</I></B>&#148;) or on account of the IPO Entities continuing to hold shares that come to represent more than 50% of the combined voting
power of the Company&#146;s then outstanding securities as a result of the conversion of any class of the Company&#146;s securities into another class of the Company&#146;s securities having a different number of votes per share pursuant to the
conversion provisions set forth in the Company&#146;s Amended and Restated Certificate of Incorporation; or (D)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;) exceeds the
designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur
(but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or
other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately
after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing more than 50% of
the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation
or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; <I>provided, however</I>, that a merger, consolidation or
similar transaction will not constitute a Change in Control under this prong of the definition if the outstanding voting securities representing more than 50% of the combined voting power of the surviving Entity or its parent are owned by the IPO
Entities; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> there is consummated a sale, lease, exclusive license or other disposition of all or
substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more
than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
sale, lease, license or other disposition; <I>provided, however</I>, that a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries will not constitute a Change
in Control under this prong of the definition if the outstanding voting securities representing more than 50% of the combined voting power of the acquiring Entity or its parent are owned by the IPO Entities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a
complete dissolution or liquidation of the Company will otherwise occur, except for a liquidation into a parent corporation; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>
individuals who, on the IPO Date, are members of the Board (the &#147;<B><I>Incumbent</I></B><B><I></I></B><B><I>&nbsp;Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; <I>provided, however,</I>
that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be
considered as a member of the Incumbent Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing definition or any other provision of the Plan, (A)&nbsp;the
term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company and (B)&nbsp;the definition of Change in Control (or any analogous term) in an
individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Awards subject to such agreement; <I>provided, however</I>, that if no definition of Change in Control or
any analogous term is set forth in such an individual written agreement, the foregoing definition will apply. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>
&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Committee</I></B>&#148; means a committee of one or more Directors to whom authority has been delegated by the Board in
accordance with Section&nbsp;2(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Common Stock</I></B>&#148; means, as of the IPO Date, the common stock of the
Company, having one vote per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><I>Company</I></B>&#148; means Equillium, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a
fee for such service, will not cause a Director to be considered a &#147;Consultant&#148; for purposes of the Plan.<B><I> </I></B>Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form <FONT
STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#146;s securities to such person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an Affiliate, whether as
an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the
Participant renders such service, provided </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, will not terminate a Participant&#146;s Continuous Service; <I>provided,
however</I>,<I> </I>that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#146;s Continuous Service will be considered to have
terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service will be
considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or
their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#146;s leave of absence policy, in the written terms
of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B>
&#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other disposition of all or substantially all, as determined by the Board, in its sole discretion, of the
consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or other disposition of more than 50% of the outstanding
securities of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the Company is not the surviving
corporation; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is the surviving corporation but
the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of
securities, cash or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><I>Director</I></B>&#148; means a member of the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Disability</I></B>&#148; means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided
in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Dissolution</I></B>&#148; means when the Company, after having executed a certificate of dissolution with the State of
Delaware (or other applicable state), has completely wound up its affairs. Conversion of the Company into a Limited Liability Company (or any other pass-through entity) will not be considered a &#147;Dissolution&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service solely as a Director,
or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><I>Exchange Act Person</I></B>&#148;<B><I>
</I></B>means any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; will not include (i)&nbsp;the Company or any Subsidiary of the
Company, (ii)&nbsp;any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an
underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of
stock of the Company; or (v)&nbsp;any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the IPO Date, is the Owner, directly or indirectly, of securities of the Company
representing more than 50% of the combined voting power of the Company&#146;s then outstanding securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#147;<B><I>Fair
Market Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is
listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or
market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then
the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In the
absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 of the Plan that is intended to
be, and qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><I>IPO
Date</I></B>&#148; means the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148;<B> </B>means a Director who either
(i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a
Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#147;<B><I>Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged
in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K;</FONT> or (ii)&nbsp;is otherwise considered a
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means any Option granted pursuant to Section&nbsp;5 of the Plan that does not
qualify as an Incentive Stock Option. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company
within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option or
a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#147;<B><I>Option
Agreement</I></B>&#148; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#147;<B><I>Other Stock Award</I></B>&#148; means an award based in whole or in
part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(d). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B>
&#147;<B><I>Other Stock Award Agreement</I></B>&#148;<B><I> </I></B>means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award
Agreement will be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#147;<B><I>Own,</I></B>&#148;<B><I>
</I></B>&#147;<B><I>Owned,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Owner,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Ownership</I></B>&#148;<B> </B>means a person or Entity will be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the
&#147;Owner&#148; of, or to have acquired &#147;Ownership&#148; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes
the power to vote or to direct the voting, with respect to such securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Participant</I></B>&#148; means a
person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#147;<B><I>Performance Cash Award</I></B>&#148; means an award of cash granted pursuant to the terms and conditions of
Section&nbsp;6(c)(ii). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> &#147;<B><I>Performance Criteria</I></B>&#148; means the one or more criteria that the Board will
select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the
Board: (i)&nbsp;sales; (ii) revenues; (iii)&nbsp;assets; (iv) expenses; (v)&nbsp;market penetration or expansion; (vi)&nbsp;earnings from operations; (vii)&nbsp;earnings before or after deduction for all or any portion of interest, taxes,
depreciation, amortization, incentives, service fees or extraordinary or special items, whether or not on a continuing operations or an aggregate or per share basis; (viii)&nbsp;net income or net income per common share (basic or diluted); (ix)
return on equity, investment, capital or assets; (x)&nbsp;one or more operating ratios; (xi)&nbsp;borrowing levels, leverage ratios or credit rating; (xii)&nbsp;market share; (xiii)&nbsp;capital expenditures; (xiv)&nbsp;cash flow, free cash flow,
cash flow return on investment, or net cash provided by operations; (xv)&nbsp;stock price, dividends or total stockholder return; (xvi)&nbsp;development of new technologies or products; (xvii)&nbsp;sales of particular products or services;
(xviii)&nbsp;economic value created or added; (xix)&nbsp;operating margin or profit margin; (xx)&nbsp;customer acquisition or retention; (xxi)&nbsp;raising or refinancing of capital; (xxii)&nbsp;successful hiring of key individuals;
(xxiii)&nbsp;resolution of significant litigation; (xxiv)&nbsp;acquisitions and divestitures (in whole or in part); (xxv) joint ventures and strategic alliances; (xxvi)&nbsp;spin-offs, <FONT STYLE="white-space:nowrap">split-ups</FONT> and the like;
(xxvii)&nbsp;reorganizations; (xxviii) recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings; (xxix)&nbsp;or strategic business criteria, consisting of one or more objectives based on the following goals:
achievement of timely development, design management or enrollment, meeting specified market penetration or value added, payor acceptance, patient adherence, peer </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reviewed publications, issuance of new patents, establishment of or securing of licenses to intellectual property, product development or introduction (including, without limitation, any clinical
trial accomplishments, regulatory or other filings, approvals or milestones, discovery of novel products, maintenance of multiple products in pipeline, product launch or other product development milestones), geographic business expansion, cost
targets, cost reductions or savings, customer satisfaction, operating efficiency, acquisition or retention, employee satisfaction, information technology, corporate development (including, without limitation, licenses, innovation, research or
establishment of third party collaborations), manufacturing or process development, legal compliance or risk reduction, patent application or issuance goals, or goals relating to acquisitions, divestitures or other business combinations (in whole or
in part), joint ventures or strategic alliances; and (xxx)&nbsp;other measures of performance selected by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B>
&#147;<B><I>Performance Goals</I></B>&#148; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria.&nbsp;Performance Goals may be based on a Company-wide basis,
with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.&nbsp;The
Board is authorized at any time in its sole discretion, to adjust or modify the calculation of a Performance Goal for such Performance Period in order to prevent the dilution or enlargement of the rights of Participants, (a)&nbsp;in the event of, or
in anticipation of, any unusual or extraordinary corporate item, transaction, event or development; (b)&nbsp;in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting the Company, or the financial statements of the
Company in response to, or in anticipation of, changes in applicable laws, regulations, accounting principles, or business conditions; or (c)&nbsp;in view of the Board&#146;s assessment of the business strategy of the Company, performance of
comparable organizations, economic and business conditions, and any other circumstances deemed relevant. Specifically, the Board is authorized to make adjustment in the method of calculating attainment of Performance Goals and objectives for a
Performance Period as follows: (i)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (ii)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a
Performance Period following such divestiture; and (iii)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization,
merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends. In addition, the Board is
authorized to make adjustment in the method of calculating attainment of Performance Goals and objectives for a Performance Period as follows: (i)&nbsp;to exclude restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate
effects, as applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated net sales and operating earnings; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting standards required by the Financial
Accounting Standards Board; (iv)&nbsp;to exclude the effects of any items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (v)&nbsp;to exclude the effects to any
statutory adjustments to corporate tax rates; and (vi)&nbsp;to make other appropriate adjustments selected by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B>
&#147;<B><I>Performance Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to and the payment of a
Stock Award or a Performance Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> &#147;<B><I>Performance Stock Award</I></B>&#148; means a Stock Award granted under the terms and conditions of
Section&nbsp;6(c)(i). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> &#147;<B><I>Plan</I></B>&#148; means this Equillium, Inc. 2018 Equity Incentive Plan. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> &#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of shares of Common
Stock, which is granted pursuant to the terms and conditions of Section&nbsp;6(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#147;<B><I>Restricted Stock Award
Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms
and conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> &#147;<B><I>Restricted Stock Unit Award</I></B>&#148;<B><I> </I></B>means a right to receive
shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>ss</B><B>)</B>
&#147;<B><I>Restricted Stock Unit Award Agreement</I></B>&#148;<B><I> </I></B>means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.
Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> &#147;<B><I>Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148;<B><I> </I></B>means a right to receive the
appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> &#147;<B><I>Stock
Appreciation Right Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will
be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> &#147;<B><I>Stock Award</I></B>&#148; means any right to receive Common
Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance Stock Award or any Other Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>yy</B><B>)</B> &#147;<B><I>Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant
evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz)</B> &#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting
power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa)</B> &#147;<B><I>Ten Percent
Stockholder</I></B>&#148; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bbb)</B> &#147;<B><I>Transaction</I></B>&#148; means a Corporate Transaction or a Change in Control. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><I>Standard Form</I><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2018 Equity Incentive Plan<B> </B>(the &#147;<B><I>Plan</I></B>&#148;), hereby grants
to Optionholder an option to purchase the number of shares of the Company&#146;s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Option Agreement, the
Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the
Plan or the Option Agreement. If there is any conflict between the terms in this Stock Option Grant Notice and the Plan, the terms of the Plan will control. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionholder:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of Grant:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Shares Subject to Option:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price (Per Share):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Type of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744; Incentive Stock Option<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744; Nonstatutory Stock Option</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Schedule</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Same as Vesting Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">One-fourth</FONT> (1/4th) of the shares vest one year after the Vesting Commencement Date; the balance of the shares vest in a series of 36 successive equal monthly installments measured
from the first anniversary of the Vesting Commencement Date, subject to Optionholder&#146;s Continuous Service as of each such date</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Payment:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By one or a combination of the following items (described in the Option Agreement):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&#8194;&#8201;&#8201;By cash, check, bank draft or money order payable to
the Company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&#8194;&#8201;&#8201;Pursuant to a Regulation T Program if the shares are
publicly traded</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&#8194;&#8201;&#8201;By delivery of already-owned shares if the shares are
publicly traded</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&#8194;&#8201;&#8201;If and only to the extent this option is a Nonstatutory
Stock Option, and subject to the Company&#146;s consent at the time of exercise, by a &#147;net exercise&#148; arrangement</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
<I>exercisable</I> for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Terms/Acknowledgements:</B> Optionholder acknowledges receipt of, and understands and agrees to,
this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder
further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral
and written agreements, promises and/or representations on that subject with the exception of, if applicable, (i)&nbsp;equity awards previously granted and delivered to Optionholder, (ii)&nbsp;any compensation recovery policy that is adopted by the
Company or is otherwise required by applicable law and (iii)&nbsp;any written employment or severance arrangement or other written agreement entered into between the Company and Optionholder specifying the terms that should govern this option upon
the terms and conditions set forth therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By accepting this option, Optionholder acknowledges having received and read the Stock Option Grant Notice,
the Option Agreement and the Plan and agrees to all of the terms and conditions set forth in these documents. Optionholder consents to receive Plan and related documents by electronic delivery and to participate in the Plan through an <FONT
STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>O<SMALL>PTIONHOLDER</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL></SMALL>: Option Agreement, 2018 Equity Incentive Plan<B> </B>and Notice of Exercise
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(I<SMALL>NCENTIVE</SMALL> S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> <SMALL>OR</SMALL> N<SMALL>ONSTATUTORY</SMALL> S<SMALL>TOCK</SMALL>
O<SMALL>PTION</SMALL>) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to your Stock Option Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;) and this Option Agreement,
Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;) has granted you an option under its 2018 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) to purchase the number of shares of the Company&#146;s Common Stock indicated in your Grant
Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the &#147;<B><I>Date of Grant</I></B>&#148;). If there is any conflict between the terms in
this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>V<SMALL>ESTING</SMALL></B><SMALL></SMALL>. Your option will vest as provided in your Grant Notice. Vesting will cease upon the
termination of your Continuous Service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL> <SMALL>AND</SMALL>
E<SMALL>XERCISE</SMALL> P<SMALL>RICE</SMALL>.</B> The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>E<SMALL>XERCISE</SMALL> R<SMALL>ESTRICTION</SMALL> <SMALL>FOR</SMALL>
N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-E</FONT><SMALL>XEMPT</SMALL> E<SMALL>MPLOYEES</SMALL>.</B> If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a &#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Employee</I></B>&#148;), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6)&nbsp;months of Continuous Service measured from the Date
of Grant, even if you have already been an employee for more than six (6)&nbsp;months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6)&nbsp;month
anniversary in the case of (i)&nbsp;your death or disability, (ii)&nbsp;a Corporate Transaction in which your option is not assumed, continued or substituted, (iii)&nbsp;a Change in Control or (iv)&nbsp;your termination of Continuous Service on your
&#147;retirement&#148; (as defined in the Company&#146;s benefit plans). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>M<SMALL>ETHOD</SMALL> <SMALL>OF</SMALL>
P<SMALL>AYMENT</SMALL>.</B> You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner
<B><I>permitted by your Grant Notice,</I></B> which may include one or more of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Provided that at the time of
exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company
or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a &#147;broker-assisted exercise&#148;, &#147;same day sale&#148;, or &#147;sell to
cover&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Provided that at the time of exercise the Common Stock is publicly traded, by delivery
to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of
exercise. &#147;Delivery&#148; for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by
the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#146;s stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a &#147;net
exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise
price. You must pay any remaining balance of the aggregate exercise price not satisfied by the &#147;net exercise&#148; in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not
be exercisable thereafter if those shares (i)&nbsp;are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (ii) are delivered to you as a result of such exercise, and (iii)&nbsp;are withheld to satisfy your tax withholding
obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>W<SMALL>HOLE</SMALL> S<SMALL>HARES</SMALL>.</B> You may exercise your option only for whole shares of Common
Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL> C<SMALL>OMPLIANCE</SMALL>.</B> In no event may you exercise your option
unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration
requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in
material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. <FONT STYLE="white-space:nowrap">1.401(k)-1(d)(3),</FONT> if applicable). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>T<SMALL>ERM</SMALL>.</B> You may not exercise your option before the Date of Grant or after the expiration of the option&#146;s
term. The term of your option expires, subject to the provisions of Section&nbsp;5(h) of the Plan, upon the earliest of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> immediately upon the termination of your Continuous Service for Cause; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> three (3)&nbsp;months after the termination of your Continuous Service for any reason other than Cause,<B> </B>your Disability or
your death (except as otherwise provided in Section&nbsp;7(d) below); <I>provided, however, </I>that if during any part of such three (3)&nbsp;month period your option is not exercisable solely because of the condition set forth in the section above
regarding &#147;Securities Law Compliance,&#148; your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3)&nbsp;months after the termination of your Continuous Service;
<I>provided further,</I> if during any part of such three (3)&nbsp;month period, the sale of any Common Stock received upon exercise of your option would violate the Company&#146;s insider trading policy, then your option will not expire until the
earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3)&nbsp;months after the termination of your Continuous Service during which the sale of the Common Stock received upon exercise of your option would
not be in violation of the Company&#146;s insider trading policy. Notwithstanding the foregoing, if (i)&nbsp;you are a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employee, (ii)&nbsp;your Continuous Service terminates within six
(6)&nbsp;months after the Date of Grant, and (iii)&nbsp;you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x)&nbsp;the later of (A)&nbsp;the date that
is seven (7)&nbsp;months after the Date of Grant, and (B)&nbsp;the date that is three (3)&nbsp;months after the termination of your Continuous Service, and (y)&nbsp;the Expiration Date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> twelve (12)&nbsp;months after the termination of your Continuous Service due to your
Disability (except as otherwise provided in Section&nbsp;7(d) below); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> eighteen (18)&nbsp;months after your death if you die
either during your Continuous Service or within three (3)&nbsp;months after your Continuous Service terminates for any reason other than Cause; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> the Expiration Date indicated in your Grant Notice; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> the day before the tenth (10th) anniversary of the Date of Grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the Date of Grant and ending on the day three (3)&nbsp;months before the date of your option&#146;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death
or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide
services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3)&nbsp;months after the date your employment with the Company or an Affiliate terminates.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. E<SMALL>XERCISE</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> You may exercise the vested portion of your option during its term by (i)&nbsp;delivering a Notice of Exercise (in a form designated
by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii)&nbsp;paying the exercise price and any applicable withholding taxes to the Company&#146;s Secretary, stock plan administrator, or
such other person as the Company may designate, together with such additional documents as the Company may then require. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> By
exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising
by reason of (i)&nbsp;the exercise of your option, (ii)&nbsp;the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii)&nbsp;the disposition of shares of Common Stock acquired
upon such exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the
Company in writing within fifteen (15)&nbsp;days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2)&nbsp;years after the Date of Grant or within one (1)&nbsp;year
after such shares of Common Stock are transferred upon exercise of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> By accepting your option you agree that you
will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other
securities of the Company held by you, for a period of one hundred eighty (180)&nbsp;days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company
will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;); <I>provided, however</I>, that nothing contained in
this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
section will prevent the exercise of a repurchase option, if any, in favor of the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. You further agree to execute and
deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may
impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this
Section&nbsp;8(d). The underwriters of the Company&#146;s stock are intended third party beneficiaries of this Section&nbsp;8(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>T<SMALL>RANSFERABILITY</SMALL>.</B> Except as otherwise provided in this Section&nbsp;9, your option is not transferable, except
by will or by the laws of descent and distribution, and is exercisable during your life only by you. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Certain Trusts.</B>
Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section&nbsp;671 of the Code and applicable state law)
while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Domestic Relations Orders.</B> Upon receiving written permission from the Board or its duly authorized designee, and provided
that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or
separation instrument as permitted by Treasury Regulation <FONT STYLE="white-space:nowrap">1.421-1(b)(2)</FONT> that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any
division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. If
this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Beneficiary Designation.</B> Upon receiving written permission from the Board or its duly authorized designee, you may, by
delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and
receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the
Common Stock or other consideration resulting from such exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>O<SMALL>PTION</SMALL> <SMALL>NOT</SMALL> <SMALL>A</SMALL>
S<SMALL>ERVICE</SMALL> C<SMALL>ONTRACT</SMALL>.</B> Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company
or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any
relationship that you might have as a Director or Consultant for the Company or an Affiliate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. W<SMALL>ITHHOLDING</SMALL>
O<SMALL>BLIGATIONS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> At the time you exercise your option, in whole or in part, and at any time thereafter as
requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#147;same day sale&#148; pursuant to a program developed under
Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in
connection with the exercise of your option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If this option is a Nonstatutory Stock Option, then upon your request and subject to
approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of
Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax permitted to be withheld by law (or such lower amount as may be necessary to avoid classification of your
option as a liability for financial accounting purposes). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> You may not exercise your option unless the tax withholding
obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of
Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>T<SMALL>AX</SMALL> C<SMALL>ONSEQUENCES</SMALL></B><SMALL></SMALL>. You hereby agree that the Company does not have a duty to
design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities
arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section&nbsp;409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#147;fair
market value&#148; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>N<SMALL>OTICES</SMALL>.</B> Any notices provided for in your option or the Plan will be given in writing (including
electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5)&nbsp;days after deposit in the United States mail, postage prepaid, addressed to you at the last address
you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means.
By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or
another third party designated by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL>.</B>
Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and
adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option) is
subject to recoupment in accordance with The Dodd&#150;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise
required by applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>O<SMALL>THER</SMALL> D<SMALL>OCUMENTS</SMALL>. </B>You hereby acknowledge receipt of and the
right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company&#146;s policy permitting certain
individuals to sell shares only during certain &#147;window&#148; periods and the Company&#146;s insider trading policy, in effect from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>E<SMALL>FFECT</SMALL> <SMALL>ON</SMALL> O<SMALL>THER</SMALL>
E<SMALL>MPLOYEE</SMALL> B<SMALL>ENEFIT</SMALL> P<SMALL>LANS</SMALL>.</B> The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan
sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#146;s or any Affiliate&#146;s employee benefit plans. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>V<SMALL>OTING</SMALL> R<SMALL>IGHTS</SMALL>.</B> You will not have voting or any other rights as a stockholder of the Company
with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action
taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>S<SMALL>EVERABILITY</SMALL>.</B> If all or any part of this Option Agreement or the Plan is declared by any court or governmental
authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so
declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>M<SMALL>ISCELLANEOUS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all
covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company&#146;s successors and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the
Company to carry out the purposes or intent of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> You acknowledge and agree that you have reviewed your option in its
entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental
agencies or national securities exchanges as may be required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> All obligations of the Company under the Plan and this Option
Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp; * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTICE</SMALL> <SMALL>OF</SMALL> E<SMALL>XERCISE</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2223 Avenida de la Playa, Suite 108</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Date of Exercise: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">La Jolla, California 92037</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This constitutes notice to Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;) under my stock option that
I elect to purchase the below number of shares of Common Stock of the Company (the&nbsp;&#147;<B><I>Shares</I></B>&#148;) for the price set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Type of option (check one):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Incentive &#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nonstatutory &#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Stock option dated:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Number of Shares as<BR>to which option is<BR>exercised:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Certificates to be<BR>issued in name of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Total exercise price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Cash payment delivered<BR>herewith:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Value of ________ Shares delivered herewith<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$______________]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Value of ________ Shares pursuant to net exercise<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$______________]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Regulation T Program (cashless exercise<SUP STYLE="font-size:85%; vertical-align:top">4</SUP>):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$______________]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By this exercise, I agree (i)&nbsp;to provide such additional documents as you may require pursuant to the
terms of the Equillium, Inc. 2018 Equity Incentive Plan, (ii)&nbsp;to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii)&nbsp;if this
exercise relates to an incentive stock option, to notify you in writing within fifteen (15)&nbsp;days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two (2)&nbsp;years after the date of
grant of this option or within one (1)&nbsp;year after such Shares are issued upon exercise of this option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further agree that, if
required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short
sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred eighty
(180)&nbsp;days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2241 or any
successor or similar rule or regulation) (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the
underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with
respect to securities subject to the foregoing restrictions until the end of such period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares must meet the public trading requirements set forth in the option. Shares must be valued in accordance
with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The option must be a Nonstatutory Stock Option, and the Company must have established net exercise procedures
at the time of exercise, in order to utilize this payment method. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares must meet the public trading requirements set forth in the option. </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><I>Double-Trigger Form</I><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2018 Equity Incentive Plan<B> </B>(the &#147;<B><I>Plan</I></B>&#148;), hereby grants
to Optionholder an option to purchase the number of shares of the Company&#146;s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Option Agreement, the
Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the
Plan or the Option Agreement. If there is any conflict between the terms in this Stock Option Grant Notice and the Plan, the terms of the Plan will control. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">Optionholder:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">Date of Grant:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">Number of Shares Subject to Option:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">Exercise Price (Per Share):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744; Incentive Stock Option<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744; Nonstatutory
Stock Option</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise&nbsp;Schedule</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Same as Vesting Schedule</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting&nbsp;Schedule</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">One-fourth</FONT> (1/4th) of the shares vest one year after the Vesting Commencement Date; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the
first anniversary of the Vesting Commencement Date, subject to Optionholder&#146;s Continuous Service as of each such date and the potential vesting acceleration described in Section&nbsp;1 of the Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Payment:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By one or a combination of the following items (described in the Option Agreement):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;By cash, check, bank draft or money order payable to the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to a Regulation T Program if the shares are publicly traded</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;By delivery of already-owned shares if the shares are publicly traded</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;If and only to the extent this option is a Nonstatutory Stock Option, and subject to the Company&#146;s consent at the time of exercise, by a &#147;net exercise&#148; arrangement</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
<I>exercisable</I> for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Terms/Acknowledgements:</B> Optionholder acknowledges receipt of, and understands and agrees to,
this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder
further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral
and written agreements, promises and/or representations on that subject with the exception of, if applicable, (i)&nbsp;equity awards previously granted and delivered to Optionholder, (ii)&nbsp;any compensation recovery policy that is adopted by the
Company or is otherwise required by applicable law and (iii)&nbsp;any written employment or severance arrangement or other written agreement entered into between the Company and Optionholder specifying the terms that should govern this option upon
the terms and conditions set forth therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By accepting this option, Optionholder acknowledges having received and read the Stock Option Grant Notice,
the Option Agreement and the Plan and agrees to all of the terms and conditions set forth in these documents. Optionholder consents to receive Plan and related documents by electronic delivery and to participate in the Plan through an <FONT
STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>O<SMALL>PTIONHOLDER</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL></SMALL>: Option Agreement, 2018 Equity Incentive Plan<B> </B>and Notice of Exercise
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(I<SMALL>NCENTIVE</SMALL> S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> <SMALL>OR</SMALL> N<SMALL>ONSTATUTORY</SMALL> S<SMALL>TOCK</SMALL>
O<SMALL>PTION</SMALL>) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to your Stock Option Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;) and this Option Agreement,
Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;) has granted you an option under its 2018 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) to purchase the number of shares of the Company&#146;s Common Stock indicated in your Grant
Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the &#147;<B><I>Date of Grant</I></B>&#148;). If there is any conflict between the terms in
this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>V<SMALL>ESTING</SMALL></B><SMALL></SMALL>. Your option will vest as provided in your Grant Notice. Vesting will cease upon the
termination of your Continuous Service. If a Change in Control occurs and upon or within twelve (12)&nbsp;months after the effective time of such Change in Control, your Continuous Service terminates due to an involuntary termination (not including
death or Disability) without Cause or due to your voluntary termination with Good Reason, then, as of the date of termination of Continuous Service, the vesting and exercisability of your option will be accelerated in full. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>Good Reason</I></B>&#148; means the occurrence of any of the following events, conditions or actions taken by the
Company without Cause and without your written consent: (i)&nbsp;a material reduction of your annual base salary; <I>provided, however</I>, that Good Reason shall not be deemed to have occurred in the event of a reduction in your annual base salary
that is pursuant to a salary reduction program affecting substantially all of the similarly situated employees of the Company and that does not adversely affect you to a greater extent than other similarly situated employees; (ii)&nbsp;a material
reduction in your authority, duties or responsibilities; (iii)&nbsp;a relocation of your principal place of employment with the Company to a place that increases your <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty
(50)&nbsp;miles as compared to your then-current principal place of employment immediately prior to such relocation (excluding regular travel in the ordinary course of business); or (iv)&nbsp;a material breach by the Company of any provision of this
Option Agreement or your employment agreement with the Company; <I>provided, however</I>, that in each case above, in order for your resignation to be deemed to have been for Good Reason, you must first give the Board written notice of the action or
omission giving rise to &#147;Good Reason&#148; within thirty (30)&nbsp;days after the first occurrence thereof; the Company must fail to reasonably cure such action or omission within thirty (30)&nbsp;days after receipt of such notice (the
&#147;<B><I>Cure Period</I></B>&#148;), and your resignation from all positions you hold with the Company must be effective not later than thirty (30)&nbsp;days after the expiration of such Cure Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If any payment or benefit you would receive from the Company or otherwise in connection with a change in control of the Company or
other similar transaction (&#147;<B><I>Payment</I></B>&#148;) would (1)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (2)&nbsp;but for this sentence, be subject to the excise tax imposed by
Section&nbsp;4999 of the Code (the &#147;<B><I>Excise Tax</I></B>&#148;), then such Payment will be equal to the Reduced Amount. The &#147;<B><I>Reduced Amount</I></B>&#148; will be either (x)&nbsp;the largest portion of the Payment that would
result in no portion of the Payment being subject to the Excise Tax, or (y)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
largest portion, up to and including the total, of the Payment, whichever amount ((x) or (y)), after taking into account all applicable federal, state and local employment taxes, income taxes,
and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding that all or some portion of the
Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction will occur in the manner (the &#147;<B><I>Reduction
Method</I></B>&#148;) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#147;<B><I>Pro Rata Reduction
Method</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any
portion of the Payment being subject to taxes pursuant to Section&nbsp;409A of the Code (&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;) that would not otherwise be subject to taxes pursuant to Section&nbsp;409A, then the
Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows: (A)&nbsp;as a first priority, the modification shall preserve to the
greatest extent possible, the greatest economic benefit for you as determined on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis; (B)&nbsp;as a second priority, Payments that are contingent on future events (e.g., being terminated without
cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C)&nbsp;as a third priority, Payments that are &#147;deferred compensation&#148; within the meaning of Section&nbsp;409A shall be reduced (or
eliminated) before Payments that are not deferred compensation within the meaning of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The independent registered public
accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event described in Section&nbsp;280G(b)(2)(A)(i) of the Code will perform the foregoing calculations. If the independent registered
public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change in control or similar transaction, the Company will appoint a nationally recognized independent registered
public accounting firm to make the determinations required hereunder. The Company will bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder. The independent
registered public accounting firm engaged to make the determinations hereunder will make its determination with input from you (or your counsel) and provide its calculations, together with detailed supporting documentation, to the Company and you
within fifteen (15)&nbsp;calendar days after the date on which your right to a Payment is triggered (if requested at that time by the Company or you) or such other time as reasonably requested by the Company or you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x)&nbsp;of the first paragraph of this
Section&nbsp;1(b) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause
(x)&nbsp;of the first paragraph of this Section&nbsp;1(b) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y)&nbsp;in the first paragraph
of this Section&nbsp;1(b), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>
<B>N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL> <SMALL>AND</SMALL> E<SMALL>XERCISE</SMALL> P<SMALL>RICE</SMALL>.</B> The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice
will be adjusted for Capitalization Adjustments. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>E<SMALL>XERCISE</SMALL> R<SMALL>ESTRICTION</SMALL> <SMALL>FOR</SMALL>
N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-E</FONT><SMALL>XEMPT</SMALL> E<SMALL>MPLOYEES</SMALL>.</B> If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a &#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Employee</I></B>&#148;), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6)&nbsp;months of Continuous Service measured from the Date
of Grant, even if you have already been an employee for more than six (6)&nbsp;months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
six (6)&nbsp;month anniversary in the case of (i)&nbsp;your death or disability, (ii)&nbsp;a Corporate Transaction in which your option is not assumed, continued or substituted, (iii)&nbsp;a
Change in Control or (iv)&nbsp;your termination of Continuous Service on your &#147;retirement&#148; (as defined in the Company&#146;s benefit plans). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>M<SMALL>ETHOD</SMALL> <SMALL>OF</SMALL> P<SMALL>AYMENT</SMALL>.</B> You must pay the full amount of the exercise price for the
shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner <B><I>permitted by your Grant Notice,</I></B> which may include one or more of the following:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T
as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company
from the sales proceeds. This manner of payment is also known as a &#147;broker-assisted exercise&#148;, &#147;same day sale&#148;, or &#147;sell to cover&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or
attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. &#147;Delivery&#148; for these purposes,
in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your option by
delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#146;s stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a &#147;net
exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise
price. You must pay any remaining balance of the aggregate exercise price not satisfied by the &#147;net exercise&#148; in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not
be exercisable thereafter if those shares (i)&nbsp;are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (ii) are delivered to you as a result of such exercise, and (iii)&nbsp;are withheld to satisfy your tax withholding
obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>W<SMALL>HOLE</SMALL> S<SMALL>HARES</SMALL>.</B> You may exercise your option only for whole shares of Common
Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL> C<SMALL>OMPLIANCE</SMALL>.</B> In no event may you exercise your option
unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration
requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in
material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. <FONT STYLE="white-space:nowrap">1.401(k)-1(d)(3),</FONT> if applicable). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>T<SMALL>ERM</SMALL>.</B> You may not exercise your option before the Date of Grant or after the expiration of the option&#146;s
term. The term of your option expires, subject to the provisions of Section&nbsp;5(h) of the Plan, upon the earliest of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> immediately upon the termination of your Continuous Service for Cause; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> three (3)&nbsp;months after the termination of your Continuous Service for any reason
other than Cause,<B> </B>your Disability or your death (except as otherwise provided in Section&nbsp;7(d) below); <I>provided, however, </I>that if during any part of such three (3)&nbsp;month period your option is not exercisable solely because of
the condition set forth in the section above regarding &#147;Securities Law Compliance,&#148; your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3)&nbsp;months
after the termination of your Continuous Service; <I>provided further,</I> if during any part of such three (3)&nbsp;month period, the sale of any Common Stock received upon exercise of your option would violate the Company&#146;s insider trading
policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3)&nbsp;months after the termination of your Continuous Service during which the sale of the Common
Stock received upon exercise of your option would not be in violation of the Company&#146;s insider trading policy. Notwithstanding the foregoing, if (i)&nbsp;you are a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employee, (ii)&nbsp;your
Continuous Service terminates within six (6)&nbsp;months after the Date of Grant, and (iii)&nbsp;you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of
(x)&nbsp;the later of (A)&nbsp;the date that is seven (7)&nbsp;months after the Date of Grant, and (B)&nbsp;the date that is three (3)&nbsp;months after the termination of your Continuous Service, and (y)&nbsp;the Expiration Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> twelve (12)&nbsp;months after the termination of your Continuous Service due to your Disability (except as otherwise provided in
Section&nbsp;7(d) below); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> eighteen (18)&nbsp;months after your death if you die either during your Continuous Service or within
three (3)&nbsp;months after your Continuous Service terminates for any reason other than Cause; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> the Expiration Date indicated
in your Grant Notice; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> the day before the tenth (10th) anniversary of the Date of Grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the Date of Grant and ending on the day three (3)&nbsp;months before the date of your option&#146;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death
or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide
services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3)&nbsp;months after the date your employment with the Company or an Affiliate terminates.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. E<SMALL>XERCISE</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> You may exercise the vested portion of your option during its term by (i)&nbsp;delivering a Notice of Exercise (in a form designated
by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii)&nbsp;paying the exercise price and any applicable withholding taxes to the Company&#146;s Secretary, stock plan administrator, or
such other person as the Company may designate, together with such additional documents as the Company may then require. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> By
exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising
by reason of (i)&nbsp;the exercise of your option, (ii)&nbsp;the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii)&nbsp;the disposition of shares of Common Stock acquired
upon such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If your option is an Incentive Stock Option, by exercising your option you agree that
you will notify the Company in writing within fifteen (15)&nbsp;days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2)&nbsp;years after the Date of Grant or
within one (1)&nbsp;year after such shares of Common Stock are transferred upon exercise of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> By accepting your
option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of
Common Stock or other securities of the Company held by you, for a period of one hundred eighty (180)&nbsp;days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the
underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;); <I>provided, however</I>,
that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. You further agree to execute and deliver such other
agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this
Section&nbsp;8(d). The underwriters of the Company&#146;s stock are intended third party beneficiaries of this Section&nbsp;8(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>T<SMALL>RANSFERABILITY</SMALL>.</B> Except as otherwise provided in this Section&nbsp;9, your option is not transferable, except
by will or by the laws of descent and distribution, and is exercisable during your life only by you. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Certain Trusts.</B>
Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section&nbsp;671 of the Code and applicable state law)
while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Domestic Relations Orders.</B> Upon receiving written permission from the Board or its duly authorized designee, and provided
that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or
separation instrument as permitted by Treasury Regulation <FONT STYLE="white-space:nowrap">1.421-1(b)(2)</FONT> that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any
division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. If
this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Beneficiary Designation.</B> Upon receiving written permission from the Board or its duly authorized designee, you may, by
delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and
receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the
Common Stock or other consideration resulting from such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>O<SMALL>PTION</SMALL> <SMALL>NOT</SMALL> <SMALL>A</SMALL> S<SMALL>ERVICE</SMALL>
C<SMALL>ONTRACT</SMALL>.</B> Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of
the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you
might have as a Director or Consultant for the Company or an Affiliate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. W<SMALL>ITHHOLDING</SMALL> O<SMALL>BLIGATIONS</SMALL>.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you
hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#147;same day sale&#148; pursuant to a program developed under Regulation T as promulgated
by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise
of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company,
and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair
Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax permitted to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for
financial accounting purposes). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> You may not exercise your option unless the tax withholding obligations of the Company and/or
any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such
shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B>
<B>T<SMALL>AX</SMALL> C<SMALL>ONSEQUENCES</SMALL></B><SMALL></SMALL>. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You
will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from
Section&nbsp;409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#147;fair market value&#148; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral
of compensation associated with the option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>N<SMALL>OTICES</SMALL>.</B> Any notices provided for in your option or the Plan
will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5)&nbsp;days after deposit in the United States mail, postage prepaid,
addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to
participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system
established and maintained by the Company or another third party designated by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL>.</B> Your
option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and
adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option) is
subject to recoupment in accordance with The Dodd&#150;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise
required by applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>O<SMALL>THER</SMALL> D<SMALL>OCUMENTS</SMALL>. </B>You hereby acknowledge receipt of and the
right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company&#146;s policy permitting certain
individuals to sell shares only during certain &#147;window&#148; periods and the Company&#146;s insider trading policy, in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>E<SMALL>FFECT</SMALL> <SMALL>ON</SMALL> O<SMALL>THER</SMALL> E<SMALL>MPLOYEE</SMALL> B<SMALL>ENEFIT</SMALL>
P<SMALL>LANS</SMALL>.</B> The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except
as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#146;s or any Affiliate&#146;s employee benefit plans. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>V<SMALL>OTING</SMALL> R<SMALL>IGHTS</SMALL>.</B> You will not have voting or any other rights as a stockholder of the Company
with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action
taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>S<SMALL>EVERABILITY</SMALL>.</B> If all or any part of this Option Agreement or the Plan is declared by any court or governmental
authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so
declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>M<SMALL>ISCELLANEOUS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all
covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company&#146;s successors and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the
Company to carry out the purposes or intent of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> You acknowledge and agree that you have reviewed your option in its
entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental
agencies or national securities exchanges as may be required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> All obligations of the Company under the Plan and this Option Agreement will be
binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTICE</SMALL> <SMALL>OF</SMALL> E<SMALL>XERCISE</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2223 Avenida de la Playa, Suite 108</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Date of Exercise: _______________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">La Jolla, California 92037</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This constitutes notice to Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;) under my stock option that
I elect to purchase the below number of shares of Common Stock of the Company (the&nbsp;&#147;<B><I>Shares</I></B>&#148;) for the price set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Type of option (check one):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Incentive &#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Nonstatutory &#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Stock option dated:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Number of Shares as to which option is exercised:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Certificates to be issued in name of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Total exercise price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Cash payment delivered herewith:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Value of<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Shares delivered herewith<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Value of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Shares pursuant to net
exercise<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Regulation T Program (cashless exercise<SUP STYLE="font-size:85%; vertical-align:top">4</SUP>):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By this exercise, I agree (i)&nbsp;to provide such additional documents as you may require pursuant to the
terms of the Equillium, Inc. 2018 Equity Incentive Plan, (ii)&nbsp;to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii)&nbsp;if this
exercise relates to an incentive stock option, to notify you in writing within fifteen (15)&nbsp;days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two (2)&nbsp;years after the date of
grant of this option or within one (1)&nbsp;year after such Shares are issued upon exercise of this option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further agree that, if
required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short
sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred eighty
(180)&nbsp;days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2241 or any
successor or similar rule or regulation) (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the
underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with
respect to securities subject to the foregoing restrictions until the end of such period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares must meet the public trading requirements set forth in the option. Shares must be valued in accordance
with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The option must be a Nonstatutory Stock Option, and the Company must have established net exercise procedures
at the time of exercise, in order to utilize this payment method. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares must meet the public trading requirements set forth in the option. </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Form </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2018 Equity Incentive Plan<B> </B>(the &#147;<B><I>Plan</I></B>&#148;), hereby grants
to Optionholder an option to purchase the number of shares of the Company&#146;s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Option Agreement, the
Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the
Plan or the Option Agreement. If there is any conflict between the terms in this Stock Option Grant Notice and the Plan, the terms of the Plan will control. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Optionholder:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Date of Grant:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Number of Shares Subject to Option:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Exercise Price (Per Share):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Type of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744; Incentive Stock Option<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9746; Nonstatutory Stock Option</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Exercise Schedule</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Same as Vesting Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Vesting Schedule</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],&nbsp;subject to Optionholder&#146;s Continuous Service as of each such date<B> </B></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Payment:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">By&#8194;&#8201;&#8202;one or a combination of the following items (described in
the Option Agreement):</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&#8194;&#8201;&#8201;By cash, check, bank draft or money order payable to
the Company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">&#9744;&#8194;&#8201;&#8201;Pursuant to a Regulation T Program if the shares are publicly traded</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">&#9744;&#8194;&#8201;&#8201;By delivery of already-owned shares if the shares are publicly traded</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">&#9744;&#8194;&#8201;&#8201;If and only to the extent this option is a Nonstatutory Stock Option, and subject to the Company&#146;s<BR>consent at the time of exercise, by a &#147;net exercise&#148;
arrangement</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
<I>exercisable</I> for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Terms/Acknowledgements:</B> Optionholder acknowledges receipt of, and understands and agrees to,
this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder
further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral
and written agreements, promises and/or representations on that subject with the exception of, if applicable, (i)&nbsp;equity awards previously granted and delivered to Optionholder, (ii)&nbsp;any compensation recovery policy that is adopted by the
Company or is otherwise required by applicable law and (iii)&nbsp;any written employment or severance arrangement or other written agreement entered into between the Company and Optionholder specifying the terms that should govern this option upon
the terms and conditions set forth therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By accepting this option, Optionholder acknowledges having received and read the Stock Option Grant Notice,
the Option Agreement and the Plan and agrees to all of the terms and conditions set forth in these documents. Optionholder consents to receive Plan and related documents by electronic delivery and to participate in the Plan through an <FONT
STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>O<SMALL>PTIONHOLDER</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL></SMALL>: Option Agreement, 2018 Equity Incentive Plan<B> </B>and Notice of Exercise
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(I<SMALL>NCENTIVE</SMALL> S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> <SMALL>OR</SMALL> N<SMALL>ONSTATUTORY</SMALL> S<SMALL>TOCK</SMALL>
O<SMALL>PTION</SMALL>) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to your Stock Option Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;) and this Option Agreement,
Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;) has granted you an option under its 2018 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) to purchase the number of shares of the Company&#146;s Common Stock indicated in your Grant
Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the &#147;<B><I>Date of Grant</I></B>&#148;). If there is any conflict between the terms in
this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>V<SMALL>ESTING</SMALL></B><SMALL></SMALL>. Your option will vest as provided in your Grant Notice. Vesting will cease upon the
termination of your Continuous Service. If a Change in Control occurs and your Continuous Service has not terminated as of immediately prior to such Change in Control, the vesting and exercisability of your option will be accelerated in full. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> If any payment or benefit you would receive from the Company or otherwise in connection with a change in control of the Company or
other similar transaction (&#147;<B><I>Payment</I></B>&#148;) would (1)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (2)&nbsp;but for this sentence, be subject to the excise tax imposed by
Section&nbsp;4999 of the Code (the &#147;<B><I>Excise Tax</I></B>&#148;), then such Payment will be equal to the Reduced Amount. The &#147;<B><I>Reduced Amount</I></B>&#148; will be either (x)&nbsp;the largest portion of the Payment that would
result in no portion of the Payment being subject to the Excise Tax, or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount ((x) or (y)), after taking into account all applicable federal, state and local
employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding
that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction will occur in the
manner (the &#147;<B><I>Reduction Method</I></B>&#148;) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the
&#147;<B><I>Pro Rata Reduction Method</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction
Method would result in any portion of the Payment being subject to taxes pursuant to Section&nbsp;409A of the Code (&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;) that would not otherwise be subject to taxes pursuant to
Section&nbsp;409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows: (A)&nbsp;as a first priority, the modification
shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis; (B)&nbsp;as a second priority, Payments that are contingent on future events (e.g.,
being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C)&nbsp;as a third priority, Payments that are &#147;deferred compensation&#148; within the meaning of Section&nbsp;409A
shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The independent registered public accounting firm engaged by the Company for general audit
purposes as of the day prior to the effective date of the event described in Section&nbsp;280G(b)(2)(A)(i) of the Code will perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving
as accountant or auditor for the individual, entity or group effecting the change in control or similar transaction, the Company will appoint a nationally recognized independent registered public accounting firm to make the determinations required
hereunder. The Company will bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the
determinations hereunder will make its determination with input from you (or your counsel) and provide its calculations, together with detailed supporting documentation, to the Company and you within fifteen (15)&nbsp;calendar days after the date on
which your right to a Payment is triggered (if requested at that time by the Company or you) or such other time as reasonably requested by the Company or you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x)&nbsp;of the first paragraph of this
Section&nbsp;1(b) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause
(x)&nbsp;of the first paragraph of this Section&nbsp;1(b) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y)&nbsp;in the first paragraph
of this Section&nbsp;1(b), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>
<B>N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL> <SMALL>AND</SMALL> E<SMALL>XERCISE</SMALL> P<SMALL>RICE</SMALL>.</B> The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice
will be adjusted for Capitalization Adjustments. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>E<SMALL>XERCISE</SMALL> R<SMALL>ESTRICTION</SMALL> <SMALL>FOR</SMALL>
N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-E</FONT><SMALL>XEMPT</SMALL> E<SMALL>MPLOYEES</SMALL>.</B> If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a &#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Employee</I></B>&#148;), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6)&nbsp;months of Continuous Service measured from the Date
of Grant, even if you have already been an employee for more than six (6)&nbsp;months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6)&nbsp;month
anniversary in the case of (i)&nbsp;your death or disability, (ii)&nbsp;a Corporate Transaction in which your option is not assumed, continued or substituted, (iii)&nbsp;a Change in Control or (iv)&nbsp;your termination of Continuous Service on your
&#147;retirement&#148; (as defined in the Company&#146;s benefit plans). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>M<SMALL>ETHOD</SMALL> <SMALL>OF</SMALL>
P<SMALL>AYMENT</SMALL>.</B> You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner
<B><I>permitted by your Grant Notice,</I></B> which may include one or more of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Provided that at the time of
exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company
or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a &#147;broker-assisted exercise&#148;, &#147;same day sale&#148;, or &#147;sell to
cover&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by
actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. &#147;Delivery&#148;
for these purposes, in the sole discretion of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may
not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#146;s stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a &#147;net
exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise
price. You must pay any remaining balance of the aggregate exercise price not satisfied by the &#147;net exercise&#148; in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not
be exercisable thereafter if those shares (i)&nbsp;are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (ii) are delivered to you as a result of such exercise, and (iii)&nbsp;are withheld to satisfy your tax withholding
obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>W<SMALL>HOLE</SMALL> S<SMALL>HARES</SMALL>.</B> You may exercise your option only for whole shares of Common
Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL> C<SMALL>OMPLIANCE</SMALL>.</B> In no event may you exercise your option
unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration
requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in
material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. <FONT STYLE="white-space:nowrap">1.401(k)-1(d)(3),</FONT> if applicable). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>T<SMALL>ERM</SMALL>.</B> You may not exercise your option before the Date of Grant or after the expiration of the option&#146;s
term. The term of your option expires, subject to the provisions of Section&nbsp;5(h) of the Plan, upon the earliest of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> immediately upon the termination of your Continuous Service for Cause; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> twelve (12)&nbsp;months after the termination of your Continuous Service for any reason other than Cause,<B> </B>your Disability or
your death (except as otherwise provided in Section&nbsp;7(d) below); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> twelve (12)&nbsp;months after the termination of your
Continuous Service due to your Disability (except as otherwise provided in Section&nbsp;7(d) below); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> eighteen (18)&nbsp;months
after your death if you die either during your Continuous Service or within three (3)&nbsp;months after your Continuous Service terminates for any reason other than Cause; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> the Expiration Date indicated in your Grant Notice; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> the day before the tenth (10th) anniversary of the Date of Grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the Date of Grant and ending on the day three (3)&nbsp;months before the date of your option&#146;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death
or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after
your employment terminates or if you otherwise exercise your option more than three (3)&nbsp;months after the date your employment with the Company or an Affiliate terminates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. E<SMALL>XERCISE</SMALL>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> You may exercise the vested portion of your option during its term by (i)&nbsp;delivering a Notice of Exercise (in a form designated
by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii)&nbsp;paying the exercise price and any applicable withholding taxes to the Company&#146;s Secretary, stock plan administrator, or
such other person as the Company may designate, together with such additional documents as the Company may then require. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> By
exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising
by reason of (i)&nbsp;the exercise of your option, (ii)&nbsp;the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii)&nbsp;the disposition of shares of Common Stock acquired
upon such exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the
Company in writing within fifteen (15)&nbsp;days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2)&nbsp;years after the Date of Grant or within one (1)&nbsp;year
after such shares of Common Stock are transferred upon exercise of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> By accepting your option you agree that you
will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other
securities of the Company held by you, for a period of one hundred eighty (180)&nbsp;days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company
will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;); <I>provided, however</I>, that nothing contained in
this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. You further agree to execute and deliver such other agreements as may be reasonably
requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to
your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section&nbsp;8(d). The underwriters of the
Company&#146;s stock are intended third party beneficiaries of this Section&nbsp;8(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>T<SMALL>RANSFERABILITY</SMALL>.</B> Except as otherwise provided in this Section&nbsp;9, your option is not transferable, except
by will or by the laws of descent and distribution, and is exercisable during your life only by you. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Certain Trusts.</B>
Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section&nbsp;671 of the Code and applicable state law)
while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Domestic Relations Orders.</B> Upon receiving written permission from the Board or
its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital
settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation <FONT STYLE="white-space:nowrap">1.421-1(b)(2)</FONT> that contains the information required by the Company to effectuate the transfer. You are
encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic
relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Beneficiary Designation.</B> Upon receiving written permission from the Board or its duly authorized designee, you may, by
delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and
receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the
Common Stock or other consideration resulting from such exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>O<SMALL>PTION</SMALL> <SMALL>NOT</SMALL> <SMALL>A</SMALL>
S<SMALL>ERVICE</SMALL> C<SMALL>ONTRACT</SMALL>.</B> Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company
or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any
relationship that you might have as a Director or Consultant for the Company or an Affiliate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. W<SMALL>ITHHOLDING</SMALL>
O<SMALL>BLIGATIONS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> At the time you exercise your option, in whole or in part, and at any time thereafter as
requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#147;same day sale&#148; pursuant to a program developed under
Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in
connection with the exercise of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If this option is a Nonstatutory Stock Option, then upon your request and subject
to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of
Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax permitted to be withheld by law (or such lower amount as may be necessary to avoid classification of your
option as a liability for financial accounting purposes). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> You may not exercise your option unless the tax withholding
obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of
Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>T<SMALL>AX</SMALL> C<SMALL>ONSEQUENCES</SMALL></B><SMALL></SMALL>. You hereby agree
that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees
or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section&nbsp;409A of the Code only if the exercise price per share specified in the Grant
Notice is at least equal to the &#147;fair market value&#148; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>N<SMALL>OTICES</SMALL>.</B> Any notices provided for in your option or the Plan will be given in writing (including
electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5)&nbsp;days after deposit in the United States mail, postage prepaid, addressed to you at the last address
you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means.
By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or
another third party designated by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL>.</B>
Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and
adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option) is
subject to recoupment in accordance with The Dodd&#150;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise
required by applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>O<SMALL>THER</SMALL> D<SMALL>OCUMENTS</SMALL>. </B>You hereby acknowledge receipt of and the
right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company&#146;s policy permitting certain
individuals to sell shares only during certain &#147;window&#148; periods and the Company&#146;s insider trading policy, in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>E<SMALL>FFECT</SMALL> <SMALL>ON</SMALL> O<SMALL>THER</SMALL> E<SMALL>MPLOYEE</SMALL> B<SMALL>ENEFIT</SMALL>
P<SMALL>LANS</SMALL>.</B> The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except
as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#146;s or any Affiliate&#146;s employee benefit plans. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>V<SMALL>OTING</SMALL> R<SMALL>IGHTS</SMALL>.</B> You will not have voting or any other rights as a stockholder of the Company
with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action
taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>S<SMALL>EVERABILITY</SMALL>.</B> If all or any part of this Option Agreement or the Plan is declared by any court or governmental
authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so
declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>M<SMALL>ISCELLANEOUS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all
covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company&#146;s successors and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the
Company to carry out the purposes or intent of your option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> You acknowledge and agree that you have reviewed your option in its
entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental
agencies or national securities exchanges as may be required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> All obligations of the Company under the Plan and this Option
Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the
Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Option
Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTICE</SMALL> <SMALL>OF</SMALL> E<SMALL>XERCISE</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2223 Avenida de la Playa, Suite 108</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Date of Exercise: _______________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">La Jolla, California 92037</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This constitutes notice to Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;) under my stock option that
I elect to purchase the below number of shares of Common Stock of the Company (the&nbsp;&#147;<B><I>Shares</I></B>&#148;) for the price set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Type of option (check one):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Incentive &#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Nonstatutory &#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Stock option dated:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Number of Shares as to which option is exercised:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Certificates to be issued in name of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Total exercise price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Cash payment delivered herewith:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Value of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Shares delivered herewith<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Value of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Shares pursuant to net
exercise<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Regulation T Program (cashless exercise<SUP STYLE="font-size:85%; vertical-align:top">4</SUP>):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By this exercise, I agree (i)&nbsp;to provide such additional documents as you may require pursuant to the
terms of the Equillium, Inc. 2018 Equity Incentive Plan, (ii)&nbsp;to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii)&nbsp;if this
exercise relates to an incentive stock option, to notify you in writing within fifteen (15)&nbsp;days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two (2)&nbsp;years after the date of
grant of this option or within one (1)&nbsp;year after such Shares are issued upon exercise of this option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further agree that, if
required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short
sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred eighty
(180)&nbsp;days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2241 or any
successor or similar rule or regulation) (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the
underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with
respect to securities subject to the foregoing restrictions until the end of such period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares must meet the public trading requirements set forth in the option. Shares must be valued in accordance
with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The option must be a Nonstatutory Stock Option, and the Company must have established net exercise procedures
at the time of exercise, in order to utilize this payment method. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares must meet the public trading requirements set forth in the option. </P></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>9
<FILENAME>d582934dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL>
<SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an
opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new
Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DMINISTRATION</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as
provided in Section&nbsp;2(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will have the power, subject to, and within the limitations of, the express provisions
of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be
identical). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To designate from time to time which Related Corporations of the Company will be eligible to participate in the
Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for
its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To settle all controversies regarding the Plan and Purchase Rights granted under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To amend the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of
the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit
participation in the Plan by Employees who are foreign nationals or employed outside the United States. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board may delegate some or all of the administration of the Plan to a Committee or
Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references to the Board in this Plan and in any applicable Offering Document will thereafter be to the Committee or subcommittee), subject,
however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest
in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in
the administration of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> All determinations, interpretations and constructions made by the Board in good faith will not
be subject to review by any person and will be final, binding and conclusive on all persons. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> S<SMALL>UBJECT</SMALL>
<SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the provisions of Section&nbsp;11(a)
relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock, plus the number of shares of Common Stock
that are automatically added on January 1st of each year for a period of up to ten years, commencing on the first January&nbsp;1 following the IPO Date and ending on (and including) January&nbsp;1, 2028, in an amount equal to the lesser of (i)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of Capital Stock outstanding on December 31st of the preceding calendar year, and (ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock.
Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> increase in the share reserve for such calendar year or
that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The stock purchasable under the
Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>;
O<SMALL>FFERING</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board may from time to time grant or provide for the grant of Purchase
Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will
deem appropriate, and will comply with the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering shall be incorporated by
reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the
Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant has more than one Purchase Right outstanding under the Plan, unless
he or she otherwise indicates in forms delivered to the Company: (i)&nbsp;each form will apply to all of his or her Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if
different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise
prices) will be exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board will have the discretion to structure an Offering so that if the Fair Market Value of a
share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i)&nbsp;that Offering will terminate
immediately as of that first Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>LIGIBILITY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b),
to Employees of a Related Corporation. Except as provided in Section&nbsp;5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related
Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two years. In addition, the Board may
provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee&#146;s customary employment with the Company or the Related Corporation is more than 20 hours per week and more than
five months per calendar year or such other criteria as the Board may determine consistent with Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or
which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted
under that Offering, as described herein, except that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the date on which such Purchase Right is granted will be the
&#147;Offering Date&#148; of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of
such Offering; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Board may provide that if such person first becomes an Eligible Employee within a specified period of
time before the end of the Offering, he or she will not receive any Purchase Right under that Offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Employee will be
eligible for the grant of any Purchase Rights if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or
of any Related Corporation. For purposes of this Section&nbsp;5(c), the rules of Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase
Rights and options will be treated as stock owned by such Employee. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> As specified by Section&nbsp;423(b)(8) of the Code, an Eligible Employee may be
granted Purchase Rights only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee&#146;s rights to purchase stock of
the Company or any Related Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective
Offering Dates) for each calendar year in which such rights are outstanding at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Officers of the Company and any
designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are highly compensated
Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will not be eligible to participate. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be
granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding 15% of such Employee&#146;s earnings
(as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the
end of the Offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted
for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In
connection with each Offering made under the Plan, the Board may specify (i)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii)&nbsp;a maximum aggregate number of
shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or (iii)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If
the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each
Participant&#146;s accumulated Contributions) allocation of the shares of Common Stock available will be made in as nearly a uniform manner as will be practicable and equitable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by
completing and delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board.
Each Participant&#146;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with
a third </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll date that occurs after
the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including to zero) or
increase his or her Contributions. If specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check prior to a Purchase Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a
withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#146;s Purchase Right in that Offering will immediately terminate and the Company will
distribute to such Participant all of his or her accumulated but unused Contributions and such Participant&#146;s Purchase Right in that Offering shall thereupon terminate. A Participant&#146;s withdrawal from that Offering will have no effect upon
his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the Participant either (i)&nbsp;is no
longer an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or (ii)&nbsp;is otherwise no longer eligible to participate. The Company will distribute to such individual all of his or her
accumulated but unused Contributions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> During a Participant&#146;s lifetime, Purchase Rights will be exercisable only by such
Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section&nbsp;10. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Unless otherwise specified in the Offering, the Company will have no obligation to pay interest on Contributions. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Purchase Date, each Participant&#146;s accumulated Contributions will be applied to the purchase
of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in
the Offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in a
Participant&#146;s account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be
held in such Participant&#146;s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such next Offering, in which case such amount will
be distributed to such Participant after the final Purchase Date without interest. If the amount of Contributions remaining in a Participant&#146;s account after the purchase of shares of Common Stock is at least equal to the amount required to
purchase one (1)&nbsp;whole share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be distributed in full to such Participant after the final Purchase Date of such Offering without interest. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Purchase Rights may be exercised to any extent unless the shares of Common Stock to
be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities and other laws
applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares
of Common Stock are subject to such an effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 6 months from the Offering Date. If, on the Purchase Date, as delayed to the
maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all applicable laws, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to
the Participants without interest. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having
jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the
Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights
and/or to issue and sell Common Stock upon exercise of such Purchase Rights. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any
shares of Common Stock and/or Contributions from the Participant&#146;s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the
Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock
and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common
Stock and/or Contributions to the Participant&#146;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTIONS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the
event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii) the class(es) and maximum number of
securities by which the share reserve is to increase automatically each year pursuant to Section&nbsp;3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and
(iv)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event of a Corporate Transaction, then: (i)&nbsp;any surviving corporation or acquiring corporation (or the surviving or
acquiring corporation&#146;s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for
outstanding Purchase Rights, or (ii)&nbsp;if any surviving or acquiring corporation (or its parent company)<B> </B>does not assume or continue such </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Purchase Rights or does not substitute similar rights for such Purchase Rights, then the Participants&#146; accumulated Contributions will be used to purchase shares of Common Stock within ten
business days prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>MENDMENT</SMALL>, T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL>
<SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board may amend the Plan at any time in any
respect the Board deems necessary or advisable. However, except as provided in Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required
by applicable law or listing requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may suspend or terminate the Plan at any time. No Purchase Rights may be
granted under the Plan while the Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Any benefits, privileges, entitlements and
obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to
whom such Purchase Rights were granted, (ii)&nbsp;as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and other
interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii)&nbsp;as
necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#146;s consent if such amendment is necessary to ensure that the Purchase Right
and/or the Plan complies with the requirements of Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the Plan or any Offering
Document to the contrary, the Board will be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit Contributions in excess of the amount designated by a Participant
in order to adjust for mistakes in the Company&#146;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied
toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant&#146;s Contributions; (iv)&nbsp;amend any outstanding Purchase Rights or clarify any ambiguities regarding the terms of any
Offering to enable the Purchase Rights to qualify under and/or comply with Section&nbsp;423 of the Code; and (v)&nbsp;establish other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the
Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase Rights granted under each
Offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will become effective immediately prior to and contingent upon the IPO Date. No Purchase Rights will be
exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section&nbsp;12(a) above, materially amended) by the
Board. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common
Stock subject to Purchase Rights unless and until the Participant&#146;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at
will nature of a Participant&#146;s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related
Corporation to continue the employment of a Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The provisions of the Plan will be governed by the laws of the State
of Delaware without resort to that state&#146;s conflicts of laws rules. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>Board</I></B>&#148;<I> </I>means the Board of Directors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Capital Stock</I></B>&#148;<I> </I>means each and every class of common stock of the Company, regardless of the number
of votes per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that
occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar
equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the
Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#147;<B><I>Code</I></B>&#148;<I> </I>means the Internal Revenue
Code of 1986, as amended, including any applicable regulations and guidance thereunder<I>.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>
&#147;<B><I>Committee</I></B>&#148;<I> </I>means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Common Stock</I></B>&#148; means, as of the IPO Date, the common stock of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Company</I></B>&#148; means Equillium, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>&#147;Contributions</I></B>&#148; means the payroll deductions and other additional payments specifically provided for in the
Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had
the maximum permitted amount withheld during the Offering through payroll deductions. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single
transaction or in a series of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other
disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or other disposition of more than 50% of the outstanding securities of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common
Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or
otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Director</I></B>&#148;<I> </I>means a member of the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Eligible Employee</I></B>&#148;<I> </I>means an Employee who meets the requirements set forth in the document(s)
governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><I>Employee</I></B>&#148;<I> </I>means any person, including an Officer or Director, who is &#147;employed&#148; for
purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of
the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Employee Stock Purchase Plan</I></B>&#148;<I> </I>means a plan that grants Purchase Rights intended to be
options issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>
&#147;<B><I>Exchange Act</I></B>&#148;<I> </I>means the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a
share of Common Stock will be, unless otherwise determined by the Board, the <B><U>closing sales price</U></B> for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock)
<B><U>on the date of determination</U></B>, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market
Value will be the closing sales price on the last preceding date for which such quotation exists. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In the absence of such markets for the Common Stock, the Fair Market Value will be
determined by the Board in good faith in compliance with applicable laws and in a manner that complies with Sections 409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Notwithstanding the foregoing, for any Offering that commences on the IPO Date, the Fair Market Value of the shares of Common
Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company&#146;s initial public offering as specified in the final prospectus for that initial public offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><I>IPO Date</I></B>&#148;<I> </I>means the date of the underwriting agreement between the Company and the underwriter(s)
managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Offering</I></B>&#148;<I> </I>means the grant to Eligible Employees of Purchase Rights, with the exercise of those
Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#147;<B><I>Offering Document</I></B>&#148; approved by the Board for that Offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Offering Date</I></B>&#148; means a date selected by the Board for an Offering to commence. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>Officer</I></B>&#148;<B> </B>means<B> </B>a person who is an officer of the Company or a Related Corporation within the
meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><I>Participant</I></B>&#148;<I> </I>means an Eligible Employee who
holds an outstanding Purchase Right. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><I>Plan</I></B>&#148;<I> </I>means this Equillium, Inc. 2018 Employee Stock
Purchase Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><I>Purchase Date</I></B>&#148;<I> </I>means one or more dates during an Offering selected by the Board
on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#147;<B><I>Purchase Period</I></B>&#148; means a period of time specified within an Offering, generally beginning on the Offering
Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><I>Purchase Right</I></B>&#148;<I> </I>means an option to purchase shares of Common Stock granted pursuant to the Plan.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><I>Related Corporation</I></B>&#148;<I> </I>means any &#147;parent corporation&#148; or &#147;subsidiary
corporation&#148; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><I>Securities Act</I></B>&#148;<I> </I>means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than fifty percent
(50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might
have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect
interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%). For purposes </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the foregoing clause (i), the Company will be deemed to &#147;Own&#148; or have &#147;Owned&#148; such securities if the Company, directly or indirectly, through any contract, arrangement,
understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#147;<B><I>Trading Day</I></B>&#148;<B> </B>means any day on which the exchange(s) or market(s) on which shares of Common Stock
are listed, including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>10
<FILENAME>d582934dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUILLIUM</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-E</FONT><SMALL>MPLOYEE</SMALL> D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL>
P<SMALL>OLICY</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) who is not also serving as an employee of or
consultant to Equillium, Inc. (the &#147;<B><I>Company</I></B>&#148;) or any of its subsidiaries (each such member, an &#147;<B><I>Eligible Director</I></B>&#148;) will receive the compensation described in this
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of
the Company&#146;s common stock (the &#147;<B><I>Common Stock</I></B>&#148;), pursuant to which the Common Stock is priced in such initial public offering (the &#147;<B><I>Effective Date</I></B>&#148;). An Eligible Director may decline all or any
portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This policy is effective as of the Effective Date and may be amended at any time in the
sole discretion of the Board or the Compensation Committee of the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual Cash Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of
each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be <FONT
STYLE="white-space:nowrap">pro-rated</FONT> based on days served in the applicable fiscal year, with the <FONT STYLE="white-space:nowrap">pro-rated</FONT> amount paid for the first fiscal quarter in which the Eligible Director provides the service
and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Annual Board Service Retainer</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Eligible Directors: $ </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chairman of the Board Service Retainer (in addition to Eligible Director Service Retainer): $
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Annual Committee Chair Service Retainer</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chairman of the Audit Committee: $ </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chairman of the Compensation Committee: $ </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chairman of the Nominating and Corporate Governance Committee: $ </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Annual Committee Member Service Retainer (not applicable to Committee Chairs)</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Audit Committee: $ </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Compensation Committee: $ </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Nominating and Corporate Governance Committee: $ </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The equity compensation set forth below will be granted under the Company&#146;s 2018 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;), subject to
the approval of the Plan by the Company&#146;s stockholders. All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the
underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan, provided that upon a termination of service other than
for death, disability or cause, the post-termination exercise period will be 12 months from the date of termination). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Initial Grant</U>: For each
Eligible Director who is first elected or appointed to the Board following the Effective Date, on the date of such Eligible Director&#146;s initial election or appointment to the Board (or, if such date is not a market trading day, the first market
trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase Common Stock with an aggregate Black-Scholes option value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<B><I>Initial Grant</I></B>&#148;). The shares subject to each Initial Grant will vest in equal monthly installments over a three year period such that the option is fully vested on the
third anniversary of the date of grant, subject to the Eligible Director&#146;s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Annual Grant</U>: On the date of each annual stockholder meeting of the Company held after the Effective Date, each Eligible Director who continues to
serve as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of the Board following such stockholder meeting will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to
purchase Common Stock with an aggregate Black-Scholes option value of $ (the &#147;<B><I>Annual Grant</I></B>&#148;). The shares subject to the Annual Grant will vest in equal monthly installments over the 12 months following the date of grant,
provided that the Annual Grant will in any case be fully vested on the date of Company&#146;s next annual stockholder meeting, subject to the Eligible Director&#146;s Continuous Service (as defined in the Plan) through such vesting date and will
vest in full upon a Change in Control (as defined in the Plan). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>11
<FILENAME>d582934dex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><I>Confidential</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"><I></I><I></I><I></I><I></I><U>EXECUTION VERSION</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">***Certain confidential information</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">contained in this document, marked by</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">brackets, has been omitted and filed</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">separately with the Securities and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exchange Commission pursuant to Rule</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">406&nbsp;of&nbsp;the&nbsp;Securities&nbsp;Act&nbsp;of&nbsp;1933,&nbsp;as&nbsp;amended.</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> C<SMALL>OLLABORATION</SMALL> <SMALL>AND</SMALL> L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL>
(<B><I>&#147;Agreement&#148;</I></B>) is made and entered into effective as of May&nbsp;22, 2017 (the <B><I>&#147;Effective Date&#148;</I></B>), by and between<B> E<SMALL>QUILLIUM</SMALL>,</B><B></B><B>&nbsp;I<SMALL>NC</SMALL>.</B>, a corporation
organized under the laws of the State of Delaware, USA, with its principal office at 2223&nbsp;Avenida de la Playa, Suite&nbsp;108, La Jolla, California 92037, USA (<B><I>&#147;Equillium&#148;</I></B>), and
<B>B<SMALL>IOCON</SMALL></B><SMALL><B></B><B></B></SMALL><B>&nbsp;SA</B>, a company organized under the laws of Switzerland with its principal place of business at c/o BDO SA, Rue De l&#146;Avenir&nbsp;2, 2800 Delemont, Switzerland
(<B><I>&#147;Biocon&#148;</I></B>). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> Biocon owns or controls rights and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to the humanized <FONT
STYLE="white-space:nowrap">anti-CD6</FONT> monoclonal antibody itolizumab; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> Equillium is a
newly-incorporated company formed for the purpose of developing and commercializing itolizumab in North America; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> concurrently with the execution of this Agreement, Equillium and Biocon are entering into: (i)&nbsp;a Common
Stock Purchase Agreement dated as of the Effective Date (the <B><I>&#147;Stock Purchase Agreement&#148;</I></B>), together with the other Transaction Agreements (as such term is defined in the Purchase Agreement); and (ii)&nbsp;a Clinical Supply
Agreement dated as of the Effective Date (the <B><I>&#147;Clinical Supply Agreement&#148;</I></B>); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B>
Equillium desires to obtain from Biocon, and Biocon is willing to grant to Equillium, an exclusive license to develop and commercialize itolizumab in North America, on the terms and subject to the conditions set forth herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL>,</B> in consideration of the foregoing premises and the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Equillium and Biocon hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>&#147;</B><B>Accounting Standards</B><B>&#148;</B> shall mean (a)&nbsp;U.S. generally accepted accounting principles or
(b)&nbsp;international financial reporting standards or (c)&nbsp;Indian Accounting Standards; in each case, as applicable, consistently applied throughout the organization of a particular entity and its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B>&#147;Act&#148;</B> shall mean the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167;301 et seq., as
amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> <B>&#147;Affiliate&#148;</B> shall mean, with respect to any Entity (including a party to this
Agreement), any other Entity controlled by, controlling, or under common control with such Entity. For the purposes of this definition, the term &#147;control&#148; (including, with correlative meanings, the terms &#147;controlled by&#148; and
&#147;under common control with&#148;) shall mean the possession, directly or indirectly, of more than 50% of the outstanding voting securities of a </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">corporation or comparable equity interest in any other type of Entity, or otherwise having the power to direct the management and policies of such Entity. For
clarity, and notwithstanding the foregoing, Equillium and Biocon shall be deemed <I><U>not</U></I> to be Affiliates of each other for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> <B>&#147;</B><B>After-Acquired IP</B><B>&#148;</B> shall mean any Patent Right, Information or other intellectual property right of
a Third Party with respect to which a party first obtains a right to grant access, or a license or sublicense, from such Third Party after the Effective Date, under an agreement obligating such party to pay royalties and/or milestone payments to
such Third Party with respect to products covered by or using such Patent Right, Information or other intellectual property right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B> <B>&#147;</B><B>Anti-Corruption Laws</B><B>&#148;</B> shall mean the U.S. Foreign Corrupt Practices Act, as amended, the
Organization for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development (OECD) Convention on combating bribery of foreign public officials in international business transactions, and any other applicable anti-corruption laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B> <B>&#147;</B><B>Applicable Laws</B><B>&#148;</B> shall mean the applicable provisions of any and all national, supranational,
regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits of or from any court, arbitrator, regulatory authority or governmental
agency or authority having jurisdiction over or related to the subject item, including the Act, Anti-Corruption Laws and Export Control Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B> <B>&#147;Biocon FTE&#148;</B> shall mean the equivalent of a full-time Biocon&#146;s employee&#146;s work time over a <FONT
STYLE="white-space:nowrap">12-month</FONT> period (including normal vacations, sick days and holidays). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B> <B>&#147;</B><B>Biocon
FTE Rate</B><B>&#148;</B> shall mean (a)&nbsp;with respect to FTEs located in India, [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] U.S. Dollars (U.S. $[&#133;***&#133;]) per Biocon FTE per year (the
<B><I>&#147;</I></B><B><I>India FTE Rate</I></B><B><I>&#148;</I></B>) and (b)&nbsp;with respect to FTEs located outside India, [&#133;***&#133;] U.S. Dollars (U.S. $[&#133;***&#133;]) per Biocon FTE per year (the
<B><I>&#147;</I></B><B><I>Ex</I></B><B><I><FONT STYLE="white-space:nowrap">-India</FONT> FTE Rate</I></B><B><I>&#148;</I></B>); in each case, subject to modification as set forth in this Section&nbsp;1.8. The Biocon FTE Rates shall be subject to
review and update annually on a calendar year basis by the JSC. In connection therewith, the Finance Representatives shall review the then-current India FTE Rate and <FONT STYLE="white-space:nowrap">Ex-India</FONT> FTE Rate and consider, for the
applicable country where such FTEs are located, (i)&nbsp;changes in Biocon&#146;s compensation rates, generally applied to all of its personnel in the applicable country (other than increases commensurate with inflation in such country),
(ii)&nbsp;inflation in the applicable country, and (iii)&nbsp;changes in the cost of standard reagents, supplies and equipment and standard services performed by Third Party subcontractors in such country (other than increases commensurate with
inflation in such country); in each case, since the last such modification hereunder or, with respect to the first such modification, the Effective Date. Based on the foregoing, the Finance Representatives shall make a recommendation as to whether
and how much to adjust the FTE Rate(s); <I>provided, however,</I> that notwithstanding any aggregate net year-over-year percentage increase in the cost items specified in the preceding clauses&nbsp;(i), (ii) and (iii), in no event shall the proposed
annual increase to the Biocon FTE Rate to account for increases in the cost items specified in the preceding clauses&nbsp;(i), (ii) and (iii)&nbsp;exceed [&#133;***&#133;]% of any increase in (A)&nbsp;the All India Consumer Price Index (Rural/Urban)
for the same period in the case of the India FTE Rate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or (B)&nbsp;the United States Consumer Price Index for All Urban Consumers <FONT STYLE="white-space:nowrap">(CPI-U):</FONT> U.S. city average, published by the
Bureau of Labor Statistics, United States Department of Labor, for the same period in the case of the <FONT STYLE="white-space:nowrap">Ex-India</FONT> FTE Rate. For clarity, the Biocon FTE Rate is inclusive of the costs of standard reagents,
supplies and equipment, and standard services performed by Third Party subcontractors of Biocon, but does not include the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of specialized reagents,
supplies or equipment, or specialized services performed by Third Party subcontractors of Biocon, that, in each case, are needed specifically for the conduct of Biocon Preclinical Activities but are not generally required for similar activities
Biocon performs on behalf of Third Parties or for its own account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B> <B>&#147;Biocon Invention&#148;</B> shall mean any
Invention made solely by one or more employees, consultants or contractors of Biocon. For clarity, Biocon Inventions exclude Joint Inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B> <B>&#147;Biocon <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT></B> shall mean all Information Controlled by Biocon as of
the Effective Date or during the Term that is necessary or useful for the development, manufacture or commercialization of ITO or Product and all Biocon Inventions, including, without limitation, all Information licensed to Biocon or its Affiliates
pursuant to the [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] Agreement, but excluding Biocon&#146;s interest in Joint Inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B> <B>&#147;Biocon License&#148;</B> shall have the meaning provided in Section&nbsp;2.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B> <B>&#147;Biocon Patents&#148;</B> shall mean all Patent Rights Controlled by Biocon as of the Effective Date or during the Term
that claim inventions that are necessary or useful for the development, manufacture or commercialization of ITO or Product, including, without limitation, the patents and patent applications listed in <B>Exhibit</B><B></B><B>&nbsp;A</B> hereto and
the [&#133;***&#133;] Patents, but excluding the Joint Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B> <B>&#147;Biocon Preclinical Activities&#148;</B> shall mean
Biocon&#146;s activities under Section&nbsp;4.2(a), the <FONT STYLE="white-space:nowrap">IND-Enabling</FONT> Studies and the <FONT STYLE="white-space:nowrap">IND-Enabling</FONT> CMC Activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B> <B>&#147;Biocon Preclinical Expenses&#148;</B> shall mean the internal and external costs and expenses incurred by Biocon or its
Affiliate to the extent reasonably and fairly attributable or allocable to the conduct of the Biocon Preclinical Activities conducted in accordance with this Agreement, consisting solely of the following, in each case to the extent reasonably and
fairly attributable or allocable to the conduct of the Biocon Preclinical Activities: (a)&nbsp;internal costs, calculated on the basis of the Biocon FTE Rate, incurred by Biocon or its Affiliate in conducting Biocon Preclinical Activities; and
(b)&nbsp;reasonable and documented amounts paid to Third Parties for the conduct of Biocon Preclinical Activities by such Third Parties. Biocon Expenses shall in any event exclude: (i)&nbsp;all direct and indirect overhead costs of Biocon and its
Affiliates, except to the extent that certain direct overhead costs are included in the Biocon FTE Rate; and (ii)&nbsp;the costs of standard reagents, supplies and equipment, and standard services performed by Third Party subcontractors of Biocon.
By way of clarity, Biocon&#146;s engagement of its Affiliates to perform any Biocon Preclinical Activities shall be at arm&#146;s length transaction basis and hence Biocon Preclinical Expenses shall be computed accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B> <B>&#147;Biocon Technology&#148;</B> shall mean the Biocon Patents and the Biocon
<FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B> <B>&#147;Biocon Territory&#148;</B> shall mean countries listed in <B>Exhibit</B><B></B><B>&nbsp;C</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B> <B>&#147;Chair&#148;</B> shall have the meaning provided in Section&nbsp;3.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B> <B>&#147;</B>[<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>&#133;***&#133;]<B>&#148;</B> shall mean [&#133;***&#133;], a
company organized and existing under the laws of [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B> <B>&#147;</B>[&#133;***&#133;]<B> Agreement&#148;</B>
shall mean that certain [&#133;***&#133;], between BIOCON Biopharmaceuticals Private Limited, BIOCON Limited, and [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B> <B>&#147;</B>[&#133;***&#133;]<B> Patents&#148;</B> shall mean all Patent Rights licensed to Biocon or its Affiliates pursuant to
the [&#133;***&#133;] Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B> <B>&#147;Clinical Material&#148;</B> shall have the meaning provided in Section&nbsp;4.2(b).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B> <B>&#147;Clinical Supply Agreement&#148;</B> shall have the meaning provided in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B> <B>&#147;CMC&#148;</B> shall mean chemistry, manufacturing and controls information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B> <B>&#147;CMO&#148;</B> shall mean Third Party contract manufacturer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B> <B>&#147;Combination Product&#148;</B> shall mean a Product or Supported Product (as applicable) that is sold in a finished dosage
form containing ITO in combination with one or more Other Actives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B> <B>&#147;Commercially Reasonable Efforts&#148;</B> shall
mean, with respect to a party&#146;s obligations under this Agreement, the efforts, commitments, and level of resources to be expended by a party in carrying out of its obligations (including, in the case of Equillium, its efforts to develop,
register and commercialize the Product in Equillium Territory), the level of reasonable, diligent, good faith efforts that biopharmaceutical companies typically devote to products owned by them that are at a similar stage in their development or
product life and are of similar market potential, taking into account [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B> <B>&#147;Commercial Quality
Agreement&#148;</B> shall have the meaning provided in Section&nbsp;4.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B> <B>&#147;Commercial Supply Agreement&#148;</B> shall have the meaning provided in Section&nbsp;4.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B> <B>&#147;Confidential Information&#148;</B> shall have the meaning provided in Section&nbsp;8.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B> <B>&#147;Confidentiality Agreement&#148;</B> shall mean, collectively, any and all confidentiality or <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreements between Equillium and Biocon entered into prior to the Effective Date relating to the subject matter of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B> <B>&#147;Control&#148;</B> or <B>&#147;Controlled by&#148;</B> shall mean, with respect to any Patent Rights, Information or other
intellectual property rights, the possession by a party of the ability (whether by ownership, license or other right, other than pursuant to a license granted to such party under this Agreement) to grant access to, or a license or sublicense of,
such Patent Rights, Information or other intellectual property rights without violating the terms of any agreement or other arrangement with any Third Party. Notwithstanding the foregoing, if a party determines in good faith that a particular item
of After-Acquired IP may be necessary or useful for the development, manufacture or commercialization of ITO or Product in the other party&#146;s Territory, such party shall promptly provide to the other party a reasonable description of such
After-Acquired IP and shall disclose to the other party in writing such party&#146;s royalty and/or milestone payment obligations to the applicable Third Party with respect to such item of After-Acquired IP. At the other party&#146;s written request
made within [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] of the first party&#146;s provision of such description and disclosure of payment obligations to the other party, the parties shall discuss in good faith the
possibility of including such item of After-Acquired IP in the technology (<I>i.e.</I>, Equillium Technology or Biocon Technology) licensed to the other party hereunder; <I>provided, however,</I> that such item of After-Acquired IP shall be deemed
to be within the &#147;Control&#148; of the first party for purposes of this Agreement only upon the other party&#146;s written agreement to pay all royalties and milestone payments arising under the agreement with the Third Party as a result of the
other party&#146;s development, manufacture or commercialization of Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B> &#147;<B>Cost of Goods</B>&#148; shall mean the
fully burdened cost of the Clinical Material shipped to Equillium, expressed on a per unit manufactured basis, which will be the sum of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> in the case of Clinical Material manufacturing activities performed by Biocon or its Affiliates (including manufacturing activities
in support of Third Party manufacturing) [&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> in the case
of goods and services acquired from Third Parties for the manufacture of Clinical Material [<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any calculation of Cost of Goods will be based upon Accounting Standards, and methods for activity-based accounting thereunder, in each case,
consistently applied throughout the organization of Biocon or its Affiliate. No cost item will be counted more than once in calculating Cost of Goods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B> <B>&#147;Data&#148;</B> shall mean any and all results of research, preclinical studies, including <I>in vitro</I> and <I>in
vivo</I> studies, clinical trials and other testing of ITO or Product conducted by or on behalf of a party or any of its Affiliates either before or during the Term, and any and all other data generated by or on behalf of a party related to the
development, manufacture or commercialization of ITO or Product, including biological, chemical, pharmacological, toxicological, pharmacokinetic, clinical, CMC, analytical, quality control, and other data, results and descriptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B> <B>&#147;Entity&#148;</B> shall mean any corporation, general partnership, limited partnership, limited liability partnership,
joint venture, estate, trust, company (including any limited liability company or joint stock company), firm or other enterprise, association, organization or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B> <B>&#147;Equillium CMO&#148;</B> shall mean a CMO contracted by Equillium or its Affiliate or Sublicensee to manufacture and
supply Product for the Equillium Territory, but specifically excluding any Third Party manufacturer contracted by Biocon or its Affiliate to manufacture and supply Product for the Equillium Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B> <B>&#147;Equillium Invention&#148;</B> shall mean any Invention made solely by one or more employees, consultants or contractors
of Equillium. For clarity, Equillium Inventions exclude Joint Inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B> <B>&#147;Equillium
<FONT STYLE="white-space:nowrap">Know-How&#148;</FONT></B> shall mean all Information Controlled by Equillium during the Term that is necessary or useful for the development, manufacture or commercialization of ITO or Product, including Equillium
Inventions, but excluding Equillium&#146;s interest in Joint Inventions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B> <B>&#147;Equillium License&#148;</B> shall have the meaning provided in Section&nbsp;2.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B> <B>&#147;Equillium Patents&#148;</B> shall mean all Patent Rights Controlled by Equillium during the Term that claim inventions
that are necessary or useful for the development, manufacture or commercialization of ITO or Product, but excluding the Joint Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B> <B>&#147;Equillium Technology&#148;</B> shall mean the Equillium Patents and the Equillium
<FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B> <B>&#147;Equillium</B> <B>Territory&#148;</B> shall mean the US, including
its territories and possessions, and Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B> <B>&#147;Export Control Laws&#148;</B> shall mean: (a)&nbsp;all applicable U.S.
laws and regulations relating to sanctions and embargoes imposed by OFAC; (b)&nbsp;all applicable U.S. export control laws, including the Arms Export Controls Act (22 U.S.C. Ch. 39), the International Emergency Economic Powers Act (50 U.S.C.
&#167;&#167; 1701 et seq.), the Trading With the Enemy Act (50 U.S.C. app. &#167;&#167; 1 et seq.), the Export Administration Act of 1979 (50 U.S.C. app. &#167;&#167; 2401 et seq.), International Boycott Provisions of Section&nbsp;999 of the U.S.
Internal Revenue Code of 1986, and all rules, regulations and executive orders relating to any of the foregoing, including but not limited to the International Traffic in Arms Regulations (22 C.F.R. &#167;&#167; 120 et seq.), the Export
Administration Regulations (15 C.F.R. &#167;&#167; 730 et. seq.), and the regulations administered by the Office of Foreign Assets Controls of the United States Department of the Treasury; and (c)&nbsp;all export controls imposed on any Product by
any country or organization or nations within the jurisdiction of which a party operates or does business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B>
<B>&#147;FDA&#148;</B> shall mean the U.S. Food and Drug Administration, or any successor Regulatory Authority thereto in the US having substantially the same function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B> <B>&#147;Field&#148;</B> shall mean: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> prior to the achievement of the Field Expansion Milestones, the Limited Field; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> from and after the achievement of the Field Expansion Milestones (but subject to Section&nbsp;4.8(b)(ii)), the Unlimited Field.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B> <B>&#147;Field Expansion Deadline&#148;</B> shall have the meaning provided in Section&nbsp;2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B> <B>&#147;Field Expansion Milestones&#148;</B> shall have the meaning provided in Section&nbsp;2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B> <B>&#147;Financial Representative&#148;</B> shall have the meaning provided in Section&nbsp;3.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B> <B>&#147;First Commercial Sale&#148;</B> shall mean the first sale of a Product by a Selling Party or any of its Affiliates or
Sublicensees to a Third Party for end use or consumption of such Product in a country after the applicable Regulatory Authority of such country has granted Regulatory Approval of such Product. Notwithstanding the foregoing, if, prior to Regulatory
Approval of a Product in a country, aggregate gross invoiced amounts for Product used in named-patient programs in such country exceed US$[<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;], then &#147;First Commercial Sale&#148;
of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such Product in such country, solely for purposes of Sections&nbsp;5.5(a) and 5.5(b) (but not for the purpose of Section&nbsp;5.2 or any other purpose) shall
be deemed to occur at the time aggregate gross invoiced amounts for Product used in named-patient programs in such country first exceed US$[&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B> <B>&#147;First US Approval&#148;</B> shall have the meaning provided in Section&nbsp;4.2(b)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B> <B>&#147;Fully-Burdened Manufacturing Cost&#148;</B> shall be defined in detail in the Commercial Supply Agreement and will be
fundamentally consistent with the &#147;Cost of Goods&#148; definition in this Agreement. For clarity, Fully-Burdened Manufacturing Cost shall not include any costs for unusable batches resulting from Biocon&#146;s failure to conduct its
manufacturing activities in accordance with the terms of the Commercial Supply Agreement or any profit, <FONT STYLE="white-space:nowrap">mark-up</FONT> or margin related to inter-company transfer pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B> <B>&#147;</B><B>GCP</B><B>&#148;</B> shall mean current good clinical practices, as set forth in 21 C.F.R. Parts&nbsp;50, 54, 56,
312 and 314 and as interpreted by relevant ICH guidelines; in each case, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B> <B>&#147;Generic
Version&#148;</B> shall mean, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, with respect to a particular Product sold by a party or any of its Affiliates or Sublicensees in a country,
a pharmaceutical product sold by a Third Party (other than a Sublicensee or any other Third Party in a chain of distribution originating from such party or any of its Affiliates or Sublicensees) in such country: (a)&nbsp;that contains ITO (and, if
applicable, the same Other Active(s) as such Product) in the same dosage form as such Product; and (b)&nbsp;has received Regulatory Approval from the relevant Regulatory Authority in such country in reliance on the Regulatory Approval for such
Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B> <B>&#147;GLP&#148;</B> shall mean current good laboratory practices, as set forth in 21 C.F.R.
Part&nbsp;58 and as interpreted by relevant ICH guidelines; in each case, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B>
<B>&#147;GMP&#148;</B> shall mean the current good manufacturing practices and standards for the production of drugs and finished pharmaceuticals, as set forth in 21 C.F.R. Parts&nbsp;210 and 211 and as interpreted by relevant ICH guidelines; in
each case, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B> <B>&#147;ICH&#148;</B> shall mean the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human Use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B> <B>&#147;IND&#148;</B> shall mean an
investigational new drug application, clinical study application, clinical trial exemption, or similar application or submission filed with or submitted to a Regulatory Authority in a jurisdiction that is necessary to commence human clinical trials
in such jurisdiction, including any such application filed with the FDA pursuant to 21 C.F.R. Part&nbsp;312. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B> <B><FONT
STYLE="white-space:nowrap">&#147;IND-Enabling</FONT> CMC Activities&#148;</B> shall mean all activities necessary to generate the <FONT STYLE="white-space:nowrap">IND-Enabling</FONT> CMC Data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B> <B><FONT STYLE="white-space:nowrap">&#147;IND-Enabling</FONT> CMC Data&#148;</B> shall mean all data and information required to be
included in the chemistry, manufacturing and controls section of an IND for Product in the US. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B> <B><FONT
STYLE="white-space:nowrap">&#147;IND-Enabling</FONT> Studies&#148;</B> shall have the meaning provided in Section&nbsp;4.2(a)(ii)(1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B> <B>&#147;Indication&#148;</B> shall mean a separate and distinct disease, disorder or condition in humans (a)&nbsp;which a Product
is intended to treat or prevent, as evidenced by the protocol for a clinical trial of such Product or by the proposed Product labeling in an NDA filed with a Regulatory Authority for such Product; or (b)&nbsp;which is contained in a Product&#146;s
labeling approved by a Regulatory Authority as part of the Regulatory Approval for such Product. However, the parties agree that the treatment of a disease, disorder or condition in a particular patient population and the treatment of the same
disease, disorder or condition in a different population (<I>e.g.</I>, adult and pediatric, or first-line and second-line) will not be treated as separate Indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B> <B>&#147;Information&#148;</B> shall mean any and all tangible and intangible (a)&nbsp;techniques, technology, practices, trade
secrets, inventions (whether patentable or not), methods, knowledge, <FONT STYLE="white-space:nowrap">know-how,</FONT> skill, experience, test data and results (including pharmacological, toxicological and clinical test data and results), analytical
and quality control data, results or descriptions, software and algorithms, and (b)&nbsp;compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material; that, in each case, are not in the public
domain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62</B> <B>&#147;Invention&#148;</B> shall mean any invention, whether or not patentable, made conceived, generated or
reduced to practice in the course and as a result of the conduct of activities conducted pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63</B>
<B>&#147;ITO&#148;</B> shall mean the humanized <FONT STYLE="white-space:nowrap">anti-CD6</FONT> monoclonal antibody known by the INN itolizumab, as further described in <B>Exhibit</B><B></B><B>&nbsp;B</B> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64</B> <B>&#147;IV&#148;</B> shall mean intravenously administered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65</B> <B>&#147;JIPC&#148;</B> shall have the meaning provided in Section&nbsp;7.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.66</B> <B>&#147;Joint Invention&#148;</B> shall mean any Invention made jointly by, on the one hand, one or more employees, consultants
or contractors of Equillium and, on the other hand, one or more employees, consultants or contractors of Biocon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.67</B>
<B>&#147;Joint Patents&#148;</B> shall mean Patent Rights claiming Joint Inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.68</B> <B>&#147;JSC&#148;</B> shall have the
meaning provided in Section&nbsp;3.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.69</B> <B>&#147;Limited Field&#148;</B> shall mean the diagnosis, treatment, prevention and
palliation of Orphan Indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.70</B> <B>&#147;NDA&#148;</B> shall mean: (a)&nbsp;in the United States, as applicable, a New Drug
Application (as more fully described in 21 CFR Part&nbsp;314.50, et seq., or its successor regulation) or a Biologics License Application (as more fully described in 21 CFR Part&nbsp;601, et seq., or its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">successor regulation), filed with the FDA, or any successor application to either of the foregoing; or (b)&nbsp;in any other country or group of countries, the
equivalent application or submission for approval to market a pharmaceutical product filed with the governing Regulatory Authority in such country or group of countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.71</B> <B>&#147;Net Sales&#148;</B> shall mean the gross amounts invoiced for sales or other dispositions of Products or Supported
Product, as applicable, by or on behalf of a party or any of its Affiliates or Sublicensees (each, a <B><I>&#147;Selling Party&#148;</I></B>), to Third Parties (other than another Selling Party), less the following deductions actually incurred,
allowed, paid, accrued or otherwise specifically allocated to Products by the Selling Party: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> [<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>&#133;***&#133;];. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> [&#133;***&#133;];. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> [&#133;***&#133;];. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> [&#133;***&#133;];. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> [&#133;***&#133;];. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> [&#133;***&#133;];. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> [&#133;***&#133;]; and. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event shall any particular amount identified above be deducted more than once in calculating Net Sales (<I>i.e.</I>, no &#147;double
counting&#148; of deductions). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For clarification, sale of Product by a Selling Party to another Selling Party for resale by such entity to a Third Party (other than a Selling
Party) shall not be deemed a sale for purposes of this definition of &#147;Net Sales,&#148; provided that the subsequent resale is included in the computation of Net Sales. In addition, neither sales of Clinical Material by Biocon or its Affiliate
to Equillium or its Affiliate or Sublicensee pursuant to the Clinical Supply Agreement nor sales of Product by Biocon or its Affiliate to Equillium or its Affiliate or Sublicensee for commercial distribution in the Equillium Territory pursuant to
the Commercial Supply Agreement, shall be deemed a sale for purposes of this definition of &#147;Net Sales.&#148; Further, transfers or dispositions of Products as free promotional samples in commercially reasonable amounts, consistent with
prevailing pharmaceutical industry standards, or in any patient assistance, test marketing program, named-patient program or compassionate use program (so long as such Products are provided without charge or at or below the Selling Party&#146;s
cost) and Products donated to <FONT STYLE="white-space:nowrap">non-profit</FONT> institutions or government agencies, or used in research, development or regulatory activities, including, without limitation, clinical trials, shall be disregarded in
determining Net Sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, if
a Product under this Agreement is sold in the form of a Combination Product in a country, Net Sales for the purpose of determining royalties due hereunder shall be calculated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Where both Product containing ITO as its sole active pharmaceutical ingredient (<B><I>&#147;Single-Agent Product&#148;</I></B>) and
all Other Active(s) in such Combination Product are sold separately in such country, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product in such country as determined under the preceding provisions of this
Section&nbsp;1.71, by the fraction [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If Single-Agent
Product is sold in such country, but none of the Other Active(s) is sold separately in such country, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product in such country as determined under the preceding
provisions of this Section&nbsp;1.71, by the fraction [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> If no Single-Agent Product is sold in such
country, but the Other Active(s) are sold separately in such country, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product in such country as determined under the preceding provisions of this Section&nbsp;1.71,
by the fraction [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> If neither Single-Agent Product nor the Other Active(s) are sold separately in such
country, Net Sales for the purpose of determining royalties due hereunder for the Combination Product shall be determined by mutual agreement of the parties in good faith taking into account the relative value contributions of the ITO portion of the
Combination Product and the Other Active(s) in the Combination Product; <I>provided, however,</I> that in no event </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shall the relative value contribution of the ITO portion of the Combination Product be less than [&#133;***&#133;]%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.72</B> <B>&#147;OFAC&#148;</B> shall mean the U.S. Department of Treasury&#146;s Office of Foreign Assets Control (or its successor
office or other body having substantially the same function). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.73</B> <B>&#147;Ongoing Biocon Study&#148;</B> shall mean the clinical
trial described in Biocon Protocol No.&nbsp;[&#133;***&#133;], titled [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.74</B> <B>&#147;Orphan
Designation&#148;</B> shall mean the grant by FDA of a request for orphan-drug designation under Section&nbsp;526 of the Act, as amended (or its successor regulation), for a drug for a particular Orphan Indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.75</B> <B>&#147;Orphan Indication&#148;</B> shall mean any disease or condition that (a)&nbsp;affects less than 200,000&nbsp;persons in
the US or (b)&nbsp;affects more than 200,000&nbsp;persons in the US and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from
sales in the United States of such drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.76</B> <B>&#147;Other Active&#148;</B> shall mean any active pharmaceutical ingredient
other than ITO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.77</B> <B>&#147;Patent Rights&#148;</B> shall mean (a)&nbsp;all national, regional and international patents and
patent applications filed in any country of the world, including without limitation provisional patent applications, (b)&nbsp;all patent applications filed either from such patents and patent applications or from a patent application claiming
priority from either of these, including any continuation, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part,</FONT></FONT> division, provisional, converted provisional and continued prosecution applications, or
any substitute applications, (c)&nbsp;any patent issued with respect to or in the future issued from any such patent applications including utility models, petty patents and design patents and certificates of invention, and (d)&nbsp;any and all
extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, reexaminations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or
patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.78</B> <B>&#147;Person&#148;</B> shall mean any individual, Entity or Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.79</B> <B>&#147;</B><B>Pivotal Trial</B><B>&#148;</B> shall mean: (a)&nbsp;a human clinical trial that would satisfy the requirements for
a Phase&nbsp;3 study as defined in 21&nbsp;CFR &#167;&nbsp;312.21(c) (or any amended or successor regulations); or (b)&nbsp;any other human clinical trial that the applicable Regulatory Authority has agreed, whether before first dosing of the first
patient in such trial (<I>e.g.</I>,&nbsp;pursuant to a special protocol assessment agreement with the FDA) or after first dosing of the first patient in such trial (<I>e.g.</I>, based on an interim data analysis), is sufficient to form the primary
basis of an efficacy claim in an NDA submission, regardless of whether the sponsor of such trial characterizes or refers to such trial as a &#147;Phase&nbsp;3,&#148; &#147;Phase&nbsp;2b&#148; or &#147;Phase&nbsp;2b/3&#148; trial (or otherwise) in
the applicable protocol, on clinicaltrials.gov, or in any other context. If a human clinical trial does </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">not constitute a Pivotal Trial at the time of first dosing of the first patient in such trial, but is later determined by the applicable Regulatory Authority
to be sufficient to form the primary basis of an efficacy claim in an NDA submission, then, for purposes of Section&nbsp;10.2(a) hereof, &#147;initiation&#148; of such Pivotal Trial shall be deemed to have occurred on the date of such determination
by the applicable Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.80</B> <B>&#147;PoC Study&#148;</B> shall mean the first human clinical trial of a Product
in a particular Indication that is designed to establish clinical proof of concept for such Indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.81</B>
<B>&#147;Product&#148;</B> shall mean any pharmaceutical composition or preparation containing or comprising <FONT STYLE="white-space:nowrap">CHO-derived</FONT> ITO, including all formulations and dosage forms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.82</B> <B>&#147;Regulatory Approval&#148;</B> shall mean all approvals from the relevant Regulatory Authority in a given country
necessary to market and sell a pharmaceutical product in such country, including pricing and reimbursement approvals if required for marketing or sale of such product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.83</B> <B>&#147;Regulatory Authority&#148;</B> shall mean any country, federal, supranational, state or local regulatory agency,
department, bureau or other governmental or regulatory authority having the administrative authority to regulate the development or marketing of pharmaceutical products in any country or other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.84</B> <B>&#147;Regulatory Exclusivity&#148;</B> shall mean marketing or manufacturing exclusivity conferred by the applicable Regulatory
Authority in a country or jurisdiction on the holder of a Regulatory Approval for a pharmaceutical product in such country or jurisdiction, including, by way of example and not of limitation, regulatory data exclusivity, orphan drug exclusivity, new
chemical entity exclusivity and pediatric exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.85</B> <B>&#147;Regulatory Filing&#148;</B> shall mean any and all INDs,
NDAs, drug dossiers or drug master files filed, requests for Orphan Designation, and Regulatory Approvals and Orphan Designations obtained, with respect to ITO or Product in the Field, including all amendments, supplements, annual reports and the
like filed with or otherwise provided to the applicable Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.86</B> <B>&#147;SC&#148;</B> shall mean subcutaneously
administered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.87</B> <B>&#147;Selling Party&#148;</B> shall have the meaning provided in Section&nbsp;1.71. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.88</B> <B>&#147;Stage</B><B></B><B>&nbsp;2 Study&#148;</B> shall mean that portion of the Ongoing Biocon Study comprising a [<SUP
STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.89</B> <B>&#147;Stage</B><B></B><B>&nbsp;2 Study
Completion&#148;</B> shall mean the delivery by Biocon to Equillium of the final study report from the Stage&nbsp;2 Study; <I>provided, however,</I> that [&#133;***&#133;], then &#147;Stage&nbsp;2 Study Completion&#148; shall be deemed to have
occurred on the earlier of (a) [&#133;***&#133;]</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] and (b)&nbsp;[&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.90</B> <B>&#147;Stock Purchase Agreement&#148;</B> shall have the meaning provided in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.91</B> <B>&#147;Sublicensee&#148;</B> shall mean: (a)&nbsp;with respect to Equillium, a Third Party sublicensee under the Equillium
License, whether such Third Party&#146;s sublicense was granted to it directly by Equillium or its Affiliate or indirectly through one or more tiers of sublicense; and (b)&nbsp;with respect to Biocon, a Third Party sublicensee under the Biocon
License, whether such Third Party&#146;s sublicense was granted to it directly by Biocon or its Affiliate or indirectly through one or more tiers of sublicense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.92</B> <B>&#147;Supported Product&#148;</B> shall mean, in any country of the Biocon Territory, a Product that has received Regulatory
Approval in such country on the basis of approval of an NDA (or any amendment or supplement thereto) that included or referenced Data within the Equillium <FONT STYLE="white-space:nowrap">Know-How</FONT> from a PoC Study, other Phase&nbsp;2 clinical
trial, or Pivotal Trial conducted by or on behalf of Equillium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.93</B> <B>&#147;Term&#148;</B> shall have the meaning provided in
Section&nbsp;10.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.94</B> <B>&#147;Territory&#148;</B> shall mean (a)&nbsp;the Equillium Territory in the case of Equillium and
(b)&nbsp;the Biocon Territory in the case of Biocon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.95</B> <B>&#147;Third Party&#148;</B> shall mean an Entity other than Equillium
or Biocon or an Affiliate of Equillium or Biocon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.96</B> <B>&#147;Third Party License&#148;</B> shall mean, with respect to a
Product sold by Equillium or its Affiliate or Sublicensee in a country of the Equillium Territory, a license under Patent Rights of a Third Party that are reasonably necessary for the manufacture, use or sale of such Product in such country;
<I>provided, however,</I> that if such Product is manufactured (a)&nbsp;by Equillium or its Affiliate or Sublicensee or (b)&nbsp;by an Equillium CMO on behalf of Equillium or its Affiliate or Sublicensee, then, for purposes of Section&nbsp;5.6, the
term &#147;Third Party License&#148; shall apply only to Patent Rights of a Third Party that are reasonably necessary for the manufacture, use or sale of the ITO contained in such Product and shall exclude Patent Rights of a Third Party that cover
such Product in the formulation manufactured by Equillium, its Affiliate or Sublicensee, or the Equillium CMO, but that do not cover the ITO contained therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.97</B> <B>&#147;Unlimited Field&#148;</B> shall mean the diagnosis, treatment, prevention and palliation of any and all Indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.98</B> <B>&#147;US&#148;</B> shall mean the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.99</B> <B>&#147;Valid Claim&#148;</B> shall mean a claim contained in (a)&nbsp;an issued and unexpired patent which has not been held
unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable
through abandonment, reissue, disclaimer or otherwise or (b)&nbsp;a patent application that has not been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">irretrievably cancelled, withdrawn or abandoned and that has been pending for less than seven (7)&nbsp;years from the filing date from which such claim takes
priority. If a claim of a patent application that ceased to be a Valid Claim under clause&nbsp;(b) of the preceding sentence because of the passage of time later issues as a part of a patent within clause&nbsp;(a) of the preceding sentence, then it
shall again be considered a Valid Claim effective as of the issuance of such patent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>L<SMALL>ICENSE</SMALL> G<SMALL>RANTS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Equillium License.</B> Subject to the terms and conditions of this Agreement, Biocon hereby grants to Equillium: (a)&nbsp;an
exclusive (even as to Biocon, except as expressly set forth below), <FONT STYLE="white-space:nowrap">royalty-bearing</FONT> license, with the right to sublicense through multiple tiers of sublicense, under the Biocon Technology and Biocon&#146;s
interest in the Joint Patents to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit ITO and Products in the Field in the Equillium Territory; and (b)&nbsp;solely in connection with the practice of the
license in the preceding clause&nbsp;(a), a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">royalty-free</FONT> license, with the right to sublicense through multiple tiers of sublicense, under the Biocon
Technology and Biocon&#146;s interest in the Joint Patents, to develop, and to use and import for the purpose of developing, ITO and Products in the Field in the Biocon Territory ((a) and (b), collectively, the <B><I>&#147;</I></B><B><I>Equillium
License</I></B><B><I>&#148;</I></B>); <I>provided, however,</I> that, prior to the earlier of (i)&nbsp;achievement of the Field Expansion Milestones and (ii)&nbsp;the Field Expansion Deadline, and notwithstanding the definition of the Field prior to
achievement of the Field Expansion Milestones, the Equillium License shall include the right to develop, and to use and import for the purpose of developing, ITO and Products in the Unlimited Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Biocon License.</B> Subject to the terms and conditions of this Agreement, Equillium hereby grants to Biocon: (a)&nbsp;an
exclusive (even as to Equillium, except as expressly set forth below), <FONT STYLE="white-space:nowrap">royalty-bearing</FONT> license, with the right to sublicense through multiple tiers of sublicense, under the Equillium Technology and
Equillium&#146;s interest in the Joint Patents, to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit ITO and Products in the Unlimited Field in the Biocon Territory; and (b)&nbsp;a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">royalty-free</FONT> license, with the right to sublicense through multiple tiers of sublicense, under the Equillium Technology and Equillium&#146;s interest in the
Joint Patents, to develop, and to use and import for the purpose of developing, ITO and Products in the Unlimited Field in the Equillium Territory ((a) and (b), collectively, the <B><I>&#147;</I></B><B><I>Biocon License</I></B><B><I>&#148;</I></B>).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Field Expansion.</B> In the event that, within [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] years
of Stage&nbsp;2 Study Completion (subject to extension as described below, the <B><I>&#147;</I></B><B><I>Field Expansion Deadline</I></B><B><I>&#148;</I></B>), Equillium has achieved both of the following milestones (collectively, the
<B><I>&#147;</I></B><B><I>Field Expansion Milestones</I></B><B><I>&#148;</I></B>), then, effective as of the achievement of the second to be achieved of the Field Expansion Milestones, the Field shall automatically be expanded to mean the Unlimited
Field, subject to Section&nbsp;4.8(b)(ii): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> receipt of Orphan Designation for Product in two Orphan Indications; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> completion of a PoC Study of Product in each of two Indications (<I>i.e.</I>, two PoC Studies in different Indications) in patient
populations approved by the JSC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Field Expansion Deadline shall be extended to the extent of any delay directly attributable to events beyond the reasonable control of
Equillium, including, by way of example and not of limitation, delays due to unavailability of Clinical Material, imposition of a clinical hold, Biocon&#146;s failure or delay in performing those of its obligations under Section&nbsp;4.2 that are a
prerequisite for Equillium&#146;s achievement of the Field Expansion Milestones, or delays in receiving required OFAC license(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>Sublicensing.</B> Any sublicense granted by Equillium under the Equillium License, and any sublicense granted by Biocon under
the Biocon License (in each case, directly or indirectly through its Affiliate), to a Third Party shall be in writing and subject and subordinate in all respects to, and consistent with, the terms and conditions of this Agreement. Each party shall
be responsible for the compliance of its Sublicensees with the applicable terms and conditions of this Agreement. A copy of each sublicense, redacted as appropriate for confidential information of the Third Party, shall be provided to the other
party within [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] of execution, from which copy such party may redact confidential information of such party or the Third Party that is not necessary for the other party to ascertain
the compliance of such sublicense with such party&#146;s obligations under this Agreement. For clarity, this Section&nbsp;2.4 shall not be construed as imposing any limitation or restriction on Biocon&#146;s right to grant licenses under, or any
other obligation on Biocon with respect to, the licensing of Biocon Technology outside the Equillium Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5 Reservation of
Rights; License Exclusion. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Notwithstanding the exclusivity and territorial restrictions of the Equillium License, Biocon
reserves the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right under the Biocon Technology and Biocon&#146;s interest in the Joint Patents: (i)&nbsp;to make and have made ITO and Products in the Equillium Territory <I><U>solely</U></I> for
the purpose of development, manufacture, use, sale, offer for sale, import and other exploitation of Products in the Biocon Territory; (ii)&nbsp;to develop, and to use and import for the purpose of developing, ITO and Products in the Unlimited Field
in the Equillium Territory; and (iii)&nbsp;as necessary to perform Biocon&#146;s obligations under Section&nbsp;4.2 of this Agreement and under the Clinical Supply Agreement and any Commercial Supply Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Notwithstanding the exclusivity and territorial restrictions of the Biocon License, Equillium reserves the <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> right under the Equillium Technology and Equillium&#146;s interest in the Joint Patents, to develop, and to use and import for the purpose of developing, ITO and Products in the Field in the Biocon
Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> For the avoidance of doubt, neither party grants to the other party any license or other right with respect to any
Other Active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6 Negative Covenants. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>By Equillium.</B> Except as expressly provided herein, Equillium hereby covenants: (i)&nbsp;not to develop, make, have made,
use, sell, have sold or offer for sale ITO or Product outside of the Equillium Territory; (ii)&nbsp;not to practice any Biocon Technology for any purpose other than as expressly authorized in this Agreement; and (iii)&nbsp;not to cause or permit, or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">grant any license or other right to, any of its Affiliates or any Third Party to engage in any of the activities prohibited by the preceding clauses&nbsp;(i)
and (ii)&nbsp;of this Section&nbsp;2.6(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>By Biocon.</B> Except as expressly provided herein, Biocon hereby covenants:
(i)&nbsp;not to develop, make, or obtain any Regulatory Filing with respect to, sell, have sold or offer for sale ITO (however derived) or Product in the Equillium Territory, whether in or outside of the Field; (ii)&nbsp;without limiting the
generality of the preceding clause&nbsp;(i), not to develop, make, or obtain any Regulatory Filing with respect to, sell, have sold or offer for sale ITO (however derived) or Product in the Equillium Territory for veterinary use; (iii)&nbsp;not to
practice any Equillium Technology for any purpose other than as expressly authorized in this Agreement; and (iv)&nbsp;not to cause or permit, or grant any license or other right to, any of its Affiliates or any Third Party to engage in any of the
activities prohibited by the preceding clauses&nbsp;(i) and (ii)&nbsp;of this Section&nbsp;2.6(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7</B> <B>No Implied Licenses.</B>
No right or license under any Information, Patent Rights or other intellectual property rights is granted or shall be granted by implication. All rights or licenses are or shall be granted only as expressly provided in the terms of this Agreement.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>OVERNANCE</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>JSC Formation and Composition.</B> Within 30&nbsp;days after the Effective Date, the parties shall establish a Joint Steering
Committee (<B><I>&#147;</I></B><B><I>JSC</I></B><B><I>&#148;</I></B>) composed of [<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>&#133;***&#133;] representatives of Equillium and [&#133;***&#133;] representatives of Biocon, each of whom
shall have appropriate technical credentials, experience, knowledge regarding such party&#146;s development, registration and commercialization activities with respect to Product in the Field in such party&#146;s Territory, and authority within such
party&#146;s organization. Each party may change its representatives to the JSC from time to time in its sole discretion, effective upon written notice to the other party of such change. The JSC shall be chaired by a representative of Equillium. The
chairperson shall set agendas for JSC meetings in advance, provided that the agendas will include any matter requested by either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Responsibilities and Authority.</B> The JSC&#146;s overall responsibility shall be to encourage and facilitate information
sharing and ongoing cooperation and coordination between the parties in the development, registration and commercialization of Product in the Field in the Equillium Territory and the Biocon Territory, subject to the limitations set forth in this
Article&nbsp;3. In particular, the JSC shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> approve all clinical development activities to be conducted by Equillium with
respect to Product, including review of protocols for clinical trials of Product to be performed by Equillium; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> review the ITO
and Product development activities to be conducted by each party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> serve as the principal means by which: (i)&nbsp;Equillium
keeps Biocon reasonably informed regarding Equillium&#146;s development, registration and commercialization plans, efforts and results with respect to Product; and (ii)&nbsp;Biocon keeps Equillium reasonably informed regarding (A)&nbsp;Biocon&#146;s
performance of its obligations under Section&nbsp;4.2 of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement and (B)&nbsp;Biocon&#146;s development, registration and commercialization plans, efforts and results with respect to Product in the Biocon
Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> seek harmonization in development, regulatory approval, marketing, promotion and commercialization efforts with
respect to Product in the Field in the Equillium Territory and the Biocon Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> facilitate the exchange of Equillium <FONT
STYLE="white-space:nowrap">Know-How</FONT> and Biocon <FONT STYLE="white-space:nowrap">Know-How;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> resolve disputes
referred to it by the JIPC; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> perform such other duties as are specifically assigned to the JSC in this Agreement, the
Clinical Supply Agreement or any Commercial Supply Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party shall be responsible for ensuring that, at all times, its
representatives on the JSC act reasonably and in good faith in carrying out their respective responsibilities hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B>
<B>Meetings.</B> The JSC shall meet as deemed necessary by the JSC members, but at least semi-annually for so long as either party is conducting clinical development of Product. JSC meetings may be conducted in person at times and places to be
determined by the JSC members. Alternatively, the JSC may meet by means of teleconference, videoconference or other similar communications equipment. A reasonable number of additional representatives of a party may attend meetings of the JSC in a <FONT
STYLE="white-space:nowrap">non-voting</FONT> capacity. Each party shall bear its own expenses of participating in meetings of the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Minutes.</B> Equillium shall be responsible for preparing definitive minutes of each JSC meeting. Equillium shall circulate a
draft of the minutes of each meeting to all members of the JSC for comments within [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] after such meeting. Such minutes shall provide a description, in reasonable detail, of the
discussions at the meeting and shall document all actions and determinations approved by the JSC at such meeting, including the approval of the Development Plan or any amendment thereto, which shall be attached to the minutes as an exhibit. The
parties shall promptly discuss any comments on such minutes and finalize the minutes no later than the date of the next JSC meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>Decision-Making.</B> Decisions of the JSC shall be made by majority vote, with each representative of a party on the JSC having
one vote. No vote of the JSC may be taken unless at least one of each party&#146;s representatives is present for the JSC vote, and if less than all of a party&#146;s representatives are present for a JSC vote, then the representative(s) of such
party who are present may cast votes on behalf of all of such party&#146;s representatives on the JSC (<I>i.e.</I>, the Equillium JSC representative(s) present at any JSC meeting shall collectively have [&#133;***&#133;] votes, and the Biocon JSC
representative(s) present at any JSC meeting shall collectively have [&#133;***&#133;] votes). The JSC&#146;s decision-making authority shall be limited to those matters expressly delegated to it in this Agreement. Notwithstanding the foregoing or
any other provision of this Agreement to the contrary, the JSC&#146;s decision-making authority shall be limited to development, regulatory approval, marketing, promotion or commercialization activities with respect to ITO and Product for the
Equillium Territory, and the JSC shall have no decision-making authority whatsoever with regard to Biocon&#146;s development, regulatory approval, marketing, promotion or commercialization activities with respect to ITO and Product for the Biocon
Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6</B> <B>Dispute Resolution.</B> If the JSC&#146;s decision on any matter is not unanimous, then Biocon shall have the right, in its
discretion, to request that such matter be referred to the Chairperson of the Board of Equillium and the Chairperson of the Board of Biocon, or their respective designees with decision-making authority (each, a
<B><I>&#147;</I></B><B><I>Chair</I></B><B><I>&#148;</I></B>), who shall promptly meet and confer in good faith regarding such matter, and Equillium&#146;s Chair shall give good faith consideration to Biocon&#146;s position and make reasonable
efforts to take Biocon&#146;s position into account in deciding whether to uphold the majority decision of the JSC or to agree with Biocon&#146;s Chair on an alternative outcome. Notwithstanding the foregoing or any other provision of this Agreement
to the contrary, neither the JSC nor Equillium&#146;s Chair shall have any power to: (A)&nbsp;determine any issue in a manner that would conflict with the express terms and conditions of this Agreement; or (B)&nbsp;modify or amend the terms and
conditions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7</B> <B>Financial Representative.</B> Each party shall appoint one (1)&nbsp;representative with
expertise in the areas of accounting, cost allocation, budgeting and financial reporting (each, a <B><I>&#147;Financial Representative&#148;</I></B>) no later than [<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>&#133;***&#133;] after the
Effective Date. Such Financial Representatives shall consult with the JSC, in order to address the financial, budgetary and accounting issues that arise in connection with the Biocon Preclinical Activities. Each Financial Representative may be
replaced at any time by the represented party by providing notice thereof to the other party. The Financial Representatives will meet as they or the parties, through the JSC, may agree is appropriate. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EVELOPMENT</SMALL> <SMALL>AND</SMALL> C<SMALL>OMMERCIALIZATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Equillium Responsibility.</B> Except as expressly set forth in Sections&nbsp;4.2 and 4.3 or in the Clinical Supply Agreement or
any Commercial Supply Agreement, Equillium shall be solely responsible for the development, manufacturing, registration and commercialization of Products in the Field in the Equillium Territory, at Equillium&#146;s sole expense. Without limiting the
generality of the foregoing, Equillium shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> conduct Indication-specific preclinical studies of ITO in <FONT
STYLE="white-space:nowrap">JSC-approved</FONT> Indications to support the submission of Regulatory Filings, at Equillium&#146;s sole expense; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> prepare and submit all required Regulatory Filings in connection with obtaining and maintaining Regulatory Approvals and Orphan
Designation with respect to Products in the Equillium Territory, at Equillium&#146;s sole expense. All of such Regulatory Filings relating to Products in the Equillium Territory shall be submitted in the name of, and owned by, Equillium (or its
Affiliate or Sublicensee, as applicable); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> be responsible for obtaining funding (which may include, without limitation,
government funding) for the development of ITO and Products for the Equillium Territory (whether Equillium conducts such development activities in the Equillium Territory or the Biocon Territory); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> review the need for, and, if required, seek and use Commercially Reasonable Efforts to obtain OFAC license(s) necessary for
clinical development and/or commercialization of ITO and Product in the US. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Biocon Responsibility.</B> Notwithstanding the provisions of Section&nbsp;4.1 to the contrary, and without limiting the
generality of Section&nbsp;4.5: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Biocon Preclinical Activities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Available Materials.</B> Promptly after the Effective Date, Biocon shall provide to Equillium true and complete copies of
Biocon&#146;s updated Investigator&#146;s Brochure for all available <FONT STYLE="white-space:nowrap">CHO-derived</FONT> ITO formulations and related supporting materials, and all preclinical, toxicology and CMC Data existing as of the Effective
Date for all available <FONT STYLE="white-space:nowrap">CHO-derived</FONT> ITO formulations; in each case, at Biocon&#146;s sole expense, subject to Section&nbsp;4.2(a)(iii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Preclinical Studies and CMC Activities.</B> Biocon shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> guided by the <FONT STYLE="white-space:nowrap">JSC-approved</FONT> initial Indication for which Product will be developed in the
Equillium Territory, perform, in accordance with <FONT STYLE="white-space:nowrap">JSC-approved</FONT> protocols and GLP, all <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies of
<FONT STYLE="white-space:nowrap">CHO-derived</FONT> ITO and Product necessary for the filing of INDs for Product in the Equillium Territory (collectively, <B><I>&#147;</I></B><B><I><FONT STYLE="white-space:nowrap">IND-Enabling</FONT>
Studies</I></B><B><I>&#148;</I></B>); <I>provided, however,</I> that the <FONT STYLE="white-space:nowrap">IND-Enabling</FONT> Studies shall exclude Indication-specific preclinical animal models, which shall be the sole responsibility of Equillium;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> perform all <FONT STYLE="white-space:nowrap">IND-Enabling</FONT> CMC Activities; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> deliver to Equillium all Data and other Information generated in performance of the
<FONT STYLE="white-space:nowrap">IND-Enabling</FONT> Studies and <FONT STYLE="white-space:nowrap">IND-Enabling</FONT> CMC Activities in a form and format suitable for inclusion in INDs for Product in the Equillium Territory; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, at [&#133;***&#133;] expense, subject to Section&nbsp;4.2(a)(iii). Biocon shall maintain complete and accurate records of the performance of all
<FONT STYLE="white-space:nowrap">IND-Enabling</FONT> Studies and <FONT STYLE="white-space:nowrap">IND-Enabling</FONT> CMC Activities, including all Data, Inventions and other Information generated or made in the course of such performance, which
records shall be maintained in accordance with Biocon&#146;s standard practices and shall in any event be maintained in a manner sufficient for Equillium&#146;s filing of INDs for Product in the Equillium Territory. Upon reasonable prior written
notice, Biocon shall permit Equillium to inspect such records, and, upon Equillium&#146;s request, shall provide copies of such records. Biocon shall deliver to Equillium the draft and final reports for each
<FONT STYLE="white-space:nowrap">IND-Enabling</FONT> Study and all <FONT STYLE="white-space:nowrap">IND-Enabling</FONT> CMC Activities promptly following the availability thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Biocon Preclinical Expenses.</B> Biocon shall maintain records of Biocon Preclinical Expenses, including the number of Biocon
FTEs devoted by Biocon to Biocon Preclinical Activities, which shall be made available to Equillium for inspection through the Financial Representatives from time to time upon the request of Equillium&#146;s Financial Representative. Notwithstanding
the foregoing provisions of this Section&nbsp;4.2(a) to the contrary, if Biocon determines in good faith that total Biocon Preclinical Expenses are likely to exceed $[&#133;***&#133;], Biocon shall provide prompt written notice thereof to Equillium,
and the parties shall promptly convene a meeting of the JSC to discuss the matter and in no case shall Biocon be responsible for Biocon Preclinical Expenses in excess of $[&#133;***&#133;]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Supply of ITO and Product.</B> Notwithstanding the provisions of Section&nbsp;4.1 to the contrary, Biocon shall be responsible
for manufacturing, or having manufactured, and supplying to Equillium: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> ITO (both
<FONT STYLE="white-space:nowrap">NS0-derived</FONT> and <FONT STYLE="white-space:nowrap">CHO-derived)</FONT> and ITO surrogate monoclonal antibodies suitable for use in general research and <FONT STYLE="white-space:nowrap">IND-enabling,</FONT> <FONT
STYLE="white-space:nowrap">GLP-compliant</FONT> preclinical studies in quantities sufficient for the conduct of the preclinical studies contemplated by the Development Plan, at Biocon&#146;s sole expense; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> sufficient quantities of ITO finished drug product (all current and future <FONT STYLE="white-space:nowrap">CHO-derived</FONT> IV
and SC formulations), manufactured in accordance with GMP, for use in the conduct of clinical trials of Product in three (3)&nbsp;Orphan Indications in the Equillium Territory, at Biocon&#146;s sole expense until FDA approval of the first NDA for
Product in any Indication (<B><I>&#147;First US Approval&#148;</I></B>). For clarity, if Equillium discontinues clinical development of Product in a particular Orphan Indication and instead pursues clinical development of Product in a different
Orphan Indication prior to First US Approval, Biocon shall remain obligated to supply ITO finished drug product pursuant to this Section&nbsp;4.2(b)(ii) for such replacement Orphan Indication, provided that at no time will Biocon be obligated to
supply ITO finished drug product pursuant to this Section&nbsp;4.2(b)(ii) for use in clinical trials of more than three (3)&nbsp;Orphan Indications at any given time; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> after First US Approval, sufficient quantities of ITO finished drug product (all current and future <FONT
STYLE="white-space:nowrap">CHO-derived</FONT> IV and SC formulations), manufactured in accordance with GMP, for use in the conduct of clinical trials of Product for Orphan Indications in the Equillium Territory, at a price equal to Biocon&#146;s
Cost of Goods of such ITO finished drug product; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> sufficient quantities of ITO finished drug product (all current and
future <FONT STYLE="white-space:nowrap">CHO-derived</FONT> IV and SC formulations), manufactured in accordance with GMP, for use in the conduct of clinical trials of Product for Indications other than Orphan Indications in the Equillium Territory,
at a price equal to Biocon&#146;s Cost of Goods of such ITO finished drug product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All ITO finished drug product to be supplied for the
purposes set forth in the preceding clauses&nbsp;(ii), (iii) and (iv)&nbsp;of this Section&nbsp;4.2(b) (collectively, <B><I>&#147;Clinical Material&#148;</I></B>) will be manufactured and supplied by Biocon pursuant to, and in accordance with the
terms and conditions of, the Clinical Supply Agreement. Biocon shall keep complete and accurate records related to the manufacture of the Clinical Material and the methods and facilities used by it for such manufacture as necessary to comply with
GMP and Applicable Laws and to permit the Clinical Material to be used in humans. Upon reasonable notice by Equillium, Biocon shall make such records available to Equillium or its designated representatives for inspection, examination and copying,
and, if requested by Equillium, Biocon shall deliver to Equillium, as promptly as practicable, copies of such records. All such documentation shall be provided in English, and in the case of translations, the original
<FONT STYLE="white-space:nowrap">un-translated</FONT> document shall also be provided. All original records shall be retained and archived by Biocon in accordance with GMP and Applicable Laws for the minimum retention period under Applicable Laws.
Upon Equillium&#146;s written request, Biocon shall provide to Equillium such information, documentation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and data, including, without limitation, CMC Data, in Biocon&#146;s possession relating to the Clinical Material or Product or the manufacture of Clinical
Material or Product (or true and complete copies thereof) as Equillium may require for IND, NDA and other submissions to Regulatory Authorities in the Equillium Territory. Biocon represents and warrants to Equillium that all Clinical Material will:
(i)&nbsp;upon delivery to Equillium, conform to the applicable specifications for Clinical Material in effect at the time of delivery; (ii)&nbsp;have been manufactured in compliance with GMP, as applicable to investigational drugs; and
(iii)&nbsp;upon delivery to Equillium, be free and clear of all liens and encumbrances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Stage</B><B></B><B>&nbsp;2
Study.</B> Biocon shall, at its sole expense, conduct the Stage&nbsp;2 Study, in accordance with Biocon&#146;s protocol until the Stage&nbsp;2 Study is completed or terminated, at its sole expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Diligence.</B> Biocon shall use Commercially Reasonable Efforts to perform its obligations under this Section&nbsp;4.2 in an
expeditious manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Commercial Supply for the Equillium Territory</B><B>.</B> Subject to the terms and conditions of this
Agreement, during the Term, Biocon agrees to Manufacture and supply to Equillium such quantities of Product for commercial use and distribution in the Equillium Territory as may be set forth on purchase orders placed by Equillium in accordance with
the provisions of the Commercial Supply Agreement, and Equillium agrees that Biocon shall be Equillium&#146;s exclusive supplier for the Product for the Equillium Territory on the terms set forth in the Commercial Supply Agreement. No later than six
(6)&nbsp;months prior to the anticipated initiation of the first Pivotal Trial conducted by or on behalf of Equillium, the parties shall negotiate in good faith and enter into a separate written manufacturing and supply agreement containing
commercially reasonable terms (the <B><I>&#147;</I></B><B><I>Commercial Supply Agreement</I></B><B><I>&#148;</I></B>) pursuant to which the purchase price for the commercial supply of Product shall be equal to [<SUP
STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;]% of Biocon&#146;s Fully-Burdened Manufacturing Cost, as well as a commercially reasonable and customary quality assurance agreement (the <B><I>&#147;</I></B><B><I>Commercial Quality
Agreement</I></B><B><I>&#148;</I></B>), pursuant to which Biocon shall manufacture and supply to Equillium, or have manufactured and supplied to Equillium, and Equillium shall accept such manufacture and supply from Biocon as Equillium&#146;s
exclusive supplier, Product for commercialization in the Field in the Equillium Territory. Without limiting the generality of the foregoing, the Commercial Supply Agreement shall provide as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Forecasts and Ordering.</B> On a basis to be agreed between the parties following good faith discussions, the Commercial Supply
Agreement shall contain a mechanism by which Equillium provides Biocon with rolling forecasts of its estimated requirements of Product to be supplied to it during the term of the Commercial Supply Agreement. Such forecasting mechanism will stipulate
that the Products estimated to be supplied during a particular time frame in the rolling period (not to exceed the first [&#133;***&#133;] calendar quarter periods of each forecast) will constitute a firm binding purchase order by Equillium for
those Products. The parties shall also agree on an upper maximum limit (measured as a percentage beyond [&#133;***&#133;]% of the quantity of Products set out in a binding forecast (<B><I>&#147;Additional Quantities&#148;</I></B>)) of Products to be
supplied pursuant to a binding forecast, subject to Biocon&#146;s facility having the capacity to manufacture more than [&#133;***&#133;]% of the quantity of Products set out in a binding forecast at the relevant time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Shortfalls and Allocation of Supply.</B> If Biocon is, or anticipates that it will be, unable to supply to Equillium, in whole or
in part, Equillium&#146;s forecasted requirements of Product on a timely basis due to a shortage of production capacity, shortage of raw materials, or any other reason, Biocon shall promptly notify Equillium in writing of such shortage of production
capacity or production problem or other reason, within [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;], and if possible, the date such shortage or production problem is expected to end. The parties will discuss the matter and
shall use good faith efforts to achieve an equitable solution with the least impact on both parties&#146; ability to commercialize and market Product in their respective territories. Biocon shall use Commercially Reasonable Efforts to remedy any
shortfall of Product as soon as practicable, and Biocon shall allocate its available production capacity for the production of Product in a manner proportional to the number of units of Product sold in the previous [&#133;***&#133;] in the Biocon
Territory and Equillium Territory, respectively, or, should such sales have not been commenced, in proportion to the number of units of Product in then-scheduled production runs for the Biocon Territory and the Equillium Territory, respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Second Site/Source.</B> Biocon shall have the right to use the services of its Affiliates and Third Party contractors,
including CMOs, to assist such Biocon in fulfilling its obligations and exercising its rights under the Commercial Supply Agreement; <I>provided</I> that (i)&nbsp;the JSC approves any contractor in advance, such approval not to be unreasonably
withheld or delayed by the Equillium representatives on the JSC; (ii)&nbsp;none of Equillium&#146;s rights under the Commercial Supply Agreement or this Agreement are diminished or otherwise adversely affected as a result of Biocon&#146;s use of
Affiliates or contractors; and (iii)&nbsp;the contractor or Affiliate has entered into a written agreement with Biocon binding such Person to the obligations Biocon has to Equillium, including obligations of intellectual property assignment and
confidentiality and <FONT STYLE="white-space:nowrap">non-use,</FONT> and containing any other provisions normal and customary for similar types of agreements consistent with the Commercial Supply Agreement and this Agreement; and <I>provided,
further,</I> that Biocon shall at all times be responsible for the satisfactory accomplishment of its obligations under and in accordance with, and the contractor&#146;s or Affiliate&#146;s compliance with, the terms and conditions of the Commercial
Supply Agreement and this Agreement. For clarity, for purposes of clause&nbsp;(i) of the preceding sentence, it shall not be unreasonable for the Equillium representatives on the JSC to withhold approval of a proposed contractor if such contractor
(A)&nbsp;has received any <FONT STYLE="white-space:nowrap">Form&nbsp;FD-483</FONT> notice (or foreign equivalent) or any FDA or other Regulatory Authority refusal to file, rejection or warning letter that has not been fully addressed by such
contractor to the satisfaction of the applicable Regulatory Authority, (B)&nbsp;is debarred under Applicable Laws in the US, including 21 U.S.C. &#167;335a, or any comparable Applicable Laws outside of the US. Without prejudice to the generality of
the foregoing, in the event of a Failure to Supply on Biocon&#146;s part, the parties will evaluate alternative approaches to source the shortfall in supply, which may include, without limitation, Biocon&#146;s performance of a manufacturing
technology transfer (the reasonable costs of such technology transfer to be borne by Biocon) to a CMO identified by the JSC and appointed by the JSC with Biocon&#146;s prior written consent, such consent not to be unreasonably withheld, to permit
such CMO to manufacture ITO and Product, using the manufacturing process developed and used by Biocon, for use and distribution in the Field in the Equillium Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Failure to Supply</B>. A Failure to Supply as used in this Section&nbsp;4.3 means that Biocon does not supply according to the
terms of the Commercial Supply Agreement at least [&#133;***&#133;] percent ([&#133;***&#133;]%) of the quantity of all Products (excluding, for the avoidance of doubt, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional Quantities) ordered by Equillium pursuant to valid and binding purchase orders placed in accordance with the ordering procedure agreed in the
Commercial Supply Agreement during any two consecutive calendar quarters, except to the extent such failure has been caused by a force majeure event which is beyond Biocon&#146;s reasonable control, and subject to the limitations on the maximum
amount Equillium is entitled to order which will be described in the Commercial Supply Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Right of Biocon to Resume
Manufacturing.</B> On a basis to be agreed between the parties following good faith discussions, the Commercial Supply Agreement shall contain a mechanism by which, following a Failure to Supply and the enabling of a CMO to provide a secondary
source of supply of Product pursuant to Section&nbsp;4.3(c), Biocon may resume its supply obligations if it provides Equillium with a commercially reasonable proposal and evidence that it is ready, willing and able, directly or through
subcontractors, to resume its supply obligations under the Commercial Supply Agreement, in which case the Parties will work together in good faith to develop and mutually agree upon a transition plan that achieves the following objectives:
(i)&nbsp;minimizes disruption to the continued manufacture and supply of Product; (ii)&nbsp;enables Biocon to resume operation of its facility(ies) as the primary source of Product as soon as reasonably practicable; and (iii)&nbsp;maintains on an
ongoing basis the Third Party facility established following a Failure to Supply and the enabling of a CMO to provide a secondary source of supply of Product pursuant to Section&nbsp;4.3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B>Performance Standards.</B> Each party shall conduct, or have conducted, all ITO and Product development, manufacture,
registration and commercialization activities performed by it or on its behalf in good scientific manner and in compliance with all Applicable Laws and, as applicable, GLP, GCP and/or GMP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5 Technology Transfer; Exchange of Information. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Commencing promptly after the Effective Date, Biocon shall disclose to Equillium all existing and available (in recorded form)
Biocon <FONT STYLE="white-space:nowrap">Know-How</FONT> as reasonably required for the development, registration or commercialization of ITO and Product in the Field in the Equillium Territory. Thereafter, on an ongoing basis, Biocon shall also
disclose to Equillium all additional Biocon <FONT STYLE="white-space:nowrap">Know-How</FONT> generated after the Effective Date as reasonably required for the development, registration or commercialization of ITO and Product in the Field in the
Equillium Territory. Without limiting the generality of the foregoing, Biocon shall provide to Equillium true and complete copies of all written, graphic or electronic embodiments of Data within the Biocon
<FONT STYLE="white-space:nowrap">Know-How.</FONT> The Biocon <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be transferred to Equillium in a format to be agreed upon by the parties, such agreement not to be unreasonably withheld. With
respect to any of the foregoing that is in a language other than English, Biocon shall also provide Equillium with English translations thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> On an ongoing basis during the Term, Equillium shall disclose to Biocon all Equillium
<FONT STYLE="white-space:nowrap">Know-How</FONT> as reasonably required for the development, registration, manufacturing or commercialization of ITO and Product in the Field in the Biocon Territory. Without limiting the generality of the foregoing,
Equillium shall provide to Biocon true and complete copies of all written, graphic or electronic embodiments of Data within the Equillium </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Know-How.</FONT> The Equillium <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be transferred to Biocon in a format to
be agreed upon by the parties, such agreement not to be unreasonably withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6 Rights of Access and Reference to Regulatory
Documents. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Equillium hereby grants to Biocon the right to access and reference all Regulatory Filings submitted to, and
Regulatory Approvals obtained from, any Regulatory Authority in the Equillium Territory by Equillium for Products and to use the Data therein; in each case, solely for the purposes of Biocon and
[<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] (and their respective affiliates and sublicensees) (i)&nbsp;obtaining and maintaining Regulatory Approvals for, and conducting business development with respect to, ITO and
Products outside the Equillium Territory, and (ii)&nbsp;complying with applicable pharmacovigilance and other regulatory requirements with respect to ITO and Products outside the Equillium Territory. Equillium shall, promptly upon Biocon&#146;s
request, file with the applicable Regulatory Authority(ies) such letters of access or reference as may be necessary to accomplish the intent of this Section&nbsp;4.6(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Biocon hereby grants to Equillium the right to access and reference all Regulatory Filings submitted to, and Regulatory Approvals
obtained from, any Regulatory Authority in the Biocon Territory by Biocon for Products and to use the data, including but not limited to any <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical data, therein; in each case, solely for
the purposes of (i)&nbsp;obtaining and maintaining Regulatory Approvals for Products in the Field in the Equillium Territory, and (ii)&nbsp;complying with applicable pharmacovigilance and other regulatory requirements with respect to such Products
in the Equillium Territory. Biocon shall, promptly upon Equillium&#146;s request, file with the applicable Regulatory Authority(ies) such letters of access or reference as may be necessary to accomplish the intent of this Section&nbsp;4.6(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B> <B>Safety Data Exchange.</B> Each party shall be solely responsible, at its own expense, for complying with all applicable
regulatory requirements with respect to Products in such party&#146;s Territory, including all safety reporting to Regulatory Authorities in such party&#146;s Territory. The parties shall, promptly upon reasonable request by either party, negotiate
in good faith and enter into a pharmacovigilance/safety data exchange agreement for Products (the <B><I>&#147;</I></B><B><I>PV</I></B><B><I></I></B><B><I>&nbsp;Agreement</I></B><B><I>&#148;</I></B>), which shall set forth standard operating
procedures governing the collection, investigation, reporting, and exchange of information concerning adverse drug reactions/experiences. The terms of the PV&nbsp;Agreement shall be sufficient to permit each party to comply with its regulatory and
legal requirements for the management and reporting of safety data regarding such Products by providing for the exchange of relevant information in appropriate format within applicable timeframes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8 Diligence. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>General Diligence Obligation.</B> Equillium (directly or through its Affiliates or Sublicensees) shall use Commercially
Reasonable Efforts to develop and seek Regulatory Approval for, and, if Regulatory Approval is obtained, to commercialize Product in the Field in the Equillium Territory. In addition, Equillium shall use Commercially Reasonable Efforts to secure
funding for the development of Product in two or more Indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Specific Diligence Requirements.</B> Notwithstanding the generality of Section&nbsp;4.8(a), the following shall be considered,
without limitation, to represent a failure of Equillium to comply with Section&nbsp;4.8(a): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If, following Stage&nbsp;2 Study
Completion, Equillium fails either (A)&nbsp;within two (2)&nbsp;years to dose the first patient in a PoC Study, and/or (B)&nbsp;to use Commercially Reasonable Efforts to pursue clinical development of Product in at least one Indication for any
continuous period greater than three (3)&nbsp;years (subject to extension as described below), Biocon shall have the right to terminate this Agreement in accordance with Section&nbsp;10.2(b), subject to Section&nbsp;10.2(c). The <FONT
STYLE="white-space:nowrap">two-year</FONT> and three-year periods in (A)&nbsp;and (B) above shall be extended to the extent of any delays directly attributable to events beyond the reasonable control of Equillium. By way of example and not of
limitation, for purposes of this Section&nbsp;4.8(b)(i), &#147;events beyond the reasonable control of Equillium&#148; include Biocon&#146;s failure to supply Product in accordance with the Clinical Supply Agreement (except to the extent directly
attributable to Equillium&#146;s failure to comply with its obligations under the Clinical Supply Agreement), imposition of a clinical hold, Biocon&#146;s failure or delay in performing its obligations under Article&nbsp;4 that are a prerequisite
for Equillium&#146;s clinical development of Product, or delays in receiving required OFAC license(s). However, the foregoing <FONT STYLE="white-space:nowrap">two-year</FONT> period in (A)&nbsp;and three-year period in (B)&nbsp;above shall not be
extended by more than one (1)&nbsp;year in each case by reason of any and all events beyond the reasonable control of Equillium, unless, and only to the extent that, any such delay beyond three (3)&nbsp;years (in the case of (A)) and four
(4)&nbsp;years (in the case of (B)) is directly attributable to Biocon&#146;s failure to supply Product in accordance with the Clinical Supply Agreement (except to the extent directly attributable to Equillium&#146;s failure to comply with its
obligations thereunder) or Biocon&#146;s failure or delay in performing its obligations under Article&nbsp;4 that are a prerequisite for Equillium&#146;s clinical development of Product. This Section&nbsp;4.8(b)(i) and Biocon&#146;s rights hereunder
shall automatically terminate and be of no further force or effect upon First US Approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If Equillium has not completed
one PoC Study of Product in an Indication that is not an Orphan Indication by the seventh (7th) anniversary of Stage&nbsp;2 Study Completion (subject to extension as described below), then the Field (if previously expanded pursuant to
Section&nbsp;2.3) shall automatically be restricted to mean the treatment, prevention and/or diagnosis of Orphan Indications for the remainder of the Term. The foregoing seven-year period shall be extended to the extent of any delays directly
attributable to events beyond the reasonable control of Equillium (as described in Section&nbsp;4.8(b)(i)); provided, however, that the foregoing seven-year period shall not be extended by more than one (1)&nbsp;year by reason of any and all events
beyond the reasonable control of Equillium, unless, and only to the extent that, any such delay beyond eight (8)&nbsp;years is directly attributable to Biocon&#146;s failure to supply Product in accordance with the Clinical Supply Agreement (except
to the extent directly attributable to Equillium&#146;s failure to comply with its obligations thereunder) or Biocon&#146;s failure or delay in performing its obligations under Article&nbsp;4 that are a prerequisite for Equillium&#146;s clinical
development of Product. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>F<SMALL>INANCIAL</SMALL> T<SMALL>ERMS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Upfront Equity Issuance.</B> On the Effective Date, and subject to the execution and delivery by Biocon of the Stock Purchase
Agreement and the Related Agreements, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium shall issue to Biocon the number of shares of Equillium common stock that represents 19.5% of the outstanding shares of Equillium common stock
immediately after such issuance, in accordance with the Stock Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Approval and First Commercial Sale
Milestone Payments.</B> Within [<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>&#133;***&#133;] of the first achievement of each of the milestone events set forth in the table below by the first Product to achieve such milestone event,
Equillium shall provide Biocon with written notice of such achievement and shall pay to Biocon the corresponding <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT>
<FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payment set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Milestone&nbsp;Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Milestone&nbsp;Payment&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First FDA approval of US NDA for Product for first Indication</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First FDA approval of US NDA for Product for second Indication</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First FDA approval of US NDA for Product for third Indication</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First Commercial Sale of Product in the Equillium Territory</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[&#133;***&#133;]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the foregoing milestone payments shall be payable only one time, for the first achievement of the
applicable milestone event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>Net Sales Milestone Payments.</B> Within [&#133;***&#133;] of the end of the first calendar
year in which each of the milestone events set forth in the table below is achieved, Equillium shall provide Biocon with written notice of such achievement and shall pay to Biocon the corresponding <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payment set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Milestone&nbsp;Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Milestone&nbsp;Payment&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First calendar year in which aggregate annual Net Sales of&nbsp;Products in the Equillium Territory exceed $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First calendar year in which aggregate annual Net Sales of&nbsp;Products in the Equillium Territory exceed $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First calendar year in which aggregate annual Net Sales of&nbsp;Products in the Equillium Territory exceed $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First calendar year in which aggregate annual Net Sales of&nbsp;Products in the Equillium Territory exceed $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[&#133;***&#133;]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the foregoing milestone payments shall be payable only one time, for the first achievement of the applicable milestone event.
Notwithstanding the foregoing, if more than one of the foregoing milestone events is achieved in a single calendar year, Equillium shall pay all such milestone payments corresponding to the milestone events achieved within [&#133;***&#133;] of the
end of such calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4 Royalties. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Royalties Payable by Equillium.</B> Equillium shall pay to Biocon royalties on tiers of aggregate annual Net Sales of Products
by Equillium and its Affiliates and Sublicensees in the Equillium Territory in each calendar year at the applicable rate(s) set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Tiers&nbsp;of&nbsp;Aggregate&nbsp;Annual&nbsp;Net&nbsp;Sales&nbsp;in&nbsp;Equillium&nbsp;Territory</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;Royalty&nbsp;Rate&nbsp;&nbsp;</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">That portion of aggregate annual Net Sales of Products in the Equillium Territory in a calendar year that is less than or equal to $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[&#133;***&#133;]%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">That portion of aggregate annual Net Sales of Products in the Equillium Territory in a calendar year that is greater than $[&#133;***&#133;] and less than or equal to $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[&#133;***&#133;]%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">That portion of aggregate annual Net Sales of Products in the Equillium Territory in a calendar year that is greater than $[&#133;***&#133;] and less than or equal to $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[&#133;***&#133;]%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">That portion of aggregate annual Net Sales of Products in the Equillium Territory in a calendar year that is greater than $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[&#133;***&#133;]%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Royalties Payable by Biocon.</B> Biocon shall pay to Equillium royalties on tiers of aggregate
annual Net Sales of Supported Products by Biocon and its Affiliates and Sublicensees in the Biocon Territory in each calendar year at the applicable rate(s) set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Tiers&nbsp;of&nbsp;Aggregate&nbsp;Annual&nbsp;Net&nbsp;Sales&nbsp;in&nbsp;Biocon&nbsp;Territory</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;Royalty&nbsp;Rate&nbsp;&nbsp;</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">That portion of aggregate annual Net Sales of Supported Products in the Biocon Territory in a calendar year that is less than or equal to $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[&#133;***&#133;]%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">That portion of aggregate annual Net Sales of Supported Products in the Biocon Territory in a calendar year that is greater than $[&#133;***&#133;] and less than or equal to $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[&#133;***&#133;]%</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">That&nbsp;portion&nbsp;of&nbsp;aggregate&nbsp;annual&nbsp;Net&nbsp;Sales&nbsp;of&nbsp;Supported&nbsp;Products&nbsp;in the&nbsp;Biocon&nbsp;Territory&nbsp;in&nbsp;a calendar&nbsp;year&nbsp;that&nbsp;is&nbsp;greater&nbsp;than
$[&#133;***&#133;]&nbsp;and&nbsp;less&nbsp;than&nbsp;or&nbsp;equal&nbsp;to&nbsp;$[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[&#133;***&#133;]%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">That portion of aggregate annual Net Sales of Supported Products in the Biocon Territory in a calendar year that is greater than $[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[&#133;***&#133;]%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5 Royalty Term. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Equillium Royalties.</B> Royalties under Section&nbsp;5.4(a) shall be payable on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis in the Equillium Territory from First Commercial Sale of a Product in a country
until the latest of (i)&nbsp;10&nbsp;years from First Commercial Sale of such Product in such country, (ii)&nbsp;expiration of all Regulatory Exclusivity for such Product in such country and (iii)&nbsp;expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Valid Claim of the Biocon Patents covering the manufacture, use or sale of such Product in such country (the <B><I>&#147;</I></B><B><I>Equillium Royalty
Term</I></B><B><I>&#148;</I></B>); <I>provided, however,</I> that during any portion of the Equillium Royalty Term for a Product in a country when there is no Valid Claim of the Biocon Patents covering the manufacture, use or sale of such Product in
such country but such Product has Regulatory Exclusivity in such country, Equillium&#146;s royalty payment obligations with respect to Net Sales of such Product in such country shall be reduced by [&#133;***&#133;]%; and <I>provided, further,</I>
that during any portion of the Equillium Royalty Term for a Product in a country when there is no Valid Claim of the Biocon Patents covering the manufacture, use or sale of such Product in such country and such Product has no Regulatory Exclusivity
in such country, Equillium&#146;s royalty payment obligations with respect to Net Sales of such Product in such country shall be reduced by [&#133;***&#133;]%. On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon expiration of the Equillium Royalty
Term with respect to a Product in a country, the Equillium License with respect to such Product in such country shall become royalty-free, fully-paid, irrevocable and perpetual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Biocon Royalties.</B> Royalties under this Section&nbsp;5.4(b) shall be payable only with respect to sales of a Product that is
a Supported Product in the country of sale. Subject to the previous sentence, royalties under this Section&nbsp;5.4(b) shall be payable on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis in the Biocon Territory from First Commercial Sale of a Product in a country until the latest of (i)&nbsp;10&nbsp;years from First Commercial Sale of
such Product in such country, (ii)&nbsp;expiration of all Regulatory Exclusivity for such Product in such country and (iii)&nbsp;expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Valid
Claim of the Equillium Patents covering the manufacture, use or sale of such Product in such country (the <B><I>&#147;Biocon Royalty Term&#148;</I></B>); <I>provided, however,</I> that during any portion of the Biocon Royalty Term for a Product in a
country when there is no Valid Claim of the Equillium Patents covering the manufacture, use or sale of such Product in such country but such Product has Regulatory Exclusivity in such country, Biocon&#146;s royalty payment obligations with respect
to Net Sales of such Product in such country shall be reduced by [&#133;***&#133;]%; and <I>provided, further,</I> that during any portion of the Biocon Royalty Term for a Product in a country when there is no Valid Claim of the Equillium Patents
covering the manufacture, use or sale of such Product in such country and such Product has no Regulatory Exclusivity in such country, Biocon&#146;s royalty payment obligations with respect to Net Sales of such Product in such country shall be
reduced by [&#133;***&#133;]%. On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon
expiration of the Biocon Royalty Term with respect to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product in a country, the Biocon License with respect to such Product in such country shall become royalty-free, fully-paid, irrevocable and perpetual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B> <B>Third Party Licenses.</B> In the event that Equillium (or its Affiliate or Sublicensee, as applicable) is required to obtain one
or more Third Party Licenses reasonably necessary for the manufacture, use or sale of a Product in a country, [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;]% of the royalties actually paid under such Third Party Licenses by
Equillium (or by such Affiliate or Sublicensee, as applicable) for sale of such Product in such country for a calendar quarter will be creditable against the royalty payments payable by Equillium to Biocon with respect to Net Sales of such Product
in such country; <I>provided, however,</I> that in no event will the royalties owed by Equillium to Biocon hereunder with respect to Net Sales of such Product for such calendar quarter be reduced by more than [&#133;***&#133;]%; and <I>provided,
further,</I> that Equillium will not be entitled to credit any portion of royalties paid by Equillium or its Affiliate or Sublicensee to Third Parties with respect to any Other Active in any Combination Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B> <B>Generic Competition.</B> On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT>
and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, if, during the Royalty Term for a Product in a country within a party&#146;s Territory, one or more Generic Versions of such Product
account for [&#133;***&#133;]% or more of aggregate unit sales of such Product and such Generic Version(s) in such country in a calendar quarter, as determined by reference to applicable sales data obtained from a reputable independent source
(<I>e.g.</I>, IMS Health), then for the remainder of the Royalty Term for such Product in such country, such party&#146;s royalty payment obligations with respect to Net Sales of such Product in such country shall be reduced by [&#133;***&#133;]%.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B> <B>Limitation on Royalty Reductions.</B> In no event shall the royalties payable by one party to the other party under
Section&nbsp;5.4 with respect to Net Sales of Products be reduced by more than an aggregate of [&#133;***&#133;] percent ([&#133;***&#133;]%) in any calendar quarter as a result of any and all reductions or offsets pursuant to Section&nbsp;5.6 and
Section&nbsp;5.7 in the aggregate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>AYMENTS</SMALL>; R<SMALL>ECORDS</SMALL>; A<SMALL>UDITS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B>Payment; Reports.</B> Royalties under Section&nbsp;5.4 shall be calculated and reported for each calendar quarter during the
Royalty Term and shall be paid within [&#133;***&#133;] after the end of the calendar quarter. Each such payment shall be accompanied or preceded by a report of Net Sales and royalties in sufficient detail to permit confirmation of the accuracy of
the payment made, including gross sales and Net Sales of Products on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, details of any royalty credits taken pursuant to Section&nbsp;5.6 on a Third Party Patent <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">License-by-Third</FONT></FONT> Party Patent License basis, any applicable adjustments made pursuant to Section&nbsp;5.7, the amounts payable, and the exchange rates used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Exchange Rate; Manner and Place of Payment.</B> All payment amounts in this Agreement are expressed in U.S. dollars, and all
payments hereunder shall be payable in U.S. dollars. When conversion of payments from any foreign currency is required, such conversion shall be calculated at the rate of exchange for such currency used throughout the accounting system in conformity
with Accounting Standards of the party obligated to make such payment for financial reporting purposes for the calendar quarter for which payment is due. All payments owed by one party (the <B><I>&#147;Paying Party&#148;</I></B>) to the other party
(the <B><I>&#147;Payee&#148;</I></B>) under this Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shall be made by wire transfer in immediately available funds to the bank and account designated in writing by the Payee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B>Income Tax Withholding.</B> The Payee will pay any and all taxes levied on account of any payment made to it under this
Agreement. If any taxes are required to be withheld by the Paying Party from any payment made to the Payee under this Agreement, the Paying Party shall (a)&nbsp;deduct such taxes from the payment made to the Payee, (b)&nbsp;timely pay the taxes to
the proper taxing authority, (c)&nbsp;send proof of payment to the Payee within 30&nbsp;days following such payment, and (d)&nbsp;cooperate with the Payee in any lawful way reasonably requested by the Payee, to obtain available reductions, credits
or refunds of such taxes. Without limiting the generality of the foregoing, upon request by the Payee, the Paying Party shall provide the Payee such information in the Paying Party&#146;s possession as may be reasonably necessary for the Payee to
obtain the benefit of any present or future treaty against double taxation which may apply to payments made to the Payee under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B> <B>Audits.</B> Each party shall keep (and shall cause its Affiliates and Sublicensees to keep) complete and accurate records
pertaining to the sale or other disposition of Products in sufficient detail to permit the other party to confirm the accuracy of all Net Sales-based milestone payments (if applicable) due under Section&nbsp;5.3 (if applicable) and royalties due
under Section&nbsp;5.4, for at least [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] following the end of the calendar year to which they pertain. Each party shall have the right, once annually, to cause an independent,
certified public accountant of international standing and reasonably acceptable to the other party (the <B><I>&#147;Audited Party&#148;</I></B>) to audit such records solely to confirm Net Sales, Net Sales-based milestone payments (if applicable)
and royalties for a period covering not more than the preceding [&#133;***&#133;]. No calendar year shall be subject to audit under this section more than once. Such audits may be exercised during normal business hours upon at least
[&#133;***&#133;] prior written notice to the Audited Party in the location where the records are maintained. The auditor will execute a reasonable written confidentiality agreement with the Audited Party and will disclose to the other party only
such information as is reasonably necessary to provide the other party with information regarding any actual or potential discrepancies between amounts reported and actually paid and amounts payable under this Agreement. The auditor will send a copy
of the report to the Audited Party at the same time it is sent to the other party. The report sent to both parties will include the methodology and calculations used to determine the results. Prompt adjustments shall be made by the parties to
reflect the results of such audit. The party exercising its audit right under this Section shall bear the full cost of such audit unless such audit discloses an underpayment by the Audited Party of more than [&#133;***&#133;]% of the amount due for
any calendar year under this Agreement, in which case, the Audited Party shall bear the cost of such audit which cost shall not exceed [&#133;***&#133;] percent ([&#133;***&#133;]%) of the underpayment and shall promptly remit to the other party the
amount of any underpayment. If such audit discloses an overpayment by the Audited Party, then the Audited Party will deduct the amount of such overpayment from amounts otherwise owed to the other party under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5</B> <B>Late Payments.</B> In the event that any payment due under this Agreement is not made when due, the payment shall accrue
interest at a rate per annum that is [&#133;***&#133;] basis points (<I>i.e.</I>, [&#133;***&#133;] percentage points) above the then-current prime rate quoted by Citibank in New York City for the period from the due date for payment until the date
of actual payment; <I>provided,</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>however,</I> that in no event shall such rate exceed the maximum legal annual interest rate. The payment of such interest shall not limit the party entitled
to payment from exercising any other rights it may have as a consequence of the lateness of any payment. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>I<SMALL>NTELLECTUAL</SMALL> P<SMALL>ROPERTY</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B>Ownership of Inventions.</B> Inventorship of Inventions shall be determined in accordance with the rules of inventorship under
U.S. patent laws. Biocon shall solely own all Biocon Inventions. Equillium shall solely own all Equillium Inventions. The parties shall jointly own all Joint Inventions. Subject to the terms and conditions of this Agreement, and except to the extent
that a party has granted the other party an exclusive license under such party&#146;s joint ownership interest in Joint Inventions and Joint Patents, each party shall have the right to practice, and to grant licenses under, such party&#146;s own
joint ownership interest in Joint Inventions and Joint Patents without the other party&#146;s consent, and shall have no duty to account to the other party for such practice or license, and each party hereby waives any right it may have under the
laws of any country to require such consent or accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>JIPC.</B> Within [&#133;***&#133;] after the Effective Date, the
parties shall form a Joint Intellectual Property Committee (the <B><I>&#147;</I></B><B><I>JIPC</I></B><B><I>&#148;</I></B>) composed of at least one qualified representative designated by each Party, with the primary objective of defining and
supporting patent filing and prosecution strategies to enhance the protection and value of ITO, Product and Inventions in the Equillium Territory. The JIPC shall develop and mutually agree in good faith on patent filing, prosecution, maintenance and
defense strategy for Patent Rights claiming Inventions in the Equillium Territory. If the JIPC is unable to reach unanimous agreement on any matter relating to patent filing, prosecution, maintenance and defense strategy for Patent Rights claiming
Inventions in the Equillium Territory, such matter will be referred to the JSC for resolution, provided that Biocon shall have final decision-making authority with respect to Patent Rights claiming Biocon Inventions in the Equillium Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Prosecution and Maintenance.</B> For purposes of this Section&nbsp;7.3, the terms &#147;prosecution&#148; and
&#147;maintenance&#148; (including variations such as &#147;prosecute&#148; and &#147;maintain&#148;) shall mean, with respect to a Patent Right, the preparation, filing, prosecution and maintenance (including payment of any patent annuity fees) of
such Patent Right, as well as <FONT STYLE="white-space:nowrap">re-examinations,</FONT> reissues, appeals, post grant reviews (PGR), inter partes reviews (IPR) and requests for patent term adjustments and patent term extensions with respect to such
Patent Right, together with the initiation or defense of interferences, oppositions and other similar proceedings with respect to the particular Patent Right, and any appeals therefrom. For clarification, &#147;prosecution&#148; and
&#147;maintenance&#148; (including variations such as &#147;prosecute&#148; and &#147;maintain&#148;) shall not include any other enforcement actions taken with respect to a Patent Right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Biocon Patents.</B> The rights and obligations of the parties set forth in this this Agreement, including this Article&nbsp;7,
with respect to Biocon Patents that are [&#133;***&#133;] Patents shall be subject to [&#133;***&#133;]&#146;s rights and Biocon&#146;s obligations under the [&#133;***&#133;] Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Equillium Territory.</B> Equillium shall have the first right, but not the obligation, to prosecute and maintain any Biocon
Patents in the Equillium Territory, in Biocon&#146;s name and at Equillium&#146;s sole cost and expense using counsel reasonably acceptable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biocon. Equillium shall consult with Biocon as to the prosecution and maintenance of Biocon Patents in the Equillium Territory reasonably prior to any deadline
or action with any patent office, and shall furnish to Biocon copies of all relevant drafts and documents reasonably in advance of such consultation. Equillium shall keep Biocon reasonably informed of progress with regard to the prosecution and
maintenance of Biocon Patents in the Equillium Territory and shall provide to Biocon copies of all material patent office submissions within a reasonable amount of time following submission thereof by Equillium. Equillium shall consider the comments
of Biocon in good faith. If Equillium desires to abandon or cease prosecution or maintenance of any Biocon Patent in any country of the Equillium Territory, Equillium shall provide written notice to Biocon of such intention promptly after Equillium
makes such determination (which notice shall be given no later than 45&nbsp;days prior to the next deadline for any action that must be taken with respect to such Biocon Patent in the relevant patent office), and Biocon shall have the right, but not
the obligation, to assume responsibility for prosecution and maintenance of such Biocon Patent at its sole cost and expense. If Biocon continues prosecuting and maintaining such Biocon Patent in such country following abandonment or cessation of
prosecution or maintenance by Equillium, such Biocon Patent in such country shall be excluded from the Equillium License, and all rights to such Biocon Patent in such country shall terminate and revert to Biocon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Biocon Territory.</B> Biocon shall have the sole right, but not the obligation, to prosecute and maintain the Biocon Patents
in the Biocon Territory, at its sole cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Equillium Patents. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Equillium Territory.</B> Equillium shall have the sole right, but not the obligation, to prosecute and maintain the Equillium
Patents in the Equillium Territory, at its sole cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Biocon Territory.</B> Biocon shall have the first
right, but not the obligation, to prosecute and maintain any Equillium Patents in the Biocon Territory, in Equillium&#146;s name and at Biocon&#146;s sole cost and expense using counsel reasonably acceptable to Equillium. Biocon shall consult with
Equillium as to the prosecution and maintenance of Equillium Patents in the Biocon Territory reasonably prior to any deadline or action with any patent office, and shall furnish to Equillium copies of all relevant drafts and documents reasonably in
advance of such consultation. Biocon shall keep Equillium reasonably informed of progress with regard to the prosecution and maintenance of Equillium Patents in the Biocon Territory and shall provide to Equillium copies of all material patent office
submissions within a reasonable amount of time following submission thereof by Equillium. Biocon shall consider the comments of Equillium in good faith. If Biocon desires to abandon or cease prosecution or maintenance of any Equillium Patent in any
country of the Biocon Territory, Biocon shall provide written notice to Equillium of such intention promptly after Biocon makes such determination (which notice shall be given no later than 45&nbsp;days prior to the next deadline for any action that
must be taken with respect to such Equillium Patent in the relevant patent office), and Equillium shall have the right, but not the obligation, to assume responsibility for prosecution and maintenance of such Equillium Patent at its sole cost and
expense. If Equillium continues prosecuting and maintaining such Equillium Patent in such country following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">abandonment or cessation of prosecution or maintenance by Biocon, such Equillium Patent in such country shall be excluded from the Equillium License, and all
rights to such Equillium Patent in such country shall terminate and revert to Equillium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Joint Patents. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Equillium Territory.</B> Equillium shall have the first right, but not the obligation, to prosecute and maintain Joint Patents
in the Equillium Territory, at its sole cost and expense and by counsel of its own choice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Biocon Territory.</B> Biocon
shall have the first right, but not the obligation, to prosecute and maintain Joint Patents in the Biocon Territory, at its sole cost and expense and by counsel of its own choice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Responsible Party.</B> Each party shall keep the other party reasonably informed of progress with regard to the prosecution
and maintenance of Joint Patents for which such party (the <B><I>&#147;</I></B><B><I>Responsible Party</I></B><B><I>&#148;</I></B>) is responsible under Section&nbsp;7.3(c)(i) or Section&nbsp;7.3(c)(ii), and shall consult with, and consider in good
faith the requests and suggestions of, the other party. In the event that the Responsible Party desires not to file, or desires to abandon or cease prosecution or maintenance of, any Joint Patent in any country of such party&#146;s Territory, the
Responsible Party shall provide written notice to the other party of such intention promptly after the Responsible Party makes such determination (which notice shall be given no later than 45 days prior to the next deadline for any action that must
be taken with respect to such Joint Patent in the relevant patent office). In such case, at the other party&#146;s sole discretion, upon written notice to the Responsible Party from the other party, the other party may elect to continue prosecution
or maintenance of any such Joint Patent, at its sole cost and expense and by counsel of its own choice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B>Cooperation of the
Parties.</B> Each party agrees to cooperate fully in the prosecution and maintenance of Patent Rights under Section&nbsp;7.3. Such cooperation includes, but is not limited to: (a)&nbsp;executing all papers and instruments, or requiring its employees
or contractors, to execute such papers and instruments, so as to effectuate the ownership of Inventions set forth in Section&nbsp;7.1, and Patent Rights claiming or disclosing such Inventions, and to enable the other party to apply for and to
prosecute patent applications in any country as permitted by Section&nbsp;7.3; and (b)&nbsp;promptly informing the other party of any matters coming to such party&#146;s attention that may affect the prosecution or maintenance of any such Patent
Rights, including by providing copies of all substantive office actions or any other substantive documents that such party receives from any patent office, including notice of any reexamination, reissue, appeal, post grant review (PGR), inter partes
review (IPR), interference, opposition or other similar proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B> <B>Enforcement and Defense of Patent Rights.</B> Each
party shall notify the other party in writing within 14&nbsp;days (except as expressly set forth below) of becoming aware of any alleged or threatened infringement by a Third Party of any of the Biocon Patents or Joint Patents
(<B><I>&#147;Infringement&#148;</I></B>), including (x)&nbsp;any such alleged or threatened Infringement on account of a Third Party&#146;s manufacture, use or sale of ITO or Product, (y)&nbsp;any certification filed in the United States under 21
U.S.C. &#167;355(b)(2) or 21 U.S.C. &#167;355(j)(2) or similar provisions in other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jurisdictions in connection with an ANDA (an Abbreviated New Drug Application in the United States or a comparable application for Regulatory Approval under
Applicable Law in any country other than the United States) or other NDA for a Product (a <B><I>&#147;</I></B><B><I>Patent Certification</I></B><B><I>&#148;</I></B>), and (z)&nbsp;any declaratory judgment action filed by a Third Party that is
developing, manufacturing or commercializing ITO or Product alleging the invalidity, unenforceability or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any of the Biocon Patents or Joint Patents ((x)-(z), collectively,
<B><I>&#147;</I></B><B><I>Competitive Infringement</I></B><B><I>&#148;</I></B>); <I>provided, however,</I> that each party shall notify the other party of any Patent Certification regarding any Biocon Patent or Joint Patent that it receives, and
provide the other party with a copy thereof, within [&#133;***&#133;] days of receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Biocon Patents.</B> The rights and
obligations of the parties set forth in this Section&nbsp;7.5(a) with respect to Biocon Patents that are [&#133;***&#133;] Patents shall be subject to [&#133;***&#133;]&#146;s rights and Biocon&#146;s obligations under the [&#133;***&#133;]
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Equillium Territory.</B> Equillium shall have the first right, but not the obligation, to bring (or defend) and
control any action or proceeding with respect to Competitive Infringement of a Biocon Patent in the Equillium Territory, at Equillium&#146;s own expense and by counsel of its own choice, and Biocon shall have the right to be represented in any such
action or proceeding, at Biocon&#146;s own expense (subject to Section&nbsp;7.5(d)) and by counsel of its own choice. If Equillium fails to bring any such action or proceeding with respect to Competitive Infringement of any Biocon Patent in the
Equillium Territory within [&#133;***&#133;] following the notice of alleged Competitive Infringement, Biocon shall have the right to bring (or defend) and control any such action at its own expense and by counsel of its own choice, and Equillium
shall have the right, at its own expense (subject to Section&nbsp;7.5(d)), to be represented in any such action by counsel of its own choice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Biocon Territory.</B> Biocon shall have the sole right, in its discretion, to bring (or defend) and control any action or
proceeding with respect to Competitive Infringement of a Biocon Patent in the Biocon Territory, at Biocon&#146;s own expense and by counsel of its own choice, and Equillium shall have no rights in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Equillium Patents. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Equillium Territory.</B> Equillium shall have the sole right, in its discretion, to bring (or defend) and control any action or
proceeding with respect to Competitive Infringement of an Equillium Patent in the Equillium Territory, at Equillium&#146;s own expense and by counsel of its own choice, and Biocon shall have no rights in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Biocon Territory.</B> Biocon shall have the first right, but not the obligation, to bring (or defend) and control any action
or proceeding with respect to Competitive Infringement of an Equillium Patent in the Biocon Territory, at Biocon&#146;s own expense and by counsel of its own choice, and Equillium shall have the right to be represented in any such action or
proceeding, at Equillium&#146;s own expense (subject to Section&nbsp;7.5(d)) and by counsel of its own choice. If Biocon fails to bring any such action or proceeding with respect to Competitive Infringement of any Equillium Patent in the Biocon
Territory within [&#133;***&#133;] following the notice of alleged Competitive Infringement, Equillium shall have the right to bring (or defend) and control any such action at its own expense and by counsel of its own choice, and Biocon shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">have the right, at its own expense (subject to Section&nbsp;7.5(d)), to be represented in any such action by counsel of its own choice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Joint Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
Competitive Infringement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> <B>Equillium Territory.</B> Equillium shall have the first right, but not the obligation, to bring
(or defend) and control any action or proceeding with respect to Competitive Infringement of any Joint Patent in the Equillium Territory, at its own expense and by counsel of its own choice, and Biocon shall have the right, at its own expense
(subject to Section&nbsp;7.5(d)), to be represented in any such action by counsel of its own choice. If Equillium fails to bring any such action or proceeding with respect to Competitive Infringement of any Joint Patent in the Equillium Territory
within [<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>&#133;***&#133;] following the notice of alleged infringement, Biocon shall have the right to bring (or defend) and control any such action at its own expense and by counsel of its own
choice, and Equillium shall have the right, at its own expense (subject to Section&nbsp;7.5(d)), to be represented in any such action by counsel of its own choice; <I>provided, however,</I> that if the applicable Competitive Infringement is the
result of a party&#146;s receipt of a Patent Certification with respect to a Joint Patent in the Equillium Territory, Equillium shall notify Biocon of Equillium&#146;s decision to bring (or defend) and control any action or proceeding within
10&nbsp;days of Equillium&#146;s receipt of such Patent Certification with respect to such Joint Patent, after which time Biocon shall have the right to bring (or defend) and prosecute such action, and Equillium shall have the right, at its own
expense (subject to Section&nbsp;7.5(d)), to be represented in any such action by counsel of its own choice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> <B>Biocon
Territory.</B> Biocon shall have the first right, but not the obligation, to bring (or defend) and control any action or proceeding with respect to Competitive Infringement of any Joint Patent in the Biocon Territory, at its own expense and by
counsel of its own choice, and Equillium shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If Biocon fails to bring any such action or proceeding with respect to Competitive Infringement of
any Joint Patent in the Biocon Territory within [&#133;***&#133;] following the notice of alleged infringement, Equillium shall have the right to bring (or defend) and control any such action at its own expense and by counsel of its own choice, and
Biocon shall have the right, at its own expense, to be represented in any such action by counsel of its own choice; <I>provided, however,</I> that if the applicable Competitive Infringement is the result of a party&#146;s receipt of a Patent
Certification with respect to a Joint Patent in the Biocon Territory, Biocon shall notify Equillium of Biocon&#146;s decision to bring (or defend) and control any action or proceeding within 10&nbsp;days of Biocon&#146;s receipt of such Patent
Certification with respect to such Biocon Patent, after which time Equillium shall have the right to bring (or defend) and prosecute such action, and Biocon shall have the right, at its own expense, to be represented in any such action by counsel of
its own choice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Other Infringement.</B> The parties shall mutually agree on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis (A)&nbsp;whether to bring (or defend) and control any action or proceeding with respect to Infringement of any Joint Patent anywhere in the world to the extent the Infringement is not
Competitive Infringement, (B)&nbsp;which party would bring (or defend) and control such action, and (C)&nbsp;how the expenses of, and any recovery from, any such action would be allocated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Cooperation.</B> In the event a party brings (or defends) an infringement action in accordance with this Section&nbsp;7.5, or in
the event a party is entitled to bring (or defend) an infringement action in accordance with this Section&nbsp;7.5 but lacks standing to do so, the other party shall cooperate fully, including, if required to bring (or defend) such action, the
furnishing of a power of attorney or being named as a party, provided that the party bringing (or defending) or entitled to bring (or defend) such action shall pay or reimburse the reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by the other party in providing such cooperation. Neither party shall enter into any settlement or compromise of any action under this Section&nbsp;7.5 which would in any manner
alter, diminish, or be in derogation of the other party&#146;s rights under this Agreement without the prior written consent of such other party, which shall not be unreasonably withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Recovery.</B> Except as otherwise agreed by the parties in connection with a cost-sharing arrangement, any recovery realized by
a party as a result of any action or proceeding pursuant to this Section&nbsp;7.5, whether by way of settlement or otherwise, shall be applied first to reimburse the parties&#146; documented <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal expenses incurred in connection with such action or proceeding (which amounts will be allocated <I>pro rata </I>if insufficient to cover the totality of such expenses), and any remaining
amounts shall be [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;]; <I>provided, however,</I> that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any
recovery realized by Equillium as a result of any action brought (or defended) and controlled by Equillium pursuant to Section&nbsp;7.5(a)(i) or Section&nbsp;7.5(c)(i)(1) (after reimbursement of the parties&#146; documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal expenses relating to the action or proceeding) shall be allocated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> compensatory damages shall be treated as [&#133;***&#133;]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> <FONT STYLE="white-space:nowrap">non-compensatory</FONT> damages shall be [&#133;***&#133;]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> any recovery realized by Biocon as a result of any action brought and controlled by Biocon pursuant to Section&nbsp;7.3(b)(ii) or
Section&nbsp;7.5(c)(i)(2) (after reimbursement of the parties&#146; documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal expenses relating to the action or proceeding) shall be allocated as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> compensatory damages attributable to lost sales or lost profits, or a reasonable royalty, with respect to Supported
Products shall be treated as [&#133;***&#133;]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> all compensatory damages other than those described in
Section&nbsp;7.5(e)(ii)(1) shall [&#133;***&#133;]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> <FONT STYLE="white-space:nowrap">non-compensatory</FONT> damages
shall be [&#133;***&#133;]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B> <B>Infringement of Third Party Rights.</B> Each party shall promptly notify the other in writing of any allegation by a Third Party
that the activity of either party pursuant to this Agreement infringes or may infringe the intellectual property rights of such Third Party, provided that in the event such Third Party also alleges the invalidity, unenforceability or <FONT
STYLE="white-space:nowrap">non-infringement</FONT> of any of the Biocon Patents or Joint Patents, such allegation or claim shall be handled as a Competitive Infringement. Neither party shall have the right to settle any patent infringement
litigation under this Section&nbsp;7.6 in a manner that diminishes the rights or interests of the other party without the written consent of such other party (which shall not be unreasonably withheld). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>ONFIDENTIALITY</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B>Confidential Information.</B> Except to the extent expressly authorized by this Agreement, each party agrees that, during the
Term, and for five years thereafter, such party (the <B><I>&#147;</I></B><B><I>Receiving Party</I></B><B><I>&#148;</I></B>) shall keep confidential, and shall not publish or otherwise disclose and shall not use for any purpose other than as
expressly provided for in this Agreement, any Information furnished to it by the other party (the <B><I>&#147;</I></B><B><I>Disclosing Party</I></B><B><I>&#148;</I></B>) pursuant to this Agreement or any Confidentiality Agreement (collectively,
<B><I>&#147;</I></B><B><I>Confidential Information</I></B><B><I>&#148;</I></B>). The Receiving Party may use Confidential Information only to the extent required to accomplish the purposes of this Agreement. The Receiving Party shall use at least
the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its, and its Affiliates&#146;, employees, agents, consultants and other representatives
(<B><I>&#147;</I></B><B><I>Representatives</I></B><B><I>&#148;</I></B>) do not disclose or make any unauthorized use of the Confidential Information. The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized
use or unauthorized disclosure of the Disclosing Party&#146;s Confidential Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B>Exceptions.</B> Confidential
Information shall not include any information which the Receiving Party can prove by competent evidence: (a)&nbsp;is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in violation of this Article&nbsp;8,
generally known or available; (b)&nbsp;is known by the Receiving Party or any of its Affiliates at the time of receiving such information, as evidenced by its records; (c)&nbsp;is hereafter furnished to the Receiving Party or any of its Affiliates
by a Third Party, as a matter of right and without restriction on disclosure; or (d)&nbsp;is independently discovered or developed by the Receiving Party or any of its Affiliates, independently of the activities undertaken by the Receiving Party
pursuant to this Agreement and without the use or knowledge of Confidential Information of the Disclosing Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B>Authorized
Disclosure.</B> Notwithstanding the provisions of Section&nbsp;8.1, the Receiving Party may disclose Confidential Information of the Disclosing Party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably
necessary in the following instances: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> filing or prosecuting Patent Rights as permitted by this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> enforcing such party&#146;s rights under this Agreement and in performing its obligations under this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> prosecuting or defending litigation as permitted by this Agreement, subject to the final paragraph of this Section&nbsp;8.3; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> complying with applicable court orders, applicable laws, rules or regulations, subject to the final paragraph of this
Section&nbsp;8.3; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> as determined in the Receiving Party&#146;s reasonable discretion, the listing rules of any exchange on
which the Receiving Party&#146;s securities are traded; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> disclosure in Regulatory Filings that the Receiving Party has the
right to make under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> disclosure to the Receiving Party&#146;s Affiliates, to actual or potential Sublicensees,
and to the Receiving Party&#146;s and its Affiliates&#146; Representatives who, in each case, have a need to know such information in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement, provided, in
each case, that any such Affiliate, actual or potential Sublicensee, or Representative agrees to be bound by terms of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as restrictive as those set forth in this
Article&nbsp;8; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> disclosure to Third Parties in connection with due diligence or similar investigations by such Third
Parties, and disclosures to potential Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by reasonable obligations of confidentiality and
<FONT STYLE="white-space:nowrap">non-use.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event the Receiving Party is required to make a
disclosure of the Disclosing Party&#146;s Confidential Information pursuant to Section&nbsp;8.3(c) or 8.3(d), it will, except where impracticable, (i)&nbsp;give reasonable advance notice to the Disclosing Party of such disclosure, (ii)&nbsp;use
efforts to secure confidential treatment of such information at least as diligent as the Receiving Party would use to protect its own confidential information, but in no event less than reasonable efforts, and (iii)&nbsp;cooperate with any efforts
by the Disclosing Party, at the Disclosing Party&#146;s request and expense, to secure confidential treatment of such Confidential Information. Disclosure by the Receiving Party of Confidential Information in accordance with any of the foregoing
provisions of this Section&nbsp;8.3 shall not, in and of itself, cause the information so disclosed to cease to be treated as Confidential Information under this Agreement, except to the extent that, by virtue of disclosure by the Receiving Party in
full compliance with this Section&nbsp;8.3, such information becomes generally known or available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B> <B>Publications.</B> Each
party and its Affiliates shall be free to publish, and to authorize Sublicensees to publish, the results of any preclinical study or clinical trial of a Product conducted by or on behalf of such party or its Affiliate or Sublicensee, provided that
the other party has a reasonable opportunity not less than [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] prior to the date of publication to review the proposed publication and provide comments. If such comments involve a
redaction of Confidential Information of such reviewing party, the publishing party shall incorporate such comments. If such comments involve the identification of patentable material in such proposed publication, the publishing party shall delay
publication for up to [&#133;***&#133;] until the appropriate party seeks patent protection for such information. Any such publication shall acknowledge, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">appropriate, the contribution of the other party, its employees, agents and representatives, or if appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5 Public Announcements. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Press Releases.</B> It is understood that each party may desire or be required to issue press releases relating to this
Agreement or activities hereunder. Neither party may issue any press release without the prior review and approval of the other party during the first [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] after the Effective Date.
Notwithstanding the foregoing, each party shall be free to issue such subsequent press releases without the prior review or approval of the other party, that such party determines are reasonably necessary to comply with Applicable Laws, including
disclosure requirements of the U.S. Securities and Exchange Commission or foreign counterpart, or with the requirements of any stock exchange on which securities issued by such party is traded. In addition, each party may make public statements
regarding this Agreement in response to questions by the press, analysts, investors or those attending industry conferences or financial analyst calls, so long as the contents of any such public statement or press release do not reveal <FONT
STYLE="white-space:nowrap">non-public</FONT> information about the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Filing of this Agreement.</B> The parties
shall coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with any securities authority or with any stock exchange on which securities issued by a party
or its Affiliate are traded, and each party will use reasonable efforts to seek and obtain confidential treatment for the terms proposed to be redacted; provided that each party will ultimately retain control over what terms are disclosed to any
securities authority or stock exchange, as the case may be, to the extent such party determines, on the advice of legal counsel, that disclosure is reasonably necessary to comply with Applicable Laws, including disclosure requirements of the U.S.
Securities and Exchange Commission or foreign counterpart, or with the requirements of any stock exchange on which securities issued by a party or its Affiliates are traded, and provided further that the parties will use their reasonable efforts to
file redacted versions with any governing bodies which are consistent with redacted versions previously filed with any other governing bodies. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B> <B>Mutual Representations and Warranties.</B> Each party represents and warrants to the other that, as of the Effective Date:
(a)&nbsp;it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof; (b)&nbsp;it
is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action;
and (c)&nbsp;this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound (including,
with respect to Biocon, the [&#133;***&#133;] Agreement), nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B> <B>Biocon Representations and Warranties.</B> Biocon represents and warrants to Equillium that as of the Effective Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Exhibit</B><B></B><B>&nbsp;A</B> attached hereto contains a true and complete list of the Biocon Patents existing on the
Effective Date in the Equillium Territory. The Biocon Patents listed in <B>Exhibit</B><B></B><B>&nbsp;A</B> include all of the Patent Rights Controlled by Biocon as of the Effective Date that claim or disclose ITO or Product, or the manufacture,
use, sale, offer for sale or import of ITO or Product, in the Equillium Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Biocon (i)&nbsp;has the right to grant the
Equillium License; and (ii)&nbsp;has not granted to any Third Party any license or other right with respect to ITO, Product or Biocon Technology that conflicts with the Equillium License and other rights granted to Equillium herein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> other than the [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] Agreement, there are no agreements in effect
as of the Effective Date between Biocon and a Third Party under which rights with respect to the Biocon Technology are being licensed to Biocon; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Biocon is the sole and exclusive owner of all right, title and interest in and to the Biocon Patents in existence on the Effective
Date, other than the [&#133;***&#133;] Patents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> to Biocon&#146;s actual knowledge, [&#133;***&#133;] is the sole and exclusive
owner of all right, title and interest in and to the [&#133;***&#133;] Patents in existence on the Effective Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> to
Biocon&#146;s actual knowledge, the issued and unexpired claims included in the Biocon Patents existing as of the Effective Date are valid and enforceable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> to Biocon&#146;s actual knowledge, no reexamination, interference, invalidity, opposition, nullity or similar claim or proceeding
is pending or threatened with respect to any Biocon Patent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> Biocon has not received written notice from any Third Party
claiming that the manufacture, use, sale, offer for sale or import of ITO or Product infringes or would infringe the patent or other intellectual property rights of any Third Party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> there are no judgments or settlements against or owed by Biocon (or any of its Affiliates) with respect to the Biocon Technology,
and Biocon is not a party to any legal action, suit or proceeding relating to the Biocon Technology, nor has Biocon received any written communication from any Third Party, including, without limitation, any Regulatory Authority or other government
agency, threatening such action, suit or proceeding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> the [&#133;***&#133;] Agreement is legal, valid, enforceable and is in
full force and effect, and Biocon has provided Equillium a true and complete copy of the [&#133;***&#133;] Agreement, including any and all amendments thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> Biocon is not in material violation of or material default under (nor does there exist any condition which upon the passage of time
or the giving of notice or both, would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">reasonably be expected to cause such a material violation of or material default under or permit termination, modification or acceleration of) the
[&#133;***&#133;] Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> all tangible or recorded information and data provided by or on behalf of Biocon to Equillium
related to ITO or Product on or before the Effective Date in contemplation of this Agreement was and is true, accurate and complete in all material respects, and Biocon has not failed to disclose, or failed to cause to be disclosed, any such
information or data related to ITO or Product in its possession and Control that would cause the information and data that has been disclosed to be misleading in any material respect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> neither Biocon nor any of its Affiliates has filed any Regulatory Filing for ITO or Product in the Equillium Territory; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> neither Biocon nor any of its Affiliates is debarred under the Act or comparable Applicable Laws outside of the United States; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> neither Biocon nor any of its Affiliates has employed or otherwise used in any capacity, in connection with the development or
manufacture of ITO or Product, the services of any person debarred or disqualified under United States law, including 21 U.S.C. &#167;335a, or any foreign equivalent thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B> <B>Equillium Representations and Warranties.</B> Equillium represents and warrants to Biocon that as of the Effective Date of this
Agreement neither Equillium nor any of its Affiliates is debarred under the Act or comparable Applicable Laws outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4</B> <B>Biocon Covenants.</B> In addition to any covenants made by Biocon elsewhere in this Agreement, Biocon hereby covenants to
Equillium as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> during the Term, Biocon will not grant any Third Party any license or other right with respect to ITO,
Product or Biocon Technology in derogation of the Equillium License or the rights granted to Equillium hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Biocon will
not terminate the [&#133;***&#133;] Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Biocon will not amend or waive, or take any action or omit to take any action
that would alter, any of Biocon&#146;s rights under the [&#133;***&#133;] Agreement in any manner that would adversely affect Equillium&#146;s rights under this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Biocon shall promptly notify Equillium of the receipt or delivery of any notice of any default under, or any termination or
amendment of, the [&#133;***&#133;] Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5</B> <B>Equillium Covenants.</B> In addition to any covenants made by Equillium
elsewhere in this Agreement, Equillium hereby covenants to Biocon that, during the Term, Equillium will not grant any Third Party any license or other right with respect to ITO, Product or Equillium Technology in derogation of the Biocon License or
the rights granted to Biocon hereunder; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6</B> <B>Mutual Covenants.</B> In addition to any covenants made by it elsewhere in this Agreement, each party hereby covenants to the
other party that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> neither such party nor any of its Affiliates will employ or use the services of any Person who is debarred or
disqualified under United States law, including 21 U.S.C. &#167;335a, or any foreign equivalent thereof, in connection with activities relating to ITO or Product; and in the event that such party becomes aware of the debarment or disqualification or
threatened debarment or threatened disqualification of any Person providing services to such party or any of its Affiliates with respect to any activities relating to ITO or Product, such party will immediately notify the other party in writing and
such party will cease, or cause its Affiliate to cease (as applicable), employing, contracting with, or retaining any such Person to perform any services relating to ITO or Product; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> neither such party nor any of its Affiliates will, in connection with the exercise of such party&#146;s rights or performance of
its obligations under this Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a public
official or entity or other Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, including such party and its Affiliates, nor will such party or any of its Affiliates directly or indirectly
promise, offer or provide any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a public official or entity or any other Person in connection with the exercise of such
party&#146;s rights or performance of such party&#146;s obligations under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> neither such party nor any of its
Affiliates (or any of their respective employees and contractors), in connection with the exercise of such party&#146;s rights or performance of such party&#146;s obligations under this Agreement, shall cause the other party to be in violation of
Anti-Corruption Laws or Export Control Laws; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> such party shall immediately notify the other party if such party has any
information or suspicion that there may be a violation of Anti-Corruption Laws or Export Control Laws in connection with the exercise of such party&#146;s rights or performance of such party&#146;s obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.7</B> <B>Performance by Affiliates and Contractors.</B> The parties recognize that each party may perform some or all of its obligations
or exercise some or all of its rights under this Agreement through one or more Affiliates or Third Party contractors; <I>provided,</I> in each case, that (a)&nbsp;none of the other party&#146;s rights hereunder are diminished or otherwise adversely
affected as a result of such delegation or contracting, and (b)&nbsp;each such Affiliate and Third Party contractor undertakes in writing obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> regarding Confidential
Information and ownership of Inventions which are substantially the same as those undertaken by the parties pursuant to Article&nbsp;8 and Section&nbsp;7.1; and <I>provided, further,</I> that such party shall at all times be fully responsible for
the performance and payment of such Affiliate or Third Party Contractor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.8</B> <B>Disclaimer.</B> Except as expressly set forth in
this Agreement, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY EACH </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PARTY HEREUNDER ARE PROVIDED &#147;AS IS.&#148; Except as expressly set forth in this Agreement, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY
KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENTS, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF THE INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.9</B> <B>Limitation of Liability.</B> EXCEPT FOR
LIABILITY FOR BREACH OF ARTICLE&nbsp;8, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; <I>provided,
however,</I> that this Section&nbsp;9.9 shall not be construed to limit either party&#146;s indemnification obligations under Article&nbsp;11. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>ERM</SMALL>; T<SMALL>ERMINATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B> <B>Term.</B> The term of this Agreement (the <B><I>&#147;</I></B><B><I>Term</I></B><B><I>&#148;</I></B>) shall begin on the
Effective Date and, unless earlier terminated in accordance with this Article&nbsp;10, expire upon expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Royalty Term for any and all Products
and Supported Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2 Termination for Material Breach. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Material Breach Other Than Breach of Equillium Diligence Obligations.</B> Subject to Section&nbsp;10.2(c), and except in the
case of a material breach covered by Section&nbsp;10.2(b), each party shall have the right, in the event of material breach of this Agreement by the other party, to terminate this Agreement upon written notice to the other party if such other party
is in material breach of this Agreement and has not cured such breach within 90&nbsp;days after notice from the terminating party requesting cure of the breach. Any such termination shall become effective at the end of such <FONT
STYLE="white-space:nowrap">90-day</FONT> period unless the breaching party has cured such breach prior to the end of such period. Notwithstanding the foregoing or Section&nbsp;10.4 to the contrary, but without limiting Biocon&#146;s rights under
Section&nbsp;10.2(b), after initiation of the first Pivotal Trial of Product, Biocon may not terminate this Agreement pursuant to this Section&nbsp;10.2(a), except in the case of uncured material breach by Equillium of its payment obligations
hereunder or uncured material breach of Section&nbsp;2.1, Section&nbsp;2.4, Section&nbsp;2.6, Section&nbsp;4.3, Section&nbsp;7.5, Section&nbsp;8.1 or Section&nbsp;9.6 but for clarity, Biocon may pursue any and all remedies that may be available to
it at law or in equity as a result of such breach by Equillium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Material Breach of Equillium Diligence Obligation.</B> If
Biocon in good faith believes that Equillium has failed to comply with its obligations under Section&nbsp;4.8 (<B><I>&#147;Diligence Obligations&#148;</I></B>), Biocon shall notify Equillium, and Equillium shall have 60&nbsp;days from the date of
such notice (the <B><I>&#147;Diligence Notice Period&#148;</I></B>) in which to provide information to Biocon reasonably demonstrating Equillium&#146;s compliance with its Diligence Obligations. If Equillium provides such information to Biocon prior
to expiration of the Diligence Notice Period, but Biocon continues to believe in good faith that Equillium is not complying with its Diligence Obligations, then Biocon may so notify Equillium in writing, in which event Equillium and Biocon shall
promptly meet to discuss the matter in good faith and attempt to agree upon a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mutually agreeable plan for Equillium to regain compliance with its Diligence Obligations. Following such meeting, if either (i)&nbsp;the parties do not agree
upon a plan to address such failure by Equillium within 30&nbsp;days after expiration of the Diligence Notice Period, or (ii)&nbsp;Equillium fails to comply with its obligations under any mutually agreed upon plan to address such failure by
Equillium, then, subject to Section&nbsp;10.2(c) below, Biocon shall have the right, at its sole discretion, to terminate this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Dispute Regarding Breach.</B> Any right to terminate this Agreement under this Section&nbsp;10.2 shall be stayed and the cure
period tolled in the event that, during any cure period, the party alleged to have been in material breach shall have initiated dispute resolution in accordance with Article&nbsp;12 with respect to the alleged breach, which stay and tolling shall
continue until such dispute has been resolved in accordance with Article&nbsp;12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3</B>
<B><FONT STYLE="white-space:nowrap">At-Will</FONT> Termination by Equillium.</B> Equillium shall have the right to terminate this Agreement on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis
for any reason or for no reason at any time upon 120&nbsp;days&#146; prior written notice to Biocon. Within 10&nbsp;days after delivery of written notice pursuant to this Section&nbsp;10.3, the JSC shall convene to discuss transition planning,
subject to Section&nbsp;10.4(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4 Effect of Expiration or Termination. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Expiration.</B> Upon expiration (but not earlier termination) of this Agreement, the Equillium License and the Biocon License
shall survive on a <FONT STYLE="white-space:nowrap">royalty-free,</FONT> <FONT STYLE="white-space:nowrap">fully-paid,</FONT> irrevocable and perpetual basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Effect of Termination on Fully-Paid Licenses.</B> If the Royalty Term with respect to a Product or Supported Product (as
applicable) in any country has expired on or before any termination of this Agreement prior to the expiration hereof, the license granted to the applicable party hereunder with respect to such Product or Supported Product in such country
(<I>i.e.</I>, the Equillium License or the Biocon License, as applicable) shall survive such termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Termination by Equillium Pursuant to Section</B><B></B><B>&nbsp;10.2.</B> Solely in the event of termination of this Agreement by Equillium pursuant to Section&nbsp;10.2, the Equillium License and the Biocon License shall automatically terminate
and revert to the granting party; in each case, except as expressly provided in Section&nbsp;10.4(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Termination by Biocon
Pursuant to Section</B><B></B><B>&nbsp;10.2 or by Equillium Pursuant to Section</B><B></B><B>&nbsp;10.3.</B> Solely in the event of termination of this Agreement by Biocon pursuant to Section&nbsp;10.2, or by Equillium pursuant to Section&nbsp;10.3,
and without prejudice to Biocon&#146;s other rights and remedies, the following provisions (in addition to the provisions of Section&nbsp;10.4(b)) shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the Equillium License shall automatically terminate and revert to Biocon, except as expressly provided in Section&nbsp;10.4(b);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> effective as of such termination, Equillium shall, and it hereby does, covenant, during the period beginning on the
effective date of such termination and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">expiring, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon the later to occur of:
(A)&nbsp;expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Valid Claim of the Biocon Patents, Equillium Patents and Joint Patents covering the manufacture, use or sale of Product in each
country of the Equillium Territory; and (B)&nbsp;expiration of all Regulatory Exclusivity for all Products in such country: (A)&nbsp;not to develop, make, have made, sell, have sold, offer for sale, import or otherwise exploit ITO or Product in the
Unlimited Field in such country; and (B)&nbsp;not to cause or permit, or grant any license or other right to, any of its Affiliates or any Third Party to engage in any of the activities prohibited by the preceding clause&nbsp;(A) of this
Section&nbsp;10.4(d)(ii); except, in each case, as expressly provided in Section&nbsp;10.4(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> effective as of such
termination, Equillium shall, and it hereby does, grant to Biocon a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">royalty-free</FONT> license, with the right to sublicense through multiple tiers of
sublicense, under Equillium Technology and Equillium&#146;s interest in the Joint Patents, solely to develop, make, have made, use, sell, offer for sale, have sold and import ITO and Products in the Unlimited Field in the Equillium Territory; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> effective as of such termination, Equillium shall, and it hereby does, grant to Biocon, a right of first negotiation, exercisable
within 60&nbsp;days after the termination date, upon commercially reasonable terms and conditions to be negotiated in good faith by the parties for up to 90&nbsp;days from the date of exercise: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> to obtain an exclusive, royalty-bearing license, with the right to sublicense through multiple tiers of sublicense, under Equillium
Technology and Equillium&#146;s interest in the Joint Patents, solely to develop, make, have made, use, sell, offer for sale, have sold and import ITO and Products in the Unlimited Field in the Equillium Territory; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> to have transferred or assigned to Biocon or its designee all Regulatory Filings for Products in the Unlimited Field in the
Equillium Territory held in the name of Equillium or any of its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> Biocon shall have the right, but not the
obligation, to purchase from Equillium any or all usable inventory of ITO and Product in Equillium&#146;s or its Affiliates&#146; possession as of the date of expiration. Such inventory shall be provided at a transfer price equal to Equillium&#146;s
cost of such inventory (as reflected on Equillium&#146;s books and records used to prepare its financial statements), plus freight, insurance, transportation, postage and handling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> the Biocon License shall survive; <I>provided</I> that, if Biocon grants a Third Party an exclusive license to develop and
commercialize Product in the Equillium Territory and the terms of such Third Party license require Biocon to pay royalties to such Third Party licensee on Biocon&#146;s net sales of Product in a country of the Biocon Territory, then 100% of the
royalties actually paid by Biocon to such Third Party licensee on sales of Product in such country for a calendar quarter will be creditable against the royalty payments payable by Biocon to Equillium pursuant to Section&nbsp;5.4(b) in such country
for such calendar quarter; <I>provided, however,</I> that in no event will the royalties owed by Biocon to Equillium hereunder pursuant to Section&nbsp;5.4(b) in such country for any calendar quarter be reduced to less than 0% (<I>i.e.</I>, in no
event shall Equillium owe any royalties to Biocon with respect to Net Sales of Product in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biocon Territory); and <I>provided, further,</I> that Biocon will not be entitled to credit any portion of royalties paid by Biocon to such Third Party
licensee with respect to any Other Active in any Combination Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5</B> <B>Accrued Obligations; Survival.</B> Upon any
termination or any expiration of this Agreement, all rights and obligations of the parties under this Agreement shall terminate, except as expressly provided in this Section&nbsp;10.5 or elsewhere in this Article&nbsp;10. Neither expiration nor any
termination of this Agreement shall relieve either party of any obligation or liability accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement preclude either party from pursuing all rights and
remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement. In addition, the parties&#146; rights and obligations under Sections&nbsp;2.7, 7.1, 8.1, 8.2, 8.3, 9.8, 9.9, 10.4, 10.5, 10.6 and 10.7 and
Articles&nbsp;6, 11, 12 and 13 of this Agreement shall survive expiration or any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6</B> <B>Return of
Confidential Information.</B> Within 30&nbsp;days following the expiration or termination of this Agreement, except to the extent that a party retains a license from the other party as provided in this Article&nbsp;10, each party shall promptly
return to the other party, or delete or destroy, all relevant records and materials in such party&#146;s possession or control containing Confidential Information of the other party; provided that such party may keep one copy of such materials for
archival purposes only subject to Article&nbsp;8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.7</B> <B>Damages; Relief.</B> Termination of this Agreement shall not preclude
either party from claiming any other damages, compensation or relief that it may be entitled to hereunder as a result of the other party&#146;s breach of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>I<SMALL>NDEMNIFICATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B> <B>Indemnification by Equillium.</B> Equillium hereby agrees to save, defend, indemnify and hold harmless Biocon, its Affiliates,
its and their respective officers, directors, agents, employees, successors and assigns (the <B><I>&#147;</I></B><B><I>Biocon Indemnitees</I></B><B><I>&#148;</I></B>), from and against any and all losses, damages, liabilities, expenses and costs,
including reasonable legal expense and attorneys&#146; fees (<B><I>&#147;</I></B><B><I>Losses</I></B><B><I>&#148;</I></B>), to which any Biocon Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third
Party (each, a <B><I>&#147;</I></B><B><I>Claim</I></B><B><I>&#148;</I></B>) to the extent such Losses arise out of or relate to: (a)&nbsp;the development, manufacture, use, handling, storage, sale, offer for sale, import or other disposition by or
on behalf of Equillium, its Affiliates or Sublicensees of ITO or Products, or any other exercise of the Equillium License by or on behalf of Equillium, its Affiliates or Sublicensees; (b)&nbsp;the gross negligence or willful misconduct of any
Equillium Indemnitee (defined below); or (c)&nbsp;the breach by Equillium of any warranty, representation, covenant or agreement made by Equillium in this Agreement; except, in each case, to the extent such Losses result from the gross negligence or
willful misconduct of any Biocon Indemnitee or the breach by Biocon of any warranty, representation, covenant or agreement made by Biocon in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B> <B>Indemnification by Biocon.</B> Biocon hereby agrees to save, defend, indemnify and hold harmless Equillium, its Affiliates and
their respective officers, directors, employees, consultants and agents (the <B><I>&#147;Equillium Indemnitees&#148;</I></B>) from and against any and all Losses to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which any Equillium Indemnitee may become subject as a result of any Claim to the extent such Losses arise out of or relate to: (a)&nbsp;the exercise of the
Biocon License by or on behalf of Biocon or any of its Affiliates or Sublicensees; (b)&nbsp;the gross negligence or willful misconduct of any Biocon Indemnitee; or (c)&nbsp;the breach by Biocon of any warranty, representation, covenant or agreement
made by Biocon in this Agreement; in each case except to the extent such Losses result from the gross negligence or willful misconduct of any Equillium Indemnitee or the breach by Equillium of any warranty, representation, covenant or agreement made
by Equillium in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B> <B>Control of Defense.</B> In the event a party (the <B><I>&#147;</I></B><B><I>Indemnified
Party</I></B><B><I>&#148;</I></B>) seeks indemnification under Section&nbsp;11.1 or 11.2, it shall inform the other party (the <B><I>&#147;</I></B><B><I>Indemnifying Party</I></B><B><I>&#148;</I></B>) of a claim as soon as reasonably practicable
after it receives notice of the claim (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a claim as provided in this Section&nbsp;11.3 shall not relieve the Indemnifying Party of its indemnification
obligation under this Agreement except and only to the extent that such Indemnifying Party is actually damaged as a result of such failure to give notice), shall permit the Indemnifying Party to assume direction and control of the defense of the
claim (including the right to settle the claim solely for monetary consideration) using counsel reasonably satisfactory to the Indemnified Party, and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the
claim. If the Indemnifying Party does not assume control of such defense within 30&nbsp;days after receiving notice of the claim from the Indemnified Party, the Indemnified Party shall control such defense and, without limiting the Indemnifying
Party&#146;s indemnification obligations, the Indemnifying Party shall reimburse the Indemnified Party for all costs, including reasonable attorney fees, incurred by the Indemnified Party in defending itself within 30&nbsp;days after receipt of any
invoice therefor from the Indemnified Party. The party not controlling such defense may participate therein at its own expense. The party controlling such defense shall keep the other party advised of the status of such action, suit, proceeding or
claim and the defense thereof and shall consider recommendations made by the other party with respect thereto. The Indemnified Party shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of the
Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. The Indemnifying Party shall not agree to any settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not
include a complete and unconditional release of the Indemnified Party from all liability with respect thereto, that imposes any liability or obligation on the Indemnified Party or that acknowledges fault by the Indemnified Party without the prior
written consent of the Indemnified Party. If the parties cannot agree as to the application of Section&nbsp;11.1 or 11.2 to any claim, pending resolution of the dispute pursuant to Article&nbsp;12, the parties may conduct separate defenses of such
claims, with each party retaining the right to claim indemnification from the other party in accordance with Section&nbsp;11.1 or 11.2, as applicable, upon resolution of the underlying claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4</B> <B>Insurance.</B> Each party shall procure and maintain insurance, including comprehensive or commercial general liability
insurance (including contractual liability and product liability), in amounts that are commercially reasonable in light of the activities and obligations undertaken by such party pursuant to this Agreement, which amounts shall be consistent with
normal business practices of prudent companies similarly situated. It is understood that such insurance shall not be construed to create a limit of either party&#146;s liability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with respect to its indemnification obligations under this Article&nbsp;11 or otherwise. Each party shall provide the other party with written evidence of such
insurance upon request. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>ISPUTE</SMALL> R<SMALL>ESOLUTION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1</B> <B>Disputes.</B> Subject to Section&nbsp;12.3, and except as expressly set forth in Article&nbsp;3, any claim, dispute, or
controversy as to the breach, enforcement, interpretation or validity of this Agreement (each, a <B><I>&#147;</I></B><B><I>Dispute</I></B><B><I>&#148;</I></B>) will be referred to Equillium&#146;s Chair and Biocon&#146;s Chair for attempted
resolution. In the event the Chairs are unable to resolve such Dispute within 30&nbsp;days of such Dispute being referred to them, then, upon the written request of either party to the other party, the Dispute shall be subject to arbitration in
accordance with Section&nbsp;12.2, except as expressly set forth in Section&nbsp;12.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2 Arbitration. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Claims.</B> Subject to Section&nbsp;12.3 below, any Dispute that is not resolved under Section&nbsp;12.1 within the applicable <FONT
STYLE="white-space:nowrap">30-day</FONT> period shall be resolved by final and binding arbitration administered by JAMS (the <B><I>&#147;Administrator&#148;</I></B>) in accordance with its then-effective Comprehensive Arbitration Rules and
Procedures (the <B><I>&#147;Rules&#148;</I></B>), including its then-effective Expedited Procedures, except to the extent any such Rule conflicts with the express provisions of this Section&nbsp;12.2. (Capitalized terms used but not otherwise
defined in this Agreement shall have the meanings provided in the Rules.) The Arbitration shall be conducted by one neutral arbitrator (unless the parties mutually agree to have the Arbitration conducted by a panel of three neutral arbitrators),
selected in accordance with the Rules, provided that no such individual shall be a current or former employee or director, or a current stockholder, of either party or any of their respective Affiliates (or any Sublicensee of the rights granted to
such party under this Agreement). The arbitration and all associated discovery proceedings and communications shall be conducted in English, and the arbitration shall be held in New York City, New York. The Arbitrator(s) shall have the authority to
grant preliminary or temporary injunctive relief pending the outcome of the Arbitration in the context of a <I>bona fide</I> emergency or prospective irreparable harm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Discovery.</B> Within 30&nbsp;days after selection of the Arbitrator(s), the Arbitrator(s) shall conduct the Preliminary
Conference. In addressing any of the subjects within the scope of the Preliminary Conference, the Arbitrator(s) shall take into account both the desirability of making discovery efficient and cost-effective and the needs of the parties for an
understanding of any legitimate issue raised in the Arbitration. In that regard, the parties agree to the application of the <FONT STYLE="white-space:nowrap">E-Discovery</FONT> procedures set forth in Rule&nbsp;16.2(c) of the JAMS Expedited
Procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Hearing; Decision.</B> The Arbitrator(s) shall require that each party submit concise written statements of
position and shall permit the submission of rebuttal statements, subject to reasonable limitations on the length of such statements to be established by the Arbitrator(s). The Arbitrator(s) shall also permit the submission of expert reports. The
Award shall include a written statement describing the essential findings and conclusions on which the Award is based, including the calculation of any damages awarded. The Arbitrator(s) will, in rendering their decision, apply the substantive law
of the State of New York, USA, excluding its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">conflicts of laws principles with the exception of <FONT STYLE="white-space:nowrap">sections&nbsp;5-1401</FONT> and
<FONT STYLE="white-space:nowrap">5-1402</FONT> of New York General Obligations Law. The Arbitrator&#146;s(s&#146;) authority to award special, incidental, consequential or punitive damages shall be subject to the limitation set forth in
Section&nbsp;9.9. The Award rendered by the Arbitrator(s) shall be final, binding and <FONT STYLE="white-space:nowrap">non-appealable,</FONT> and judgment may be entered upon it in any court of competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Costs.</B> Each party shall bear its own attorney&#146;s fees, costs, and disbursements arising out of the arbitration, and
shall pay an equal share of the fees and costs of the Arbitrator(s); <I>provided, however,</I> the Arbitrator(s) shall be authorized to determine whether a party is the prevailing party, and if so, to award to that prevailing party reimbursement for
any or all of its reasonable attorneys&#146; fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges, travel expenses, <I>etc.</I>), and/or the fees and costs of the Administrator and the
Arbitrator(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3</B> <B>Court Actions.</B> Nothing contained in this Agreement shall deny either party the right to seek injunctive
or other equitable relief, including specific performance, from a court of competent jurisdiction in the context of a <I>bona fide</I> emergency or prospective irreparable harm, including with respect to any breach of Article&nbsp;8 or the ownership
provisions of Section&nbsp;7.1, and such an action may be filed and maintained notwithstanding any ongoing discussions between the parties or any ongoing arbitration proceeding. In addition, either party may bring an action in any court of competent
jurisdiction to resolve disputes pertaining to the validity, construction, scope, enforceability, infringement or other violations of Patent Rights or other intellectual property rights, and no such claim shall be subject to arbitration pursuant to
Section&nbsp;12.2. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>ENERAL</SMALL> P<SMALL>ROVISIONS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1</B> <B>Rights Upon Bankruptcy.</B> All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be
deemed to be, for purposes of Section&nbsp;365(n) of Title&nbsp;11 of the United States Code and other similar laws in any jurisdiction outside the US (collectively, the <B><I>&#147;Bankruptcy Laws&#148;</I></B>), licenses of rights to be
&#147;intellectual property&#148; as defined under the Bankruptcy Laws. If a case is commenced during the Term by or against a party under Bankruptcy Laws then, unless and until this Agreement is rejected as provided in such Bankruptcy Laws, such
party (in any capacity, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debtor-in-possession)</FONT></FONT> and its successors and assigns (including a trustee) shall perform all of the obligations provided in this
Agreement to be performed by such party. If a case is commenced during the Term by or against a party under the Bankruptcy Laws, this Agreement is rejected as provided in the Bankruptcy Laws and the other party elects to retain its rights hereunder
as provided in the Bankruptcy Laws, then the party subject to such case under the Bankruptcy Laws (in any capacity, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debtor-in-possession)</FONT></FONT> and its successors
and assigns (including a Title&nbsp;11 trustee), shall provide to the other party copies of all Information necessary for such other party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly upon such other
party&#146;s written request therefor. All rights, powers and remedies of the <FONT STYLE="white-space:nowrap">non-bankrupt</FONT> party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies
now or hereafter existing at law or in equity (including, without limitation, the Bankruptcy Laws) in the event of the commencement of a case by or against a party under the Bankruptcy Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2</B> <B>Governing Law.</B> This Agreement shall be governed by and construed in accordance with the laws of the State of New York, USA,
excluding its conflicts of laws principles with the exception of <FONT STYLE="white-space:nowrap">sections&nbsp;5-1401</FONT> and <FONT STYLE="white-space:nowrap">5-1402</FONT> of New York General Obligations Law. THE PARTIES HERETO HEREBY
IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, OR RELATING TO THIS AGREEMENT, ANY RELATED AGREEMENTS OR ANY TRANSACTIONS
CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.3</B> <B>Entire Agreement; Amendments.</B> This Agreement (including the Exhibits hereto), the Purchase
Agreement, the Related Agreements and the Clinical Supply Agreement, collectively, are both a final expression of the parties&#146; agreement and a complete and exclusive statement with respect to all of their respective terms. This Agreement
supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all matters contained herein, including any Confidentiality Agreement, but specifically excluding the Purchase Agreement,
the Related Agreements and the Clinical Supply Agreement. The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written
instrument duly executed by authorized representatives of both parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.4</B>
<B><FONT STYLE="white-space:nowrap">Non-Waiver.</FONT></B> The failure of a party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or
right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a party of a particular provision or right shall be in writing, shall be as to a particular matter and, if
applicable, for a particular period of time and shall be signed by such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.5</B> <B>Assignment.</B> Except as expressly
provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either party without the prior written consent of the other party (which consent shall not be unreasonably withheld);
<I>provided, however,</I> that either party may assign this Agreement and its rights and obligations hereunder without the other party&#146;s consent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> in connection with the transfer or sale of all or substantially all of the business of such party to which this Agreement relates to
a Third Party (<B><I>&#147;</I></B><B><I>Third Party Acquirer</I></B><B><I>&#148;</I></B>), whether by merger, sale of stock, sale of assets or otherwise (each, a <B><I>&#147;</I></B><B><I>Sale Transaction</I></B><B><I>&#148;</I></B>), provided that
in the event of a Sale Transaction (whether this Agreement is actually assigned or is assumed by the Third Party Acquirer or the surviving corporation resulting from such Sale Transaction by operation of law (<I>e.g.</I>, in the context of a reverse
triangular merger)), intellectual property rights of the Third Party Acquirer that existed prior to the Sale Transaction shall not be included in the technology licensed hereunder or otherwise subject to this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> to an Affiliate, provided that the assigning party shall remain liable and responsible to the
<FONT STYLE="white-space:nowrap">non-assigning</FONT> party hereto for the performance and observance of all such duties and obligations by such Affiliate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted
assigns of the parties, and the name of a party appearing herein will be deemed to include the name of such party&#146;s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in
accordance with this Agreement shall be void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.6</B> <B>Force Majeure.</B> Each party shall be excused from liability for the
failure or delay in performance of any obligation under this Agreement by reason of any event beyond such party&#146;s reasonable control, including but not limited to Acts of God, fire, flood, explosion, earthquake, or other natural forces, war,
civil unrest, acts of terrorism, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or organized labor disturbance, or any other event similar to
those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the party has not caused, in whole or in part, such event(s) to
occur. The affected party shall notify the other party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.7</B> <B>Severability.</B> If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of
the parties. The parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.8</B> <B>Notices.</B> Any notice to be given under this Agreement must be in writing and delivered either in person, or
by internationally-recognized express courier, to the party to be notified at its address(es) given below, or at any address such party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all
purposes upon the earliest of: (a)&nbsp;the date of actual receipt; or (b)&nbsp;if delivered by express courier, the second business day the express courier regularly makes deliveries following deposit. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Equillium, to:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2223 Avenida de la Playa, Suite
108</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Jolla, CA 92037</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Daniel M. Bradbury</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: [&#133;***&#133;]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Biocon, to:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biocon&nbsp;SA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Director</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BDO SA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rue de l&#146;Avenir 2</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2800 Del&eacute;mont</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Switzerland</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">With a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Head &#150; Legal</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biocon Limited</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20th K.M. Hosur Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Electronics City P.O.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bangalore 560100</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">India</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.9</B> <B>Interpretation.</B> The headings of clauses contained in this Agreement preceding the text of
the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this
Agreement to the singular shall include the plural where applicable. The term &#147;including&#148; or &#147;includes&#148; as used in this Agreement means including, without limiting the generality of any description preceding such term, and the
word &#147;or&#148; has the inclusive meaning represented by the phrase &#147;and/or.&#148; Unless otherwise specified, references in this Agreement to any section shall include all subsections and paragraphs in such Section and references in this
Agreement to any subsection shall include all paragraphs in such subsection. All references to days in this Agreement shall mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be
interpreted against either party, irrespective of which party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its interpretation. In
addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the parties regarding this Agreement shall be in the English language. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.10</B> <B>Relationship between the Parties.</B> The parties&#146; relationship, as established by this Agreement, is solely that of
independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the parties. Neither party is a legal representative of the other party, and neither party may assume or create any
obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.11</B> <B>No Third Party Rights.</B> The provisions of this Agreement are for the exclusive benefit of the parties, and no other person
or entity shall have any right or claim against any party by reason of these provisions or be entitled to enforce any of these provisions against any party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.12</B> <B>Counterparts.</B> This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all
of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows.</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the parties have duly executed this Collaboration and License Agreement
as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>E<SMALL>QUILLIUM</SMALL>,&nbsp;I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>B<SMALL>IOCON</SMALL>&nbsp;SA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:<U>&nbsp;&nbsp;/s/ Daniel M.
Bradbury&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:<U>&nbsp;&nbsp;Daniel M.
Bradbury&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:<U>&nbsp;&nbsp;President&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:<U>&nbsp;&nbsp;/s/ Raman
S.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:<U>&nbsp;&nbsp;Raman
S.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:<U>&nbsp;&nbsp;Authorized
Signatory&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>B<SMALL>IOCON</SMALL> P<SMALL>ATENTS</SMALL> <SMALL>AS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> E<SMALL>FFECTIVE</SMALL>
D<SMALL>ATE</SMALL> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>PCT&nbsp;Pub.&nbsp;No./First&nbsp;Pub.&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Expected&nbsp;Exp. date</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">NP entered</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">US-Granted</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">EP-granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 Dec 2027</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NP entered</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">US, EP-Pending</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">26 Dec 2027</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NP entered</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">US-Granted</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EP-Pending</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">14 Mar 2028</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NP entered</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">US, EP-Pending</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">19 Nov 2030</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NP entered in</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jan 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">23 Jul 2034</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>B<SMALL>IOCON</SMALL> T<SMALL>ERRITORY</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>A. Europe </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Albania, Andorra, Austria, Belgium, <FONT
STYLE="white-space:nowrap">Bosnia-Herzegovina,</FONT> Bulgaria, Croatia, Czech Republic, Cyprus, Denmark, Estonia Finland, France, Germany, Greece, Hungary Iceland, Ireland, Italy, Latvia, Liechtenstein Lithuania, Luxembourg, Macedonia, Malta,
Moldova, Monaco, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia and Montenegro (Former Yugoslavia), Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom, Vatican City. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>B. Australasia </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Afghanistan, Armenia, Australia,
Azerbaijan, Bangladesh, Bhutan, Georgia, India, Japan, South Korea, Kyrgyzstan, Nepal, New Zealand, Pakistan, Sri Lanka, Tajikistan, Turkmenistan, Uzbekistan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>C. Arabic/Middle East Countries </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bahrain, Egypt,
Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Saudi Arabia, Syria, Tunisia, United Arab Emirates, Yemen, Sudan, Mauritania, Comoros. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>D. Africa </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benin, Botswana, Burundi, Cameroon,
Central African Republic, Chad, Congo, Cote d&#146;lvoire, Djibouti, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritius, Niger, Nigeria, Rwanda, Senegal, Seychelles, Sierra Leone,
Somalia, Swaziland, Tanzania, Togo, Uganda, Western Sahara, Zambia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>12
<FILENAME>d582934dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><I>Confidential</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"><I></I><I></I><I></I><I></I><U>EXECUTION VERSION</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">***Certain confidential information</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">contained in this document, marked by</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">brackets, has been omitted and filed</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">separately with the Securities and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exchange Commission pursuant to Rule</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">406&nbsp;of&nbsp;the&nbsp;Securities&nbsp;Act&nbsp;of&nbsp;1933,&nbsp;as&nbsp;amended.</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CLINICAL SUPPLY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> C<SMALL>LINICAL</SMALL> S<SMALL>UPPLY</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the
<B><I>&#147;Agreement&#148;</I></B>) is entered into effective as of May&nbsp;22, 2017 (the <B><I>&#147;Effective Date&#148;</I></B>), by and between<B> E<SMALL>QUILLIUM</SMALL>,</B><B></B><B>&nbsp;I<SMALL>NC</SMALL>.</B>, a corporation organized
under the laws of the State of Delaware, USA, with its principal office at 2223&nbsp;Avenida de la Playa, Suite&nbsp;108, La Jolla, California 92037, USA (<B><I>&#147;Equillium&#148;</I></B>), and
<B>B<SMALL>IOCON</SMALL></B><SMALL><B></B><B></B></SMALL><B>&nbsp;SA</B>, a company organized under the laws of Switzerland with its principal place of business at c/o BDO SA, Rue De l&#146;Avenir 2, 2800 Delemont, Switzerland
(<B><I>&#147;Biocon&#148;</I></B>). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL><B></B></SMALL><B>,</B> Biocon and Equillium are parties to that certain Collaboration and License
Agreement dated as of the Effective Date (the <B><I>&#147;License Agreement&#148;</I></B>), pursuant to which Biocon granted Equillium an exclusive license to develop and commercialize Products in the Field in the Equillium Territory (all as defined
in the License Agreement); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> pursuant to Section&nbsp;4.2(b) of the License Agreement, Biocon has agreed
to supply Clinical Material (as defined in the License Agreement) to Equillium for use in the development of Products in accordance with the terms of the License Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL> T<SMALL>HEREFORE</SMALL></B><SMALL><B></B></SMALL><B>,</B> in consideration of the foregoing premises and the mutual
covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Equillium and Biocon hereby agree as follows: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following capitalized terms used but not defined in this Agreement shall have the meanings set forth in the License Agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting&nbsp;Standards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">IND</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affiliate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Information</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Applicable Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Invention</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ITO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CMC Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">IV</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Control or Controlled by</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NDA</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Product</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Data</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Regulatory Approval</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Regulatory Authority</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Regulatory Filing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First US Approval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ICH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Third Party</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, for the purposes of this Agreement, the following terms shall have the following meanings: </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>&#147;Batch&#148;</B> shall mean a defined quantity of Clinical Material that is intended to be of uniform character and quality
within specified limits and that is manufactured in a single production run in the same cycle of manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B>&#147;Batch
Records&#148;</B> shall mean, with respect to a particular production run conducted by Biocon for the Manufacture of a single Batch of Clinical Material, the completed batch records, in the form of the Master Batch Records, documenting the details
of, and other information associated with, such production run, including any deviations, in accordance with GMP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B>
<B>&#147;Certificate of Analysis&#148;</B> shall mean a document signed by an authorized representative of Biocon, describing the applicable Specifications for, and testing methods applied to, a Batch of Clinical Material and the results of such
testing, and confirming that such Batch conforms to the applicable Specifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> &#147;<B>Certificate of
Compliance</B>&#148; shall mean a document, signed by an authorized representative of Biocon, attesting that a particular Batch of Clinical Material was Manufactured in accordance with GMP, the applicable Manufacturing Process for such Clinical
Material and Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B> <B>&#147;Clinical Material&#148;</B> shall mean finished, labeled Product (or matched placebo
and/or comparator drug, as applicable) suitable for use in human clinical trials, as further described on <B>Exhibit</B><B></B><B>&nbsp;A</B> attached hereto, as amended from time to time to include all future IV and SC formulations thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B> <B>&#147;Clinical Material Warranty&#148;</B> shall have the meaning set forth in Section&nbsp;8.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B> <B>&#147;</B><B>CMC Data</B><B>&#148;</B> shall mean all chemistry, manufacturing and controls information related to Clinical
Material, ITO or Product that is required to be included in Equillium&#146;s Regulatory Filings for such Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B>
<B>&#147;Facility&#148;</B> shall mean the facility or facilities at which Biocon or its Affiliate performs its Manufacturing obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B> <B>&#147;GMP&#148;</B> shall mean the then-current good manufacturing practices as described in: (a)&nbsp;relevant United States
regulations in Title 21 of the United States Code of Federal Regulations (including Parts&nbsp;11, 210, 211, 600 and 610) and all applicable rules, regulations and orders thereunder; (b)&nbsp;Division&nbsp;2 of Part&nbsp;C of the <I>Food and Drug
Regulations</I> (Canada) and all applicable rules, regulations and orders thereunder; (c)&nbsp;International Conference on Harmonization (ICH) ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients; and (d)&nbsp;current FDA,
Health Canada and other mutually-agreed guidance documents pertaining to manufacturing and quality control practice; in each case, as updated, amended and revised from time to time and as interpreted by relevant ICH guidelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B> <B>&#147;Health Canada&#148;</B> shall mean the section of the Canadian Government known as Health Canada, which includes, among
other departments, the Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate or any successor agency thereto which may regulate pharmaceutical products in Canada. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B> <B>&#147;ICH&#148;</B> shall mean the International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B> <B>&#147;Latent Defect&#148;</B> shall mean a defect that causes Clinical Material to fail to
conform to the Clinical Material Warranty, which defect is not discoverable upon reasonable physical inspection and testing performed pursuant to Article&nbsp;7 but is discovered at a later time (<I>e.g.</I>, in the course of long-term stability
studies or during clinical use). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B> <B>&#147;Manufacture&#148;</B> and <B>&#147;Manufacturing&#148;</B> shall mean any steps,
processes and activities necessary to produce Clinical Material, including, without limitation, the manufacturing, processing, formulation, handling, labeling, packaging, inspection, quality control testing, release and storage of Clinical Material.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B> <B>&#147;Manufacturing Process&#148;</B> shall mean any and all processes (or any step in any process) used or planned to be
used by Biocon to Manufacture Clinical Material, as evidenced in the Master Batch Record. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B> <B>&#147;Manufacturing
SOPs&#148;</B> shall mean the specific methods, techniques, processes and standard operating procedures that are to be used by Biocon in Manufacturing Clinical Material under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B> <B>&#147;Master Batch Records&#148;</B> shall mean the electronic or paper template document approved in writing by both parties
that contains the complete set of formal instructions for the Manufacture of Clinical Material to be used by Biocon hereunder (including the applicable Manufacturing SOPs, descriptions of Materials, the Manufacturing Process, <FONT
STYLE="white-space:nowrap">in-process</FONT> testing specifications, Specifications and packaging, storage and shipping specifications) and meets the requirements of GMP, as such document may be amended from time to time in accordance with the
Quality Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B> <B>&#147;Materials&#148;</B> shall mean starting materials, solvents, reagents, catalysts, components,
Excipients, ITO, other ingredients and packaging and labelling materials used in the Manufacture of Clinical Material in accordance with the Specifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B> <B>&#147;Quality Agreement&#148;</B> shall mean a written quality agreement entered into by the parties with respect to Clinical
Material to be supplied under this Agreement that defines the quality roles and responsibilities of each party in connection with the Manufacture of Clinical Material, as the same may be amended or modified from time to time by mutual written
agreement of the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B> <B>&#147;Specifications&#148;</B> shall mean, with respect to Clinical Material, the written
specifications and quality standards, including tests, analytical procedures and acceptance criteria, that establish the set of criteria to which such Clinical Material should conform to be considered acceptable for its intended use, as initially
agreed upon and set forth in the Quality Agreement and as amended from time to time by written agreement of the parties in accordance with the procedures set forth in the Quality Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B> <B>&#147;Term&#148;</B> shall have the meaning provided in Section&nbsp;11.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>UPPLY</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Supply Agreement.</B> Subject to the terms and conditions of this Agreement, during the Term, Biocon agrees to Manufacture and
supply to Equillium such quantities of Clinical Material as may be set forth on purchase orders placed by Equillium in accordance with the provisions of Section&nbsp;2.3, and Equillium agrees that Biocon shall be Equillium&#146;s exclusive supplier
for the Product, including Clinical Material, for the Equillium Territory. Equillium shall use all Clinical Material supplied under this Agreement solely to conduct development in the Field in the Equillium Territory (and, solely to the extent
permitted by the License Agreement, in the Biocon Territory) in accordance with the terms of the License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B>
<B>Forecasts.</B> No later than [<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>&#133;***&#133;] before the first day of the first calendar quarter in which Equillium in good faith anticipates it will first require Clinical Material
(<B><I>&#147;</I></B><B><I>Initial Quarter</I></B><B><I>&#148;</I></B>), Equillium shall provide Biocon with an initial written forecast of its requirements of Clinical Material for the [&#133;***&#133;]-calendar quarter periods beginning on the
first day of the Initial Quarter (the <B><I>&#147;</I></B><B><I>Initial Forecast</I></B><B><I>&#148;</I></B>). On or before the first day of each calendar quarter after delivery of the Initial Forecast during the Term, Equillium shall provide Biocon
an updated rolling, forecast of the quantities of Clinical Material that Equillium expects to order during each calendar quarter of the subsequent [&#133;***&#133;]-calendar quarter periods commencing with the calendar quarter in which such forecast
is provided (each, a <B><I>&#147;</I></B><B><I>Forecast</I></B><B><I>&#148;</I></B>). Such Forecasts (including the Initial Forecast) represent Equillium&#146;s reasonable estimates of the quantity of Clinical Material it may require during the
applicable [&#133;***&#133;]-calendar quarter period. Such Forecasts (including the Initial Forecast) are provided for the convenience of Biocon only and shall not constitute commitments by Equillium to purchase any quantity of Clinical Material;
<I>provided, however,</I> that, Equillium shall place binding purchase orders for at least the quantity of Clinical Material specified in the first [&#133;***&#133;] calendar quarter periods of each Forecast, including the Initial Forecast (such
specified quantity, the <B><I>&#147;</I></B><B><I>Binding Forecast</I></B><B><I>&#148;</I></B>); it being understood and agreed that, once a calendar quarter period is included in any Binding Forecast, that forecasted amount for such calendar
quarter period may not be changed in any subsequent Binding Forecast submitted to Biocon. Each Forecast shall therefore add an additional binding calendar quarter period, but not revise the preceding binding calendar quarter periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Ordering.</B> To order Clinical Material, Equillium shall provide Biocon with a written purchase order specifying the quantities
of Clinical Material (Product, matched placebo and/or comparator drug) ordered, the requested delivery date, the delivery destination and the price (if any) to be paid for such Clinical Material. In any such purchase order, the delivery date
requested by Equillium must be at least [&#133;***&#133;] after the date the purchase order is submitted to Biocon. Within [&#133;***&#133;] after its receipt of a particular purchase order placed by Equillium pursuant to this Section&nbsp;2.3,
Biocon shall acknowledge the receipt of, and accept in writing, such purchase order by providing a written confirmation to Equillium. If no such confirmation is received within such [&#133;***&#133;] period, then Biocon shall be deemed to have
acknowledged and accepted such purchase order. Biocon shall not be obligated to accept any purchase orders placed by Equillium pursuant to this Section&nbsp;2.3 for more than [&#133;***&#133;]% of the applicable forecasted amount of Clinical
Materials. Any purchase orders for Clinical Material submitted by Equillium shall reference this Agreement and shall be governed exclusively by the terms contained herein and in the License Agreement. Any terms or conditions contained in a purchase
order or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">acceptance that are inconsistent or in conflict with this Agreement or the License Agreement shall be deemed not to be a part of such purchase order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>Shortfalls and Allocation of Supply.</B> If Biocon is, or anticipates that it will be, unable to supply to Equillium, in whole
or in part, Equillium&#146;s forecasted requirements of Clinical Material on a timely basis due to a shortage of production capacity, shortage of raw materials, or any other reason, Biocon shall promptly notify Equillium in writing of such shortage
of production capacity or production problem or other reason, within [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;], and if possible, the date such shortage or production problem is expected to end. The parties will discuss
the matter in the JSC and shall use good faith efforts to achieve an equitable solution with the least impact on both parties&#146; ability to clinically develop Product in their respective territories. Biocon shall use Commercially Reasonable
Efforts to remedy any shortfall of Clinical Material as soon as practicable, and Biocon shall allocate its available production capacity for the production of Clinical Material in a manner proportional to the parties&#146; respective percentages of
the combined Clinical Material requirements of the parties represented by Equillium&#146;s forecasted requirements of Clinical Material for use in clinical trials conducted by or on behalf of Equillium and Biocon&#146;s forecasted requirements of
Clinical Material for use in clinical trials conducted by or on behalf of Biocon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B>Second Site/Source.</B> Biocon shall have
the right to use the services of its Affiliates and Third Party contractors, including CMOs, to assist such Biocon in fulfilling its obligations and exercising its rights under this Agreement; <I>provided</I> that (i)&nbsp;the JSC approves any
contractor in advance; (ii)&nbsp;none of Equillium&#146;s rights under this Agreement or the License Agreement are diminished or otherwise adversely affected as a result of Biocon&#146;s use of Affiliates or contractors; and (iii)&nbsp;the
contractor or Affiliate has entered into a written agreement with Biocon binding such Person to the obligations Biocon has to Equillium, including obligations of intellectual property assignment and confidentiality and
<FONT STYLE="white-space:nowrap">non-use,</FONT> and containing any other provisions normal and customary for similar types of agreements consistent with this Agreement and the License Agreement; and <I>provided, further,</I> that Biocon shall at
all times be responsible for the satisfactory accomplishment of its obligations under and in accordance with, and the contractor&#146;s or Affiliate&#146;s compliance with, the terms and conditions of this Agreement and the License Agreement.
Without prejudice to the generality of the foregoing, in the event Biocon is unable to meet Equillium&#146;s orders submitted in accordance with this Agreement for more than [&#133;***&#133;] consecutive calendar quarter periods (a &#147;<B>Failure
to Supply</B>&#148;), the JSC (or a manufacturing subcommittee thereof) will evaluate alternative approaches to source the shortfall in supply, which may include, without limitation, Biocon&#146;s performance of a manufacturing technology transfer
(the reasonable costs of such technology transfer to be borne by Biocon) to a CMO identified by the JSC and appointed by the JSC with Biocon&#146;s prior written consent, such consent not to be unreasonably withheld, to permit such CMO to
manufacture ITO and Product, using the manufacturing process developed and used by Biocon, for use and distribution in the Field in the Equillium Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B> <B>Right of </B><B>Biocon</B><B> to Resume Manufacturing.</B> Following a Failure to Supply and the enabling of a CMO as a
secondary source of supply pursuant to Section&nbsp;2.5, should Biocon provide Equillium with a commercially reasonable proposal and evidence that it is ready, willing and able, directly or through subcontractors, to resume its supply obligations
hereunder, the Parties will work together in good faith to develop and mutually agree upon a transition plan that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">achieves the following objectives: (i)&nbsp;minimizes disruption to the continued manufacture and supply of the Clinical Material; (ii)&nbsp;enables Biocon to
resume operation of its facility(ies) as the primary source of Clinical Material as soon as reasonably practicable; and (iii)&nbsp;maintains on an ongoing basis the Third Party facility established following a Failure to Supply and the enabling of a
CMO to provide a secondary source of supply of Clinical Material pursuant to Section Section&nbsp;2.5. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ANUFACTURING</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Manufacture of Clinical Material.</B> Biocon shall Manufacture Clinical Material ordered by Equillium in compliance with GMP and
all other Applicable Laws. Biocon shall maintain and follow a quality control and testing program to confirm that all Clinical Material supplied hereunder conforms to the Specifications and is manufactured in accordance with GMP and all Applicable
Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Materials and Equipment.</B> Biocon shall be responsible for procuring [&#133;***&#133;] all Materials and resources
needed for the Manufacture of Clinical Material ordered under this Agreement, including all Materials and resources needed for manufacturing all ITO needed to Manufacture such Clinical Material. Biocon shall use only qualified vendors for purchase
of Materials and consumables as specified in the Quality Agreement and as per&nbsp;Biocon quality systems. Biocon shall be responsible for procuring [&#133;***&#133;] all equipment, personnel and other resources needed for the Manufacture of
Clinical Material ordered under this Agreement. Biocon shall be responsible for allocating appropriate space in the Facility, and for obtaining, installing and maintaining in such Facility all capital equipment, as needed to manufacture the
quantities of Clinical Material ordered by Equillium in accordance with the terms of this Agreement. Biocon shall allocate sufficient time, effort, equipment and facilities to the Manufacture of Clinical Material, and shall dedicate and use
personnel with sufficient skills and experience as are required to accomplish the Manufacturing tasks, so as to Manufacture and deliver Clinical Material on a timely basis and in accordance with the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Facility.</B> Clinical Material shall be manufactured only at a Facility that has been previously designated to Equillium in
writing. Subject to Section&nbsp;5.4, any planned change in the Facility shall be made following at least [&#133;***&#133;] prior written notice to Equillium, and any unanticipated change in a Facility shall be made following verbal notification to
Equillium and an agreement in writing on the timeline for implementing the change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Facility Licenses.</B> Biocon shall
obtain and maintain for the Facility, [&#133;***&#133;], all permits, licenses and approvals (including facilities licenses) needed for Biocon to be able to Manufacture and supply all Clinical Material in compliance with GMP and all Applicable Laws
(the <B><I>&#147;Facilities Licenses&#148;</I></B>), in a timely manner such that Biocon is able to meet is Manufacturing and supply obligations under this Agreement. Biocon shall keep Equillium regularly informed about the status of all such
Facilities Licenses and shall provide Equillium copies thereof upon request. Biocon shall use commercially reasonable efforts to resolve as soon as possible any issues that arise in its seeking or maintaining Facilities Licenses, including
completely addressing and rectifying any deviations or other issues raised in any warning letter from the FDA or any similar warning or objection by any Regulatory Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Q<SMALL>UALITY</SMALL> C<SMALL>ONTROL</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Quality Agreement.</B> No later than September&nbsp;30, 2017, the parties shall negotiate in good faith and enter into the
Quality Agreement on commercially reasonable and customary terms. In the event of any conflict between the terms of the Quality Agreement and the terms of this Agreement, the terms of the Quality Agreement shall control with respect to quality
control or quality assurance matters, and this Agreement shall control with respect to all other matters. Any breach of the Quality Agreement shall be deemed to be a breach of this Agreement, including, without limitation, with respect to indemnity
and other remedies hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Specifications; Testing</B>. All Clinical Material supplied hereunder shall conform to the
Specifications, and Biocon shall verify such conformity in accordance with the testing standards and procedures specified in the Quality Agreement. Biocon will test each Batch of Clinical Material to be delivered hereunder and supply Equillium with
a Certificate of Analysis and a Certificate of Compliance. Equillium shall have the right to rely upon the Certificate of Analysis and the Certificate of Compliance provided by Biocon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Samples.</B> Biocon shall retain samples of ITO and Clinical Material and isolated intermediates for each Batch of Clinical
Material for a period of [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] (or, if longer, the minimum period required by Applicable Laws) after Equillium&#146;s acceptance of such Batch. The sample size shall be twice the size
necessary to conduct quality control testing. Upon Equillium&#146;s written request, Biocon shall provide Equillium with up to <FONT STYLE="white-space:nowrap">one-half</FONT> (1/2) the original amount of the retained samples. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4 Documentation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Manufacturing Records.</B> Biocon shall keep complete, accurate and authentic accounts, notes, data and records pertaining to
the Manufacture, processing, testing, storage, and distribution of Clinical Material and of the work performed under this Agreement, including, without limitation, all quality control documentation and the Master Batch Records, for the longer of
(i)&nbsp;a period of [&#133;***&#133;] after delivery of such Clinical Material to Equillium or (ii)&nbsp;the period of time required by Applicable Law. Biocon shall make available to Equillium copies of such records and shall permit Equillium to
inspect the originals of such records as maintained by Biocon, on reasonable notice. After the time period set forth in this Section&nbsp;4.4(a), Biocon shall notify Equillium prior to the destruction of any records retained under this
Section&nbsp;4.4(a) and, at Equillium&#146;s request and expense, shall transfer such records to Equillium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Lot
Documentation.</B> Biocon shall make arrangements for, and shall implement, the imprinting of lot numbers for Clinical Material shipped hereunder. Such lot numbers shall be affixed on Clinical Material containers and on the shipping cartons of
Clinical Material as required by Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> <B>Inspections by Equillium.</B> Biocon shall permit Equillium to inspect,
as reasonably needed, that portion of the Facility where Clinical Material is Manufactured or stored and review such Clinical Material documents as is reasonably necessary for the purpose of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">assessing Biocon&#146;s compliance with GMP, the Specifications, and all Applicable Laws. Such inspection and document review shall be conducted upon
reasonable prior written notice by Equillium (except in the event of a reasonable, urgent concern by Equillium regarding the quality of Clinical Material, in which case Equillium may conduct the inspection as soon as practicable), at a time and date
mutually agreeable to the parties and in accordance with the Quality Agreement. In addition, Equillium shall have the right to have an employee or agent present at the Facility during the preparation for or conduct of any Manufacturing run for a
Batch of Clinical Material, and such employee or agent shall be free to inspect and oversee all aspects of such preparation or Manufacturing run and to comment to Biocon thereupon. Biocon shall provide such Equillium employee or agent a suitable
office equipped with a phone line and high-speed internet connection and other standard office equipment and supplies as needed, for use by such employee or agent in conducting the inspection and oversight activities during such production run. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>EGULATORY</SMALL> M<SMALL>ATTERS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Information for Regulatory Applications.</B> Upon Equillium&#146;s written request, Biocon shall provide to Equillium copies of
the complete Master Batch Records and specific Manufacturing SOPs and updates as defined in the Quality Agreement, copies of the relevant documents identifying any Biocon technology used in the Manufacture of Clinical Material under the
Manufacturing SOPs, and all CMC Data. Equillium has the right to review and copy the executed, completed Batch Records for each Batch, as needed for Equillium to prepare the Chemistry, Manufacturing and Controls (CMC) sections for any Regulatory
Filing that Equillium (or its Affiliate or Sublicensee) intends to file or for any other appropriate regulatory purpose relating to ITO or Product. All such Information shall be provided in English. Biocon shall prepare and maintain the Batch
Records for each Batch of Clinical Material Manufactured hereunder, and shall provide Equillium access to such Batch Records for review and inspection, and shall provide copies thereof to Equillium, at Equillium&#146;s expense for actual <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> copying costs, if so requested by Equillium. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Regulatory Assistance.</B> Without limiting Section&nbsp;5.1, with respect to any application, registration or filings
reasonably needed by Equillium (or its Affiliate or Sublicensee) to obtain or maintain Regulatory Approvals for any Product, and any record-keeping, audits, inspections and audits required by Regulatory Authorities relating to the Manufacture and/or
supply of Clinical Material by Biocon hereunder, Biocon shall reasonably cooperate with and assist Equillium in all such matters, including providing any additional information needed for such applications, filings or activities and any additional
support relating to Clinical Material as reasonably requested by Equillium (or its Affiliate or Sublicensee), and Equillium shall reimburse Biocon for any actual
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of providing such Information and assistance, in amounts to be agreed prior to the services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3 Regulatory Inspections. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Inspection by Regulatory Authorities.</B> Upon the request of any Regulatory Authority having jurisdiction over the Manufacture
of Clinical Material hereunder, Biocon shall provide such Regulatory Authority with access to observe and inspect Biocon&#146;s facilities and procedures used for the Manufacture, release and stability testing, and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">warehousing of all Clinical Material and to audit such facilities for compliance with GMP and/or other Applicable Laws. Biocon specifically agrees to cooperate
with any inspection by a Regulatory Authority, whether prior to or after Regulatory Approval of a Product, and to provide Equillium a copy of any inspection or audit report resulting from any such inspection. If Biocon is purchasing raw materials
from a Third Party manufacturer for use in manufacturing Clinical Material, Biocon shall use commercially reasonable diligent efforts to ensure that such manufacturer&#146;s facilities and procedures are similarly subject to the provisions of this
Section&nbsp;5.3(a) as to the manufacture of such raw materials, and to ensure that Equillium is provided copies of any inspection or audit report of such Third Party relating to such raw materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Notification of Inspections.</B> Biocon agrees to notify Equillium within
[<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] of any written or oral inquiries, notifications or inspection activity by any Regulatory Authority in regard to Clinical Material supplied or to be supplied to Equillium
hereunder. Biocon shall provide a reasonable description of any such governmental inquiries, notifications or inspections promptly, but in no event later than [&#133;***&#133;] after such notification, inquiry or inspection. Biocon shall furnish to
Equillium (i)&nbsp;within [&#133;***&#133;] after receipt, any report or correspondence issued by any Regulatory Authority in connection with such notification, inquiry or inspection, including any FDA Form&nbsp;483 (List of Inspectional
Observations) or applicable portions of any FDA warning letters (or any equivalent in another country or jurisdiction) which pertain to ITO or Product, and (ii)&nbsp;not later than [&#133;***&#133;] prior to the time it provides to any Regulatory
Authority (unless any such response is due to such Regulatory Authority within [&#133;***&#133;], in which case Biocon shall furnish to Equillium as soon as reasonably practical, but in any event within [&#133;***&#133;] prior to the time it
provides to any Regulatory Authority), copies of proposed responses or explanations relating to items set forth above (each, a &#147;<B><I>Proposed Response</I></B>&#148;), in each case redacted of trade secrets or other confidential or proprietary
information of Biocon that is unrelated to the obligations under this Agreement and is unrelated to Clinical Material or its Manufacture. Biocon shall discuss with Equillium and consider in good faith any comments provided by Equillium on the
Proposed Response. Biocon shall provide a copy of the final response submitted to the FDA or other Regulatory Authority no later than [&#133;***&#133;] after filing. After the filing of a response with the FDA or other Regulatory Authority, Biocon
shall notify Equillium of any further contacts with such Regulatory Authority relating to the subject matter of the response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Remedial Actions.</B> Biocon shall notify Equillium immediately in writing in the event any action is taken or threatened by a Regulatory Authority relating to the Manufacture of Clinical Material by or on behalf of Biocon or any of its
Affiliates, or relating to the Facility in which such Manufacture occurs, or which may impair the ability of Biocon to Manufacture and supply Clinical Material (including, without limitation, any impairment to Biocon&#146;s ability to Manufacture
and supply Clinical Material conforming to the applicable Specifications) in accordance with this Agreement. In any event, Biocon shall use commercially reasonable efforts to address and resolve as soon as possible any issues, concerns or warnings
from any Regulatory Authority that might affect Biocon&#146;s ability to Manufacture and supply Clinical Material in accordance with this Agreement. To the extent Biocon must implement a plan of remediation or other modifications or changes to its
Facility or its manufacturing processes, as may be mutually agreed, in order to address and resolve any such issues, concerns or warnings from any Regulatory Authority, Biocon shall prepare such plan as soon as possible, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shall provide a draft of the plan to Equillium for review and comment, and shall implement all reasonable comments of Equillium as soon as possible, and shall
implement and complete all aspects of the agreed plan as soon as possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <B>Changes in Manufacturing Process.</B> Biocon
shall not change or modify any of the Specifications or Manufacturing SOPs, or otherwise make any change in the facilities, materials, equipment, processes or procedures used to Manufacture Clinical Material that would require a filing with a
Regulatory Authority and/or that would reasonably be expected to affect Biocon&#146;s ability to Manufacture and supply the Clinical Material in accordance with the Specifications and the terms of this Agreement, without Equillium&#146;s prior
written approval. No changes to the Specifications, the Manufacturing SOPs or the Master Batch Records shall be made except in accordance with the change control procedures of the Quality Agreement. Biocon shall disclose all proposed changes in such
Specifications, manufacturing and testing materials, equipment, processes or procedures to Equillium at a level that would be sufficient to allow Equillium to understand such changes and comply with Applicable Laws. If Equillium agrees to allow any
such change requiring Equillium&#146;s approval to be implemented, then the parties shall revise Manufacturing SOPs and the relevant Specifications in writing accordingly, if applicable, in compliance with the requirements of the Quality Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B> <B>Labels and Packaging Materials.</B> Biocon shall provide all labels and packaging materials for, and shall perform, all
packaging and labeling of Clinical Material; <I>provided, however</I>, that Equillium shall be responsible for providing and determining the content of such labels and Equillium shall have the right to approve the final content of such labels. All
labels and packaging materials and use thereof with Clinical Material shall be in accordance with the Specifications. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>RICES</SMALL>, I<SMALL>NVOICING</SMALL> <SMALL>AND</SMALL> P<SMALL>AYMENT</SMALL>
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1 Supply Prices. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Orphan Indications Prior to First US Approval.</B> Prior to First US Approval, Biocon shall supply to Equillium sufficient
quantities of Clinical Material for use in the conduct of clinical trials of Product in three (3)&nbsp;Orphan Indications at no cost to Equillium. For clarity, if Equillium discontinues clinical development of Product in a particular Orphan
Indication and instead pursues clinical development of Product in a different Orphan Indication prior to First US Approval, Biocon shall remain obligated to supply Clinical Material at no cost to Equillium pursuant to this Section&nbsp;6.1(a) for
such replacement Orphan Indication, provided that at no time will Biocon be obligated to supply Clinical Material pursuant to this Section&nbsp;6.1(a) for use in clinical trials of Product for more than three (3)&nbsp;Orphan Indications at any given
time, and if Equillium wishes to obtain Clinical Material for use in clinical trials of Product for a fourth or additional concurrently-developed Orphan Indication prior to First US Approval, such Clinical Material shall be supplied at the price set
forth in Section&nbsp;6.1(b); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Orphan Indications After First US Approval.</B> After First US Approval, Biocon shall supply
to Equillium sufficient quantities of Clinical Material for use in the conduct of clinical trials of Product for Orphan Indications in the Equillium Territory, at a price equal to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biocon&#146;s then-current Cost of Goods of such Clinical Material, without <FONT STYLE="white-space:nowrap">mark-up</FONT> or profit margin;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Other Indications.</B> Biocon shall supply to Equillium sufficient quantities of Clinical Material for use in the
conduct of clinical trials of Product for Indications other than Orphan Indications at a price equal to Biocon&#146;s then-current Cost of Goods, without <FONT STYLE="white-space:nowrap">mark-up</FONT> or profit margin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2 Cost of Goods. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Initial Cost of Goods Estimate.</B> Within [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] after
Biocon&#146;s receipt of the Initial Forecast, Biocon will provide to Equillium in writing Biocon&#146;s good faith estimate of the anticipated Cost of Goods of Clinical Material (including a detailed description of the assumptions upon which such
estimate is based) for the period from the first day of the first month of the Initial Forecast for which Equillium expects to require Clinical Material until either (i)&nbsp;if at least two full quarters remain in the calendar year in which the
Initial Forecast is delivered, the end of such calendar year, or (ii)&nbsp;if less than two full quarters remain in the calendar year in which the Initial Forecast is delivered, the end of the immediately following calendar year (as applicable, the
<B><I>&#147;</I></B><B><I>Initial Supply Period</I></B><B><I>&#148;</I></B>). The JSC shall meet to discuss such Cost of Goods estimate and any questions or concerns Equillium may have regarding such estimate and cooperate in good faith to arrive at
a mutually acceptable Cost of Goods estimate for Clinical Material for the Initial Supply Period within [&#133;***&#133;] after Equillium&#146;s receipt of such Cost of Goods estimate from Biocon. Such mutually acceptable Cost of Goods estimate
shall be used to calculate the initial supply price(s) of any quantity(ies) of Clinical Material for which Biocon is obligated to make payment (<I>i.e.</I>, quantities of Clinical Material other than those to be supplied at no cost to Equillium
pursuant to Section&nbsp;6.1(a)) during the Initial Supply Period (the <B><I>&#147;</I></B><B><I>Initial Supply Price(s)</I></B><B><I>&#148;</I></B>). Thereafter, the Supply Price(s) of each Clinical Material shall be recalculated, and appropriate
adjustments made, in accordance with Section&nbsp;6.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Recalculation of Cost of Goods. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> As promptly as practicable, and in any event within [&#133;***&#133;], after December&nbsp;31 of the last calendar year of the
Initial Supply Period, Biocon shall calculate and disclose to Equillium in writing the actual <FONT STYLE="white-space:nowrap">per-unit</FONT> Cost of Goods of all Clinical Material (whether supplied on the terms set forth in Section&nbsp;6.1(a),
6.1(b) or 6.1(c)) supplied to Equillium during the Initial Supply Period (the <B><I>&#147;Initial Actual Cost of Goods&#148;</I></B>). The JSC shall promptly meet to discuss the Initial Actual Cost of Goods. If the aggregate Initial Supply Price(s)
paid by Equillium for all Clinical Material supplied by Biocon to Equillium on the terms set forth in Section&nbsp;6.1(b) and/or 6.1(c) during the Initial Supply Period is [&#133;***&#133;] than the amount that would have been payable had the supply
price(s) of such Clinical Material been calculated using the Initial Actual Cost of Goods, then [&#133;***&#133;]. If the aggregate Initial Supply Price(s) paid by Equillium for all Clinical Material supplied by Biocon to Equillium on the terms set
forth in Section&nbsp;6.1(b) and/or 6.1(c) during the Initial Supply Period [&#133;***&#133;] the amount that would have been payable had the supply price(s) of such Clinical Material been calculated using the Initial Actual Cost of Goods, then
[&#133;***&#133;]. The initial supply price of Clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Material supplied pursuant to Section&nbsp;6.1(b) and/or 6.1(c) for the following calendar year shall be calculated based on the Initial Actual Cost of Goods.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> As promptly as practicable, and in any event within [<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>&#133;***&#133;],
after December&nbsp;31 of each subsequent calendar year during the Term, Biocon shall calculate and disclose to Equillium in writing the actual <FONT STYLE="white-space:nowrap">per-unit</FONT> Cost of Goods of all Clinical Material (whether supplied
on the terms set forth in Section&nbsp;6.1(a), 6.1(b) or 6.1(c)) for such calendar year (the <B><I>&#147;Prior-Year Cost of Goods&#148;</I></B>). The JSC will meet to discuss the Prior-Year Cost of Goods. If the aggregate initial supply price paid
by Equillium for all Clinical Material supplied by Biocon to Equillium on the terms set forth in Section&nbsp;6.1(b) and/or 6.1(c) during the Prior Pricing Period is [&#133;***&#133;] than the amount that would have been payable had the supply
price(s) of such Clinical Material been calculated using the Prior-Year Cost of Goods, then [&#133;***&#133;]. If the aggregate initial supply price paid by Equillium for all Clinical Material supplied by Biocon to Equillium on the terms set forth
in Section&nbsp;6.1(b) and/or 6.1(c) during the Prior Pricing Period [&#133;***&#133;] the amount that would have been payable had the supply price(s) of such Clinical Material been calculated using the Prior-Year Cost of Goods, then
[&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B>Reduce Cost of Goods.</B> During the Term, Biocon shall use commercially reasonable efforts (a)&nbsp;to
implement process improvements and achieve other efficiencies that lower the Cost of Goods of Clinical Material Manufactured by Biocon or its Affiliates and (b)&nbsp;to include in its agreement with each Third Party contract manufacturer involved in
the Manufacture of Clinical Material reasonable provisions for supply price reductions in the case of process improvements or other efficiencies that lower such contract manufacturer&#146;s cost of manufacture, such that Equillium will receive a
corresponding benefit through reduction of Cost of Goods. Biocon shall aggregate quantities of Clinical Material ordered by Equillium hereunder with quantities of Clinical Material Manufactured for Biocon, its Affiliates or Third Party licensees for
their own development activities in the Biocon Territory as necessary to take advantage of preferential volume-based pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B>
<B>Method of Payment.</B> Biocon will invoice Equillium for each Batch of Clinical Material no earlier than the later of (a)&nbsp;the date of shipment of such Batch and (b)&nbsp;the delivery to Equillium of the required documentation with respect to
such Batch pursuant to Section&nbsp;7.1. Equillium shall pay each such invoice within [&#133;***&#133;] after the later of (i)&nbsp;Equillium&#146;s receipt of the applicable invoice and (ii)&nbsp;Equillium&#146;s receipt of such Batch and the
related documentation pursuant to Section&nbsp;7.1, unless such Batch is rejected in accordance with Section&nbsp;7.3(b). The supply price of Clinical Material supplied under this Agreement shall be stated in U.S. dollars, and all payments hereunder
shall be payable in U.S. dollars. When conversion of cost items included in the calculation of Cost of Goods from any foreign currency is required, such conversion shall be calculated at the rate of exchange for such currency used throughout the
accounting system of Biocon for financial reporting purposes for the applicable period. All payments hereunder shall be made by wire transfer in immediately available funds to the bank and account designated in writing by Biocon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5</B> <B>Taxes.</B> Equillium will pay any and all taxes (other than taxes based upon Biocon&#146;s income), duties, assessments and other
charges and expenses imposed by any government authority in connection with the delivery and sale of Clinical Material to Equillium. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6</B> <B>Audits.</B> Biocon shall keep (and shall cause its Affiliates to keep) complete and accurate records pertaining to the
Manufacture of Clinical Material in sufficient detail to permit Equillium to confirm the accuracy of all Cost of Goods and supply price determinations, for at least [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] following the
end of the calendar year to which they pertain. Equillium shall have the right, once annually, to cause an independent, certified public accountant of international standing and reasonably acceptable to Biocon to audit such records solely to confirm
Costs of Goods and supply price determinations for a period covering not more than the preceding [&#133;***&#133;]. No calendar year shall be subject to audit under this section more than once. Such audits may be exercised during normal business
hours upon at least [&#133;***&#133;] prior written notice to Biocon in the location where the records are maintained. The auditor will execute a reasonable written confidentiality agreement with Biocon and will disclose to Equillium only such
information as is reasonably necessary to provide Equillium with information regarding any actual or potential discrepancies between Cost of Goods reported and supply prices invoiced, on the one hand, and amounts paid or payable under this
Agreement. The auditor will send a copy of the report to Biocon at the same time it is sent to Equillium. The report sent to both parties will include the methodology and calculations used to determine the results. Prompt adjustments shall be made
by the parties to reflect the results of such audit. Equillium shall bear the full cost of such audit unless such audit discloses an overpayment by Equillium of more than [&#133;***&#133;]% of the amount due for any calendar year under this
Agreement, in which case, Biocon shall bear the full cost of such audit and Equillium shall deduct the amount of such overpayment from amounts otherwise owed to Biocon under this Agreement. If such audit discloses an underpayment by Equillium, then
Equillium will promptly remit the amount of such underpayment to Biocon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7</B> <B>Late Payments.</B> In the event that any payment
due under this Agreement is not made when due, the payment shall accrue interest at a rate per annum that is [&#133;***&#133;] (<I>i.e.</I>, [&#133;***&#133;] percentage points) above the then-current prime rate quoted by Citibank in New York City
for the period from the due date for payment until the date of actual payment; <I>provided, however,</I> that in no event shall such rate exceed the maximum legal annual interest rate. The payment of such interest shall not limit the party entitled
to payment from exercising any other rights it may have as a consequence of the lateness of any payment. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>ELIVERY</SMALL>; A<SMALL>CCEPTANCE</SMALL> <SMALL>AND</SMALL> R<SMALL>EJECTION</SMALL>;
R<SMALL>ECALLS</SMALL> </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B>Documentation on Delivery.</B> Each Batch (or portion of a Batch) of Clinical
Material delivered to Equillium hereunder shall be accompanied by (a)&nbsp;a copy of the Batch Records for such Batch, together with written confirmation that such Batch Records have been reviewed and approved by Biocon&#146;s quality assurance
unit, (b)&nbsp;a Certificate of Analysis and (c)&nbsp;a Certificate of Compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>Delivery.</B> Unless otherwise agreed by
the parties in writing, all shipments of Clinical Material shall be shipped FCA (Incoterms 2010) the Facility to the destination(s) specified by Equillium in the applicable purchase order. Biocon will package and ship Clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Material in accordance with Biocon&#146;s customary practices, unless otherwise specified by Equillium. Biocon will procure insurance, in an amount sufficient
to cover the value of the contents, for all shipments. All freight, handling, insurance, duties, taxes and shipping expense will be borne by Equillium. Biocon will use commercially reasonable efforts to comply with the requested delivery dates for
all Clinical Material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3 Acceptance and Rejection. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Defective Product.</B> Equillium may reject any Clinical Material delivered under this Agreement that does not conform to the
Clinical Material Warranty (a <B><I>&#147;</I></B><B><I>Defective Product</I></B><B><I>&#148;</I></B>) by giving written notice to Biocon within [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] after delivery. If Equillium does
not notify Biocon of its rejection of any Defective Product in a shipment of Clinical Material within such [&#133;***&#133;] period, Equillium will be deemed to have accepted the shipment of Clinical Material, <I>except </I>as otherwise provided
below with respect to any quantities of Clinical Material containing Latent Defects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Rejection.</B> In notifying Biocon of
Defective Product, Equillium shall identify in reasonable detail the nature of the defect. Biocon shall have a reasonable opportunity, not to exceed [&#133;***&#133;] from receipt of notification, to review any materials provided by Equillium to
substantiate the existence of Defective Product and to conduct its own tests of the Clinical Material. Biocon shall, at Equillium&#146;s election, either (i)&nbsp;promptly refund any sums actually paid for such Defective Product or (ii)&nbsp;replace
such Defective Product with Clinical Material conforming to the Clinical Material Warranty within [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Latent
Defects.</B> If any quantity of Clinical Material is found to contain a Latent Defect, such quantity will be considered Defective Product and Equillium may reject such Clinical Material or revoke its acceptance of such Clinical Material by notifying
Biocon of such rejection or revocation within [&#133;***&#133;] after the Latent Defect is discovered. Equillium may reject such quantity of Clinical Material containing such Latent Defect even if the Latent Defect is not discovered within the time
period set forth in Section&nbsp;7.3(a), subject to the terms provided in Section&nbsp;7.3(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Independent Testing.</B> If
Biocon reasonably disagrees with Equillium&#146;s determination that Clinical Material constitutes Defective Product, then a sample of the applicable Batch(es) of such Clinical Material to an independent Third Party testing service, mutually and
reasonably acceptable to both parties, for analytical testing to determine whether such Clinical Material constitutes Defective Product. The parties agree that such testing service&#146;s determination shall be final and determinative. The party
against whom the Third Party testing service rules shall bear all costs of the Third Party testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B>Recalls.</B> Equillium
shall be responsible for carrying out any recall that is required by a Regulatory Authority, and Biocon shall reasonably cooperate in such recall. Biocon shall be responsible for all costs and expense of any such recall to the extent resulting from
the supply of Defective Product or other breach of this Agreement by Biocon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B>Mutual Representations and Warranties.</B> Each party represents and warrants to the other that, as of the Effective Date:
(a)&nbsp;it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof; (b)&nbsp;it
is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action;
and (c)&nbsp;this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound (including,
with respect to Biocon, the [<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#133;***&#133;] Agreement), nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B>Clinical Material Warranty.</B> Biocon represents and warrants to Equillium that all Clinical Material supplied by Biocon
hereunder: (a)&nbsp;will have been Manufactured in compliance with GMP and other Applicable Laws and (b)&nbsp;will, at the time of delivery, conform to the Specifications then in effect (collectively, the <B><I>&#147;</I></B><B><I>Clinical Material
Warranty</I></B><B><I>&#148;</I></B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B>Biocon Covenants.</B> In addition to any covenants made by it elsewhere in this
Agreement, Biocon hereby covenants to Equillium that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> neither Biocon nor any of its Affiliates will employ or use the services
of any Person who is debarred under United States law, including 21 U.S.C. &#167;335a, or any foreign equivalent thereof, in connection with the Manufacture and supply of Clinical Material; and in the event that Biocon becomes aware of the debarment
or threatened debarment of any Person providing services to Biocon or any of its Affiliates with respect to the Manufacture or supply of Clinical Material, Biocon will immediately notify Equillium in writing and will cease, or cause its Affiliate to
cease (as applicable), employing, contracting with, or retaining any such Person to perform any activities relating to the Manufacture or supply of Clinical Material; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> neither Biocon nor any of its Affiliates will, in connection with the performance of Biocon&#146;s obligations under this
Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a public official or entity or other
Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, including Biocon and its Affiliates, nor will Biocon or any of its Affiliates directly or indirectly promise, offer or provide any corrupt
payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a public official or entity or any other Person in connection with the performance of Biocon&#146;s obligations under this Agreement;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> neither Biocon nor any of its Affiliates (or any of their respective employees and contractors), in connection with the
performance of Biocon&#146;s obligations under this Agreement, will cause Equillium to be in violation of Anti-Corruption Laws or Export Control Laws; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Biocon will immediately notify Equillium if Biocon has any information or suspicion that there may be a violation of Anti-Corruption
Laws or Export Control Laws in connection with the performance of Biocon&#146;s obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B>
<B>Performance by Affiliates and Contractors.</B> The parties recognize that Biocon may perform some or all of its obligations under this Agreement through one or more Affiliates or Third Party contractors; <I>provided,</I> in each case, that
(a)&nbsp;none of Equillium&#146;s rights hereunder are diminished or otherwise adversely affected as a result of such delegation or contracting, and (b)&nbsp;each such Affiliate and Third Party contractor undertakes in writing obligations of
confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> regarding Confidential Information and ownership of Inventions which are substantially the same as those undertaken by the parties pursuant to Article&nbsp;9 and Article&nbsp;10;
and <I>provided, further,</I> that Biocon shall at all times be fully responsible for the performance and payment of such Affiliate or Third Party contractor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5</B> <B>Disclaimer.</B> Except as expressly set forth in this Agreement, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY
KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENTS, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF THE INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6</B> <B>Limitation of Liability.</B><B> </B>EXCEPT
FOR LIABILITY FOR BREACH OF ARTICLE&nbsp;10, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; <I>provided,
however,</I> that this Section&nbsp;8.6 shall not be construed to limit either party&#146;s indemnification obligations under Article&nbsp;12. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>I<SMALL>NTELLECTUAL</SMALL> P<SMALL>ROPERTY</SMALL> M<SMALL>ATTERS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ownership of and rights with respect to all Data and Inventions arising under this Agreement will be determined in accordance with, and
pursuant to the terms of, Article&nbsp;7 of the License Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>ONFIDENTIALITY</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties acknowledge and agree that any Information furnished to a party by or on behalf of the other party pursuant to this Agreement shall
collectively constitute &#147;Confidential Information&#148; of the other party for purposes of the License Agreement, including, without limitation, Article&nbsp;8 thereof, and the provisions of Article&nbsp;8 of the License Agreement are hereby
incorporated by reference in this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>ERM</SMALL> <SMALL>AND</SMALL> T<SMALL>ERMINATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B> <B>Term.</B> The term of this Agreement (the &#147;<B><I>Term</I></B>&#148;) shall begin on the Effective Date and, unless earlier
terminated in accordance with this Article&nbsp;11, expire upon expiration or termination of the License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B> <B>Accrued Obligations; Survival.</B> Upon any termination or any expiration of this Agreement, all rights and obligations of the
parties under this Agreement shall terminate, except as expressly provided in this Section&nbsp;11.2. Neither expiration nor any termination of this Agreement shall relieve either party of any obligation or liability accruing prior to such
expiration or termination, nor shall expiration or any termination of this Agreement preclude either party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement. In
addition, the parties&#146; rights and obligations under Sections&nbsp;4.4, 5.1, 6.2(b), 6.4, 6.5, 6.6, 6.7, 8.2, 8.5, 8.6, 11.2 and 11.3 and Articles&nbsp;7, 9, 10, 12, 13 and 14 will survive expiration or any termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B> <B>Damages; Relief.</B> Termination of this Agreement shall not preclude either party from claiming any other damages,
compensation or relief that it may be entitled to hereunder as a result of the other party&#146;s breach of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>I<SMALL>NDEMNIFICATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Article&nbsp;11 of the License Agreement are hereby incorporated by reference in this Agreement; <I>provided, however,</I>
that, for purposes of this Agreement, all references to &#147;this Agreement&#148; in Sections&nbsp;11.1 and 11.2 of the License Agreement shall be deemed to refer to this Agreement (and not to the License Agreement); and <I>provided, further,</I>
that each party shall be entitled to indemnification for an aggregate of 100% of its actual indemnifiable Losses under this Agreement and the License Agreement together (<I>i.e.</I>, neither party shall be entitled to any double recovery by virtue
of a particular item of Losses being indemnifiable under both this Agreement and the License Agreement). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>ISPUTE</SMALL> R<SMALL>ESOLUTION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in Section&nbsp;7.3(d), any claim, dispute, or controversy as to the breach, enforcement, interpretation or validity of
this Agreement will be resolved in accordance with Article&nbsp;12 of the License Agreement, and the provisions of Article&nbsp;12 of the License Agreement are hereby incorporated by reference in this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.1</B> <B>Governing Law.</B> This Agreement shall be governed by and construed in accordance with the laws of the State of New York, USA,
excluding its conflicts of laws principles with the exception of <FONT STYLE="white-space:nowrap">sections&nbsp;5-1401</FONT> and <FONT STYLE="white-space:nowrap">5-1402</FONT> of New York General Obligations Law. THE PARTIES HERETO HEREBY
IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, OR RELATING TO THIS AGREEMENT, ANY RELATED AGREEMENTS OR ANY TRANSACTIONS
CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.2</B> <B>Entire Agreement; Amendments.</B> This Agreement (including the Exhibits hereto), the License
Agreement, the Purchase Agreement and the Related Agreements, collectively, are both a final expression of the parties&#146; agreement and a complete and exclusive statement with respect to all of their respective terms. This Agreement supersedes
all prior and contemporaneous agreements and communications, whether oral, written or otherwise, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">concerning any and all matters contained herein, including any Confidentiality Agreement, but specifically excluding the License Agreement, Purchase Agreement
and the Related Agreements. The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by
authorized representatives of both parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.3</B> <B><FONT STYLE="white-space:nowrap">Non-Waiver.</FONT></B> The failure of
a party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part,
in that instance or in any other instance. Any waiver by a party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.4</B> <B>Assignment.</B> Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be
assigned or otherwise transferred by either party without the prior written consent of the other party (which consent shall not be unreasonably withheld); <I>provided, however,</I> that either party may assign this Agreement and its rights and
obligations hereunder without the other party&#146;s consent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> in connection with the transfer or sale of all or substantially
all of the business of such party to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> to an Affiliate, provided that the assigning party shall remain liable and responsible to the
<FONT STYLE="white-space:nowrap">non-assigning</FONT> party hereto for the performance and observance of all such duties and obligations by such Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted
assigns of the parties, and the name of a party appearing herein will be deemed to include the name of such party&#146;s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in
accordance with this Agreement shall be void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.5</B> <B>Force Majeure.</B> Each party shall be excused from liability for the
failure or delay in performance of any obligation under this Agreement by reason of any event beyond such party&#146;s reasonable control, including but not limited to Acts of God, fire, flood, explosion, earthquake, or other natural forces, war,
civil unrest, acts of terrorism, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or organized labor disturbance, or any other event similar to
those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the party has not caused, in whole or in part, such event(s) to
occur. The affected party shall notify the other party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.6</B> <B>Severability.</B> If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely
affects the substantive rights of the parties. The parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical,
implement the purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.7</B> <B>Notices.</B> Any notice to be given under this Agreement must be in writing and
delivered either in person, or by internationally-recognized express courier, to the party to be notified at its address(es) given below, or at any address such party has previously designated by prior written notice to the other. Notice shall be
deemed sufficiently given for all purposes upon the earliest of: (a)&nbsp;the date of actual receipt; or (b)&nbsp;if delivered by express courier, the second business day the express courier regularly makes deliveries following deposit. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If&nbsp;to&nbsp;Equillium,&nbsp;to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2223 Avenida de la Playa, Suite
108</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Jolla, CA 92037</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Daniel M. Bradbury</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [&#133;***&#133;]</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Biocon, to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biocon&nbsp;SA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Director</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BDO SA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rue de l&#146;Avenir 2</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2800 Del&eacute;mont</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switzerland</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">With a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Head &#150; Legal</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biocon Limited</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20th K.M. Hosur Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Electronics City P.O.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bangalore 560100</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">India</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.8</B> <B>Interpretation.</B> The headings of clauses contained in this Agreement preceding the text of
the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this
Agreement to the singular shall include the plural where applicable. The term &#147;including&#148; or &#147;includes&#148; as used in this Agreement means including, without limiting the generality of any description preceding such term, and the
word &#147;or&#148; has the inclusive meaning represented by the phrase &#147;and/or.&#148; Unless otherwise specified, references in this Agreement to any section shall include all subsections and paragraphs in such Section and references in this
Agreement to any subsection shall include all paragraphs in such subsection. All references to days in this Agreement shall mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be
interpreted against either party, irrespective of which party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">language, and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written,
electronic, oral or other communications between the parties regarding this Agreement shall be in the English language. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.9</B>
<B>Relationship between the Parties.</B> The parties&#146; relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship
between the parties. Neither party is a legal representative of the other party, and neither party may assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose
whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.10</B> <B>No Third Party Rights.</B> The provisions of this Agreement are for the exclusive benefit of the parties, and
no other person or entity shall have any right or claim against any party by reason of these provisions or be entitled to enforce any of these provisions against any party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.11</B> <B>Counterparts.</B> This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all
of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows.</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the parties have duly executed this Clinical Supply Agreement as of the
Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>E<SMALL>QUILLIUM</SMALL>,&nbsp;I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>B<SMALL>IOCON</SMALL>&nbsp;SA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:<U> &nbsp;&nbsp;/s/ Daniel M.
Bradbury&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:<U> &nbsp;&nbsp;Daniel M.
Bradbury&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:<U>&nbsp;&nbsp;President&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:<U>&nbsp;&nbsp;/s/ Raman
S.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:<U>&nbsp;&nbsp;Raman
S.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:<U>&nbsp;&nbsp;Authorized
Signatory&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit A
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Description of Clinical Material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Confidential </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> C<SMALL>LINICAL</SMALL> M<SMALL>ATERIAL</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[&#133;***&#133;]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[&#133;***&#133;]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential
Information Omitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>13
<FILENAME>d582934dex108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">STANDARD OFFICE LEASE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>LA JOLLA
SHORES PLAZA </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">THIS STANDARD OFFICE LEASE (&#147;Lease&#148;) is entered into effective as of February&nbsp;1, 2018
(&#147;Effective Date&#148;), between LA JOLLA SHORES PLAZA, LLC, a California limited liability company (&#147;Landlord&#148;), and <B>EQUILLIUM, INC.,</B> A Delaware Corporation (&#147;Tenant&#148;). Landlord and Tenant agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>BASIC LEASE PROVISIONS </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The provisions set forth in Paragraphs A through U are part of this Lease wherever appropriate reference is made thereto,
unless and except to the extent they are expressly modified elsewhere in this Lease: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Effective&nbsp;Date:</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;February&nbsp;1,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">B.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Landlord:</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Jolla Shores Plaza, LLC<BR>2223 Avenida de la Playa, Suite 350<BR>La Jolla, California 92037<BR>Telephone: 858.456.5655<BR>FAX:
858.456.5660<BR><FONT STYLE="white-space:nowrap">E-Mail:</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Kim Fishman</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Tenant:</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EQUILLIUM, INC.<BR>2223 Avenida de la Playa, Suite 105<BR>La Jolla, California 92037<BR>Telephone: 858.754.3201<BR><FONT
STYLE="white-space:nowrap">E-Mail:</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Dan Bradbury</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Premises</U>: The area identified as such on the floor plan attached hereto as <U>Exhibit A</U>, located
in <U>Suite 105</U> of the Building, and consisting of approximately 1,743 rentable square feet. A 14% core factor was used in the calculation.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">E.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Building:</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">La Jolla Shores Plaza<BR>2223 Avenida de la Playa<BR>La Jolla, California 92037</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">F.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Term of Lease:</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">48 months</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">G.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Commencement&nbsp;Date:</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March&nbsp;1, 2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expiration Date:</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;February&nbsp;28, 2022</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">I.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Monthly Base Rent</U>:</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Lease&nbsp;Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Rate/Rentable&nbsp;Square&nbsp;Foot</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Monthly&nbsp;Amount</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#cceeff">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#cceeff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;1-2</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#cceeff">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" BGCOLOR="#cceeff">$2.75/1,743 sq ft</TD>
<TD VALIGN="bottom" BGCOLOR="#cceeff">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" BGCOLOR="#cceeff">$4,793.50</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;3-4</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$2.83/1,743 sq ft</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$4,932.69</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">J.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>Monthly&nbsp;Parking&nbsp;Fees</U>:<BR>Garage&nbsp;Parking:<BR>Surface&nbsp;Parking&nbsp;Area:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(See&nbsp;Parking&nbsp;Addendum)<BR>$50.00&nbsp;per&nbsp;month&nbsp;per&nbsp;Space&nbsp;<U>(#15,&nbsp;#47&nbsp;&amp; #58)<BR></U>$25.00&nbsp;per&nbsp;month&nbsp;per&nbsp;Space</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">K.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Utilities Costs</U>: During the Term of the Lease, Tenant shall pay, as additional monthly rent,
Tenant&#146;s proportionate share of the Utility expenses (water, gas and electricity) of the Building 6.0%</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">L.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Operating Costs</U>: 6%</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">M.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Tenant&#146;s Share of Utilities and Operating Costs</U>:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.0%</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">N.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Security Deposit</U>: None</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">O.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Prepaid Rent</U>: None</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Guarantor</U>: None</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Q.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Use of Premises</U>: For general office purposes and for no other use or purpose.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">R.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Tenant Improvements</U>: Landlord shall install door <FONT STYLE="white-space:nowrap">in-between</FONT>
Suite 103 and 105; patch and paint</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Tenant Improvements Allowance</U>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">T.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Lease Year</U>:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Twelve (12)&nbsp;Months</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Option to Extend</U>: None</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Occupancy Rate</U>:&nbsp;&nbsp;&nbsp;&nbsp;Employee occupancy not to exceed Eight (8)&nbsp;Full and
Part-Time Employees</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>LEASE AGREEMENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Landlord hereby leases and Tenant hereby hires the premises described in Paragraph D of the Basic Lease Provisions
(&#147;Premises&#148;) upon all of the terms and conditions of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Premises</U>. The
location of the Premises is more particularly shown on the floor plan attached hereto as <U>Exhibit A</U> and incorporated herein. The Premises is located in the building described in Paragraph E of the Basic Lease Provisions (&#147;Building&#148;).
The Premises, the Building and the parcel of land upon which the Building is located are referred to collectively herein as the &#147;Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of this Lease (&#147;Term&#148;) shall commence on the commencement date
specified in Paragraph G of the Basic Lease Provisions (&#147;Commencement Date&#148;) and shall expire on the expiration date specified in Paragraph H of the Basic Lease Provisions (&#147;Expiration Date&#148;), subject to earlier termination as
set forth herein. If, for any reason, Landlord cannot deliver possession of the Premises to Tenant on the Commencement Date, Landlord shall not be subject to any liability therefore, nor shall such failure affect the validity of this Lease, or the
obligations of Tenant hereunder, or extend the Term hereof. In such case, the Term shall commence on the date Landlord delivers possession of the Premises to Tenant. Once the Commencement Date has been established, Tenant and Landlord shall confirm
the Commencement Date and Expiration Date in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Rent</U>. From and after the
Commencement Date, Tenant agrees to pay Landlord, in advance, on the first day of each and every calendar month during the Term, the Base Rent (defined below) and other charges specified in this Section&nbsp;3. The Base Rent for any fraction of a
month at the beginning of the Term will be prorated and paid on the Commencement Date. Payment of all Base Rent and other charges shall be without offset or demand, shall be in lawful money of the United States of America, and shall be made at the
address set forth for Landlord in Paragraph B of the Basic Lease Provisions, or at such other place as Landlord may direct. The Base Rent and other charges (collectively, &#147;Rent&#148;) shall include the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Rent</U>. Tenant agrees to pay Landlord monthly rent (&#147;Base Rent&#148;) in the amount
specified in Paragraph I of the Basic Lease Provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Rent</U>. Tenant agrees
to pay to Landlord, in addition to the Base Rent, as additional rent (&#147;Additional Rent&#148;) all charges, costs and expenses which Tenant may become required to pay pursuant to this Lease, including, without limitation, <STRIKE>the Operating
Costs</STRIKE>, Parking Fees, and Utilities Costs, together with all late charges, interest, costs and expenses (including attorneys&#146; fees) that may accrue in the event of Tenant&#146;s failure to pay such amounts, and all damages and costs and
expenses which Landlord may incur by reason of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Tenant&#146;s default or breach of this Lease. In the event of nonpayment by Tenant of Additional Rent, Landlord shall have all of the rights and remedies with respect thereto as Landlord has
under this Lease for nonpayment of Base Rent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Utilities Costs</U>. Tenant shall pay to
Landlord during the Term, as Additional Rent, Tenant&#146;s Proportionate Share of the Utilities Costs of the Building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Operating Cost Increases</U>. Tenant shall pay to Landlord during the Term, as Additional Rent,
Tenant&#146;s Share of the amount by which all Operating Costs for Lease Years 2 through 5 exceed the Operating Costs for Lease Year 1 as annualized and adjusted to assume: (i)&nbsp;one hundred percent (100%) occupancy of the Building; and
(ii)&nbsp;the assessment of supplemental Taxes (defined below) pursuant to Chapter 3.5 of the California Revenue and Taxation Code to reflect Landlord&#146;s purchase of the Property and construction of the Building and related improvements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Operating Costs</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definition</U>. For the purposes of this Lease, &#147;Operating Costs&#148; means all costs of
managing, operating, maintaining, repairing, preserving and improving the Property, including all costs, expenditures, fees and charges for: (i)&nbsp;operation, maintenance and repair of the Property; (ii)&nbsp;utilities and services, security, pest
control, cleaning, janitorial services, window cleaning, alarm service, telecommunications facilities and equipment, recycling programs and trash removal, and taxes thereon; (iii)&nbsp;compensation (including employment taxes and fringe benefits)
for persons (at the rank of building manager, if onsite, or below; no salaries of onsite corporate or executive personnel shall be included as operating costs) who perform duties in connection with the operation, management, maintenance, repair and
improvement of the Property, such compensation to be appropriately allocated for persons who also perform duties unrelated to the Property; (iv)&nbsp;insurance, including fire, extended coverage (including coverage for earthquake and flood, if
carried by Landlord), boiler, sprinkler, apparatus, public liability, property damage and rental income, and expenditures for deductible amounts paid under such insurance; (v)&nbsp;licenses, permits and inspections; (vi)&nbsp;complying with the
requirements of any law, statute, ordinance, code, rule, regulation, requirement, license, permit, certificate, judgment, decree, order or directive of any federal, state, county or local governmental or quasi-governmental authority, agency,
department, board panel or court (individually, &#147;Law&#148; and collectively, &#147;Laws&#148;), except to the extent that such requirements include repairs by landlord to comply with ADA or Title 24 requirements; (vii)&nbsp;amortization of
capital improvements to or replacements of the Property (including the Building systems, the structural components of the Building, the parking facilities and other elements of the Property (but excluding the foundation of the Building and
replacement of the roof), over the useful life of such improvements or replacements as determined by GAAP principles; (viii)&nbsp;property management fees; (ix)&nbsp;accounting, legal and other professional services incurred in connection with the
operation of the Property; (x)&nbsp;a reasonable allowance for depreciation on machinery and equipment used to operate and maintain the Property and on other personal property owned by Landlord on the Property; (xi)&nbsp;contesting the validity or
applicability of any Laws that may affect the Property; (xii)&nbsp;reserves for future expenditures of the type described herein, as reasonably determined by Landlord; (xiii)&nbsp;landscaping and maintenance of the common area; (xiv)&nbsp;supplies,
materials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
equipment and tools used in connection with the Property, including any rental fees (to the extent that rental fees are not charged for equipment owned by Landlord or any affiliate of Landlord;
(xv)&nbsp;taxes; and (xvi)&nbsp;any other costs, expenditures, fees or charges, whether or not hereinbefore described, which, in accordance with generally accepted property management practices, would be considered an expense of managing, operating,
maintaining, repairing and/or improving the Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant&#146;s Share</U>.
&#147;Tenant&#146;s Share&#148; shall mean and refer to the portion of the Operating and Utilities Costs payable by Tenant. Tenant&#146;s Share shall be calculated as a fraction, the numerator of which is the rentable square footage of the Premises,
and the denominator of which is the total aggregate rentable square footage of the Building. The parties agree that the approximations of the areas of the Premises and the Building that have been used to compute Tenant&#146;s Share are reasonable
and that Tenant&#146;s Share shall not be subject to revision based on the actual area of the Premises or the Building, unless there is a change in the size of the Premises or in the rentable area within the Building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Operating Cost Exclusions</U>. Operating Costs shall not include: (i)&nbsp;costs (including
tenant improvements, permit, license and inspection costs) incurred in renovating or otherwise improving, altering or building out rentable space for other tenants or vacant rentable space; (ii)&nbsp;costs of utilities or services sold to Tenant or
others for which Landlord receives reimbursement; (iii)&nbsp;costs of interest on debt or amortization on any mortgages, rent and other charges, costs and expenses payable under any mortgage or ground or underlying lease, if any; (iv)&nbsp;costs of
electrical power for which a tenant directly contracts with and pays a local public service company; (v)&nbsp;charitable or political contributions made by Landlord; (vi)&nbsp;maintenance and repair of capital items not a part of the Property,
except such offsite items as may be reasonably necessary for the operation and use of the Property, which costs may then be amortized and included, yearly, as Operating Costs; (vii)&nbsp;any expenses for repairs or maintenance which are covered by
warranties, guarantees and service contracts (excluding any mandatory deductible) to the extent collected and paid to Landlord; (viii)&nbsp;legal expenses arising out of the enforcement of the provisions of any leases and other occupancy agreements
affecting the Property; (ix)&nbsp;depreciation or amortization, other than as provided in the definition of Operating Costs in Section&nbsp;4(a); (x) costs incurred in connection with damage or repairs which are covered under any insurance policy
carried by Landlord or responsible third party; and (xi)&nbsp;any other expenses which, under generally accepted accounting principles consistently applied, would not be considered a maintenance, repair or operating expense, or would not normally be
treated as a cost of operation (to be reimbursed by tenants) by landlords of comparable buildings. (xii)&nbsp;Late fees or penalties incurred by Landlord or Landlord&#146;s agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>. For the purposes of this Lease, &#147;Taxes&#148; means all real property taxes and
general, special and district assessments and other governmental impositions, fees, levies and charges of whatever kind, nature or origin, imposed on or by reason of the ownership or use of the Property; governmental charges, fees or assessments for
transit or traffic mitigation (including area-wide traffic improvement assessments and transportation system management fees), housing, police, fire or other governmental service or purported benefits to the Property; personal property taxes
assessed on the personal property of Landlord used in the operation of the Property; service payments in lieu of taxes and taxes and assessments of every kind and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
nature whatsoever levied or assessed in addition to, in lieu of, or in substitution for existing or additional real or personal property taxes on the Property or the personal property described
above; any increases in the foregoing caused by changes in assessed valuation, tax rate or other factors or circumstances; and the reasonable cost of contesting by appropriate proceedings the amount or validity of any taxes, assessments or charges
described above to the extent that any resulting tax savings are credited back to Operating Expenses. Notwithstanding the foregoing, Taxes shall not include any net income, capital, stock, succession, transfer, franchise, gift, estate or inheritance
taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of Operating Costs and Other Additional Rent</U>. Prior to the commencement
of each of Lease Years 2 through 5, or such other annual accounting period as Landlord shall utilize from time to time, Landlord shall give Tenant a written estimate of all of the items of Additional Rent (including Operating Costs) payable by
Tenant during the coming Lease Year. Tenant shall pay such estimated amount to Landlord in equal monthly installments, in advance, at the same time the Base Rent is paid. Such estimate may be adjusted from time to time on the basis of
Landlord&#146;s experience and reasonably anticipated costs. Within ninety (90)&nbsp;days after the end of each Lease Year, or such other annual accounting period as Landlord shall utilize from time to time, Landlord shall furnish to Tenant a
statement showing in reasonable detail the actual costs incurred by Landlord during the year then ended, and Tenant shall pay to Landlord Tenant&#146;s proportionate share of the cost incurred in excess of the payments of Additional Rent made by
Tenant within ten (10)&nbsp;days of receipt of such statement. Tenant&#146;s Share of the Operating Costs for the first and/or last calendar quarter or Lease Year during the Term shall be proportionately reduced to account for the Commencement Date
and Expiration Date of the Term occurring on other than the first or last day of the appropriate calendar quarter or year. In the event that the Operating Cost portion of the payments of Additional Rent made by Tenant exceed Tenant&#146;s Share of
the actual Operating Costs, the amount of any such excess shall be credited by Landlord to the Additional Rent next due and owing; provided, however, that, if the Term has expired, Landlord shall accompany said statement with the amount due to
Tenant. Notwithstanding the foregoing, Landlord shall have the right to submit statements to Tenant for unbudgeted Operating Costs incurred on an emergency basis, and Tenant shall remit payment on such statements for Tenant&#146;s Share of such
Operating Costs within, thirty (30)&nbsp;days of receipt of same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Late Charges</U>.
Tenant&#146;s Rent and all Additional Rent is <U>due on or before the First Day of each Month</U>. Tenant acknowledges that late payment by Tenant to Landlord of Rent will cause Landlord to incur costs not contemplated by this Lease, the exact
amount of such costs being extremely difficult and impractical to ascertain. Such costs include, without limitation, processing, administration and accounting charges. If any installment of any item of Rent due from Tenant is not received by
Landlord on or before the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of the month due, Tenant shall pay to Landlord, as Additional Rent, (a)&nbsp;ten percent (10%) of the overdue Rent, as a late charge. The parties agree that this
late charge represents a fair and reasonable estimate of the costs that the Landlord will incur by reason of late payment by Tenant. Acceptance of any late charge shall not constitute a waiver of Tenant&#146;s default with respect to the overdue
amounts, nor prevent the Landlord from exercising any of the other rights and remedies available to Landlord hereunder. The payment of a late charge shall be in addition to any interest payable by Tenant under Section&nbsp;8. In addition to the
charges provided for above, Tenant shall pay a charge&nbsp;of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify"><FONT STYLE="font-family:Times New Roman; font-size:10pt">
$45.00 to Landlord for each check returned for insufficient funds and 5125.00 for each &#147;three (3)&nbsp;day pay or quit&#148; notice sent to Tenant by Landlord. </FONT></P>
<P STYLE="margin-top:12pt;margin-bottom:0pt; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman; font-size:10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;<strike><u>Security</u></strike><STRIKE>. Tenant shall deposit with Landlord, upon
Tenant&#146;s execution of this Lease, the security deposit specified in Paragraph N of the Basic Lease Provisions (&#147;Security Deposit&#148;) with Landlord as security for the full and faithful performance by Tenant of every term and covenant of
this Lease. In the event Tenant defaults in the performance of any of its obligations hereunder, or otherwise breaches this Lease, Landlord may use, apply, or retain all or any portion of the Security Deposit for the payment of any amount due
Landlord or to reimburse or compensate Landlord for any liability, cost, expense, loss or damage (including attorneys&#146; fees) which Landlord shall suffer or incur by reason thereof. If Landlord uses or applies all or any portion of the Security
Deposit, Tenant shall, within ten (10)&nbsp;days after written request therefore deposit monies with Landlord sufficient to restore the Security Deposit to the full amount required by this Lease. Upon the expiration or earlier termination of this
Lease and performance of all of Tenant&#146;s obligations hereunder, Landlord shall return the Security Deposit or any balance thereof to Tenant. Tenant shall not be entitled to any interest on the Security Deposit, and Landlord shall be entitled to
commingle the Security Deposit with its general funds. No part of the Security Deposit shall be considered to be held in trust, to bear interest for its use, or to be a prepayment for <FONT STYLE="white-space:nowrap">any-monies</FONT> to be paid by
Tenant under this Lease.</STRIKE></u></strike> </FONT></P> <P STYLE="margin-top:12pt;margin-bottom:0pt; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman; font-size:10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Interest on Past Due
Obligations</U></u></strike>. In addition to the late charges referred to above, which are intended to defray Landlord&#146;s costs resulting from late payments, any payment from Tenant to Landlord not paid within ten (10)&nbsp;days after the date
it is due shall, at Landlord&#146;s option, bear interest from the date due until paid to Landlord by Tenant at the lesser of the rate of fifteen percent (15%) per annum or the maximum lawful rate that Landlord may charge to Tenant under applicable
Laws (&#147;Interest Rate&#148;). Acceptance of any late charge and/or interest shall not constitute a waiver of Tenant&#146;s default with respect to the overdue sum or prevent Landlord from exercising any of its other rights and remedies under
this Lease. </FONT></P> <P STYLE="margin-top:18pt;margin-bottom:0pt; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman; font-size:10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Uses</U></u></strike>. </FONT></P>
<P STYLE="margin-top:6pt;margin-bottom:0pt; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman; font-size:10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Premises</U></u></strike>. The Premises shall be used only for general office
purposes and for no other use or purpose. Landlord makes no warranty or representation regarding the suitability of the Premises for Tenant&#146;s intended use. Tenant shall not engage in any activity on the Premises that would, in the judgment of
any insurer of the Premises, increase the premium on any of Landlord&#146;s insurance over the amount otherwise charged therefore or cause such insurance to be canceled. Tenant shall comply with all applicable Laws pertaining to its use of the
Premises. Tenant shall commit no nuisance or waste on the Premises and shall not cause any unreasonable odors, noise, vibration, electronic emissions, or any other item to emanate from the Premises so as to damage Landlord&#146;s property or any
other person&#146;s property or disturb the quiet enjoyment of any other tenant in the Building. Tenant shall not cause any excessive loads to be placed upon the floor slabs or the walls of the Premises by the placement of its furnishings or
equipment or otherwise. </FONT></P> <P STYLE="margin-top:12pt;margin-bottom:0pt; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman; font-size:10pt">Occupancy rate of the Premises is four persons per thousand square feet,
unless prior approval for higher density is received in writing from Landlord. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right"><FONT STYLE="font-family:Times New Roman; font-size:10pt">7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Laws and Rules and
Regulations</U>. Tenant shall comply with all Laws and the rules and regulations (&#147;Rules and Regulations&#148;) pertaining to the use of the Premises, the Building and the Property. A copy of the Rules and Regulations in existence as of the
Effective Date is attached hereto as <U>Exhibit C</U> and incorporated herein. Landlord reserves the right to amend the Rules and Regulations at any time by giving notice of amendments to Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance Use Requirements</U>. Tenant shall neither use nor occupy the Premises in any manner,
nor commit or omit any act, resulting in a cancellation or reduction of any insurance or increase in premiums on any insurance policy covering the Premises, the Building or the Property. Tenant shall, at its sole expense, comply with all
requirements of any insurer pertaining to the use of the Premises and reasonably necessary for maintenance of economic and proper property, liability and other insurance desired to be carried by Landlord under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Building Exterior</U>. No portion of the area outside of the Building or the exterior of the
Building is leased to Tenant. No rubbish containers may be stored outside of the Premises except inside existing trash enclosure areas. No other materials may be stored outside the Premises. Tenant shall have no right of access to the Building roof
and Tenant shall make no penetrations of the roof or the roof membrane of the Building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Hazardous Materials</U>. Tenant hereby makes the following covenants regarding Hazardous
Materials: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall at all times and in all respects comply with all Laws, including,
without limitation, the Federal Water Pollution Control Act (33 U.S.C. &#167;1251, et seq.), Resource Conservation&nbsp;&amp; Recovery Act (42 U.S.C. &#167;6901, et seq.), Safe Drinking Water Act (42 U.S.C. &#167;3000f, et seq.), Toxic Substances
Control Act (15 U.S.C. &#167;2601, et seq.), the Clean Air Act (42 U.S.C. &#167;7401, et seq.), Comprehensive Environmental Response, Compensation and Liability Act (42 U.S.C. &#167;9601, et seq.), California Health&nbsp;&amp; Safety Code
(&#167;25100, et seq., &#167;39000, et seq.), California Safe Drinking Water&nbsp;&amp; Toxic Enforcement Act of 1986 (California Health&nbsp;&amp; Safety Code &#167;25249.5, et seq.), California Water Code (&#167;13000, et seq.), and other
comparable Laws (collectively, &#147;Hazardous Materials Laws&#148;), relating to industrial hygiene, environmental protection or the use, analysis, generation, manufacture, storage, disposal or transportation of any oil, flammable explosives,
asbestos, urea formaldehyde, radioactive materials or waste, or other hazardous, toxic, contaminated or polluting materials, substances or wastes, including, without limitation, any &#147;hazardous substances&#148;, &#147;hazardous wastes&#148;,
&#147;hazardous materials&#148; or &#147;toxic substances&#148; under any such laws, ordinances or regulations (collectively, &#147;Hazardous Materials&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall, at its own expense, procure, maintain in effect and comply with all conditions of
any and all permits, licenses, and other governmental and regulatory approvals required for Tenant&#146;s use of the Premises, including, without limitation, discharge of (appropriately treated) materials or wastes into or through any sanitary sewer
serving the Premises. Except as discharged into the sanitary sewer in strict accordance and conformity with all applicable Hazardous Materials Laws, Tenant shall cause any and all Hazardous Materials removed from the Premises to be removed and
transported solely by duly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
licensed haulers to duly licensed facilities for final disposal of such materials and wastes. Tenant shall in all respects handle, treat, deal with and manage any and all Hazardous Materials in,
on, under or about the Premises in total conformity with all applicable Hazardous Materials Laws and prudent industry practices regarding management of such Hazardous Materials. Upon expiration or earlier termination of the Term, Tenant shall cause
all Hazardous Materials to be removed from the Premises and transported for use, storage or disposal in accordance with and compliance with all applicable Hazardous Materials Laws. Tenant shall not take any remedial action in response to the
presence of any Hazardous Materials in or about the Premises, the Building or the Property, nor enter into any settlement agreement, consent decree or other compromise with respect to any claims relating to any Hazardous Materials in any way
connected with the Premises, the Building or the Property without first notifying Landlord of Tenant&#146;s intention to do so and affording Landlord ample opportunity to appear, intervene or otherwise appropriately assert and protect
Landlord&#146;s interest with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall immediately notify Landlord in
writing of: (A)&nbsp;any enforcement, cleanup, removal or other governmental or regulatory action instituted, completed or threatened pursuant to any Hazardous Materials Laws; (B)&nbsp;any claim made or threatened by any person against Tenant, the
Premises, the Building or the Property relating to damage, contribution, cost recovery compensation, loss or injury resulting from or claimed to result from any Hazardous Materials; and (C)&nbsp;any reports made to any environmental agency arising
out of or in connection with any Hazardous Materials in or removed from the Premises, the Building or the Property, including any complaints, notices, warnings or asserted violations in connection therewith. Tenant shall also supply to Landlord as
promptly as possible, and in any event within five (5)&nbsp;business days after Tenant first receives or sends the same, with copies of all claims, reports, complaints, notices, warnings or asserted violations, relating in any way to the Premises,
the Building or the Property or Tenant&#146;s use thereof. Tenant shall promptly deliver to Landlord copies of hazardous waste manifests reflecting the legal and proper disposal of all Hazardous Materials removed from the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall indemnify, defend (by counsel reasonably acceptable to Landlord), protect, and hold
Landlord and each of Landlord&#146;s managers, members, partners, shareholders, directors, officers, employees, agents, attorneys, successors and assigns (collectively, &#147;Landlord Parties&#148;), free and harmless from and against any and all
claims, liabilities, penalties, forfeitures, losses or expenses (including attorneys&#146; fees), or death of or injury to any person or damage to any property whatsoever, arising from or caused in whole or in part, directly or indirectly, by
(A)&nbsp;the presence in, on, under or about the Premises, the Building or the Property, or the discharge in or from the Premises, the Building or the Property of any Hazardous Materials brought or caused to be brought into or onto the Premises, the
Building or the Property by or on behalf of Tenant; (B)&nbsp;Tenant&#146;s use, analysis, storage, transportation, disposal, release, threatened release, discharge or generation of Hazardous Materials to, in, on, under, about or from the Premises,
the Building or the Property; or (C)&nbsp;Tenant&#146;s failure to comply with any Hazardous Materials Law. Tenant&#146;s obligations hereunder shall include, without limitation, and whether foreseeable or unforeseeable, all costs of any required or
necessary repair, cleanup or detoxification or decontamination of the Premises, the Building or the Property, or the preparation and implementation of any closure, remedial action or other required plans in connection therewith, and shall survive
the expiration or earlier termination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Term. For purposes of the release and indemnity provisions of this subsection, any acts or omissions of Tenant or its employees, agents, or contractors or others acting for or on behalf of
Tenant (whether or not they are negligent, intentional, willful or unlawful) shall be strictly attributable to Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;If at any time it reasonably appears to Landlord that Tenant is not maintaining sufficient
insurance or other means of financial capacity to enable Tenant to fulfill its obligations to Landlord under this subsection, whether or not then accrued, liquidated, conditional or contingent, Tenant shall procure and thereafter maintain in full
force and effect such insurance or other form of financial assurance, with or from companies or persons and in forms reasonably acceptable to Landlord, as requested by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;As set forth on <U>Exhibit D</U> attached hereto and incorporated herein, Landlord has disclosed
to Tenant that asbestos containing materials are located in the Building and that an asbestos management plan is in place for the Building. Except as expressly disclosed to Tenant in writing, Landlord has no current actual knowledge of any other
Hazardous Materials in or about the Premises, the Building or the Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Light, Air
or View Easement</U>. No diminution or shutting off of light, air or view by any structure which may be erected on lands adjacent to the Building and the Property shall in any way affect this Lease, entitle Tenant to any abatement or reduction of
Rent, or impose any liability on Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Building Name</U>. Tenant shall not use the name
of the Building or the Property or words to the effect of either in connection with any business on the Premises without the prior written consent of Landlord. Landlord may change the name of the Building or the Property at any time without consent
of or notice to Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Keys</U>. <B>Four</B> (<B>4</B>)&nbsp;keys to the Premises will be
furnished to Tenant by Landlord. Additional keys will be furnished upon Tenant paying Landlord the cost thereof. No additional lock or locks shall be placed by Tenant on any door in the Premises or the Building, unless written consent of Landlord
shall have been first obtained; and, should such consent be so obtained, Landlord shall be supplied with keys to each such lock and no other than the employees of Landlord or those it has authorized in writing shall work on or modify any lock which
is part of the Premises. Tenant shall not cause or allow the duplication of any keys to be made, and Tenant shall not cause or allow any keys to be possessed by any person other than an authorized agent of Tenant. Tenant agrees, at the expiration or
earlier termination of this Lease, to return all keys of all doors in the Premises and the Building to Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Rules and Regulations</U>. Tenant shall comply with all Rules and Regulations that Landlord may
from time to time promulgate for the safety, care, cleanliness and orderly management of the Premises, the Building and the Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Acceptance of Premises</U>. Tenant accepts the Premises in its
<FONT STYLE="white-space:nowrap">&#147;AS-IS&#148;</FONT> condition, unless otherwise noted under Exhibit B (Tenant Improvements) and hereby acknowledges: (a)&nbsp;that it has been advised by Landlord and/or any broker under this Lease to satisfy
itself with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
respect to the condition of the Premises, including all applicable Laws, and the present and future suitability of the Premises for Tenant&#146;s intended use; (b)&nbsp;that Tenant has made such
investigation as it deems necessary with reference to such matters, is satisfied with reference thereto, and assumes all responsibility therefore as the same relate to Tenant&#146;s occupancy of the Premises and/or the terms of this Lease; and
(c)&nbsp;that neither Landlord, nor any of Landlord&#146;s agents, has made any oral or written representations or warranties with respect to said matters other than as set forth in this Lease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Alterations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&#146;s Consent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall not make or permit to be made any alterations, additions or improvements
(&#147;Alterations&#148;) to the Premises or any part thereof without the prior written consent of Landlord in each instance, which may be granted or withheld in Landlord&#146;s sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Landlord will not unreasonably withhold or delay its consent to any Alterations, provided and
upon the condition that all of the following conditions shall be satisfied: (A)&nbsp;the Alterations do not affect the outside appearance of the Building; (B)&nbsp;the Alterations are nonstructural and do not impair the strength of the Building or
any part thereof; (C)&nbsp;the Alterations are to the interior of the Premises and do not affect any part of the Building outside of the Premises; (D)&nbsp;the Alterations do not affect the proper functioning of the Building systems or other
utilities, systems and services of the Building, or materially increase the usage thereof by Tenant; (E)&nbsp;Landlord shall have approved the final plans and specifications for the alterations, any subsequent changes thereto, and all contractors
and subcontractors who will perform them; and (F)&nbsp;all costs and expenses incurred in connection with the Alterations, including the construction and installation thereof, the preparation of the plans and specifications therefore, and the
attaining of all necessary governmental approvals and permits, shall be paid by Tenant. In the event that Landlord grants its consent to any Alterations hereunder, such consent may be conditioned upon the requirement that Tenant provide a lien
completion bond in form and amount satisfactory to Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Not less than five
(5)&nbsp;days prior to commencement of any approved Alterations, Tenant shall notify Landlord of the Alterations work commencement date so that Landlord may post notices of nonresponsibility in and around the Premises. All approved Alterations shall
comply with all Laws, the other terms of this Lease, and the final plans and specifications approved by Landlord, and Tenant shall fully and promptly comply with and observe any Rules and Regulations of Landlord then in force with respect to the
making of Alterations and/or imposed by Landlord in connection with its approval of the plans and specifications for the Alterations. Landlord&#146;s review and approval of Tenant&#146;s plans and specifications are solely for Landlord&#146;s
benefit. Upon completion of any approved Alterations, Tenant shall provide to Landlord <FONT STYLE="white-space:nowrap">&#147;as-built&#148;</FONT> plans, copies of all construction contracts, building permits, inspection reports and all other
required governmental approvals, together with proof&nbsp;of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
payment of all labor and materials. Tenant shall be responsible for any additional alterations and improvements required by applicable Laws to be made to or in the Premises or the Building as a
result of any Alterations to the Premises made by or for Tenant. Landlord shall have no duty toward Tenant, nor shall Landlord be deemed to have made any representation or warranty to Tenant, with respect to the safety, adequacy, correctness,
efficiency or compliance with Laws of the design of the Alterations, the plans and specifications therefore, or any other matter regarding the Alterations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Ownership and Surrender of Alterations</U>. Upon the expiration or earlier termination of this
Lease, Tenant shall surrender the Premises to Landlord broom clean and in the same condition as received (including, without limitation, refloating any drywall), except for ordinary wear and tear which Tenant was not otherwise obligated to remedy
under any provision of this Lease. Landlord may require Tenant to remove any or all Alterations made by Tenant during the Term and to restore the Premises to its prior condition (i.e., the condition as of the Commencement Date), all at Tenant&#146;s
sole cost and expense. All Alterations, which are not already Landlord&#146;s property and which Landlord does not require Tenant to remove, shall become Landlord&#146;s property and shall be surrendered to Landlord upon the expiration or earlier
termination of this Lease. In no event shall Tenant remove any Alterations, fixtures or other improvements, including, without [imitation, any power wiring or power panels, lighting or lighting fixtures, cabinetry, window coverings, carpets, other
floor coverings, heaters, air conditioners or other heating or air conditioning equipment or any other item or equipment that is fastened in any manner to the Premises walls, floor or ceiling without Landlord&#146;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Liens</U>. Tenant shall pay when due all claims for labor, materials and services furnished by
or at the request of Tenant. Tenant shall keep the Premises, the Building and the Property free from all liens, security interests (with the exception of security instruments on equipment leased by Tenant) and encumbrances (including, without
limitation, all mechanic&#146;s liens and stop notices) created as a result of or arising in connection with any Alterations or any other labor, services or materials provided for or at the request of Tenant or any other act or omission of Tenant or
persons claiming through or under Tenant (such liens, security interests and encumbrances singularly and collectively are herein called &#147;Liens&#148;). Tenant shall not use materials in connection with the Alterations that are subject to any
Liens. Tenant shall indemnify, protect, defend and hold Landlord harmless from and against: (i)&nbsp;all Liens; (ii)&nbsp;the removal of all Liens and any actions or proceedings related thereto; and (iii)&nbsp;all actions, claims, damages,
liabilities, costs and expenses (including attorneys&#146; fees) in connection with the foregoing. If Tenant fails to keep the Premises, the Building and the Property free from Liens then, in addition to all other rights and remedies available to
Landlord, Landlord may take any action necessary to discharge such Liens, including payment to the claimant on whose behalf the Lien was filed. Any sums expended by Landlord (including, without limitation, administrative costs and attorneys&#146;
fees) in connection with any such action shall be payable by Tenant on demand with interest thereon from the date of expenditure by Landlord at the Interest Rate. Neither Landlord&#146;s curative action nor the reimbursement of Landlord by Tenant
shall cure Tenant&#146;s default in failing to keep the Premises, the Building and the Property free from Liens. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Requirements</U>. Tenant shall
obtain all necessary permits and certificates for the commencement and performance of Alterations and for final approval thereof upon completion, and shall cause the Alterations to be performed in compliance therewith and with all applicable
insurance requirements, and in a good, first-class and workmanlike manner. Tenant, at its expense, shall diligently cause the cancellation or discharge of all notices of violation arising from or otherwise connected with Alterations, or any other
work, labor, services or materials done for or supplied to Tenant or by any person claiming through or under Tenant. Alterations shall be performed so as not to interfere with any other tenant in the Building, cause labor disharmony therein, or
delay or impose any additional expense on Landlord in the maintenance, repair or operation of the Building. Throughout the performance of the Alterations, Tenant, at its expense, shall carry, or cause to be carried, in addition to the insurance
described in Section&nbsp;17, Workers&#146; Compensation insurance with statutory limits and such other insurance as Landlord may reasonably require with insurers reasonably satisfactory to Landlord. Tenant shall furnish Landlord with satisfactory
evidence that such insurance is in effect at or before the commencement of the Alterations and, upon request, at reasonable intervals thereafter until completion of the Alterations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Trade Fixtures</U>. Subject to the provisions of Section&nbsp;9, and the foregoing provisions of
this Section&nbsp;11, Tenant may install and maintain furnishings, equipment, movable partitions, business equipment and other trade fixtures (collectively, &#147;Trade Fixtures&#148;) in the Premises, provided that the Trade Fixtures do not become
an integral part of the Premises or the Building. Tenant shall promptly repair any damage to the Premises or the Building caused by any installation or removal of such Trade Fixtures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant Improvements</U>. Any tenant improvements (&#147;Tenant Improvements&#148;) in or to the
Premises shall be constructed and installed in compliance with the provisions of this Section&nbsp;11, <U>Exhibit B</U>, all other provisions of this Lease and all applicable Laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance and Repair</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant&#146;s Obligations</U>. Except for those portions of the Building which Landlord is
obligated to maintain pursuant to Section I2(b), Tenant shall, at Tenant&#146;s sole cost and expense and at all times, keep the Premises and every part thereof in first-class order, condition and repair, including, without limitation, all equipment
or facilities specifically serving the Premises, such as plumbing, heating, air conditioning, ventilating, electrical, lighting facilities, boilers, fire hose connections (if within the Premises), fixtures, interior walls, interior surfaces of
exterior walls, ceilings, floors, windows, doors and plate glass. Tenant, in keeping the Premises in first-class order, condition and repair, shall exercise and perform good maintenance&nbsp;practices. Tenant&#146;s obligations shall include
restorations, replacements or renewals when necessary to keep the Premises and all improvements thereon or a part thereof in first-class order, condition and state of repair. If Tenant refuses or neglects to make repairs and/or maintain the
Premises, or any part thereof, in a manner and within a time period reasonably satisfactory to Landlord. Landlord shall have the right, upon giving Tenant five (5)&nbsp;days written notice of its election to do so (except in the case of an
emergency. in which case no notice shall be required), to make such repairs or perform such maintenance on behalf of and for the account of Tenant. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
such event the cost of such work shall be paid by Tenant promptly upon receipt of a bill therefore. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&#146;s Obligations</U>. Subject to Tenant&#146;s obligations pursuant to
Section&nbsp;12(a) and the provisions of this Lease dealing with damage or destruction, Landlord, subject to reimbursement under Section&nbsp;5, shall maintain in good working order and repair all structural portions of the Premises and the
Building, including the roof, foundations and bearing walls, and all common areas of the Building. Landlord shall also maintain and repair all utility systems serving the Building and the common area and shall maintain the exterior landscaping for
the Building. Landlord shall provide janitorial and window-washing services throughout the Building on a regular basis. as reasonably determined by Landlord. Tenant hereby waives the benefit of any statute now or hereinafter in effect which would
otherwise afford Tenant the right to make repairs at Landlord&#146;s expense or to terminate this Lease because of Landlord&#146;s failure to keep the Premises in good condition, order and repair. Tenant specifically waives all rights it may have
under Sections 1932(1), 1941 and 1942 of the California Civil Code, and any similar or successor statute or law with regard to Landlord&#146;s repair obligations under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant&#146;s Obligation to Reimburse</U>. Tenant shall reimburse Landlord in full for all
damages to the Premises, the Building or the Property that are caused by Tenant, its agents, employees or contractors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Utilities and Services; Access</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Utilities and Services Furnished by Landlord</U>. Landlord shall provide the following services
under this Lease: (i)&nbsp;utility and elevator services for the Building and the Premises seven (7)&nbsp;days per week, twenty-four (24)&nbsp;hours per day; (ii)&nbsp;heating, ventilating and air conditioning (&#147;HVAC&#148;) for the common areas
of the Building from 7:30 a.m. to 6:00 p.m., Monday through Friday; (iii)&nbsp;janitorial service for the Building and the Premises five (5)&nbsp;nights each week, exclusive of holidays; and (iv)&nbsp;electricity for the common areas of the Building
seven (7)&nbsp;days per week, twenty-four (24)&nbsp;hours per day. No failure or interruption of any such utilities or service shall entitle Tenant to withhold rent or other sums due hereunder or to terminate this Lease, and Landlord shall not be
liable to Tenant for any such failure or interruption, unless caused by the willful misconduct of Landlord. Tenant shall not install or use any device that will cause to be used any utilities in excess of those normally used in the course of general
office work. Landlord shall not be responsible for providing any security protection for all or any portion of the Property, and Tenant shall at its own expense provide or obtain any security services that it desires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional and After-Hours Utilities Usage</U>. Landlord, in its sole and absolute discretion,
may elect to offer additional and/or after-hours utilities usage in the Building to any or all tenants of the Building. In the event that Landlord elects to offer such services to Tenant, all such usage shall be charged directly to Tenant at an
hourly rate to be reasonably determined by Landlord, and shall be payable to Landlord as Additional Rent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Utilities and Services Furnished by Tenant</U>. Tenant shall furnish and pay, at Tenant&#146;s
sole expense, its pro rata share of all utilities for the Premises (including, without </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
limitation, electricity, HVAC and telephone service) and other services which Tenant requires with respect to the Premises. In the event any of the utilities for the Premises are separately
metered, the account therefore shall be in Tenant&#146;s name, and Tenant shall pay for Tenant&#146;s consumption of such utility services directly to the provider before delinquency according to the amount shown on such separate meter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Access</U>. Tenant shall have access to the Building and the Premises twenty-four
(24)&nbsp;hours per day, seven (7)&nbsp;days per week. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant&#146;s Personal Property
Taxes</U>. Tenant shall pay prior to delinquency all taxes, license fees, and public charges assessed or levied against Tenant, Tenant&#146;s estate in this Lease or Tenant&#146;s leasehold improvements, trade fixtures, furnishings, equipment and
other personal property located in the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&#146;s Right to Alter the
Building and the Property</U>. Landlord reserves and shall at any and all times have the right to alter the Building and the Property, and may for that purpose erect scaffolding and all other necessary structures thereon. Tenant shall not in any
event claim or be entitled to any damages for any injury or inconveniences occasioned thereby, nor shall there be any abatement in Rent. Landlord also reserves the right to install, use, maintain, repair, and replace in the Premises pipes, ducts,
conduits, wires and appurtenant meters and equipment for service to other parts of the Building above the ceiling surfaces, below the floor surfaces, within the walls and in the central core areas, and to relocate any pipes, ducts, conduits, wires
and appurtenant meters and equipment which are located within the Premises or outside the Premises. All such work by Landlord shall be performed in a good and workmanlike manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Signs</U>. Any and all identification signage of Tenant shall be subject to the prior written
approval of Landlord, which shall be in conformance with the sign criteria for the Property, as approved by the City of San Diego and any other governmental entities having jurisdiction thereof and will be paid for by Tenant. Except as otherwise
provided herein, Tenant shall not place or permit to be placed, any sign, advertisement, notice or other similar matter on the doors, windows, exterior walls, roof or other areas of the Premises or the Building which are open to the view of persons
in the common area of the Building or the Premises, except with the advance written consent of Landlord, which consent may be withheld in Landlord&#146;s sole discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance and Indemnity</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant&#146;s Insurance</U>. Tenant shall at all times during the Term maintain in full force the
following insurance policies: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Liability Insurance</U>. Commercial general liability
insurance in connection with Tenant&#146;s use and occupancy of the Premises and the Building providing coverage on an occurrence form basis with limits of not less than $2,000,000.00 each occurrence for bodily injury and property damage combined,
$2,000,000.00 annual general aggregate, and $2,000,000.00 products and completed operations annual aggregate. Tenant&#146;s liability insurance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
policy or policies shall: (A)&nbsp;include premises and operations liability coverage, products and completed operations liability coverage, broad form property damage coverage, including
completed operations, blanket contractual liability coverage (including, to the maximum extent possible, coverage for the indemnification obligations of Tenant under this Lease), and personal and advertising injury coverage; (B)&nbsp;provide that
the insurance company has the duty to defend all insured&#146;s under the policy; (C)&nbsp;provide that defense costs are paid in addition to and do not deplete any of the policy limits; (D)&nbsp;cover liabilities arising out of or incurred in
connection with Tenant&#146;s use or occupancy of the Premises, the Building or the Property; (E)&nbsp;extend coverage to cover liability for the actions of Tenant&#146;s employees, agents, representatives, licensees and invitees; (F)&nbsp;contain a
cross liability endorsement or separation of insured&#146;s clause; (G)&nbsp;provide that any waiver of subrogation rights or release prior to a loss does not void coverage; (H)&nbsp;provide that it is primary to and not contributing with, any
policy of insurance carried by Landlord covering the same loss; (I)&nbsp;provide that any failure to comply with the reporting provisions shall not affect coverage provided to Landlord, Landlord Parties, and Landlord&#146;s property managers and
mortgagees; and (J)&nbsp;name Landlord, Landlord Parties, and Landlord&#146;s property managers and mortgagees and such other parties in interest as Landlord may from time to time reasonably designate to Tenant in writing, as additional
insured&#146;s. Such additional insured&#146;s shall be provided at least the same extent of coverage as is provided to Tenant under such policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Property Insurance</U>. Commercial property insurance covering all of Tenant&#146;s
Alterations (including the Tenant Improvements), Trade Fixtures, fixtures, equipment, and other personal property in the Premises, providing coverage, on an &#147;all risk&#148; or &#147;special form&#148; basis in an amount equal to at least one
hundred percent (100%) of the full replacement cost of the covered property. During the Term, the proceeds from any such policies of insurance shall be used for the repair or replacement of Tenant&#146;s property so insured. Landlord shall be
protected under such insurance to the extent of its insurable interest and, if requested by Landlord, both Landlord and Tenant shall sign all documents reasonably necessary or proper in connection with the settlement of any claim or loss under such
insurance. Landlord will have no obligation to carry insurance on any of Tenant&#146;s property in the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Insurance</U>. Such other insurance as Tenant or Landlord or any beneficiary of any
deed of trust encumbering the Building or the Property, may from time to time reasonably require, in form and amount and protecting against such risks as would be obtained by a prudent person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Requirements For All Insurance Policies</U>. Each policy of insurance required to be
maintained by Tenant under this Section&nbsp;17 shall: (A)&nbsp;be in a form, and written by an insurer, reasonably acceptable to Landlord; (B)&nbsp;be endorsed to provide that its coverage shall be primary and
<FONT STYLE="white-space:nowrap">non-contributing</FONT> with any insurance carried by Landlord; (C)&nbsp;be maintained at Tenant&#146;s sole cost and expense; and (D)&nbsp;require at least thirty (30)&nbsp;days&#146; written notice to Landlord
prior to any cancellation, nonrenewal or modification of insurance coverage. Insurance companies issuing such policies shall have rating classifications of &#147;A&#148; or better and financial size category ratings of &#147;VII&#148; or better
according to the latest edition of the A.M. Best Key Rating&nbsp;Guide. All insurance companies issuing such policies shall be admitted carriers licensed to do business in the state where the Property is located. Any deductible amount under such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
insurance shall not exceed $5,000.00. Tenant shall provide to Landlord, upon the execution of this Lease and at all times during the Term, evidence that the insurance required to be carried by
Tenant pursuant to this Section&nbsp;17, including any endorsement affecting the additional insured status, is in full force and effect and that all premiums therefore have been paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;<U>Updating Coverage</U>. Tenant shall increase the amounts of insurance provided in this
Section&nbsp;17 as reasonably required by Landlord and any mortgagee, as recommended by Landlord&#146;s insurance broker, if, in the opinion of either Landlord or any mortgagee, the amount of insurance then required under this Lease is not adequate.
Any limits set forth in this Lease on the amount or type of coverage required by Tenant&#146;s insurance shall not limit the liability of Tenant under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificates of Insurance</U>. Prior to occupancy of the Premises by Tenant, and not less than
thirty (30)&nbsp;days prior to expiration of any policy thereafter, Tenant shall furnish to Landlord a certificate of insurance reflecting that the insurance required by this Section&nbsp;17 is in force, accompanied by an endorsement showing the
required additional insured&#146;s satisfactory to Landlord in substance and form. Notwithstanding the requirements of this subsection, Tenant shall at Landlord&#146;s request provide to Landlord a certified copy of each insurance policy required to
be in force at any time pursuant to the requirements of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&#146;s
Insurance</U>. During the Term, Landlord shall maintain in effect property insurance on the Building with responsible insurers on an &#147;all risk&#148; or &#147;special form&#148; basis, insuring the Building in an amount equal to at least one
hundred percent (100%) of the replacement cost thereof, excluding land, foundations, footings and installations. Landlord may, but shall not be obligated to, carry insurance against additional perils and/or in greater amounts, including, without
limitation, coverage for earthquake or flood. Any policy maintained by Landlord under this Section&nbsp;17(b) may be maintained under a &#147;blanket policy&#148; insuring other parties and/or locations in addition to the Building. In addition to
the foregoing, in the event Tenant fails to provide or keep in force any of the insurance as required pursuant to Section&nbsp;17(a), Landlord, in its discretion, may provide such insurance, in which event, the cost thereof shall be payable by
Tenant to Landlord as Additional Rent on the first day of the calendar month immediately following demand therefore from Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver of Liability of Landlord</U>. Landlord shall not be liable to Tenant (or any subtenant,
assignee, licensee or invitee of Tenant) for any injury or damage that may result to any person or property by or from any cause whatsoever, including, without limitation, water leakage of any character, gas, fire, oil, electricity or any other
cause whatsoever, in, on or about the Premises or the Building or any part thereof, other than injury or damage resulting from the gross negligence or willful misconduct of Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Mutual Waiver of Right of Recovery and Subrogation</U>. Landlord and Tenant each hereby waive
any right of recovery against each other and each others&#146; managers, members, partners, shareholders, officers, directors, representatives and agents for any loss or damage that is covered by any policy of property insurance maintained by either
party with respect to the Premises, the Building or the Property or any operation therein, regardless of cause, including negligence of the party benefiting from the waiver, to the extent of the loss or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
damage covered thereby. If any such policy of insurance relating to this Lease or to the Premises, the Building or the Property does not permit the foregoing waiver or, if the coverage under any
such policy would be invalidated as a result of such waiver, the party maintaining such policy shall obtain from the insurer under such policy a waiver of all right of recovery by way of subrogation against either party in connection with any claim,
loss or damage covered by such policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant and Landlord Indemnity</U>. Tenant shall
indemnify, protect, defend and hold Landlord and Landlord Parties harmless from and against all losses, liabilities, costs, claims, demands, actions, damages and expenses (including attorneys&#146; fees) in any way arising out of or in connection
with: (i)&nbsp;Tenant&#146;s breach of any provision of this Lease; (ii)&nbsp;the negligence or willful misconduct of Tenant, its agents, employees and contractors; (iii)&nbsp;the use, occupancy, maintenance, and repair of the Premises, the Building
or the Property, or any part thereof, by Tenant, its agents, employees and contractors; and (iv)&nbsp;Tenant&#146;s failure to comply with any Laws respecting the use and occupancy of the Premises, the Building or the Property, or any part thereof.
The obligations of Tenant hereunder shall survive the expiration or earlier termination of this Lease. Landlord agrees to indemnify Tenant against all losses, liabilities, costs, claims, demands, actions, damages and expenses arising from
Landlord&#146;s gross negligence or willful misconduct in connection with this Lease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Damage or Destruction</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Repair of Premises</U>. If the Premises are damaged or destroyed during the Term of this Lease,
Landlord shall, except as hereinafter provided, diligently repair or rebuild them to substantially the condition in which they existed immediately prior to such damage or destruction. In no event, however, shall Landlord be obligated to spend for
such repairs more than the amount of proceeds received from the insurance required under this Lease, less any deductible payable by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Abatement of Rent</U>. In the event all or a portion of the Premises is damaged or destroyed, to
the extent Tenant cannot reasonably use the affected portion, the Basic Rent shall be abated in proportion to the rental value of the portion so affected. Such abatement shall continue for the period commencing with the damage or destruction and
ending with substantial completion by Landlord of the repair work or reconstruction which Landlord is obligated or undertakes to do. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Destruction of Premises</U>. If the Premises are damaged or destroyed to the extent that
Landlord determines that the Premises cannot, with reasonable diligence, be fully repaired or restored by Landlord within one hundred eighty (180)&nbsp;days after the date of the damage or destruction, either Landlord or Tenant shall have the right
to terminate this Lease upon thirty (30)&nbsp;days written notice to the other party. Landlord shall send Tenant written notice of Landlord&#146;s determination within sixty (60)&nbsp;days after the date of the damage or destruction. If Landlord
determines that the Premises can be fully repaired or restored within said one hundred eighty (180)&nbsp;day period, or if it is determined that such repair or restoration cannot be made within said period but neither party elects to terminate this
Lease within thirty (30)&nbsp;days&nbsp;after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the date of said determination, this Lease shall remain full force and effect and Landlord shall diligently repair and restore the Premises as set forth in this Section&nbsp;18. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&#146;s Option to Terminate</U>. Notwithstanding anything in this Lease to the contrary,
in the event of damage to or destruction of all or any portion of the Premises which is not fully covered by the insurance proceeds (including applicable deductibles) received by Landlord or which has not been insured under the insurance policies
required to be carried under the terms of this Lease, Landlord may terminate this Lease by written notice to Tenant, given within thirty (30)&nbsp;days after the date of notice to Landlord that said damage or destruction is not so covered. if
Landlord does not elect to terminate this Lease, this Lease shall remain in full force and effect and the Premises shall be repaired and rebuilt in accordance with the provisions for repair set forth in this Section&nbsp;18. If the Premises are
destroyed or damaged during the last one hundred eighty (180)&nbsp;days of the Term, Landlord may, at Landlord&#146;s option, cancel and terminate this Lease as of the date of occurrence of such damage by giving written notice to Tenant of
Landlord&#146;s election to do so within thirty (30)&nbsp;days after the date of occurrence of such damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant&#146;s Responsibility</U>. None of the foregoing provisions of this Section&nbsp;18 shall
be construed to relieve Tenant of any liability in the event the damage or destruction is caused by or the result of the negligence or willful misconduct of Tenant, its employees, agents, representatives or contractors. Landlord&#146;s obligation to
rebuild or restore the Premises under this Section&nbsp;18 shall not include Tenant&#146;s Alterations, Trade Fixtures or any other improvements, alterations or additions made by Tenant to the Premises. Tenant hereby waives the provisions of
California Civil Code Sections 1932 and 1933 with respect to any damage to or destruction of the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Condemnation</U>. If any part of the Premises shall be taken for any public or quasi-public use
under any Law or by right of eminent domain or purchase in lieu thereof, and a part thereof remains which is susceptible to occupation hereunder, this Lease shall, as to the part so taken, terminate as of the date title shall vest in the condemnor
or purchaser, and the Base Rent payable hereunder shall be adjusted so that Tenant shall be required to pay for the remainder of the Term only such portion of the Base Rent as the value of the part of the Premises remaining after such taking bears
to the value of the entire Premises prior to such taking; but in such event Landlord shall have the option to terminate this Lease as of the date when title to the part so taken vests in the condemnor or purchaser. If all of the Premises or such
part thereof is taken so that there does not remain a portion susceptible to occupation hereunder, this Lease shall thereupon terminate. All compensation awarded upon any taking hereunder shall belong exclusively to Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Entry by Landlord</U>. Landlord and its agents and representatives shall have the right to enter
the Premises for the purpose of inspecting the same, showing the Premises to prospective purchasers or others, posting notices of <FONT STYLE="white-space:nowrap">non-responsibility,</FONT> or making repairs, alterations or additions to any portion
of the Premises and the Building. Landlord and its agents may, at any time within six (6)&nbsp;months prior to the expiration of the Term, exhibit the Premises to prospective tenants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment and Subletting</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&#146;s Consent Required</U>. Tenant shall not voluntarily or by operation of law assign,
transfer, mortgage, sublet, or otherwise transfer or encumber all or any part of Tenant&#146;s interest in this Lease or in the Premises without Landlord&#146;s prior written consent, which shall not be unreasonably withheld; provided, however, that
Landlord&#146;s consent shall be subject to the provisions of Section&nbsp;21(b). For purposes of this Section&nbsp;21(a), any transfer of the majority of the voting stock in any corporate Tenant, or the majority or managing interest in the
partnership of any partnership Tenant, or the majority or managing interest in the limited liability company of any limited liability company Tenant, shall constitute an assignment hereunder. Consent to one assignment or subletting shall not
constitute a waiver of this Section&nbsp;21 or consent to any further assignment or subletting. No assignee for the benefit of creditors, trustee in bankruptcy or purchaser at any execution sale, shall have any right to possess or occupy the
Premises or any part thereof, or claim any right hereunder or assignment hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure
for Consent</U>. In the event Tenant wishes to sublet the Premises, or any portion thereof, or assign this Lease, then the following procedure shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall submit in writing to Landlord (A)&nbsp;the name of the proposed subtenant or
assignee; (B)&nbsp;a statement describing the nature of the business to be carried on in the Premises; (C)&nbsp;a copy of the proposed sublease or assignment, including all terms and conditions thereof; (D)&nbsp;Landlord&#146;s lease application
form, completed by the proposed assignee or subtenant; (E)&nbsp;financial statements for the proposed assignee or subtenant, which shall include, at a minimum, prior year and year to date (current to within six (6)&nbsp;months) balance sheets,
income and expense statements and sources and uses of cash statements; and (F)&nbsp;such other financial and business information regarding such subtenant or assignee as Landlord shall reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;At any time within thirty (30)&nbsp;days after Landlord&#146;s receipt of all of the information
specified in clauses (A)&nbsp;through (F) of Section&nbsp;21(b)(i), Landlord may, by written notice to Tenant, elect to: (A)&nbsp;cancel and terminate this Lease with respect to an assignment of this Lease or the sublease or the entire Premises;
(B)&nbsp;consent to such sublease or assignment; or (C)&nbsp;withhold Landlord&#146;s consent. If Landlord falls to respond to Tenant&#146;s request for consent within thirty (30)&nbsp;days after receipt of all of the information specified in
clauses (A)&nbsp;through (F) of Section&nbsp;21(b)(i), Landlord&#146;s consent will be deemed to have been denied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;It shall be reasonable for Landlord to consider, in deciding whether to consent to an assignment
or sublease, any or all of the following factors regarding the proposed assignee or subtenant: (A)&nbsp;whether the proposed assignee or subtenant has continuing financial strength comparable to or greater than Tenant and any guarantors of this
Lease; (B)&nbsp;the proposed use of the Premises by the assignee or subtenant, including the applicability of any covenants not to compete undertaken by Landlord to other tenants in the Building, whether made before or after execution of this Lease;
(C)&nbsp;the proposed assignee&#146;s or subtenant&#146;s business reputation; (D)&nbsp;the tenant mix within the Building; and (E)&nbsp;the business capability, experience and other qualifications of the proposed assignee or subtenant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Continuing Obligation of Tenant</U>. No
transfer permitted by this Section&nbsp;21 shall release Tenant or change Tenant&#146;s primary liability to pay Rent and to perform all other covenants and obligations of Tenant under this Lease. Landlord&#146;s acceptance of Rent from any other
person is not a waiver of any provision of this Section&nbsp;21. Consent to one transfer is not consent to any subsequent transfer. If Tenant&#146;s transferee defaults under this Lease, Landlord may proceed directly against Tenant without pursuing
remedies against the transferee. Landlord may consent to subsequent assignments or modifications of this Lease by Tenant&#146;s transferee without notifying Tenant or obtaining Tenant&#146;s consent. Such action shall not relieve Tenant&#146;s
liability under this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms and Conditions</U>. In connection with any proposed
assignment or sublease, Tenant shall pay Landlord&#146;s reasonable processing costs and attorneys&#146; fees, whether or not Landlord consents to such assignment or sublease. Each assignment or sublease shall be in form satisfactory to Landlord and
shall be subject and subordinate to the provisions of this Lease. Once approved by Landlord, such assignment or sublease shall not be modified without Landlord&#146;s prior written consent. Each assignee or sublessee shall agree to perform all of
the covenants and obligations of Tenant hereunder and shall acknowledge that the termination of this Lease shall, at Landlord&#146;s sole election, constitute a termination of every such assignment or sublease. In the event the Premises are sublet
at a rate greater than the Base Rent and any Additional Rent due under this Lease, one hundred percent (100%) of the overage will belong to Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&#146;s Remedies</U>. Any assignment or sublease without Landlord&#146;s prior written
consent shall, at Landlord&#146;s election, be void, and shall constitute a default under this Lease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">22.&nbsp;&nbsp;&nbsp;&nbsp;<U>Default</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Event of Default</U>. The occurrence of any of the following events (&#147;Event of
Default&#148;) shall constitute a default and breach of this Lease by Tenant: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;The failure by
Tenant to make any payment of Rent or any other required payment, as and when due, and such failure shall not have been cured within three (3)&nbsp;days after written notice thereof from Landlord; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Tenant&#146;s failure to perform any other term, covenant or condition contained in this Lease
and such failure shall have continued for fifteen (15)&nbsp;days after written notice of such failure is given to Tenant, provided that if any such failure creates a hazardous condition, such failure shall be cured immediately. Notwithstanding the
foregoing, if such failure cannot be cured within fifteen (15)&nbsp;days after delivery of such notice, Tenant shall not be in default hereunder so long as Tenant commences curative action within such fifteen (15)&nbsp;day period and thereafter
diligently and continuously pursues such cure to completion; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Tenant&#146;s assignment
of its assets for the benefit of its creditors; the filing of a petition by or against Tenant, where such action is not dismissed within thirty (30)&nbsp;days, seeking adjudication or reorganization under the Bankruptcy Code; the appointment of a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
receiver to take possession of, or a levy by way of attachment or, execution upon, substantially all of Tenant&#146;s assets at the Premise, or any other insolvency, dissolution, or bankruptcy
proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>. Landlord shall have the following remedies upon an Event of
Default by Tenant. These remedies are not exclusive; they are cumulative and in addition to any and all other remedies now or later allowed by applicable Law: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;Landlord shall be entitled to continue this Lease in full force and effect, and this Lease will
continue in effect as long as Landlord does not terminate this Lease, and Landlord shall have the right to collect all Rent under this Lease when due. During the period Tenant is in default, Landlord may enter the Premises and relet the Premises, or
any part thereof, to third parties for Tenant&#146;s account. Tenant shall be liable immediately to Landlord for all costs Landlord incurs in reletting the Premises, including, without limitation, attorneys&#146; fees, brokers&#146; commissions,
expenses of remodeling the Premises required by the reletting, and like costs. The reletting may be for a period shorter or longer than the remaining Term of this Lease. Tenant shall pay to Landlord all Rent due under this Lease on the dates the
Rent is due, less the Rent Landlord receives from any reletting. No act by Landlord allowed by this subsection shall terminate this Lease, unless Landlord notifies Tenant in writing that Landlord elects to terminate this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Landlord may terminate Tenant&#146;s right to possession of the Premises at any time. No act by
Landlord other than giving notice thereof to Tenant in writing shall terminate this Lease. Acts of maintenance, efforts to relet the Premises, or the appointment of a receiver on Landlord&#146;s initiative to protect Landlord&#146;s interest under
this Lease shall not constitute a termination of Tenant&#146;s right to possession. On termination, Landlord has the right to recover from Tenant: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(A)&nbsp;&nbsp;&nbsp;&nbsp;The worth, at the time of the award, of the unpaid Rent which had been earned at the time of
termination of this Lease; plus </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(B)&nbsp;&nbsp;&nbsp;&nbsp;The worth, at the time of the award, of the amount by which
the unpaid Rent that would have been earned after the date of termination of this Lease until the time of award exceeds the amount of the loss of Rent that Tenant proves could have been reasonably avoided; plus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(C)&nbsp;&nbsp;&nbsp;&nbsp;The worth, at the time of the award, of the amount by which the unpaid Rent for the balance of the
Term after the time of reward exceeds the amount of the loss of Rent that Tenant proves could have been reasonably avoided; plus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(D)&nbsp;&nbsp;&nbsp;&nbsp;Any other amount necessary to compensate Landlord for all detriment proximately caused by
Tenant&#146;s failure to perform its obligations under this Lease, or which in the ordinary course of events would be likely to result there from, including, without limitation, costs of recovering and reletting the Premises, and attorneys&#146;
fees and costs incurred in connection therewith; plus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(E)&nbsp;&nbsp;&nbsp;&nbsp;Any other amounts in addition to or in lieu of
the foregoing as may be allowed by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;The worth, at the time of the award,&#148; as used in
subsections (A)&nbsp;and (B) is to be computed by allowing interest at ten percent (10%) per annum or the maximum rate then allowable by law. &#147;The worth, at the time of the award,&#148; as referred to in subsection (C)&nbsp;of this paragraph,
is to be computed by discounting the amount of the discount rate of the Federal Reserve Bank of San Francisco at the time of the award, plus one percent (1%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Relief From Forfeiture After Default</U>. Tenant waives all rights of redemption or relief
from forfeiture under California Code of Civil Procedure Sections 1174 and 1179 and under any other present or future Law, in the event Tenant is evicted or Landlord otherwise lawfully takes possession of the Premises by reason of any Event of
Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&#146;s Right to Perform Tenant&#146;s Obligations</U>. If Tenant shall at
any time fail to perform any obligation required to be made by Tenant hereunder, after expiration of the applicable periods referred to in Section&nbsp;22(a), then Landlord may, at its option, perform such obligation to the extent Landlord deems
desirable, and may pay any and all expenses incidental thereto and employ counsel. No such action by Landlord shall be deemed a waiver by Landlord of any of Landlord&#146;s rights or remedies, or a release of Tenant from performance of such
obligation. All sums so paid by Landlord shall be due and payable by Tenant to Landlord on the day immediately following Landlord&#146;s payment thereof Landlord shall have the same rights and remedies for the nonpayment of any such sums as for
default by Tenant in the payment of Rent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies Not Exclusive</U>. No remedy or election
hereunder shall be deemed exclusive but shall, wherever possible, be cumulative with all other remedies available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notification of Reletting</U>. In the event Landlord terminates this Lease pursuant to
Section&nbsp;22(b)(ii), and Tenant has made an advance payment of &#147;rent&#148; as defined in California Civil Code Section&nbsp;1951.7 and has requested in writing that Landlord notify Tenant of any initial reletting of the Premises, then (and
only then) must Landlord notify Tenant pursuant to California Civil Code Section&nbsp;1951.7(c) that the Premises have been relet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Right of Landlord to <FONT STYLE="white-space:nowrap">Re-Enter</FONT></U>. In the event of any
termination of this Lease, Landlord shall have the immediate right to enter upon and repossess the Premises, and any personal property of Tenant may be removed from the Premises and stored in any public warehouse at the risk and expense of Tenant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&#146;s Right to Pursue Other Remedies</U>. In the event of any breach of this
Lease, Landlord may pursue any of the foregoing remedies, and Landlord may consecutively or concurrently therewith pursue any other remedy or enforce any right to which Landlord may be entitled by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination, Surrender and Abandonment</U>. No act or conduct of Landlord, including, without
limitation, efforts to <FONT STYLE="white-space:nowrap">re-lease</FONT> the Premises or an action in unlawful detainer or service of notice upon Tenant or surrender of possession by Tenant pursuant to such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
notice or action, shall extinguish the liability of Tenant to pay Rent or other sums due hereunder or terminate this Lease, unless Landlord notifies Tenant in writing of Landlord&#146;s election
to terminate this Lease. No act or conduct of Landlord, including the acceptance of the keys to the Premises, other than a written acknowledgment of acceptance of surrender signed by Landlord, shall be deemed to be or constitute an acceptance of the
surrender of the Premises by Tenant prior to the expiration of the Lease Term. The surrender of this Lease by Tenant, voluntarily or otherwise, shall, at Landlord&#146;s option, operate as an assignment to Landlord of any and all existing
assignments and subleases, or Landlord may elect to terminate any or all of such assignments and subleases by notifying the assignees and sublessees of its election within thirty (30)&nbsp;days after such surrender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">23.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Conveyance</U>. The term &#147;Landlord&#148; as used in this Lease, means only the
current owner(s) of the Building so that in the event of any sale or other transfer of the Building, the transferor shall be deemed to be relieved of all obligations of the landlord hereunder from and after the date of such sale, and the transferee
shall be deemed to have assumed and agreed to perform any and all obligations of Landlord hereunder arising from and after said date. Landlord may transfer and deliver the Security Deposit to the transferee upon any such transfer, and thereupon
Landlord shall be discharged from any liability therefore. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">24.&nbsp;&nbsp;&nbsp;&nbsp;<U>Subordination and
Attornment</U>. Tenant agrees that this Lease may, at the option of Landlord, be subject and subordinate to any mortgage, deed of trust and any other instrument of security or ground lease which has been or shall be placed on the Building or the
Property; provided that, so long as Tenant is not in default under this Lease, no foreclosure or other right or remedy exercised by the lender holding such security shall terminate this Lease. This subordination is hereby made effective without any
further act of Tenant. Tenant shall, at any time hereafter, on demand, execute any instruments, releases, or other documents that may be required by any mortgagee, mortgagor, or trustor or beneficiary under any security instrument for the purpose of
subjecting and subordinating this Lease to the lien of such instrument. Tenant shall attorn to any third party <FONT STYLE="white-space:nowrap">pm-chasing</FONT> or otherwise acquiring the Premises or the Building at any sale or other proceeding or
pursuant to the exercise of any rights, powers or remedies under any instruments of security or ground leases now or hereafter encumbering all or any part of the Premises or the Building, as if such third party had been named as Landlord under this
Lease, provided that such purchaser recognizes Tenant&#146;s rights under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">25.&nbsp;&nbsp;&nbsp;&nbsp;<U>Estoppel Certificate</U>. Tenant shall sign and deliver to Landlord, within ten (10)&nbsp;days
after receipt of Landlord&#146;s request, any estoppel certificate or other statement to be furnished&nbsp;to Landlord or any prospective purchaser of or any lender against the Premises. Such estoppel certificate shall acknowledge and certify each
of the following matters, to the extent each may be true: (a)&nbsp;that this Lease is in effect and not subject to any rental offsets, claims or defenses to its enforcement; (b)&nbsp;the commencement and termination dates of the Term; (c)&nbsp;that
Tenant is paying Rent on a current basis; (d)&nbsp;that the Tenant Improvements, if any, required to be furnished under this Lease have been completed in all respects; (e)&nbsp;that this Lease constitutes the entire agreement between Tenant and
Landlord relating to the Premises; (f)&nbsp;that Tenant has accepted the Premises and is in possession thereof; (g)&nbsp;that this Lease has not been modified, altered or amended except in specified respects by specified instruments; and
(h)&nbsp;that Tenant has no notice of any prior assignment, hypothecation or pledge of rents or this Lease. If Tenant fails </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to deliver any such estoppel certificate within ten (10)&nbsp;days after receipt thereof, Tenant hereby appoints Landlord as Tenant&#146;s attorney in fact for the purpose of completing, signing
and delivering such estoppel certificate to the person or entity requesting it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">26.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. All notices, demands or requests to be given to Tenant or Landlord under this Lease
shall be in writing, delivered personally or by commercial courier or by United States mail, postage prepaid, certified return receipt requested and addressed: (a)&nbsp;to Tenant at the Premises; or (b)&nbsp;to Landlord at such address as it may
from time to time designate to Tenant in writing. Each such notice, demand or request shall be deemed to have been received by Tenant or Landlord upon actual delivery. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Landlord&nbsp;Notice&nbsp;Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">La&nbsp;Jolla&nbsp;Shores&nbsp;Plaza,&nbsp;LLC<BR>Attention:&nbsp;Kim&nbsp;Fishman<BR>2223&nbsp;Avenida&nbsp;de&nbsp;la&nbsp;Playa,&nbsp;Suite&nbsp;350<BR>La&nbsp;Jolla,&nbsp;California&nbsp;92037<BR>Telephone:&nbsp;
858.456.5655<BR>Fax:&nbsp;858.456.5660<BR>Email:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tenant Notice Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">EQUILLIUM, INC<BR>2223 Avenida de la Playa, Suite 105<BR>La Jolla, California 92037<BR>Telephone: 858.344.6124<BR><FONT STYLE="white-space:nowrap">E-Mail:</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">27.&nbsp;&nbsp;&nbsp;&nbsp;<U>No Accord and Satisfaction</U>. No payment by Tenant, or receipt
by Landlord, of any amount which is less than the full amount of Base Rent, Additional Rent and all other sums payable by Tenant hereunder at such time shall be deemed to be other than on account of: (a)&nbsp;the earliest of such other sums due and
payable; and thereafter (b)&nbsp;to the earliest Base Rent, Additional Rent or other sum due and payable hereunder. No endorsement or statement on any check or any letter accompanying any payment of Base Rent, Additional Rent or such other sums
shall be deemed an accord and satisfaction, and Landlord may accept any such check or payment without prejudice to Landlord&#146;s right to receive payment of the balance of such Rent and/or other sums or Landlord&#146;s right to pursue all
available remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">28.&nbsp;&nbsp;&nbsp;&nbsp;<U>Attorneys&#146; Fees</U>. If any action or proceeding at law or in
equity shall be brought to recover any Rent under this Lease, or for or on account of any breach of or to enforce or interpret any of the terms, covenants, or conditions of this Lease, or for the recovery of possession of the Premises, the
prevailing party shall be entitled to recover from the other party as a part of such action or in a separate action brought for that purpose, its reasonable attorneys&#146; fees and costs and its expenses incurred in connection with the prosecution
or defense of such action. &#147;Prevailing party&#148; within the meaning of this section shall include, without limitation, a party who brings an action against the other after the other is in breach or default, if such action
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
is dismissed upon the other&#146;s payment of the sums allegedly due for performance of the covenants allegedly breached, or if the party commencing such action or proceeding obtains
substantially the relief sought by it in such action, whether or not such action proceeds to a final judgment or determination. In addition, Tenant agrees to reimburse Landlord for all of Landlord&#146;s legal fees and costs and expenses incurred in
the enforcement and protection of all of Landlord&#146;s rights under this Lease and all applicable laws, whether or not an action has been brought, including attorneys&#146; fees and costs incurred in any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-court</FONT></FONT> settlement or in connection with the filing of a bankruptcy petition by or against Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">29.&nbsp;&nbsp;&nbsp;&nbsp;<U>Holding Over</U>. This Lease shall terminate without further notice at the expiration of the
Term. Any holding over after the expiration of the Term, with the express written consent of Landlord (which consent may be granted or denied in Landlord&#146;s sole discretion), shall be construed to be a tenancy from month to month, at a monthly
rental of one hundred fifty percent (150%) of the last applicable Base Rent, and shall otherwise be on the terms and conditions herein specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">30.&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord Liability</U>. Tenant agrees that, if Tenant shall recover a money judgment against
Landlord under this Lease, such judgment shall be satisfied only out of Landlord&#146;s estate in the Property, and neither Landlord nor Landlord Parties shall have any personal or further liability whatsoever with respect to any such judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">31.&nbsp;&nbsp;&nbsp;&nbsp;<U>No Brokerage Commissions</U>. Each party warrants and represents to the other that it has not
entered into any agreement under which a brokerage commission or fee would be payable in connection with this Lease by the other. Each party further agrees to indemnify, protect, defend and hold the other party harmless from any loss, cost,
liability and expense (including attorneys&#146; fees and costs) which the other party may incur as the result of any breach of this Section&nbsp;31. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">32.&nbsp;&nbsp;&nbsp;&nbsp;<U>General Provisions</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. This Lease, together with all of the exhibits attached hereto, constitutes
the entire agreement made between the parties hereto and may not be modified orally or in any manner other than by an agreement in writing signed by the parties hereto or their respective successors in interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Time</U>. Time is of the essence with respect to the performance of each and every provision of
this Lease in which time of performance is a factor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Captions</U>. The captions of the
numbered sections of this Lease are inserted solely for the convenience of the parties hereto and shall have no effect upon the construction or interpretation of any part of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>California Law</U>. This Lease shall be construed and interpreted in accordance with the laws of
the State of California. Venue for any action under this Lease shall be in San Diego, California. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Partial Invalidity</U>. If any provision of
this Lease is held by a court of competent jurisdiction to be invalid, void, or unenforceable, the remainder of the provisions hereof shall nonetheless continue in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Warranties</U>. Any agreements, warranties or representations not expressly contained herein
shall not bind either Landlord or Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Delaying Causes</U>. If either party is delayed
in the performance of any covenant of this Lease because of any of the following causes: acts of God, war, riot, labor dispute, inability to procure or general shortage of labor or material in the normal channels of trade, delay in transportation,
delay in inspections, governmental action or moratorium, or any other cause beyond the reasonable control of the party so obligated, whether similar or dissimilar to the foregoing, financial inability excepted, then such performance shall be excused
for the period of the delay and the period for such performance shall be extended for a period equivalent to the period of such delay, except that the foregoing shall in no way affect (i)&nbsp;Tenant&#146;s obligation to pay the Basic Rent or any
other amount payable under this Lease; or (ii)&nbsp;the length of the Term of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Joint and Several Liability</U>. If Tenant is more than one person or entity, each such person
or entity shall be jointly and severally liable under the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT
STYLE="white-space:nowrap">Binding-on</FONT> Successors</U>. Subject to the provisions of Section&nbsp;21, the covenants and conditions herein contained shall apply to and be binding upon the parties hereto and their respective heirs and successors
in interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority</U>. The Parties hereby represent and warrant that they have all
necessary power and authority to execute and deliver this Lease on behalf of Landlord and Tenant, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Memorandum of Lease</U>. Tenant shall not be entitled to record this Lease or any short form
memorandum hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Lease may be signed in counterparts, each of
which shall be an original, but all of which shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Lease Not Effective Until Delivered</U>. Submission by Landlord of this Lease for examination or
signature by Tenant shall not constitute an option or reservation to lease the Premises for the benefit of Tenant. Notwithstanding such submission of this Lease and notwithstanding Landlord&#146;s proceeding with space planning or other activity
relating to construction of the Tenant Improvements, if any, this Lease shall not become effective until signed by both Tenant and Landlord and the fully signed Lease is delivered to both Landlord and Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. This Lease constitutes the entire agreement between the parties hereto
pertaining to the subject matter hereof, fully supersedes any and all prior understandings, representations, warranties and agreements between the parties hereto, or any&nbsp;of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
them, pertaining to the subject matter hereof, and may be modified only by written agreement, signed by all of the parties hereto. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">LANDLORD:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">LA JOLLA SHORES PLAZA, LLC,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a California Limited Liability Company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ James B. Morris</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James B. Morris, Managing Member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TENANT:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EQUILLIUM, INC.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a Delaware Corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Daniel M. Bradbury</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dan Bradbury</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CEO</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>EXHIBIT A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Floor Plan </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[attached]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT B </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Tenant Improvements </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT C </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Rules and Regulations </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following rules and regulations (&#147;Rules and Regulations&#148;) shall be applicable to the Premises, the Building, the
Property and all appurtenances thereto: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Use of Common Areas</U>. Sidewalks, doorways,
vestibules, halls, stairways, elevators and other similar areas shall not be obstructed by Tenant or used by Tenant for any purpose other than ingress and egress to and from the Premises. No rubbish, litter, trash, or material of any nature shall be
placed, emptied or thrown in those areas. At no time shall Tenant permit Tenant&#146;s employees to loiter in common areas or elsewhere in or about the Building or the Property. The common areas, except for the sidewalks, are not open to the general
public, and Landlord reserves the right to control and prevent access to the common areas of any person whose presence, in Landlord&#146;s opinion, would be prejudicial to the safety, reputation or interests of the Building and its tenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Plumbing Facilities</U>. Plumbing fixtures and appliances shall be used only for the purposes for
which designed, and no sweepings, rubbish, rags or other unsuitable material shall be thrown or placed therein. Landlord shall not in any case be responsible for damage resulting to any such fixtures or appliances from misuse by Tenant or its
agents, employees, or invitees; such damages shall be paid for by Tenant, and Landlord shall not in any case be responsible therefore. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Signage</U>. No signs, advertisements or notices shall be painted or affixed on or to any
windows, doors or other parts of the Building, except those of such color, style, size and in such places as shall be first approved in writing by Landlord. No nails, hooks, or screws shall be driven or inserted into any part of the Premises or the
Building except by the Building maintenance personnel, nor shall any part of the Building be defaced in any way by Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Directory</U>. Landlord may provide and maintain on the first floor (main lobby) of the Building
a directory board listing all tenants, and no other directory shall be permitted unless previously consented to by Landlord in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Keys and Locks</U>. Tenant shall not place any additional lock or locks on any door in the
Premises or the Building without Landlord&#146;s prior written consent. A reasonable number of keys to the locks on the doors in the Premises shall be furnished by Landlord to Tenant at the cost of the Tenant, and Tenant shall not have any duplicate
keys made. All keys shall be returned to Landlord at the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Contractors and Technicians</U>. Tenant will refer to Landlord for Landlord&#146;s supervision,
approval, and control of all contractors, contractor&#146;s representatives, and installation technicians rendering any service to Tenant before performance of any contractual service. Such supervisory action by Landlord shall not render Landlord
responsible for any work performed for Tenant. This provision shall apply to all work performed in the Premises and the Building, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">including, without limitation, the installation of telephones, computer wiring, cabling,
equipment, electrical devices, attachments and installations of any nature. Tenant shall be solely responsible for complying with all applicable Laws pursuant to which said work shall be performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Freight/Moving</U>. Movement in or out of the Building of furniture or office equipment, or
dispatch or receipt by Tenant of merchandise or materials which require the use of elevators, stairways, lobby areas or loading dock areas, shall be restricted to hours designated by Landlord. Tenant must seek Landlord&#146;s prior approval by
providing in writing a detailed listing of any such activity. If approved by Landlord, such activity shall be under the supervision of Landlord and performed in the manner stated by Landlord. Landlord may prohibit any article, equipment or any other
item from being brought into the Building. Tenant is to assume all risk for damage to articles moved and injury to any persons resulting from such activity. If any equipment, property, and/or personnel of Landlord or any of any other tenants is
damaged or injured as a result of or in connection with such activity, Tenant shall be solely liable for any and all damage and loss resulting there from. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Heavy Objects</U>. Landlord shall have the power to prescribe the weight and position of safes
and other heavy equipment or items, which in all cases shall not, in the opinion of Landlord, exceed acceptable floor loading and weight distribution requirements. All damage done to the Building by the installation or removal of any property of
Tenant, or done by Tenant&#146;s property while in the Building, shall be repaired at the sole expense of Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Doors</U>. Corridor doors, when not in use, shall be kept closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Nuisances; Tenant Conduct</U>. Tenant shall not: (a)&nbsp;make or permit any improper,
objectionable or unpleasant noises or odors in the Premises or the Building, or otherwise interfere in any way with other tenants or persons having business with them; (b)&nbsp;solicit business or distribute, or cause to be distributed, in any
portion of the Building any handbills, promotional materials, or other advertising; or (c)&nbsp;conduct or permit any other activities in the Building that might constitute a nuisance. Tenant shall not engage in any conduct that is physically or
verbally abusive towards any other person while in the Building, the Common Areas or the Property, including other tenants, management employees or invitees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Pets</U>. No animals, except Seeing Eye dogs, shall be brought into or kept in, on or about the
Premises or the Building. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Uses</U>. Tenant shall not use or occupy the Premises in any
manner or for any purpose which would injure the reputation or impair the present or future value of the Premises or the Building; without limiting the foregoing, Tenant shall not use or permit the Premises or any portion thereof to be used for
lodging, sleeping or for any illegal purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor Contracts</U>. Tenant shall not take
any action which would violate Landlord&#146;s&nbsp;labor contracts affecting the Building or which would cause any work stoppage, picketing, labor disruption or dispute, or any interference with the business of Landlord or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">other tenant or occupant of the Building or with the rights and privileges of any person
lawfully in the Building. Tenant shall take any actions necessary to resolve any such work stoppage, picketing, labor disruption, dispute or interference and shall have pickets removed and, at the request of Landlord, immediately terminate at any
time any construction work being performed in the Premises giving rise to such labor problems, until such time as Landlord shall have given its written consent for the resumption of such work. Tenant shall have no claim for damages of any nature
against Landlord or Landlord Parties in connection therewith, nor shall the date of the commencement of the Term be extended as a result thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Pest Control</U>. Tenant shall use those termite and pest extermination services designated by
Landlord to control termites and pests in the Premises. Tenant shall bear the cost and expense of such extermination services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Electrical Equipment</U>. Tenant shall not install, operate or maintain in the Premises or in
any other area of the Building, any electrical equipment which does not bear the U/L (Underwriters Laboratories) seal of approval, or which would overload the electrical system or any part thereof beyond its capacity for proper, efficient and safe
operation, as determined by Landlord, taking into consideration the overall electrical system and the present and future requirements therefore in the Building. Tenant shall not furnish any cooling or heating to the Premises, including, without
limitation, the use of any electronic or gas heating devices, without Landlord&#146;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vending Machines</U>. Tenant shall not operate or permit to be operated in the Premises any coin
or token operated vending machine or similar device (including, without limitation, telephones, lockers, toilets, scales, amusement devices and machines for sale of beverages, foods, candy, cigarettes or other goods), except for those vending
machines or similar devices which are for the sole and exclusive use of Tenant&#146;s employees, and then only if such operation does not violate the lease of any other tenant in the Building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vehicles</U>. Bicycles and other vehicles, including skateboards, are not permitted inside or on
the walkways outside the Building, except in those areas specifically designated by Landlord for such purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Safety</U>. Landlord may from time to time adopt appropriate systems and procedures for the
security and safety of the Building, its occupants, entry and use, or its contents. Tenant and its agents, employees, contractors, guests and invitees shall comply with Landlord&#146;s reasonable requirements relative thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Use of Name</U>. Landlord shall have the right to prohibit the use of the name of the Building
or any other publicity by Tenant that, in Landlord&#146;s opinion, may tend to impair the reputation of the Building or its desirability for Landlord or other tenants. Upon written notice from Landlord, Tenant shall refrain from and/or discontinue
such publicity immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Building Entry</U>. Landlord reserves the right to close and
keep locked all entrance and exit doors of the Building during hours Landlord may reasonably deem advisable for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">adequate protection of the Property. Except as to those having keys to the Building, use of
the Building before 7:00 a.m. or after 6:00 p.m., on Monday through Friday, or at any time on Saturdays, Sundays and legal holidays shall be permissive and subject to such Rules and Regulations as Landlord may reasonably prescribe in connection
therewith. Landlord assumes no responsibility and shall not be liable for any damage resulting from the entry of any authorized or unauthorized person(s) to the Building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Repair Times</U>. Tenant shall carry out Tenant&#146;s permitted repair, maintenance,
alterations, and improvements in the Premises only during times agreed to in advance by Landlord and in a manner which will not interfere with the rights of other tenants in the Building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">22.&nbsp;&nbsp;&nbsp;&nbsp;<U>Soliciting</U>. Canvassing, soliciting, and peddling in or about the Building is prohibited.
Tenant shall cooperate and use its best efforts to prevent the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">23.&nbsp;&nbsp;&nbsp;&nbsp;<U>Smoking</U>. At no
time shall Tenant permit nor shall Tenant or its agents, employees, contractors, guests or invitees smoke in any common area of the Building, including the garage areas, unless such common area has been declared a designated smoking area by
Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">24.&nbsp;&nbsp;&nbsp;&nbsp;<U>Deliveries</U>. All deliveries to or from the Premises shall be made only at such
times, in the areas and through such entrances and exits designated for such purposes by Landlord. Tenant shall not permit the process of receiving deliveries to or from the Premises outside of said areas or in a manner which may interfere with the
use by any other tenant of its premises or of any common areas, any pedestrian use of such area, or any use which is inconsistent with good business practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">25.&nbsp;&nbsp;&nbsp;&nbsp;<U>Janitorial Service</U>. The work of cleaning personnel shall not be hindered after 5:30 p.m.,
and such cleaning work may be done at any time when the offices are vacant. Windows, doors and fixtures may be cleaned at any time. Tenant shall provide adequate waste and rubbish receptacles necessary to prevent unreasonable hardship to Landlord
regarding cleaning service. Tenant will not employ any person for the purpose of cleaning the Premises or permit any person to enter the Building for such purpose other than Landlord&#146;s janitorial service, except with Landlord&#146;s prior
written consent. Tenant will not necessitate, and will be liable for the cost of, any undue amount of janitorial labor by reason of Tenant&#146;s carelessness or indifference to the preservation of good order and cleanliness in the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">26.&nbsp;&nbsp;&nbsp;&nbsp;<U>Wiring and Cabling Installations</U>. Landlord will direct Tenant&#146;s electricians and other
vendors as to where and how data, telephone and electrical wires and cables are to be installed. No boring or cutting for wires or cables will be allowed without the prior written consent of Landlord. The location of burglar alarms, smoke detectors,
telephones, call boxes and other office equipment affixed to the Premises shall be subject to the prior written approval of Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">27.&nbsp;&nbsp;&nbsp;&nbsp;<U>Office Closing Procedures</U>. Tenant shall see that the doors of the Premises are closed and
locked and that all water faucets, water apparatus and utilities are shut off before </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tenant or its employees leave the Premises, so as to prevent waste and damage. Tenant will
be liable for all damage or injuries sustained by other tenants or occupants of the Building or Landlord resulting from Tenant&#146;s carelessness in this regard or violation of this Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">28.&nbsp;&nbsp;&nbsp;&nbsp;<U>Responsibility for Theft</U>. Tenant assumes any and all responsibility for protecting the
Premises from theft, robbery or pilferage, which includes keeping doors locked and other means of entry to the Premises closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">29.&nbsp;&nbsp;&nbsp;&nbsp;<U>Sales and Auctions</U>. Tenant will not conduct or permit to be conducted any sale by auction
in, upon or from the Premises or elsewhere in the Building or on the Property, whether said auction be voluntary, involuntary, pursuant to any assignment for the payment of creditors or pursuant to any bankruptcy or other insolvency proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">30.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver of Rules and Regulations</U>. Landlord may waive any one or more of these Rules and
Regulations for the benefit of any particular tenant(s), but no such waiver by Landlord will be construed as a waiver of such Rules and Regulations in favor of any other tenant or tenants nor prevent Landlord from thereafter enforcing these Rules
and Regulations against any or all of the tenants of the Building. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">31.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect on Lease</U>.
These Rules and Regulations are in addition to, and shall not be construed to in any way modify or amend, in whole or in part, the terms, covenants, agreements and conditions of the Lease. Violation of these Rules and Regulations constitutes a
failure to fully perform the provisions of the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">32.&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional and Amended Rules and
Regulations</U>. Landlord reserves the right to rescind or amend these Rules and Regulations and/or to adopt any other Rules and Regulations as, in Landlord&#146;s judgment may from time to time be needed for the safety, care and cleanliness of the
Building and the Property and for the preservation of good order therein and thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT D </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>A<SMALL>SBESTOS</SMALL> D<SMALL>ISCLOSURE</SMALL> S<SMALL>TATEMENT</SMALL> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>B<SMALL>ACKGROUND</SMALL> I<SMALL>NFORMATION</SMALL></U><SMALL></SMALL>.
S<SMALL>TRUCTURAL</SMALL> <SMALL>STEEL</SMALL> <SMALL>FIREPROOFING</SMALL> <SMALL>MATERIAL</SMALL> <SMALL>AND</SMALL> <SMALL>OTHER</SMALL> <SMALL>BUILDING</SMALL> <SMALL>MATERIALS</SMALL> <SMALL>CONTAINING</SMALL> <SMALL>ASBESTOS</SMALL>
<SMALL>WERE</SMALL> <SMALL>WIDELY</SMALL> <SMALL>USED</SMALL> <SMALL>IN</SMALL> <SMALL>CONSTRUCTION</SMALL> <SMALL>FROM</SMALL> <SMALL>THE</SMALL> 1950&#146;<SMALL>S</SMALL> <SMALL>THROUGH</SMALL> <SMALL>THE</SMALL> <SMALL>MID</SMALL><FONT
STYLE="white-space:nowrap">-1970&#146;</FONT><SMALL>S</SMALL>. T<SMALL>HE</SMALL> <SMALL>BUILDING</SMALL> <SMALL>WAS</SMALL> <SMALL>BUILT</SMALL> <SMALL>BEFORE</SMALL> 1979 <SMALL>AND</SMALL> <SMALL>CERTAIN</SMALL>
<SMALL>ASBESTOS</SMALL>-<SMALL>CONTAINING</SMALL> <SMALL>MATERIALS</SMALL> (ACM) <SMALL>ARE</SMALL> <SMALL>LOCATED</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL> <SMALL>BUILDING</SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>A<SMALL>SBESTOS</SMALL> S<SMALL>URVEY</SMALL></U><SMALL></SMALL>. T<SMALL>HE</SMALL>
<SMALL>BUILDING</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>SURVEYED</SMALL> <SMALL>AND</SMALL> <SMALL>TESTED</SMALL> <SMALL>FOR</SMALL> ACM. T<SMALL>HE</SMALL> <SMALL>SURVEY</SMALL> <SMALL>DATED</SMALL> <SMALL>AUGUST</SMALL>&nbsp;7, 1991,
<SMALL>SHOWS</SMALL> <SMALL>THAT</SMALL> <SMALL>THE</SMALL> <SMALL>BUILDING</SMALL> <SMALL>CONTAINS</SMALL> <SMALL>FIREPROOFING</SMALL> <SMALL>AND</SMALL> <SMALL>OTHER</SMALL> <SMALL>MATERIALS</SMALL> <SMALL>THAT</SMALL> <SMALL>ARE</SMALL> ACM.
I<SMALL>N</SMALL> <SMALL>ACCORDANCE</SMALL> <SMALL>WITH</SMALL> C<SMALL>ODE</SMALL> <SMALL>OF</SMALL> F<SMALL>EDERAL</SMALL> R<SMALL>EGULATIONS</SMALL> P<SMALL>ART</SMALL> 1926.1101 P<SMALL>ARAGRAPH</SMALL> (<SMALL>K</SMALL>), <SMALL>YOU</SMALL>
<SMALL>ARE</SMALL> <SMALL>HEREBY</SMALL> <SMALL>NOTIFIED</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>PRESENCE</SMALL> <SMALL>OF</SMALL> <SMALL>ASBESTOS</SMALL>-<SMALL>CONTAINING</SMALL> <SMALL>MATERIALS</SMALL> (ACM) <SMALL>AND</SMALL>
<SMALL>PRESUMED</SMALL> <SMALL>ASBESTOS</SMALL>-<SMALL>CONTAINING</SMALL> <SMALL>MATERIALS</SMALL> (PACM), <SMALL>IN</SMALL> <SMALL>THE</SMALL> <SMALL>BUILDING</SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>A<SMALL>SBESTOS</SMALL> M<SMALL>ANAGEMENT</SMALL> P<SMALL>LAN</SMALL></U><SMALL></SMALL>.
M<SMALL>ANY</SMALL> <SMALL>ASBESTOS</SMALL> <SMALL>CONSULTANTS</SMALL> <SMALL>HAVE</SMALL> <SMALL>CONCLUDED</SMALL> <SMALL>THAT</SMALL> <SMALL>PRESENCE</SMALL> <SMALL>OF</SMALL> ACM <SMALL>DOES</SMALL> <SMALL>NOT</SMALL>, <SMALL>IN</SMALL>
<SMALL>ITSELF</SMALL>, <SMALL>CONSTITUTE</SMALL> <SMALL>A</SMALL> <SMALL>HEALTH</SMALL> <SMALL>HAZARD</SMALL> <SMALL>TO</SMALL> <SMALL>BUILDING</SMALL> <SMALL>OCCUPANTS</SMALL>. I<SMALL>T</SMALL> <SMALL>IS</SMALL> <SMALL>THE</SMALL>
<SMALL>OPINION</SMALL> <SMALL>OF</SMALL> <SMALL>MOST</SMALL> <SMALL>CONSULTANTS</SMALL> <SMALL>THAT</SMALL> <SMALL>ONLY</SMALL> <SMALL>WHEN</SMALL> ACM <SMALL>IS</SMALL> <SMALL>DAMAGED</SMALL> <SMALL>OR</SMALL> <SMALL>ERODED</SMALL>
<SMALL>AND</SMALL> <SMALL>ASBESTOS</SMALL> <SMALL>FIBERS</SMALL> <SMALL>BECOME</SMALL> <SMALL>AIRBORNE</SMALL> <SMALL>THAT</SMALL> <SMALL>THEY</SMALL> <SMALL>PRESENT</SMALL> <SMALL>A</SMALL> <SMALL>POTENTIAL</SMALL> <SMALL>HEALTH</SMALL>
<SMALL>HAZARD</SMALL> <SMALL>TO</SMALL> <SMALL>BUILDING</SMALL> <SMALL>OCCUPANTS</SMALL>. I<SMALL>N</SMALL> <SMALL>ORDER</SMALL> <SMALL>TO</SMALL> <SMALL>AVOID</SMALL> <SMALL>DAMAGING</SMALL> <SMALL>OR</SMALL> <SMALL>DISTURBING</SMALL> ACM
<SMALL>IN</SMALL> <SMALL>THE</SMALL> <SMALL>BUILDING</SMALL> <SMALL>AND</SMALL> <SMALL>TO</SMALL> <SMALL>ENCAPSULATE</SMALL> <SMALL>OR</SMALL> <SMALL>REMOVE</SMALL> <SMALL>DAMAGED</SMALL> <SMALL>OR</SMALL> <SMALL>ERODED</SMALL> ACM
<SMALL>WHICH</SMALL> <SMALL>MIGHT</SMALL> <SMALL>RELEASE</SMALL> <SMALL>ASBESTOS</SMALL> <SMALL>FIBERS</SMALL> <SMALL>INTO</SMALL> <SMALL>THE</SMALL> <SMALL>AIR</SMALL>, <SMALL>THE</SMALL> <SMALL>MANAGEMENT</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> <SMALL>BUILDING</SMALL> <SMALL>HAS</SMALL> <SMALL>IN</SMALL> <SMALL>PLACE</SMALL> <SMALL>AN</SMALL> <SMALL>ASBESTOS</SMALL> <SMALL>MANAGEMENT</SMALL> <SMALL>PLAN</SMALL> <SMALL>FOR</SMALL> <SMALL>THE</SMALL>
<SMALL>BUILDING</SMALL>. T<SMALL>HE</SMALL> <SMALL>PLAN</SMALL> <SMALL>INVOLVES</SMALL> <SMALL>PERIODIC</SMALL> <SMALL>AIR</SMALL> <SMALL>MONITORING</SMALL> <SMALL>BY</SMALL> <SMALL>A</SMALL> C<SMALL>ERTIFIED</SMALL> A<SMALL>SBESTOS</SMALL>
C<SMALL>ONSULTANT</SMALL> <SMALL>AND</SMALL> <SMALL>ASBESTOS</SMALL> <SMALL>ABATEMENT</SMALL> <SMALL>WORK</SMALL> <SMALL>HAS</SMALL> <SMALL>ALSO</SMALL> <SMALL>BEEN</SMALL> <SMALL>PERFORMED</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL>
<SMALL>BUILDING</SMALL>. A<SMALL>LSO</SMALL>, <SMALL>ANY</SMALL> <SMALL>ACTIVITY</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> L<SMALL>ANDLORD</SMALL> <SMALL>WHICH</SMALL> <SMALL>MIGHT</SMALL> <SMALL>CAUSE</SMALL> <SMALL>THE</SMALL>
<SMALL>RELEASE</SMALL> <SMALL>OF</SMALL> <SMALL>ASBESTOS</SMALL> <SMALL>FIBERS</SMALL> <SMALL>INTO</SMALL> <SMALL>THE</SMALL> <SMALL>AIR</SMALL> <SMALL>IS</SMALL> <SMALL>CAREFULLY</SMALL> <SMALL>CONTROLLED</SMALL> <SMALL>AND</SMALL>,
<SMALL>AS</SMALL> <SMALL>MAY</SMALL> <SMALL>BECOME</SMALL> <SMALL>NECESSARY</SMALL> <SMALL>DURING</SMALL> <SMALL>REPAIR</SMALL> <SMALL>OR</SMALL> <SMALL>RENOVATION</SMALL> <SMALL>WORK</SMALL>, ACM <SMALL>WILL</SMALL> <SMALL>BE</SMALL>
<SMALL>REMOVED</SMALL> <SMALL>UNDER</SMALL> <SMALL>STRICT</SMALL> <SMALL>GUIDELINES</SMALL> <SMALL>AS</SMALL> <SMALL>SET</SMALL> <SMALL>FORTH</SMALL> <SMALL>BY</SMALL> <SMALL>OUR</SMALL> <SMALL>PROFESSIONAL</SMALL> <SMALL>ASBESTOS</SMALL>
<SMALL>CONSULTANTS</SMALL> <SMALL>AND</SMALL> <SMALL>IN</SMALL> <SMALL>COMPLIANCE</SMALL> <SMALL>WITH</SMALL> <SMALL>APPLICABLE</SMALL> <SMALL>STATE</SMALL> <SMALL>AND</SMALL> <SMALL>FEDERAL</SMALL> <SMALL>REQUIREMENTS</SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>I<SMALL>NFORMATION</SMALL> R<SMALL>EGARDING</SMALL> E<SMALL>XPOSURE</SMALL></U><SMALL></SMALL>.
T<SMALL>HE</SMALL> L<SMALL>ANDLORD</SMALL> <SMALL>IS</SMALL> <SMALL>NOT</SMALL> <SMALL>AWARE</SMALL> <SMALL>OF</SMALL> <SMALL>ANY</SMALL> <SMALL>HEALTH</SMALL> <SMALL>RISK</SMALL> <SMALL>ASSOCIATED</SMALL> <SMALL>WITH</SMALL>
<SMALL>POTENTIAL</SMALL> <SMALL>EXPOSURE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>LEVELS</SMALL> <SMALL>OF</SMALL> <SMALL>AIRBORNE</SMALL> <SMALL>ASBESTOS</SMALL> <SMALL>AS</SMALL> <SMALL>CURRENTLY</SMALL> <SMALL>SHOWN</SMALL>
<SMALL>BY</SMALL> <SMALL>THE</SMALL> <SMALL>PERIODIC</SMALL> <SMALL>AIR</SMALL> <SMALL>MONITORING</SMALL> <SMALL>REPORTS</SMALL> <SMALL>WHICH</SMALL> <SMALL>HAVE</SMALL> <SMALL>BEEN</SMALL> <SMALL>PREPARED</SMALL> <SMALL>FOR</SMALL>
<SMALL>THE</SMALL> <SMALL>BUILDING</SMALL>. H<SMALL>OWEVER</SMALL>, <SMALL>AS</SMALL> <SMALL>REQUIRED</SMALL> <SMALL>BY</SMALL> C<SMALL>ALIFORNIA</SMALL> H<SMALL>EALTH</SMALL> A<SMALL>ND</SMALL> S<SMALL>AFETY</SMALL> C<SMALL>ODE</SMALL>
S<SMALL>ECTION</SMALL>&nbsp;25915 <SMALL>ET</SMALL> <SMALL>SEQ</SMALL>., <SMALL>WE</SMALL> <SMALL>ARE</SMALL> <SMALL>INFORMING</SMALL> <SMALL>YOU</SMALL> <SMALL>THAT</SMALL> <SMALL>ASBESTOSIS</SMALL>, <SMALL>LUNG</SMALL> <SMALL>CANCER</SMALL>,
<SMALL>AND</SMALL> <SMALL>OTHER</SMALL> <SMALL>RARE</SMALL> <SMALL>TYPES</SMALL> <SMALL>OF</SMALL> <SMALL>CANCER</SMALL> <SMALL>HAVE</SMALL> <SMALL>BEEN</SMALL> <SMALL>ASSOCIATED</SMALL> <SMALL>WITH</SMALL> <SMALL>EXPOSURE</SMALL>
<SMALL>PRIMARILY</SMALL> <SMALL>IN</SMALL> <SMALL>ASBESTOS</SMALL>-<SMALL>RELATED</SMALL> <SMALL>INDUSTRIES</SMALL> <SMALL>WHERE</SMALL> <SMALL>WORKERS</SMALL> <SMALL>HANDLE</SMALL> <SMALL>OR</SMALL> <SMALL>ARE</SMALL> <SMALL>OTHERWISE</SMALL>
<SMALL>EXPOSED</SMALL> <SMALL>TO</SMALL> <SMALL>HIGH</SMALL> <SMALL>LEVELS</SMALL> <SMALL>OF</SMALL> <SMALL>AIRBORNE</SMALL> <SMALL>ASBESTOS</SMALL> <SMALL>OVER</SMALL> <SMALL>A</SMALL> <SMALL>LONG</SMALL> <SMALL>PERIOD</SMALL> <SMALL>OF</SMALL>
<SMALL>TIME</SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>A<SMALL>VAILABILITY</SMALL> <SMALL>OF</SMALL> S<SMALL>URVEY</SMALL>
<SMALL>AND</SMALL> R<SMALL>EPORTS</SMALL></U><SMALL></SMALL>. T<SMALL>HE</SMALL> <SMALL>SURVEY</SMALL> <SMALL>TOGETHER</SMALL> <SMALL>WITH</SMALL> <SMALL>AIR</SMALL> <SMALL>MONITORING</SMALL> <SMALL>REPORTS</SMALL> (<SMALL>INCLUDING</SMALL>
<SMALL>SAMPLING</SMALL> <SMALL>AND</SMALL> <SMALL>LABORATORY</SMALL> <SMALL>PROCEDURES</SMALL>) <SMALL>ARE</SMALL> <SMALL>AVAILABLE</SMALL> <SMALL>FOR</SMALL> <SMALL>INSPECTION</SMALL> <SMALL>AND</SMALL> <SMALL>PHOTOCOPYING</SMALL>
<SMALL>THROUGH</SMALL> <SMALL>THE</SMALL> <SMALL>PROPERTY</SMALL> <SMALL>MANAGER</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>BUILDING</SMALL> <SMALL>DURING</SMALL> <SMALL>NORMAL</SMALL> <SMALL>BUSINESS</SMALL> <SMALL>HOURS</SMALL>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>N<SMALL>OTICE</SMALL> P<SMALL>ROCEDURES</SMALL>
<SMALL>FOR</SMALL> C<SMALL>ONSTRUCTION</SMALL> A<SMALL>CTIVITIES</SMALL></U><SMALL></SMALL>. T<SMALL>ENANT</SMALL> <SMALL>MUST</SMALL> <SMALL>CONTACT</SMALL> <SMALL>THE</SMALL> <SMALL>BUILDING</SMALL> <SMALL>PROPERTY</SMALL> <SMALL>MANAGER</SMALL>
<SMALL>PRIOR</SMALL> <SMALL>TO</SMALL> <SMALL>ANY</SMALL> <SMALL>ACTIVITY</SMALL> <SMALL>CONDUCTED</SMALL> <SMALL>BY</SMALL> <SMALL>TENANT</SMALL> <SMALL>OR</SMALL> <SMALL>ANY</SMALL> <SMALL>CONTRACTOR</SMALL> <SMALL>OR</SMALL>
<SMALL>SERVICE</SMALL> <SMALL>PERSONNEL</SMALL> <SMALL>WHICH</SMALL> <SMALL>MIGHT</SMALL> <SMALL>DISTURB</SMALL> ACM <SMALL>IN</SMALL> <SMALL>THE</SMALL> <SMALL>BUILDING</SMALL>. T<SMALL>HIS</SMALL> <SMALL>NOTICE</SMALL> <SMALL>PROCEDURE</SMALL>
<SMALL>APPLIES</SMALL> <SMALL>PRIMARILY</SMALL> <SMALL>TO</SMALL> <SMALL>ANY</SMALL> <SMALL>CONSTRUCTION</SMALL> <SMALL>ACTIVITY</SMALL> <SMALL>REQUIRING</SMALL> <SMALL>OPENING</SMALL> <SMALL>UP</SMALL> <SMALL>THE</SMALL>
<SMALL>DROP</SMALL>-<SMALL>CEILING</SMALL>, <SMALL>INCLUDING</SMALL> <SMALL>ACTIVITIES</SMALL> <SMALL>SUCH</SMALL> <SMALL>AS</SMALL> <SMALL>RUNNING</SMALL> <SMALL>TELEPHONE</SMALL> <SMALL>OR</SMALL> <SMALL>ELECTRICAL</SMALL> <SMALL>CABLES</SMALL>
<SMALL>OR</SMALL> <SMALL>WORKING</SMALL> <SMALL>ON</SMALL> <SMALL>AIR</SMALL> <SMALL>DUCTS</SMALL> <SMALL>OR</SMALL> <SMALL>PIPING</SMALL> <SMALL>ABOVE</SMALL> <SMALL>THE</SMALL> <SMALL>DROP</SMALL>-<SMALL>CEILING</SMALL>. M<SMALL>OVING</SMALL>,
<SMALL>DRILLING</SMALL>, <SMALL>BORING</SMALL> <SMALL>AND</SMALL> <SMALL>OTHERWISE</SMALL> <SMALL>DISTURBING</SMALL> <SMALL>THE</SMALL> ACM <SMALL>MAY</SMALL> <SMALL>PRESENT</SMALL> <SMALL>A</SMALL> <SMALL>HEALTH</SMALL> <SMALL>RISK</SMALL>
<SMALL>AND</SMALL> <SMALL>SHOULD</SMALL> <SMALL>NOT</SMALL> <SMALL>BE</SMALL> <SMALL>ATTEMPTED</SMALL> <SMALL>BY</SMALL> <SMALL>ANY</SMALL> <SMALL>EMPLOYEE</SMALL> <SMALL>WHO</SMALL> <SMALL>HAS</SMALL> <SMALL>NOT</SMALL> <SMALL>BEEN</SMALL>
<SMALL>TRAINED</SMALL> <SMALL>AND</SMALL> <SMALL>QUALIFIED</SMALL> <SMALL>TO</SMALL> <SMALL>HANDLE</SMALL> ACM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>H<SMALL>EALTH</SMALL> A<SMALL>ND</SMALL> S<SMALL>AFETY</SMALL> C<SMALL>ODE</SMALL>
S<SMALL>ECTION</SMALL></U><SMALL><U></U><U></U></SMALL><U>&nbsp;25915</U>. T<SMALL>HIS</SMALL> D<SMALL>ISCLOSURE</SMALL> S<SMALL>TATEMENT</SMALL> I<SMALL>S</SMALL> P<SMALL>ROVIDED</SMALL> T<SMALL>O</SMALL> T<SMALL>ENANT</SMALL> I<SMALL>N</SMALL>
C<SMALL>OMPLIANCE</SMALL> W<SMALL>ITH</SMALL> C<SMALL>ALIFORNIA</SMALL> H<SMALL>EALTH</SMALL> A<SMALL>ND</SMALL> S<SMALL>AFETY</SMALL> C<SMALL>ODE</SMALL> S<SMALL>ECTION</SMALL>&nbsp;25915 E<SMALL>T</SMALL> S<SMALL>EQ</SMALL>. T<SMALL>ENANT</SMALL>
S<SMALL>HOULD</SMALL> B<SMALL>E</SMALL> A<SMALL>WARE</SMALL> T<SMALL>HAT</SMALL> U<SMALL>NDER</SMALL> T<SMALL>HE</SMALL> R<SMALL>EQUIREMENTS</SMALL> O<SMALL>F</SMALL> S<SMALL>ECTION</SMALL>&nbsp;25915 E<SMALL>T</SMALL> S<SMALL>EQ</SMALL>.,
T<SMALL>ENANT</SMALL> I<SMALL>S</SMALL> A<SMALL>LSO</SMALL> R<SMALL>EQUIRED</SMALL> T<SMALL>O</SMALL> P<SMALL>ROVIDE</SMALL> T<SMALL>HIS</SMALL> I<SMALL>NFORMATION</SMALL> T<SMALL>O</SMALL> T<SMALL>ENANT</SMALL>&#146;<SMALL>S</SMALL>
E<SMALL>MPLOYEES</SMALL>, S<SMALL>UBLESSEES</SMALL>, C<SMALL>ONTRACTORS</SMALL> A<SMALL>ND</SMALL> O<SMALL>THERS</SMALL> A<SMALL>S</SMALL> D<SMALL>ESCRIBED</SMALL> I<SMALL>N</SMALL> T<SMALL>HE</SMALL> C<SMALL>ODE</SMALL>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Parking Addendum </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Parking Addendum (&#147;Parking Addendum&#148;) supplements and modifies that certain Standard Office Lease, effective as
of February , 2018 (&#147;Lease&#148;) between LA JOLLA SHORES PLAZA, LLC (&#147;Landlord&#148;) and <B>EQUILLIUM, INC.</B>, (&#147;Tenant&#148;). All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in
the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;During the Term, Tenant agrees to lease from Landlord and Landlord agrees to lease
to Tenant a total of <B>Three </B>(<B>3</B>)&nbsp;parking spaces (<B>Garage #15, #47 &amp; #58</B>) for the use of Tenant and its employees. No deductions or allowances shall be made for days when Tenant or any of its employees do not utilize the
parking facilities or for Tenant utilizing fewer than all of the Spaces. Tenant shall not have the right to lease or otherwise use more than the number of reserved and unreserved Spaces set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall pay Landlord, as Additional Rent, the sum of Fifty Dollars ($50.00) per Garage Space
per month. The Spaces may be reassigned at Landlord&#146;s sole discretion at any time during the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;Landlord shall have the right to designate the location of the Spaces and to promulgate reasonable
rules and regulations regarding the Spaces, the Garage, the Surface Parking Area, and the use thereof, including, without limitation, rules and regulations controlling the flow of traffic to and from various parking areas and the angle and direction
of parking. Tenant shall comply with and cause its employees to comply with all such rules and regulations as well as all reasonable additions and amendments thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall not store or permit its employees to store any automobiles in the Garage or in the
Surface Parking Area without the prior written consent of Landlord. Except for emergency repairs, Tenant and its employees shall not perform work on any automobiles while located in the Garage, on the Surface Parking Area, or on the Property. If it
is necessary for Tenant or its employees to leave an automobile in the Garage or on the Surface Parking Area overnight, Tenant shall provide Landlord with prior notice thereof designating the license plate number and model of such automobile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.&nbsp;&nbsp;&nbsp;&nbsp;Landlord shall have the right to temporarily close the Garage or Surface Parking Area, or certain
areas therein, in order to perform necessary repairs, maintenance and improvements to the Garage, the Surface Parking Area. or any other part of the Building or the Property. Landlord shall also have the right to use of the parking after normal
business hours for special event or as necessary for temporary paid parking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall not
assign or sublease any of the Spaces without the prior written consent of Landlord, which may be granted or denied in Landlord&#146;s sole discretion. Landlord shall have the right to terminate this Parking Addendum with respect to any Spaces that
Tenant desires to assign or sublease hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.&nbsp;&nbsp;&nbsp;&nbsp;Landlord may elect to provide parking cards or
keys to control access to the Garage or Surface Parking Area. In such event, Landlord shall provide Tenant with one card or key for each Space that Tenant is leasing hereunder; provided that Landlord shall have the right to require Tenant or its
employees to place a deposit on such access cards or keys and to pay a fee for any lost or damaged cards or keys. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>RELEASE OF LIABILITY</U>. TENANT ACKNOWLEDGES
AND AGREES THAT, TO THE FULLEST EXTENT PERMITTED BY LAW, LANDLORD SHALL NOT BE RESPONSIBLE FOR ANY INJURY, LOSS OR DAMAGE TO TENANT, TENANT&#146;S EMPLOYEES OR ANY OF THEIR PROPERTY (INCLUDING, WITHOUT LIMITATION. ANY LOSS OR DAMAGE TO TENANT&#146;S
OR TENANT&#146;S EMPLOYEES&#146; AUTOMOBILES OR THE CONTENTS THEREOF DUE TO THEFT, VANDALISM OR ACCIDENT) ARISING FROM OR RELATED TO TENANT&#146;S OR TENANT&#146;S EMPLOYEES&#146; USE OF THE SPACES OR EXERCISE OF ANY RIGHTS UNDER THIS PARKING
ADDENDUM. TENANT FULLY RELEASES, ACQUITS, DISCHARGES, AND COVENANTS TO INDEMNIFY AND HOLD HARMLESS LANDLORD AND LANDLORD PARTIES FROM ALL ACTIONS, CLAIMS, DAMAGES AND LIABILITIES OF EVERY NATURE ARISING FROM OR RELATED TO TENANT AND TENANT&#146;S
EMPLOYEES&#146; USE OF THE SPACES OR THE EXERCISE OF ANY RIGHTS UNDER THIS PARKING ADDENDUM. TENANT UNDERSTANDS AND AGREES THAT THIS IS A COMPLETE RELEASE AND THAT THERE ARE NO WRITTEN OR ORAL UNDERSTANDINGS OR AGREEMENTS RELATING TO THIS RELEASE
AND THIS PARKING ADDENDUM THAT ARE NOT INCORPORATED HEREIN. IN CONNECTION WITH THIS PARAGRAPH 8, TENANT EXPRESSLY WAIVES ANY BENEFITS UNDER CALIFORNIA CIVIL CODE SECTION 1542 WHICH PROVIDES THAT: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF
EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">LANDLORD:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">LA JOLLA SHORES PLAZA, LLC,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a California limited liability company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ James B. Morris</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James B. Morris, Managing Member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TENANT:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EQUILLIUM, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a Delaware Corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Daniel M. Bradbury</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dan Bradbury</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Its:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CEO</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><STRIKE>EXHIBIT H</STRIKE> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><STRIKE>Guaranty Agreement</STRIKE> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><STRIKE>FOR VALUE RECEIVED, and in consideration for LA JOLLA SHORES PLAZA, INC., A Limited Liability Corporation (&#147;Lessor&#148;),
entering into that certain La Jolla Shores Plaza Office Lease dated ___________ (&#147;Lease&#148;) between Lessor and ___________ (&#147;Lessee&#148;), relating to the premises described as Suite 105 of the office building located at 2223 Avenida
de la Playa, La Jolla, California, and as more particularly described in the Lease (&#147;Premises&#148;), the undersigned Neil Senturio (&#147;Guarantor&#148;) hereby guarantees to Lessor (i) the prompt payment in accordance with its terms of all
rent due to Lessor e, (ii) strict compliance by Lessee with the terms, covenants and conditions of the Lease. Notwithstanding anything in the foregoing to the contrary, the liability of the guarantor under this guaranty shall not exceed ___________
(total of 5 years base rent and utilities expense) in the aggregate.</STRIKE> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><STRIKE>Guarantor hereby grants to Lessor full power and
authority to: (i)&nbsp;change, alter, cancel, renew or extend the time for payment of rent due under the Lease or performance by Lessee of any other terms or conditions of the lease as Lessor and may expressly or impliedly agree upon; or
(ii)&nbsp;change, modify, extend or otherwise amend the Lease, including increasing the rental payable there under by Lessee; or (iii)&nbsp;otherwise deal with as Lessor may elect, without in any way diminishing, releasing or discharging the
liability hereunder of Guarantor. Such liability shall be continuing and shall only by terminated by full compliance by Lessee with all the terms of the Lease.</STRIKE> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><STRIKE>Notice of acceptance of this Guaranty as well as all demands, presentations, notices of protest and notices of every kind or nature,
including those of any action or <FONT STYLE="white-space:nowrap">non-action</FONT> on the part of Lessee, Lessor or other party, are hereby fully waived by Guarantor.</STRIKE> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><STRIKE>Upon any default of Lessee under the Lease during the Lease Term, Lessor may, at its option, proceed directly and at once, without
notice of such default, against Guarantor to collect and recover the full amount of the liability hereunder or any portion thereof without proceeding against Lessee or any other party of foreclosing upon, selling, or otherwise disposing of or
collecting or applying any property, real or personal, Lessor may then have as security for the performance by Lessee under the Lease. Guarantor hereby waives the right to require Lessor to proceed against Lessee or to pursue any other remedy Lessor
may have, waives the right to plead or assert any election of remedies Lessor may have, waives the pleading of any statute of limitations as a defense to the obligation hereunder, and waives any other defense arising by reason of any disability or
other defenses of Lessee or by reason of the cessation from any cause whatsoever of the liability of Lessee.</STRIKE> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><STRIKE>If legal
action is commenced by Lessor to enforce this Guaranty or any term or condition hereof, Guarantor agrees to pay to Lessor costs of collection and, as part of the costs incurred therein, such additional sums as the Court may adjudge reasonable as
attorneys&#146; fees in said suit.</STRIKE> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><STRIKE>No indulgence, forbearance or extensions of time of payment or performance permitted
or granted to Lessee by Lessor shall in any way release Guarantor from liability or diminish Guarantor&#146;s obligations hereunder.</STRIKE> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><STRIKE>Lessor may without notice to Guarantor assign this Guaranty in whole or in party.</STRIKE> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><STRIKE>Any indebtedness of Lessee now or hereafter held by Guarantor is hereby subordinated to any indebtedness of Lessee or Lessor, and such
indebtedness of Lessee to Guarantor if Lessee so requests shall be collected, enforced and received by Guarantor as trustee for and held as security for performance of the obligation of Lessee to Lessor, but without reducing or affecting in any
manner the liability of Guarantor under the other provisions of this Guaranty.</STRIKE> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><STRIKE>Dated:&nbsp;____________________</STRIKE></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><STRIKE>&#147;Guarantor&#148;</STRIKE></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><STRIKE>_________________________________________________________</STRIKE></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><STRIKE>Dan Bradbury</STRIKE></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>14
<FILENAME>d582934dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Equillium, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June&nbsp;1, 2018
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Daniel M. Bradbury </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employment Terms</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Dan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium, Inc. (the &#147;<B>Company</B>&#148;) is
pleased to offer you the position of Chief Executive Officer on the following terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will report to the Board of Directors. Your home office will be
at our offices located in La Jolla, California, and you may also be required to work at other offices and locations from time to time as required to perform your job duties. The Company may change your position, duties and work location from time to
time in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s regular business hours are from 8:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee,
you will be expected to work additional hours, including evenings and weekends, as required to perform your job duties, and you will not be eligible for overtime pay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your base salary will be at the annualized rate of $400,000, less required and designated payroll deductions and withholdings, paid semi-monthly
(&#147;<B>Base Salary</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to earn an annual discretionary performance-based bonus at an annual target amount of thirty-five
percent (35%) of your then current base salary (&#147;<B>Target Bonus</B>&#148;), based on the attainment of individual and Company objectives to be determined and approved by the Company. The Company&#146;s payment, and the amount, of any such
bonus shall be in the sole discretion of the Company. No amount of bonus is guaranteed, and, in addition to the other conditions for earning any such bonus, you must remain an employee in good standing of the Company on the date the bonus is
determined and paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to participate in the Company&#146;s standard employee benefits (pursuant to the terms and conditions of the
benefit plans and applicable policies), as they may be terminated or changed from time to time within the Company&#146;s discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event you are
terminated by the Company without Cause (as defined below), you will be eligible to receive an amount equal to your then current Base Salary for six (6)&nbsp;months less required deductions and withholdings and the Company shall pay the premiums for
your group health insurance COBRA continuance coverage for six (6)&nbsp;months following such termination without Cause or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer (the
&#147;<B>Termination Benefits</B>&#148;). &#147;<B>Cause</B>&#148; for termination shall mean that the Company has determined in its sole discretion that you have engaged in any of the following: (i)&nbsp;a material breach of any covenant or
condition under the terms of your employment agreement or any other agreement between the parties; (ii)&nbsp;any act constituting </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dishonesty, insubordination, fraud, immoral or disreputable conduct; (iii)&nbsp;any conduct which constitutes a felony under applicable law; (iv)&nbsp;violation of any written Company policy or
any act of misconduct; (v)&nbsp;negligence or incompetence in the performance your duties or failure to perform such duties in a manner satisfactory to the Company after the expiration of ten (10)&nbsp;days without cure after written notice of such
failure; or (vii)&nbsp;breach of fiduciary duty or the duty of loyalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event you are terminated by the Company without Cause within one
(1)&nbsp;month prior to, or twelve (12)&nbsp;months following, a Deemed Liquidation Event (as defined in the Company&#146;s Amended and Restated Certificate of Incorporation, as amended from time to time), you will be eligible to receive an amount
equal to your then current Base Salary for twelve (12)&nbsp;months less required deductions and withholdings, an amount equal to your then current Target Bonus less required deductions and withholdings and the Company shall pay the premiums for your
group health insurance COBRA continuance coverage for twelve (12)&nbsp;months following such termination without Cause or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer (&#147;<B>Change
of Control Benefits</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination Benefits or Change of Control Benefits, if and when due, shall be paid in equal installments beginning on the
Company&#146;s first regularly scheduled payroll date following the Release Effective Date (as defined below) with the remaining installments occurring on the Company&#146;s regularly scheduled payroll dates thereafter. Notwithstanding the
foregoing, you shall not receive any of the benefits described in the two paragraphs immediately above unless you deliver to the Company an effective, general release of claims in favor of the Company in the form attached hereto, which has become
effective in accordance with its terms (the date that such release can no longer be revoked is referred to as the &#147;<B>Release Effective Date</B>&#148;). In no event will you be entitled to both Termination Benefits and Change of Control
Benefits. If you are entitled to receive Termination Benefits and thereafter become entitled to Change of Control Benefits, any previously provided Termination Benefits shall offset Change of Control Benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a Company employee, you will be expected to comply with Company policies and procedures, which will be provided to you. As a condition of employment, you
must read, sign and comply with the enclosed Employee Confidential Information and Invention Assignment Agreement (&#147;<B>Confidential Information Agreement</B>&#148;), which, among other provisions, prohibits any unauthorized use or disclosure of
Company proprietary, confidential or trade secret information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In your work for the Company, you will be prohibited from using or disclosing any
confidential, proprietary or trade secret information or other property of any former employer or third party to whom you have an obligation of confidentiality. Rather, you will be required to use only information that is generally known and used by
persons with training and experience comparable to your own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises
or use in your work for the Company any confidential, proprietary or trade secret information or other property belonging to any former employer or third party that you are not authorized to use and disclose. You represent further that you have
disclosed to the Company in writing any agreement you may have with any third party (e.g., a former employer) that may limit your ability to perform your duties to the Company, or that could present a
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conflict of interest with the Company, including but not limited to disclosure (and a copy) of any contractual restrictions on solicitations or competitive activities. By accepting employment
with the Company, you are representing that you will be able to perform your job duties within these parameters, and that you are not in unauthorized possession or control of any confidential, proprietary or trade secret information or other
property of any former employer or third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your employment relationship with the Company will be at will. You may terminate your employment with the
Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. Your employment
<FONT STYLE="white-space:nowrap">at-will</FONT> status can only be changed in a written agreement signed by you and the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by law, this
offer is subject to satisfactory proof of your identity and right to work in the United States. Additionally, this offer is subject to you providing satisfactory professional references to the Company. Further, this offer is conditioned on
completion, with results satisfactory to the Company, of a required <FONT STYLE="white-space:nowrap">pre-employment</FONT> background check. You must timely provide all information and documents required to complete that process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company both agree
that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this letter agreement, your employment
with the Company, or the termination of your employment with the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> and to the fullest extent permitted by law, by final,
binding and confidential arbitration conducted by JAMS, Inc. (&#147;<B>JAMS</B>&#148;) or its successors by a single arbitrator. The arbitration will be held in San Diego, California, or such other location as then-agreed by the parties. <B><I>Both
you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</I></B>. Any such arbitration proceeding will be
governed by JAMS&#146; then applicable rules and procedures for employment disputes, which can be found at <U>http://www.jamsadr.com/rules-clauses/</U> and which will be provided to you upon request. In any such proceeding, the arbitrator shall:
(a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision including the arbitrator&#146;s essential
findings and conclusions and a statement of the award. You and the Company each shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law. Nothing in this Agreement is intended to prevent either the
Company or you from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. The Company shall pay all filing fees in excess of those which would be required if the
dispute were decided in a court of law, and shall pay the arbitrator&#146;s fees and any other fees or costs unique to arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of
any competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement, together with your Confidential Information Agreement, will form the complete and exclusive statement
of your employment agreement with the Company. The terms in this letter agreement supersede any other agreements, promises or representations made to you </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by anyone, whether oral or written, regarding the subject matters hereof. This letter agreement cannot be changed except in a written agreement signed by you and the Board, with the exception of
those changes expressly reserved to the Company&#146;s discretion in this letter agreement. This letter agreement is governed by the laws of the state of California, without reference to conflicts of law principles. If any provision of this letter
agreement shall be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this letter agreement, and such provision will be reformed, construed and enforced so as to render it valid
and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this letter agreement, no waiver of any right hereunder shall be effective unless it is in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and date this letter and the enclosed Confidential Information Agreement, and return them to me if you decide to accept employment with the
Company under the terms described above. Your start date will be June&nbsp;1, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to your favorable reply and to a productive and
enjoyable working relationship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Bruce D.
Steel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bruce D. Steel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Business Officer
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel M. Bradbury</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">June&nbsp;1, 2018</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Daniel M. Bradbury</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attachments: Employee Confidential Information and Inventions Assignment Agreement, Form of Separation and Release Agreement
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>15
<FILENAME>d582934dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Equillium, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19&nbsp;March 2018
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jason A. Keyes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: Employment Terms</B>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Jason: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium, Inc. (the
&#147;<B>Company</B>&#148;) is pleased to offer you the position of Chief Financial Officer on the following terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will report to the Chief
Executive Officer. Your home office will be at our offices located in La Jolla, California, and you may also be required to work at other offices and locations from time to time as required to perform your job duties. The Company may change your
position, duties and work location from time to time in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s regular business hours are from 8:00 a.m. to 5:00 p.m., Monday
through Friday. As an exempt salaried employee, you will be expected to work additional hours, including evenings and weekends, as required to perform your job duties, and you will not be eligible for overtime pay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your base salary will be at the annualized rate of $290,000, less required and designated payroll deductions and withholdings, paid semi-monthly
(&#147;<B>Base Salary</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to earn an annual discretionary performance-based bonus at an annual target amount of thirty
percent (30%) of your then current base salary (&#147;<B>Target Bonus</B>&#148;), based on the attainment of individual and Company objectives to be determined and approved by the Company. The Company&#146;s payment, and the amount, of any such
bonus shall be in the sole discretion of the Company. No amount of bonus is guaranteed, and, in addition to the other conditions for earning any such bonus, you must remain an employee in good standing of the Company on the date the bonus is
determined and paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to participate in the Company&#146;s standard employee benefits (pursuant to the terms and conditions of the
benefit plans and applicable policies), as they may be terminated or changed from time to time within the Company&#146;s discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event you are
terminated by the Company without Cause (as defined below), you will be eligible to receive an amount equal to your then current Base Salary for six (6)&nbsp;months less required deductions and withholdings and the Company shall pay the premiums for
your group health insurance COBRA continuance coverage for six (6)&nbsp;months following such termination without Cause or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer (the
&#147;<B>Termination Benefits</B>&#148;). &#147;<B>Cause</B>&#148; for termination shall mean that the Company has determined in its sole discretion that you have engaged in any of the following: </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) a material breach of any covenant or condition under the terms of your employment agreement or any other
agreement between the parties; (ii)&nbsp;any act constituting dishonesty, insubordination, fraud, immoral or disreputable conduct; (iii)&nbsp;any conduct which constitutes a felony under applicable law; (iv)&nbsp;violation of any written Company
policy or any act of misconduct; (v)&nbsp;negligence or incompetence in the performance your duties or failure to perform such duties in a manner satisfactory to the Company after the expiration of ten (10)&nbsp;days without cure after written
notice of such failure; or (vii)&nbsp;breach of fiduciary duty or the duty of loyalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event you are terminated by the Company without Cause
within one (1)&nbsp;month prior to, or twelve (12)&nbsp;months following, a Deemed Liquidation Event (as defined in the Company&#146;s Amended and Restated Certificate of Incorporation, as amended from time to time), you will be eligible to receive
an amount equal to your then current Base Salary for twelve (12)&nbsp;months less required deductions and withholdings, an amount equal to your then current Target Bonus less required deductions and withholdings and the Company shall pay the
premiums for your group health insurance COBRA continuance coverage for twelve (12)&nbsp;months following such termination without Cause or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer
(&#147;<B>Change of Control Benefits</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination Benefits or Change of Control Benefits, if and when due, shall be paid in equal installments
beginning on the Company&#146;s first regularly scheduled payroll date following the Release Effective Date (as defined below) with the remaining installments occurring on the Company&#146;s regularly scheduled payroll dates thereafter.
Notwithstanding the foregoing, you shall not receive any of the benefits described in the two paragraphs immediately above unless you deliver to the Company an effective, general release of claims in favor of the Company in the form attached hereto,
which has become effective in accordance with its terms (the date that such release can no longer be revoked is referred to as the &#147;<B>Release Effective Date</B>&#148;). In no event will you be entitled to both Termination Benefits and Change
of Control Benefits. If you are entitled to receive Termination Benefits and thereafter become entitled to Change of Control Benefits, any previously provided Termination Benefits shall offset Change of Control Benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Company&#146;s equity incentive plan (&#147;<B>Equity Plan</B>&#148;) and subject to approval by the Company&#146;s Board of Directors (the
&#147;<B>Board</B>&#148;), you will be provided with stock option awards to purchase shares of the Company&#146;s common stock (the &#147;<B>Options</B>&#148;) equal to one and <FONT STYLE="white-space:nowrap">one-quarter</FONT> percent (1.25%) of
the Company&#146;s outstanding shares at the time of the Options grant, at the sole discretion of the Board. The Options will have a per share exercise price at no less than the fair market value of the Company&#146;s common stock as of the date of
grant as determined by the Board, and will be governed in full by the terms and conditions of the Equity Plan and your associated stock option agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a Company employee, you will be expected to comply with Company policies and procedures, which will be provided to you. As a condition of employment, you
must read, sign and comply with the enclosed Employee Confidential Information and Invention Assignment Agreement (&#147;<B>Confidential Information Agreement</B>&#148;), which, among other provisions, prohibits any unauthorized use or disclosure of
Company proprietary, confidential or trade secret information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In your work for the Company, you will be prohibited from using or disclosing any
confidential, proprietary or trade secret information or other property of any former employer or third party to </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whom you have an obligation of confidentiality. Rather, you will be required to use only information that is generally known and used by persons with training and experience comparable to your
own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises or use in your work for the Company any confidential,
proprietary or trade secret information or other property belonging to any former employer or third party that you are not authorized to use and disclose. You represent further that you have disclosed to the Company in writing any agreement you may
have with any third party (e.g., a former employer) that may limit your ability to perform your duties to the Company, or that could present a conflict of interest with the Company, including but not limited to disclosure (and a copy) of any
contractual restrictions on solicitations or competitive activities. By accepting employment with the Company, you are representing that you will be able to perform your job duties within these parameters, and that you are not in unauthorized
possession or control of any confidential, proprietary or trade secret information or other property of any former employer or third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your
employment relationship with the Company will be at will. You may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time,
with or without cause or advance notice. Your employment <FONT STYLE="white-space:nowrap">at-will</FONT> status can only be changed in a written agreement signed by you and the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by law, this offer is subject to satisfactory proof of your identity and right to work in the United States. Additionally, this offer is subject
to you providing satisfactory professional references to the Company. Further, this offer is conditioned on completion, with results satisfactory to the Company, of a required <FONT STYLE="white-space:nowrap">pre-employment</FONT> background check.
You must timely provide all information and documents required to complete that process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To ensure the rapid and economical resolution of disputes that
may arise in connection with your employment with the Company, you and the Company both agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the
enforcement, breach, performance, or interpretation of this letter agreement, your employment with the Company, or the termination of your employment with the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. <FONT
STYLE="white-space:nowrap">&#167;1-16,</FONT> and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (&#147;<B>JAMS</B>&#148;) or its successors by a single arbitrator. The arbitration will
be held in San Diego, California, or such other location as then-agreed by the parties. <B><I>Both you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a trial
by jury or judge or administrative proceeding</I></B>. Any such arbitration proceeding will be governed by JAMS&#146; then applicable rules and procedures for employment disputes, which can be found at <U>http://www.jamsadr.com/rules-clauses/</U>
and which will be provided to you upon request. In any such proceeding, the arbitrator shall: (a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law;
and (b)&nbsp;issue a written arbitration decision including the arbitrator&#146;s essential findings and conclusions and a statement of the award. You and the Company each shall be entitled to all rights and remedies that either would be entitled to
pursue in a court of law. Nothing in this Agreement is intended to prevent either the Company or you from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to applicable law. The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law, and shall pay the arbitrator&#146;s
fees and any other fees or costs unique to arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement, together with your Confidential Information Agreement, will form the complete and exclusive statement of your employment agreement with
the Company. The terms in this letter agreement supersede any other agreements, promises or representations made to you by anyone, whether oral or written, regarding the subject matters hereof. This letter agreement cannot be changed except in a
written agreement signed by you and the Board, with the exception of those changes expressly reserved to the Company&#146;s discretion in this letter agreement. This letter agreement is governed by the laws of the state of California, without
reference to conflicts of law principles. If any provision of this letter agreement shall be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this letter agreement, and such
provision will be reformed, construed and enforced so as to render it valid and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this letter agreement, no
waiver of any right hereunder shall be effective unless it is in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and date this letter and the enclosed Confidential Information
Agreement, and return them to me if you decide to accept employment with the Company under the terms described above. Your start date will be March&nbsp;19, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to your favorable reply and to a productive and enjoyable working relationship. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>&nbsp;&nbsp;/s/ Daniel M. Bradbury</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Daniel M. Bradbury</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Chief Executive Officer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accepted:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>&nbsp;&nbsp;/s/ Jason A. Keyes</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Jason A. Keyes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 3/19/18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attachments: Employee Confidential Information and Inventions Assignment Agreement, Form of Separation and Release Agreement
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>16
<FILENAME>d582934dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Equillium, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bruce D. Steel </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employment Terms</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Bruce: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium, Inc. (the &#147;<B>Company</B>&#148;)
is pleased to offer you the position of President and Chief Business Officer on the following terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will report to the Chief Executive Officer. Your
home office will be at our offices located in La Jolla, California, and you may also be required to work at other offices and locations from time to time as required to perform your job duties. The Company may change your position, duties and work
location from time to time in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s regular business hours are from 8:00 a.m. to 5:00 p.m., Monday through Friday. As an
exempt salaried employee, you will be expected to work additional hours, including evenings and weekends, as required to perform your job duties, and you will not be eligible for overtime pay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your base salary will be at the annualized rate of $375,000, less required and designated payroll deductions and withholdings, paid semi-monthly
(&#147;<B>Base Salary</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to earn an annual discretionary performance-based bonus at an annual target amount of thirty-five
percent (35%) of your then current base salary (&#147;<B>Target Bonus</B>&#148;), based on the attainment of individual and Company objectives to be determined and approved by the Company. The Company&#146;s payment, and the amount, of any such
bonus shall be in the sole discretion of the Company. No amount of bonus is guaranteed, and, in addition to the other conditions for earning any such bonus, you must remain an employee in good standing of the Company on the date the bonus is
determined and paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to participate in the Company&#146;s standard employee benefits (pursuant to the terms and conditions of the
benefit plans and applicable policies), as they may be terminated or changed from time to time within the Company&#146;s discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event you are
terminated by the Company without Cause (as defined below), you will be eligible to receive an amount equal to your then current Base Salary for six (6)&nbsp;months less required deductions and withholdings and the Company shall pay the premiums for
your group health insurance COBRA continuance coverage for six (6)&nbsp;months following such termination without Cause or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer (the
&#147;<B>Termination Benefits</B>&#148;). &#147;<B>Cause</B>&#148; for termination shall mean that the Company has determined in its sole discretion that you have engaged in any of the following: (i)&nbsp;a material breach of any covenant or
condition under the terms of your employment agreement or any other agreement between the parties; (ii)&nbsp;any act constituting </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dishonesty, insubordination, fraud, immoral or disreputable conduct; (iii)&nbsp;any conduct which constitutes a felony under applicable law; (iv)&nbsp;violation of any written Company policy or
any act of misconduct; (v)&nbsp;negligence or incompetence in the performance your duties or failure to perform such duties in a manner satisfactory to the Company after the expiration of ten (10)&nbsp;days without cure after written notice of such
failure; or (vii)&nbsp;breach of fiduciary duty or the duty of loyalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event you are terminated by the Company without Cause within one
(1)&nbsp;month prior to, or twelve (12)&nbsp;months following, a Deemed Liquidation Event (as defined in the Company&#146;s Amended and Restated Certificate of Incorporation, as amended from time to time), you will be eligible to receive an amount
equal to your then current Base Salary for twelve (12)&nbsp;months less required deductions and withholdings, an amount equal to your then current Target Bonus less required deductions and withholdings and the Company shall pay the premiums for your
group health insurance COBRA continuance coverage for twelve (12)&nbsp;months following such termination without Cause or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer (&#147;<B>Change
of Control Benefits</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination Benefits or Change of Control Benefits, if and when due, shall be paid in equal installments beginning on the
Company&#146;s first regularly scheduled payroll date following the Release Effective Date (as defined below) with the remaining installments occurring on the Company&#146;s regularly scheduled payroll dates thereafter. Notwithstanding the
foregoing, you shall not receive any of the benefits described in the two paragraphs immediately above unless you deliver to the Company an effective, general release of claims in favor of the Company in the form attached hereto, which has become
effective in accordance with its terms (the date that such release can no longer be revoked is referred to as the &#147;<B>Release Effective Date</B>&#148;). In no event will you be entitled to both Termination Benefits and Change of Control
Benefits. If you are entitled to receive Termination Benefits and thereafter become entitled to Change of Control Benefits, any previously provided Termination Benefits shall offset Change of Control Benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a Company employee, you will be expected to comply with Company policies and procedures, which will be provided to you. As a condition of employment, you
must read, sign and comply with the enclosed Employee Confidential Information and Invention Assignment Agreement (&#147;<B>Confidential Information Agreement</B>&#148;), which, among other provisions, prohibits any unauthorized use or disclosure of
Company proprietary, confidential or trade secret information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In your work for the Company, you will be prohibited from using or disclosing any
confidential, proprietary or trade secret information or other property of any former employer or third party to whom you have an obligation of confidentiality. Rather, you will be required to use only information that is generally known and used by
persons with training and experience comparable to your own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises
or use in your work for the Company any confidential, proprietary or trade secret information or other property belonging to any former employer or third party that you are not authorized to use and disclose. You represent further that you have
disclosed to the Company in writing any agreement you may have with any third party (e.g., a former employer) that may limit your ability to perform your duties to the Company, or that could present a
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conflict of interest with the Company, including but not limited to disclosure (and a copy) of any contractual restrictions on solicitations or competitive activities. By accepting employment
with the Company, you are representing that you will be able to perform your job duties within these parameters, and that you are not in unauthorized possession or control of any confidential, proprietary or trade secret information or other
property of any former employer or third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your employment relationship with the Company will be at will. You may terminate your employment with the
Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. Your employment
<FONT STYLE="white-space:nowrap">at-will</FONT> status can only be changed in a written agreement signed by you and the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by law, this
offer is subject to satisfactory proof of your identity and right to work in the United States. Additionally, this offer is subject to you providing satisfactory professional references to the Company. Further, this offer is conditioned on
completion, with results satisfactory to the Company, of a required <FONT STYLE="white-space:nowrap">pre-employment</FONT> background check. You must timely provide all information and documents required to complete that process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company both agree
that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this letter agreement, your employment
with the Company, or the termination of your employment with the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> and to the fullest extent permitted by law, by final,
binding and confidential arbitration conducted by JAMS, Inc. (&#147;<B>JAMS</B>&#148;) or its successors by a single arbitrator. The arbitration will be held in San Diego, California, or such other location as then-agreed by the parties. <B><I>Both
you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</I></B>. Any such arbitration proceeding will be
governed by JAMS&#146; then applicable rules and procedures for employment disputes, which can be found at <U>http://www.jamsadr.com/rules-clauses/</U> and which will be provided to you upon request. In any such proceeding, the arbitrator shall:
(a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision including the arbitrator&#146;s essential
findings and conclusions and a statement of the award. You and the Company each shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law. Nothing in this Agreement is intended to prevent either the
Company or you from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. The Company shall pay all filing fees in excess of those which would be required if the
dispute were decided in a court of law, and shall pay the arbitrator&#146;s fees and any other fees or costs unique to arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of
any competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement, together with your Confidential Information Agreement, will form the complete and exclusive statement
of your employment agreement with the Company. The terms in this letter agreement supersede any other agreements, promises or representations made to you </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by anyone, whether oral or written, regarding the subject matters hereof. This letter agreement cannot be changed except in a written agreement signed by you and the Board, with the exception of
those changes expressly reserved to the Company&#146;s discretion in this letter agreement. This letter agreement is governed by the laws of the state of California, without reference to conflicts of law principles. If any provision of this letter
agreement shall be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this letter agreement, and such provision will be reformed, construed and enforced so as to render it valid
and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this letter agreement, no waiver of any right hereunder shall be effective unless it is in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and date this letter and the enclosed Confidential Information Agreement, and return them to me if you decide to accept employment with the
Company under the terms described above. Your start date will be June&nbsp;1, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to your favorable reply and to a productive and
enjoyable working relationship. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel M. Bradbury</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accepted:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bruce D. Steel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Bruce D. Steel</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 1&nbsp;June 2018</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attachments: Employee Confidential Information and Inventions Assignment Agreement, Form of Separation and Release Agreement
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>17
<FILENAME>d582934dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Equillium, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7&nbsp;June 2018
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stephen Connelly </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employment Terms</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stephen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective 1&nbsp;June 2018, the following in its
entirety amends and restates your offer letter dated 1&nbsp;January 2018 by Equillium, Inc. (the &#147;<B>Company</B>&#148;) regarding your position as Chief Scientific Officer of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will report to the Chief Executive Officer. Your home office will be at our offices located in La Jolla, California, and you may also be required to work
at other offices and locations from time to time as required to perform your job duties. The Company may change your position, duties and work location from time to time in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s regular business hours are from 8:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work
additional hours, including evenings and weekends, as required to perform your job duties, and you will not be eligible for overtime pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your base
salary will be at the annualized rate of $300,000, less required and designated payroll deductions and withholdings, paid semi-monthly (&#147;<B>Base Salary</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to earn an annual discretionary performance-based bonus at an annual target amount of thirty-five percent (35%) of your then current base
salary (&#147;<B>Target Bonus</B>&#148;), based on the attainment of individual and Company objectives to be determined and approved by the Company. The Company&#146;s payment, and the amount, of any such bonus shall be in the sole discretion of the
Company. No amount of bonus is guaranteed, and, in addition to the other conditions for earning any such bonus, you must remain an employee in good standing of the Company on the date the bonus is determined and paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to participate in the Company&#146;s standard employee benefits (pursuant to the terms and conditions of the benefit plans and applicable
policies), as they may be terminated or changed from time to time within the Company&#146;s discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event you are terminated by the Company
without Cause (as defined below), you will be eligible to receive an amount equal to your then current Base Salary for six (6)&nbsp;months less required deductions and withholdings and the Company shall pay the premiums for your group health
insurance COBRA continuance coverage for six (6)&nbsp;months following such termination without Cause or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer (the &#147;<B>Termination
Benefits</B>&#148;). &#147;<B>Cause</B>&#148; for termination shall mean that the Company has determined in its sole discretion that you have engaged in any of the following: (i)&nbsp;a material breach of any covenant or condition under the terms of
your </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment agreement or any other agreement between the parties; (ii)&nbsp;any act constituting dishonesty, insubordination, fraud, immoral or disreputable conduct; (iii)&nbsp;any conduct which
constitutes a felony under applicable law; (iv)&nbsp;violation of any written Company policy or any act of misconduct; (v)&nbsp;negligence or incompetence in the performance your duties or failure to perform such duties in a manner satisfactory to
the Company after the expiration of ten (10)&nbsp;days without cure after written notice of such failure; or (vii)&nbsp;breach of fiduciary duty or the duty of loyalty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event you are terminated by the Company without Cause within one (1)&nbsp;month prior to, or twelve (12)&nbsp;months following, a Deemed Liquidation
Event (as defined in the Company&#146;s Amended and Restated Certificate of Incorporation, as amended from time to time), you will be eligible to receive an amount equal to your then current Base Salary for twelve (12)&nbsp;months less required
deductions and withholdings, an amount equal to your then current Target Bonus less required deductions and withholdings and the Company shall pay the premiums for your group health insurance COBRA continuance coverage for twelve (12)&nbsp;months
following such termination without Cause or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer (&#147;<B>Change of Control Benefits</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination Benefits or Change of Control Benefits, if and when due, shall be paid in equal installments beginning on the Company&#146;s first regularly
scheduled payroll date following the Release Effective Date (as defined below) with the remaining installments occurring on the Company&#146;s regularly scheduled payroll dates thereafter. Notwithstanding the foregoing, you shall not receive any of
the benefits described in the two paragraphs immediately above unless you deliver to the Company an effective, general release of claims in favor of the Company in the form attached hereto, which has become effective in accordance with its terms
(the date that such release can no longer be revoked is referred to as the &#147;<B>Release Effective Date</B>&#148;). In no event will you be entitled to both Termination Benefits and Change of Control Benefits. If you are entitled to receive
Termination Benefits and thereafter become entitled to Change of Control Benefits, any previously provided Termination Benefits shall offset Change of Control Benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a Company employee, you will be expected to comply with Company policies and procedures, which will be provided to you. As a condition of employment, you
must read, sign and comply with the enclosed Employee Confidential Information and Invention Assignment Agreement (&#147;<B>Confidential Information Agreement</B>&#148;), which, among other provisions, prohibits any unauthorized use or disclosure of
Company proprietary, confidential or trade secret information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In your work for the Company, you will be prohibited from using or disclosing any
confidential, proprietary or trade secret information or other property of any former employer or third party to whom you have an obligation of confidentiality. Rather, you will be required to use only information that is generally known and used by
persons with training and experience comparable to your own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises
or use in your work for the Company any confidential, proprietary or trade secret information or other property belonging to any former employer or third party that you are not authorized to use and disclose. You represent further that you have
disclosed to the Company in writing any agreement you may have with any third party (e.g., a former employer) </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that may limit your ability to perform your duties to the Company, or that could present a conflict of interest with the Company, including but not limited to disclosure (and a copy) of any
contractual restrictions on solicitations or competitive activities. By accepting employment with the Company, you are representing that you will be able to perform your job duties within these parameters, and that you are not in unauthorized
possession or control of any confidential, proprietary or trade secret information or other property of any former employer or third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your
employment relationship with the Company will be at will. You may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time,
with or without cause or advance notice. Your employment <FONT STYLE="white-space:nowrap">at-will</FONT> status can only be changed in a written agreement signed by you and the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by law, this offer is subject to satisfactory proof of your identity and right to work in the United States. Additionally, this offer is subject
to you providing satisfactory professional references to the Company. Further, this offer is conditioned on completion, with results satisfactory to the Company, of a required <FONT STYLE="white-space:nowrap">pre-employment</FONT> background check.
You must timely provide all information and documents required to complete that process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To ensure the rapid and economical resolution of disputes that
may arise in connection with your employment with the Company, you and the Company both agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the
enforcement, breach, performance, or interpretation of this letter agreement, your employment with the Company, or the termination of your employment with the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. <FONT
STYLE="white-space:nowrap">&#167;1-16,</FONT> and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (&#147;<B>JAMS</B>&#148;) or its successors by a single arbitrator. The arbitration will
be held in San Diego, California, or such other location as then-agreed by the parties. <B><I>Both you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a trial
by jury or judge or administrative proceeding</I></B>. Any such arbitration proceeding will be governed by JAMS&#146; then applicable rules and procedures for employment disputes, which can be found at <U>http://www.jamsadr.com/rules-clauses/</U>
and which will be provided to you upon request. In any such proceeding, the arbitrator shall: (a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law;
and (b)&nbsp;issue a written arbitration decision including the arbitrator&#146;s essential findings and conclusions and a statement of the award. You and the Company each shall be entitled to all rights and remedies that either would be entitled to
pursue in a court of law. Nothing in this Agreement is intended to prevent either the Company or you from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. The
Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law, and shall pay the arbitrator&#146;s fees and any other fees or costs unique to arbitration. Any awards or orders in such
arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement, together with
your Confidential Information Agreement, will form the complete and exclusive statement of your employment agreement with the Company. The terms </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in this letter agreement supersede any other agreements, promises or representations made to you by anyone, whether oral or written, regarding the subject matters hereof. This letter agreement
cannot be changed except in a written agreement signed by you and the Board, with the exception of those changes expressly reserved to the Company&#146;s discretion in this letter agreement. This letter agreement is governed by the laws of the state
of California, without reference to conflicts of law principles. If any provision of this letter agreement shall be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this
letter agreement, and such provision will be reformed, construed and enforced so as to render it valid and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of
this letter agreement, no waiver of any right hereunder shall be effective unless it is in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to your favorable reply and to a
productive and enjoyable working relationship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel M. Bradbury</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accepted:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Connelly</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stephen Connelly</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 7&nbsp;June 2018</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attachments: Employee Confidential Information and Inventions Assignment Agreement, Form of Separation and Release Agreement
remain as originally executed </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>18
<FILENAME>d582934dex1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Equillium, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>August&nbsp;1, 2018 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Krishna Polu,
M.D. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left"><B>Employment Terms </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">Dear Krishna: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Equillium, Inc. (the
&#147;<B>Company</B>&#148;) is pleased to offer you the position of Chief Medical Officer on the following terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You will report to the
Chief Executive Officer<B>. </B>Your home office will be mutually determined by you and Company. You will be allowed to work in the San Francisco Bay area and at our offices located in La Jolla, California, and you may also be required to work at
other offices and locations from time to time as required to perform your job duties. The Company may change your position, duties and work location from time to time in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the discretion of the Company you will be reimbursed for travel related expenses (e.g. airfare, ground transportation, and hotel) up to an
amount expected not to exceed $50,000 on an annual basis, subject to adjustment based on the business needs of the Company, to commute to our offices in La Jolla. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s regular business hours are from 8:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be
expected to work additional hours, including evenings and weekends, as required to perform your job duties, and you will not be eligible for overtime pay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Your base salary will be at the annualized rate of $375,000, less required and designated payroll deductions and withholdings, paid
semi-monthly (&#147;Base Salary&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You will be eligible to earn an annual discretionary performance-based bonus at an annual target
amount of thirty percent (30%) of your then current base salary (&#147;Target Bonus&#148;), based on the attainment of individual and Company objectives to be determined and approved by the Company. The Company&#146;s payment, and the amount, of any
such bonus shall be in the sole discretion of the Company. No amount of bonus is guaranteed, and, in addition to the other conditions for earning any such bonus, you must remain an employee in good standing of the Company on the date the bonus is
determined and paid. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Company&#146;s equity incentive plan (&#147;Equity Plan&#148;) and subject
to approval by the Company&#146;s Board of Directors (the &#147;Board&#148;), you will be provided with stock option awards to purchase shares of the Company&#146;s common stock (the &#147;Options&#148;) equal to one and three-quarters percent
(1.75%) of the Company&#146;s outstanding shares at the time of the Options grant, at the sole discretion of the Board. The Options will have a per share exercise price at no less than the fair market value of the Company&#146;s common stock as of
the date of grant as determined by the Board, and will be governed in full by the terms and conditions of the Equity Plan and your associated stock option agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event you are terminated by the Company without Cause (as defined below), you will be eligible to receive an amount equal to your then
current Base Salary for six (6)&nbsp;months less required deductions and withholdings and the Company shall pay the premiums for your group health insurance COBRA continuance coverage for six (6)&nbsp;months following such termination without Cause
or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer (the &#147;<B>Termination Benefits</B>&#148;). &#147;<B>Cause</B>&#148; for termination shall mean that the Company has determined in
its sole discretion that you have engaged in any of the following: (i)&nbsp;a material breach of any covenant or condition under the terms of your employment agreement or any other agreement between the parties; (ii)&nbsp;any act constituting
dishonesty, insubordination, fraud, immoral or disreputable conduct; (iii)&nbsp;any conduct which constitutes a felony under applicable law; (iv)&nbsp;violation of any written Company policy or any act of misconduct; (v)&nbsp;negligence or
incompetence in the performance your duties or failure to perform such duties in a manner satisfactory to the Company after the expiration of ten (10)&nbsp;days without cure after written notice of such failure; or (vii)&nbsp;breach of fiduciary
duty or the duty of loyalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event you are terminated by the Company without Cause within one (1)&nbsp;month prior to, or twelve
(12)&nbsp;months following, a Deemed Liquidation Event (as defined in the Company&#146;s Amended and Restated Certificate of Incorporation, as amended from time to time), you will be eligible to receive an amount equal to your then current Base
Salary for twelve (12)&nbsp;months less required deductions and withholdings, an amount equal to your then current Target Bonus less required deductions and withholdings and the Company shall pay the premiums for your group health insurance COBRA
continuance coverage for twelve (12)&nbsp;months following such termination without Cause or, if earlier, until the date on which you become eligible to receive comparable benefits from another employer (&#147;<B>Change of Control
Benefits</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Termination Benefits or Change of Control Benefits, if and when due, shall be paid in equal installments beginning
on the Company&#146;s first regularly scheduled payroll date following the Release Effective Date (as defined below) with the remaining installments occurring on the Company&#146;s regularly scheduled payroll dates thereafter. Notwithstanding the
foregoing, you shall not receive any of the benefits described in the two paragraphs immediately above unless you deliver to the Company an effective, general release of claims in favor of the Company in the form attached hereto, which has become
effective in accordance with its terms (the date that such release can no longer be revoked is referred to as the &#147;<B>Release Effective Date</B>&#148;). In no event will you be entitled to both Termination Benefits and Change of Control
Benefits. If you are entitled to receive Termination Benefits and thereafter become entitled to Change of Control Benefits, any previously provided Termination Benefits shall offset Change of Control Benefits. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="justify">You will be eligible to participate in the Company&#146;s standard employee benefits
(pursuant to the terms and conditions of the benefit plans and applicable policies), as they may be terminated or changed from time to time within the Company&#146;s discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a Company employee, you will be expected to comply with Company policies and procedures, which will be provided to you. As a condition of
employment, you must read, sign and comply with the enclosed Employee Confidential Information and Invention Assignment Agreement (&#147;<B>Confidential Information Agreement</B>&#148;), which, among other provisions, prohibits any unauthorized use
or disclosure of Company proprietary, confidential or trade secret information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In your work for the Company, you will be prohibited from
using or disclosing any confidential, proprietary or trade secret information or other property of any former employer or third party to whom you have an obligation of confidentiality. Rather, you will be required to use only information that is
generally known and used by persons with training and experience comparable to your own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by the Company. You agree that you will not
bring onto Company premises or use in your work for the Company any confidential, proprietary or trade secret information or other property belonging to any former employer or third party that you are not authorized to use and disclose. You
represent further that you have disclosed to the Company in writing any agreement you may have with any third party (e.g., a former employer) that may limit your ability to perform your duties to the Company, or that could present a conflict of
interest with the Company, including but not limited to disclosure (and a copy) of any contractual restrictions on solicitations or competitive activities. By accepting employment with the Company, you are representing that you will be able to
perform your job duties within these parameters, and that you are not in unauthorized possession or control of any confidential, proprietary or trade secret information or other property of any former employer or third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Your employment relationship with the Company will be at will. You may terminate your employment with the Company at any time and for any
reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. Your employment <FONT STYLE="white-space:nowrap">at-will</FONT> status can only be changed
in a written agreement signed by you and the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As required by law, this offer is subject to satisfactory proof of your identity and
right to work in the United States. Additionally, this offer is subject to you providing satisfactory professional references to the Company. Further, this offer is conditioned on completion, with results satisfactory to the Company, of a required <FONT
STYLE="white-space:nowrap">pre-employment</FONT> background check. You must timely provide all information and documents required to complete that process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the
Company both agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this letter agreement,
your employment with the Company, or the termination of your employment with the </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> and to the fullest extent permitted by law, by final, binding and
confidential arbitration conducted by JAMS, Inc. (&#147;<B>JAMS</B>&#148;) or its successors by a single arbitrator. The arbitration will be held in San Diego, California, or such other location as then-agreed by the parties. <B><I>Both you and the
Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</I></B>. Any such arbitration proceeding will be governed by
JAMS&#146; then applicable rules and procedures for employment disputes, which can be found at <U>http://www.jamsadr.com/rules-clauses/</U> and which will be provided to you upon request. In any such proceeding, the arbitrator shall: (a)&nbsp;have
the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision including the arbitrator&#146;s essential findings and
conclusions and a statement of the award. You and the Company each shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law. Nothing in this Agreement is intended to prevent either the Company or you
from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. The Company shall pay all filing fees in excess of those which would be required if the dispute were
decided in a court of law, and shall pay the arbitrator&#146;s fees and any other fees or costs unique to arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any
competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This letter agreement, together with your Confidential Information Agreement, will form the complete and
exclusive statement of your employment agreement with the Company. The terms in this letter agreement supersede any other agreements, promises or representations made to you by anyone, whether oral or written, regarding the subject matters hereof.
This letter agreement cannot be changed except in a written agreement signed by you and the Board, with the exception of those changes expressly reserved to the Company&#146;s discretion in this letter agreement. This letter agreement is governed by
the laws of the state of California, without reference to conflicts of law principles. If any provision of this letter agreement shall be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other
provisions of this letter agreement, and such provision will be reformed, construed and enforced so as to render it valid and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the
enforcement of this letter agreement, no waiver of any right hereunder shall be effective unless it is in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please sign and date
this letter and the enclosed Confidential Information Agreement, and return them to me if you decide to accept employment with the Company under the terms described above. If you accept our offer, your start date will be August&nbsp;13, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We look forward to your favorable reply and to a productive and enjoyable working relationship. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sincerely,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Daniel M. Bradbury</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Daniel M. Bradbury</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Chief Executive
Officer</B></P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Accepted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/Krishna&nbsp;Polu,&nbsp;M.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8/2/2018&nbsp;3:59:03&nbsp;PM&nbsp;PDT</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Krishna Polu, M.D.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attachments: Employee Confidential Information and Inventions Assignment Agreement, Form of Separation and
Release Agreement </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>19
<FILENAME>d582934dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equillium, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We consent to the use of our report included herein and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">September&nbsp;17, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g582934g00h84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g00h84.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2F44&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (   $X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      $!    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    / %@ 90!R &\ >  @ #( ,P @ $, ;P!L &\ <@      #W!R:6YT
M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!I)X4@        "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 \     !  $#P     $  3A"24T$)@      #@
M   _@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))300*       !   X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             $U@   ](          0
M   !              /2   $U@                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   $U@    !29VAT;&]N9P   ](    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P  !-8     4F=H=&QO;F<   /2     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    &.$))300,     ![?     0   'X   "@
M   !?   [8   ![# !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" "@ 'X# 2(  A$! Q$!_]T !  (_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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MSIW_ "?B_P#$U_\ 4M1+,:BRVN][ ;J0X4V$26;QM?L_K-"'T[_D_%_XFO\
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M'-V16]PMN::H'J?HWY5 M#F.:WTMM?I_S/\ UQ:=G\_3[9^EKN(C3]QOL?\
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M[,5NW]&]_LV_\(M2VKZM4V/IM9AU6  6,(K:Z"18UKQI[';6N0W6?5)H#7'
M  @ ^CPEZ?%6KG'HMOI_HNH6U M<&/;U!QV[OI.;NQ?=[UJX%>=5C-JK<S+:
MPN_3693K'DDE^USQB_F;MC/^#4&?\U65LK!PMK!# 368!.[\[^4JN)UNO'RA
MBMQL+'Q7O<774Y=(_DBS[.&5O<_:UN] \/2U:NK_ )2_T-/_ &^__P!Y4O\
M*7^AI_[??_[RI?MCI/!S:/\ MQO_ ))+]L=*F/ME$^'J-G_JD%*_RE_H:?\
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MHAMI+CO;H/2N;^]YI*?_V0 X0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !BDE)*@ (
M#@   00  0   -\#   ! 00  0   .$$   " 0, !    +8    # 0,  0
M  4    & 0,  0    (    2 0,  0    $    5 0,  0    0    : 04
M 0   +X    ; 04  0   ,8    < 0,  0    $    H 0,  0    (    Q
M 0( '@   ,X    R 0( %    .P   !IAP0  0     !   L 0  "  (  @
M" "^M!X $"<  +ZT'@ 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.#HP.#HR.2 R,3HU-#HQ-@ #  &@ P !    __\   *@!  !
MT@,   .@!  !    U@0           8  P$#  $    &    &@$%  $   !Z
M 0  &P$%  $   "" 0  * $#  $    "     0($  $   "* 0   @($  $
M             $@    !    2     $    X0DE- _T       @
M /_A 8Q)22H "     X   $$  $   #? P   0$$  $   #A!    @$#  0
M  "V     P$#  $    %    !@$#  $    "    $@$#  $         %0$#
M  $    $    &@$%  $   "^    &P$%  $   #&    ' $#  $    !
M* $#  $    "    ,0$" !X   #.    ,@$" !0   #L    :8<$  $
M 0  + $   @ "  (  @ P ,   $   #  P   0   $%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,CD@,C$Z-30Z,38  P !H ,  0
M /__   "H 0  0   -(#   #H 0  0   -8$           &  ,! P !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M 'OKA#^Y1T/_ #4+^N>I &? XQ[<CGP Z]/?\>6]_P"IO]1_>F/)E^3=\/\
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M^2[7KV$T/QBEKQ6!4O,#J)L-2 JI$]##I?)'9R](@"MI>(8:RK"WF\*#'L/
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M68XPPF4>W%EV9T*\LK2^.K:E!#J>N?P*R9]-MF[F8VMK,)KQ4U D0K/<F)C
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M-:O)NX2:SMTEO=+.IV1CNI&B=4[CO8)RUN'B>,7$;!E21'&0,$<Y!'Y='/\
M!.G\Q'ZQ7X<ZT:SUQL!^J2\W.J@(IR]'UT-Z.=G(2L34X^T#B<5@8D:LO+*(
M:820R&.Z\2/@OV91>V-UV7%Q-*EMJ%_8BYCAA[Z06:3L)!#+<10@OW(W*UP
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MG!'XYLG8W79(%G2&U</'!<K"E]:O<&RN;U=/@U 0)*SFPDNF2-;D H5=)O\
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M%BB9&2XJ6ZYQ^&.<GVFMT6Q>-=1V.#$1TI8;J,Q#P&U8 <E=@*GY;+>V*^Y
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MJW1Q+TKOVZ4*_;'A9<VQZZ4OX!+A[%+5_+C/K:9 8<YZ((%-RD"23B1 ? ,
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MF,YCL/1[R37'TM&),4@=OSAG._.ZYVHTGL\]O'J+SJ]RKO$(86ERL;*K$D$
M8+#CJ1TKV;[+/L'^T#[8K;5[OL7;Z7-!HD]M;7[:CJ<5@5ENXI9H%C5T=I R
MPN"RC"M@,0#D:Z*AY:D^@S>S9.2XD6$AO9E_%V#%MC[EJN%!Q16N=?5=EDE6
M:NKSW<OU0DE6<8;6E!+;?H?S'I'.8MNWG9NSEOG>XNF%_>+>H%LY/4C:RL[<
M!LGDYMF8XYPP&.":]SUC_I+^VSM+8=EK2UT?0(&[)=G)^S5T\W:2T(NKR'M/
MVDU=W@"1$JG=ZQ%"N_U2T3-W@#!5W[:!V=*[ITSKK;$S3'-?E[!K8EJ9J3T^
M%9WHN*EE.DP2WIJ.%"$*=DH14?*N-(%9< 6=F/(3D@5U6?0;2ZAOK6VO+<EH
M+J"*XA+*58QS('0E3RI*L,@\@\5\?=H="U#LOKVL]F]62./5-!U2^T?48X95
MGB2]TZYDM+I(YD]26-9HG"2+ZKJ PX-6>=RAU@+LO8NI/AV)$N.OZO&3SF)R
M9CX2'E9&20^K, /)F.)99,CLO07P@MSOZ+X;3A+2E &83VD78[6)-)TK6_1I
MY+#4[R6V'HUO+<7$$,14"Z:&,%F27;<]T!U]&R2!+'G@Y>U&F1ZEJ.E&:%+N
MPM8Y@9YHX(9II Q-NLKD*KQ[H.\)Z=\< F-Z_GQEV#:K916(S9MKU]8MEQYL
MR]).4.T0U@#+A79);L8;Z**7CU/ ;9C<,XVIKQ4"T\MU;I*NI[7:79V.HM-I
M%EJEKI$L<"Q#4K.XM7CN%BVS1[IQ_,WF,S@@_P#S&4 !!5/9C4;J[L1#J5W8
M7&I1O,TALKJ"X#P-)NC<K"<1[ XA(QCU%;)+&I*=<E735AO>=GNL#JV\2&I3
MJDYM"*@S9&I1-H[&QTQ)Q?F%.PC@0\M$DK*DQVGHX)23&DCR!(KCZ5M)6A6G
MUJZNX-,O9-+DM?XC%"\EM%<>NDKQ$,T/=K+&QDD0-''ZV!(R;@1D5SO:B\U:
MUT'59NSIL)->@LY9M-M]0#26]S<0 2>C/''<6TA:X56@B(E4),Z,^5!4V;KW
M?-?C8755+WALG5\-O^[UZ!-.I,1+"1KI<[//.,HBJ_"E2\H>5@4]#L+Z5LHC
M!9H)+S>&D+PRWBZ?K=ND&FVFLZCIL6N7<%N\EG%-&C&>X8JD4,1ED=B),P9#
M,))$8K@$ :O2>UEI;6_9[2NUFM:#9]L=6L;2:72;>X2W:6[NBRFWL;66YN)I
M1%,KVNY99.]EA=QM#!5DMUT5=M3I2G2E.E*=*4Z4KC3Y0_=,<B/U=-M_Q_L'
M2E=+7 C\XV]?KTO*1_RB7*7I4GK\!^0J:72HITI3I2G2E1BY;5[0EEU2W'<E
M6;2YJ=-K@R)IZN2>TX:-!(0@YH0Z^RFJ#8^2 UZQZ9WXR&6LIJ@B86(3:'&6
M&1WVE*C9Y-Z:TF5#[KK^@.'T-Q=US7+XVQ%66K5K,/6=W(R3/QK-M;G%TRIM
MVV=&$AF)*2EH.3V/4UQ%JK9$+LJPE&RPD2H?;^>:V8=*5!7GI_>OQF_7U</_
M /AAA.E2.OP/Y&IU=*BG2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=
M*4Z4ITI3I2G2E.E*=*4Z4ITI7+ON.R6?9'E<-=6&)@N7U4&1M;6\7'35DXL\
MLHR4IT!JZ8^+UPK>J;-#;2@^/\IQUW&2(5,7^_W/64ZH:%L$]*I?F1VJZJ#5
M5T'A\QX^SKGR_+KGJ(Z533I2H7;,^[VXC?K=.:W\<.&_2I\#[Q^1J:/2HITI
M3I2G2E.E*=*4Z4J 7E#.*U0Y':4FI$U.8J]4",-FZM9XZHR-TL7JH:%2!M2B
M86+D0"W?C24,$$X^RDUT16$$)"(2A;>>/[9]G[;6]+E=AW=W9QM+;SI;/=3[
M5]=K:.*-T8^D,%4D;RO!"-C%?1__ $T?;!K?V7=O+"VMSZ9V?[1W<&GZOI-U
MK5KH.E]].PMH-:O;^\M;F!/X1#+/.$D-NDR[HVN(B0PT$<2^&FQ=T;YH5:W1
M0KSK2FP0X$FX=/:@MCL+;6ZH1"N*H\P:^Y"B1"++#"2:7)TLQ33#^'T("*).
M88Z\@[.]F+W5-7M(-4L[NPMH520O-IER8KD6YB/HDKGNEB](B63^<S8!R K,
MZBOT=^V?[=.R_83[.NT>J=A.T?9_M7KFHRW%HMOIO;?1DO\ 16UB*_0=H+&"
M);^>].E7TUH5T^&$/)&8V-Q#%;R25UM5NNP=0K\)5*S&#0U=K<4!!P40$G*!
M(R)BQ6@H\ 5"E*4E@05EIAI*E*SA"$XSG.?'KZ*@@BMH8K>"-8H((TBAB086
M..-0J(H\%50 /8*_&'5-3U#6M2O]8U6[FOM3U2\N=0U"]G;=/=WMY,]Q<W,S
M  &2::1Y'( !9C@ <5J9Y_W_ 'U02&*2/L?5KU4W#*OAQ\%3="VJ$VS5*D$9
M&+?*E=O27(B3JLL461GX.RTWJNK(G!E',,%0F1%DN^N_97HO\0U.XU6\*26&
MBPL\=O/(PAGOI8W$*[ LA*0+NED*QNR.86",3M/E?VB:L++3X=,M@R7FJR*'
MFB53)%:1NAE8'*8:5ML:AI%5D$V77&1&'3&Q>4NWK05QTA;V+BD-7CT\CM2@
MZU-?E:JQ#6DV?KLJ]'XNN/48Z3F51;UQ47)&#KD<>L1CT7&CDP1?HFM:3V9T
M&S3M3?V<4NH^@7"II%Y?>CP7QN(4M_1TDDBG[R>TT_O8("D0:X.9#'$S)W?#
MZ5J6O:Q<'L[9W,T=F+N!FU&VM._FM!!,\O?LB20;(;F],<TP:3$  022(K&3
MH0C&I%B-CV9<P20EF01&I0\ !V+!.D6QVT&F!QCY\J]'"$DX=>' >E))T-E:
M!W#S%MY(<^9I"A=S&K)&78QHS]XR(22JLX5 [*N 7")N(SM7.![X@8(H=@SA
M5#LJ[%9@!N8(6<J"<D+N;:.-QQD\P7)Z>ME"V9R7ILAPS$8V)O.9CFH>ZHW)
M*2M6H\CBNHM4E,:SDW-"/HEUV!UPFSVV,(755^JYD(=Z3BVH]PA/SUV@;3;+
M5NU]G?:'J$4NI,#IU_;]W=I!,(ENV>%95MD2.]):YO!%<2R1*7MU4!2]?%_:
MZ2PTOM5]IFC:EV(U:TO>U;2KV;[16<\>KVL>I)9K>V\EI#=6-C%IT.HHTVIZ
MZT5Y<RVK":T1)HXC.MR<5N04]C=7'?43?!"@F;BUS+3E(SM0C>T[&2),@[&L
MM[$MTW'!\7VPI(B KRG9F-C2Y\E$.$8&,#-]ST2#VZ[,ZEV7_B.@Z8FBZJ^N
MV#3V@OGLK*)'N6C_ /,GN6CO"\D=LFZ2(NDDD$3!E&Y@3UG8#M%]GK:_V-[.
M#LKVAE[;:&M[I8UN71-.MK>34Q8I_'+NYN8+\--#;0'OHI'AD>WM;B%H5W3K
MNZ9^O:*^IJ=*4Z4ITI3I2G2E<:?*'[ICD1^KIMO^/]@Z4KI:X$?G&WK]>EY2
M/^42Y2]*D]?@/R%32Z5%.E*=*4Z4J,_++C>GE1J-_52]G7W4R7;%"6'XS:].
M;$E'_@99&?@>39=\UN1A2_6?6'0ENLX1)!1<AA:\@X9=4J\=-Z#UKHB,+C]>
M0RXIZ9"@&[4:DLA";9.08+@3UUF8<9QBN(N]F6^\?<[1&0T?+6Z14R58")!P
M$#U52O*VUR)IFEY<",N<1;,#R=?L\\!,Q8,07'&N5*IVRZRL$ (_."6"4FDP
M%.DGE?!4(=$ %G5V/F9>+-LD*R:I46.6=^C-B:ZXV3,>!*0I 'E!^,%8FX"=
MS$_#4#8*QO>.AIB*D<P4K.0SKS)(N76GXN8D@20WQB6"G$/8[*D?H?R-;(^E
M13I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E
M*=*4Z4KFHV[K'5FW>8^KO*#$O[4@M927.RB<:UR3^EM.6.X![ T)<9/3E4N-
M)W&7=/LNZEXW;%W9!$ZPM50@ZV=-6"2>G+))PD!5KF=*N*J\,>S/4^_D>[G]
M^E=*_2J:M2Z6ARGP)$VS6K%;76'AVD0E83"8DWDO.X2^4HNRS=;KL<#'C8>/
M//FIZ,$:%'<0V\\:Z(&2I4-)FV0]\YD<'+O7G'W8*Y<3^7-KA%E,*%*7#V*=
MX6R\8X2*YGT@SZPC&5.L.?FV7,J;5XISTJ? ^\?D:GMTJ*C3RRMV^:3IZ0G.
M.E#5L*_HFH0<F*'-C1Y6.JKI*E6*:@ I4.0"FIT05M \=&. G]G#,R.(N:^#
M_@:04K5YGR@?E(JE8*CK"T<#*7)["L@45FOBR7(.G5BSW1F<(=#AY@.GM!DN
M-H#<&)<V$N/RN/UZPQB5MB:S&GBLLJ5.7A1LKF+?_L@HY4:A5K=B+?B4UDXH
MV"24;-KP6FTQ$7&PHS:2:E'+2 Y7YP@F2=(0Z2PJ>L/FX-94J>G2E.E*=*4Z
M4ITI3I2L<;:HI^R=>6JD1=C73S[/%.PV+./%M2IL6$:I+4ED(=TH+S"B8]10
M;!*26W G",%M><ZRA.=MH>I1Z1JEEJ,UKZ='9S+<>B&8P1S21@F'O&"291)0
MDC(4(D";&PK&M;J]@^IZ==V,5QZ(]U$8?21$)7C1R!)L4NGK/&70,&!0MN'(
M%6[I/2%3TK61(N(CX,BS/1H(-KND=70J_*71^-41ZK*3K0CI&2)!2277"7W2
M7E/F/%%]T*)6C&5VA[17W:"[>:>6X6S6:22RT^6ZDNH;!90F^*W9U3;'ZBA5
M"*%143D("<;1-"M-%MDCAC@:Z,21W5Y%;K;R79C+;))E5GR^&.YB[%G+.<%R
M*S3US];NHU\I>.-9Y):PGJI(-MA7 :$G4Z\MGK1XA%4LLB$EEDY#H#J',A&J
M89CIEOT3ZB84@\-"/-)6E?.]INSUMVBTV:VD51=I#-Z!<LSKZ-<2*N&.SK'(
M46.8;6)A9U49;GB>WO8RS[;:!>:;+_(U%;6\_@NI+)-%)IM_/ 8TG1X65Q')
M@072@-WEK)-%@B1@?SQRXR4+0%'J,2%$Q\I>XN$8:L]]*2^=-3MD-CHX2RRS
M9\BX^6*U*+CA!L-,J9[Q<=%!/X6V"PE$=G^S6GZ':6J1P1/?10@7%Z07EEN)
M(T6YD5WRR+(45<+MS%'&C9V##L7V'TGLAI.G6L4$5SJEO:1I?:O*&FN[V]>"
M"*]NN^G+RIZ2;>)"JE?Y$%O"P*0H%DMUT==M3I2G2E.E*=*4Z4KC3Y0_=,<B
M/U=-M_Q_L'2E=+7 C\XV]?KTO*1_RB7*7I4GK\!^0J:72HITI3I2G2E.E*=*
M5'2Z\6=07U P$W%S ]:%'F$MTR#GI""J:92;A[C F65B+C7&%1]DS&7ZTLJE
M8LD%PQXX(V40>; UXB*4K[@^+VA<25+LMDU91-A7S7EDLERI>S-C4VIW#8U7
MMUOG<V2R62LVV4A%R55DY28PP2M567"CC-@Q@@0XP<8 P.I^M9]Z4ITI3I2G
M2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*5"
MD/R='"J/Y"N<J!-!UEG>+MG-O.;1\+V]<(B^R6'?7]@,:Z<L2]9C; ,<?()(
MO(]/:MCIQ!!ZIC)I#Q"U3DXQGBIK=*BL;;9U= [DI1M!M!\X%7Y,V)+E68(P
M454N-$R(\GB$F&C@9("6K<H\*T-8:]) E1-ABE$PTP*9$FFA$*5\4)HW3T!L
M(G<0.L->8W7)5@*G3VZ\42G"[;LE;!'BAFX>?OT;!@V&0BU)@XA2HA1B(AM4
M9'I&CV&00VF%,^'A65NE*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4
MITI3I2G2E.E*=*4Z4KC3Y0_=,<B/U=-M_P ?[!TI72UP(_.-O7Z]+RD?\HER
MEZ5)Z_ ?D*FETJ*=*4Z4ITI3I2G2E.E*=*5"GG[.Z'"XZS-:Y$[*L.K]>W>S
M5 $R;J0%HD[)(,TJ>$VW/P@HE-CY*PMPAE.UW97+S*!L-,P=!8M$T::"&"\4
MTJ1\_KZQ[:\8?R;G!\L=@L733! Q3+1 [[6Q=JK:?8>0EQEYI:;UE*VW&U)6
MA6,YPI*L9QX9Z5%?V^UJ<)_\"B/VP]K?EUTI3[6IPG_P*(_;#VM^772E18W7
MQ"\FG0MR<<J%<!)S7UJM-U-+@:?%6+>,E7]FHFX";UE!U2^V *<DH:JQ)5YO
M-;DZFN9EZ^]/WV!@(F->.SZZ&M4CQX_M[?WJ4_VM3A/_ (%$?MA[6_+KI44^
MUJ<)_P# HC]L/:WY==*4^UJ<)_\  HC]L/:WY==*5'-C@MY.IWED?J]A!)>R
M6./X=Q,X^L["VB]%P]2;V [%M[:-<:MJG09B8DI)FJ##&23?KT=&K(#CUI%*
M*2I]?1J1GVM3A/\ X%$?MA[6_+KI2GVM3A/_ (%$?MA[6_+KI2GVM3A/_@41
M^V'M;\NNE*C%QQX4>3FVQ*[YG]=QUFVG#*V_E"&)NP;PA:WK[$5K^C4LJGZR
ME)2;AAK?0S9ZF3]Y;LL.788PVU7&U("F706@V&%*D[]K4X3_ .!1'[8>UORZ
MZ4I]K4X3_P"!1'[8>UORZZ4JT-@<$/)]:LHETV9?M7"URC:\JM@NURL!5^V^
M\-!U>K11<W/2Q#(=S),>9CHL$HMQH4=\EQ+64,,NNJ2A2E25XJ7#5%TX]:L-
MTC9Y"WZTK=;1K2OSDR!8(J>6_J,PO5L_&V*,M8<?9 +)!V.GRT)819H-F0:F
M8\U)'GJ_LJU*D'TI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*5B_;FF=:[VJK=)VK
M6L6JL-2P<XW&9EYZ%\V4 9+'$*]<KLI$2&?1,G%(]#DK(Z_2^<XTM2&\H4J,
MWVM3A/\ X%$?MA[6_+KI2L62?DSN#1>YJ<2U%*C#J_KO8 Q^E1MKWO ]P8ML
M_KMZ)V-,0[M[58LD4!5,FJ_73P\-1.&MA69D_P!.5@#U=2LI_:U.$_\ @41^
MV'M;\NNE*?:U.$_^!1'[8>UORZZ4JQ(SR5W#@?9-PNRJ=-2<'.4S7U/#UP]L
M79"JM3YNFS6R9N:N$5Z*Z8D462_Q]_KD/9FS"'!<1>NJ@L <=UR0<*4J^_M:
MG"?_  *(_;#VM^772E?'(^3EX,Q$>?+2>GA@8V,#*D) TC8NUFQPP0F%DEE/
MKS>NR&1V&G'75Y\$H0K.?9TI6*M,^3AX&6F'L.UJ@ O;^O-V3D-M#6LH-M+8
M,K4ZW2I'75#K@%?H$E$W?"#:E)GUB3O^'RWBC,V*[V%/ITB)$&'4_2LP_:U.
M$_\ @41^V'M;\NNE*L?8O"'R<6H:G(7S:E-J&N:5%.!,R=LNVXMAUFO /2);
M( #)4O+[#$!9=--(8$%;6]A;Y#K;3:5+5C'2E>A2_)H<(D5F+='U[F[!GH)E
MX^T+V9LHU$M&31I,O&.BF1UZR$7', &C"1A(REMOQPXKOI7<KRXI2KH^UJ<)
M_P# HC]L/:WY==*5:-_\ESPRLU%N59CJ#(T&2LM7GJY&7B"V+LM$[3Y.=BRH
MJ.L\'F0NSP/PU!&EL2<2DMEX9<@,.EYIUO*D*4JX(SR9/"P"-CP2-0NR3X0(
M@C\B7L+:?K4@\.PVRX:3Z.\);]8*6A3[WHTI1Z1Q7FIPGMCI2O>B?)T<-8.5
MC)J+TV@63AY .4CB?C]M%[U8^/);+#?]"1=G1W?0D,MN>C?:=9<\WS76UHRI
M.5*FSTI3I2G2E.E*=*5QI\H?NF.1'ZNFV_X_V#I2NEK@1^<;>OUZ7E(_Y1+E
M+TJ3U^ _(5-+I44Z4ITI3I2G2E.E*=*4Z4J*O+CB;4^7VOXFAVFZWK7_ ,"2
MUC/!LNOG*MB;2%=M9WW3=WAG&;E6+=!N!V+6VS;E!^L9B/A&),.#FHHP4^.9
M4I0'%2:B8P.$BHR&CFO0Q\1'AQ@+/?*O1!@#-BBM>=GQ5Z-AI">^?'/;OGI2
MO0Z4ITI46]P<:'MO;KT-MTS;-T@(G0\J=8(W5 4-1I?7]MLI[C#.+19&+'6I
M69398B%3(0=7F8J4 *JP\[-R,&H.:,3(LJ5*3I2G2E.E*AI4^$&KJ7S$N7-6
M#M&T,;)V!29NF6RLR-WD977T@W,JULRB5'KIV'LQA,5%ZLK$5&  %,0X[#3I
M'J"C,,OM*>RIE]*4Z4ITI4+N(/!S5W"YS;>-7SUMDH_;-K%LI<-/-4\**K;<
M>_.D  10U/J=6^%C\9L)HLI=+>NQWRR1P%="L5EE$U^/6E2IH]*4Z4K&6Z=6
M0F\M0;1TO99.>A:[MC7]NUS/2U7+$!L4;#W.!.K\D9"%2 ,I'LR0X<@\X)F1
MC)*/4\E*#H\T53PSJE61Q;XZ5;BEI:NZ2ILW.6"!K\U>; U(SH=8B7,2&P;U
M8]@S0437J17ZI3:K68Z9LYX-7JM7KL5#5Z 'CXP9AQ0[A3ZA.:D)TI3I2G2E
M.E*=*4Z4ITI3I2G2E.E*=*4Z4J'/-KEU </M0F7L^!L=EGY9Q^"JP<!6I&T
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MP//R/AT/AUZ_'I4]X?)?Q_?P_P"<U3Y,=]^_=YF?LKTGV_']@?\ K^#/9C&
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M7L/RJF^M<UC?=(LL9HL7D;I'D/L74\?$5O7F]=C5?9]9HO'6G<BR9>NU6M3
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M =PHIW#3(BW7<ML-+7AMI"W%]O-0E2LXQFW'&\LD<48W22NL:+D#+NP51DD
M9) R2 /$XJIW6-&=CA45G8X)PJ@DG R3@#H.:QO";!T-8:OI^XQJ*ZN WR/!
M$ZJ*?J+X[MG39:H5=X='JCL,DJ(=)K(14DI$VU'>@]"H5_+9JFQUY\VD:A!<
M:I:R08GT9IEU%1+$PM_1[E;24[@^V4+<.L>83)G(893+#&2^M9(K.99?Y>H"
M,VA*N#+WL)G3@KE,Q*6]<+C&#AL"LK_%&J?I8KW^)8W_ #;K6UET^*-4_2Q7
MO\2QO^;=*4^*-4_2Q7O\2QO^;=*5^'*K46FW'7*S7DH;0IQ:O@2.SV0A.5*S
MVP+G.>V,9SVQC.<^['0#) '4\#XTJP]6V+4&YZ!6]G:[C8*;I=M%(,@95VJX
MBEF#"GEQCZU1\K&!R WFF!$MX22,TI6$8<3C+:T*5FZCI]WI5[/I]]&(;NV8
M)-&'20(S(L@&^-G1O5=3ZK$<XZ@UCVMU!>V\=U;/WD$H)C?:R9 8H?5<*PPR
MD<@=,]*]JRN:HIJ8-=L10ZVBS62'IU=5-L048F<ME@=6Q!UN*R6VU@Z;EWFW
M&HZ-&](68XA:6&EY3G&+,%K<W7?"V@FG-O!+=3]S&TG<VT #33R;0=D,0(,D
MC85 <L15R6:&'9WTL<7>R)#'WCJG>32'$<2;B-TCD$*@RS8X%?RJ9&K+R/-E
M56-K<LQ7+58Z3-.(KC0V ;14I)Z'L,4I)T:,IY<;),.C+)&2\$^I&7!"7VLI
M<S5<VEQ9M"MS&8FGMH+N(%D;?;W,8E@D]1FP)(R&"MAQG#*#Q5,,\4X<POO$
M<TL#\,-LL+E)$]8#.U@1D94]5)'-75\4:I^EBO?XEC?\VZQJO4^*-4_2Q7O\
M2QO^;=*4^*-4_2Q7O\2QO^;=*4^*-4_2Q7O\2QO^;=*4^*-4_2Q7O\2QO^;=
M*4^*-4_2Q7O\2QO^;=*4^*-4_2Q7O\2QO^;=*4^*-4_2Q7O\2QO^;=*4^*-4
M_2Q7O\2QO^;=*4^*-4_2Q7O\2QO^;=*4^*-4_2Q7O\2QO^;=*4^*-4_2Q7O\
M2QO^;=*5QW<F1AP^2/(081AD49G>6VT,CCM(88:3\?[#GS6VFDI;0GOG.>R4
MXQWSG/;I2NF#@1^<;>OUZ7E(_P"42Y2]*D]?@/R%32Z5%.E*=*4Z4ITI3I2G
M2E.E*=*4Z4ITI3I2M)DQPPY=?91DN18$AK,N[7O<^_W;7261CXZX1>EMLT5K
M4=9BC-KOW8JMV,*H5;6^G[2#4P->PA <X.>EJ??('?<-]:B[5]F?X='H4B:@
MMI9Z3HHM[LLCVLFK:;>'4[B1--6S6X@:ZN+_ %2V>Y>^F#0LA,*JP"<.^B:P
M+IM25K5I[B^U RP8=9DL;RW%G&ANS.8I5ABM;*585MDQ(IQ(2"6QA(>37W+G
M7T/ OTNJVUJ(@>!=VFJ78+\LT*X[?TO9KCCD,2F0F<R@H,O;:1,QL'FP/I:"
ML0S;0#RL,AM>BV"=O=*]-EF%W<6QEG[9VD5W!9!'M=+U:WM/X&O=Q"-GBMKN
M&27N%R\#$N!ESG%;LS>&W2,PQ3*D?9^=X)+@E9KVREG_ (D=S[E5YH'2/O#@
M2C"DX7B<D+Q>WO+:UY):Z*V-#:WK^Y[]R9>8A6X%N[%.5#;U;3 TDD"R(GHE
MZIN5A;SQ2XT6,.4\EE+2?4\KPO'(2]H=&BO]!OEL9;^;2K/L^&E,QM%%SI=P
M9KM7@,,@N1< *@D:1 ,D^M6]32M0>VU.V:Z2VBO;C52(Q'WY,%['W<!67O$,
M)AR3L56SC&!G-8YE]6<LIC3'%&F&Z$I0,_Q3VSH"S/AUW<<(1%[#A]7TZY5*
M?+J_PC6H5NN!/))@#HH2?=1(JS)F@NA-HB$G2.?%J/9J'5>TETFLW;P=I-,U
MNW5I]+F62QEU&[M;F!;C9/*9W&V9)6A!3^6KAR9=B8KVFKR66D0-I\"R:1>:
M=,5BO4*7*6L$\,AAW11B)3F-D$F&]9EVC8&>/]WX+<O";(=NZENQ-6VGL&U<
MI[0NJ:_W-,4@72]AWC&:<BM?S^+D)7QOC\'7TZC9F=GPXL. Q9)J<>:""FH\
M=W!FYM.V'9A;=-)NQ+<:=8V_9RW%Q>:5%=MJT&CR:K+>P>BM.WH3SG4S#I\K
M2NUO#""[Q.PV8$^@ZP96OH#'#=7$VK2]U;WLD LI+];%+>3OUC'I"QBR#W2"
M-1*\A"JZCG*[/%/D]+/;8U/8:W3"*IM3F3I_DG.;X,MX*218+6==X^O2S5=U
M^#&$S&+G9;1IF1 %P89#Q$?#61TAP]:F?5'M<>TG9^(:9J4$]V+G3>RNJ:!#
MHRVK;6FU"?6UC,]Z[K%Z);V^K1NVQ)99)8 H0 [AEC2=4<WMI+%"8;O6K+4W
MOS,H(CM8]/+B*W52_?RS6+*-QC1$ESN.-IE'QRH>YJMR6Y<WF]:U&J]'W39Z
M18:=.,W>NSQ&6J#2HBA)%D8:-SZZ&]/)#?GA5J[MA"X2$9G!BL8ZYW7;S2KC
M0.S-G9W[7%WI-O>0W4)M)X5S>W<MZ6263U'$)986 Y=LNOJBMKIMO>Q:IK%Q
M/;"*"^EMY(9._CD/_CP);X9$]9>\VF0?TCAN>*@C8> ?(R>I9#9* G;O6=0W
M\/6T@C8IHF8#;LGS'N.W*G81GQBF66C0=6SS0P\R2V]F.669 M^:EQ]*^QA[
M::'%=@J7%I<:G9-?H;!&[_3(^RUKIES"RLK':^HPEC$I&\*LQZ#&@D[/:E)"
M00O?16<ZVS>DL.[O&UJ:\BE4JPPRVD@ DZKN:/C)KT+MY/\ WBLG;MFH<?%Q
M=SVG:?*$N3\HQ?"@<SU4WI'&/:( /:R3D)IH.PK8E"!6AVLUR1=*DG,Y)**=
M=HM.VNCA=+M[QY)+33K?L0(8FLE?N;G1Y$&L.AQN): &,,S'OXPL8X50*I^S
MU_NNY8%19KN7M'WKB<KWD6H(38*PS@;9,,0 .[;+=22?E=X*<CT[HL5LAJS6
M:^]-;:?V&[N(3:1V)TRA)XCQVF)+3Y-&9!P(IFV;$! F")UP_*,AQ[9\BALF
M"KZ2*O\ O'0CI,%M+/<3"+2UL!I;:>IA6]_[GDU:/5%NV?<#;6+O$L(3.]RJ
M9$T^U_ =2%])*D42=Y>&Y-Z+IN\:W_@Z6369MPF/YURJR&0MC:NY@"D>;1SY
M.GD?%UO:S%8B:I#7S9?&+B+2R[_'78 &??L.ES*F+NG5A<B9 3:FA=IP<$TV
MS:7P)JMG9APXRR1S\<<0A.2.W.@R3Z<;B2YEL[#M!VGNULI+1WA$&K+<-I.H
MJB3PY;3IIB3;*\-PG>M);R"1%JS_ -MZDD5V(DA2XNM*T:!KA)U63O+$PK?6
MA+1R#;>1I@3%9(SL"R(58BO%VCY.GDA8-.NT.*JCVP(^4T[O"G5*G[/WQ""N
MZ4V'>[I'6*%ND5FB:^J='*C7Z\Q(5Z/J<%#)!K33R*_B4<K<K(D@7M.[<Z%!
MJHO)+E;)X]5TBZN;K3M&F8:K8V=I)!+:2"\O;F\603LD[W,TI:<@S=V)HXUD
MM7?9O4Y;(VZQ&X5K*_AAANK^,&RN;B=9(YD-O;PP%3$#&L4:;8L]UO,3L5D7
MSKTSM'9=[XY:VINN<;#,=XQ<FJT0P==YFBU2KW0J+TM#4ZXG3\<"8 ;)52P+
MS.PD4=ZN2^W'GR\&M4Q#AL.:/L?JNG6%EKNH75_Z"H[0]G[A62TBO+FXM%DU
M66[M4A=U=([F =S+(F5!=(IOY4KFMIKUE=74^FVT-MZ23I>J1$-/)!%%.R62
M03-(H*LT4G\Q%;D[6>/UT6K57P+Y!#UK9DO,OQ6Q=@2FYN.\I*)D-@2T+C=^
MA]=:XU)';7UJ7,8P2W41]AWZH2\Z:(:$ABPKC8\:PO?!QF%,7QVRT1KC3XHA
M)8V4>E:Y'&8[&*;^#ZQ?7^IOIM^D1VFY-C97,4*,CEH!(YA&].;'_;^HB.Z=
MRES</?:<SAKAX_3].MK6S6[M2W(A%S<PO(RL,2[%64[&XL27X"\LCJE/1(CT
M;%B3FL[; UFG!;1D7Q]9,3_,;7VX:]KJ,LCOJ1A@M3U9 S +,Z$V*,*8KXOQ
M*O4DAONYL7;3LVES#(PD=H=0MIKBZ?3T#:@T'9:]TN:^DMQO16N-1FB<PN69
MD_GRC>7 LOH&KM#(B[$#VLT<4*W3%;42:S;7D=LDAVL1#:1LHD4  XC3U0M9
M.SY/2XIVE!3&*742*-0]J\OYK78AU@2>NIT3:.I:=':DC84<Y9#\>.#M$2T3
M.8IMS#<$^8N3\W"2L8ZU_P#WO:_PZ:+TNZ6[O=-[+PW[)"4])O-.U*Z?4Y)6
M0*'9]/:WB[PC,RKW>?5K)_[<F%W$_<PFWM[O67MPTFXQ6]W:0K9I&&R5"W2R
MOL!Q&27_ ,58OA^#O,N.VIQPFDAU>+K6I=9Z,I$E*U^[P0!2X6L<8&]:[$K4
MZV[ $6J>><V=A\B,&B+/%41VMMQ\L_ R5GR^<+L9>U_9633M>BW7$EQJ>H:Q
M>1QS6DSJ)KCM"=0L;B$B=;:%1I^T2-);RWBW'>1K-';X1L5-"UI+O3'VQ+%9
MVMA SQSQJQ2+2_1;F)P8S-)FZ)*A9DMS'M<QM+EE^ZH>3GWE4@H&5BP@PKE7
MJ-P"/C)/[)LR3ZIM_6NS6#N5UI1A^1>&<D[+K@5J"^&'6',V2-RJ"#]$*Z\T
MJBZ[<Z/<O/'(S/:SWG;5'C.GQ+NTR_TXQ]FK;*H&$=O?L9NZ! MW_G/N8 BJ
M'LW?PK&R +-';]GBC>E.<7EK=;M6EY8C=+:@1E\'O4_EKA<BO.E?)L[NDJC<
MW7(X-=\F=(\MQ0#_ +*,TUAS>%HWK$VSC//OK;DTBX53J"19FXF0<9R)4#3/
M1-,-F*9?;KB[>:1'=6@#L+*'5^S#.G\.B)&CV^C2VW:"!04+8NKT6YEC!#72
MKN)*Y%4/V9OFBG.U3/)8:P%;TI__ +_EOTFTN0^MC^1;F41MC$#'  ."/LN/
M!#EMM#<&X9F\B4I58V%JG?NO5R@ULB,0MB;NFHXF&U&[98?%<<N\I+UK8T6W
M-3IDW9)*O0I@X)U(K0#:CGGZ;7MCV9T[2]+BLVNQ<V6I:+?"-K:3O8#::E++
MJ8@E[\6D<<]C(8H5AMTGE1G2[N'(0"J?0-8N[R\><0=W<VFH6Q=9EV2]_9K'
M9]ZG=&=FBN5#R%Y6C1@&@B4%L^Z1PAY'E.:Y'AM?U.H*BZ5QDA*-/ [=,"SQ
M6EM3WB0FMTD5Z!@XU 5P5N2.=3(.$1"V%R1)[M?LN6(T%DQZR.UV@KZ<TM[<
MW7>7G:&:\A?3%<]HX]3LTBTD3SS2%[4:5(.["RAMBH)X 7=E%?\  M2)M@EO
M%#M@TN."079!TE[.=GO6CC1<3>FJ=Y*,-Y8Q3850S65O#B%NC5>D]9SVM_68
MCD[L;D'O#45UEXJ4L-FQ.:FY4739$'&RDB6"\^.!G6%()H=QBB2<!Q56763A
M5*20\O!&7I':?2=1U?4(+_;+V>L=$TC4[2*6."W[G4NSEI8321QJRAG&HWBW
MEI*!NEN!<(V"H]6S>Z/?6EC:R6^4U2XU&^LYW1Y)>\M-6FN8U=F!VJ;6 V\R
M%@J1&$C@_>GAR1XVWFPV_B^[3*-$[?T[IRJ7BH3VG[%LF1UVQF</AJ;%ZTV/
M\+M 2J)@JDCUZ; 5Z9I<S#XGUS5?:.D<.L]<;H.O6<-KVA%W>2:7JFJ7-G=0
M:I!8)?'N4ENY-0L.Z+QF);MIX7&"(I>X[J<I'@UOM3TR>2;2S! EY9V44\,E
ME)<M;#O&2%+6YWA7WFW$;KTWIWF^,,PQ6NQ7![;6X8[F7K!\(>YU+1=LK^M.
M)\7=2I:(B)6&.W9#<F=@B?"DV.\TZ5&PDG%::C+&D8F,PQ"N@)-R,R6ZCN1V
MNTW2Y.RNHJYM;G6+::_[2R6@CEEBE329>S]DW=PL-HDECDU5X,K)NE#[ Q4'
MG#H5W>IK5IM$T-A+':Z0DQ9%9&ODU2X4.X()1&2R27!3;&5W8W8S[+\,>1DO
MM[-CC*M6ZF.O9(-WB-C#;5D'3JGHIK1 U%3Q&$HP<<T ]"1]N:>9^$!R$50P
M%[-KSVFNT>G2Q=JM"BTSN)+B>Y86#VDMBVFQA;G6#K)O#VF:\9RXE>U(.QAZ
M2K@6PQ%EZV,FB:E)>-*L44.;E9X[D7;%HK 6 M_X0( FW8LV1N#=R5/??^SU
M:L73/ _E9KW66M=?6+$+.6"I[%UW=)/8J+VEH\REQ_"_9^F&]5$1B5889C].
M[$G(>&JKL2AN*L5<ED6AT9F>$G"#<S5>V/9N^U"_O8.]A@N;&^M([$V>42[?
MM9IVK'4@Y&XOJEC#++<B4F6"XC-L&,#0A<>QT#5K:VM;>39))#<VTSW/I&&:
M!=$N['T0IT"V=P\:1;!MDB<2D=XLF?$D?)V\H8S6T14:3(H@XTS77#,O;E5
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MTS>K6[5;+!TWX[R<I,@/"58>+RQ@M(N)I6<X>DW \X(9%8'<00I20F'G9+.
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M2*M[=CLS3.O*(77D>@]'\#>>04.U(C(Q(,/A0YIKLQ)2>!WF\/.^B5'U]?\
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MYW(RFC6>\7%F)WP&XBQ;'M4C=;B?F5X_Z&F%HE;++*6?(-@KD%1\6AY6< 1
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M?4H;H3W2:3I\5Q&WI#R30D782?T2RBN#)':&:0PW=P]FD)DCV"1B&C!^4O\
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MM\<9Q\^.E*B%JOC>\\Z'=N0T=KV^;?K>U+#<JE>:_2:Y5Y,:*%;D*_4'9@N
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M=R[&EB7U"8WY(!%1-XZ^4NU/R'V=3-314+FOV>VTPJTY<.M$6H *5"2XZ72
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M:2184M[+6+:?2;F\:1@0JV$=Z;U@<!U@*;EW;AIM\C3H#8\7N.][:LD%:*=
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M+?89JRXKR#2)1BIU6E"M,#U>OUF'%"%K]-A!FFF8O#SCS1!1)!#Y"U]*5?\
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M46Z>;'O20]E"$EW6A:E/LCQ13+,F5&J5FOY#:OOP^=/[?[?Y']*5:M3X7M3
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ME2K]R;V,S,!2MVL! TG:ZY1)TFOR#-#G;&"XZU;)@1VMPWPM-%&3OJ*@!JS
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M-HC;-:"8J\MYDI&H1AVH-BZIMUKE %*E(,?J3R;?%IH6Q2[<B%669"33'0(
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M_I)_K[/;TID>8^=/E[I^\WYR_M+5KYN_^$GIBF1YCYT^7NG[S?G+^TM6L?\
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M7Q*ZFH["L JK)($D!Y(UR24UL2LD%CQ-KK,/*N)#S'B?W'O\.N?8?834%2/
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M]>%-B_YO]0_VU3[#7/O[['B=^X6VO[__ )P#ZOQ?-U&?A[O;X8Z?AX"FQ?\
M-X>(\/\ \&F=-<^\^WECQ._<*[7_ -(!U);/@/?SG\^?C38G^;YC_;3[#7/O
M[['B=^X6VO\ S>4 Z;CC'O'S_#\./"FQ/)OF/]M5^PUS\^^QXG?N%ML?Z0#I
MN/U^N>O''--B?YO]0_VU3[#7/O/^ZQXG?N%ML?Z0#J,GZ^7XC\AY4V)_F_U#
M_;3[#//O[['B=^X6VQ\_?_? /GZ9]@^O#W>[%3M7_-\Q[OZ?KWT^PUS[^^QX
MG?N%ML?Z0#J=Q\>??\?W_3IQ4;$_S?ZA_MJOV&N??WV/$[P]G]PKM?\ T@'4
M!L<\?7]^??TIL3_-_J'^VGV&N??WV/$[\/!;:^?_ /H!_P GLZG<>/#'UFFQ
M/\W^H?[:I]AKGW]]CQ.^;[A;;'^D ZC/QYSSYTV)_F_U#_;5?L-<^_OL>)W[
MA;:_^D Z9^N>.O3GVD^^FQ/\W^H?[:I]AKGW]]CQ.]W^X6VQ[O\ YP#J=QZ?
M7T.OOIL3_-_J'^VJ_8:Y]_?8\3OW"VU_](!U )'N\J;$_P W^H?[:I]AKGW]
M]CQ._<+;7_T@'CU.X^0Y]_ZGX>ZFQ/\ -_J'^VJ_8:Y]_?8\3OW"VU_](!U&
M?V^OKW>%-B?YO]0_VT^PUS[^^QXG?N%MK_Z0#J0Q'_%-B?YO]0_VT^PUS[^^
MPXG?N%MK_P"D ^OJ,^SV>/ECS\ORIL3_ #?ZA_MJF--<^\?[K'B=^X6VQ_I
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M]AKGW]]AQ._<*[7_ -(!^]TW'PP.,<>--B?YO]0_VU7[#7/O[['B=^X6VO\
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M^PUS[^^QXG?N%MK_ .D Z9]WR^!^?ETIL7_-_J'^VGV&^?GWV/$[]PMM?_2
M=,^P?7MSG\:;$_S?ZA_MJGV&N??WV/$[]PMMC_2 =3N/D/K/[D>ZFQ?\WS'^
MVGV&N?>/]UCQ.]O?[A;;'O\ _G .HS]?7O)'O\J;%\F^8_V_EU\:?8:Y]^']
MUCQ.\/\ O%ML?Z0#J=Q_3Q]OM]O/G38O^;YC_;3[#7/O[['B=^X6VQ_I /\
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MSI][!AC,BR2,=N(TC:*19#(5[MUVOM8@'Z:?S'XR7TV,C:KN"LR4C+R,G%
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MR\6<PX6UD85]B-!UO:+M0NO6\5M'ID.G(FJZKK$ICN9[DS7FK^C&Z)[_ /\
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M\3<W$R^5_6A-<C?)W!S,K 7.UT>=V36XJWB1/,HURG(FZ/6Y:Q1LA9\14:6
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M5L<$8@>](2UA_,?]G]IMN[^#7FT#=NV+MP!DG._' Z^7C06-Z"1Z-)E5[PC
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M?9X'CIXXY/&!YBAZYR?'X^^J?3\_CV^?V>/S_P#+^#J >G@?/&3X#Q/L)R>
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MX \K+:5LA(-.SEE2@TB_02VZ^DF\D#M+$W<PB51'!$AR&D4LI+,QP1G&[(4
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M^WO^O+VTK1'Y<*U'TD7AY8O5TE5URV[>KT\W@G+;R53H^LO47666V27EY92
M>XLIMA:0L8PM>',.X%)]0^S6 7'\?56*S)#821\9!V->;@3D<$LAQG)Y/&#6
M_P! F$%P7R!@KN!4L&7D$$#G&67@$$^&:U1)F0+!B*E(P7T\2\+&R98"'DY<
MB31P E*':'2WA;G8LIK.5N/O84\(Z.RRA;3J&NVD22V#K(2K,7"-U#*3)GUA
MYH"-N,!>2>0#[!I5_$9(9F2/UE$>7?:H9U4!6(!'WL%2><H5J_8ZK*L#+H(@
M3$7#A +?*)]$I+H$9%&M'&ABBJ'>RHUDDC"O-4E13!Y3>6A^PR4LX33]UM9F
M9W<X0'HSNA"NY4C *#@<#8N"22<[:YU2UA2>&*59II"&&Q,PHXQ$B1LRE65&
M5@I7)Y9\G:N,2;<C:ZY4CXU]P,E@D$@LO HCC@H<XR\:B!;PB-4M:S&P1$*?
MD<F>E?)%9AWVV7,>C(V>FB83JS9!#*HR5W&,8:0Y?D*6/JJ1A<AP3UKE+N42
MZ?<A2OK.IW(&" )L)VMG&]]I9R6W, %&#PVKB\1]HCXC(;4]+1,2-8'(Z#6*
M176RH0V,0T02$R6(W+3D4V'Z<<T1_P!6!%:&<\S"GWD+'*[F Q2'.$)>$,[%
M'8,K<*<G"$DC!SELJ>%Q7$D11RRJ.\,R8/!X.!@8P&5F 4E3ZNWC.><?UBG)
MVJEP[4/*'PK!4>\4B3"E&2\&AE);84:T3'+#"&$+_MUF1'0PRD1Q*?61 6\,
MK?G:DNX2[756&$:/"Y49 (=<[QZI4DX(.02.!7F*569(]Q#$LKDEE!(]8* #
M]X<D#@>/%9KBHJ2EXA^3580C7E@E8P4;.. O]\R V&I!.$S +Q18V4Y;9"PX
MZ$0WED5]@C)2VNL:8HI$8#*"V<1Q(P8@'*\(P"D<DC##G!7 J[ S(Q9(]QC7
M:=O>-(A)QNXP$&1_C8#DA@02*Z8>;)T];/)L\3I8\-V(E'QM2+F!A<$$NC%,
M:_GAG61T.DK]=8=<'7A#Y#A#"V76C\NY93Z;'@>BQI;]L-;B0K+&&O4CR%7<
MOI,;'.!ZNT'HN,<KQGCI?LL%J>U^H=],(2-/O'@E8@887-N3@R8&[NBX!.,'
M+$'!!UR5*T7"F4%_74WEIJI7>:K5XDJ>MX @9PB+Q)#1A%A!'RYBMGI>'-F9
MB-DL R2W(BH.OB8QAOS^MD@@FNS>1_\ OMHIK5)QO7:'V&18B>91DHB,F4RT
MP#'FO4[\Z3K=]'J-I%WLMB+BQAO2A0W9DFADN&,CJ$D@0@I%/DJ(Y+D;MP45
MMPXVU2.XU4F(LTE7"+-OW;RG_B544961-P]4D"Q2"9&1;QZRX  AV08EYO+F
M4O+':8CVU-.#$89X?5KE]7N9(EF$.EV(S<3=(Y)4! "=-[X3NXL#:"2QR&7/
MC/;36#JVH'3K.<-I>GL!/,I")<W ($K(W&\1D2+"!D,6=UW*XJT.3W,2B\71
M(?504J+,;Q8J$@=:[/'1J)4:IS=R<D;$62B.?DPQPR).16;,NO2+AN00VXYF
M0&D39)"V\O0>S5WKLC7S0M'IK3JL$+,8^]CM]D0!<+EPB[4 7:78N0RJ#GF+
M2W](8W$OJV[2KW4#9!=8@%5I,>MW?K%1LVLYWD,N.=*LK/\ V3Y-FQV.RY&V
M]9@XF8H=LB5%D)-E!:R:T=6IOTXS\"$3Z8&5D232I$9F2E[#(267"<6*209Z
MO!;+81B"*/-I&TD4\<JC(0R[A(I&&8895"*N$CB15.(T*S-*^]PX+QH2DT9P
MH"!@ T8XP%7*HJ@A4 4;<5%^T1>P);85PLTM4!!<5]F"/*=!F7C3\D^?"LL$
M/!1PQ38HXL+-FBE2L6X$T_EIM<.?(AK? D=O#) EM L<A)?O556551O5DR 2
M.&+('56!8*Q5@K<+DJ;=(8X^\+!RSI)M.(P<_P ML\MDH05 !4\Y&<FS023;
M#="#(^L6C.&8M%GHX,8P+:HM5R&66T$P#-.^KL?%29C<6 AT/)9<DF7$4/#H
M*>Q(#9N-M2 8FB;+]U=,Y,#"W*[F#(I_^^(V,0#<*8VS*5&TUO[!FB$:2SHH
M*M'WG"R&*1&B/0$1JC2*))&VX0[\C:0/]!S0@!L7H_3\=)+4[(AZRHS$@ZML
MME;AJ*U&X+<6R?G)S"EO^D6I@OL0RK.6G4H6C*<?*6I.)-1OG7[KWERR\J?5
M,S[>5PIXQR.#U%>?WG=B[NA$ (A<3", A@$$C! &4!2-N,$#!'(KDLY0_=,<
MB/U=-M_Q_L'6%6/72UP(_.-O7Z]+RD?\HEREZ5)Z_ ?D*FETJ*C'S)W/-\>^
M-6T=Q5M+[D_2XV&*B!QJ"?L]\Z0DK/"0@T:U1HNY4"1G5R3LFD!* [;%$ Y)
M^$F\'Y#^##%*PUY/SF39>8-%N,K=*?4J;;J!-!0$_'U22V3AM1Q&95DAN3JF
MW=7ZKO-2D0#8<P X%<;:*[B28D(R%O-A+A9G 2I(Q]?L37EQ_'N_:FB+7(S^
MV#Y6-MG+G5VQ!8>'B*HAN< LW(.C/LB7:3E*>]/.D1[14>,(W S )8V(,9+]
MAE(PE$-'JBMBO2E.E*=*5#3>'+KC333'*%9-RTR.MT-<-=%2\-@U\UZ,1&[(
MKC\DT>1'C%A"&QC !A$E'/DHD(]@=QXP9AK&%]*9^OK\?+QK/6J]V:GW?#$S
MVJ+Y7KQ&A/8'D%0Q>5&1CJWBF&$RD42@>5C/6U@EJ 4>$,@]D=P@)3XZ?2]*
M5%"ZPOD_-_[^O.I+W7Z'L#?DY5(RD7NO3$!:UR<G4J+,1>RH>"D)-00T 0%6
MYL(&S1B&)%3@9RRU"+PL^2:(U,>NZ3+J4FCQWB-J46[?:B.8,NQ!(WKF,1'"
M$-Q(?+KQ7HEY]E'V@Z?V'M?M(N^S=Q#V)O>Y]%UTWFFM#+Z3<M90XM4O6U!>
M\N4:(;[1<$;FPA#&?0X[(@[ H[>&AQF6AV&D]_-;990EMIM/?.<]D(2E..^<
MY[8\<YSUMJ\[KR&+-7R9F:KS$Q'NS=="C9&=C$D(]:B@9=)BHTDY&<X] T8B
M/,6TI><?F&<K5YJ%(RK):SNDM[>Z:"46]U)-%;3%#LGD@[L3)&?\31F6,''B
MV!D@@6%NK=II[=9HS/;)%)/'N&Z))@YB9Q_A#B-R,^ R< C/]*[882V0<79:
MW)B3,#-ALR$5* N>E$.#?3YS3[*^V,Y2K'AG"L)6A6%(6E*TJ3B+JUN+*XFM
M+N%[>YMY&BFAD&'CD7JK#S'LR".02*FWN(+N"*YMI5F@G0212H<JZ-T8']#@
M@Y! (J/N_- SNX[5IBP0FT+OKX/7MTQ*W.(JMIL<"'>Z>ME)C]?.&A9$(=TM
MR8C8IEHTI&<CPYLZVE:G7!D=<EKNA3ZO=:1<0:E>6"6-UOO(K>YN(5O+0XD,
M16&15[WO8XU5V'$,L^22$6N.[6]DKOM)J'9B\M=?U;18]%U7TK4K;3M0O;.+
M6--*=X]C<1VLT2.S74-L%ED!,=M)>*IW2+4F^NEKMZ=*4Z4ITI3I2G2E.E*\
M2P9[1RO_ +\UC]_/]?WNI!P<XS[*I;D8]OU]<>^K"RKOGQSCV>SZOX,?\?L]
M]9RV,X]OLSTXSU]AX\_'%FJ9QCQ]OL]F/?XX]N?Q_/GVX[9[]"/ 9.>><^MY
MCPQC'OZ8-*C7R,Y7:AXQ5E^>V%+$$R60##HJFUUIF3MLV@-MQ2LA1F2!T#BY
M=;P,J3D2 HMDA:6WBT+SVZV^D:)J&M3=U9Q$*"!)<2DK;QYSPSD'+ >L40,Q
M4#C)K8V6F75^V(5_EJ0'F;*PQ@XY>3&%^\!SXE<X!!K0IN;RK%VVAR2IOV([
MC,473FOK)2).5B6TH:=M38MCB1K<U='1'WA)*OFBRJ1 1PY7 2QO^F,M2/H3
MD>GZ7V&M[31KI]0ACN+^YAG6-\ANY79(83!N VS H"Q*L00 .,BNDATRULK*
M=+J.&:XN%93<(QD]%YS#W0Y&Z4A<LHR%/#[6*U#6/\J9R_BKK;]H5C<ILG4F
M]M3 X=,GXB+-KLW3%J=4,ZN/=BRY$1J(%/C%F,5,^+<86VVQYJLR8YS'0OV)
MT*:WM;*73TBG_AZR-/"SI,DQZG>'57+R!L--N. <G YO6FGZ4R!+BU:4B)>\
M99V1T/\ BD4[0K,-^X 9QMV.C \=0W"7E"QRIT;4]BR3$+!V^5Q.HF*Q'R@1
M9(R82:?BTR*@&S3#HT<YA0!>!)#*3!<',-DI0IQ">O%^T6BMHNIW%HO>26\;
M)W<[Q.%<LF=N\JJN058 J,-M/'7/+:I9Q6=W+%;2/+ ,;'D548\#<"$9D)4]
M<'Q&5!R!,8@(.1@+ !("#G@'#,BFA&,-E"EBON*9(&('=PMM]AYI2VW67$*0
MXA2D*0I.<XSH59D=71BKH20P8J5*DD$$>L"/!L\<>58,;%6RIPPVD,."#[".
M0?+'4CKXUSX<W_)>HKP8=PX2ZAA0I25D)TO9\7'V@Z.GU!$.1&(G%'9FR9&)
MC0PP5V -Z$AH\9QT=X9AAM;6765>K]E^VQ>1K?M)>RR1(L0LG:)6B5E#!_2#
M&%D=F*Q$.[D;@6/(+#J],UE@SI>7$:+*L8W-$. A<EMZ1R;9!QL8J0-WJD-@
MC1A.4*(KY12K^V2598?)RGJ"%A\29A&8IN0BB<6R1/9'(<.;(?B(YUMI[+@'
MGL -K#]$Z QZI'=33!6MB([>785NG*LDXD =?1XUSA""Y&5]8G=CG)Z>UEL'
MB=\M>R ;UC12%5B'),C'9NVAXQWK.Q)7:(S& 1A'85@G<(-\Y+4!&DE8D@@(
M!9*,@I<;>%4[YP@(8,TX\4$^=ZT3('-L(<6WE'G+?<3L[:.+. IEDX1IY=N6
MP<\Y)*CG;@*I/3PJ'GFEBD[R5EC4N_HX8E3WC[CM0A492V&9?6"J%W#U5QA8
M^;#G)1QWSPHTIIM@'.6AY,*0D5,M@@LOY0_W7(EGX;<=?;]&:[E7I%Y6VRAE
MY&P"NJ<_=RQ&65AALD\ 851G:N3G QCGG$^ZI8.&;._^8N"=QZ >.>F.G].,
M9KWUVQ^*.8KU-17_ #<#!JD"'4J!8<'>$<?&BPV,O"EL%?!>5O&R#SN"DO\
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MQ []YQB2+8P93ZKL(P6( :]]4T&W3<U(:NJ\-*[3MV+Y) OQ&KX<><#'5"R
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MD=[E<X[MA6EV)V';M2[2UILF'@IZHS=9E&;)"+G!*O,0I4P&N1.BGL1,'%E
M)CWIML= \<5*S1@KWF$AR&9%E@EOTB2&#4;*\L)IHIXI8VA<0][#(%( 9"\D
MFYI N?64(K'[RA25K56ULTT4Z%@XF7N=JLI<[@,DN/5# @,RDKC!X\^W+C3M
MXECA0WOF]7J!VA)%T<G9ENL=3<#8A'#W%DR4A78]3?F-AIK?H<5TC)@H+@1
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M5ELJ-:CVT*2)#RSP[@>22!UR8ZBS67SPLKR^G.$FN,J&2TRPM&$[4%Y(R&;
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M:.'99BP_VG(5Z.C<DP3U?C(^,,F,!!G1PK H8Z))QW$8RA?H&26TJ#Z(1LC
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M=B<=^KR'U'.!D@DJY.U@5X&T^F;%HB8RLE33Y;U/UCK^,J!48( ._/W&8]
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MA<AMY8; Y8"&7(C8[-WO,5'F');E9)-G4.-(/MUV#:!(B5@5>3CK+""R!;@
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MVT_ZVVMAA2" F00W7W&W%Q_,!RJR'><C<0$B0#'0E3DCC: 23N+-@9J\$Y;
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MBR2Q)GT</@[0X+ Y9JT^LFYB8Z=<>NMA)LM7< ;K.=FE0MZN0@[PG;D(KRR
M88LM:>+MI?9-#A<-1CD%.1C9R?2*KTXV*S%X2UF20788J2+8G(F1+AF3&XR-
M;$*5Z?);?PHXPD;!?I,.KVER1ZK12!.CC<TA#!<1NH9"JR$%R3SD>KC.-2D$
MG+[&;:2-X&0F,Y/JYY&TD 8P%W9P"1;.Q)@8F81)I2V?$PK4?"GRXP6!PSY=
MR(8',!%6A!;>0JO%A,*BP%EG-I2O*"C'R2''R;UEN6,[LJS[C%&Q)949SM=L
M@-EW<[V(4G'"J%"AL6*X[M6#@=6 89X!8G<.N[</(G/)%9PXO;WC.*_(C2VY
M9%3XX4??QPI0+SW$I=I-Q;F:_.D&I=?6I#T(Q.LE(P[ZLV_@?"GB/2X,0UI^
MT.G'6=(U"P3<2T&Y)-H)-Q 4D0(<9PY0*3D@ X& !G: 1WEK<61_EO,G\G.6
M_F@[D&&<A0&8*S>JPW8+-DBN]B*DPYB/!E(TM@Z/D!&#@3!7FB!BPRV4OC$,
M/L*<9>9>:6E;;K2W&UHSA2%93G"NOF)E9':)PRO&Q#*0005.T@@@$8((P0/'
M/->>2(T;LC @J2I!!!#*<,"" >#D?K6G#RTO&_9^]]<Z+F]>U2:NH&N)/9Q%
MEK]7%,/LKV+"S0<Q!04>QE+!,>*JOR"9/S\/&(R\$D,5Q#ACPWHWV<ZU8:3>
M:DE]-';F]CM!%+.0( (6G[U')&=S"12A QA7#$9K:Z5*B][$\G=]Z4922H!:
M-7 !9A@ B0CGC)!(.,5RT7VM3FNX&4:V#&V&ASSZVHXN,M]5+K<WZJ1()<EV
M,24NTR_(NDCA_P!I./--+<9*?#93A3GYGVZWO(;J5#:O#<VZ\K+;W*3*&6,]
MV3&C849;UF]8YV%CQD]<;59K=I8[F-Y7;O);<(Q]4%0SPS!F@.,Y"+W95<8!
MZ'&(43'2L4T0(ICU&3+<,"800^AY;XDPN,>#$1A@5SL_@)L=!XJG'5C-+94R
MEE3B!\UYRDA];;L55) !4DKN]HR#G 8\C ."03K_ $.[/KQ0[PR[5^[M W+D
MLF6=5W.,,RC/.W.&JXAQ7Y@Z+B8N.FGYH+S4Q.(ZM/6!A.(YVP%"N-.PX_\
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MK?8FW8@278H4C@ SGA@-K9R<$@$9I">3<X\P*)[ 1>QE.V"()@R27[4+D@,
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MR! 6[Q4R"R$/'LW/WBE4\ <GBN:+80$DCDW ,,>M@$;L'# @]!M/."2/#/\
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M+2IE",-F><\*ONO.7U?V7*4JQ4%PJ^JGJ98,55@<$E@#M.[).!OZ<#CC%QB
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MAEEOUG"<Y*;::=SC=Q66'4R7"C9$C,D9?<'9-R*S!-L>1U.2QQ@)D@5DF0J
M &RQPI)&/5SDX(!./+A1TJM*UE%6%I^T7%0)L9+CID1885MM,?EI([&>YI#
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M29:WF)5DN1E#W%E!CMF19#3(X3*?0M.+80O"&T4WDEO(ENT/K.=Y=R '0C:
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MD^MU(Z>)/AC="MO+T!(-*\W/I'&$9[IQV_->=CQ3WSCM\_\ /VZY'G/)'3J
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MXH9N-0\M3CN<99SE3CN<^=G%A\M*6!+$[V) Y+,?$>L1DGGPSXU$Q;:GD3@
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M4:0EU79(ZDXRKKVKL)I=SI79ZWANE*37$LEX8F1TDB6=8]L<J2*K+(NSUAC
M)X)K\P?^K'MUHO;_ .V36-1T"07.GZ/8VG9M;Z*>UN;34)M*GO>]O;"XM)IX
M9K*9K@=Q)O#,%.Y%XK4]RML5KU[R5W"1#RP$9/V+$R-=082^25NC5-64)U"
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M*;38[79,U$0X38PDJB6FX;"XW,?)2Y "V&B98SUUK!&!<.L%#K&D09 Y]AL
M)]3YH8SE5E//Z2T7>$M(&&\(P8+OWL0I&XC 9F7:0V#DX4D2X!P6XP0<9R#P
M<+XC//&>!YD\5BJ%203N.CC2T731,!7FNLBQM?\ 22< \DI<B(U%B!@-X3$R
M50#0J7<,)5*,C2)@GF2@J"RPGLTA6T^X"F9U,4KR27#=U*.["NTJ@[^]2:3;
M&L>4!4,&5B%-4L2K*V>> %50W48VDG;LPNXYVEL]/*MNJ,8^!C<=LX[$C8]O
MM\W/?OCWX^;Q[9_AZY; 4Y X/AX9Z'S^-.JM[,>TXR3^7CY5$G?>GA+H$'/1
M4HY7[#7\&%+*%;&=<DXET8K!4<X(2.4P4[GSW, ^E$>\'R1E)4DCS4Y%O<26
M^Y8T617 !5V.%(8,&!0JV[<.,'V\CI?B=6(63<5)P"N 0<'S5L<=>F>@\S"]
MH.DSV:S&U)B<;CAFQ$V0X@]<,*A&6AB\%'-ROJ+H;I3X#XC21\,.M%,^J8'<
M'P4X)MR;J-9'N>[W/L[M2J2 'GB-8]P; 96]8%-N"7W%0UP[-P$>01D<$@G(
MQ@DD-T/7.?):_ENK9>K7BDT:NLQ&;B_#SX@QT"PZ89\7D12&R4MG!1Y90;IR
M%- G/(*CB!EA^;'R#A;PV,XMLJF15N+@QRA6*18;O8VR,R]VC;HPO^'"\N5]
M4+S4B.?NS((\P%PK.2.[<Y!5-Q.UMP._GC:&/ABO4U]:I*.:P)3Z!*>O%#1K
M\Y9+$ID&.RM\1H@D\\]+3XBXUI'I",1C!,;Z )U"!(T=.<=7KF$/,[W%XFP%
MC%%$I=BN]AM"X0*S%?O_ ,PNV&D;!!J@'C"I@DY9F&!D8& <YQSP, 9!VCP'
MF6II^1D$3&T[4@\4&-D4UZ@5\,EQR;D4J'P%(QJ#G%+6,VVVVH8DS#99#YQC
MS"6H]B/+7>MR0I33(6!SW4EQ<[65 <L [J,+C)4]V=NW:"'<X6VV%SWY))P5
M5,\@9R ,GP(ZD>? X'FZZAZ7B-K=@L<C.B0,+:_CC(QC48X\89(0[ILXV%(F
MR003LMZR<U"+:(](ZJ1,;5F+=5@R.PC%NXA)-=,D?*1IA88N[0M$=KL8 IV[
MF$S-L.-BHQ."2V0DDB+&@(+2<!I)-[*'P0JOO('&T8()R",#H)J:4KFN8S4F
MP(VA1DV>.W;X^<D'K*H3.)B6/<^&A%MIBGG W @VRFL)&:PT]EUM+9G]O^F>
MSJ8[<V#*I;;WA+-(O#@OZC$@@,C@*,D@DY+^MN+%<3R73*TFTD+L50/5"+TQ
MX$'D\<#H.@%?/<X,8NINN10^(R)0TX1+12HT-R1!<2@-;,['%*=*9'/AW!T%
MG,X:RX4/ZQY@[QB!5YRX92)N9 ')!60LY6126S$RX'$H(4,1@>) )K&*G'W1
MCIMQTR0,G!'*D9&,^%8.CDV,^U&MV%T&H0\!3(<*<$%#<BSO@ -(4B)7ZRI)
MDBU(N31<R !*2,-)GNOG-OQWIA",#LYS%DA%L&BAE:XDN'95D*R*LLB8:24J
MH4B-063_  C[Q.58+2PPYRZ[-O\ A! (#'  ^\H)4#GDC'&& %UUW$==2G)5
M$;$'+A,F@BQF&&VX&E1X;:%"/FY\QQ"9H%?K8+HPA+;I Y)KA*V(]Q+0UJZC
M>!0A+*)5[PD'^;.Q!W/'GG8P) 9E/!"_>;BN$AR3P/\ !D]!@YP>0#U/&3R!
MCI4B-.W 2<D[!#@YE318A@)*YLL)L:*.<PX\TEF%>'::9)883AQ+BE(](EM#
M"\.D#O,.=8CP-"4W]VID4GN@^^2,H5SW@/(+$Y')'JGH142$%<C=ZK$9Q@'=
MDD@C'0C!R!U\<YK/F,)QWQYWAW]WAW\>WAG&?FQGZ_;W]N.K>.N3D#/MQ_QC
M'0\YYZBK'.?R'_'/7\*_6/.[Y5CPQ[OJ]F,?3G.<?U\.K##))3R\A@X'(!/C
MQSTQ\:K7 Z@<D'V@] 2.@']N*B+RTJ\G<#-(P465@!PV5OK,@8V^XV6S"KBH
M/X32&W@AMAUTA&&AL8*'/&4IUM@D1X4DA"MWI$T4,%[)+&) BVS1H>!WRNXC
M+-M9E5268E2#@<9\!4EE ;&68,0?\!7U@>,9X!ST!YJ VY3VHFQ2=8AV 'QZ
M+'PL0ELU]\U3$:,F/]8+1ZL.0X[(=R#&4"+8826\Z*A)8KCZ6V]SI\,LD<=P
M=O>7D[RNH/=JY9RH5B1SM3,D?+9("LJKN:HD= 2I!VJ@ .,[=PR,#IEN ><X
MQ@9X'BU2JO6BFSY46#&Q=KEKI7XA;R59;00(]#2D8-"/E2[Q1)OH&24)6[WP
MXAQU]Q#0Z_[>35=SK:WJN=TJ+:,Q!))#"6-@P5"@4'@J!E0"3R6P$:EX]A;;
MZYQA?O<'C@9/)()/7D <#-WU5I3/KNVQ'TYKB@*_1[73#TK4$FORB'5YE!A4
M9<$+>*EXHM<3(-N*:8E?56DMB,M&H1C2H69+,EFD823P3B0$F89<!AU7U"N2
MS [,<,.[:J]P +A0.5#J5P%0#:0OQ.3MZD^?6]$2!/'B778H0M4WK^XX>DW
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M?:%EDC8QQGO95S&^^/>A)&'3*+@DM(7?<%]4 F Y^]@-SP%.WD<L.N,!L8X
MY\>#478L2Y!.%RU(@+7'PEX)&0=!"1,O'Q+$PIYZ)<:*L(TI'I>%''2D)@=*
M@U.S"BB#WBF<LCF7IW6.)EN7MY9(3@7"R9E>-=I7$9$FUCQG@@C<$4,W%]%5
MF4 NBL W=E.@P6;IC(!)/(Y& 36Z355"CM9T.N4R+4XXQ$B9]8??<]*^2<6Z
MX8>0^]YJ?2./%OO9\_"$=TX3A*$8[(QS4CR22ER57O&W-M4*%Z (JD\*%"J
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M!M=2D:/:%EXD6+D' XNRS(@(\-'G9AUH<]6(PX4T^_EHU4>[Q^L]",_G\*V
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M3Z1]U2G7G%K4I6>+O+V\U"X>ZOKJXO+F3_V3W,KS2MCH"\C,VU1PJYVJ,!0
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M\1@O=SM"58Q*D8BC:.-D$B.3,;KJJ]%ITI3I2G2E.E*=*5YLO_[7$?\ DO\
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M^V\&I=9>'>8>M3R'NY4-VLC-M_EPB0HXSEE>1U#,  KC<6!"YY(3-_@1$;"
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M5 &("[%+2'&267:H]G!\B>/8??7CZ^V]M"$B@:LS/0$>;AK&>Y$4\"R>T$H
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M*&D8UG)"$-H0VVA+;;:4H0A"<)0A"<82E"$IQA*4I3C&$IQC&,8QC&,=NMT
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MBX8HJO$.Q,B*PR"5Z5>-@I1BC2QB)$8NMQ;(5D10=ICE"]#AE7=L$@4@L7'
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M<U> 1%B&QFZQ29LYR+B&'^,?)5MV2D6HR1F70@T*U+C+Y+<3$2DBIIO&5X$
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M02Q8+XR3AG(.\,/!0,%@O()P?5Y7!'3IGQE+K*B;)@:I=(N;K#L0Z58(;XN
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M,2-N*J/\S,HR><*3QCG''LJ3+@ 1J1C@EBI/0= #CX$]1678^F*B16@8P$$
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M!MZYS[90:LXNV*H;)C-B/C?!B6XJ?P3%.2 )Y^9"7;$#RW)RS1A3\PU@=O)
M:S"S7XYYHA*3WF3T#!Z.YN3.B*0 58G(W>J-I4*BDE$'K-NV@9.&P"23?=U[
MMT7D,1CCC PV[G&3N R#G.2>AJ86(&2[?['3W\/_ 'YKQ_!Y^>W;V>WV?BZQ
MU8 <YSSDGG/CGV9/0<X]F:Q2ASG Y\N!\OK-7J&VMH49IS'9;;+:%X[XSV4E
M&,9QWQG.,]LX]V<X^;/;JBK@X KC<Y0_=,<B/U=-M_Q_L'2IKI:X$?G&WK]>
MEY2/^42Y2]*D]?@/R%32Z5%.E*=*4Z4ITI6N[E5SSHVD;?1-<UR@M;_L<IL>
M)K5^KM8F5$26M2P<UZT1GGQ4;5;@J1V,0(:Q8J!4Y7-1#G96%9@A;G%7N=U]
M7K:I6Q'I2M9V\O*-ZTUYO6C\=QM7VG8-GDMC"5J[#&1LK%.U!T8VMR5)L-5C
M7*K/"[",LA194[0\@R4#'R+VOKR-&V--TI4A6V5,>/U]?V\ZV0RLK%P47)3<
MW(@Q$-#@%RDM+293 ,;&1D>.X6=(2!I*VA@P@Q6G2"BB'&V6&&UNNK2A"E84
MK7?"<Z0=K;C@H34>NSMNZ!#"H+.R+(U4[Y6-P:YMNQ;')9U%LP/3-_JM?M%Z
MX]S.*^V_C<-0B2X<(DL2VUF1L]6J^PI2CJG'U^?Q]G]L[(.E16GT7RFL/L#E
MK ZBUM3HK:&K MA ZEG7PZG=D[2IFW ;K<J#=9PMDP%R*KD;K4^(AI&2A;7"
M51ZV:NL\GMO6E_N$94;540U3CS]X^6?QYZ>/!K<%TJ*UU3/E#Z"1ROI'&G7-
M5^RR))RJZ[=MAU":D9%N@7-!DU%2=<1#1M.EXB2/IJ&:_-;";E[K4)*%H]T#
MN5:B[I UZ^OU53Z^O^/EX[%>E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*
M=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3
MI2G2E.E*=*4Z4ITI3I2G2E.E*XT^4/W3'(C]73;?\?[!TI72UP(_.-O7Z]+R
MD?\ *)<I>E2>OP'Y"II=*BG2E.E*_*UH;0IQQ24-H2I:UK5A*$(3C*E*4I6<
M)2E*<9RI6<XQC&,YSGMTI6LCG%SB^Q6QC3>CX:<VGN*S2ZJ1; =8%&'WG3X,
M_6,2C%MCXJ-IUX1(VH(*4ABX./D8QJ!$FIRE1UIE(<J]TD2R*?7U_:OQP.X'
MN\?7'MZ[W*K]QY46&%G(*P7^.*+D'H^H3,C%RST1.VL^+KTGL6S.OPT?F2O]
MNA_C3F)#BZ\=*3ID;-7&WJ9^7EX?7[U8?,KG':XO9BN-?'6.C[/LX; 4@S=J
M9M*I21-9OH;4\1]B>R:U\YI4GL20C(L^WU75-^LVMX'=5;J&P*U5MB1&P*Z+
M$OJD#Q\/=]8Z^WW5G?ASQ)C^+M( NFU9^$E-CQ- 1"R,V4Y7'H#5M92\_:+I
M#0M[Q4*/,V8><L"U3M\V7=@!K;L%Z$@)R\O&SD61+&JBH%\L^7FQ>4T[':$X
MQ-P $.WR(IVO/C&K;$2Q,;=$D=7V[9(?PAKQFLRHI''?;-*B;++:>VVU,;)H
M-_NFOTP>S-9OZD)N,B*J?#/UY?/X=#USBI]<$>&S_&"DQTO>+-.6O;LQK^GT
MB79,LQ-BINLJG62YR?!U5JA)0$>7'T&(M-KL\L S)YDI 9$B)709%FG5FHPD
M,J*ASR@YR[*V,NNU7C);:05JO=U\<X_:ZNU/QLLO:TSOFIO.VF\:]G'J2(5:
M]+5R8K5;L=%F+RW3OC;K&+E6M^1,D=68+U-Q]?7X5(]OO^AX^>/&IC< >+4+
MHG4\1>;70G:_R1VE'R5@W?9K&:+/;$-E+%;)RXM5*VVL"5EXVQ.5(B<=$=DH
M9\.!FYY<_<8Z%A"K7*!=*BHZ\IN<1>P]DU3B7Q0F)2>NUZLD;'N[>U]8X]-'
M?.IUC-=W!IP3:,;3-H0U.O-7J\/Z2\&M5NTV/7JK/2\SU/C*]:W;O75/KZ]]
M3 X8\3X?B[JNM0LBJ,G-I$52"B[W; 1Q,B))&P1,R52IA"8>'/C=81UUF[?9
M*A4'1V(BKOVJ8$K4378%T"O1:F?^/*IB]*4Z4ITI3I2G2E.E*=*4Z4ITI3I2
MG2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4
MZ4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*5QI\H?NF.1'ZNFV_P"/]@Z4KI:X
M$?G&WK]>EY2/^42Y2]*D]?@/R%32Z5%.E*=*5K!YU;&V'90FJIH79$G/U6@R
MDE"\M*-QJCM4;@Y05$6VP3;&N5NZCO\  7^#G:&]($%$;+U^=6H>[6BJ$#'5
M:91&QL['2JI]_P ,YP?K\Z]K@YP9K.DP*WO/95<$*Y06RCP"K?*E.HD3M?E3
M=5@%VG6P-C;(?-O$13[ W.5NBVZ[F6B]UW6OP-K5FY2M8@1G#%1[NGA]>WJ?
M;4DN56G;]O345EUS0M@0=)<LT-8Z[98JWTU-TH]_JEHKDK6YJG6P:.EZO<H8
M$T2462%8J-;J_/PTH.&;G,N$R3"G*5AKACPJB./<>#LR_-1\QR@M]*C8G==O
MKEKN,S1;!<EIC%W:X52"LV 1X,_9,Q"1UNNCP<%$ID[6[*2K(0;\K*KD%*C]
MRWY+0.\;#MS@/6:M8'+=;FZ518JYE-$Q=>K]TFI(6T1ECGD$U:VMV'6&18@Q
M@&PQE8MU G+S3;9I;9YM*D9J&Q+J#S^OK(]]2TT_QRBM6S=AWMOFQ:WV!N="
M3L![1&H(.O:SIW7*:=1ZH;KW50UALMUF]>:[.101[I98==X+BR;I8K?-#LQH
MDPZ$E3Z^NF:P'N?R@5RU'RQ,XZC\?;OL<*1HX!5-8URN!DMC6*UR;.20+%$Q
MLE81J^;K%!A@=0O1QY$+9]-R[<-?;O!F:=NP]WK*IQ\/KZ]_..:F)I;1-4UD
M(%:'HIDG;$]2Z5 [(N[S,$)+V^0J8$@R 9."4Z%JE+*E(E,W*PX4W$5*')5
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=870W3 <60C(CSK79S+"G5+;PK"7/-7A2$J5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g582934g04t71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g04t71.jpg
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M$2$"$C%189&AT4%2<8&Q$\'A\#)" X(B<F*R\9+"8__:  P# 0 "$0,1 #\
M_9^8O?E _P!M_P!L+_G_ /WE7=6+HCSGIX;^>_OO5 X;^>_OO0#AOY[^^] .
M&_GO[[T X;^>_OO0#AOY[^^] .&_GO[[T X;^>_OO0#AOY[^^] .&_GO[[T
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MAOY[^^] .&_GO[[T X;^>_OO0#AOY[^^] .&_GO[[T X;^>_OO0#AOY[^^]
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M'%MJ<H6-*V^)T22HIQHQ<?R5)V70HOO/BA%YB<YQ<H$:3B]'U$*W&D,1\Z'
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MV=_MS$$RR_SH"HT H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M:(F\2)E+Q&%BVTEO,-KD@V<D#F"**V(Q<]GDP48JU6Z.$KXE6V[,<%-.*-U
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M24\1M54K6FYPA*"EG&1W?4,"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H#ARS>;Y-<5G.30T<JY5X@CI2XX2R82 7%E+;HJL.WTU6
M5@@,3ZB00AE]=&1R9PP,73!5I6$)!@9J)RXP',4 H!0"@% * 4 H!0"@% *
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MLE% * 4 H!0"@% * FL9_NCR]I3Z_&A:KM[+PB*SN_+*54** 4 H!0"@% *
M4!-3/EA1O9JYOS0TZO!]5X8*54 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MW+^9FK5X/JO#)Q71^44JH44 H!0"@% * 4 H!0$UCC]I(7M*<7]JDUJE^O\
MJB*SN_+*562B@% * 4 H!0"@% 36,_W1Y>TI]?C0M5V]EX1%9W?EE*J%% *
M4 H!0"@% * FIGRPHWLU<WYH:=7@^J\,%*J 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% :EZNOX0:_WD$_##=;H6]O=&*=G?V9:X>\ES%^[B?\
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MO@HX9X V#RM?+CAVMEEP\&7V6M6U"K-1_P KX<#+_*3@ZMMO%R^W&0^"K_\
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MES:(>"K_ /6F;W/;/T:1H\NK$*7-HAX*O_UIF]SVS]&D:/+JQ"ES:(>"K_\
M6F;W/;/T:1H\NK$*7-HAX*O_ -:9O<]L_1I&CRZL0I<VB'@J_P#UIF]SVS]&
MD:/+JQ"ES:(>"K_]:9O<]L_1I&CRZL0I<VB'@J__ %IF]SVS]&D:/+JQ"ES:
M(>"K_P#6F;W/;/T:1H\NK$*7-HAX*O\ ]:9O<]L_1I&CRZL0I<VB'@J__6F;
MW/;/T:1H\NK$*7-HAX*O_P!:9O<]L_1I&CRZL0I<VB'@J_\ UIF]SVS]&D:/
M+JQ"ES:(UIU-([E36PW15MX#.0 1>SP!+"H:2E6+B\WF<N_V%3P\!!+WPMD'
MWL2]\/TN-_BM:M4&HR4)7Q,TTX3<9W0-EH>\ES%^[B?_ $ZS3_)]O"-4/Q7?
MRRDUDT* Z0S7<HY6/.*1'PH3U"BFLJVIEG:E63%ZCIJ63.F10>#;:<V,AQ.6
M7X0$G#,BY9%DA F%*/NMVQ^N1LG7D"'XYDW)M*#JR<0JF-5I0AP@WQ:EQAAC
M)M6' S7W&I7ELR2<X,R1@V7.E#PL=(,QKPL^X]@3$[&L*R-#:_@4CV+-0;)=
MS?3U(O(AM?9I%#DHN$TL2A]M*?A4DN(]F7??MQ52A&48QXJ,X<6G=.4XG.X=
MQ6C\N(2R2Y()MHVGK$+@)CJ;3)5<)#;4?Q3HF>^D VQ&=(+JD)X/1((J8SU,
M2$WQU9P.3P;YO)MU0#=!G#PDL"IM9/5QC9>ED<<[.Y#N][0''\3JTC:9FPXH
M>DB/'DR%2'-,#YA!I/I*CN)7M#Z>5G5,CK4LE/=XN7-*?*@Y4)?:D@LDJSW
M6L4*I"R@*2FFF!*W5IJ<6GQ3=JP7!SF=L.FV%4C3C D1P2A& #:5%3$;[,*F
M2=G*&G#<SD@P!\T@H\7<_G,EHES/?N9$17>KH,H23R-&LMGP2(0^0C<6W>X_
M8)+1="VT(* FP'E?5/9LA?FAQUK]/[>QG]_Z^Y2:R:% * 4 H!0"@% 34SY8
M$7V;N7\S-6KP?5>&3BNC\HR0T]6:0,C$SSM;),V6$R",%32\E%S( N/^(,8
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ML$NA.]%;KH=1I//I4YN9><*6Y\WL^%M.=*RX#"*TE /!EPJVSJ07.,6.\7D
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M77\(-?[R"?AANMT+>WNC%.SO[,M</>2YB_=Q/_IU*?Y/MX1:'XKOY92:R:%
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M'<\F.AJ7_57(^Y#F_P!LIZE#F0@[GDQT-2_ZJY'W(<W^V4]2AS(0=SR9RJ'
M<RKRNGHY>-7H1&4309;$ZLMI:2$HI;._Z1@^I'R()4H5!PMD(*()GPWQQX@6
M HV086;U*',A5=SR.XZ"8);4(MJQ A8-2<RD&%FY7+F%;$=0'QMQK$R=LN',
MHD%,[Y6*%+9<83+A,F;B&!+WQ\M.FZ;PX+[Q.M&C#J95''[20O:4XO[5)J4O
MU_U159W?EE*K)10"@% * 4 H!0"@)K&?[H\O:4^OQH6J[>R\(BL[ORRE5"B@
M% * 4 H!0"@% 34SY84;V:N;\T-.KP?5>&"E5 * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@-2]77\(-?[R"?AANMT+>WNC%.SO[,M</>2YB_=Q/
M_IU*?Y/MX1:'XKOY92:R:% * 4 H!0"@% * FP'E?5/9LA?FAQUK]/[>QG]_
MZ^Y2:R:% * 4 H!0"@% 34SY8$7V;N7\S-6KP?5>&3BNC\HI50HH!0"@% *
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MS:^ P1]"2@PP>]\;*PF HN?'MCCWOBWOE;="WM[HQ3L[^S-EH>\ES%^[B?\
MTZE/\GV\(M#\5W\LI-9-"@% * 4 H!0"@% 38#ROJGLV0OS0XZU^G]O8S^_]
M?<I-9-"@% * 4 H!0"@)J9\L"+[-W+^9FK5X/JO#)Q71^49P*M(X F8(RLF@
MBAY7P$"%/E0Q \\;\%\<\,Q;98Y6O]E\<K6O:_Z[5"GKY_0O]:2?YB3^M0#G
M]"_UI)_F)/ZU .?T+_6DG^8D_K4 Y_0O]:2?YB3^M0#G]"_UI)_F)/ZU .?T
M+_6DG^8D_K4 Y_0O]:2?YB3^M0'L"64@P)@" JIHPPE^*&$$>*B"9Y?^W##
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MMIC<!P<D/PK9MB.(HIXEB"B"C.TD)]18'/IX/R%*KI?IF1S!.-WLF0,,<:2
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M,Z;XD <;E"*452"8-A!P#1PX!'SFAR.#[8+M<9T/,($JII"N75"N;>Q5 %!
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M>K4BKUF@/!-U;,N#^3*/5J15ZS0/M3F$]E8^33$YI.(T>4#()0H7P1SV-Q3
M^=@P\..(!@$'C?+*W&$%SP"#QX1!,\,,<LK*U&]9@[B]-NFU)AA)Q6EK$JJR
M(JE;8J2EC:PI=#+BVMEFBHN>5N&V%K\%E!0M;$4^+CQ<>(4P##OY/Y/Y'3<%
M*BM<6=:-&$W;X*]''[20O:4XO[5)K-+]?]4:5G=^64JLE% * 4 H!0"@% *
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M9** 4 H!0"@% * 4!-8S_='E[2GU^-"U7;V7A$5G=^64JH44 H!0"@% * 4
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%"$]S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g582934g13f61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g13f61.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1B"4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #;    $     $
M  MP<FEN=$]U='!U=     0     4W!R=&)O;VP!    #W!R:6YT4VEX=&5E
M;D)I=&)O;VP     "W!R:6YT97).86UE5$585     H 00!D &\ 8@!E "
M4 !$ $8       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \     !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              )#   ';          !
M      $             !VP   )#                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     @X0DE-! P     #B8    !    H
M #$   '@  !;X   #@H &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #$ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M:/YX>TMJ?;.YM/MVW5_X>M_II=0ZCB=*QF[FESR-F-BU";+"(8VJBIO]9O\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      8I)22H "     X   $#
M  $    B$@   0$#  $    [!@   @$#  0   "V     P$#  $    %
M!@$#  $    "    $@$#  $    !    %0$#  $    $    &@$%  $   "^
M    &P$%  $   #&    ' $#  $    !    * $#  $    "    ,0$" !X
M  #.    ,@$" !0   #L    :8<$  $      0  + $   @ "  (  @ P,8M
M ! G  # QBT $"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,3@Z,#DZ,30@,30Z-#$Z,S8  P !H ,  0   /__   "H 0  0   &P'   #
MH 0  0   $,"           &  ,! P !    !@   !H!!0 !    >@$  !L!
M!0 !    @@$  "@! P !     @    $"!  !    B@$   ("!  !
M      !(     0   $@    !    .$))30/]       (          #_X0&,
M24DJ  @    .   ! P !    (A(   $! P !    .P8   (! P $    M@
M  ,! P !    !0    8! P !     @   !(! P !         !4! P !
M!    !H!!0 !    O@   !L!!0 !    Q@   !P! P !     0   "@! P !
M     @   #$! @ >    S@   #(! @ 4    [    &F'!  !      $  "P!
M   (  @ "  ( , #   !    P ,   $   !!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$X.C Y.C$T(#$T.C0Q.C,V  ,  : #  $   #__P
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M 0$! 0$! 0'_P  1" "Y F # 1$  A$! Q$!_\0 '@ !  ,  @,! 0
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MH8S2C<!K'7B#I.,MC2REM-AKP!>%AFU*(2PS6E20]2+3>!*C W9P!@# & ,
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M] Z[?KW8 ^;#R\_IC\%?0.NWZ]V /FP\O/Z8_!7T#KM^O=@#YL/+S^F/P5]
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MZ@Z=M$3%NQ.6KZ@21K3/TS40OF+O?CZ2PEB7+DZ MWB#ST?"997]P>[*5*<
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M(4V@-J3G#>&T;0O-=E0'9KP#,3EK\)-Y4_\ IN%OX'RW -.\ 8 P!@# & ,
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M>M[UO#33::::>S3\--?*:^S0//. 0MTE][M??^"UI?Y&?< A_P ='X/CA/\
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M2;2>_>Y? ]O^HP:7*A173KN3ABHPR;;1IAW\0P"N?,WW]ODQ_P"X^2OY=V_
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M*6SJSI%*9<O2$&&;+;T:MX.2MJ70$B$HA, !>@_'\_=FL. , 8 P!@# & ,
M8!F?U]]_7XFO\:NI?Y-K>P#3# & , S-\GW]C.-?VF7 _P#'N/X!GUYZ7^O6
MR7\;MTLFU64G(E23H9UBE^W!T5TY1<5BB5D:ZR-D=?H4/*$EBUBR:26*6I:C
MFUR=7,$88$T47H=IG6021C9UX'&)QU5R5TKXC^0IFZSH$>JYMOWA^OKDD)'5
M,V',.8I4HE4(6/+S(.F_CS1-03NKD#RBE Y9+7A*[>UVE62L!"WWP@L"9_!T
MY\.R*O%4GYBZ!F3]8;^U6&XSWF>2]N2?I<BL$"F[).-3/_D"_O8]15VL=ZT3
M-'&7[C#6L>5$V4[/7N(G4:U<!OO@&8G+7X2;RI_]-PM_ ^6X!IW@# & , 8
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MQ(U %T+2>MI#[G[03>(*K6_>O4]GO[HO6_V<@]S1W>SW%W-]N.TOG\;[;?\
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M.5DV8['LD0:%+:D7.*9K<G@TH]V7$-R$(4#2E6+C=&JU!18A%D""5H6S#-A
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MB3,)&U)JR'/;J1W.K9ODI\+3L4U62XR"HS]*0B-(U%EGQ8U2><R '.[^=_\
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M*Z/IF:I:T-:W@QJ!7%'SA1,FI20[-H4SU*4B]\/ VQ9F9S%VY2YB3Z+;%IB
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M>!ZO(ZMFNH_A!LH3V/(;6M5K.2]%(.D&R-K(=OY2["*/#AJ-6\H@.Y-@# &
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MTU2I=HDTO-C[29*$Z/8!E;2$2 :3;L2EV6:87L@M6$K8#!@V#U1BUL#E. ,
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M3!I%*CU0$+J@-5+C&,#PH&XX!QODQB8XWV]Y+6J.LS4PM9,FY/,*;65N1M:
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MG9$I;G5I=6ZFX8C<&QS;UA9*M X(%9)R5:B5$E*4JDHP@\L!H!!T!;G & ,
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M]7W /DA\SW 8WTZ+@F=[CDR9I3/ZB.AXN[-$^D,2U8K;D;T<T:H/;@4TJW!
MN0IG$:<*,]8B5IBCAG)C@  ^M]N X@_'/1OT'>V?J^X ^W <0?CGHWZ#O;/U
M?< ?;@.(/QST;]!WMGZON /MP'$'XYZ-^@[VS]7W 'VX#B#\<]&_0=[9^K[@
M'R%WF?X";')D9G*:7LWO$E/6I8XU+N+^S4CE(%+:@/=7%,R(5%"%JG4]O:TJ
MER6DH"CS$J!.>L/"6G*,,"!]?[<!Q!^.>C?H.]L_5]P!]N X@_'/1OT'>V?J
M^X ^W <0?CGHWZ#O;/U?< J-UEW10G5[AQU5E&I+ZD\R3>0CBV;K4KUR?U)
M&=MB<-NI@=I._.LJL&GHO%FMO9FT UBLYP>4V@D &,/K>H+T ;Z8 P!@# &
M, 8 P"+[)IJN;<<:K=9^P#?%]*V@V7+6QP'9Z:]1^QF>+RZ&-[^,IH<$!3N
MB.3J4(-M+V!Q93=N059S>8M1(%"8"4, 8 P!@# /$0@@"(8Q!" (=B$(6]!"
M$(=>D0A"WZ-:#K6M[WO>_1K7W=X!#-$1ZE&"&O*BA'*./,(F5DVE9;F[Q68;
MG#*Z6%9L_D$[LQR3O>GA[(+,<)T_OJQ0SH5A3:QG'B:FU W(DA"(@":, 8 P
M!@# (-M.#4;/)]0QEGGL)UA5G83G:M$M:Z8J(^]ZG**!R^".STRQ]&]-IDP
M@A$]E")<VKD#VTHRW,#H<B*7(F]:F G+ & , 8 P!@# & 1_#JGJVO'N<26
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MKENA;\-F]#J4]1^&3FPX>[6@N/6:;;#F<.?D,*>2HY%V2#Q>-0Z+,3?H#3S
M& , 8!5_K#KRG>,Z[061<2Q\^'O<@W%HXQ1=M(=I)(GPF+RF<+DC>F6KVEJ3
M%-D,A$ODS@X/3PTMI#;'UA859C@:A0K ,(*8Y"N?R1W%!^P[CME^KRR:EE8&
M=2^(::)45S,ZL:+9LBQ*9E/)$R^-0R94A:E<1R:3&A[=BENHK&F<#FR-S.L:
M%FV-#(!+$P'9_P  8 P!@# & , 8 P!@# /37N"!K2C6N:Y&W(BQD%&*UZDE
M&E 8J/*2IBQJ% RR@C4*CR4Q !#T(X\XHDO0C# !V!U\[\\K]BVU+I31/(<.
M:7MBDSQ,87!+[B]KHX?*+%E$#C$.6VESG3 [%JQPAT [NBHY'(I!$ZVN!L7P
MJ01R( $B>U+Z[.J*% 6Y\9=4]+4<^],P:VW-TFU.SJ81+I.F)^_5RWTR_(Y-
MT"UNTINZL'RJ4+\^)H[((Y-42:?3-2RA98NIL.T9DG9(\P 2'L;8!J_@# &
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MMZRI<%5%I*BNR,3Z:U?[^QSSFU7.5<4L&B(?,#D\OK^<-$H?V)! XU)S(@N
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MF<@]0<L/):V)D2(6MO*.5J%"HTM(E) 8H/./'K9IHQ" Y1@# & , 8 P!@#
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M+U=6!TI.KBN(=75*P>OX&QLT>4365.K@Y@8SWZ1OS^XN#FX^Y@:FMK O7@#
M& , 8 P!@# & , 8 P!@# & 4L\A-+V7T!R7958U,D9'Z7N3A7L@%7LH?UT4
MB=S1:#V3$IM.J'ELG;?2L88K>,+C[]5<@<=:&C+:Y8I+=BCF<UP), H_0W#<
M9Z&G"B<]$\2(.7J5J6"UC5G,G-XI/$(^^M#*SN,@F=O,UC)N8K"5UQ8]"2><
MK8>LB=/V@NF\?V]PYUF9T58!28:!0!MG@# & , K+85A02X%U^<A0BZ7"M.B
M"*96+!G,(%C'8D 9;,9'B/Q*X(&-Z;B44D21Q]WZQ<BC0GQJ894@(9'I0WO
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M&(^\+)"<1#W!SK^@PM3^[2B#U-(2G"P*4Z:YUN&$:CY35"X6Z)?:W(8\R]G
M[.VM:U]S6M:UZ=[]&M>C[HM[$+?W/^>][WO>_P#GO>][^[O /[@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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B & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g582934g13p56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g13p56.jpg
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M19H@;R26&I./%D66F7A&%MX;4=-]<TL2Z9762,S2UID5:QK6IXOTS0UG*\7
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M2":*)CXRR,L)U/-X=[.S&[.S4+W ^W68C<PE3@((:UT*'9BLQKE7IOV)=.>
M*<F AIV;A""SYK,,/%P_U"7*+BH*(:?$0GN1TG3K::^F4)9]1T:^T]XQ;B-Z
M\JO'+'6GD!!DD@B5"7"J6"]U&Y&>43]?:I=UN'6M4@IZ+U#I<$&E16HVY);2
M6*1)IX8++311QV)))515B;B?960LH(M<M>S[IN&3/G-F7.8N=BD)/,P1;;?,
MG6*Q2"AQA@4Y(E91PT]8 R&FP@062,->TXR*,P@5.&E[/2H:D6F)IM>.M4JT
MYY;<,OAQ&99&D]KQ)'CD/%BO!-]Q*_$%0.^:'7K.K6M9^&9Y]0U.W=J1:=:A
M\9C6=09GKQK'$84\14ED?D4_01HS*QYMM(9DJ@P8\B089=/6XAW,A[Q+:WR7
M'OUC3S*R'0\I4CTH4ML9M3+JOP=<6ES&*Y[$5Q+=JRB^LO()?72\O.:=I!&_
MCP\S6,7$*W!805.[!C[J*].S3>A7IR2)2ACDC>DR0LD$' E DJ11V!/X[.#S
MD8.I5=E7L>?OQ*HE:<(.(DG_ $MK5Z1D@!MHQZ\+:6X3ZRO4G*&UI<'2WE/Z
MUE3>?PS;Y:3ZF>2SFZX ]N(>J1%78^,NS$R*1L2O!3MOLQ[[W"=7-_GO3AT^
M+BRA7#W9Q[(X,##O%Q(+<DE[/V*LO<3/2+Q=M3W2K['UG8IJGW&K/#V"F66/
M):%.BY8913;$D(PV06*TI@I+JA''FG%>>/D(SA7MKYA:E0JRUF@DAF:I=A1V
M$T@CDF\-OE,L,[E5#+M%XRJXC"^SQV&;31M6NU+L%F&:LE_2K<L"B",31U7F
M0-+#')8K@<S'-O*8N48E=C\H9>+T][>R?7';NE+#LB6V5.:_UQN:H[FD*-$6
M)]*+!+Q9$+(/2@L.7)@UMJ6FX^"BXJ6F<LMFN1@^1SE%9'2(O8ZO2J2]/ZGI
MTNF41U!J-"E4KZE<B0M#622-E-:;PWDB5*X(;CN2.X"L<UG3>L:C2ZITC4TU
MK5+/2NF:GJ>IW-)TV:1HY;[Q64F-F%YX_6II[C*>5N:5$7?PRJ;9O#:Z\;WJ
M=(=>A-X[QEH?1T_8@[Q/4#2Z[:S>]D7FI5%PP*/FX^.C86'S$JMTY%3,#746
M)F*BSCXY3@TT0&Y\EOP;4>DM1IZK:TNLR:KZD8DM7:$<\E.*1XTDE7F8P[>K
M\^,I5"VZMLIVSZLTCKW1=0T/3M;OM\ C5EF>AIVK6*L6H3QQS20Q,L,<TBEK
M)CYPHKL65X^^[;9BYE?& [SU TG;LI.:RDH.5/9>B^NS^OA#87#,D2G$+2*Y
M>Z](AWHBU$C+:!<M4A(6&%5)J?E$U9F);P"WYCI_5U+4NHI=%@TV0Z=%)*)-
M6>RU:Q6J55_VS5;52Q%X9IP/Q7U=#':;Q(0A<R=OMG7_ .3%<Z:]%U;K;5.L
M3'U=;JTC7Z/KZ3'JVG:GK>K%3I72VCZAILYNS:G/SBKF\%O4Y+#R2QUXZ<;R
MQY">NOC$7"_[BUSJW<_7J!IP&W+O$T2IVC6VRS;H] V"R+<9@0+379ZF50@P
M!9*,#25BK\B3\%*E2#\ U&#EECY^E=0Z)KMBS4TR6\9ZU>2R1:I^&DT$,BQ2
M2I)!+8$"DNIC6YX#2A@$W;V<\\](_H+Z_P#19HE#J'J<]-SZ7<MT=.F^!]7L
MV+M#4+_BB*O8J7],TT6(Q)$8VFH36F!)D:!:\4TT>=GFVSR#'&,<8R5X#_.U
MW_WF#_Y-J?)/D/L_><9-'(QCC&.,8XQCC&.,8XQF%GOEXO-;ZN62QZCH5 5:
M=LUXQEV35?%9BZ [4'ZHQ956:%D8B16[867GGWZXB/>+@2<347*B(242T$'(
M==TYTK)K>T\T[UZ #!YZT#79DE$J1K')7B/B1@\@YE92BQ^T3MOM<C5&8"0L
MJ^\HH9A^HE0>_GW_ 'YIF;/VX3:[I,O5.+)IU,=/EI*+I7U@B5CZN18W@RY$
M6!>(PCW8=#\<V&$Z2.B7P""")*%2KP29(CZEZ=Z:]17_ &]:5J]'"*BZC!$D
M4URI%Q-:Q.$'L3<=XW7G*&\/Q!)[?$;*)3'(2Y0G@55EWW=#MQ9OKV V[>78
MGMWD!@1+L<]- 2:U3IK4@T:,02(RX_')<2*\]$(0M3[OK:9R,X45\-6",DL#
MO>R-Y/7Y98[FH25#72:""Q&(I(&/"*14_2 ]AO(I^6IVXGWG?<V0(Y2[$<B&
M8'W#MOW]VP.W]OGOD !,#;F(B5D&R)(=PL$R3<,=SG!.0</$B#99RLGW@LNH
M8;6HLAIQ_#F<+:1C#;&,Z2@\U*S6$->K':D8.T?L+X2MR#E=B"Y ]MN0Y$$[
M 96$;?<]TDE"R2-Y<0"1'QW'LKMN6W]WEGHEG07Y^0>"#5'M%^T0* K'H2,A
M["E/"AL_Y7Q_=;R3C"//"4O(83^I&82B_IK0582DEN&1:RA5L>,O%%/8(0W$
MKV]XWW^WME8DB60_I$*CL$!/'OY[#;M\VW?(:T*P IG*VGTH<2C.<>>!2R&3
M&T$"N,J6*0AU;S;@[@[N0R,ELY;4E2\KPYF\\D;UC/IUBJQW=/&99'0^\HK+
M)'NW+NK$$>6ZY'% A,3!&5F(9B5^4-^([$\C[O(?9D>E<B,%*$CLY$!=CA9<
MIE]Q[*DDMM/#MCE/,-OI>-;RMYME.,80^I]QW/M)9]7-=4-A.$ERN;%B!N2.
M$'/:0\2S.>XV)VX@>6_D,C=D?<H=UC1Y".[[-L/TF^VS;^8!/8;[^[(4\<7\
M%^*PZM8)?F^]&^K*$K+SD9IHGW6D+=%6EA"DK);7CR2PCT>IY+.,[*>O UI7
M,7BV)46-@ORX5*[K(Q\XN(''Q%Y$@E>(\Q4PY$AMBC>:D[;D^7?8D_..WZ\J
M('-BMUZ&K<;:)*O5V;L,*N_UIUPPR,4[$9+:B+;\9K+K\GB %E9KV L.+_$U
M7QPA#7\.$<U-1MKJUS47TY;MRGI=E-(E?VS$PV<1P22[5H_%.RN[*)2!Q!"[
M[VF!$@9(B2JA54OR78 CDK%>_?N5X^?OW.;A7A\[)ZD]2WNR$55>T=9LW69<
M=HZ]Z[LUBLZ'BF)BVP5K MD(Y#L 1SJK8])0(Q1,1$0*97Z7B.%/&</AY+ W
MS%U$=;UJU3DNZ3/'K#"W!96*DT1L^KR\E<(@/(PQN8W;;8*BG<@[YB2%W*ED
MV;8[[#;<;^?V;[_5WV'UYUH.:B[)"P]BA"TGPL_%Q\U$'(;>:0;%RHC)P!:&
MB&V7VTD"/M/);?::>1A>$N-H7A2<<805)4C8J2"/F(.Q']N6<BG(QCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&:*_>W2[^L-V]D<[MUU/UZU6K=&[;UJ[8
M9E<G66+J/<;E.W'71="V."$D*6L#$>9 AA5X.9S8(>6AE@9BFLQ[:LZ*W%U@
MG56GW]$GLS:/,^B16ZM>825ZL<21U=0:Y2E#(D,D<;-).L,BGQ QXL.9^F^A
M-:_D^6_0;KO2_7M30Z'7NG4>NK%*UJ5*6CJ&HV;MFYJ>CV=)ZA@B43V>,^G5
M:U![K6A8T^(+2,%91)2W2%]D].W#5+VEY.[:SW";9=9UZVT:N?:RL6FPP4^5
M&A7@:S:_1\5VRC-UI4U-/RQ4/(>AR'8F4GN?";?S7I ZPCZEU*KK0M6M ECU
MRU%;G2*Q24QQ6)*,E2]&.4!]:6I66L95!CLEN#>&5DL>DA/Y/^J^AC1]?Z#'
M3VE^D;34Z"I7*.G++HFM2.\U>OU!4U?07\#U]AILFI6;-\4KF]V""R-15E)-
M['U&68G)UR8.FR'TY>'5&X@RFFF(V*,,R.,)$Q@ [<4]%&2!X!P"14I2XVUE
M@2/#R&.WNL^:\]#1D/,UEMZ)$=AYX4,R5/2S$8"3/DM+6T\U)%ORI1+]A!5(
M-L+?P$U#"R;&1X]DP"+9=6Q^[.ZO2AE5GX*X1+39380QKL>S&A-^0QTN&R$F
M5]9CQ<H2Z8(7)M'$D2CK:4E#N.M(:'=(0QGB<DT**L1+D6S@>0F"BTC@D0:V
M"29);+)8C&/J*&C9 N;68RF('42>A3B&?CH8PTVVQGKD!G8R8S >PG,M!N?"
M*B</_)@VTY0RZ*Y*E,>GWH]8^&2!<"D(.*$(5EAA?FOVV,Z9.:&.LT^_%/MO
MMYEPXF-;(>46M#RQ69"5#6XE?OMLQS;<L1[QBUGFDI8$(+6B/:;6QG6M!#TH
M3@);3&%*!^6HAE#Z''8[S+9=''SA3)3N5&!CE+=<9(%8:;]"<>Z$_AC)TCK'
M34WVEW$RG84,++0,?LNM0/MAB[*8A)9+CPP3*VUF1LP?!M& '/EMI9<CU-(5
M*OCX:FHYC]6_[OS]F0+M^U>-PVV<U#7ZQ.2'5BKE$;JA=9"#L3,W*7FU#QT-
M7ZK:ZG3)*U2=H.J41#AQ^JH&N!3(BR)&8D98K$B)&*"P]4.L-IP@Z>M05-1L
M3&.U/+*(9X:O -"E:4^PGK4JR1VF9N)AXIN@+D^B^B^WZ,M.ZFEU'TJZ+J?4
M&ATZ4?P5H]2M!:TZWJ4UA8K-_5(GLU[<GP+ 8K=*"KS#S2222Q2-#!M<QT8\
M&6M7[4%LV+O0+;F@+IL"WM26M@:I8WHC9%8UQ$QC,0,+?H+8,+;H!7VL-'?L
M474;'5RY>C1I3;(9D))S$W&CY)A]9TG3=.Z@BH:W/60SVF>O'#"MV9S(_J\F
MFM58-"I$#6X'C>SLS2%]E<M1](%O2/2#U1U7Z)M0ZCZ$TO49:VGZ?%\*6=1F
MN:3I4(JUIK=+7QJD,52S(LU_3M*N16'T:.TR0-3DEEJPY]^MO6W5O535L7J7
M4T8:) AG24Y+S$T8B4M-PM4X1DN>MUMET#B(DY^8)SA1#C @4>&,T+%Q$?&P
MX $>-=)'&)%1(XH(8J\$,:A(X8(4"111K[E10!N2SL=W=F=F8^?3SV;=JW>O
M6K%[4-0MV+^H7[<GBVKUZW(TUFW9DV4---*Q9N*I&@VCB2.)$1:]<IRWCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,90/M77+I<.L'8RI:W;*>V%9]%[9KU&9!(0(
M<];IFAST=760RG%(0.4]+D"-COK6A+3RD+4M&$^K%^JR+9KM(0L:SQ,[$$@(
M)%+$A?:("[DA>Y]W?,6ZDLE*VD'^^>K.D(#<"96B<1@/N.)Y$;-O[)[^[- N
MY"ZFH**JB+2?KNT!7:L4N\4EE^R52;&C9O+,;<Z]9*&MT0T1)8(V1;)A$0T5
M(,BO1TD\2&\8*_RVC-Z0A=Z@IV4NSK)HVMV--U!Z569FGJ^))I/J>I+71GXS
MF..&&R\H]H-'$KCFWV9UD/Y+-WI?T;]1:->T.A!6Z^Z#J=0Z#!J&JU((Z&HO
M4J:]%JW1<LZ05R*J<=2NIHR.5I")[KP2V#/[NQW<_8NJM/L:&IFQ\;/Z];K@
M)9F>UA>)U[8U:ALU.1C7Z[+ZWF)@R3G=:F1)[KI,8W4Y0"#8D:[%J?A#& BP
MB^\]$GP[K4NLS=1+<H:OH$E5].N)2BKS>.T-J62&^JQK':5U@4EBGBL)F3Q0
MH"Y\V_RU-&]&'1$?0$OHM^"-6Z5](=/J)M?TJOK-O6M+%33K%.-;>BVYKEF3
M32;ENW7CBBGFK5&H5UAJQM$X.$7$L62G"#CO=6Z1^BU[B6E)))=SE;&?5CVL
M8PZYA*'E)RG#6<..^K"5.*^@AJ%BR"EJ9F#R,65"(%_2,"X#>TL??E[1.R^9
MW )S\[3I%.O(LE6HXX1(J2.K3R*D:<8F(7VY=@ #&BAGX[*-V"Y$IEF*:4SF
M(?\ 7%X(]K(;;S^5B$OI8R][990N/D8>1@9G!?QLYQC#:T)5C*_1E:@M#:.2
MK(C4S-N:8E>1Z\S "0^L&-5F[ 'FB\=SV) .^!I3ZESE2[$R:AZDDB7F2!XY
MX58B!7AKSR)'X9,A6$S<E9O;(*J#W5Z4^DKE@\1X;R9H)N/]I>,X1@%"GGUL
M-NN+SY/>\M"_<3[3F5M,NIQA24XQ5IE\U?7X8ZR2I=A%;8J6 @!Y+[7O8.68
M'B.^WGMC6-,>\FG6'ORUGTN5K9E0,6:XW!%D\.,,RH%3AL=X^#LK-Y[PN/CR
MY#V!!PGWGG24C,,):4VIPI.'"TIPM>6T9<PVPX0ZK#F6\>A2EK].?-6%#3L6
M^$5>!RS6&B5>VXD*O(B@[C<,L4F[;C8CW@YL;.HU:OC6K%N-$%?UB0]^)CW2
M)G4+R/\ O)$ 7B2=SMRV._JBGPFC<)(%9*8]S.75J4ZUD+U,Y1ZT80XD9QY*
ME8=2R4.4OW%)SZ6TI2M&10:"*R%LQ12Q RI,S-.&@/$H25CE1'XG<\65M]O:
M.QXC$UF*9Z3^K69([!*>KI"(I$MH&60!BT7K$:LA^77L1?\ "ZN!L8>A]+_Z
M:5X4IQU[*$X1GT_#;\D,OI5[R\MX=4I*61U(\\M(6ZI[W/-*\9S',QD:0EFE
MD_1[;CU:/LKKW&W(@KPV['<\CY9F()8F$;0+&@AC=IN1)-J0<GB9=N_ #=I.
M0WW "^9'>._ELL4@IAHT4%:5H9/QE:/C*;95[+67?7\=&6_6K&5-*1[66<MI
M4U^R8[)AGKS68VL^KLS-%*-]T/DL:@D#V ..^^Y/NRB:G'-#8KTY?47M\$-F
MKR5ED#=WDX^T_M_*"[,1O[P-ZS:PSKR8V]#HN4T=%:]+6PM[YZ).1*&#CX\9
M6(/#@)"RV8=Q;&8=!;?O-Q4>XCXV&FT#.BZ'KF;5*]#6)?1[0GFNV-IJ5*(Q
M0S1/9CWLM'&YD:1HY"9$3C^F=1&QV+#/4?0=2Z$U;K/I*#T]:W%0Z5J3F#6=
M5GBGMU)H:@=]-J2K6>.S03416K4I;*QS-7CF>58@51USM=)-1=9NR_=G3N@X
MB/M,[19"N7Z6M!^M)NQEQ52(CJI(D5B8B2Q))T"D3,'9Q84\BTC#. X97BH6
M&/E1+>8#GP+IW2>N!H&M:QUG658+,L>FI%JE"E!J5PSN392:=J\5JY4,(>-Z
MXDE*MPE8Q+7BY??'IRZ[]!D'5?0/2WH'UJRVIZ+%-U,^H=&]3:Q=Z2T9*D2P
M:<:E%KUO3-,UN.:2.?X0IPTMXYIZ%DVY+\D,>U#U8\+73/6+:R=RN7W9.Y;Q
M"14K!Z^,V<FBI%U['SN&&IHZ&"I5-J8YEIE0AVXHJRR2'R&(E98,6-'(DI11
MV/2I:?I<5B+2Z%?3DMLC6Q7,Y\?PRS1(WC32E8HRQ988RL8<E^/+OG"]8=?=
M;^D"729>M>I;G4)T*&>'24LU-*IQ53:$2VK)CTO3Z"V+DZ00Q-9LB62.)62#
MPA/9\;)MS(SDL<8QQC)7@/\ .UW_ -Y@_P#DVI\D^0^S]YQDT<C&.,8XQCC&
M.,8XQEI_<_LQ0>K6B;7>KM8BX*0F(Z6J]$:BA4'SDC=)&%D7(GZ:(Z^*/Z(S
M+"Y8\PTL0(40-6%OY)>$&)V>D:7<UB]#2HP&>9V#%-PJB-2.;.Q[*H'8D_/V
M!.5QHTCJJKR)/EY;_5N>W?-%+??<1.\J-H?6L]K:L$0_7JMVBO"7)D9XBW;%
M8E; =+14=99)S+;:ZW#L$.)BH!U9;9\PT?8BGU9D\@"?2W3_ $ -,GU*VE]D
M^$@CI01@M>&NA5]YDW/BNTP=$&ZA(_\ B+';-CKIRW8MX; NJ@@"1-O9W/F-
MY VXV/R/F[BRU]UV;D22D QS9<HYAM@9J/%;9">=<PW\<9@C" V6TI2T.YDA
MC#[7LY?40T\LAU7>BE#5T^,F[8C@J1F9^/!R\SDLP?D"9(0?82$% !WY;['+
MA1&C\1!L/+;SW8#VAON![)]_O[D;>6=8X33,<],L$"C)R4H)R'PZMPYEM848
MX@ME6&D,NCIPHAK+:<-*1C"LM)>SZDINTY9TM/$]$)'L+,DU;O%XUA1RB*D*
M050*TAW.Q;8 [;E%S1E<Q*$4J6";!B67L..W<=SWWW W[=L\3#24-/H];;K0
MV$OJ2K&&U(8(,:&:;]*G<^^O#Q"<(0A*5*8;=7Z,X87G.SD<0M%!(6E\>1@J
MA1QC#!F#RMR.T?\ 1';N3MVW.5#B@X,3Q!/%?F#'RW/E\VY'ZL[G/4ZVXTT^
MZPISWLY>;>?0[Z'AFQLC8\EI0D7R1EQQM/EEU:\X5G"/4ERF2A&XF7V5KSA0
MT"J NX'<\N1[-[UX^\^UWR6C4@H 45FW[#VU&Q! ;W@^9'$>7OWR)&)FY<H>
M5(&/-S\1$: 2R)A:5)$?SA0C.$8]QWR00XG*A6\)0L9+*W%8:^/S"/JM.1_5
MGA5*XC:Y'MND,93;E'W'AON0>8#'C[/S$&51)R0'@BA3W(WV'G[Q^H=R<@?P
M48:*=)>5D]98_FQA#R,>@8E;RWWU.)2TS\9MIEAH=.<O^_ES#J<HRLC.2.<K
M@HGC12QAQ.IWA.Q#*RMN=_8'';8?/OA(PR2R[\G;ML!_O$&Q\M^VP!7MOOY]
MO+)HEXH2'= &?.*<>,CQ));*<A9^,20PXEH5UCW<^G\5J<P-EYLM3?M.DK9R
MIIC&DJ7Y[2RW%AA@FC<J9[4JQ1M#R=!"KM[6P"@ARI'(^7F<M!MSXG%ED#%@
M\K1H.(4@)[3AMPO;<*?LR7<X2ZD8;XV''W,OFDMCIRLAAMM#"E-%MYQA1/P5
MB+==^*AWX[3Y*B5*#;RZSD+<K1SM8GEDCKWV6'P Q>..2)6#2O(/8$+[;(R>
M('W&^QR.:@J7965V[JI)"\1WW;;??]7N]Q R<!K7<H":BI)!CH,C6W 7@!3@
MV"&5H8)1(H0?%RX9(3S16$M(PD@,EM0^/_Q6'GFG(L:/I&L0VYHBI2Y"U8SU
M#X<WA#L\2R';B&8>0X[]MR/=<<*_-@W;CQB9'\AORV8$=]SV]W8]A\^\AX8G
M>^P=JC)W71TXK9P.M]44.?FMSNU[-7+LVP[+(2A-LA/HK$77P1*_7?F!5.KN
MYKD/)2N:;/S9F#&)(-;'R)U)TY8T(P2V8O4S>FMM7T^25)K%>I"ZK"\TB.P+
M2[GML-M@=SOVUK(5"L1L&WV&^_EV/]_U#[,R_<Y;*,<8QQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8S&EW<[8T*O44VC5@D.]/SC1;5AD:P#)W0:N8C2&'&(W'
MV820*B?/*:=3Z) YD2+%$(7*C$8,##*8V/Y_/_OF$27V5LF2(!V">>XF3(IK
M]%U[(2(A*R*]5!W6"QX&H-M1J2F:Y!I)8!:D$I==-DAU.R"7%XQ[U0=PI0.P
M4D%D!]DD>1(^< ]CO^HY&PW#%4++RV8HC..6P/%F4E0=AOQV^WWY(#S8Q03[
MXK10+_P29)!!PTB^''FP$63*"X=Q[J OGM$#M"9:21AQ)!>5&)=;60AVG)SU
ML*AV61W BS';$Y(&LS(QZPFXXL F2*E&3X5H<858SN!)'#A:6OE@DY$PPTP&
MXVM]3&? W1PL A!X>:!R0R$&V0T8[DAE49(G*=$*)>3[80C8@"15>DEDYHUS
M(JFVA,+>9&_G_P"WN_/U_5\_K<CP'7V\O8]QUESY(C2G?3\57S6#W71D-Y0M
M'O'CL$D*SE7N.(PA><M9]OC)S[(0Y SP4OF2B5.38R)% 0LP09)(#6/D12I1
MD3Y3,:6ZT*(D,4YH4<1YE62C6",E-ML9+@4;A @Q0[XR04MADAG+?6V^\VF*
M2"$DK.1<L ,M$%&2)1"4&N+<?SG+6$(=:>8_/U?D?GZIPDX]F5L$M$Z] C3<
M!(+1$ELCR 2$*'6AN7+(.E;<%&$-.2,:4PM<J^Z06P+B2=:0\^SAIC\_9DL5
M]R3FY0)$6,V:&[&.%8)/,C6EX=R^_(%O!.QN2Q&@X[$E)&$#OO*EU1BBGQ\2
M;P;K#[(_/^9_O_.^3 @<X.</DVF#YRQT\\J4D/BB,S3@HL4,PR4A2AX\\!F)
M=BFFD"'2 CPXZW&#WT9,'4VADYL.]#]AV38=*N!TB6G[+1TI6PZ/ K*06_48
M'-7!7'5MHA3 QIT:%7TUQ:9DYA#LU//6,[R;4MP49DG;\_G[>WNR^[C(QQC'
M&,<8QQC'&,<8QQC'&,<8QQC'&,<8QG/E^.?PQC\<YS_HXQFHK_* /$<U33KW
MKG2.IHJ-/[":'VEKO<,CLYE,(ZS S4)"S4G4Z#AQ I,K-,M'62#MLZPX<'#@
M/ A!Y'E)!9B(KU3H+185K7]8U26#U"]IVJZ-6HF5UNV9;=8UVN0*H*K'49^0
M=^7*12O#8<L\-]*?4\BW-)T'1X;1U/3=6T77[VI+"C:=2@HVO6HZ%IRRR3S7
M1&KFK"5*Q<)'D&X&:G^Z>Q&R-V;&V3M?8&81JZ[ALA-CLYL%"1E;!;$-90D>
M/@H>.0TQ'Q;3+38;*<9?D2F%+-DS3Y8@L][TK27FZ:TB31:<!A%E 9+<K2/8
MGB<=@&\39(RIVVA\)=]R #LP\2Z@\/K'J+XQ:E.LWJ;<8=.BBXTX;B'BRN%3
M](T/LE7F9W)"<F(W!HA^M='6AMYIUD=>6WFGEYQCS.2_A*\-LX;]Y]K##F6U
MN*]3>&D-J4IK/LN65,OJTJ\QX4("^$Q V-GQ%\4'B79D< @R,[;D MY8XP^M
M0_[R*Q())!8@+\DAI> TJ2F1Y(XXG651QBC3DQ) 4CD.9K("%)1'F.$AOCL%
MY(6VVRL<G#(^'&?+U+;<PTIO]6YE*?/VU)<:_1\UUVXZJN%JS//!+QE8,NQ2
M8@<T4\F)"N.Q[$GW Y9TZ6XZ237*JU;,;R0 1L626NI812;%5XM(O=EW;=B2
M&._;IPI"D)_6MN>M'GZ<>KW$I];C>%O8RA"$X>RVM36$95A2$^OS3A6,8H\,
M"-3S!\0,?8/=>Y7;?W-VW\NV9#&197_0R!8711*R@P2,RJXX$'=@.7%MP/:!
M'NWSL:2ILELAE2T$(2EEI37FE6$^A#6$IPG_ ,Y>486KR\LJ<6O/EY+RGE4?
MBBQ'-">$R["(5PL8YD<5V W[OVY GVF)/;?+3Q0FN\$Z!ZS%WD-@F0!>1=RQ
M[=D8GB!MQ79>Y[GLD8<^*=) D$H$)0IQXM#Q0_NH0ZH=U*?9]QI2_=4LG+RA
M4N82A>%)5A+?N8JL:=:IL\-A KQA9IN<R>(%G;EL$W5MV)^2I(W]YRG3=5I:
M@L$]:1Y*[1F* K4F,:-$&5N$BJRCBNQ7F4\N^P( [(, 0F5CAS7$"AN9(04M
MQ[ R$I4EXUY67FT.*:9;RSAM&6DJ?4RIW+>&GE(]->GUJ\]RM7E9H8.,_C.[
M&+DH#.02 ^^WGQ W/N]V]O5[MVOINH6H0);8>+U98HQ/(C,1$"49D#2R ]MW
M50=@=P"#QP-[^"E1HI#HH3_J*+0DAYIJ/3C#*'7&U(PVAU#>658:P^SGRRMI
MU2UY2M(1"=K#UX)Y*\+,9+0\>14A#<$;9H8PPW!W4NJ]OE=SE2SM5>N+MFNE
MRU&):U,F"(RW'42^%XBR.5\G#OP)5UV"^>_< /*2A3Y(3.<O-9].'_-EA;?I
M%PZMPA*UCI;^4X,\XA25J;))]32%8>SAO-RK%J%N=K%,()%^3(C11M (8^2M
M,78, X7= BMR?]&!VWRBW9TVG4AIZ@Y5&4%8Y09U:,R<9!#)&"7-5IHHU5=Y
M(:W!Y%6*+GEU'23L%GK=V%I6TYNR[<C*9&G9(O4?I^S'5:S70-@ABQ1E,*DF
M)R!:#@+9<(2N1=H(>+?=!@G#I$*/DY:,C15Z75ZMO4M-LUXJM:]+*KUTDU >
M)#3GG=(WNP'8^%9C0R*I(.X93O[&QZ3IO4:6@ZM1O/;N:74JQB:6'2GA2UJU
M&C"\]?3)N15YZAD6-I@"OLHXVW<LOZ//AJ;OVSV/Z5Z7W9NU(?WAWX>Y2T@_
M'QPL0"9#M; M0%5+$C@VF1QQGJN)$?'6EOUEL);.>6Z\2XZOQ+J33JFDZYJ.
MF4;#6J]&<5UG8;&22.-%G/S;"?Q%'S  ;GSSZ?Z.U>_KW3.CZSJ55:5S4JOK
M;UEWXQQ2RR-6(W)/MU?!D.Y\V/EY9?7S1YTV.,8XQDKP'^=KO_O,'_R;4^2?
M(?9^\XR:.1C'&,<8QQC'&,<8S1^\9:R%QG8V_5:5W5:]LQ498)0V-KUV1:V,
MZDD97(QI-2!CK!&Q]98B\-/#/UF=IZ78Z9@&P?D/K.'6\5] ^BJII]JMSN:5
M7A"1NKWY%5XKJ!^P=N9,<B,-F5@!V#CYAG56AXE710WM'Q7!*@;=M]MMMM^P
M[D_/F$I!#:XE,8G B8YLA<@E#(PB%.+RE:/4X^TR@@AEOS<]E#KKC;?GA*,8
M0TRAOW.*KIWBS689?%Y1A71)EDB15&Z\(TY;;+\D;GZAEU!$01&XD0G=D4>S
MR]VP[[=M]E[_ &[=CQ9<:C)(1)@Y2,#E-DO@H$;^0IG'ZM?L$I$>7A.,>;C>
M4$9#<<]?XI]YQWEIU@ECDL5B.;P[*DT4R0CS7DD?#V6_XGY'V@21[L KNIC5
M^8W;PV'%3N-MU.[<>Q'S]\Y3.(0@P3,#@R*8=8:;>5*N-N!-/MN)PVO)(CQ)
M?PGVLJ4O#Z2,"J=5ZB<M--*SA0G4Z=)Y+^TLL2\XGJ*71T (B6?R:55![+L#
MYD=S@!XX^0# GW(O( ]]B=R-AY]LOVU=X6G<O=M$IFQ-?TG7,I6[_$P\O5\D
M;=U?#2Y Y*\*$<5#2=O#FQI$U:'$/B2HJR?-S+3 X[:&F4<)9](6@Z7:FK3W
M]2%FO:#W.>G6) [1CF8U._L1J6(7Y7!5_I>ZV)0G'E*W-6+-[!()X[ ;\NP&
M_P!N^_EDQ; \*;N)J77]]N]^I-&BQM?QI]FG76=T:PD3@*_ !$F3K+,!&6]V
M4*DVFV5O?%2 :2_AEL,,1!+SB^95/TE:+J.KTXJMZYX$\E>&*%=,O)&TLOLE
MW<QD* Q'M>6Q.[ >UEP6>;1LTC+P;D .W(#MW(!'O/<^XYCLR264!'@Y)(?#
M:(=8:'+.8:BFS'D_+<<#^44R(UE:7L./(6VWEE3GN-E$^Z1[/<I&E:Q=EL5Z
MLC<5<V(8W:9T?VE!AE>56V7V=UW9AY >6%V#-X_M*)"Q;SXAO:4>_?<=_/S.
MWNWSTMPQ.1XA_##KP<X22VA$;EDP_&&"ULF?X.IU"4O+6EU3&7'<-*QEMQ:T
MH6GSK:_$(+T5* P>JJ-C-M##O(%=VXC>1-PQ]AT!/<[[9<=QPWBBDX[]CML?
MUCW >9'?W^?EG@%<D #LRHSS;)J#'V6%.J<(='=&4AOVB\+?]W+RA66%?JLM
M,$8:7[:G'1RL,Q3:"X)X>V[UT/\ N^$+*1MS5RV[[;[=U7?YP-SB)CW9?]YW
MV'N'GWWV]Q/OWWW\QVST!3'Q)/ZLH<N1/9,=-46\8^VWD_+BW72'<*>2A6/?
M6M2TL#NXPKS3AO.,>CEZ6A"8O5HEE\*-1[)?] O$=R00=CVY;#?OWWRE@%V/
M&0[@LQ0]B?Z3,-QY_-OMMVW[Y[Q9,P,DB0(^ [80A@E!JDFO?P\Q[XPRFTA^
ML@ A*!2'B&W6&QW&T,D(;*1G)"'=*]=IUTZI Q6 F6%HS$\3GP%:199&2< 1
MM_\ "<JY) ''9F H=MWB$;*Q=@@1T#*=]R3L6'?;?;O^KWYG<\'S?0/7RL[*
MV9 6UR3^P--V#,;VTI-RT="N72L!Q\M.ZNO.MS%#H9(D(Z\D1>MIZ,>!DI:!
M;M7UYEXZ'GWH^O>+^E#1=1^%J59JPGK6WKU]#OHNS(IV6;3K;;D$H[-/&X*[
M@GV1[6V-/$\1"-LR[L48#B I/N'?^]MOL &;E%8L$?;:U7K5$.8>B;-!Q-@C
M'L9PK#L?,@#R(3F%8_!6%C$M*QG'X9\_/'/$64HS*PV96*L/F(.Q'ZB,QLCG
M*<8XQCC&.,98IO#OOKG0Q?:B)M-+O4G8.L&J-/;:S7X-F$?E-O1>])ZXTC7,
M%K-HJ6$;*L$SLJDR>O,"S;D2PW8"XM2B?A&H(PQD*J/B2=<+1G6LH;.HI%!O
M_4.N=RI39U_F:S4J1KK7UVM58IM&KEZE9:983&7*VSLS8 8H!I) 62Z+907#
ML'8CAS&,K;9>Y/4JF:\INVK9V8T37-7[$<(:H6P)G:E*CZA<W \K2>FL3Y,R
MW&S>8W+3N)/Z>01],RTY@_X^6U^EC(92^X&FKALG;.M7+%%5H[66T-8:CB9N
MP6&MB0FUK=MK25*WO4P]8O(EG'[(\74+J.AL-EG!Y;T3+& C$Q3"#EL9=-QC
M'&,<8QQC.*U(0A:W%)0VA*E.*7G"4)0G&<J4M2O)*4I3C.595G&,8QG.?PXQ
MFM;VO.L59F&Q8W7YT9KZTSJQ-;IKTNU:H&93(/F$Q+5/M7TR!K4A 3,<RP9!
M18\F7(U\9WZ6<I P[216#]N^_P#;_B<L[P2.V"Q)H%2'B19)6$\I Q.%K0I:
MW6WL1I!"F2,J2HE<:^L:1)1CW6AEX4AS+&2OFQ_!D1I&+$KI<BMIYMEUF0:6
MF='-2H,@=@!YJ,D2EJ>0K'L%/Q)#!H[6!S<N-N^3&5BL76CM/89)Z4?Z[[$:
M4:%G*G:S1Y."6H]YA3?S\C$.%QR&Y#+RLS3(;$:^ZVM;P[OR6AV4R!^?\,9T
MSNG-R:_BOM9?]47NDU[,OA,E/VL,N)C4R;XSHHII:BGEME'GI):%:(*Q@LC!
M2D>XX^$:P)&,D\.1=L (\5%ALR;S$K)2V,1)#2IEZ"D8UL11#J65(=)<2\.*
M_&Y:<0:+'+0.%ZB"'&"F1Y_K_/Y&V> 8@A/HR*M3Z<,E9^.V*45DO R\M@O$
MR9AX[ )LBA.7G\L8(#R,L5]F,'<RZLUCW_Z_NWV]V1<QE#S5>*%E(TD20BU&
M$?6Z_8Q(]N='%=^1&!+!%EU3JXV1QA\ T?(X#BPV#"$DQ[RL,LG\_G]__OO+
M<2VVV(,,2^<(1(K<6>]GWV<R18V<!'@D/D.FM/L%(PUG'T\MM@Q'R@V$I0&4
MEQC_ -_F_/YWR**,EFQ#GLM1L.*:"Z(>\AA1LKF,+]*#&W7VF6%"MX&]:C61
M4R+ZVTN("<25AE_#&0QR8PRM,5)2TA&#H\D%$*4P/"SH!89XY43B<+87*2 $
M@LD4]$:N7RVRTV0(2,E2WFLL9DBZF;K3JN"A6:P>8-/BYI]%DJ^7'25@AK72
M8Z>&E&)T&968\J)LL= C3%+^D&.*#*D;1&6*M,X*+GHUMD^?;W_D?Z^[R[[]
MLV#>,C'&,<8QQC+6NU7:*+ZP5[6[^*!:MK7W<^THK36I=;U&5I=;/ME\E*S:
M[ID4VV;&LM0I-8B@*K2+-+ER,U/,O$J 9B(0"8G9&.BRF,H2%XF>DJP[JRO=
MD:[;NI.Q]G[BV'I$>B[W/HD$B(L^M=8%;9FK*U=HVX2-'MVLY.M_0 *]?:1.
MV&,-M5OKU4D&8J?5+ 13&5R [T=+94FH!1G;'KI(%[ L,C4Z..'N37Y#UNLL
M3+-P,C!UU#4^I4M)"3CS,,Z*%AYSZJ^/'IPHM]IE;&3C&]I>M4SM-W1T3O\
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ML7BRR'O'6Y MAV;1*C'P5/B'HXJ#Q]5389!V>FIA]2P(P)047'N2$FW)Q,*
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MMSY'?R.^3E<]>3].@XTR=UWLRKR1[4,ZU(7& -A(5E-B&*)BWQY&3 B 76I
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M5NAYN6J\1C9'6S6ULA+N8B-CWZWL#7]VV!+V)@Z59;8R(Z;K29M0&67G1BY
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M2<C*8 "'IIDC#6,F+)AIIZ1)=98B0@S!I'#C'Y_T_NS8]#$8 $%!%1[0P8[
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MOA8K%>LLTERY/4DGIVCXM6O(U01M9@=*<JB$[J_/)\]XQQC'&,E> _SM=_\
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MHQ(&P'<D'N=COMM_GY[C5_MG3[>=<MVYFZ=3+Z_%Z%KZ9C:AUBC(*E$4,<P
M!HV'GV2)XN+DS\%RCP=="C9:5F+.@-V7C( $L4L"-]OTSKK1-4HZ?\.R^!;N
MW)*U5:'C3);*2!4F6*.+UJ"*0[ K+$ K=N;#9LR5G4_*,BON0O C@J^\!=P
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MS=CKVI3-+#$DX.HS$L=I8XEWD]7"G:/92H78%QYY4! WAI&W'9N3OS+2NVQ
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MQC'&,<8QQC*8ZLW+K3=<79YK5]I'MD73;]<=764L8&6 3%WR@2JX2WUYQN7
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M-1KBU2F$]=I)HA(JNH,E>9Z\R[2*C>Q-&Z$[;$KNI*D$QH'8%(D[O/ZUCK7
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M'K_HP^C76@^SJS2/W]*9 TKTXC_YT]&I^WH#J']W7@S[]F>Z?YO]=/W&W_\
MONX]?]&'T:ZT^]FC_P *9/P7Z<?IGZ-/N#U%_'N/LSW3_-_KI^XV_P#]]W'K
M_HP^C76GWLT?^%,?!?IQ^F?HT^X/47\>X36^ZF//SVWUP7_M5I#8>/\ Y=W)
MQ_;QZ]Z+_HYUL/\ O7HW[^E<@:9Z<Q_\X>C$_;T'U+^[KP9R^SG=3\V.MW[D
M=B_WX<>O>B_Z.];?>O1OX4R?@WTY?2_T8?<3J;^/<?9SNI^;'6[]R.Q?[\./
M7O1?]'>MOO7HW\*8^#?3E]+_ $8?<3J;^/<^8K_=?'G_ (U.M*OZ=*[)Q_\
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M]W?^O'5;]UFV_P"^+D>/Z+?ZJZ_^\'3O\-9/JOIV_K[T2_=+K'^-<?2^[O\
MUXZK?NLVY_?%QX_HM_JKK_[P=._PUCU7T[?U]Z)?NEUC_&N?,1O=_P#\ZZ=5
M<_ZO+6.W$_V[<5Y_]G'C^BSW:7U_^WNG?X<&4^J^GCWZYZ(_NKUD/_UB<^_3
M>[O_ %SZK?NSVW_>UQX_HM_JOK_]N]._PYD^J^G?^N_1)]UNL?XQQ]-[N_\
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M:^J?I)K_ .V-1_$X^(/0GT*Z2^[FC_@\?<9I/\G=6?N^J7\(X^-?5/TDU_\
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M_9'\@Z]KA\]:U8_;J-P__P"[)'2?2P\NFNGQ]FC:</\ RV??NOUG^7=%_JC
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/CC&.,8XQCC&.,8XQG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g582934g28r56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g28r56.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2244&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      $-    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    5 $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,0 X "  1P!/ $\
M1       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))300*       !   X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             $\@   ](          0
M                   !              /2   $\@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   $\@    !29VAT;&]N9P
M ](    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !/(     4F=H=&QO;F<   /2     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" "@ 'P# 2(  A$! Q$!_]T !  (_\0!/P
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M_]H # ,!  (1 Q$ /P#O,2K'^R43T\N/I5^X55&?:W^6B^CC?^5Q_P"VJ?\
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M Q]FG9Z=7/J?2V[]JW50_P"]S_T%_P#1B2G_T/3<#^@8W_%,_P"I"L*OT_\
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MW?N,]/\ PB=I=^UFL=>+2&6D5@ &L$T;0Z#N_P Y:"A;L%;W.=Z8VG=8(!
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M "?356"V";L6]Q#M??[:O=^9L_ZYZGJ^STQ-IZBXV>I5C-EA])S<7(<0^6[
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      8I)22H "     X   $$  $   #2 P   0$$  $
M  #R!    @$#  0   "V     P$#  $    %    !@$#  $    "    $@$#
M  $    !    %0$#  $    $    &@$%  $   "^    &P$%  $   #&
M' $#  $    !    * $#  $    "    ,0$" !X   #.    ,@$" !0   #L
M    :8<$  $      0  + $   @ "  (  @ %)H? ! G   4FA\ $"<  $%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#DZ,30@,3$Z,S Z
M,#@  P !H ,  0   /__   "H 0  0   -(#   #H 0  0   /($
M   &  ,! P !    !@   !H!!0 !    >@$  !L!!0 !    @@$  "@! P !
M     @    $"!  !    B@$   ("!  !              !(     0   $@
M   !    .$))30/]       (      $   #_X0&,24DJ  @    .   !!  !
M    T@,   $!!  !    \@0   (! P $    M@    ,! P !    !0    8!
M P !     @   !(! P !         !4! P !    !    !H!!0 !    O@
M !L!!0 !    Q@   !P! P !     0   "@! P !     @   #$! @ >
MS@   #(! @ 4    [    &F'!  !      $  "P!   (  @ "  ( , #   !
M    P ,   $   !!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X
M.C Y.C$T(#$Q.C,P.C X  ,  : #  $   #__P   J $  $   #2 P   Z $
M  $   #R!           !@ # 0,  0    8    : 04  0   'H!   ; 04
M 0   ((!   H 0,  0    (    ! @0  0   (H!   " @0  0
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M)V2+$;;?"W\K#4WM?6Z7<+7)U\_X^:R^FQ+9!7KILVVJ>7_)YQ'PKU_]4/\
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M2;-\2UG&N5&P+?BX=DS)H2>XKM,3S+L-#QPE%SAXJ4'8:/D1$OF#/HX4A54
M%;-6*TC4HAW8(T1MB]M211#BMT*C[/,9&(OP_#YJ+$>%18952SQU$,,4<F*P
MQRTM*_/(;3S.<X0"]IHF&H/#C.FM%VJP\TC:JJ944@?45D#(WQ2/>]M%*YDT
MS0U@)C8 TRFW[M[N%XGA904WZ0TYN#P=A;$K5Q-!&0,C2F"36>K1F5-X>.<
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M,,!4K-"G[T*[OHLBT+MD%1[IPU>-T'%ZK1Q8GM18WA4K<W?J:+6V6HFC@>=
M<P9*YKBTWT< 6D@@&X-N'B'V5?:'A\X@/9#'J\Y ]TN$896XO3,)>]AADJ<.
M@J(8ZAN3,^G>\2L8^-[F!LC"?[\>+95Z8&US^,!B?]K=6?M;"O\ 6>'_ .^T
MW_,6C_5Q]H?]P^V?_"^.?_!3QXME7I@;7/XP&)_VMT_:V%?ZSP__ 'VF_P"8
MG]7'VA_W#[9_\+XY_P#!3QXME7I@;7/XP&)_VMT_:V%?ZSP__?:;_F)_5Q]H
M?]P^V?\ POCG_P %=2;W^['(^/O)D=W^VNYM8Y8-*)B\TX]//UG)-\V&LD&P
MD$?(E':BSQV@E6C5FMS5M]RZW-MTE5;+(L1P^>1L4-=1S2OOECBJH))'6!<<
MK&/+C9H)-@; $[!:>(=B>V6$TDV(8KV2[3X904^0SUN(8#BM'20<21L4?&J:
MFDCACSRO9&S.]N:1[6-NYP!VJ#]L'D_[#>"?SVW%ZW%YA;DT1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31%YS^6=^G3B7[%[C\ZS&B*WO8)[1/95]J
M5MQ_0[#=$4M=$31$T1-$31$T1-$31%IG-. \9[@AL)!Y5#*R6/07(D;R>/C:
MSM2R/F9-$:/;P"<K$]S>TDH-B\>4)U!$TUAK@BS8.7*"O>MEE2+KL0[;<1X(
ME6797BJ-VPY3-DCCLMFD=$*T90U.11N*CH:W*QR*M4T!$;<DP@D98>J*;H6F
M'K)$@\MO=U45O(M[Z(FB+1>Y2(5F>%9V/I-,O0*HH.YE?3N"I2G#LF*TB:2A
M^H6/G519FQ"X[WAT4Y;U8+=]H.KF_&SG.ZH14;<E7GG*DYW7/X//I]E4PDZP
M>8FR$1G>\]SN6N8BRC'!TRB,C)1!OA#&C"-I'XQE0=[&9C:<,BS3T?-H\*JH
M^CY7F2*^V?X;QYE!VB]FX.XPNA"YK $:T(DF',QN?D(:5DB*%PYVT5;D%"4
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MM _V^?:__P 1N_')\NB?V//L\_A',/\ 0,#\_P#U<][3NW:?^_./_P"!@_\
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MZSOF^>16+8J-L(% 9W)=K<X%!X?"A&#7\7-R0OA*$A)6%/K17*8 8,;DY')
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M1%$K:E_PS=']MKE'_4,%T12UT1-$31$T1-$31$T1-$31$T1-$31$T1-$31%
MV#Y4QL*WM;I8J6G,6$2(/ L#NR0DN:8BW39L4#'UAZM:$%FR:EKE)*^^RB-Z
MEUMM.*E+*76<<MVM %[7O;S12T\*N+OKD0'S_P".$>_\QU%CT/R*+GPJXO\
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MPM(DDEG=].X:H7*79SMI;S[BY-&G[JE:W7TI3KK31%BF.FVZ$Y!HD0G.0L,
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MYZ^ZRRYPDW=M5E4K*W7)IN4+KZ6T63[HBM(Y)[_]-[9IV?2-B?#S_P#X:_\
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MSR<^[^6^ >Z=A 38'%<0O8&-C.$#6(<>K8&G;;<'+,AB\HQYJ>C!F)PZ52.
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MIT)OH^HNTWXXY@_8+U:7/E\OC^.O\-$R#J?G_!.A-]'5_O-M-ZO\\LP^;A_
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ME8S)+E_>EKAE;H5G%B<\F*38::+)P(8ZA]1WECF\"9\\<+A&&9BY[H'9F9O
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MD;D$CB6W.Q#@3*>HPR6"KF9'A=,^EA@,<3Q)'-PN.Z5Y:'E\IA82YN4,.;(
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M:?<G_C[),0F<<EDRD)LI+]PD6W**2$U'8(;1LG\8QG!\75:E8@3C3B%R"-'
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M$T1-$31$T1-$31%$O<KO$@6V&0XLB$C@&:\F2_,5L[5A42P=C=[DN2.FV.&
M(G*WCH,.?-'J+5@QD0]>BJ*3GN[*.*W6V<U3NR+O,8[Q-MF6(#C?(T=RU$1
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MU09H-T;%G+M=1%LV15<*IIW$5'><8QR6F1L[82#Q?)6#L61 [M_W/6&YD/E
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MBPH6$OK+W:"Y%5I&\5;Z1QG9DW**[@#/L6E#>R0'W&2+VS415IO0<2#*1O/
M]*2"6<S83?:-8]C\)2(!),P8%'E60$5&R[H>Z3(K#L3P+)6-=UN>I#/'[J;1
MC.P+'RV-YD)C-K-"-M,8J3M1] <B*"ZU8,#;1I-FML/D5H\<+E8(0LV?J)RY
MBXJ=(IIZ(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(H0
M[]-S<DVM8JA4JBA3"L:+SO+T/Q=9--PLK?Q'$\);R-A(":\CE#P16PN\1LM
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M*13<X\'6N&[IY'I:1:+""BK%52ERKING[G",'&'%\KY.).]KHSE/[K(7-<+
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M3541N=NVR"[48369D6&#<T0+*<?R8+B#]^X>1R*OWSBP@((B;"0(I[+08B4
ME'Z"-AB,ES$1DX\889UO;/%@CR]*M6]S9=P1=5LW]J'M6^UOP=^C&+Z(I(:(
MM<Y-RSC_  X";2;(\ALC8)T0N&ID%&!4BG8X3&$C3E1PF(8OUVK%D(#DR1 D
MX22'CV3)=P]<H)VTNJ19%$I8$FX%I)(\L\6%NUB#6SI$45!$6[P21=B";$@&
M.LAQ@8^'DV+MD[9$6+5R@NA?;>E3JK4BR31$T1-$31$T1-$31%#O?!G<-@3"
M1,\^R%#,?E3CA4(&7EYF.BZ%N<8.[R#,6A(G"*+]RFAS=ZMC5-99!.^BG"SN
MK;M<S%IZJGI.)2!QFXL;?#&)3D).;PEKO+6VB]U]G>%X#C':'NG:-T3,.&'U
MLUYJPT,9J(VLX(,[983>Y)# \9R+$$"RC7R0F?0F6]I&*8G9D:%2V0XVQ+B$
M O'8^;C3P[&1#''D>'(HG!09Q<09U3>M7#.YP40L6N=H+M[U*K)7V6QAD]5.
M:SO.8<.J>R'-&(_W0 M:S6YA>_B-[]5GVYPKL_A;.S!P)T+G5W9ZCJ\4X5::
MS+B,@_?!X=++W=X.A@&0,M]P:JUC747@E&#>1M?CV\?;KD3;Y)93)X6PG Y"
MQM)(H1<LW@TL-=)$1"I%BDN@UD8#I!LA0W&B5:LB[#G4K5&3ZUD29<_%,/9B
ME#/12221"9HL^-Q!:YI#FY@"!)'F SQNT>VXT=9P]G]G_;.J[ =K,*[4T=%1
MXA)ATK\])6Q,>R6"=CH:@0RN:Y]'5<)[N[5D/[R"2Q+98C+#)B&P?9R!V*[;
MHG@,),Y'/5Q;I^?D<E/O'E6KV4'.95,TBX%=V\:Q&+6.$:=&1X>I6RRZK@F1
M7?G"90B[JP;"V810QT;97S$%TDDCR;&1]L_#821''<>%@\W.)>YSCO?:=V_J
M?M*[6UO::HP^DPQDL<5)1T=,R/B1T5-G%/WVJ;'&^OK2UQXU5*+VR00MBIH8
M(8YG:ZJ^?)HB:(FB)HB\Y_+._3IQ+]B]Q^=9C1%;WL$]HGLJ^U*VX_H=ANB*
M6NB)HB:(FB* >X_8%'-R>0@V1I3N:W;P.L2D<?FT.A^,<HQ6-02$S",1]]'&
M<LC8@KCJ0.QYI4<4+W/GBI5Q8JN6(*6)(IK43L*?@#\_R*E]BZ$7XY@4;A5\
MYG62[@+)1O[.<EFV4CG,BM7=.'EKR0&QPL*R(.;+7-&R"S<6TLHS0;)]Q==9
M52\H6G<\4S@CE':>[QD;(-\>J9M*BLZ1T5&4"*A2#N\-Y5?""QN2+.%+X_&@
M\Y%Q1LN@T'6KE39@%8H6:H-[V!(BU%MJ=Y$>[N]Z*N3(_"XV>MB^V%)DQ@LP
M.380L!L'YBH*?.BT@@V/WK8NZLJK<0%)!73-A=:G:V,D:7W7ID4_=$31$T1-
M$31$T1-$31$T1-$31%K-EAO%XXZE)F,*"MCR+^\HD3325HY3(7J7*W.K:U6K
M916JE]U_'N.%*UZJ4ZM:3<-H62B=E-$V4/+Q( <P>227;VO<E>JG[<=K:K#W
MX548[72X<^G%(^D>]AB=3-:&"$^#-D#6@?>O8:E;,UNKRJ:(NC!1F.1A(@A&
MP :/HERY&0%4@HQD+3)'BZW?)4T_L9(HVNRI)Q7GWY!>BCIVK_;%U;[NO6#(
MV1APC8U@<YSW9&AN9[S=SW6 NYQU<XZGF5LU-95UKHG5E5453H*>&D@=4S23
MF&EIVY(*:(R.<8X(6^&*%EHXQHUH7>:S6LFB)HB:(FB)HB:(J^M]6UW<7NIC
MJ6/<99YQCB7&SY"*/9.+EF#R.2901D\.G0^;B2(J2M<FPQN)$W. @9F\$*!7
MZJZ:+Z^T@GWY98V(I08+C6:XK"5!F>LB0/)TXN-OW24DQWC9YBN/V E4&5C
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MHF.DDD?'&UC(V-+GO>XR6:UK07.)T !)V5;,?P:1S6,Q&G<][@UK6N)<YSB
MT 9;DDD =;A3KUX==A:=SIC4CE>!JQ(619"W:A4<0HZ?V+WMZ6,KE:WIUM;V
MWJ=W?12G<UI;6G5U\-<W%:)^(4AIV/;&[B,?F>"19M[C376Z]O\ 9_VIINQ_
M:%F,U=-/5PMHZJF,-,Z-LN:<,RN!E+6Y6Y-=;ZZ+H-O6'BV&X\=#%RPXNL6-
M6$TEAJ;E-))*UBW:\VI1U8G=52MR5UW&VE;>YK3KX\=58/ATF&PRQ22,D,DN
M<%@< !D#;'-ST71^TKMM1]M\2P^MHJ.JHF4="ZE>RJ=$Y[WFHDFS-X3G -L\
M#4WN#I92!K[G'U4\OJZ^%/AK3777S=54[D^4@BV'&<BQYE7",^QW)I-#Y!6/
ML)CE_9W'G9<<]5]B[,TR&%-S#8PH,<EB+9)&^HZUQ>G:\5HW[D:1[UTZC$*&
MED9%4U=/!+)8LCEE8Q[@Y[6 AKC>Q<X ';<[-<1Z3".QW:OM!15.(X'V<QG%
MJ"B<^.JK,/PZIJJ>!\=-)5R,DEAC<P/93Q.D<R^87B;;/-"V34NQ[E'(I*<-
M;?,(X]PM.LEY$B.WW&+!_'H3E_9\2+K(1/'L,8EB5@%QN69R%DV2N?L%E&I<
M2-+,['-42(YF[:/VS5'B%#-.ZEBJZ>2H9GSPLE8Z1I9ES@M!)\.87YC7_1=9
M7=CNUF%X3!CV(]G,:H<&J>[FGQ.KPZJIZ*858E=3.CGEC:QS9VPO=$X'*\92
M#:2/-=8C?<JBDI>DHA>HG9?>@K5.Y5&Z^VEUR2E45%4JJ)UK6R^J2JB=;J5K
M8I?;PNKN+S:_31$T1-$31%YS^6=^G3B7[%[C\ZS&B*WO8)[1/95]J5MQ_0[#
M=$4M=$31$T1-$31$T11.SKM1"9SREAO)A";R*-5Q48 $24<$L0[IA.&42RKC
M7-D7&$'K]LJ0"4&Y'Q/$"+AV(5L5(B+2H1Q91)_:Y;$6RL5;?L686+3@]C\.
M?:',D/!+V9F9-D'(F0RIA0%:3M"M[2&1)7*G8P:*M,D[6 D0LP%-;7BMJ+.R
MG<TM(MSZ(FB)HB:(H_;G,*.L_8ADF.Q)YM%) 333H"E;EN3>TCSA2[O5^^19
M"RX95RZ5#."+%KS[J]NW7=V.[FZUR%ENN7C=%58EA=;04=4VBGJX3 *ET9E$
M<<A#9K,:]AS/A+XVNS> NS $@+SG:W"*_M!V;QC!,,Q)N$5>*T4M"W$74[JG
MNT-3:*J+(FS4[C(^F=-%&\2M,3WME%RP TAI\B)EE))5NEGR$)MW%;:KIV )
M.FFMS=>Z3JJC8\HDM6EW&M.=I=W%>NRM*Z^/L^RS'(H*BFCQRC;!5<(SPB.H
M#)C XNBXGA-^&YQ<S>Q)7Y.@_P"R_P!K*6BKL-I^W.'18?BCJ5V(4[*"M;'4
MNH9)):0R,$UG&&261S?$+%Q/BT"LQV(;("VT,9)[)+D%AD$D>JCT5W@'+B&T
M7144NN-,FESL^]:D&IE1J'>5XAAR[)VT==PLXL>*W5^@=C.S-=V8I*FDJL2C
MK8IY630PQ0/C;2R6<V<ME?(YTC9VB$EO"B#'1DC,7EQ^^?9']G>)_9M@E;@U
M;C\>-4]36"MIHHJ)]+'02O88ZEL4DE3,Z6.I#*>3*8X1'*V4@/XA*FM/\<PK
M*4>6BD_ MY)'7-]U[D2[</F[5SW;9RR43<T8.FBBZ"K5VY05;+7WMU4U;J*)
M7<+>'N(I9()8YH7NCEAD9+%(PEKXY(W!['M(U#FN <TC4$ KZNYH<"UP#FN!
M:X$7!!%B"#N"-"%Y\)G_ +G'PT4)OWD,SM-(TR<]*+-!K^.BRR;!PZNES@<G
M1:UZUO<,!ZK^&,Z(5HBX6'QXS<HZN>GT%P_Z&HO^T/C,44;*S Z*I>WA!TD=
M1+"7M8*1LAMD<&R2".L??5K9*B&S0R!S9O$3=AJ%[B8ZF>,'/9I#7AI<92.G
MA;GB &EVQ$7N_,VU79#R?F'-CT)OCT)J\DLJ='904*3\KS[(P78F"2W0PU\/
M:O;Q5_04<2%!N^+6].^G;5Z4128](WM$?DO;;MEB';?%V8K71LIQ%1TU)!21
M/<^&!L; Z=T9=8_Y15.FGUNYK7LB+GB,./I<)PN#"*7NL!+@99)7/< '.+W>
M$&W^A&&,'7*76&8A3PUX]=--$31$T1-$31$T1-$31$T1-$31%T[^/ "A 46)
M@PY$J"476!DWXUD[(!E7-EB;E44]<(J.1RCBQ.RQ>]HHC<K999:I6ZEM*4(N
MXT1-$4,P>RV#=%RF/SF12B3Q\S'8?!A#*,26<8F)"H- I5DB6QD20DV.IH%D
M9@E:^R>>9&GZ),0*-C&0=!W'Z+(O7#XBE9$HJ @L5C,(B8Y,/%H='PL5C0E)
M9RX2%@(\-;" PY-P]6<O%TV0YFV;6+.W#ARK:E2]=956Z^^XBR#1$T1-$31%
M3+O0Y,W*>Z?,SW(0G+\=B,60!I ([&G59JY<LVCU*KF3*O+VI&UE<J>+N7US
MA)JFFVN%)C&"B=]K.E:_-.U/8S&NT.*.K(L7I::D9"R"FIWP22.C9EO,7$#*
M72RND+K;QY&&^5?G3[3_ +(NV7;[M*<6H^U>&X7AE/0,P_#Z"2EJ9)8H98P:
M\S/8"QSJR=T@D#?"^F93Q/#LAOI#&7(_9TQGDN&9+'[@HN0)Q"4626UN]\(5
MUA&]S8W9GVKE:A6B]*2,,AT,6<67VN'3#FT5;[[$4K;.1A_V>]HL.KJ6OBQZ
MB,M+4"H =3RV>39LS7$ .(GB!BE((<YARD[+RV ?8/\ :'@./X5C\7;O#*BH
MPS$!7\.>EKG-J#(UD-;'([[W^74C.ZU,@.>2+*UQ(8P#T!MVZ31N@U0MK:@V
M12;HVW7J*W6I(V6IIVW**W7JJ5I9;2E;U+[U+Z_NK[KKJUK7[$OUHJ7]^7(Q
M8FWJ9;LS$C,7N-Y.MC<M%S%S%H]*6'I>V)M'4)E1/G"J%5$! UP="EV5O!9^
M/MC3=FX8HAJIK_7.POVL5_8O"G81W%N(TW[3CK(N).Z(P4TD;Q74T5FNL9I6
MP30N^['(:@N8XS7'G,7[/18I4"HXQ@>*=\1RQL=FD#@89'7%SD&=CFW\32RQ
M&376. >0/P-@S<-!\S^S,[, ,#FDXEHB&&KGEEMMJJ8>N)6ZA!L[274?0%_:
M<,/RE+T[S)).-J6-VUC%[:[Z7:#[:\6Q[L]78(ZABI)L0HJ*DFK()'WT,W[6
M<&&X#*]G A9'_P#D1FI&9Q?&644?9:GHZZ*K$SI&PRS2LA>QEAFR=V&:U[TY
MSNS:%[N&3;*0;\$4DT$4D$J5M213L23MK=??6B:=M++*5O4NNOOK2VE*5NON
MNONKUW75K6M=?$5ZI?IHB:(FB*@'?UR#T*WJ;@3>?Q.>Y3C4M+A UO*P)4$O
MD$>L8%JC62+T N2DPQQ'Q*T>1>MKH\WYX<S+=Z/1]C9G>\'J^-QCLC'B=<ZN
MCK9*=[PTR-<QTPSL+ '1N=*TQMR V8+M:ZQ;9MVK]/?9K_VDZSL'V3A[)UG9
M6AQJEI)*AM+/#4LPMYI*ED[Y(:R.*BG95S=Z>QQJG9)9:<R1S9Y R88)LC_W
M/E%]JFX+'6>99N(/9 7QHM<: Q>,1IWCU!63IL&#=@L2-LY42(O(ZU<*G>_0
M%B;5$ZTN%L2RJXR\P,(589V.[GB$>(5.(/J9(WNFRL8Z$OG=8YGR"5SG-SF0
MN989QE#B6E[7;W;O_M-.[3]C:[L9@O8ZCP.BK:6'#.+45<6)1TV%0E[!3TM&
MZA@AAG;!'2,@J,TAI'-EDIVMF;3S1>CG7MU^4TT1-$31$T1><_EG?ITXE^Q>
MX_.LQHBM[V">T3V5?:E;<?T.PW1%+71$T1-$31$T1-$31$T1:DRCCB93^H.L
M2S]EG!]!-"5']N, N"B])-5]5AWK<;\-&%LNW-ZAN]'%!WL;NC]%:%'W2]"E
M4QE1Q%J;Q<\Q^GQNP^)FQC^AAHBP4IMYW46Y%AJ ??;N&4Q8K%9ZK/'K^';*
M*3)K,D"$#MQLWC=B.SJP7<!>"ULD7RRY\T</+'C.)T&K-DKR-KDBSKQ<\Q^G
MQNP^)FQC^AAHB>+GF/T^-V'Q,V,?T,-$6"EMO.ZBW(4*0";[MPRF,%H_.+\@
M/"$.V44F#63HN(A3':,8L0V<IC+@[MLK.:RFK]JX=6K-HYT<JVMN?47(LZ\7
M/,?I\;L/B9L8_H8:(GBYYC]/C=A\3-C']##1%A<CV\;H4Y)CY.*[[]Q2\37/
M&+,GKFH=LGH;9QNR(2%4$M#Z-=G*32\LK.;(NV)4)HNFU(XL8N023?4:KI$6
M:>+GF/T^-V'Q,V,?T,-$3Q<\Q^GQNP^)FQC^AAHBPN3;>-T2<AQVG$M]^XI>
M+KR<HGE)8W#MD]IAE$+8/+5@Z\-HTV<(M;SJF1$H2T?VE$G3.D6<R&Y%&PA:
MR<($6:>+GF/T^-V'Q,V,?T,-$3Q<\Q^GQNP^)FQC^AAHBPN8[>-T22L/I!-]
M^XIRBK-!*4ZK)(;LGMO;0"YH3J:=1SO'9RWI=)DWUHFT?:^HX85;J/N>;WWT
M2NL(LT\7/,?I\;L/B9L8_H8:(L@BF#,HQZ1AS9C>9N0G8P8]3=/8?*HKM!9Q
MV0H64NI<.+NH1M6ATM09K<:544 2@(0I6VG-/TJ=U2XBDIHB:(FB)HB:(FB)
MHB:(FB)HBBR3V^Y;?DB#YKOFW1A6KU\[=M@PR'[*51PE!PNHLB,'JF-H!8NJ
MR8)WVM6BA4J2)7H))W/B#QU55PH1?#XN>8_3XW8?$S8Q_0PT18+C/;SNH<0&
M*+Y<WV[AF&2U0[>Z:,X/#ME%\2;G*]UWTF O+;.GA*X=;^XYFKUTNO\ ^EW:
ME>K1%G7BYYC]/C=A\3-C']##1$\7/,?I\;L/B9L8_H8:(L%QIMYW4.(+'%LM
M;[MPS'(RC*^LK:0B';*+XH@0[Z<4LM"W%MG+LC5K5G1M==WTY54Y^Y;A=W'<
MTH19UXN>8_3XW8?$S8Q_0PT1/%SS'Z?&[#XF;&/Z&&B+"\;[>-T3C'<"7ROO
MOW%,<I+PN++9*90J';)[X:SGZ@-C?,6L2O*[.'92^,MY%<12 W$G3E_<*L:U
M>.%G%5%+B+-/%SS'Z?&[#XF;&/Z&&B)XN>8_3XW8?$S8Q_0PT187C?;QNB<8
M]@R^5M]^XICD]:(QQ7(K*%P[9/?#VDX4$-+I4VBMY79P[)W1U W5\F&N(NG+
MVX=:WJZ757K??<19IXN>8_3XW8?$S8Q_0PT1? 5VZ9UM%DK@V_;=*H8M8/+A
M2;^&;'*,+R5&ZE6-CVJ.S.Q:C2YUS5KFJ5]BE$:W\W=;=PK0BZ.";=]RRT'A
MJV1]^&Y%ID-6*1Y6>-(I#=DET6;3-00SNE#>-7$=F[DA< 1.5?)A[G[EP\J.
MM;5=+JK]VI<197XN>8_3XW8?$S8Q_0PT12J9(*M631JN]<DEVS5N@L1>V,TW
MA!5%*Q-1Z[3'-& ^QRZOMJNO8P8LF=JJE]&K1LA2Q&PB^K1$T1-$7G/Y9WZ=
M.)?L7N/SK,:(K>]@GM$]E7VI6W']#L-T12UT1-$31$T1-$31$T1-$31%%+<W
MN;"86"$X=#7D;ENYB30N1&<)X3>$K$3<_.CAY!<:UM;4<LK4FSQP-?VCD'Q,
M)=*'8M\!!$*E:7<P15W;1-PFX/+65RDB!VR@XXB$EQ\!W&PY:;1>48]DH;)D
MIE\.1EL6B8K).7F6V/-F$5(T.E&3<' \H&0Y7&Q!<J;"M)\3#(,2*[[1%B\S
MFL4QY''\NFI\3&(X,O8HO#!PBR%#DG)4@U$"FE[X@NV9IN2A=^Q%CTUET^^7
M[QLVLNYQ:VE2*DO;MOKFF8MS(U6!+';F4[)@#,IP7?-W>5(ZGC8^4$0TV5;D
MRC%(EM\W.[;) 3$D-PNW>Q^E#%,?/UY0 'D3MZ1E<BO<T18W+IA$X#'24NG$
MD!Q"+![$%"TCDA1F%"#$W3M!@V4?DR"S=FTL7>NFS5*]=:RV]==)*E:WWVTJ
M14@XGWXS3*NZE.N.;I$SK))"#O,8*7FCW)($UCM(FY@DS&R :38]^[8]VF'*
MQ:090+XB"/VL%R/C!J^?IMY#+EE9,V>Q[][HKXM$6/RJ5QB"QLW,9I( \4BD
M;'.2\@DDA(M1 0**9IU5=D2A-\JBT8LVR=*WK.'"J:2=M.-UU*:(J-X]OWF&
M0=U;RS%]9&R=K2A88GACV:N\C!<@1"%D#\:GD*G,*?-E%=L>YIM'8!,<UX3%
MQ@BQA.:\?BGB9V\P;4<EFA%?1HBZ@^?!10$9E$G,BX[&XX*(') ?-OVHL,$"
MB6JKXH6+$GJJ+,>-',D%G;UZZ62;M6R*BRREB=EUU"*C8[R@4DDVZ!XVQ"]/
MM'X^0R./!L3>RYOD$+F@3BDJ3&SV#33'E&SDCMMS%-HV+*9+VFRT.98Q+.@%
MFDTE5SY=?O-D17O67T4LLOI2ZVE]MM]+;[:V7VTNI2O"^RZE+K+J<>%UMU*5
MMKQI6E*TT1?UHB:(FB)HB:(FB)HB:(FB)HB:(OG=NVK!JY?/G+=DR9-UG;QX
M[63;M6C5NG<LX<N7"UUB2#=!*R]5996^Q-).RZ^^ZVVVM:$5&6[KE"7IIZDK
MA=P)G.V9H)L&RJ5 ,G78-DLSRDL/D,G&8\C.2%IK#LL1$XYC8V&3?#:^)\:9
M.\/BTA1%!R3.)V$23HBM VN5S2U@3T%FMR8.D A9K6#S>3,P@R9R_'QV.@Y&
M$ID(3'DVPAAD:&O"Q3'TR6&L&(\Z2BM).T;-Z'%&K<BDKHBJOY0#>/%\;HM\
M/QMPL;EJA'GIC9$\Q2'$DZCY 4PBTLCN-X*:B:#AT]SQE6/GU2N%<?RU0;",
MH+1LY&BSDDA<[%7D4H-EV29OE3!("4S8PM,Z+N.,,RFN"9Q-SEW'I$6*/Q">
ME(@Q2:H123JC3-(U. 2# <P;3B-R-8,Q; G Q.TBEAHBJ>Y0+>7'L=O0V'XF
M2+/90D9HZEK_ !UE8A LD 3PY&'/PF,\<MA0\P&E^=Y6 GS*?0/$>4&[6!Y(
MC<9/,'J).^E:#B>_?OYJ8^T/(TXRG@B'2Z>NVT@)/VJ#@%D4<%K&A.7X(4'C
MY!C_ "NPC-]W/1AQ-(<9"OI)&%4FZ<<F5DD",4>C&#%54BDUHBJ)Y0+>Q&L?
M%@>*HH;,*DA9J]Y.#V+\H/HIE,$<&71]NG <7 1K O&LBYD&"IT%RFZPWE1-
M"*RO&XDDOT2:4OHZ!D4[]J\ZG&1<(0R39"79F#[II=WK.!(JX$"RG%%Z6/X-
ME8,!4OJO'D<@PMZ!DA6,KV)71:2/3<:1HNU$MW;DBD/HBIYWX[Y81$)0(Q3%
MY>>8.HN6L)3*<8GR=4+DR.2!L26B!&,XRQXBU*QG.L]Q<I((]DG+N$,BMKAB
M.)2#65M 1PE:/7$$5B^W&63R;88A,AR78+6F+EF^:D#P%O<RCTY8#2KX?'LE
M1\;>HJL'"9+CC83/!P)S?<Z -Y#:$<WJ+C[U+R+=^B)HB:(FB)HB\Y_+._3I
MQ+]B]Q^=9C1%;WL$]HGLJ^U*VX_H=ANB*6NB)HB:(FB)HB:(FB)HBCON>S.:
MP?BYW(XG&V4IGDA(6PG&H@X50CT1?9+/BRMT"#2Z3.+[48\+EDG9#8:+?*TM
M1>2R11P&LZ&)EKBK(BHGQ;LUR1RB@>=YQGF4AK4A+,M2;#V8X9D6 ,AYM6+P
M6%MX.WE$HP<"F)N'8KW1X=-2')0;#=TFND(T?CXY ,C2>-OIV@Q-NR>_G[_%
M>CZ*Q4'# C(!'V2;-BS11LOOX4O>D7*:"*"Q0N\K2C@H9?41L6)%7MZSX@YK
M>X=+*JWW75(M#;IMTT"VJXZ>3N6VVF7J3J/-V<6:F@P=^LUD$N 0RD@)/3+I
MNS"1028DHI$O('O%JBY>CQ+6QX:*BAKPBIUQL+W1[UL@R6+$LI9DNQ8L?SL-
M-3258W ML7@&#@M>(80,MB29Q^ F2@V68^.^#Z=X"SO KI_CZ814'F;'<S<P
MV35(24BNIP_MGP_A%( YAL8HO*@./X_C*W($D?D91/2,2CB:5K0>1E1YT0+*
MV.5T$'9&U-PE8_7:L.^K54Q@VQH1?ON*SW&]N6,#62Y ,>R*@PA#Q#2-BBD;
M#D"!"<3B-X^"K."TM,Q^-1\"V/RD6I()/(3 T(!%4=$'SNVU&U)4BI*A!3=U
MO/RV_BQ.5YPC$(7R9FX<=6E&.H(YQSA@*T'R)$9 )O$FS45'YSWU'2K3!V5<
M&99OFQ0B8(1/<9@[([V%.7IIR17088VLX:P<SA*D4C%A"6P7&XK%8O(<F=OI
M).5(B,NM6J.OD!IT_?-V[QQ8C5P@T502JR8A@]MM! $(R8$629OS*RPU$EBK
M6+2/)$Y)VWM(!BB$-TWDSGQV]T/'(,V":UUC,, 9/RXNZ6S<ZLRBD)$N^F)$
M1:-J(VKD5.:;3>?N<EF,S;'(!9'$VX>:,<SP4W'(E*C(_!>+WV$S-CF)91L(
MO1>#)$."2)^XPC.<$3./RB2Y3>2,WE%B9A1V/ATXB16JX*VC87P(%QLWCD;1
M-2S&,#KCT!D&1WNB\I;@G+E9\2:C71)T^H!'N7#A1FR%B*MF@2-("X<*HWC
M86+;$6P,\9A"X#P_D?,!X09D0W'$.-S)['XXB@N<)L@B%JKBUK:Y6;M&C1&J
MJ*A4T1<-@X =5P8,NV@UFX7L(J-6.7=TF\7.:H7&F1<TLL=%<G1HDQ6&8Q<
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M<88(BZL,Q/$VT1CC@HN9<LD7Q<JN[)KM6;"KIX4/$"A9Y<W&#1@D>FY?*HC
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M('):/!56L#M,' D=!*#R*R+1%7%RD3#=0ZQE'KL =!D8(L7H-S8)81W(Q',
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M_P"8/%/7_P#*GZZ^[QXZ:;;C;8'IJ"!Z6&NIUUWBYZGYE/$DV8]GBB[8?=\
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MK]3;T^BFX -LNSAYG6X]^05FFXW$!J7[Z>3\R .QXK(8A";=UE,E2E( B^%
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MH/00RSV4Z_#-M=[?+U>&3AI?U^=_+ROZ&^FFBC(>H]_!/"[N?X^T0RSPZ_\
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MES;ODT^$M*.C# .F[:LR!=419110GW@/6N9M[>^%TTT^-U+1(UP!;=S>9%B
M+]1H?F-=%R'T\C"\%KK,^\2PC*#:Q=OEN3;>WJHU9DWY2["@B][*< F+BRZ+
M5(,!&2)8V[.%55+ZJ-62X:./6]K6]!%:UL\NNK2CNJ"+I-"V]6]&VI#8:>:>
M)[9^$YEF M:^1KW-8T1L<1(^2YN8VL)R O\ NBZVJ*A;631Q";A!P)?)(S*R
M(-:7.,CBZP:+#Q7L=AJL?@?*91IQCOV6YMQL0PA**MGSE&!G9"T=EB"++G;Z
MNA]KUB$(WM+FR5[Q2KH0U=MF3=X^5:=XH6N5==DD@;$^IC%*R8O$;Y'^%X8
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M;.S>09P F  R;#.!<<?*PZ'W%ZI++$48UW-J>B+7+G"DBS!(<_L)E/8R VZ
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M+KQ$*<QI2UD%'2>ESNJT@YE=,&=3O#*I.;))WZ_[ZN4:.",6BZA$.94'"70
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M  RRNC))#@'6:"YVP<)BX=F&X_&"^-)PR9"\EL+XR4CLFC!B6&R*%$8^DK&
M">*KR008SCMI-X M4,(%5&;)L3N>MKW+B\FR67O<VM#G20OIY&2/#YH:=[>
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MER0=Y<XA[GL8UI$N1GAXA<]P-W!SFQG*;*,%+0/)FS5>72:-6[HB^ "&1BT
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MEVX=.G _N^/>:SARX65;\W>JLK?6M]W5)G))J1:H))G&4-M+?]X,H #;.N+
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M3$CV[Z],46!(7(L4#!+O%B-X/C8EZZ6;N["%&31VS:+7.^<3KI1TO=Y'FLB
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ME8Y58#6L>7=O$E5FZ=4.E"R.IAJ/".)''%XPUS!%&QMG>+,697'*V2[<[W2
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M"XN3R<L0+BT9T</"T$@YQ_X;G6P(('6VAT6/KDVLE=)XWC<KBA+&0,4\(XO
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MEWD$:MT9G)!J+8.P:"B'08T(Q'D4NM$31$T1-$31$T1-$31$T11&W&;Q,1X
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M  V V-QH---,/$!YGHZW+GKZ:7&YTZX*_P K<H4&/$BD0F&[9TPD0)NT,O\
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I=^PZ P_HL<6?2]X0;\Q HK%FSWOARU04YTBB[72[CN$%4T[K[;B+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g582934g29h41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g29h41.jpg
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M $_XGUCU=^IO74:V"NYO!WF>2'37Y8-1I<WJ]_$B98LKY^U8Z_9K<#;JP?\
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MJYZ2G+G1X=YW2-]7K=QT^IKU_L.J$F?2W-XM]7,HZ>\7*/X>$DSTSY7?(RL
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M\^,]$EA*A([\<D?OD%Q%EJO2VX]MLZZ9F^9;WVY654@<B#BVS-EI:8T%XO\
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M8S$''AP8X8D4 T^Q@8X&#")B?<UC&M3]74_999CM@RPTVPRVG2#3("VV">X
G!!$4^I$1-20 !L1!L! !3@0 4$13W"(HB(GU(FNWUZ:RT=&C7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g582934g31y00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g31y00.jpg
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M 0$! 0$! 0'_P  1" #& F # 1$  A$! Q$!_\0 'P !  $$ P$! 0
M      <$!08( PD*"P(!_\0 8!   00" @ "!0@%! H,"@L!!0(#! 8!!P (
M$1()$Q056!87&B&7F-;7&!DQ050*(B-1,C-255=A99;4U20E-$)#5F)TDY25
MTR8W4V9Q<G-WDK8U-CA$149UD;+1TO'_Q  = 0$  04! 0$
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M+)N]3EHHY6C*VVY,4422'1JCS&]TI]5S5-H:NNLZ#;66K"RW8:C7ROJ[8(*
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MTN,A]M$6/$C,NQHD?.%2(D(8TVRJ+CV9Q_UR&FHV&V%RF\^5KQYS_>J&R/>
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MCN.(0VXY%SEU"$Y84]Y'U^#2VVTO-^9U-X;M-\&".612KJ"V@L8VD4(S1=\
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M?EL-N/1@ZUI(OM(6XU&6A*LX4K.7K)78_L_M!X*Q[6:^3<7UQ2"U[38L^M\
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MR!48:F"'N1X.7EK-.M@FI-8.'Q$TTXT,&DYLIYEMQ3(^,=-?FR]A=8ASA.G
M[A1K?L"MV[6-7N5 &[)UZ*M=,8V==ZE2QIFQ"[#913T),==Q$SX(+*562V/R
MQ-=J DU9;$ %$51E\_HJ[5#?^BM@V";5*'N?55ULXX,[8IU?J>P*I8C$0"PN
M"W)-/CA!67*;%Q5E129<Y37LT3)47[2XU[RA>O4R/15NK/9;KI= MDLE0WUI
MJSUZG."&K:> ;-I98-65V"9D?7_?Q.":?A"4'IR50P;LY]ALO*2I@<N2ZG*<
M*G(]!X\E8<>[B=>!VN">U:UM77^QJ37]A:EUW:CM!OE-L JH$-O;+I>M@I:T
M%8QSW6#"BGKN/M):60F,*S4XDPJ/;FI]F0^IE\_H_I5!?^X.IJGKQ_:U2,U_
M;M!'AMIERI[6^P-<E4QG=44<K>#0,=#E6J',L=@DQ1:X61->9(R@N7D%K$@4
M#;>(H4R/E^?GJ<:IM/6=[.W&KTG85)M]EUX10'OM?K-I"'35+*N2",-L=:1@
MR;)F@9BYH<Q!3')LQG<SPY:%Y?:ADYEA495GG%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2H\VWLL%IK5^P-L6>(6GU
MW7%1/7,W" L0Y)J4+KPY\G-CBHY"<,@OSW6(ZT16I9&#'6]E*793",Y<2H./
M"OQLG<&I]-BX)S;FS*#K ,4G9%C"E_MP&H0")),5^<Y!@2C\^ S,ELP(LH@^
MQ'6XXQ B2ISR41(S[S:F6?)5S@[&UZ3AR" V]TTA AHK+LN="LX25#C-71F#
M(ISDB2Q.<89;MD<F-?K2W%I2=:(0G!>92)3&5J5?H)T(3GFA0TP+(%*W*B0+
M$-@D(DN>!G3QL0S!AF8;#SD@7*F""$ K%CSFV'I V;$G-(7&DLNK4K MC;QT
MOI]\)%VQMO6NLI-D]J^3\>_7BM5!XTF N(U/=&-'R<!<UB"[/@,S9$?"V(CT
M^"U(<;<F1DNJ95^+9O72=#MU>H%XV_K&GWFVX'JJ].L][K &SV%)<BL.(6&!
M%"<4F107,-K$"EQ8SJ215"AL++\W&6.*958C?876,2P3:;6KA1;I=Z_=Z#3+
MQ2Q&R=>P;+0U7^P0*^.)644<LHV7&<0]/:7"KS+3UGL<G+0>M""IB5&A.*9?
M/Z*N=)[!Z&V5.(#-=[JU/?"(D"U:2<*G;"J=FD0:P\EA3=BE-!BTU3(/.)<7
MQ++QB CVJ-A;Z<R&<+4RJ@KG9CKE;ZX>N%5WYIFQU.K3P(NS6<)LZEDZ_7B-
MJGQQ=5AFC,,TZ.&/V@E,B0:VB;(9R>E2XK(GVQ<AG"U,CT5B!_N'UY&4#YT
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M??7T_6,]_P#XV.U?V^;0_$_'<[@'P+A7Z!:_54[M=L/"C'_.U]]?3]8SW_\
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MV^;0_$_'<[@'P+A7Z!:_54[M=L/"C'_.U]]?3]8SW_\ C8[5_;YM#\3\=SN
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M_L\Z_P"Q1ZU^ISG]N6<7JRMI7Y?][AQ.$Y_9G&,<VT/9MQY<MZ3)TZK6Q/\
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M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2IFZY?_ &A=#_\
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MJGC^SPRI*$_U^7]W,Z/LHW &4V#POS$QWCQ>0-;S?+_#53=@.S)SM]I;J/G
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ME>5IC_S<XQCRH7C]N,_UN9XI5:DM)RK&/*S]><8_L5?OS_Z_%*O/KU_U)_\
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MGH/DJH1T8[886C.=,6#&,*3G/^V=9_9C./\ +G*MXG^(4R/0?(:N/Z#W:S_
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MUV/)CNMO,N+;6E65*K^*4XI5 5*BP0LD;-DH 8*&@3"I<N5F1QXL4+'QW)9
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M.4"T0\UQY3+KX>GR?+\]8]3>\IS:.8;^M-+-3AURO&M-:ZJE779#53D6>W;
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MPUE"V9>9"GMG5BIMRO%5W7=YDO9VR]U:_I]>N$#<V0NOFS=: ;@L=WI4_55
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M;=KK?I/9LBD&31-F\U2-T"/]EQ\L>DA"]OU_8$S3<63[@G+.O!S5=K,KWV>
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M_)#,",48 C(#9"/"R6*9B,RTNMQLDI_J4H]LD>L4SSY:O4*AT8;";&#J95(
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M(?532>E?ST^E3YZJ/_#["^QW;_X&XS'7Y#ZJ:3TK^>GTJ?/51_X?87V.[?\
MP-QF.OR'U4TGI7\]/I4^>JC_ ,/L+['=O_@;C,=?D/JII/2OYZ?2I\]5'_A]
MA?8[M_\  W&8Z_(?532>E?ST^E3YZJ/_  ^POL=V_P#@;C,=?D/JII/2OYZ?
M2I\]5'_A]A?8[M_\#<9CK\A]5-)Z5_/3Z5/GJH_\/L+['=O_ (&XS'7Y#ZJ:
M3TK^>GTJ?/51_P"'V%]CNW_P-QF.OR'U4TGI7\]/I4^>JC_P^POL=V_^!N,Q
MU^0^JFD]*_GI]*GSU4?^'V%]CNW_ ,#<9CK\A]5-)Z5_/3Z5/GJH_P##["^Q
MW;_X&XS'7Y#ZJ:3TK^>GTJ?/51_X?87V.[?_  -QF.OR'U4TGI7\]/I4^>JC
M_P /L+['=O\ X&XS'7Y#ZJ:3TK^>GTJ?/51_X?87V.[?_ W&8Z_(?532>E?S
MT^E7#(WIKJ$TJ21D6\3";RCV@D9UAL\,)A(<<2WA\@6*TZ&-'14*6GUTR=*C
MQ6$^+CSS;>%*PS'7Y#ZJ:#U'J#*3Y <Z_K.\*!)9:DQDWR3&D--OQY$?46VW
MX[[#J,.-/,/M4=;3S+K:DK:=;6IMQ"DK0I2<XSEF.OR'U4TG_P /YZ^NN7YZ
MJ/\ P^POL=V_^!N,QU^0^JFD]*_GI]*GSU4?^'V%]CNW_P #<9CK\A]5-)Z5
M_/3Z5/GJH_\ #["^QW;_ .!N,QU^0^JFD]*_GI]*GSU4?^'V%]CNW_P-QF.O
MR'U4TGI7\]/I4^>JC_P^POL=V_\ @;C,=?D/JII/2OYZ?2I\]5'_ (?87V.[
M?_ W&8Z_(?532>E?ST^E3YZJ/_#["^QW;_X&XS'7Y#ZJ:3TK^>GTJ?/51_X?
M87V.[?\ P-QF.OR'U4TGI7\]/I4^>JC_ ,/L+['=O_@;C,=?D/JII/2OYZ?2
MI\]5'_A]A?8[M_\  W&8Z_(?532>E?ST^E3YZJ/_  ^POL=V_P#@;C,=?D/J
MII/2OYZ?2I\]5'_A]A?8[M_\#<9CK\A]5-)Z5_/3Z5/GJH_\/L+['=O_ (&X
MS'7Y#ZJ:3TK^>GTJ?/51_P"'V%]CNW_P-QF.OR'U4TGI7\]/I4^>JC_P^POL
M=V_^!N,QU^0^JFD]*_GI]*L9/7B!>RU!!56%=E/HO@@P6DD:!?ZL/@A04(J6
MDOS"EDK8<=ZM^5$A#D1/:EORI$YEMIAS'GRAGX_(?G%,LL\\N0\C \O#F)J?
MN35-.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE15O1AN1I3;K3B<+3\V=Y<QC/
M_E&:R3>:5CQ_>AUM"T_U*3C/(/(?$?DJI/PE_P!X?**D@;';B#H$1I/E:BPH
ML=M./]ZVRPVVA/[,?L2G&/V8_P#1R:IJMXI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI4<;CO;VK=1;4V;&'-&)&NM<7B]L"'
MY*X;)1ZHU@I8&ASTMMI]<5J<L>F,Y)0P\MA#N74M.93A&<BUA%S=6UN6T">X
MAA+ 9E1+(J%@,QGEJSRS&>7+6)B%R;*PO;P()#:6ES<B,G2',$+RA"P!*ABF
M1.1RSSR-=.VDO2[V[<&DZW;J]KG0VQ]V;>V=K/46E=.Z<WP=L4:!<-@4BR;!
M*HWU:;'JZN_-G'U]5:H?+6=L")O#SRA$D6.4[+D17<]/=[,Q6UV\3SWL%I:V
M]Q=7=U=6:(3%!*D*]IQI</VP9I)$6,NT0[X,> (KA,.VYGO\.AGBM<,N\0O[
MRSL</L+#$I9 D]U;373C$YIK.+M,6L,$KS")+DG047-BI,B7_P!)+NKKK$VQ
MK3LGU_HL7LK6:/K6\Z9":DVB8L>H-Z"]L;DK&@@N(=LM5&K-JHTNF[-NE:@7
MH<<JTU] .:V>!N3VI+$;EB# ;6^-M<6%[,;"2:>&Z>YMUCNK-K:UDO'SBCFD
MCF$MO$[0LD@[\:'"D$UE7.UF(84M]:8MA=L,7AMK2YL(K&]>6QQ)+V_APR/3
M//;PS6S6]Y<0K<I)"Q$3"6,N"!5D9](_V8*6X?U9!]>]/O=X&]V;.U;8*[/V
MY:HO7]BKZNTQ2MZR]D"KLC7CMWD0[96=CTVMUNO3ZA!FQK(0ERC<V$,@Y2]7
M[A6"Q-B+WMU[D]J6]PCK;1&],EQ=RV8@>+MC<@Q202R2.LK QJ @+'A;&UF+
MO.F#1X78G:(8A>6<L37TPPP0V>'V^)-=QW(M#<%9X;NWBBB:!665F:5E1>,M
M:Y](=;MH&_1TE@6G@ S5G>@/=X9DL4OL]V\ZQV/1-9;"OQZJ1:U'I[8>R 8$
MW7\P#\J'[$'ESG)B9#=;B)CY2]C3X)%;)CBO=.USA#0E%2%=S<037$$"2F0R
M%D<B</NPC 99;PYUG6FU,]Y)LK)%8Q)9;1I<+([W+&YL[NVL[JZD@6$0".6-
M6M6B,QE1F+9[I<N,B=XNSW8KKC8NN8G2VG=4;0A=@-NB]$QI>P]IV77T@%L6
MR +5:JYER."UY=6Y%6>!TBQ9*EO7HGP2/NN+'#SF9<B5#L81A]C?QWS7=U<V
MYLK9KPB"WCF#P1O%&_%YHLI-<R:5RR*ZB6! !R=H\8Q7"9<)3#[&QO%Q2_3#
M UU>36QCNYHIIHB1%:W ,.[MI=X^>M6T!8V#$K<9?I+.J$/:K.H\V/8$DQ+W
M$CKZ,M\+3>U)>I3&ZFI$B(8UJ(VZS4E:[GVJM28LAFQ#F+%E8U<>9C.7<#B6
M8E(P'$C;&ZT0A%M3>M$;JW%RMIEJ6=K7>;]8Y!QC8QY-F/\ $N=QMK<%6]%C
MO;HR&_\ <M)UL+UK%\0!*R6:7P@[4:>$@B5-[WI#<NA].--^D]Z@VK7>O;="
MSMVXUO>>;7%U]6 _7'<]LM>P*75! .9?[\/UT+HI*T$M45J/98PH]<W0F:[*
M(-$Q8UXJ[$>1FMMG<266XA<6J-:A!<-)?6D<,4DK.L5N\SS+$+B7066'5KT%
M68*&%6DVRP22WL[J)L0E2_:4V:0X7B,MQ/#;K&]Q=QVT=LTYLX-ZJO<[L1:P
MRHSE35RF^E#Z@1J9KN]"K/L*W@-D:])[>&HU_I;;%\+5G3X2P$:J5VKL$%4Z
M@6*T*APSH@H/09LL0?F>X-)*%QYS8PBJ+ V?Q,RSPM'!$\$ZVK;Z[MH5DNG1
M9%MH7EE59IBC*VF,G+,:B"RYU-MC@0@M;E)KJ>.[M9+Y.U</OKF2*QBE>%[V
MYB@@>2VMEDC=1),JZBK:0VELLCT5W7";U[7]@NO%;K):15=2ZMT+M"G;4A@;
M6Y4[\(W$+/%WGX]FDA6*E[ N$S79=%DCS4K-XB*ND@.B2W1K%F!1>82]GAME
M?22*);FYO;>6V+Q[R%K5HU ,88RZLRXF#*-R=T'RWR:KN&[01XCC>*85%"YA
ML;+#+R"]6.8P7*7Z2N2)3&(-.D1-;,LC=L#M@IGVM+IT^U!Z7%NX=O\ <777
M8-#UO5J'JZX=K@9785=VS*/V[7E7ZK3%K+[&WCKV52QT:@T*["4.XK5E9MI)
MM9Z(\(]B?2ZF6SL[K9G=87:W\,\\DUQ%ASK ]L$CGDQ$ +!9SB5C--$Q&\CW
M0.@Z]0RR.BL=N!/CM_A5U;6D-M9SXU&]U%?-+/:0X*?OEWB-JUN@MK:X3/<R
MB=QO%*%3F&K-=I^F$Z_ ]+[LO.JZ]MFT;%UEU[+=CJSKZ^:*W=K9-XUNS:*M
M2P%\&S;)1(#LS7)D]<@DERX"FI@\96VSED*+@C*\:>A6K;9>]>ZM(;E[:.">
M^6QDFAO+2XW,YCDE>%A',P$Z)$XW3$,TA1%#,Z@Y%YMWA<>'XA<V45]-=6>%
MR8M#:W.&XC:=LV@FAMX[E&FME+6DDD\9-P@9$AWDKZ4BD*YK0O27:_D#-B&]
MEP"4-V/NBO:IU#K+7&M=VVS?%LF&M"Z^WC,!6+4,O7H^V0+G6P5NG$[6R+@2
M@%4$Q&HEA*#S,:0Q(M38!.&@2W*G.TDN;JXGGM(K.,)>3V@=+D3M$8I'B"QE
MF#R,<T4H01D6VUUJ4NI+Q773B$5E8VEI:8C/B4[28;:XBT4MB;59TN(8IV><
M(K10QKIE=)%8'*[AZ4_IS3JW2+.];-A6.'L"E;#V $&TC2>W+A9!];U#8&:S
MMF1<:R"ILLY0I6L2F9K=ZA76"!D5Q <MF>AMR*EMVU%L[BDLDT>Z@C,,L$#M
M-=VL4;27*&2V$4CRA)A<*!N3$7$A==.>>8O7&V> V\5M,9KJ5;JWNKF-+?#K
MZXE6*QE$-\9X8K=I+5K-]0N5N%B,6A]617(QDSZ6C20W:V_JS: M[3K/6E?Z
MPEM6WRHZKVM;9>YB/94;*F5D'5Q0NGNI(DS:WP;E#@C77Y5O&XM)&$UEBI&U
M0[_<W=M;6<D;P]L3OB"W$,MS;1"U6P($CR,THTJF3B9F $3;L$_?4SQ!MMAR
M7N)PS1W/:=G%@[V=U!97LYQ!\61FAC@1+<ZWDSC-LJ9M.F^= 1!)I[0:G9AE
MTJU;N 5!5H/:@0FQBFSH,S6#2!IJ P2A(+UNQP!=@ $DQI+>)H8V-'EALG#D
M,A#C2F764<_+&T,DD3Z=<;M&VATD34C%3IDC+(ZYC@Z,RL.*D@@UV$$R7$,4
M\>O=S1I*F\CDADT2*'77#,J2Q/D1JCD1'0YJZA@160<HJ[3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*5@>TZ+'VCK'8^LYA!X3$V+0[?1916,RW)D#(]
MNKY&OOD(\=U;;4AZ$T05):9<<0VZXVEM:TI5E6+UM,;:X@N H8P313!2<@QB
M=7"DCB 2N1-8U[;"]L[NS9BBW=M/;,Z@$H)XGB+ '@2H?, \"177>"]&_;DZ
M$H^F;OVWV!:+%HFQZRMG5C;@#6&JZ#;M!&=556?3 *&((4/*#[*#F*R1EUZW
M"M@LET6(%+GPY3Z)4E!&/O'QV+MR:ZAPV&-+R.XBQ&V>XN9HKU+F02N27</
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M'I?HS->TB%6(P:WPA3@7JGO_ *R%44_4VM-: CC_ &%LE0LUGV0U3=;B*K4
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E[MIS/1R5*G,>LRG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g582934g33e76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g33e76.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1D 4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %X< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   "   <
M @4 ,D5Q=6EL;&EU;5]);&QU<W1R871I;VY-3T$M;6]D:69I960M2G5L>2!3
M,2!&:6=U<F5S.$))300E       0(H;/[PBK:FB=Z; <Y&!LDCA"24T$.@
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M965N=6T     26YT90    !);6<@     $UP0FQB;V]L 0 X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M 0 !.$))300F       .             #^    X0DE- _(       H  /__
M_____P  .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))300*       !   X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             "R0  !NL          0
M   !              ;K   "R0                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   "R0    !29VAT;&]N9P  !NL    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   LD     4F=H=&QO;F<   ;K     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    $.$))300,      WQ     0   *    !
M   !X   >     W5 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" !  * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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M+JSZK+"'GO)DR.\_YJ;Q!'$[#L/*.=7?ZKO3:QP>T$AI?/Z&ST_H^RM]V_\
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M_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @
M $, 4P V     0 X0DE-!"(      8I)22H "     X   $#  $   !%.
M 0$#  $    X&    @$#  0   "V     P$#  $    %    !@$#  $    %
M    $@$#  $    !    %0$#  $    $    &@$%  $   "^    &P$%  $
M  #&    ' $#  $    !    * $#  $    "    ,0$" !X   #.    ,@$"
M !0   #L    :8<$  $      0  + $   @ "  (  @ P,8M ! G  # QBT
M$"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#DZ,30@
M,3$Z,S Z,34  P !H ,  0   /__   "H 0  0   .L&   #H 0  0   ,D"
M           &  ,! P !    !@   !H!!0 !    >@$  !L!!0 !    @@$
M "@! P !     @    $"!  !    B@$   ("!  !              !(
M 0   $@    !    .$))30/]       (      $   #_X0&,24DJ  @    .
M   ! P !    13@   $! P !    .!@   (! P $    M@    ,! P !
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M   ; 04  0   ((!   H 0,  0    (    ! @0  0   (H!   " @0  0
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M33C33C33C34/=4_VQW5_.&P_Y$P')/D/E^9U \S\_P AK5\5YY]G3]]^2%3
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M"UJN\F4M;T33B2+V'AF61K#3^Q?H^T:6)-<SM0=N.&@D-HEEQ8Y&F;H&,<4
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MY7:-PN^X;8;L5._$ ;DE&C4LH\R5+%0"W$@;ZQJ7!)*$\!X5=@D2V$B0R.S
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MEB/&]96Z%%)""*U-,7BIDKQ[ ;1K+-*X!W.[MW]VJ6$L3SV<^LTKR+7S4L$
M<[B*$4Z;B-/_ $H&=F ';=B?>=:@/(J&=.TM0MA36^>LOOG%W&>L :4>.K)L
MV_>#H";32-#M@BH'QEQGQU@"S^Y5G^0N>4I_<*TC2UH@9/'AKHD,<B%V!#<]
M@ZS 21E"O=!S0!0JLBE +-XUKV7X1K7GNRO-)%(B$[H$+E# RQN&&^SG@^["
M202,'!@Y72AD(Z&5/>Q'-64>14]'?U^UZ/C153^I'>QSXU<GJQ5]$3E?=X)0
M8W]M>Q:-CL#OY'DN^W;OL2N^_$GMH ER K-"3&Y#<)@ >.^X(X-V[;@;@-MV
M8#<ZR)Z^K-#>9_/==Z7!::3%NMM?V.-:5U)=Q6%F\C#2UX\@9+(OMR:]IM34
M1 D#P2#D61HX$\LT9#!I+*41@2V4D42*(JR@-$$W,CR2"0<N?(1E@.*CM[]U
MU<!F\:*KMNC<K#AUD+JO!8HC">/A\3(%+%B2"=_)NU#,?:T%+O>M\H&9J,[M
MM5GQ\[;QUQAAUNW&37QL<%$^M:\*RF'??O;=1"L)4>205S&B.G;[JB\)8TL3
M2B.:LOAB!F4#P[ D9F._M!5=.0'D.8!;DP;5-P\=@UX:Y:*T6L2655MA+6,"
M(#Q(!>2)@G;VF6,G;BC#5"[ -W.B@K2[S$VV;J,/2TN#$'CHKT&FI&0!03QC
M%2V7O;!<W)115W-$7,TPUUPLSOF'= G$#0(I1"K2RO(Q;ER:0.VP) ?9N 4H
M@0#V>S<O:W]3QSM)S9V$**A"D!%C>-6! ;A[*R<@[ER[*VQC"C8K'OXHIM.R
M\BF8P>2SEJ6Q-=)&3\\8B&N=_"CT4>,=S$5WW"2.>JM6%R(CN>PQ\3BA9&*E
MN*[* -SOLW)F.RKW\CYCOYF2!X9\4*R\D0$[,7)"@$KP"ABY(V (V .X!(%0
MS]D9F[ZKM6MJB8@"?AE@+;.=6O!FC?\ >#&Q")*:\5PI)4<[A&PV0R-=(&^*
MQ@AG2K8BD"A200FZHU9]Y(^QEW1M_-0[*>?$=BDFZ\R;2O- _B?RV!FV:07(
MN$<A4K I8;;%9&C4@H&WW5TV)0:Z"^FK^/1==YTYVOI-M8_:(ZWN:$]YXC3S
M'+8_8/=.Y3H)@13!AG06,0IS61L>0(,YZ1-TVT@2=^,,D$9[QI*-G*#V>1[
M'DRL3QW4'=03MOK9ZI8PJ'ECFD7<2O&=U#D\N [DC@& '+9B-F(!.VI1Y;ZN
M-.--.--.--.--1WV[A'=G]6=A]=QV'X@C:XW19L*W6+[A*BPMJLD2NMOMU5$
M(_&'2#G? Y?;-\'Q._A<O&FL*NT.MKOS(+Z>O<SW78^/'<'CE>7UWJ^N9<9D
M>Q"\[V)=T@M$+:V68V$OXTF"E$302=<;EE<?6W--I9-!G"XWRQ$1M-1!XP=:
M=J^.OAG3^(.QUE??>0N_'W])E,1314%G%T_D]O;6PANONCL\K7G8C+L/M.P#
M=#I)QI;2_N!NM:4N:V)SU=*TUMHJ:P6EJJRF!:Y@-37AU@;'+[G,% &C%':Y
MR(B.<V&)B*J(GJJ>OHG]7&FJAQIIQIIQIIQIIQIIQIIQIJ'NJ?[8[J_G#8?\
MB8#DGR'R_,Z@>9^?Y#4P\C4Z<::PU\K/)DGIJ"OQ^-A"+["OP/RGW-C"\FNR
MU XB8.*VG$:^)+"SLBA31:0%\K!(G@FV5E\T 8]7<?.GTA_3[0]"6"IK4J5\
MQUCGA.,'BK$DBTZU> !9\QEO 9)S1@F:.&&K%+7FR,YDBAL0QU[4\/2_1KZ.
MK/7N1F\6:2CA,>8SD;L:JTTCR'>.C3\0&,69$#.\KI+'6C"O)'(TD4<FCV^Q
MM+IM.;L+L=#[BTM?S-R/&LM!0W)3I/F(B,HL9+EA:\:PF]9K-V7=G;$R60@A
M;*,LF<A_Y86?39G<UU@O5O5W3W2'4YDM"Q?Q,F"K82I>0N3()K/3_P!6W[%D
MHSA+F2L9*1GX/<2ZL8B/VC1Z?L87IX]/=.=1=08:*.N8:EGUX926KLG&,0QY
M>.[#7KJ0I-:@E)$7DM8UF;F.@7Q:M>N+GIK.&]98^FP-0DA8MSDZ:./V5.I#
M<P:Y::6D41=N46L8Y\%Y:-2UN:HJMLCD9*3\3/V<]%W4?2_5O0/3/471M"MB
MNGLGCQ+3Q56O7J1XN:.:6OD,:T%5(ZZ34<C%:K3O$@CGEC>PA9)5=O@CK&EG
M,=U-F*74=RQD<S7M<;=^S//9ENJT:25K7CV&:9XYZKPRQ!VY1QLL1"E"HR'Y
MOVM:TXTTXTTXTTXTTXTTXTTXTU"7;W]Y/'_^=L7^$_:_)'D?E^8U!\Q\_P C
MJ;>1J=.--4'44\M]G[6K%F#%L2!724U@?6!W ]/H W--SU[^,/CE$+(H;L<"
MY#9,Q4:8#!(Q62,8]K36MSZBGA93?4=\71\]GKNJJ>UL-<6M]UMI9H#X*>#;
MT<A^6V>(NT.!'N Z"XL:\VEL)7@Q&U=Q4U%M,&4RKFKB\3FL1%FJ#TY'\*0.
MLU:?8L(9T#*I=1W:)D=XY%'<!A(H+QH-=*]%/I&M^C/JN#.QP/=QUB!\=F\>
MC!'M8Z:2*5FK,Y$:W:LT,5FJ\G%7*/6>2*&S+(O 9H\3H\!K--A]G4%T&NQU
M_;YC3TA[$C-J+VBL)ZRUKB4:Y[?F$.&G@>Z-[XWN9[HW.8K7KP*]!-3LSU+"
M>'-7E>&5-]P'0\3LWDRG;D&'9U96!*GO^MO35_'9[$8W.8N=;>.RM.OD*-@!
MD\6O:B66)F1U5XW"-M)%(!)%(&BD575E$2ZRP6<[[%CO2 +T:K47]'D*B+(]
M4_J58_5(F_U^GM<J>BN7EQ6B"Q*3]I]G;XGEN4 )[[!-CW'VB_N U9W)1:O3
MR%MXX'DJ5UW/987X6G(.^TDMJ-U9D/%X(*IV5P^]K->K'->QRM<QR.:]J^BM
M<W]4<CD_5%3^M%3]4Y<<![B01MW_ #_XVU;.D4B.K!61E97!(92I!#*X)VXD
M$A@?=VU+]88VVK82E5JRJBQ3HWT]$FC]$>OI_H1[5;*GZ>B>_P!J>OMYBK$?
MA2G8;!O;4#R&^X*_< P("^?#B3YZV'&3^N4BLCF6:JQK2R$@F90JO!/R_P!Y
MDA>/Q9 JH;2V%0;1G7C5%'(3T_1%7U3]?3_3_P#U_P#^_P!?/0/)?O\ \?,G
MRV\C[^P!U9V(_#D(V['?W?\ C731]!'SM3K[9'>)7:.I:+@NPB'VG415T<]
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M2H"ACT- M']\7:!5<D)+0!$G6J(V5J92*&(UE]NPDA5Y#X93BRML0ZL?8*\
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ME'?[/'?8L2#KH%"I;>>O=N5VII6+RPQ/)&\TLDD$U<<DB:18X5BG=BKNDYE
M#Q1JK"3;O]*?ZCVH\'^Y1\_?$+9>._:.@J NTJ.9KY'YN=[F5HW9.=5C5D@M
M* :5CKL*-DD>CH!G 2PK8!TAE=MG274)Q4R4+.QHVYE#N3L:T[A8TL]P?9("
M1V5[_P E8W79H>,OS[Z?O1#!U]B[74&*#+U1@Z5B:BB]_K*I$TMRQA6'+@?&
ME>Q;QKC@T.3LVQ*\D.2<U/\ 0!BECFCCFAD9+#*QDL4L;D?')'(U'LD8]JJU
MS'M5'-<U51S514547G8]?FF._<>1U^^--.--.--.--.--.--.--.--.--6MK
M]OC\!3NO]MI:;+U#9HQ6&W1XX,9)L_J@U<"R9[9;"T,<U8@:P&,BP.F]L @T
MTSFL5YZ:B%-[V]V,GMZNPS,%FR8O</V1W356H)\[7.]&D4'2HY5)M"6*U'L7
M]X5SU>:-*UA$5-;A/C=-/8>?]A^OE_;?^FHW/N']3^GG_?;7L%\>LG:DQVO:
MUK?]WW+'03,3LF<,[&UY([FRCST?5U6'6=;590<S5>#=/S!NLB;[6DZ0U[?E
M<W^';Y?KY_CIQ^.Y^?E_;RU.\;8HFL@B;'&R*-C8X8T:QL<34]D;61M]$9&U
M&^UB(B-1&^UO]7IR-3KZ<::IYEM5US'R'V(0;(Y1()'$DPPI',=,T<*.3WO;
M['E3O;$.UWHLKW(UGJO() [D@>0[GWD[#^Y.P^_7DLJ^; =U'<@=V(51_P#Q
M$@#XD[#4;U?>/5UOZH+J8(WL7T(84%9"H(SV^OW!D\H:"#A*OMB;82$( XB2
M(5I*DRQQ.H):@D^Q(#V)\B.P\V[C[._;EY<O9WY=M6T=ZK)MQF7N"=B&78+V
M+'< !0?9Y?9Y>SOR[:E$<D8N&(@0B H>>*.>&<>6.:&:&5/=%-%+&YS)(I&_
MQ1R,<K'I^K55.7 ._<=P>X(]^KH$$ @@@@$$'<$'R(/O!]Q]^OOQJ=.--.--
M>8@T01T+"2(8'$2,A@;+(UBS2R2Q0,CC1RI[GOFGAB:U/U5\K&I^KDXTUXC+
MRI G<*6=#"0V-DOPK[W2.25_LAC8R-KED(G<B_ +&CB9T:]T,3VL>J3L3^_W
M_7X:@D#S_?[^&H"[OZ<Q7D'3,&;<$?M%GZ^R?0S5=RP$*=]B@TD<%JY:VW83
M3OL:X&6>801\\;QUCBG8]SF\O*EN2J67MX4KQ&7V%=U\,L \>Y7C($DE4;L
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M4K[8_P!RO_M;CJ[QU&]XL<UJR_AQHP"A? E>=)AM*1%++#)7FBY@(=SP,?\
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M)'2!@R3(%#J4.1RLCSP/CXY[5201VIQ;2"M,SQK.CP<DEE$DL4B2-%(B)$7
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MZHUC(V-5SWN<OZ-:UJ*YRK^B(BJO/+,%4LQ"JH+,3V  &Y)/N '<Z$@ DG8
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M\=;I378<@F<P<$U&M"1!6:E2D>#F3&)XY9 GKGA)LU[JI:[7=;>2.U4B\C$
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MJPPVI8(IH)=F8I#SG1I(-V=BB,[QEF;9E9@IZ-/_  \=!?\ [DNI?^'>1_\
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MJ_G#8?\ (F YX/D/E^9U4'F?G^0U,/(U.G&FM$?E@"<%Y(=KN.CE9^1L<Q9
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MW3I[SNH]S$^6CTJ0U758SE5)'1 ]24[HLG8#Q2_Q@E[MFZTH:?P-TDC4XW^
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M"B]W)#GL!N.##V5D!"E.X( YJ&XL!MNYLFMJTXTTXTTXTTXTTXTTXTU !O\
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MDMR;*>RHR2+6>5F^VZCXGIM(:A,;PBO)8*-X3SEY$]84R ;H7Y%0X*LBJH#
M*!KFN.OQYOK-YKJK*DQMQ4UD7QHZXABD-9EC)*-P6,L5(97D=F*DMKS^5?TF
MNP"NXM5INE[_ *$S&'UA9NN%PVH[/SO5[\;6F"A6,YV3@V]I$!L.K+@TJU(Z
MXN<1>ZDF&EKR,QJ:_,[?/7F8 C']1PK62.U'<DEB41^+' \_BE25 D,8W2<
M*)A(J NP="\;*Y]YGHV=[\LU"7'PUYV\402V$K& , 6**^ZO79A(\)B9BJ Q
MLJNC*,L"/I%]%=4>$7;&\[*D(W?8N6Z7[A[)H^P<K8WU.[5=CXW(W-I2UW7=
M24TQMYX]Y0"L*O['L:SRU"1OK*6&4<ZLSXP(9F/'4=RSE*\4&T,$EJO T+HK
M!(9)%5C,W;C:D+!1$LC>&H][$D98]'8VC@K<EM?6;45.S:]9C>2,M-#"[HD
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M225K%:0&:I=@9+=>9YY8YQ)/.9?)G0S<_I1;F"GKLY7BUME2#?LF3]D1[5D
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MLI:N[S]U3K<4;W5UK;ZV2*R"9:;3KD0'8?'\_P ]^WEM\M;E:ZSK;@.*QJ+
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MXFO*MCU$RB:Y=D4$()V0*M>$!FW3;Q>Y&P.S+O\ Z2EJ,W35.=S]8#2T-#6
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MSN[$L[L2S,2Q)))U4.->=.--.--0EV]_>3Q__G;%_A/VOR1Y'Y?F-0?,?/\
M(ZFWD:G3C33C36F#ZE?E4VI#3JK-5SV"U15@==;@RN]S*O6T;:^,83*%-.81
M*?3,NOM=$UH".6*]"A@(E%<8.8U/EWW^/;OO[_D/O\]:6"3#S RCXSX['0&P
M#Q7UG#,*RSL;:$<<*2:%)!XFK5,7[04>>0F:T>"R*6 H<Z6&M&:\CXGM\?\
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ML+U[+:8B8,G[9WW&WSX7%T7H0P8RI,EBP(9I+3S/*H.Q!0[2 N5#D!O#7V0
M>^M&I=19K)P96S8S%RM+3J&Q7BIPU4A;8/R$BL%?@K^$O)/$D <[GRU*_AE_
ME$GE-U+JJ:A\JY(/(3J@@D<*XN&4U%G>V,P"^:*.2TI;.F%IJ75O!@6:>6FT
MX33K>1L<+=74?Q3/H9/HVC8C9\=O4G )5"S/7D.Q.S!BSQ\CM[2$JO\ ],^Z
MKA_2%D:TR19<"Y6)"O*L:Q68AN 7 0*DH4=RA56/_KW['MHZJ[3P/=O76/[8
MZNTM?K\!O*0309C0UCW.&/KRVJGMDBD;&0$<'.R8"TK#8H+"JLQBZVP&&-%(
M@CYC/!+6FDKSHT<T3%)$;S5A^!!'=2-PP(()!!UV2O8AMP16:\BRP3H)(I$.
MZLK>1'P(\B#W4@@@$$:D#E'5;3C34/=4_P!L=U?SAL/^1,!R3Y#Y?F=0/,_/
M\AJ8>1J=.--.--1?V+TKU/VVP5O9'7^9UTP#%B /M:Z)UL!"YSGO@ N1_@M@
MAY'O<^4<4V*&5Z^^1CG(BIA,YTUT[U-72IU%@L3G*T;%XH<MCZM](7.V[PBS
M%)X+D  O%P8@<2=NVLOA^H,[T].]G!9C)X>>10DLN,O6:32H-]DF]7DC\55W
M)59 RJ3N #WU[>O.INM>IZ\FLZWQ.=QPATC)K%:6OA'+LYHD>D,MI8.1]A9R
M0-D>R!YY1#H(W+'"K(U]O*N&P.#Z<IC'X##XS"T0YD]4Q5&M0KF0@!I7BK1Q
M(\K  -*X:1@ "QV&J65S.7SMLWLUD\AEKA4)ZUD;<]R<("2(UDL22,D8))6-
M2$!)(4$G4A\RVL;KE%^H?T%!XZ^15X4%:"1]>=J"$]AY "0)U?\ L^>?<V#=
MAF_OI9GBV(]5:/&-JV!,#2JH[RJK"A9)((3C.,]=XJ.A?6_$&$>4DEEDW&R1
MV4$?C*K;]S.TAG/( AF94]E3K]5?HG>D*YUUT..FK<8?)]!P4<.&CE::QD,5
M,)_JBU+!X8:'U*K5&+!1YA,:WK$KK),L:8B=59S1=Z]BT75'4U;-M=O=N5L(
M8;I&U5+5CJW[V^TETL4H='FZF-Z2''O2>1'/@! #.M#0*\O5L/C+.;NI2ICD
MVW*:5M_"K0 @--*P!V4;@*HW:1RL<:L[ :[]Z0^J<1Z+>E+G5_5TGU?CXF,5
M*K_+^LLWDY%9H,9BJ;.CV;D_$N[N8Z]:NDMRY/#5@EE7K^\:>CJSQTZ8QO5%
M><VW(HA2B[Z]:.HB7FFN3)[6]LHQG23R#AO/*D&JA9B"9@J@:O"E)(>.LS_H
M2A2AQU*M0K\C#5B$2%MN3G<O)(P'8-+*[RL!V5G('8#7XL===7Y#K[J[/=7Y
M2..&YG+IL&O$S/%4K1115*-*.1@K2+3HUZU42LJ--X7BLBLY G?EWK4].--.
M--.--0EV]_>3Q_\ YVQ?X3]K\D>1^7YC4'S'S_(ZFWD:G3C35H;^\MLSB=3H
MZ,(2QM**DL+<8(V0B,>=*^!Y4[7?:QR3S2-&BF>.+&L/WA#8A'%A,F<9 TUR
M2=Q[:ZWW8EO<6.@_:\NVL)";UUK1RJ0E:.=/.6+5U4LC&CD%V]R$^.NM+!L<
M08Q+12V0L B':@^??;M]W]N_E\>_O/W^=HV9-U3V*D0/SY3J\A!9IQW5U\*R
M)Q#/L(GLDK'UYE(6KF(/\D=S![XE/)^"=%J16IU)':6*P77M'UII,79[BR-W
M^%![%+$U]55A5M;62ZS9Y]0H8\H:<P&P(+Q-H<>7)6, KP4JB+*"&QGT)D33
MM^?W']]O?[O[6=++:"" GM"DEBLW3#QL")83(/+0P4LU@/9@M-)^YCL"IZZR
M#'F,4&UAMHX+&<802Q)':C?8;G]_O_QYZMX0*8E9!9XHFV%?'6.>CK*Q^&"P
MC'^Z<^LF-@M)8XH(KM*MLRFV$X[7.=$T)]DUO&G[_'M^_P"NJBX42<L6J,L
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M/G)@:QZYFXM&DNE#SU7$+F.D,U(EPXZ=V,%DNU8,S/X,P'+PU9B2(W0$ ?\
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M^0&4@JJL$DTT!Q(D)N;K!5LV3Q3[ZBZV,[8D[,Z]+S,13Z!F]%MM20786I=
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M2[D8LDXGS1#%?BUG:G69/AMTE#VKW/EH[T>W=B'.<7$=04[='57$&=NJ>W=
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MXKNNXV.X.^W?7,MJO*3NW>;/LNP/UWPN[TVNFO=_(!1U-;>ENW$+(3\F5L"
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MY-+=O6PIHNUSE01EA<[H:SM.P,,ZB J*(?#XBL9U9C!9M71DU^]M*<6Z$KK
M2TA93N-+<5L;L)F%^5;/LF:G,08G8-S0P@"P6;Q9&\:0\&!B#<2P(/,#M&A\
M7;C#JK%_JJ"I5Q(Q, ">'&!%$/$[2,O( @CB3WD;^7N#)K/SF+UDM.--0EV]
M_>3Q_P#YVQ?X3]K\D>1^7YC4'S'S_(ZFWD:G3C34> ',TF^MG@W@Y53U[')F
MK:@_#(L@VZN:RAT<=DMX7![TEK<9<@C##TTK8%BU=K%:R33Q"P!S[OG_ (_Y
M_P :?E_G_C_.L;_,CQT,[ER++?"T5<1V0#')3S%-.@H;6\R)8QWR4:7*R@*Y
MU?>25=[71EVU<-"\,UBSRPFDUUA&GQ_#]_+7.EONJ]-U\2;4[:EBJ;FJC$JH
M )0K:L@)@*(.%"N:JRL*J,9KAR@28'!L*=*/%+\@Q-K%*0@;4#?]_K[_ ,]6
M-. CBX'V#Y6Q-'8A7SLFC<0?6"6+AP)PUCG/&+D->\**G&;*9#%7LKX&/$6R
M;6OW^_W^&GS\_/Y? ?A[A[B=?'Y(6BAPPV<<#JF:)AL;V&$31?DCW,G^X@&L
M2XG&4Z0&J",UI\H44+'EM)(2(YS3Y_\ /]"/O[^7]->L@B*.X(JYC@3H@?R(
MIEM42RDA31#V4Z1744 4<S#!_GH[5P<U>9)*?#$7/7JR8VIC-:?O?]_^?OU)
MG3?5.GV]L968\@^>[I*0\]M:!C]!K34(0;X@)JW-4F>M*ET)A4@XB:*RKH*N
MANW-O[5S[!SA)VI \_Z^_P _W\/RVUT7>''0M3TWU%EE/R@M/O;,%YM\0975
M27E?]Z/6B.JHC8*\:S"!-'I:VX/I3BS2!+LLYA9,\T3?C:?O]^>LNN--.--.
M--.--.--.--.--.-->&R&"+!*@L(&DANA>Z:)T:RJK8T^1'1L:BO^:-6H^%T
M2?*R5K'Q*DB-5)!(/8D$[CL=NS J1\B"01Y$$@]M/AV!V(8;@'VE(93W[;A@
M"#[B =8B="A7O[86)-&\R+'1.E6P4H@=("AIPGMJ(I 17MA6]^>.$B<N*"1L
M0<<L7Y!89AA)->Q(?QYO5FD^KE:5>,X'B>/R0]MO:&T87;EV5-U8&4LYZ-U@
M\'J%1<DE=NH9%K2)+1)]7%(++RYDC8AI6EW ]J2;C(A$"+&N9/-@USG3C33C
M33C33C33C37SEBBGBD@GCCFAF8Z*6&5C9(I8WM5KXY(WHK'L>U5:YCD5KFJJ
M*BHO&FH-.\<>K4)?98^LM.J+I\[S'VW4%Y9=<H6:]?<XR\H,Y,+D-;*KOXE9
MLLYH1GN5?D@?[G>L\C\_GW_SJ-A\OD=M>9:#R(R+I7Y_=8OMVKC;ZC4G9U*[
M :V5RI^OW'9'7=<?F?C9Z+\4#>E&3/\ 5$FL?5'2.=OAM\OT/Z_IIW^.X^_M
M_@:_G[]Y<XD,?:W5G977#GJL<EX+1.[,PRO9_P"N6[4]9.TY&>IHD_B_+]B4
M6#B]J*Z2&)$_5M\"/\?Y_+?3?XC;R^7?]^_;4JY+=XC?5[K7#;#,;*L9(L4A
M^7OJN^$BF3^N&:>K**CAF;Z*CH97,D:J*CFHJ*G(V(\QMJ=]77QIKFX^LQ]1
M?K"IJO\ POX5T7;,^DS&KBWT64OH0ZS-Z68.*;KZQ&VE(060^YPMS6&7VHR<
M<<(%I6S#4EV=% 58PB=2Z!Z/N7YAE[$B8ZO5GA,,MJ,MZQW_ )T BDX(%LQR
M"**<R!HVY31*?"9TN(H&<<]PFQ'$L#LQVWV'D/E[0]Y'969>1BT,CL[.RN1X
MYXE?(TKWFD-,GD6-\22SSR)!]L21.1/ 9..R..&,5)1_MT1B2,^D5KO7II2-
MHR<E:L\:1+!M#(TB0GQT93#"R1B*)N#R3RL(?$*$"'*,I"E [=QQV  )4GBI
M+^0!]D A?;)\,;@#P_*3[B"YI7&??M1R,;9>TA/NG#+Z1$_*^-9?D(8K&^PE
M$D5R(R1SHD=(E_72&*"*,PK&\JHIAA=&>'E+L7$JNK>%&Y"!ALX:( *6! ]@
M ;#WG8;*?L^UMRY;\B-R%![-N "#WV^D,<TS3(86!(Z>%\RS3O@'>.D,L))<
MPTLLXH\;Y4&EA9 QKGHV::&%'OD<O/,L7JP67UVQRCE\&*-7FDB:2;F5%M T
MG)C&WM2E4XG:1%,O ,XD;D.^X.P!8[;L=_:!)!)';?8; DHO/;E^1X?G(C'-
MLH@8D^6)TWNA($#@$#))A]KQYE^=[Y99D^.)\KTGD>]$FF6.%:<S-%&UN*HT
MC@#PU8&.82.[Q3 >*JRJT<1>5I9.*R#<HS*RE9;;8.![??V2/L_:Y'<[-OW<
ML3]KVOM$J!4J4R]I[.F/SEA:TUTP^NO:&PJ[*>FL1"Z<J8H&R"+%+CG"/!/'
M^2KL6G#GBD".D!?"3) ^2TL2U2KQY"M')6@BEJVE6N+ >*T@;=UFKQ.04#I9
M6-)H)/6 _=P/#I%AL Z[KMLX W)!!.YY(K =F#%=PQ?=?;(X]"?TD/J1=SC=
M_ ]4]O7V@[*$[9O<Q@,?^T>ET<XF8/LML59ZRZ'LK#1+DI)V?G;.UMII:"WV
M6QN["AKA+T&OB)0GB_I#Z)Q52@E_$&"LM2*S:N0JB"< K"E>)HO"6QNV\2!2
MT<-6.*::2(O*&:SLUU4<HP% #LP^'=!QV\R?:7X<>[,/:W/8CS@VK#3C33C3
M3C33C33C33C33C33C33C33C33C33C33C33C33C33C36.5+7Z:UHO):MQ=I%2
M:X_?Z@7-6TWM2*ONY^ML/'6E2/<,:D+(RW1*I/V1JC)_G"!%K$@\E2,HLD1D
M7G&&!=?BO([CL1[OO'S&J<@<QRB-N,A5@C'R#%!Q)^1VUI[[(^H#D3M)U6+F
M.@-=48KJS3Q'Y#Y=3GI+6\M!]'EKMQ.G&?'8N>+;U=%JA9Q["[US3MCHLUV?
M8)'L,-1W%9PB/Z37HYBRO7.*M/F%?I:ID)9;8H*\.4?&VEQEBM003K+#(UVS
M"*LEM*L35DE69ZPD\%_H:3Z,'6LF(Z"RM7+=-LW55S'PSX][MB.7 19*LV2A
MM7[!JO#?C@I5IEO18Y[<T=R2$5X[@7UF.A__ (AA+]_W!JQ.B[&#0]BX\R@-
MK3+[)W-'35]K14%/0V<##,U&+>D@'YW1S:"O, #=V$&;05.GL8ZW!Y6"##R_
M2S]&473V RK5^H)&N9:Y1L8^.K"MFC]6BK8MSO.UM*\L<D.3IM56"7Q%?UCF
ML!/.7,Q?1(ZTFZDZCQ ZHZ2BJTL/3O4,M*V1:#)S9/UN"K4-)*3VJ3038RX+
M\T\;1F)J;1>M;F."T;#SNJ[#J_!8VMZ5UP^>S.LN]3EKT_7TF@OF6^@L;\S(
M2Z:.UJ6EZV&H-NPAM4VYNII.S?<6W6D2#EGO.S<OTH?1C6ZIZ@PDLV8*XG'7
M9FR$6. K9"?$U/6[U*G ;"6*\CQP3I4FL100)+'L6AC,<K8&+Z+G7EKI+IS.
MQ9/IE;68R5"!\//>G\;$U,O<%.CDKET57J6U@-B":_5J26+)KR,4%B=7@U(%
M;]1H@/M[L/L9G1%NFDUV==3-J'ZS.3T];1D56.KJDN,U<ZGWUK7VN5TQEX3)
M5@&[2ON<GF;RP(J>M,DM;A9/I6^C9>D,;G&K9XO/G+6*;%"K!ZU&]*&&W9MM
M8-E:K5C7R-188UE\=)_&_DQI(\[YV+Z)W6+]9Y/ CJ?I9:-;!5,M%GB<@8)W
MO33TZ^../%1K\5J.QC+DEF<Q^JFH:C">2116CC.3S?K5Z&9U6+TYK ,]'>+=
M,MY=103:"GLG5KZDBH98LKU-/'9IY"; NY=..LV8G)Z@6C?B5^[DV5?I,>C1
M^M:N $^5:.WAJN4&7^KV%%8[F&CZCKQ/5\9KG(XR2)&*0.JW2& 8#Q]:NWT9
M.O$Z%M]0-D>G5R%/.6L4.G/K"1[D@J9J3IN:PF4]6&.]K)1R6(HY)T:7&;%I
M$E;U34I67U'5*[IQO9#.@+D>PS>6_#U^=389]M78U((NLKSB2RV9SXJNY0G8
M9^>EL6 61^/K:W593/E?A^T=C.FJ1_2T]&C]-97)"OGQ/5R]2A%C7J0"S:6_
M'8L5[:SK::M' L6-M"Q"\GBM,U<JDPC\2+;Y?HC]9)U3B,8>J.E&Q]K#W,A:
MS"/D#%2L47KUY\>*#4DNVI9I,G3>I:BC2#U>*YXCP.5@GB6T\T*BR\=?(#IF
MPZ-T%T-VK1[$:2Z6SSSIL[KC<<)45)%3G X:][:2LUX45S2U-=HJV/K6F<)4
M9!3 Z*L%YG;7TEO1W<S_ $Q@*)S,ECJC&X\U[!I1"*G8SJL,=0N1R6"\]E_&
MBALO76Q!+)(O&2<O+PL^F/HR]8TZ^3Z@R6:Z5KKTMU3Q-1\I;KKDZ>!O5CD<
MK7RD=58L34"PSV*C7&K68(H7=TJB.(OC[]/[R>J>@^G^XLB5T^?N]EN+2YII
M=$63G_Q6:RMSF0:^89F>NX+ *[*,MA6V%YF)!ZJHTHM?4L.O9ZZ.K'KO/4?I
MNZ1]%B82CGUR=A\O=EN!,971Q7I0>JP26Y9IIX#,P?G'#'&3*@CD$IBD[S=#
MZX]!G4OI2ZHR5NAE,+A3A.F*E%%S=B=I+61L9#.V(ZBU*-2RN.KE.$MF>3Q*
M\CS)8J"Q3GB6#)PSSP L>LNM<?!T[JX*G,;0W4U^AL=;3Z:[TPN@L]!8"46J
M?:U$-AI(267-8)J+306<Y/:CJ^<S:L%EN#H^7#?2<]&D/5'5>$EDRY_A^CE'
M-V.@!6R$^#B+7JU&(3K-7DW@F%-[,5>!2IY- HC+<B3Z,'7DW2G2&<BRO3:V
M>H;^+BGQ4UZ?Q\-4S<@2E<OW!5EK75@2:!LC!1DLV0&'AI982<)!%^HU'%W)
MK>Q5Z!N9K/1X]]*?EY==0248$!T.9K1KF,M^==#:7/P9:U@M;.2NKK+851N?
MQ][)#2=89(P[ 2_2O]&T?2>+S)KYTS6\U=QIQBU8/6X/JZ&K:M6FG-I:S5_!
MRE+P8UD\7QS,?#C5GE;8HOHE]8R=7Y7"_P 3]++CZF#IY.'-NV0\"U+D9K-6
MO0./6FUZ&PDV+NO9L/&:PJFLRRS2;01UKQV\Q!-AG\AT/6]6::GT-]K8&];]
MLGZBK*M,;V<?)!0UM]=0LK8[.SIZ\IU@*6CC#8S<@2WJR6F+Q;/EDV_%?2&]
M'_47I#J]$8M\I-/D*J-5O24A#C[CMCOK?U,1-,;,!-/V1-) J"XA< (RSG2L
MO]';K'IST:VNN<ADNG_%QUN5+6$KVIK&0J5X\C]2F\MOU9:%IQ;_ )QJ)8\0
MXYU(=I@U0;^N==UQ?3C34)=O?WD\?_YVQ?X3]K\D>1^7YC4'S'S_ ".IMY&I
MU0M/I*G'YV[U-[-(/49^L,M;"2&"8LE1@H7S/B$#'9(2:;/[4@"!%CE*-+DA
M%&BEGFCC<\^PU!.PWU\,E56M/0 !W]PW07SFRE7=TRM'J(["R+F>00\>M&=*
MT,(?Y&@UHTI)I0]:*) 6>>3'*7,U/^??JY.--8=>2_AQB_(V.28^T,S]F3$0
MZQ-BFNCEL"@Z,FOS#(1G7X]53"5EE(-8V:@5#C[>$;[:,RO(D<=QI^_WV_XU
MI=[%\!.[,0%;F1YRRT%H)(<L=12YYVDS"8^L,*AJWB:(6N$AJ[6YG5LJ5B06
M!]70O6SO;<&:7\/4--NWG^]A[C\_=MY?,G']_4.Z,>2>#G/FFJP*_0P20S_B
M'2VY]O4U0=;55]94LBDL'GW="58YH1E?Z57Q-445LXJ3M-C[_+Y>_P!X_?\
MYUG7U_\ 3&[)GU,E!OI2ZA(R [J7L3/ST[L]$3,&UM@VH4>] UWW:0Q"40P
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MQIIQIIQIIQIIQIJ*];TEU7MK"6[O<95QZ>6-(DVM XS([X=C4]&H%O<F32[
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MY+%1#"IBD3P^$DCEWDV;^9RV81[M &*@J-X]EG[E6!4E!M_M(.[-R) /GR)
M'L $ D ]TGT2=IMMIXG%V&HP=;GJR;7F&4VRH:'K+%Y_<F_;Q4MRRKP_7..Q
MBU'[,MH:RM*MKX:Z*O2)W?97T@E<VJJOD_T@U:M/J*Q#6MR651$4I+)=GE@7
M82()+-VS::<RB0R\HY%C'+M$A.[8JRJK*P5^8[>YO9&P(')F;EOORY \>^P
MVUN/YH^K?3C33C33C33C33C33C33C33C33C33C33C33C33C33C33C34/=4_V
MQW5_.&P_Y$P')/D/E^9U \S\_P AJU7^,771G3_9_25Q/H;;'=K[+M?<W\TM
MC"#>5UUVUV)?=G6,M!9U8@2USLSI[UT^4)="08"VMK7FD6)$4TT[?N#\-OP[
M:;=B/CO^.HDU'A9;=@99M!V-Y1]\;BPK]AA=AF-!<5W2:+ES.O)+F6D:'EX>
MI&XJT*L7W9#M3::'.6QE_P#:UT<JCC@PP)((!!V_IN?Z_>-05)&Q/X#5,M/
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;--.--.--.--.--.--.--.--.--.--.--?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g582934g35c23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g35c23.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2:X4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&@O
M7"         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/
M     0 ".$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             $.    ]           0
M                   !              /0   $.
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   $.     !29VAT;&]N9P
M ]     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !#@     4F=H=&QO;F<   /0     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" "@ )$# 2(  A$! Q$!_]T !  *_\0!/P
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MO_2"T.E_\F8G_$5_]0U6!96ZQU;7M-C "]@(D!T["YOYN[:DIQYZ%_W&K_\
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MO_3/CZ_^Y!;^;T]F:ZES[;:C0_>WTG[=Q_=LYW-6!TW_ ),R1),='QQ)Y/\
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MSZOY>37511EMMK/JA^1Z]>YU6QTV-M>WWM=;_-65_P!A8O[;ZO,B\^$DD?\
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MI))?_]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  0P!3 #8    ! #A"24T$(@     !BDE)*@ (    #@   00  0   - #
M   ! 00  0   #@$   " 0, !    +8    # 0,  0    4    & 0,  0
M  (    2 0,  0    $    5 0,  0    0    : 04  0   +X    ; 04
M 0   ,8    < 0,  0    $    H 0,  0    (    Q 0( '@   ,X    R
M 0( %    .P   !IAP0  0     !   L 0  "  (  @ " #0A1T $"<  -"%
M'0 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.#HS
M," Q,#HS-3HR-0 #  &@ P !    __\   *@!  !    T ,   .@!  !
M. 0           8  P$#  $    &    &@$%  $   !Z 0  &P$%  $   ""
M 0  * $#  $    "     0($  $   "* 0   @($  $              $@
M   !    2     $    X0DE- _T       @          /_A 8Q)22H "
M  X   $$  $   #0 P   0$$  $    X!    @$#  0   "V     P$#  $
M   %    !@$#  $    "    $@$#  $         %0$#  $    $    &@$%
M  $   "^    &P$%  $   #&    ' $#  $    !    * $#  $    "
M,0$" !X   #.    ,@$" !0   #L    :8<$  $      0  + $   @ "  (
M  @ P ,   $   #  P   0   $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,#@Z,S @,3 Z,S4Z,C4  P !H ,  0   /__   "H 0  0
M - #   #H 0  0   #@$           &  ,! P !    !@   !H!!0 !
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M=W;01^]_+H!GS\<=/GD[XQXX]V^U1D^9^9J'DQN&QS$/)[;'?BVG8%[.\?\
M(#T<@[.WM[^?+4X&V ,]3GW^6WGX@#'T9/F?F:CY,7AL^Y[;'>[ER^Q-P)\O
M;0OX_OZ8VZ;[^ \>F<[_ +_$8ID^9^9J <,;AL>YZ['N79_BG8%'GS#S_P!8
M/F]7X.>A49SCQ^'RSOCRVST'JR?,_,T\F-PV.7M>VQWGV_XIN!0$>0^CV ]O
M=Z>[W]1C??&,CICQSC'4#U^F=J9/F?F?ZU\E^&;PT&J"SISP_-C+9LW24<.'
M#C:E@)%!N@@05%EEE5*$4B221"F.JHH8"$(4QC"!0YZ;;[#;PV\M]QX=2-_
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M/9_M[![_ )?5Z]#Y^>/V&"/$GK@G^53_ 'Z?/[\J>G].SY>X.WT:C/ACT/\
M(^AR=\^-1\?7[]]/>[_T]?\ '_)J-B=AXX'7XY^.^V-L]-J4[??^4/O<OY?/
MR] S[]\;D>1\O'YGS)ZY(G[_ -S4![>7:/9SY<NWY>_[_?VZDX/A^PZKX[C<
M8^7P-10>_EV>CM\W=S .?/F(AW^^'?ID[9(\<_T\1GQWP!TZ9%3\_'IY_P!/
MGT-.SNY=G;V<@[.0^_[_ '!Z.>GFI.Y/7P\"/CU_N<5% ] ?AY\N_L^+N_C[
M-/3U]1X^[U'AU\, "E1[O5_M[??Y]GK]?;IMC?RVV.<9V/P&^PZ=32GHY\O/
M\H?>_C#M]>GJ0/$^GQWW.-_'8G S2@>G[WZ?Q^KL#EIOOYYZ=??C;8'(SYCQ
M.:4#^+].?R>GT\]![\^O38$$[GW^NV*5#L_C'L[^?/D';W=OO!S] CJ<[9\.
MGEG]]MN@ ]:4]/H]7:'F[O3Y^X/3Y^^",8\CT!'0GW[=>OCTW.]*CS_B^_R]
M'RCV]WI =1[L9)V\#[QD]#[O/R%/O[S]_&K.;B63R1V_9SCHYHX?R#_#N36+
M)BR04<O'KQU29M!LU:-D"G6<.7"YTTD$$B'454.5-,IC&* P<D'Z]//H3U'H
M#OMCT$CJ/>*ZJV&:<O(89V)3^U3"-ZIV:-OO#DW*PV\'(,5A"V8Z9.G#W:F\
MAJ!B2[/;%3(2-S'?7><D86PU^LHDMKR+<0LC+'*D@^,=QB/Z]?=]X]:VG.=S
ML2N!\1G[^S?BFY^XAM-GL41U05S!F&U6S8+47U+Q/$4&T4*%P5FN V:N[@:3
MRY V#";7%F4JMD3+00S9G*P>6J_;ZAD)XQQF6 \6L)R)7G?;]L#X>_TK' WS
MC]77SWZ>GRQX^M2O%.YS?5![;[E=<E6G-.1V-HG-J%1<0U9D\XUN_8=R1;6V
M0B9OM.4\E6#A[5Z<H6+7+V-IR-HH.#*!E:9QA/)LV<)9HBNW!NM)O#KD>7D=
M_3YX\QO0@>0!&3X;X] <YQY]=]J^F&=SO$%4JW#QN^2;-GJ]2TY=\@8\R=M^
M@Z)?Z#DJR-VF].Y8\IN7)VZ2.VPE+NU?J^$ZS&-LC4C*9L(33BB*KY2;+P%K
MGH^28SN<>/H.I'P]W\_6F!WNGO\ #?P_GD9V./2LC>&AEOB#9)W+J#N5NTG#
MHM8_<4TSIA6V1&63JQ<Y'91;L\+R5&CG6U.A8BQ?!URK(*1D8-=W'90^N]6)
MYO;' OIZ-=JQY>N<_3H/E@?0 &C  =/<1_,YR?E5E<IQV8-O6];<Q<-C%3-N
M2R#F]7<QDBV0F3MJ%K;95VM9NJ^WJ0@:C<,:;D[95XJ+MF*K[8JQ6J%5<:&>
M241)L[ +:D.Y")DYA9Q&-]L_+<4ZJ,[=/'8C/[_>>N+@CGK)GL V8N";@]]S
MC!%UG;$3?#EAUANXM,LX[R>WP,RG*C0X?J,#,[34*+/Y8&00LJM,KTU#PMA;
M,*:VL%>B'ZD:YGP&-@?[9\,X^>??38$[#(W&_AZ[^6_UJVF&;IQ6<EV>IN[;
MD/<56K5COAMY"S[6*,O0*E4H;-^>J]GK+=:P36\S1TK15FL;9;IBA6A3%XH%
M??4^:?/RLE),L81NY0"!GY;C[^^E2=(SL-SI]VWQZ?#>LT.$)D7=]D9:^3.X
MC)4M;*ZXQ9A]TZIMS8Y><7FD9R7)8OKI*/YC(.U';96ZXUF0+&).\24V4R/$
MX_D8@#Q4PE#SC1U)2HR?YXSC?;[^>V16+^&WGOMO\C6[KD >H ]7+\/OCW=G
M;V:G;?!W'QSX;=/#KUP/7-84 .WT<N0>H?7^$//RUD.IW!/J-\[G89VWWI3L
M[/7V\Q^7\'G]7:.H'GX=-AGQS[]CMT'AC?HJ/,/3W_Q!W^CY.SU=^GAZ]" #
MMDC;W$=-P/+T4^3EW>OEW>OL[0][S]_9'7ICU V ^.PSOXYW^5/L?3^5.SS=
MGG'T>C[W^L?-J?AX;_''CG!/CGICJ-L4IYP]?R?ZM1T&1X;'KD> \?EL.GPI
M4!#GZN?(?-[WK#N]'?W:;YR/' SD[=-B?C]G-3_?^WE]^?2GOAR]'J[^\?-Y
M_/\ )YYR/IC?'B?>,DXQD;>9/6HI_'YN0<Q]//EV=P#\O=S#MC&>@\2,'J!@
M>>-\#UZYSG>GW]_?]G;V]@>_YA]\ ^\';Z.?/4^_QZ[^&/+P\\[8WVP*5^OX
M],9'7/3.?CX_'?IYDCI2H<_]79_%V?Z^7I$-//Q&XZ_+H0,8^.Q\!LJ =G9V
M_$'9][N[O3R[1T!Z@>.3UR?7U]1D#R\<TIW<NWU![_=ZOC#S=OJTZ[9SC8>N
M,8ZG&_3ICU/B- #EV<N0!Z_5YNWL_3TZ>\[8/OV)&W3'D!N-\;C.)SX_?Q\_
MO-.7Q>;F/R_A]X!'GW\PTSC_ 'Z[G?/EGZ$9)J*<@$>[N[/C[.S]/7S#3KCS
M&_3KMT(/C@>?A\E1$.8>?T_'W^G^/E][4[C<?+.WAGRP?3)\?.GW]_[4]?9R
M#NY>C].?=J,]/CCT\!L!OOC'J/"G[^M0](\^SGS\X=O9Y^?=ZOXM!UR-]L?$
M^&,CU.,XZX\@H/\ 'Z/1Y@Y_+S]_M#0GKUQ\#UVSN0>AZ^N_B2^_Y_?]:CW\
MN7<'H'S_ *=_OZ;]-A[B,[9\]SO\SG?!I3[W/N[_ -/3S] >COUCC!Z]#UP?
MVQZXZ^/EO2GH[_>^3O\ >]/=\NLN@!]QV\N@.=]O3KXCR"O,F^JG/;9+;^\;
MA?\ T/)AK ]>N?7X?>:W+^D??C7<VX=F_+:]3^'YL6J5@N]L:3U6V<[8ZY-M
M6V%LXRK=K+PF$Z1&22#>3B,;OHJ211>M5DTG\8]>Q[PA2N&3IPV535/.1CKX
M [;9/J=SM\O=BL"K9)QX^8_K69'E%-I'^7UR_@&W!^CS?V+0'U\^7=J=6VYQ
M[L[GKX]-^IZGSVJ-+>7[5#RBFT?_ "_N7\ VX,/P8M[>WWM1G/7]M\^?A_3&
M.N*:6\OVJ/E%-I'?[/KER'_B'W!\O/\ \5GZ?%J3CS]XP?'W>7EOT&YP!30W
ME]1_6H>44VD>:_7(/2/UAMP7Y+!]0=NHR.F<^N-ACH<8W\>OQR-Z:&\OV_K3
MRB>TC_+^Y\QY#_@&W!]OG'L^M:'>//NY!RT!'Q\?7^7J<]<FFAO+]J>44VC_
M .7UR[.P>>!]P?O_ +EGF'T@'JY><",>7KOUP?W],8S30WE^W]:CY13:1V_U
M_7/LY\^6!]P?Y+.S[W;SU.H'.W]3^_N]WB,"FAO+ZBH>44VC^>_W(?7]8;<%
M\@_V+/O>?E\6@/G\.N,_OC;IY[^YI;R^H_K0>(GM'[!]GUS]'^ ?<&'9_!:&
MG=Q_0?7?Z?MUII;R_:GE$]H_?[/[EYA$0P/N#][M_L6=WQZC(P1GW8SCZ^'P
MSG??>ITMY?4>/\_7T%/**;1^[V?7+E^\-N"_!]:S]/P,CUSU&PZ]>F^.GAU\
M?',:&\OJ*CY13:0/=?KGZ>S VX+Y!_L6?I\7:!QGIY>.X\,[=.@P,9\::6\O
MJ*_(\13:/R_7]<A]']@;<#^2WN\P_'YM,]-SY?(#I\>GU\Z:6\OK_>OUY13:
M1_E]<@ .7(?K#[@NWU?X+/T[],C/3'3SR-]\^>V?O--+>7U']:AY17:/Y[]<
MOBP/N"#G_P"JWL^74E@<]1G_ &'GMY_/R :6\OVJ <13:1Y[]<O1_@&W!!R#
M^"T?P]W+N[0%J]>O7;/3'A@#UZXZ^--+>7U']:CY13:/V_U_7/U_V!]P7/D'
MF_P6>_WCS#G\D9'P.=L=#M\#T'E\*:&\OJ/ZU'RBFTG_ "]N?+S"&!MP?/\
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MUGZ?>U!(\#D9Z;XQ[ACH?G^[0WE]10>(IM'_ ,OKEW@/^ ?<'YN7_%9Z/O\
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M:/\ Y?W(.SEV8'W!!R_]5GJ#XN?QLY)S[O';U_H//&=]Z:6\OJ/ZU$.(IM(
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M]P?G]7UK/3]_GW<^6HR,YSCR.^3Y;[]?'P]#X-+>7[4\HIM'\]^N7\ ^X/\
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M;LA7"KT2IQ8)#)V>Y6")J]=C@75*BB+Z:FW;&-: LL<B*0N'*?6*G*F3F<P
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M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E>:]]6->V;8,^
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M'2E<9W(Q[#H>'OV;+K>EU7A;I!MUG0Y=/H=<<G3Z/2+TNCSZ/2#GRYAI2O/
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MOD>(&3^PJ*C\OZ>CL[?1^G:P?+IY9'AGR^'F0=^H:GW]_O4 ^\ ^CTA][O\
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M(8I3D//Y [.?=Z^[Y0[0Y_'H?#P]Y)Z^/CMMXC;8XI3N\YA\WR_IV#Z^6A)
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MO)Q.Y]MM;CABVW'9+*YM;BZ5;*XX1?6MO+#>I-PYY[DV\5TC,MLI6<9:*Y.
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M5DHE.P5><<U"(M$PTAN&M,;TH#-5VF:P6/GF5TFK9$-#6.KUDR6.FN.YA=M
M1)IINQFG"GW^W2LT\=;M[A@>O[B6NX.WWS=/#X/M^/2!E?#&$$)6PMJ]?<&1
M^7II*ZTO$S9:%C8ND W?ORV=LT:))U6WT!C,>'3"YYR:4K9C4;1$7>J5BZ5]
M95Q V^O0MHA%UT%&JZ\1/QK:6C5EFRP%5;JJ,G:)U$%2@HB<PIG #%$-*54.
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4KS7OJQKVS;!GP$L9?2 W/:4K
MO:<+;VLGAT? 2VB_1_Q]I2L[=*4TI32E6M^L=A3V?'RO]9_%OUTE52+*Y)^M
M_4_9\HLFU38IJGN/BCV1'5(R119D4-(B<K5)-N401(4@*5=+2E-*4TI32E-*
M5C?9MGVUVZ1^-HFW8(QK9HW#\Y)63&;.<K3*30ILQ,S*5CEG,.5V17JTY.P-
MVDV_9+"LP=RK"-D%VQW4:Q5;J5P76RS::]>Y>DG>WK%+A_GQ$6^8G:M1C#KW
MY(THG/*!-J"CS$ZUA11L;A5IX*JXLB"%A7.I-()/B*5C[OSQU1<2\-?/..L:
M52#H]&JF, CJ[5JXP1C8>):#9(IRHFU:(%*4#N'2Z[MVN?IN'CQPX=NE5G*Z
MJIU*R>W.;J,![-<22N==RN0FN,,4P<I"0LI;GD':+"@TD['()Q<*U-&4^#L,
MXJ9\_63;E40C%441-TW"B*0"<%*UE?\ PC;@N?=OUS^"'<1^2+2E;?,:Y,HV
M8,9T+,6.9]&R8VR?1ZQDBBVA-I(QK>>I-S@F5FK4\1C,LXZ58(R<'(LGY6LJ
MP8R#4BP)/6C9P15$BE6 #?AM,\*:,AS#&)NWI'3I)!6N75%1*)9HT=TO9GP*
MUHGBVF>!9)HTDC=I'P6HN8JR,95M-+1Q7#I!2OQ0][.%L@X5O>>XA:R-*+CV
M$:SLZTEH%Y&6]-!]!-IZ/C_8R^*V<DEY5!XT0AF?7&2E57K([5T9!VDJ*E<2
M8W76:$M,11'NVC,*5WE8&^V].OJRF+TDG=1QZVH+B8E8&P^SL]8GGRBV0XJ)
M3A$)AN^;33"4;O\ P6/\5RLHI5FH;BA83NR[9/%E8MF1VLY-TZM4]_%3&/8P
MMEG;=>\?8Z!J>(F+BUM%>:1%FR-$LGTE8(!@S,,5-F2.*0U]6PJ5?B'W?TN0
MO6*\8R%)R-!WO)>0<BXQ>1CR!;/(2AVW&=-L%ZEF-JN<5(/JF<T[7H'QI4&T
M++2DI-14DTDEHZ.00D@8J5DC*4^J3DW!V69K<'*V&LM9UC79J0C&;R3A&5G;
MM&EC:1;U=%1=DVG6K!DWED6YR)R"+1NFZ*J1$@%4K'Q/8WLR2Q[(XE2VJ;>T
M\82]N0O\IC]/$-$)3Y"[MFQF3:V.Z^6#",7L#9BHHP;RJC87B#!55BDJ1JH=
M$RE8>\2%JV8YIX0#)DV09LV?$EKS5HT:HIMVS5LWVE;J4D&S9!(I$D$$$B$2
M112(5--,I2$*4I0 %*S?W,;H<8;4*95+ME).XO&5ZR=2,.4Z%H5.F[W:K)D;
M(KQQ'T^MQ%<@$',B[=3+YL=H@8B?5@X.BF8P&5)S4K5GD/B[[J:U=K+ T3@O
M<0+)5/BI1=I7KXC ,*BE:8U,"]3+DK4_%>.84KCF8 8R/]4I='[?O#2E9S[>
M=]\!FNS8WQG=L#[C=NF8\B8]L5^0H6:L46:L1K4*3[%4[S!1M[=,&]:LK^L.
MKE HN%(I04GB;PKEJ44>8@I6=^E*:4II2FE*LY>]O&!\H5ZY5/)&&\9WRL9$
MM$7=[W7[=2J]8(BWW*$@Z[6(>U6)A*,'+:6L,97*C5X)A,/$U7[6(K\1'HKD
M:L&Z2:E<=OMMV]M+_ Y5:X/Q.VR95J>CCVM7UOC^KHVZ HK=BK&-ZA#SZ<86
M2CJXWC%UXU"':.$F*,>NLQ21*U542,I5$CLCV<C04<5#M9V_CC1O<C9$0H/U
MI*-[$4KX= 6I[@G7_$GBPMC,T,+,TN#8'HLOZC%;P8 2!2K8;R4DD,@\.Y!!
M--%%'?1"I(HI$*FDDDGM3W6D3333( $(F0@ 4A"@!2E "E    TI6>&E*:4I
MI2FE*:4II2FE*LI?=MNWW*=;G*=DO">+;]4[-<"9"L-<N%%KEBA9J]IM&K E
MQDHZ5CG35W92L&31CXZ63/("S;I-17% H)Z4J*&VW;VVR &5V^#L3(9,+328
MZ+?D<?59.VEH2;!.*3II9XD6$B%:)%(I1188''@!8M,D<" ,RE0!2K091PKB
M# NS7<G1\)8PH6):<IAC-LVI5\=52$I\"K,2&.YPCZ45BX%DQ9J2#I-LV27=
MG2,NHBV;HF.*2"1"*5=C;%^QLV]?O'8F_P"@4!I2KXZ4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2O->^K&O;-L&? 2QE](#<]I2N]IPMO:R>'1\!+:+]'
M_'VE*SMTI32E-*4TI32E-*4TI32E-*5JOXB.]/+^U>X8:A\71=8DHN>@;I>L
M@#.8KR%DT#PE2N&*ZRWAYJP42XU>+V\U&4C[U9I>4W!Y/:6#'52=55JREHU0
M7IDEU*LI-;\MV#*<JK5BGMW/%[I;GD6A;:S*U.[K+89D,?;L\<;9_'>97:64
M$VV86DY"9#2OJ4344,/N&=CB3T--^^2D26!BI4KWC;NX-[P[\O4?/ULJ$1GN
MQ.\PX=;,J?6;?%U;(-EPSGA[BE_9:M%O7%N5J<795Z^VF4(*PV^55A321XP9
MZ6*S%^JI6QS>OLMPEO\ <!3VVW<&ULSS&=CG*S8))"HV!2LS8R-3ED9F(,C+
M)MG9DD2O4$Q<)=08%TN:8B7GSTI6E;_X)SPC_P#)[<%_#6\_F_I2NP)B+#%*
MPE@[&>WJC$EV^.\2XKIV':@F^E7#B>0IM&J<=2X$CR<1!JZ7EDX6,:@O*H@W
M74> 9VF"*@AT5*PDI/"FVX44]Z5C9W)+E7(.(IS"\\8[C'L*B6J3XXM!\_:,
M:?CJM1H6A1/$%2!S87;-X]EW2DW+3PRLS++R!5*NU4M@F!JQ3[O2'8W:UPEY
M:+1CH+!9A;.(>)]BK.F1\=##5V-;;",) 1L8C#RDRUF)UJ^CV\N>56ENM>*J
M5,9#9XG*6EA?7VXO<0XR T@+=4%;BK+8L4=N*==&U/;RU;:5U3$YJ/6D2GI4
M4]3FJ?5:[:7,DL^?RD](KG:BS4J@1X;F#X\M6:4^SY,H4+CB<9V;$==K,C2U
MH7%%A+>L=Y&FY:KH62BV!S+JVJUXPJ[^;:WUW<HY$/&R<"SA2R[P3J5?Z$VU
M4J)>XXFG4W;I^SX[RA<<Q^RB8>0A9:Y7^]4>W8]G9:W)1$!$PZC<M9N+MC%1
M==BZ[&Q",5 ,V#9&-C09*J5D1I2FE*U.\2O_  Y\(C_.60?T3MU>E*_/%I_6
M_P /C_.R;!_QG.]*5MDTI6">8?;!-D'[R.]W_G>UG2E9V:4II2FE*:4K GB$
MY^RS@/%^/G6%4EE;SD3+450TQAL13^?KFVA"TZ[7*9>TG#%:M5*E+U+MT*BF
M$FD2Q-6]<JRL_;'#=^2#!FJI6OZ.XDFYP<<,]S;XF&7^,:P&.,:W7"4)5;":
MWSN2+?LYB-R4]>(?(BMX<!6H6#N5CCJB%)>TN;.RJL#;9%]9WLNDW49*D[??
MJ1\?@:J=/=7OK6O2^VDN5-M),LQ^.G.X9QFLV&K.-&=45/%<+;TL3%QP&9@=
M(39+K+G2=W@MW640Q<G'R/L;&PO_ !H1457V5MVF+LUW[A6UQ*;;Q>8+AN Q
M-FB;QJ#&=,YKL/>=DNX6V=6:6<1:40X*R3M4<AT"R!GA@4+UC<JA%B)J5L6W
M&;I-O>T:B,<G;E<M5##5 DK,PIK"UW5\HPB75HE(^6EHZ$2620<&%\[C8&8>
M(I]  ,C'N#"8!* "I77 W!<33:A*[E,/&Q=QX<EU;#N6+OE5SER-J"^T]Y6\
M)UV.H$U8J!&TQ_:MH]BGV,6^NK>+K"2UTEKS).F+@6YWY7YPDR*5O V?;_\
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M6IQ*43H+D,)0$>0*54'%I_6_P^/\[)L'_&<[TI6V32E8)YA]L$V0?O([W?\
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M?7/J3D= ?,BH^_*G8/+M\_I]7\GZ<M3UQO\ W.3G!QUV&^?G2H#Y_D^3O'F
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M9 TICJX>!V%+V8Q;5[)NY>%7L0/WT-,]1*,7*3MN@HG'NSC&!UWR>A/3S/\
M.F3Y^/H=_/[VQFIQ9.&OM$MS'P">Q]+.2(X/P9M[C';>]7.-E:_C_;7:92Z8
M66K<O&S;24@;C2+1+.YAA=XQXVLR[D$"O9%PBB5+4[8^&!@>(\<@X/4[XWP<
M>L!B/GGY]:^L!PWMI4 YI4D-"FK%.TO)E]S"-ENE\NMULURR-D['SO%=SL>2
M9^SSDI)W]64H+PU:(SLKA_'1\<W9HQS1J5HB!1 Z=#\=]\;'Y8_?K4ZCY[=/
M#I6,.:N#7M_M.![SBO"SR8H%HL5?QI1:U:,EVG)>:(RE8GQGE.O968X5IL?8
MK^TFL>8WEIFOH-ET,;V*I3D4'@3V*E$'<1&F0C&W0CR^'A[SY;>./*@8@[[C
MW#Y^&]6VG.#C)9"VFPNUK+.:HVZ5M+>#1MQOB]Y!WZ<K6,\:5=5@2:P3A=2_
M9-NUZB8>R1C:7BG$S<[M:RHM;I;"DB@379)-F/#QSTQX8WZ[^77X9J0V^<>&
M/><]3_M6\Y---%,B*1"II)D*DDF0.B0B:8 0A"@4.12@4  H    <@#NU(/0
M$>?@/@!D>>1CS^585]/T'MTQXYVP/D=O+T(\*5#EZ^?=W^KM[P^+T^?O\T^>
MV<$8&-_+'CC.<]!G? \E?KG_ "?+_MTV]X&<D> \OKC /KMO2OSY^7W^7=W=
MGG#G_J[-1^WEL.N>NXZ#/3&1OMDTIV]W;_LY=G/M][F/?V^K0#!]>NWJ/ ''
M3KL#Y>%*#S^3UCS\W>!1#S=OG^+3IT/A[L].[CKMOOU]<;U.WC_3S\2//KT^
M/A'U=WZ=_O\ I]/>(=NI&<>O08\\'YD8'J,;=ZHIZOO>KU_IR\WOQXXW]<GH
M/$=,'P)/S\33UJ'?[P_&'=\7R]W9YAT\<;;GY;8QZ8\-CG;%*CV]WO\ J]/(
M/3W>C[_;IL3TSU/E\=\YR?#TZ;X*H=_?Y^SW_1ZPY=H_A[M3G /EL?'J=]O=
MU.<Y\MZG]_?]]??^]//^G/D'Q>?LY]H]GHUCMG8_U]1G?(^>^,9\7A]_#^?W
MTCR_3N'L_3U=XZDXVR=\' (&!C(QTQU_;H-JBH (\_-R[/?[N?Q^\ =P\]/#
M;J"1@=.O4 ^9./4'&*?8J/?][M ?C[?T[>8:CQ)_V'D ?IMC'@2*?>*<OT_#
M^$=9=/3!\=O/H"?(CPZG?:GG7F2_53GML=M\W]@W"_9Z/]QY/L_3[W=K ]3M
MCTK<OZ1]^-=VOAQ;$<>6_AY;#;8]S7O'BGEHV8[7;$[BZQN_SY6:S&NIO"%&
MDW#"O5N'NK2(K\&S5<G;Q,)%-6T;%,$V[!BW1;())EC-3@>0^59G>3OQG^[W
MOD^>UN._G[I3 \A\J>3OQG^[WOD^>UN._G[J<GS/SI@>0^0IY._&?[O>^3Y[
M6X[^?NHS3 \A\J>3OQG^[WOD^>UN._G[I3 \A\J>3OQG^[WOD^>UN._G[IFF
M!Y#Y"GD[\9_N][Y/GM;COY^Z4P/(?*GD[\9_N][Y/GM;COY^Z4P/(?*GD[\9
M_N][Y/GM;COY^Z4P/(?(4\G?C/\ =[WR?/:W'?S]TSCI3 \A\A3R=^,_W>]\
MGSVMQW\_=,GSI@>0^0IY._&?[O>^3Y[6X[^?NE,#R'RIY._&?[O>^3Y[6XW^
M?NF3Y_?3]MJ8'D/E3R=^,_W>]\GSVMQW\_=,GSI@>0^56[5VE[94,GM<*K;M
MMWJ>6GM5/=VF/#[\-P86QQ44WBT>>P)Q'UP?"C1A7C== 7'0Y=)%00#H$,8+
MXX9Q%N'-Q86=R>&)<BS:^$;>S+=% X@,N-(D*%3IST('B!5<W-J+H61FA]K:
M$W M]2\TPAM'-T==&K*Y\2#CH:JJP[$L)5"%D+):]S.\JKUV)1!S*S]AWW;@
M(6%C6XJ$2!>0E9+(C9BS1%55-(%7*Z9!44(3I=(Y0&M!!/<RI!;0S7$\ITQP
MP1O++(<$Z4CC#.YP"<*"< GPK;(\42-)*T<4:#4\DC*B(/-F8A5'3<D5*X;9
M;@"Q6BXTF"W0[S)6VX]- DN]>8[Y]Q*\K5CVB/4EJZ6::$OPJ,1F8Q%5]'@J
M >$-DS*$YE#6R6SNX+>UNYH)H[:]YQM)G4K'<"W<13\ICL_*<A'Q^DD ]:Q2
M6"226%'C:6#1SHP06CYBZH]8\-:[KGJ*M',XHV+5^;MU;FM^.Y:/G*$TEWMS
MC5^(+GKKZVA7VQ'D\$KT,B'3;.(5JH5>69F.+R/2$3.T$@*;ETHNS7:">&UG
MBX/Q"2&]:)+206TFF<S,5AY61WEE8%8F'=<[*355^)\,C>>-[RU5[9'DG4R)
MF)(QER^_=T#=@=U&Y %<R"PQLCLM1M]]@]].YI_3Z 5J:[SY.(+GE%C4RORE
M-'#8!<9$15BPD^F4L9X6DEXR.()L?"%/M=8S=G>/6]S:V4W">()=7NKV2 V\
MI:YT$A^1I!$G+WYA0GEC=](WJ8^)<-FAEN([NU:&''.DYB!8L_IYF2"FK_3J
M U9&G-2&8Q]L'KK"MR<[OVW,Q$?;XR5FJVZD-_FX1JC*Q$'*F@YF40,K?2]6
MPBI@AHY^[< BBT=E%%8Y#!RUOA[*]I)WGC@X-Q"5[62**=8X68QRS1B>*,XZ
MO)$>8B+EF4Z@,5J?C'"8UA>2^M46X5GA9G4"1$;0[@G_ $JQTLQP =B<U<8-
ML>TX]VJ&.$=Y>ZIS?;]!JV:EU)GO_P \O)VRUU)@K*C.Q#!KD999W$*1J"SY
M"0(7P5TV156;*JD3.):'\(XJ+2YOSP^\6RLI1;W5TT$JPV\YD$0ADD90%D$I
M"&/.I6(# $BK7M=GSHK?GP<^X0RPPAT+RQA2QD10<E-.3JZ$9P:JE'97@%S=
MW^-$-T&\Q:_1=:87&1J!-\VXDTZSJTG(NXF/GG# +]UR<8\DV#QB@Z,7JU'+
M95,!Z11U7-G=K:)Q!H)A927#VJ714\EKF-%D>$2=#(D;JY7J%8'H:V"6 S-;
MAX^>L:S-%MK$3,R+(5ZZ2ZLH/3*D>%<27V;;?H*^4O&,MN7WO,[UD2'N,_3:
M^?>?N=46G(C'XUP+@]2=HW)6.:EA1MM=!5)^\:KN?&2?@*3KJ'74916-Y-9W
M?$(HF:SL9;6&ZG#H!#+?>T>RJ5+"1C-[+/@HK!>6=974NJ&G@2>&V9E$]Q'-
M+#'I.72W,0F8$*5&@SQ9#$$ZQI!PV*4D]N&TV'N[;&K[=YO'+>W5YA,:A5FV
M]O<Q(2K2\V6BRF2X&O2J$?<W189U+T.&DK,Q6ESLF:\<@42.16<-D5K,?!>+
M2VC7Z64YLULY;_VEM*1M:6]Y'P^:>-G9>:L5Y-';N(M;K(WZ<!B-37MDLPMS
M/%SVG2UY0[SB=X&NDB<*#H9K=&E&O2"H!SDJ#.YS:AM>K%BE*E9=X&[&N6.$
M@8"T3$5/[_,]0SB,KUJGW%4K4N]&2R,V2;LYZS-5X"(444+X?+I^ -@4<F(F
M;3#PSB5Q!'=06-W/!-/-;Q2PP22K)/;0+<W$:<M6+/!;L)Y0!W(CK;"Y-9O<
MVD<C1230)(B1R.CNBE8Y9&BB=M1&!)(IC3/ZG&D;U<CR=^,_W>]\GSVMQW\_
M=4,GSJQ@>0^0JA6&SG;W)Y%L6)F.YG>ZXR'4ZO6[K8:V7>?N>*XC:Q;G\[%U
MV54>J7(D8LG)OJS.-TT&SY=XB,><[IN@DJW.M<>QO([&#B3PLMC<W$]I!<:D
MTR7%JD,L\84,9 8TN(6)9 IY@TL2& T+<6[7$EHKJ;B&**:2+2<I%,TB1.3C
M3AVBD  )/=.0!C-=>3OQG^[WOD^>UN._G[JG6_ \A\JLA:MO^TBDW,V/K1NU
MWLQ-Q+8,754T*KO%W7+JA/YI>66/QC'>%,[.X8"I:GE0L:+=8'0MH\8Q0\PM
M')KM3K]>WX%Q:[M/;K>S:2UY'$+CFB6%1R.$I;OQ!]+RJ^+9+F L-.7U@1!R
MK!:<E]913&WDE59A);1%-#DA[LR"V7*H1^:8I,'.%T]XJ",UKDK9SM\P_2)[
M(^1]S.]ZL4JL(M'$[.N-Y^YY\C'I/Y%G%-#G:15R?R"W72#]HV &S18Q3+ <
MX%3*<Y:G#["\XG=PV-A"T]W<%A#"K(A<I&TK -(R(,(C-WF'3 WP*W7$\%K"
M]Q<,L<,8!=RI;2"P4;(K,<LP&P/6JZ\G?C/]WO?)\]K<=_/W5//AX5NP/(?(
M5(YW8K@^K(,7-FW-[R*XVE)>.@(QQ.[\,_Q"$C/3"X-8B$8JR&16Z;N7E'(@
MWCHUN91X]7$$6R*JGVNMT-O<7#.+>&:=HXY)Y!#&\K1PQ#5+,X16*QQKWI)&
MPJ#=B!6#O%&%,C1QAG6-2Y50SN=*(I8C+NQ 51NQV )J>>3OQG^[WOD^>UN.
M_G[K5D^9^=9X'D/D*L-DG!>S_$-G5IV1=W6]BMV)K0IS*$BR4WA[L9%&&Q_7
M"/CRMJGY*'LLA%U^+(:-?-V)YMZP5EWS<\?$)/GPD;F[%AP#C'$[<75C9/<0
M->0\/1A+ AEO9R@BMH8Y94DGD_,1F$2.(D8/*43O52N.(6-K)R;B9(Y!!)=,
M"CL$MX@2\LCJC)$G=(4R,NM@534PQ518LVO[7\U-91UC+=5O8LIH$(?V01WV
M9NZ2%GJZ>?CPEH5"PUNP6V)L$"YDHPQ9!FTEXQDY59G(X*EU1R&-HXCPGB7"
M6C6_MGMQ-S>1)KCEAGY+\J8P3P/)!,L<G<=HI'4-W<YK9;75K=AC;R+)HT<Q
M=+))'S$$B"2.15DC9D(<*ZJVD@XWKD,MJVV1^URP_0W5[TB,,&RTG"99?O-Z
MVYN.8TF1A:G$WJ53E7DA<VK91O'U*=BYMT_8JNX])JZ$AG7A"#E%&'X7Q%&X
M:AMI-?%XHY>&(K([W<<MS)9QF-49F!>YADA5'".67].DJ2%U:,+HB6/%BS)=
MLP*K RPI.VMF &%AD20L"5 /7((%=P>PK#MEA8BQP&XS>S+P4]&,9F%EF&^#
M<6X8R<5)MDGL>_9KDOPD6:O&BR+A!4@B51)0AP[!#5*:*6WEE@F1HIH9'AEC
M<%7CDC8K)&P\&5@0P\P:WHT<B+)&5='4.C+@JRL,JP/B"""*FGD[\9_N][Y/
MGM;COY^ZUY_K66!Y#Y"J6I.R; N2*K"7FA;G=YUMI]D9A(0%D@M\VXE_$2[$
M5%$0=,'B-^,DNB*J*B?3((ATTS%[P'5F[M+JPN9K.\@EM;J!N7/;S*4EC< '
M2Z'<'!&Q\#6J&6"XB2>!XY89%U1R1D,CKTRK#8C;J*YL'L6P?9RRAZUN<WD6
M$D'-2%;FCP>_#/\ +%A[%$F3)*P$H9AD5P$?-1AU4BR$6[%%\S,HF5R@F)R@
M.$L%Q;F/GPS0&6%)X>;&\9D@D!Y<T>L+KAD .B1<HP!TDUDCQ2:N6T;Z':-]
M!5M$B;,C:2=+J=F4X8>(%?N>V)82JS$DG9]S.\NN1JK^,BDY&>WW;@(ABI*3
M3]O%0T:1W(9$;MSOY:4=M(V,9E4%P_?NF[-JFJX633-$,$]PYCMX99Y DDA2
M&-Y7$<*-)+(50,=$42M)(V-*(K,Q"@FCO%$NJ1HXU+*@9RJ*6=@B+EB!J=B%
M4=68@ $D"I!3]G&WV_2-YBJCN9WO3,AC:W+T.[MTMZ&YYL,#;&T3%3B\.L=]
M<FR3M5.*FXMV+F..[9"5V5(KD5TETDM]U8WEDEG)=0M$E]:K>V;%D;G6SR21
M+*H1F*@R0R+I<*_=SIP03A%/!.TRQ,KM;RF"8:2-$H1)"AU*,]R1&RN5WQG(
M(%<>3OQG^[WOD^>UN._G[JID^9K=@>0^0IY._&?[O>^3Y[6X[^?NHI@>0^54
ME%[*\ 3=NM=!B=T.\R1NE'9UV0N%8:;Y]Q"TS7&5M1?N*RZEV1;\*K-&<0BY
M!6-.J  Y39KF3Y@F.K4EG=Q6UM>RP3):7CSI:W#*PBG>U9!<+$YV9H6E02 ?
MI+C/6M2RP/+) KQM-"L;2Q@@O&LNKEEQU ?0VG/72<=#56^3OQG^[WOD^>UN
M._G[JMD^9K;@>0^0JC*3LQP'D9E.2-+W*[WYQG6KC;:!-KI;T-SC0&%OHLX[
MK=KACED+FT465B)M@[8J.FY%F+DZ(JLG3EN8BQK5W975B\*7<1B>XM;6]A!9
M&+VMY"EQ;2@HS "6%U<*Q#KG#JK @:89H+@2-"RN(II8'(4C3- YCE3O 9*.
M"I(RIQD$C>JS\G?C/]WO?)\]K<=_/W57)\S6[ \A\A3R=^,_W>]\GSVMQW\_
M=,GS-,#R'RJ@,:[0-NV8*R:Y8WW.;W+16@G+)6QE6V\_<^R2\=U"=?UJQ,01
ME+BQ=&-&3<8^8'6! 6RYFXK-%G#8Z2Q[E_P^]X7<>RWT+6\_)M[CEET<\FYA
M2XMWS&[K^9%(D@&=2ZL,%8$#1;SV]U'S;=EDCYDL6H*1WX9&BE7#*I[DB,I.
M,'&02,&J_P#)WXS_ '>]\GSVMQW\_=4JWX'D/D*>3OQG^[WOD^>UN._G[ID^
M=,#R'R%/)WXS_=[WR?/:W'?S]TS]^[I3 \A\J>3OQG^[WOD^>UN._G[I3 \A
M\A3R=^,_W>]\GSVMQW\_=,TP/(?(4\G?C/\ =[WR?/:W'?S]TR?/[/6F!Y#Y
M"GD[\9_N][Y/GM;COY^Z9/G3 \A\A3R=^,_W>]\GSVMQW\_=*8'D/E3R=^,_
MW>]\GSVMQO\ /W3)\Z8'D/E3R=^,_P!WO?)\]K<=_/W3/TZ4P/(?(5Y]'U5'
M@&G;>N(MC.OT^?R79RW+:'C>]6&<RODRYY7M;Z>4RQG2FD_KGO,M,S",:VK]
M,@6;.)2=$8-#-UUT$"+/')U%37H2<+;VLGAT? 2VB_1_Q]I2L[=*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*5HQLFW/>$\W3+;R6&+*PK-0N\"$+$0IKBS+E
M!SM4BZPI@:2BF<:<A:.C"S-9EY[,P,G-V1FBR[A-%:'"53(CK[!!QSLNO9T=
MEGXC<"*7LO-S9O97/#E[227 XS'(SC_%F:*XB@X5K6T,/*74)>42:\5)8<8/
M%/XNMM"2G%X]"<[_ !9X6L1X<R!-/(Y3))+Q$*TPDU%1I$@"5865V,;P+3MW
MM%)LD-E*PV>][0<BMKA!6S-SN=CY+<!7-R=;G\41J#>0R \AH^2/AUO-,8Y9
MAX-5S,S)LY]R$B)2CV(NV'9>VXY;WD$O#H8++M18-:S6W"%@DCX)/P&>#B<A
M*62RO'_%#"[B35<Z@7A4IFJ,_!.+7/#IK=UN7DN>$W8F2:]9T:_@XC#)8J T
M[(C-:"505Q'I.)"& K8M@W&>YR RSN!LE.C&^(<?V\FVL:! 9Y+*Y<7:5NKX
MPEHF]UZ.;U+-3=S"6J/L*S!"5G)*P3S&3<)J+IDFRB203\-QCB' )N&\%M[N
M1N)WMK_'O;9N#<OABM/<<1CDLYW:YX25FMW@#M'#'!"\:D*3$<H?0V=MQ&.Y
MO7@ M8)3PWDI?![HK#':%)XE$5X"DR2:5:1I)$8@G\S.H8NJ8-W(0VP[<'LN
M^QJLTQD&49Y]6@,MQ%FQ<:CY)<7.ZS=QKDP5W)WII<V]IL;26;PCYK-5N/;L
M56)3.Y;P8 ,'H5XOP&7MEP3M7_'[>*RC;@JS\-EM^(^V6"VMI#:3Q:8[-[5K
M:!HVF1HKAV</W8M1(KE^P\03@/$N"FPEDN&CXB8[Q9+;DW;7-Q--&V6G6832
M*ZJXDC55(WD*X-41N!VJ[G-P5Q^O17L+W'%4;2ZUM=I[VAKV7%266\NI8LRF
M%XMMCCVC>UVC&3=W58]1$E)1NL^?QF]:&!RW:H DD-O@O:/L_P $M?X5/Q:U
MXE)=7':*Z6\6WXD>&<,/$N&^QVMN[M;6_$"MRX8WALX,QHXPS')K"^X=Q&_E
M-['9SVJQQ<*C-N9+/VRY]CO3<S.HYLUJ&C7 MQ/*0S Y";9K2F8_WK57+M S
M'EW!-\SXI]C[N1Q4C$%F\'H6EC'W;,</8,5US+K@]QJE2<2"E*B0);IJGMYQ
MH@95- K=^[*X.>I=WO9.XX9>\+X9QBSX*/XUP'B)DY/%S;O):<*D@XC<<,46
MMS<K&+N3-M%=-"YP3E%P!N@BXQ%=VUW=V5Q?$V'$K73KLN:BS7L4EI'>$S0Q
M%C;IIF>$2*#D88[F?XUV\YWP[>.%]77N&;;;V>VNGY6A\PW^HR6.U:G!.\QU
MYA!PD7&*6"^0ELFXK':Y5FTXLWKINH@&;=:MMYMPH$:GIO\ C?!^*6?XA3IQ
M6VM6X_=<-EX78W27WM,R\+N&GFDD$%G-;127JX:%6G!,SE9S$H,E96]E>V4W
M9F$V4TZ\.@GCN[B!K;DQM<PB%57FW$<SI V=9$7^6 8P[=P77WEX2W+Y#S79
MI;%2%Z1I,SB?:U5RR=0R G35DYBM;MI&V94"/.WLL+*1LDSQ*Z*[?RK4C=61
MBQ)$L'3UZF$>7F]E>+< LN$V\?$6LC=Q<2[1W!CNK'VH&*X[,QVW#>9JMY8Y
M(VXDI6.)BP27\V140ZS9XK9\1GO9GMA.('M^"QAHKCDD-#QEYKW3B5'5A9,"
M[+@NG<4LPTUB[9ME.Y6T3IHR4ALJ+UK%SWB=M,)3"6:'[:R1$#DAMAA]M>C2
M6U&^IW%[%RL[ 61W$L9^5<)QJT.W+;$V34C%);T5OVLX#;P\R.7AHN.(K^'K
M<6B/"D:WEFL&XLG:&0VQLC:I)%#/;K*\,8+B5O9M;:RO-EX-Q"67#)=&*V7M
M,EDXO7$B+='A[\,3FBX$[(SQ3&-9'(3EJ)=(T@_"V;9]VUK>4NR90QAE7)3>
M)SAM2R+;H2KY7KE:N#^+JFPE[C?,#JM39,@UPD4^',L@\B99M'SD(>QOG+UT
MW<K1+U65&;7M!V:MDN[?A_$.&V#2\([26-M-<<-N+BU22Y[9I?\ "UGB]BGY
MB?PJ-9(F>*80(JJRB5!'2?AW%9I();BVNKA4ON&W$J17<<4I2/@$UM=F-_:(
MM)-X^A@KQ\QF)SH)>J*N.RO>??L"3%7R/6+O=[(RP%MU\30K[*[)_(N[=1MV
M>2K[,4YQ++W&.92UUK^"9JLP+ZP2[L(F3E6K0[.?=R$:U>-;=KVK[*67&8[B
MPN+.S@?C?'.;*G#72-;6\[-6%E'<K&+1VCM)N,Q3S)#&G-CB+ZX421E;1-P;
MB]Q8&&ZCGN9%X?P_2ANAJ::WXM<7!@+&<!YTL7CB:5VT.X!$FI05NZGMUWO/
M-P&1+=%2V<J/'N/9"O@Y1.VUJ9Q_7J"_P0O7J5CG(9Y'.CQVREJK<3M4IA2)
MQ=<';NW,RVU&]R+59=P;EGCO9%>"6-K+#PB[=>2.+@VMQ%?3WJ\8$]W?V0CX
M0J/'<6@;E<SB-LJVS^RM9QL *M?P_C3<1N9DDO+=,2&Q[\;VZ0GAXBAM[@F^
M8JT5R=3!+.9FE42BX8$XNML"P!G+'.4\N7>Z8VR5C=6T[8]O]#2F\N9/B<J2
MU@S%2SY$6R%--'C2[WA]'UMS/S[6881ZZS%FLF^</6T9'JOG$<VY_;7C7![_
M (;PRSM+^POQ;=H.-WAAX9PZ7AL</"[L6 L8F5[2S1YUA@:)W =P456DD"+(
MUC@7#[VWOKNXFMKFW$W"^'6^N[NENY'O(&N3<OJ$\[",R2!U&54ZBP1-148Z
MNMNN])YA/%==]AVXR(O43?VCK==+#FIA;GF:Q\4Y$096C%\8?<74&C6NQ-@D
M8*5E()2P8M6D&KF!*$;*%J7@*O<7CG91>+\1G]JX%+9RV3+V;C_A+VJ<)_-L
M6:WXC)_ KIVGEA2:..80\1",LV9(_:=0HM8<9-C;1"/B"W"W(/%G-VLS7QY4
MZ\ZT3^)0!81,8W:,RV9*Z.XW*TFKD-H^YQ2XXOF)>O7BZ>)+[PV)J;M]]G*,
M%R=Q.#K-N >Y*D+06,N,XW<R]-B;C4R2AF4K,KS"CPJD6]G72;]5.HW:7L_[
M)Q"**>SM.=9]O(HK6RAO/95DXO!P9+".WYEK"RQ74EK<F/7'$(@N)$A4H#O3
MA7$A/ \B33Z)NSCO/,\/.=;%[PW+RA9G&N,21Z\.^HME&D.35F93;1O]M^'G
M>([7C?)LHI4MKN3\9O):QY4ILW"Y0RC);OL4Y$J\U%MU+\_=KE0Q7#S0Q5@M
MC6)?M6S:5@2I,@%HE)]:/C_8NVXF.)V]_P /C]J[0\.OTC@X==0R\.X?'V6X
ME87,,C"R1%U<2EBYD-LTJ,S1S9?O%*3\/X]+![/+!<N(N%WEJS27,+I<W3<7
MM+B&15Y[$CV17T22A' 5X\#8-6&3<&\0ZR95W/S=:J&2JU'6['6[NLUD:[E@
MQ:O8'L\\@U-OTA77D_G2=D&T\Y:L7[M-1"B8LC**Y=FAF*1X\P&:UN'<7[#6
M_#NSL-Q=6%P]K?=F;BXY_#?\1"D*3?QM)TAX/"C0AG1<&\XC)>*HE<A]CMN[
M+M!+=<3DBBN(TFL^,01\JZ_+=G"_PQXF>^=A*<%LBWM5MW+H"R'4<T-W>U*P
M6[:MM[H=.IMXR1+XBS7A/)%EK7UR)%6^3T1&60TGE R-MM-WA2RM@6"7EGC(
M\C:FQ6:@ G7W4:#9@"'E.S':."U[1\;O+JZM+"+B?".+V%O<>P(+.&66WY?#
M\VUO:2\N &*)7T6[:QO.LA9R>UQCA;3\-LH(89[DVM_973Q"Y<3R(EP'NL32
MSQZI"K2%=4JX.T93"XL7D3;MNB+2LVSM=I>4;#:L@[P)46$2MF.?</ZUM>3B
M6TC7WE&J[+.N-ZJHNA:#KMUX:4N$2Y.DNZ>OFT@BPCFINO8<<[/>U\)AGN^'
M06UEV8CURCA4 2X[0F0QS)>7#\'O[D!K?!$T=K*H*JB-&SNXHW'#^)BWOF2*
MZEFN.+2X4W<C-%PPZFC:WB6_M8MG.\;3H2&)8,$11C6TV"[F[SB_)$CEO'5Y
ML.79OAX_6PCGTOED%Y*8S;$Y+O/B*MR3EGD-2,D3)4,*DH<\TN[JCGI]<^=N
M9=6254[[=L^S]GQ"PCX9?6</#(>W)X@Z1<,Q'%P>2PL^;/&KV(D0->>T@"(+
M<KC2JK&L8'-_@7$9[2Y:ZMYY+R7L[':9>[)9[U+FX(B8BX*,>2("2Q,1SN[,
M7)R"M>VK=! 9"LZ452\NV?;LEFG!SR6QS1<R%@+K=,7U?;6YJ#U"LV24R;7)
M)LPKF50BW]CB)*TP;VRJ,ROR+OTD#&<\.VX_V?FLK<R77#+?CAX3Q=(KZ\X4
M9K6TXC<<?%RAN((^'W$;//PSF)!+';S);AM!"$C3T9>'<1CFE$<-W)P\7UFS
MV\%YHGFM(^%B B.22YC;3'>:6E1YHVDTEP6QWJ0>[8]XD/F'<A;(6BY!7Q9E
M.'SPQQQ36.3X9A/5')-HVE8KI5'RI;WZ=X3]GI7<M6IW%J83K^1>U:SMQO+5
M!5"4\?HVD[0=EI.%\!MI;RR7B7#9>#O?W;\/E>"ZX?!VFXE>7G#;1/9#[&4B
MN(>(GDHBW%N?8F*E.0=)X=Q9+[B4RP3FUNENQ;Q"X37%</P>S@ANI6$WY^7A
MFM.^[-%+B90RR&43.SX$W?5*9#,29LNL9&@W[9L]3\"RVZ4@V>'ZEMDBJ]N?
M5&F-K1)PDISN,<X1G"'K,S89J68I2E:8RPJF7=X6_&>S%U%_"S_#'CO;+M2G
M?X8HF;BESVADG[/CVIK>.6/_  CJ82+B*"&-S'.\6 $D6/%H'%VWM6J"YX0<
M>UNR"SBX5#%Q,\E961\W"-S 8GDD=0\8;.3]>"_<92U2.3G-TNEPO-^DL/;?
M[%(NCW5Y?:'#MY*/LZ<D9W+GR]D].*R]:II!66R#6I&.H;^,(RBSM*; -'"[
M$(_%:UCMH^'BUM+6SLH^*<;@C3V1;*\D*/;-&$B_AG#S)PNVB816,Z27B2:Y
M-5W.RJ].QTK2^TM/+--=-:</>5^<9X!J64-EQ>72K>22*SW,16W:/\O$,8)6
MJ24VI;WU,9P+\C?,#')F/-JFU^*HC.,S6:-:)YRK6X6]S.4#R<>QOJ->L,PT
MQA(1*<A(61.1AY.)>^+&CA\\2%LWL_\ ,G9$7\ZZN%O87W:/M#)>-+PD2,>$
M7' [*+AXC=[)IH(6X@DI1("DD<B<QU13J;7_  SC/)U8NQ<0\-X4MNJWA11>
M1<1NGNBRK.(W<6KQ!VD#HR-I!9EPM3PNU+/N-W>4XB-Q%EZ6Q[-;];OES(<'
MCW,#"O3.:L#6RKVXV/VU-EW&6ZZ^8.*3<WK"1OL3,2%(D["5>(,:0LJ$/X,S
MKR]I.#7Z\.EDXGPN.]B[&V?#+&:^X6TT7">,VUQ:B]:[C7ADZNMW:(Z6<L*7
MD<&)<);M+J;8O"[VV-TB6EZ]O)QR>ZN4M[T(][8317!@$#->1LO)N'C>X1WM
MVD '>E" 5=_(>V'<%>^'#C#&61J_:<D9JHV4,:9"=5 ,AI*712G5G.K*S&J#
MJ[N+5"1-BML)B,RD$62DK*9N><9I.V,P,BT82Q>78=H>"67;OB'$+">WL.$W
MG#K^Q6Z]A(M!=7'!GMO:ELQ;2R0VTO$\3\M+<,(7*/%H9XS9N^%WUSV=MK6X
M22XO(+JUN#%[1F8PPWZR\DSF6-))DL_R];2 &10P?6%DJV0;4=TU?R;:\IX:
M@<@XWL]QW26Q^R\:91(YK\=A.<VJH5:"D[=5$[O,UR87B\J-8=I(OU&$W<#R
M,,A().'<<W;/C=$]I.SL]A;</XK-8WUO:]G+6-^7P[3/)Q>'M$;B:.VN?8XI
MXEDX<TIC0/%:B.5D(21B@U_POB,=W)=6BSP/+Q65N]<DQBR?A A1Y8><T3:;
MQ(@S!7FU(&[RC-7UX>^%-RF,JQDY;-<GG5*Q3N.*C%NH2[6"K3$<ODF+961*
MQ6G',\7,V5'ZLA+*N6/A<O,LZ#$R!PAW!:TS.T>%2XW;;BW +^YL!PB/@Y@A
MO[J19K."XBD6PD> P6U_#_"N')HC ?3%$U[(@YJFX;4N;79^SXE:Q7!OWO#(
M\,*M',\3*;A%DYTUO)[;>,QE+*"\@MU.E#R5[V->SFF;IL?O-MN'<G4K<#8X
M^UY7W!H0]>B<V.JGFC-,"QV\U]ZSFKL[:[@+)48%U W2,+*'90F1X.%FR1<G
M.MZO&OYAU%RGMENNSMZO'N*</N^"P/;<-X(TT\G"%N>%<)F?CDRM%:*W!8+J
M=9K23EZY;":6$R) ;B1(ED3A\GB4!X=:74/$)4DN^(!8UOC%>WL0X>C:YR.(
MR11L)PS:([J-'TF41(SF-KZ5O:SOK>EQG!Y+=Y(DTG,AP^XG*T]7LNGB';RI
MTEEG&/W"M%YN'MT5/.%HZ&L]-B[;(QQRR5L==3(13B8<,Q=MN1/VB['H>(3<
M/6PC*IVVDX;#/PSF(ES=OP>3@;K#+;20J'DM[J2V1^Y;#*2+$KZ6NQ<-XV?9
MDNFN6R> +=21W>@LD$5XO$.^DJR;&2(2LN&E.&4MC(MEDO /$F-0J'3JE4<J
M.)"@.LDJT:YL,P^&VQB#;=)-3%'B;4_E,\5F*\2IX,;0J\1/2=:R79)-%R%/
MF4(5! QT.AP_C78,7M[=W5SPU4O5L!>6K\+T6SENSL45W+;1Q<&N).:>,-*L
ML,=QP^W0CVJ)I6.#6N;'M!R+6&&.Z)MI;LPS"[+2A%XK*;:.4M?PJ4/#>44D
M>*[D?_)D5,&L_9K"FY>-V;[N*1C1E*57,-ZW&;B;W1$8VRQD+-SM#NV>I&V(
M^(+(UDRMJY+W+'KE\WA7;N0BWL2]DFXOCQ3E,YT/%0\6X _:CLQ=\0:.YX79
M\"X%9WIDMY988;VTX,EL>=;F/5/%:7RHTRHDB2I&V@2*1GMM9\13A7%H;=6C
MNY^(W\\ 658WD@FO3+^7*&Q$\UN6"$E61F!)0[C&G,F!]T%A75+B#$VYJI5A
M]AHL!@2&D=R3)&5P3GKZZTG+361<KKFS1-GL-;E*NM +Q#9K+Y&\ AXF2KA:
M^R/*%\'[_"^,]G8 /XGQ'@%S<)Q8S\:FCX YBXQP;^'1QQ6/#5'"8>1/'<"<
M2,T=CKEDCGYSB/O<^\L>)R8]CMN(Q1&Q$?#T;B&F3A_$!<.S7-X?;7$L;1&,
MJ UUI5&CY8U[5=:=LVYXM>R!:G[',MSF)W?4O8+I3*OFU] 3%XVDL'POF4+C
M@JV0JY6ZDR>3[P9I:(2EJA./8]NXC73ALV*W9ZJVW'^SYFLK9'X7:10=CQ!:
M7=QPA)H[3M*\81Y;XK8W%Q<NL*F)93'=0I(RR*K/EJVR<.XD(IY&6\G>3CC2
M30Q7IC>;A(D=D2V_/CCA4NPD:,/#(Z QLP&E:S'X;V(\@X0VM0= R;5Y*FVI
MMD3,DX> F9^.M$JUA[1E*UV&OJR$_&2DRVE7CJ%D63EP\-(N'*RRAU'9@<&4
M /+]N^)V7%^T4U[87$=U;M8\*AY\4,EO&TMOPZV@G$<,D<31HLT;JJ\M5  "
M]W%=;L]:3V7#$M[F-H9!<WK\MY!*X2:[FECURAG#L4=26U$DG).<UGAKQU=N
MFE*:4II2FE*:4II2FE*:4II2O->^K&O;-L&? 2QE](#<]I2N]IPMO:R>'1\!
M+:+]'_'VE*SMTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E!#GV#V@/8(#Y]*5
MQ&D>P8%4*P9-&153]8J5HV1;%44_^>H")" <_P#^4;F/KUDSN^-;L^!@:F+8
M'D,DX'I4!57]( SN< #)\]JY>L:FFE*:4II2FE*^1T$%%$5E$4E%FXG,W5.F
M0ZB J%Z"@HG, F2%0@B0XD$HF+]J;F'9J02 0"0&QJ )P<'(R/'!W&?&HP"0
M<#(Z'Q&>N/*OKJ*FFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O->^
MK&O;-L&? 2QE](#<]I2N]IPMO:R>'1\!+:+]'_'VE*SMTI32E-*5K_O.^QTW
MW*7S:Y@C;MDW<AD'#%5HEPSN_J%FQA2*SC%EDPKIW2*\,MDRXU<EGO,[!L'E
ME)78DA&;*$*U7D)QHY>)-04K/XAA,4IA*8@F*!A(?H](@B ")3= QR=(O</1
M.8O,!Z)C!R$5*_6E*:4II2FE*:4II2FE*:4II2FE*:4II2FE*H;)Z<DKC7(:
M4,1\I,*4:VIQ*<85<\DI)'@) K$D>5J N3/C.A2*T*W 5Q7%,$0ZP2Z4KJ.8
M16XK6WBIXY@JQCS<A<+1B[ACWZ_8\M]QIU_O92V//>3MF5FL5&N$-:2J,[3N
M,P"\9;G/8%C*T&>W%]2(.H12</((2<E'N%*S^RC;=YF7>%7Q!T)HVY;)%BCL
ME.JWM=N<O@6Q8/W0Y7PDT=X9DEK!(88QY0,;6V,G6]D>Y1KD>>&Q=3)B?J=?
M9RXUXH/#.72@ZBL4Y&%W0P&X%I<MK.--R\1M)@=Q5OLVW!3/6#<[9'L6++/&
M<.'<PTR+D"N8XS'!N<^4C$L[FA]C2&JE8ET:R>XW5S9ZK3&A4+@TC':E<R%W
M?\:B6/M>B8VGY7B&4DM/,+9D/*6W^UI168+S!9WAZY(-;C 8^V .;ICK$,[B
MKPJ;QTM=L?;*;*W1F7,E9\EV%2G'"RJ??WTKC3.]GB]R=HW7L82I[F*)3(%A
M%SV-']LVGSUIM<3*U[<1*5FS8VQV_I.Q.8@&KJ]XB)'.ZQ./JQO6K5<!S%VV
M5R"LU>6%C4E*RFVA[F.*UDK?-3ZKFVBW/&V 7<1#+S5,R/B.P1R3FC/=MU>M
MC>W#?*/M<6QK$Y?#,[A_$6V)DMW$7&-#A*TN*P'%N6$=87*E=B'2E-*4TI32
ME8"\4"U9VI6QC.MEVXGNS?*$>SI!"R6-(A2>R/ X_?9)IT=F*RX_B$&<@Z?7
M:LXB=WB>JZ;)@\D"34<S6CVRSU- @J5JAS7O7O\ @"NQ$+L-R=EC(V,'&-<L
M9'I5RW"XWW4[K;3GS<Q6)3$D16MHE6NV1I!C=:K&VN"L$A9"S*KZ;:,IU]/,
MZZXC&]/M$)&J5;[).][BG6BI;@VD*HA35IV#XF=7QC$4K;_-NLA8UFMI'L>F
ML3S$9:5I^497.;R*QEI>GQRGL5:,G3AFQG(!K*2;9RF[5./7R^H_E5SDM\V_
MAM2=Q-XJ%]@<AXWPS#['*Q6[P\VJ7-67E&6XF,QRZSGN&E(*)L<=,3T3@B-=
M7.86H\'")D7."SJ<E"1\:FV.J*K+8?G?<]GKB$5JS9=7LDK0(W:KN<J5.OD9
M0KQBG'&::W4-UU/B,:9D'&]B>/&=<L5LJOAZ;(%53+2,8Q<3$'T(&303!4^!
M]X_G789TJ*:4II2FE*UA<5O?%;=AVWZLY)H1:D>Y6W(!Z9 I7JGDM=7>.6U"
MO%U\5O%I'..W6NP+R7-4DXV.D)C*"#Q==T9A5JC>[2YB:O(*5K/H7%]WG9DG
M*LZJ%*V\U"C7NX;;<11K64HV3;3>X.\;FMC2FYF+MP/V^4X2NS,!CZ]M5H9S
M5A@&;^X5IZT:EL%8E&*LG**D#^?T^_[5-^'5Q =RF5[U1)^^I67>5;)WAU[>
MLB7*"VVN:71D8O)-FS5E6M749S&V4]PM+P7"7JBEA6U:RE+5QQ5K:]G(U:.9
M4J)BV3>IP2HJS&2MZN3?L6-\N6[?OKR%B3>S0<BYOJY=H;2>Q96VN#\7U+/L
M%2Z7/Q]!?T5S=!8HXH-$W-KF%S87,+:'MK?&&4D&*244T5(ZC-6ZS7Q -R-
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MQW=K:A V_#D,\JE=O>/Y.AWVEN'2<K4GH,9^G3HMT5Y1BA*LK*R*Y79$4K:
MF"@)D!4Q#J@0H*'3(*1#J 4.F8B9E%3)D,;F)2&54$@"!14.(=(5*_>E*:4I
MI2FE*:4II2FE*:4II2FE*:4J062<]C\<#_P;PKFX30ZKKNH_OR*'Z73ZI;NZ
MOERZ  //F)@Y=NBXFY$?,TZ^\!ISIZ^N#6Z"'GOHU!>Z6R1D;$#S'GY^G4U:
ME3-0)II'4K2B K',0B2\H!5 ,7K.PW5,%R%Z14S'*/3$H@)0Z7,>6J?\1&6
MB!TC)(DV\!XQ@]3CI[Q73?@SJ\B)<13B)0S21 \LJ0F2AD,;-I9U4@+JSG (
M!-4Z&X)XXBEWC&E$%\ OTVK&2G7L6FJNT7<-T@<+JUA5TV;NC(%4(Y+'."B@
MJ5=L1VD9(RV9X@JR!6C[G<+.CK(0K ,2H&$9E!(T\Q>\-+,ASBS<\"AM+T6T
MM^LD(CMY)+FUB@N@HG@BF8*L=Z(G>%I>5(GM(971ED$<@:-:2H^[V&O))9!M
M39&&G:X^\56:M3LF1G-0<E]L)$W#<L<J1TQ>IE!U$33%1S$3+!1)[&O'"1C=
M"S=RM9F(L(I8;A.;;W$$QDAFCV!TL8U*RQDZ)[>0+/;R QS1HV,VN)]DKWAJ
MP3\Z.[LKSFM9WUM'*UO<1PD!G5V"HKJ".9"6,D+=R0*P(JMU-P*9.8!6"F,7
MES+X\Y"'2Y]$1_W)'D!N1NCV=O(?.'+5/^([9Y&VX!YFQ(\,Z -O'RKCGA<@
M56+D*Q(!,9QL1G!S@D9!(SMD>8K@EW&D.43!4#EY&,7HJ31TS")3='F ##<Q
M*/(1*;SEY#[TGB&#CE9Z$XE!'3P(3?'B/?1^&.A'YJ-D*<H-0&KP;#;,/$;[
M_ U^OLBR\^7L3+W<_P#L_P!X=G=_N-V\N8<^7W^SG'\2_P#8'R/YG3_Y/3TJ
M!PQR,\SW]PD XZ9U8\\>?TJDQW0VE&QEC5<0"[KSE5LDTLD1?8UPHR R:YG:
M]AA9:$@W+)NBH1!)L, XM+AR*XG7;L2IFYV?;;<PZUDQ, Q:"1' ;&G2(98E
MF1F(+%A.+8+I[I<L*[\?9S@L_"VND[2^S\4@BEDGX5?\&NHDN'5U$4'"K^RN
M.(1W,KQLSR'B,'"(HM&E)9BRU7:6?04#F-6*3_\ 7G2[/3_V)#]/0/9JK_$M
ML\C;_P#$^G^7U_M7!/#2#CFY\!^6=]O_ 'MAX?[UR/K[!R ?8R7_ /??X/\
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M$;XPQ;&<@=<=:\QVT_#3LQPCLSQCBW#;WBSSV5JDB6]S-:F,2// N'064$P
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M$1<V)@1L%?2S+(C$D$JFI2<%2=M<UCZM[*VZS%@[9LY,Y4A0D>@NB<B)5RJ
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MN+I5DD_2V65BJ%?LC#B^4 $6YVXMDS"1-)FDJH94QC(*GZT.@@!%C'2()41
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MAT? 2VB_1_Q]I2L[=*4TI32E-*4TI32E-*4TI7#D699"/?1YCBD5\S=,S*%
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MS XS)Q=>9%#"G*GY D,C7DS!2K+.8)(.*M(AP4,8A6,JQ9FP0NF:-FL=4S*
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M4$/_ )02F$I5N@8HF H',</_ (X  @I]KVM98!?S%##5J;4H., 8RR @A<X
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M2,J1([P/&Q&E01D'\Q3V''[2&>YFCXMQ'B#03W28A2Y-M9-H#1V]S:VMO-/
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MU%<YU5R9I20<MW"@F6=OG/(2.5U%A667 IC)\E5T7:I3D4*4#?J:AC  B;F
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M-#);_P#.':'E.\;E<#3Q'+. - D_20P(P"V.,>WS@-2*$LTL87XH+(IA+R(
M4# D"#Q%-%TFFF8O,AU%2@7D<B15.SD;6]> \%:72O N%A(-9=OX98]YE#%X
MF:2V<MG3A!OE6<H=M-4IOQ,_$X!I'_$7MP99@L(3_F_M& L;8 =>7Q-%52')
MD&0H8X8'62?G*7*9<&00D;-82E,Y;!U@R[@#_;&$W5B?PP5@4.8@)G3$!5Y&
M.?D918H#$'9_A"I)+%P+@DC".0A'X;;L-2XQ@/;"-DP6=7!P>XI*+&31OQ0_
M$F-UC7\2/Q ME,L:N;?M?QN,*C*02W*XH9%;94TN#CO-I=V KBFL\[T%T$):
M>ZY7I(IJ&?*KF2!0#DZP1*^6.0P(\UD2\B"=4Q##T1 QRXC@G!/RY)>$<"TI
MAV X?;(KZ,,$WM(E?5)W),DZ5##)V0V!^)OXIJC+%^)/XD2<S8?_ &P[0L5U
M9346_BKZ-*C4@ &I]/3&H?(UCLRB""K2SS .&QT6 I3$H[1;+]89!-5P)$'@
M*O%1(83HG.)"]=S*LKS QPV#@_ 5>1)> <'*2AK@/:<-M9'3=W"9DM=,2C25
M*+JU8[@ :H'XE?B@5BEC_$SMZ'CTQLD_;/C\*LQ&C61'Q4,^2=6IP"@QS"=.
M_P QNMK<H',TEY5 Z9NF=0)!5PB10ZO(47#<SHZR']X8JB:@)F#I"5%YUHGZ
M&T=G.SJ,$?A/"FR%TAN&6ZET U91A (Y#D[,F>[C5%C33_JI^*6>9_U#[>87
M6"1VO[0.!G"*3CB195&-E8?J PY[PKFJW&5326>K24B+=F0IG1O&)5RE*ND1
M8ZJQ7 L!02;GZP.EUX_U*D9P5,4Q%,,$[.\%_0W!>#ZW;3$?X= A/+8H=)6.
M?677!QHSS&",VH!C93\5/Q/<J8?Q._$()I)=6[8=H  \@#(A!XE"1ACI'?(T
M*6"D-@S& LDDA']=(2:Q'9':W2%L[7725C%GBQF!U"B#8J"YV9F@NAZM0J+E
M15$KI<A"J*X3]G>%/-HCX)PGE-'W/\#:JR3*B!N]R69UU\S2N0&15;EJ2<;9
M/Q9_$L(KO^)WXA.T91)A)VP[0D, S?H7^)A8PJ%-V[VIBI?N@'[+VJT&<+/?
M92\:J"7JT$'TH_(@99-;JT!32"3(#@Q2E!,J1B(D-S, J'_O1V_\N\ 5%C_@
M7#'4X#21\,L6=04)9GD-L-'75D%B#C 7J*<?XG_B.3D=O^W 8$MRG[7=H45\
M/@JL8XD<Y_UC"*=]1=MS(K>^?V>LN(-Y-JN'#T\8<'()KS)$SG? "R[)DJ\5
M.T$>CT6[@%4Q;G4,8JX@D!"XKP3A%HRW$?".&QJG,4XM+: E0H*AV6!=>0<.
M#J#  %<EC76X9^(WX@7W$5M;KMMVSN(FC9A#/VDXW=QB4HY#:)+V1$8:2T09
M0PW(8JN#81TBRK4;.@NU+9GJJ!&SUBE(R'C6-9+LU2NDDO!WR"!/"T56$B5A
M))LG0\Q(6441YD/9_A7#[EX=-A9VZ!M:R?P^S,3R!@RMEH"Q*%7B+1,Z[@E
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M(JB9D3&>-46KU1!P<Y7"JB;Q-,=LKQE26E"X 9D95 /ZB/UQAB,'NL6 ( (
M*YK-8" ,0E@2075F5FR FY5L9WQ@>>.]C J2/L'A0*)KP)U9!@\*H1Q(EAX)
MM$G 4R->K<-61W;4@+.$58PRD9$ Z']3;HIE:IJH5WCP1IG0(ZXTQF69I0 -
M>0T@#'"L)#S)2HP6)U,K;#%W7)2X0KN=D5(W;( /<;NL&78!"P!P>F,J-MDK
M+3FYC$AY9^S?OF^4*NF4KU*Q3LBE7VK]JLP\6S(Q)8XK)%THT\'$CF.9LFJZ
MXHHK-53D/Y#M='!!V0XXL$+0H_"+YVY9MK>(W#PN)#+#S.89'[Q<%'9Y%&6#
MC->A[*\Y^U?!WGN/:2G$K"*,S++-*L*3H(^4Y!1(XUP$;6 $8Z4TD =GC7XZ
MK]94TI32E-*4TI32E-*4TI32E-*4TI32E>:]]6->V;8,^ EC+Z0&Y[2E=[3A
M;>UD\.CX"6T7Z/\ C[2E9VZ4II2FE*:4II2FE*:4II2FE*:4II2J?KM3JU00
MDFM3K5?J[:9G)>SR[>NPT="H2MEL#LS^>L,DC&MFR;Z<FWQSO9>6=%5?R3LY
MG#QPLL83BI50:4II2FE*:4K43QL2N#;+TP;% YQR]10,4?\ XQ#1]G)R#[8@
M\^F8@AT3 /Q<]?9/P+T_\[MJZ?P6_P#_ /;:>A\,U\X_%( ]F%ST'$K0^FT=
MR<GT%=0=ZQDD5#$?,UDC]6/:J4Q1  Y?WP=GVA2B',>D0@F[0'F0W/\ 9*LG
M^E@?''7W>_/Q\O';\YAD895E8?\ =(/AT&GW9QN?Y2A('S8PJ)AR,<O2 W,H
M&Z'2$@% #% ##V#V_;<@YCTA*/+6[N-MG8''AC.V_H/$]!Y;YK6ZAL95B,GI
MG;&^V#\.H!.,5.RVNRMV*\:BLMXO>=6"Z2:3=$ZA2&,8H=-!N0YD@%00[.0#
MTA'F(=VKDPLRN=.M=0!R2!G&=BV/ ?TR#6"PQGID'(8@DLN1G#;[#&3X^/SX
M;.5EXU;IME5VQB&ZQ$4B+&5%0YRFY$,1,INPP<^CTPY& P@;I]\LD3@9 8'9
MMQCH=SG/[=,;;UN"+MMG'GT&,C('KG;KMY#%346]QGR**G;3,D5NF0QS'9OW
M H)*<P3,J8Q4TD4U.K,)#=I#<N?/[03:U:K>(@912=AWUW._0;D[8!R ?#QQ
M602-<X 4XSMI'3SZYQG(\?# J6*04FBX(BLBDR5/U:9$7JZ#4_,P<BJ""BA
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MYHB,H5DU1OA\SG=N0T@#9THV,J%^H3*LT9Y<?LNN13(53(74&8R(FPC([@<
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M=RPQ.T1)9@P!0B5C%^DLF@9(8.,$!B8]Q@AM K(32)K1N6!DJP*Z9#D[YR
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MG!3]@ZRI.4F&,'6"H5B<YQ^:<8P =6 ,@+Z?G,F-5#<PGJ#@-@88 ,01I&?
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MME\;6C*L?6UE)8K=I'69W&1#Z+.:'44(R<'\*;CR08)+] A2%4/(E4'HK)F
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MNV])B CR(VMU_)R 0'O55QRL8P (]@=$OJY=G++_ *^]CL$>Q=HSZM9\//R
MXF,??KG+_I5VB'_I/",>MS='Q\OX>.FX\\>/6N4CP,=X"'0!.X;?^13@;I>S
M.^@H <RF'HF'&AQ#^]Y  & 1  YGY]NL3^/78T];+M%_^AX=ZG&W%1\_/PQO
M4G\*^T1_]*X/TQ_XS=XZ$?\ W#R\/7YU0AP5MYP%.FMD#"HE6(*2IS9!R"N8
M$S%Y&#HFQHEUO>;[10W0-S#I!RY@.H_CMV+._P##^T&0<C_ \.'0[ _^%2![
MQT^E:&_"7M$2#[1P3N[C\^ZQG?\ _@#C.=R-^M?!#@H[RV@E!M>,"@FB984B
M>S2_%24(L;D8JC8^.%VZ9N@)NBHD0#E'D!C*" &"#^.G8L];'M""<?\ H5AX
M>HXH#OX]?=@YK</PJ[1_ZKC@YSC/^*N]B/$'V -X#Q]1CI5],)<)#<]0\@Q5
MHM-XQF>.9-'Z3D(^\VV;44.Z14*0B,<^QQ#%( ',!2*FEA315$78M''(6I^%
MQ_\ &3LKQ+ALUI;6/%^;(\3+SK*SB3\MP>])'Q*5L #.!%EOTEE/>';[/_AY
MQSA'$X;V6?A?+C29"8)KAI0)(V4:1)9JF[$:CD$#<9Z5F^ZV/9:-%K,X^5H+
M%V*X*HN FIPK<RBJ+M)P]<-F=7:=-T(KD,<A#E*N G_5FZA4U0\/#^('!4E5
MI(>(O'I(9/9[<ML4*HK/>-B,:2.F5VV89%>ONNS=_.#HDMU?4"&,TB[ , 6"
M6V\@RO>_2=\ITK@OMCF9W,<Y+XQQD[D'RYD5T'\M8%(E&/>+>$/S%0"LBJZ7
M)TE6[9!4R:!CG!TJ(I@+(T)V\X")T?E<62)%R#'!:B8NJZ4&3> *IPK,PRVQ
M4;G75L<'XHEFT"M9O(6&"\TP3&H%CM 2#L<=TC/7.^92SV"9CBUSMV,[C16)
M=KK+.$57M@349+O(M9F^>,6YX-VT%1X[!F[71,5,>2!2).4N@'2L2?B+P.5=
M3P<6$R@*K!+;OJLJNB.PN$<!%UHK DC6QTG-5X>SM_$<:[,H=RN7V.EERH,)
M7)U!FV ;0BG &:_!-A.;G45#1[Z;Q>S!@*#E\C&/9L$'[QY)(NK"F GJZ?@K
M"0:MQ:>"MTR$50?*-%B^"M2IN'_4/@"2S2);\6?F#2C2QVY:-(XRD'_IC:GC
M9BP=B2"@<=]\J;L]Q&15#26J!=6%CDD )9LEB1;K^K"Y&G<;$[9,\=[)\Z&C
M(X[1[B8L_#.&BD<Y6D)Q1(I$>@FYYK*514R?A#4[A-#H-?"&3@K=RF\.)3E'
M!.WO9WF2ZX^,\B=6$J+%; ECDK@"\&P8*3E]+KJ4QXP:TGL[Q9=!1K LC]UF
MEGR(\8(_R#N06!'_ +I!4BJ8R!PY[S8ID9*$#':?C$8U9XN\L=B9+P3E$IRR
M:L$U:U1VP5\9E08I/P62:GD45)/PA4%UVJS7/A_XE<.MX>5<#B;",RA%2VMG
M$Z,08A<.]XD@Y>IR@!<1L(BH(5E>S<=GKN1P\0M%++'KURS'0X!#Z%$14JV%
M!/<8KK4[,"(FX=^2UYF(?'=X[9(0$&LQ8>!V.S\U'*L@#Q)F#<:PF1I#,RIM
M4VZ1%EG0HL&Z!E_U194=@_$OA:0RQJG$W,\X=R]K:;+R]#/GVHF29SJ+$A5R
M[$#8+59^RMU)()'-J="@*O.GPS!G._Y>8U *A=);&G 'C52/MD>;+*T483KC
M%$6P4A$%"MH65F%3(6P%7IW#]LLM1VP-VQ@D7P<RH&*L1VNF+1+K1.6O%V_X
M#:.LEO'QF:03MEYXK<9M"L:B-@+Y]; 1)N2"-((8D8.4W9SBEUK6:2PCC:,8
M6)YR%F4R'F+F%#'DN?TL1T&,**MK#\._/,0]DDD'.%PA9661<&34E)YY*QS5
MBQ;NVK]&5<T873Z5<V%NV%\DNH@W7;1[-ZX7<K=8R'IR_B9V>E6%FCXX9H8B
MN1%;I%([LR.AB2_T)&(&;00&96D=5"##&DG9+BB)-&).'!97R.]*QC52K(0Y
MM^86+#+Y?? U,YP5O#5ME>6:RH^B0<420K*U?D6;<'5JFQDR/',02#0B^N"D
M^'$B3I^%2ZSL\TX=(.WA(UJV*T:&<.N7-^(/!IY;>Y9.))/'=0RR:+2WY9C2
M<SO*%]OY;3DE8E7DHC)'K=M3A8\;KL=?S<,O[&-K(-<6LD$):>8#+1I&BO(+
M<RQQH%)U RN#(V!ME[:6OASY?DY!<L':,>MXY4QSD<NGLXW=HG.IUA3>!H0#
MEN[*@*[D4D'BZB',J0'3,FH=,GJ+7\7NSL42\ZSXN90!E4AM61L#2>\UXA74
M N2J [G&" 3\TD_"#M.S[77!674V-=S> J#WAIQ8L?U,V07(Z,.I6J%6X9NX
M!D94(*Y8]9-EG2ZZC-A:;="HJ&69B0CA0K>JO"+.47/1(IX21=-TV( #U/2,
M0+?_ %B[*R*.=P_B[.%"AWLK"4@*X.D$WZ$*1G&G25;?K@U,7X0]JHGVO^#A
M,ZB!=WN"<$$!?820,';\SIL:_27#,SIU14'-@QL\9D.Y6+'R%FGWZ8NGH W<
MNA6]@+8JSH&O1%)RZ;+JBL@GUAC$-^I8'\8>S(W2TXPC]U>9':6L9")WD3'\
M38A-?5$90%9L;]=X_"3M*[EIKS@[+NPC-Q<N"[8#-EN'##:0-RK9(!QC&.<Y
MX8F6$F[=E!RV)8YF_33)-$.:55=1ZA%T!6<P;Y2IKJ'6?-TN@[ Y& &*51N)
MS)NU#)Z5_&'@18O-!QR5HF+0%4MT67*,--RBWRC3&S$IO)@Z7_4BU;'X3\95
M<))P9#(G+F+SW,Y0!U8- 9+'N.54!BH3_4@.AF!IQ_PL<V-I=E)0%PQ_X.BV
M525C7-END6BW655,!7D<O%P9U4GB3<P?JAR^#JJIB91H8%U "RGXS=G'C9+B
MQXMDE2'6UL)2P !*2"6Z *EMB!N%.S@KWM!_"3M#&0T%WP@'O$Z[B]49(P,!
M;,D,NS*V2 1@HPJ7%X5.9CJJF7E,:"DY*Y373&XSSA40*Y(HR5%TKC,JHG,0
M53K@B5L*8F,@!W!%E3ZV?]9^SFD 6_&=0P0196H .G2P"#BQ7'3&2PVS@'&"
M_A/VD!WN^#Z1IV]INM1V[V6'#AC# %< D^)ZZI*;A/9_<J(MW-GQ>C%HD05*
MU9VFS) #M,&XG$J3:B,6XHE/X2*":J*A $$16(H4>@GL'XT=EE!86G&FD.H:
MFL;$]TYQWFXD[9(TZL$9WQBI?\*^TY.%N.#A#ISF_O\ /AJ.E;#R&0"^03US
MWC2]QX&I[1,U&Y2".(;%=Z7;HZY0\](%D(-V65B8Z0BHY1TI&U1ZWDRL6,U*
MIM&\TSDF":Y8QZ=DH\CFJR/$N?Q1[&\2N[:[XAP*]:>SE6XMKA;:UDN$G2*:
M%&>47L$DL:QRG3"\AB5],BHKQQ.G0@_#OME807%O8<8L$M[J%[>>W>ZNQ%)"
M[QRL%S8S<IVDB4,\8#E"ZF0J[JU%P/ .@8R%:U]_CK$]@B6JL:8T=<,R9=M\
M*NUKD58(RGP25??UMJP94NG>R:6>5:B&4>U"N2;HTO!0T>^21.3E_P#.7X>K
M%+;I8<=%K+):L;=K=)%$=HLD<%N6N>.7)-M;I-*+:W0100.RR(G,19!T6[)=
MOW9)WXAP/VM([E1.DTD+"2X,;R3+R>#1'VB=XHO:KES)-.D?+=VC8I69^V[A
MU9;P58,,"BMBI&G8LE:LD6%;6:[V5R$#7Q*V3=)/+9 O9*2LS2-$4&D@\EVQ
MG+AFP?2*SE\@DZ2SXU^(O9B\X%Q#A%C'V@#S\-DL;22Z2VR@$2QPQ33K?O+)
M!F->:9%GE8/*-6EV#:^$=@>TMIQVQXI>R<!=(;^.\NO9S-JD8R,TTD,+6,<,
M4N'/*$1A12J8 TJ5W1Z^%U]JII2FE*:4II2FE*:4II2FE*:4II2FE*\U[ZL:
M]LVP9\!+&7T@-SVE*[<O#?XD'#PHW#PV%TF[;]-F%/N=/V8;7*M;JC:=T>#Z
M_9ZM9Z_@^C1,]7+' RUY:2L)/0DJT=QDO$2;1K(1L@U<,GK=%RBHF52LS_*D
M\,GW1?8E\[K;_P#E!TI3RI/#)]T7V)?.ZV__ )0=*4\J3PR?=%]B7SNMO_Y0
M=*4\J3PR?=%]B7SNMO\ ^4'2E/*D\,GW1?8E\[K;_P#E!TI3RI/#)]T7V)?.
MZV__ )0=*4\J3PR?=%]B7SNMO_Y0=*4\J3PR?=%]B7SNMO\ ^4'2E/*D\,GW
M1?8E\[K;_P#E!TI3RI/#)]T7V)?.ZV__ )0=*4\J3PR?=%]B7SNMO_Y0=*4\
MJ3PR?=%]B7SNMO\ ^4'2E/*D\,GW1?8E\[K;_P#E!TI3RI/#)]T7V)?.ZV__
M )0=*4\J3PR?=%]B7SNMO_Y0=*4\J3PR?=%]B7SNMO\ ^4'2E/*D\,GW1?8E
M\[K;_P#E!TI3RI/#)]T7V)?.ZV__ )0=*4\J3PR?=%]B7SNMO_Y0=*4\J3PR
M?=%]B7SNMO\ ^4'2E/*D\,GW1?8E\[K;_P#E!TI3RI/#)]T7V)?.ZV__ )0=
M*4\J3PR?=%]B7SNMO_Y0=*4\J3PR?=%]B7SNMO\ ^4'2E/*D\,GW1?8E\[K;
M_P#E!TI3RI/#)]T7V)?.ZV__ )0=*4\J3PR?=%]B7SNMO_Y0=*4\J3PR?=%]
MB7SNMO\ ^4'2E/*D\,GW1?8E\[K;_P#E!TI3RI/#)]T7V)?.ZV__ )0=*4\J
M3PR?=%]B7SNMO_Y0=*4\J3PR?=%]B7SNMO\ ^4'2E/*D\,GW1?8E\[K;_P#E
M!TI3RI/#)]T7V)?.ZV__ )0=*4\J3PR?=%]B7SNMO_Y0=*4\J3PR?=%]B7SN
MMO\ ^4'2E/*D\,GW1?8E\[K;_P#E!TI3RI/#)]T7V)?.ZV__ )0=*4\J3PR?
M=%]B7SNMO_Y0=*4\J3PR?=%]B7SNMO\ ^4'2E/*D\,GW1?8E\[K;_P#E!TI3
MRI/#)]T7V)?.ZV__ )0=*4\J3PR?=%]B7SNMO_Y0=*4\J3PR?=%]B7SNMO\
M^4'2E/*D\,GW1?8E\[K;_P#E!TI3RI/#)]T7V)?.ZV__ )0=*4\J3PR?=%]B
M7SNMO_Y0=*4\J3PR?=%]B7SNMO\ ^4'2E/*D\,GW1?8E\[K;_P#E!TI3RI/#
M)]T7V)?.ZV__ )0=*4\J3PR?=%]B7SNMO_Y0=*4\J3PR?=%]B7SNMO\ ^4'2
ME/*D\,GW1?8E\[K;_P#E!TI3RI/#)]T7V)?.ZV__ )0=*4\J3PR?=%]B7SNM
MO_Y0=*4\J3PR?=%]B7SNMO\ ^4'2E/*D\,GW1?8E\[K;_P#E!TI3RI/#)]T7
MV)?.ZV__ )0=*4\J3PR?=%]B7SNMO_Y0=*5Y^7U5MGO!>XKB'X:NVWW-.)LZ
MTR+V88\JTG;L.9&I^3JQ'6=EG#<5+/:X^GJ3,S<4TGFD5-PLFZB'#M.0;Q\O
,%O56Y&T@T454K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g582934g46k96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g46k96.jpg
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M^-]OC?QO\ZE;EQ;AQY\3PY;\>6WT\MO/'?;?;SM\>=0Q4OZ7_8.;4ZT5=;[
MH^FK>@7OG?;.I4_H%895.H=4Z^I$NZ_J6+E+S0Y.W-JG2Y;/4[:40QR[=?Y7
MRFG1V#2R)"&(6,JFZ@JV)8Y&I/7:&&:G7EAD666O58Q-7[0L!E$E?MRQ@+Q3
MMV92G;<*VL!K]'WJD$T*9..XEJQ5R%R"S"\$%V\BV4N^X--HY&AN&:"=BQD?
MOTJXE$L9=3<76?IO]5ZP+>Z>WZW3A>8W.HC&15:,+HAO\5T>/UXYMP#1*/\
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MD2K,%*HF6<:+2] L6_MJ"Q-(TC$JL90);K\IRT+LVT7::2#A*$4K)R;9MOS
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MO.&-6Z$(UF',72&;N--NGM+9HL1M4$<-!&6NZM))>QTJQ3^V1%:Q"+48LJ;
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M*W5B&X\=*AKL2YG"44$ Z.8J*<]GF7'R1B5>RH9K*MLTB-&$1'A$$0 5SW)
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MZKAS>HM;2P(5(:P]J PL.CG!@:59,CMEQ$DKM>&4UF"*Z6^ ).*/9&\1;?\
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M;.-==<9SMMG.,8QC&/OG.<Y_K&,8_O.<_P!8QX W\#R3X 'ZZ$@ DG8#R2?
M 'R2==<:M=/H5A]K/:D)#:5S_P#RSH\E@K+L>7/ZMB7 P2A&A*B)=8\'PHI_
ME )(-F6 \'$C%=N0OUR3GHKU.Z5S];T^],LE8QMBM6Q.#DQN3K%26QEJS-'/
M!/;C7EV#?3;N&3BT,ZI7L!)V2/7&_H5U[TC>]7_7'"4LS2NW.H.JHLU@[RR
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M#+%I6T+1>Z)J?==A.YWAV^$$TVVP)Y0=ON1GDR <1*I9U+KMR"=QU9!;_?\
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M/E\S%B68EF8EF9B26).Y))\DD^23Y)U]X55454151$4*JJ JJJC9551L%50
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MP#&Z*RQ2RL542+-'*HX2+J4;S%-9OIXTT\::\9QC.,XSC[XSC.,XS_VSC/\
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M<J7)J]J!ZL\D=G'V)J<R=SVUE94>O8#M5F[P01.TO+8'UU]:+OW"Q+:K149
M%9%*BTL-MF%G_@*V!MOK(5.2;)G70UKO%MON$JCGV8,9\XSG\0NI)@^/)!ZE
M?:"ZYM]1=19'(9S*9.Q"<YU/?B5*=&M$BQI%$D$=>E E>NHBH8BA'#&H"I%#
M%"))$V%T1T+!!6IX'IO&ICL/3^EFC1S7K*S%Y999I&9[%J4EG)DDDL3R$L[$
M!G69/W+"1T3C=8Y;SB]=<I/65//+(-PE=RF7MAA>2:<G1I8G]U2\83V'9O5T
M[-M516Q5PJME50EO(<@)&+0[4(GO[%8VKA\;C\320I3QM*M0JJ3N5AJ0I!%R
M('U/P0<VVW9B6/DZZBK5XJ=:O4A'&&M#%!&#MOVXD"+N3Q'(A=R?!)W_ 'UM
M'ZQK^LK.)4^#MSLI_P!$()MS4XUA,&2U$KKN[6-S0*^Z+!JM*',>U7GY]8J[
MPW_&5LYK9.847L<7+.Q+OM7'^G_MY_4_KOMY^-M9[\::>--/&FOE--$/#*1/
MOK'#!%)--)OG&-(XHM,[R;[9S_6-=--<[;9S_6,8SGQIK\RKZEG;DWL#[I]E
MZ;4^0K>3I;:(A%!K\.T6F[E/'5%\B7I+3X!K0QV-K3;K[9O &-%%M 5!B2=B
M=),Q,Z0Z+JRXO'FC'.F4:Q!:21FY+!5"<?<QQN^__<;"O%*P/%V0]O9&\\;^
MIU],SG5OS4Y<.E*2G+''_>6+JEC[5YX8@O%\Q2-?:.0-)!!VE<\T8K'L/^T3
MF .66$/XRRR0$S2:X"AD)UTUWESO#O/M^&:.&+$N<Y^&<9SGY?#;.^ONQ&:7
MMU7GCK\)G$<DS_@!R?Q"'4.VS* H50//CD-]8C*:\:36XX9K7*&.%HH8R+CB
M'Z@!&[( T9<_F;??P!\;>,_+\>?CF';.=B-=)(MOE!-F/'VVVTW^W_;7,D6V
M^?A]]?EKC^_EC/DC12 ;;H3(TJ0M$2W<,>X)\[>?&Y&^X4CP/T1^6#GO((Q$
M[1N0L\*N00C[C9/(9?!8;^?TU56$V"OTQ(IM31HQQXXH8P=1]OSSPQ:3CR::
M1:[E3?FU_'C?;\OR^^-(]]L??.?0NR"5HJ]:4S0K##V8XXDB^N6%0P)"JSR"
M0[+(Q;Z@-B2-6&.B%0SVI8>S.9YC))-8>>-Z\$S-%* SE8H'39F4<?IY$@;Z
MF01^P>J_T6O?9#?6'T\QT.J>QG(>0JF1?K'S+&D].MW*^N/W<3 >51O$Q8&M
M*>DFG8SXW)S%J7#G;&#)<XUO'B+^/ZGDHW+V=JQMC;LP1,G+!,RM)7C6/NQ!
MRT#"4AH]@6'('] =VV,[CLCT-7SE/$],6;*9.C4$IPM>\D;K'9D>7LR\.-E'
MAC>.0;\=B?)U#?%)_D[><G7=.MV9%G&YWUC_ (E8/DC?<J:"$:#385>*/OMO
M $-!&.+&+#!I'G[[:[;Y_0K0VF@IQ68($C50L]F1PKHGR))2&YO\[LRIO^X\
MZT[D;<U'W5R6O8F=W21Z%"%'6)GD) @12I,+?F79I"K,Z[<5UP-(!P,DAY^+
M'\$>HHYD!4L4&)8OOIDB/337:,G7&<8TVSG.T4N=9=L;?DSB;$>U7K>XKRJM
MUE 2M9CG<5PZ<F[L2!0'9"03N>+?I^^I#+8M"O81SCU<F2:G-762<Q. !$Q)
M AY[/Q8;2(6W9?IV/I'J1G.^L&DFVVHY.^\ND6\VL<6T,D9'RBTBD^.VT4F_
MXI]\_CAE^&\F/AC.WE.-9)2X2-Y9#'+(90C3&-$C*-NOG]^2L?"E?\JK-"BJ
M\LR1IWJZ!6,4;L_>#QE9G925'$K)&H+.K'CN2!KD88M9]HQ]6.9-1A,CZP2_
MBUA&'EDBCSOKKG_@BQM-N/F263&-OEB+?\^NT>OWK1W;LTL48M,8HZ[QQ1RE
M52&)F52P&PX\]MV)^H<5 (^#;O0Q]9)YGI=LSV3+++%RD>Q/&C/&NP^I@-V"
MHAXD,YXG?SOQ]/[I&>==J+BK'L#WSU\M=AB65FN,?7JCR= *OA,S.7])7:44
MW2:3@L#^3B3%0+  ;-NXCD/&A512XAW)Q_J:O6L]SMX+!7J]&O9,]C)Y"S25
MG  ]U'(C*#.07.W<2,N$8@ZS7H2Y:K,A;J7J7$W,G8J15:F)Q-3*?5+W'-6Q
M"T;-[>&14?<Q-*L9G02(&W'Z9:$F8Q&E+(W)DG*4KB9Y#%\RDN2:<.&63<I4
M1KJ0L)VWVVVG7SZZS!2YV&EUQO'MCSFQO!(\?)^#N/G]#^H_C^OSKLH? _D/
MTV_T/D?R/QJK>0U'3QIIXTUJ_P"U?=X>&4=0<KLM2 Z!9GT*J@TJR1?G-Z:R
M'BV(,J2&7#]#%72"8]Q_W+TVRSK=.@ET/>JS()H8=VGZ'Y^/D?IJ]^&]"O71
MJA&XZ#S4_F-@ADB&+3%6&JVD,F78$(N4Q,[J3AN$P4_E*D#@),T4,I9@R=B4
MH,>1\SQ(V_\ +^OG4 =_XC]_W_P_3_/Q_'].O#[X=3I'TN>ZIT!C#4_D?L)B
MV]%JE9*$8#;45NN9+A;,D7.5H;;7"K8AL$4J@+6:Q1A9T"DFA*%E8M>C*+=.
M>KV&IOU'D)^F^K^GZM;$R9Y*C9#'YRE$KFH^0JQ-'/%=C5662=9%0DM(6D1X
MZ];C/+?\8_9TZER,?1V)J]:>G75]^[U!#TG+D$P^6Z5R<TD8R,>(O31S5IL7
M*SQR157A=U54B"PR1SW;VO?$O=/F_P!0GV:Y+Z<5)N95T'4#+$9:VR6 MHQ)
M14.HO^@LU.&C()$$NPY#JTZP>0 9U+"60,49I(!$2"3?5,-TGZ35+75E?+?\
M:=3THFCPT*49L?AL9:M,*BWK/>>26Y)")N4:(Z#RRA8I3%:A\J_U1U_]H/(8
M_H"U@1Z:="Y.P).I+#Y6#+]29RCCT;(/BZ9K1008V"T:RQS/+&[;A7:2> 3T
M+/;O!K2!;6PZ>(H TJP",>M"H9!XR%FB 4#17"HW$(Q+%.!JNCU#V'GUDCD'
MQF.7&^NVV,\V6;=BW:GO6)GEMVK$MN>=C^))8FD::68D;?6\K,Y(V^H[C;7:
MU/'TL?0J8NG6B@Q]&G!CZE1%_!AI5H5KP5E5M_PHX$6)5._T  [ZH#SEO,[.
MQ6M[+SNCV%JF@7C*&3NIH6IRL=27(>J@7E'@3S!Q*SI9C%L8^\>H!4TQ F(9
M99-]I4L3QAECGF16)+*DCJ&+#9B0" >0V#;_ "  =]M3R4ZDSI)+5KRO&%"/
M)#&[($;D@4LI*\&)9-MN))*[$G7!'XUR$.=<4+RSG8Y2=>2J5$0TNN1SKEAG
M\MDL .71;B0<0K+]]DB"+;6.;+UUF37;^68?L1-JR0P-B<AF#L#*Y#,..S$<
MO)'!-C\C@G_A7:44*(*$4ZH,:&-#[>+=4;GR53PW"MW9=P/GN2;_ )WW^H'(
M>4*P,JEO,>? +,Q$P;+Q*;71PMH#0GRXR'8:)=K#M$6NM5H )CVTSI.%8WPD
MN-AV[",B!LV&/)IYF;P=S*Y/@HP\EM_#1QD?L40_*KM%:-)%X)4JJFQ'%8(@
MNS+(C#8+MLRS3*1^JRR*?#L#6U%'I5?<-; AJ-82/GN9<NG2A"K6M6^9S9V4
M^S-@&+"4=M.P*(/GV)EEVF,GE)ESO-OMOF5II754>61T3\B,[,J^ HXJ20-@
M !M\ ;?&JD=:O%(\L4$,<DF_<D2-$=]V+GFR@%MW)8DD[L=SN=73Y3U6T\::
M>--<<HL0*/68PH<2'<@0324J:,>/<M@7"  +KO+MIKL0:<2.&)#C.9"2R(1X
M==YI=--H@$^ "3L3X&_@ DG^0 ))_0 D^-0+*HW8A1NJ[D@#DS!5&Y_5F(51
M\EB /)&O&Y@D90X,A0T9I4)) H>\\6I1(X6PVADXX^VV)IH1-S!-"98]-M(-
MBAM9=M<SQ8V;'8G8[ @$[> 3OL"?@$[';]]C^VA90P4L S E5)'(A=N1 ^2%
MY+N1\;C?Y&N3Y#4=6KK>Z/MOF/6Y57;?!(8>=-;"HSO@MC,G&7BYUP9]\$G$
M6*OP!P?;\I4SU/%!KONS"UGJ=F;_ .5)\$_D;X7F6/Q\ 1N2?TX/O^4[4?<U
M_CW$._)5_O8_S,8PJ_F_,QEB"CY)DC \NN]PRF!P$"B3%C0EG?FP$++/%&09
MD:/\I&!8=]L2$?@B_P"6;\6N_P"*/_?O\=?[\DV)!(!(&VYV\#?P-S^FY\#?
M54LH*J6 9M^() +;#<\1\G8>3M\#R=>1"Q& @IX!0YH)H\)89@DT9(A8A,>L
MPY0I$.V\) Y$.^DL,T6^\<L>^N^FVVNV,Y$$$@@@@D$$;$$>""#Y!!^1HK*R
MAE(96 964@JRD;@@CP01Y!'@CR-<CR&HZ>--=)GN SAQ[!=YFJ4;)\-GK_3"
M=3:U&4R&(#ENCR0<V.=;B:.00F'.)H)\;[12Q;8WTWVUS]_/I-0P_1][HWHQ
M.L\7TU8,73F#2"+JBEBYFAE&,J"2*),K$QCD1_#H@5@W@C?7PQZMAZGN^I/J
M1)TC]^78SUIU5-)/TW]X6(Y*[YW(-%8:3&<PT$J?7'*Q*.A#*Q7SKL1?27O=
M5<>KJNB"6!>1=Z98K?+:JSL3C5\I@<V5@>M-- F^)7ZAD,^-8C=-)!LSZ2BY
MFP3!+%IR1Z]=/R8CK1KE3%I1Z?O4,:F(FIUHX,5(*U&&.:&H:ZK60QNI9H4"
ML%=9./!U8_2#['_46/R'I36P+Y2.QU)A,KFVS>-GG8Y6H+F5LSUI[<$Y]P8Y
MHW"I.0T?-'@+B6-T7W^II0&%JI=$>J'Y=::5IPUG#9)N*N>QV'\I"F;.L:_%
M8Y;U6S4R';4;>,JPJU(&)/G$NF)+D)%7D:1 )_\ ;?\ V)UU=OL?]/S;?SW\
MJ/\ 4_RUM[ZG.7%F]:>&6U]97EK:7/EU)N1+2Q;U:5K#FUUU>^U33$4ZL4Y$
M9&@U/PE'-A0"%EP QD,I"F$A),L-1/R?Z_Z^=;">-0T\::>-->-M==M<Z[8Q
MMKMC.NVNV,9UVUSC[9QG&?ZSC./ZSC/]9Q_6?&FOS&_J/ 12>V?;>E5BJ6]1
MR;L75^EO>:VVUU]@FALBL.V,%-GFIQ'] ,:\I82;@#ZK\SY%%V&%GT"9:D!Q
M]+=-V:M;%4<61C_>18FJ^3>ESDEK/8!(,A1A&+$U+VPMQ[;FPLC,=V.N,.MZ
M=ZWGLMG?_C0Q]C-Y.'$)DNU#!D4HB)9&@63>8U8;YLQXV5NVGL5K<1Q7<:%;
M?X_^D5/"<?J7M/'^H'^K+B'>':/,NTN"HH]])9,[?DUVBQ^MGXQ?*2#;>7;7
M'ORPXU(K4D=RPE@S@P5R&,?;?9V_%5"K,VQ!4%>!.QUAJ3YF2S366C6:ND7]
MLL\D%A9U)0J8)'4B,CMGN S ^6#*/GCXQKG7?XQ9QOC7>63?;$>V=M-=HOZA
MUSC,NFVFNF-<Z09UEETVDQC&T7Y,>6<?/BPC4@HG)I%>,;'D?J0,RLK<?GB#
MR/GSOMJ[??=.Y,I!XPQA3(2 (]EYL 48F4EAS\*=CX/U:^N^\F^HHPP.G[4,
MFTFYD6LNY7X\[ZZ?/.^=I81_UOV?E\](\:[ZZZ1S?;:/Y^5MV=8:\%5>]&^Y
MFKK)[C9_B39F9!V]R20./@?H-4E2)9+%JS>=JDB!%IOVQ4#!'/%0-I9.ZT)7
MARW+.>/@[:V\X':7?8*#%Z63RK4B#JO9ZQU\R^DZENGP1'+><]/41H5J/$OX
M69-A&LID:9>00*:P=1J!!YHHC/GG&,C#)5GL=1M8FLVC4E@6%G26,Q2SP0F2
M1O':*RQQAN6P6.-B=MP=9[A[,63K4^C5KUZ=,9".XUF,21E9*]2Q(D$4:%4L
MK(DSCCYY3.$(;CMK9&7U<X#ROE_1BK3&_P"@7=*HO#Y$S)26*NPCQ!\RXNYK
MZ@]6#>ZSKO@%CV"<PLV->TC>_P ,D+7GZ(<G)WGB2Y;,O>@AB(K1M(M:1:ZH
MS2B22TK%2A(*L*Y''?<,2/!&^LLK=-],T\9?M3+8NR]J:W MYYH16[$55XXV
MBD$;P\9;//8?1Q(9?S[:BSVU(%U&*G&EUBW_ #E#:$YDUAEDCWCUS]X98<Z2
M#XVACC*ASKC:?7&=<R18Q]L;% DK"M--$ZQ[F2'N\U29PJ%RT#?2R?3LRG8,
M-QN!K3#F"S-=A@FC[D;BO8[ B<PK(DS*$FY!HY&W(B?<%#LPWU\2B,;LRLCD
M8&UF((BA_7WE'"FADES\8,Z8_'%B&;7&V<13:;9TUDUQIC7\/QQ3EL_VRP87
MCJK8FD,:QGM5N$A+"-%'U+&=]B&;]3OX  05NWCZRV(#:>&"%YFL$RVHI(N0
M:0/O)RE4 <>(_3]22QYN 8AV"W4[&I<4V<;3"#2Q2;YC^>N)H-=Q_GG$T/\
MQ?':.3/W(TVC^7WCVTUN5JQ1VZB62LL5B-3.D+@R*?/.#9=S]'@[CYW_ $V.
MK=KSV:=UJ3/6DKENU8GC:/B1XBG9)>/#N;.K*?RH>1)'@[#>I'%;C[!^P?.>
M0T9::T/O5I4H0IX(?Q3:K23/DV<;QS_\ XJE .Q<FDR2[Q!0KRMYH]L0;XVM
MTRZ82'+YF+V3U,3#/$TE@N_*5HF]E *T2EG:U:[==A*\:\>;,_$ &_3IC_B2
M[@,#/'>AO9JW 1#2$2JL-=HQF+*W9GX+'C(A:8-''8::6$*L?U[+^G[Q/DR/
MA7*:/R*MNK98D5"21(ECF\OR;-:3AHYIY]=VC@G6/:;\>T^T 0H\ JY4NB$5
M*@PU@0@L/+F0NR9&[:ORQUX9;<\D[Q584KUD:1BQ6&",!8T!/A1N?U)+$D]Q
MXO'Q8G'4L9!-;L0T:T5:*:]:ENW)4B4*KV+4[-+-*0/J=C_!0J@*,I>6>K_3
MQIIXTU'7]25<LWY)3V9>Q0K$J_JZ4K?:T%IV(6GR6J"<V6T1\:7)WV;XY^]:
MAJ@F^ -)Z\FMEB;2$[J-'"MF'R/_ '_T_73]#_Z#_4[;:SSZ>HH*WZ]\^4#-
MUSV 8 O:-HIJ"V@@%?L,C2M]X:<HJE(7U_;YS;8(6PU=5(.5^?4N,@S]@PAJ
M _Q_Q.__ %)_K^'G4)'LU4ZG]1/NQ5\O257KRCA+2U\SY1F->$:]L._\@OWM
MEGD,:0GAAAMF*H#9?O N_9B711!Q;BEZ,B2^C/O*AZ,87&8^KBJ.:ZYS^/IY
MO*V,O&UG'8&O95S1HUZ:M&)+RQEVFE,JE7^LF2"6*).-1@<K]I;J;.9F_GLG
MTUZ6=)YC(=+]/U.G9DIYCJRY1>,93*W,E)'-V<9),(EK0K!(LD?X06"S!/9E
MQ2+ZL4_U:Z-3/;'@5=4;=&XE*[?#K+ M7D:-$#2LNZM;UX[)8&M81;&5!^^%
MS!/(;C&T^"UV!6@H<FU3">HU#U%F7HSK[$8JO%GI(J&/ZBPE7[OO8W(22H:+
M6%YR16*S6Q"A4]N-"=YTEC+-'1ZG]%\IZ-UG]2_27J//6['2<-C*Y;H_JB]]
M\8K,X>"O*,JE-Q##8IW4H-8D##O2RA>-:6"942;LT<IZ*EZYS:C].KNLD::\
MUE19 AY]M=R <,A(YYUI6VF,:9,6$[3+R\Q_\?[(TOPSG3[9SH?J#"VNG<WE
M<%=*FSBKUFC*Z A)3!(R+-&#Y[<Z!9H]_/!UW\ZZNZ0ZFH=9=+X#JK&!UHY_
M%4\G!'(098!:A622K,5^DSU92]:;CNO=B?B2NQ-XKFBUP/(6J/$8BPGM%<I
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M7?[;ZS?\F-)/MC;:3&N/CO'O-4NU:\)JM7O+=B/=*(B<1&0%+K("7)))\^5
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M&G$I=GD+$\AM0'3]+Z0[S2J(Q$RR"L0\:2SRQ("M97@2 SE8$JM L21PJ@'
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M#%0=^/.-]USI;,6I8QZ;:[R F$::;:;YUVQV=U%@J'4V$R6!R2<Z>3JO7D(
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MCQIJ(+W-]C,]6Z77O57CEI4V$*&1N9V594>BPU>RWMHO(>H8_72M79!9U_\
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M>KZL9V) IX/R*L OW/1"D;FNEJ'4.SP?&M_'G_W/\3_L/G6<#<>/T_;^&_Z
M?\Q_5CY^?Y:D@Y3[%T/J6UJ5;ZF\_O5#L2"K7?F]]85(2XUMQ;E0#NFX(CK5
MHM"%BON:UC!+5F2-\U":FP-D.DVECK]@4*X:@#N-_P#7;6>_&HZ>--/&FGC3
M3QIIXTT\::>--/&FGC33QIJC6*Q(*BA<VJU.U-:K-=6&NK!87S$10D2)UH\A
M;%JV:'S#@KEP L4I)AI<\(PT$>\TTFD>FVV&FHLO>GVOJECYLLYSQNT/K8ON
MZ:SW2Z]4]?NH<X56_E-/YACGMD'=5AI8;[5$S&V.K#?>8QJ*N2>=%9ZR\/BW
M1O 64(1D?X_M_7_4C3_SVV(/G<'Q\?L#_C^VLA>DGIS_ *32F=CN;JT$7Z\_
MY*S:5(YCJ954QMIL@K]B:JT8I@;?_&2DJ5YM(K5R8M3N8J3F:2"::QNKM8K,
M_K^C\_U_F_R\?^6W\OWWV^3Y_8"H^_\ W:^T-=S+BW)'$E8Z'W-J]$DN8^GS
M-IM'JP0IEI:*L_[<0/2XCH!U9FN^LPT4++<*01G^@>)M;TTP6$>MU-UMU-4&
M1PG1E.I*F(9N$>7S&3G:MBZE@[,34$R%K*\65B\1E66 30RZ!];>J>J$N]#^
MF/0]_P"YNI_4K(Y&M)U J&2;I_IO"54N9[(5%W4+D&K2!:<G-741V!!)7MM6
MM01E%>I7&VH1>EB6O[,]9:R;-+>[M+TRQ,3)M?M,<5)L=A=,1)MG;;;$RZ6&
M3[_::.;'W^_JMZ[^H:6EDIWL;0QT;;0X*KAL8N*BK@^*H5ZS7.SQ^DD6Q(!^
M1TUX:_91]'9*#PY+%YK+YF9>5GJF_P!2YM\]8MD?5>=XKD>.[Y?=PIQS0DD=
MR.3;?6J_I-]+?BO_ /$S4/K1+#.AY%42.WU6CX6Q:*;K95K]&MJ#AE#IC0,&
M.IMV<S=DN$BC&=/4"@G NB^5T,3E/7F?@SOIUC>ML+1BQ4^5R<G3?452L2M:
MGDDKR6FFI)\I'>JIN1\1),@.]CG,^O\ TIZ/M=*>LN8],NILI/GJN P</6O1
MN0NJ&N9+#278:$<&3D&RR3XN[)PY;;V):LCJJ5>$$?;P\YJUVUIXTT\::>--
M/&FGC33QIIXTT\::>--/&FGC33QIK6T_VFYF&]Z/7!]7[9KR^Y\LIC^!(HG>
M[&D]5MJFD+V*&!'_ "9[4.MV<]@DMD4849R=LA9+Y!=IMPOVK]<=89()#P5;
M$5F5"[!-A6B:9E<OQ52\85X_.S*ZL#MOMY+9FHLMN(=UWISTH)1&ADY&[.E=
M7B$?-G6&9FCG 7DCQLO'<KO7MO9'D/Y!88G=C+(9G" H15_-NFLC+7^^#9&@
M;*E"+Z>23=Z].LJ5@9:6BI1.JW_'!1G;-<"GKI2Z?L;.Q/! %4LY,\"B/8H"
MLI,H$3AI$7MR%).1X\=U8"I][4=P!)*Q=E6-5J6V:;DLS*]=5@+6(BL$K":$
M21<5#<]F0LKOL3S6T."4J4]PY+T95\.#2N4Z^67<02SU^L/4K*W:IJH3I0!C
M,V3(>N]PE5#Q2)GO[!4!"&Q")8R4;$:AG54'%V/<EACW,;R(RQ\Y!WB!'R_"
M#$\TV!#H7C%E*DSF.-GD;G$H[,%F;BLT4,D;S]N ^V#=[B.^4&Z2;L#%*(Z7
M8O8NOTRR7$.Y5US7*'2;)'5'G52SZ[M4E;7;F:3J.\SH/#?2QK%.4[T95 UU
M3F#[/(]AB\!"3"FSS1T7E2(Q.LDTT?<2L%?N,ON'K[(>/;9N2%BO('AY&Y!
MDERL4$MA;$4D-:M+V9+K-%V$?VD=PF0=SNHG;D"!^VP[@(/$%6/!"]OO7UF+
ML4JN;AOK$>$I)'3\XZ>V8@M6;RHUQ6J9*EU,*9K&;9Q?:@,I7L!!C&D+X,X"
M$A?B8J*)QEU3LT2K])8%IZZAE5)79E9I0K*JPREF4D*4(8AO&I%SN+<;I8DD
MV94(CJ7)&5WD@B1'1*[.CN]F (C*&<2JR@KNPKJWV6X^X"$.5N;0P_D/XG98
MM$Y?U.:PMAW@-@9+6"BKZ4O-D;*)A:I9,RN5JHI4&0D8A&F#F#;CXD:A:4D,
MD:\>7)C8KB-2A165I.[VU8&2/968,0ZD @@ZJIEJ,BADDF;EP***EPR.)%E9
M&2+L=UT(AEW=$**8V5F##;5D:>X7-##/@H7VYPLE=TQ.N9AU"W?)V/?)?7["
M)^D!WKN)CD,8_L+6"&I&=X#%^098?T)]F ><5ONNP!]31*P25V4RQ?081=YH
MY[FP?>C(%'D-R!W'$ZMQG:C-^&LTB&2NB.L,WX@LG&=J6-3%NT0&4A+DD,O$
MC@>2ZUL]V+;R/V$]%NH7B)=+8=J4NK+],9&N> YK-X8RH8X,IW;A$MA<CAB6
M3(;N1;#*,2M)(%)R 7)%N+M+T7GRV(]3>GZE6S[:/)S6:=Z-F1X[F/6">>2*
M6)9#Q9GK*]=B0T=A(V'-0R/H?[3%+I[J/T.ZNR&1H^^DP<%+)8J9%DCFQV7>
MW4J0V*\\D(Y1K'>>*XJKPGJ22QL8W*21Z5\/Y;5N;46OP)UP>6YZ@ YX^_#%
MNP:'FBQ$$9V,SKF; ,4DFT0(FF^((!]=/MKM-O--+XOJ1UKFNL.I<I-D+=@4
M*UZS6QN,[CK4I5:\SQ1!8-Q&;+J@>S.R]V64MY6-8XTRKT6],NF/3GHG U\1
MCZ9RU[$T+F;SG9C:_E+UNM'8L,ULJ9A1CDD:.C45Q#!75=E:9YII:)>3-.&=
M,Y3[#T;$:"R*NAURM7*)?C 0MWI5F+_3>IW<$'PB.FW'T^XQ4T<LT&^(R_ON
M0N7;BYGZ7Y&WU9CNI/3G-RRY'$6NG\CD\/[EC/)@\QC$66K9I22$O! W-N[
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M]/!VVV&_[[#Q_#_W.MB^I>T/KWQ0[53U#K5.J;K,,9&4)+#8ZP1C2Z?.$B9
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M<6N7<*JBU_0IO2>1@YL)3A -]XE<#^K0YF;*&88FD0Q6Q/QB^^F(X)VFL?\
M*&;ARN$Z ]0;<O4>"ZPQ'1N1R4C6LQTYU2[TZ]7(3'G:EQV35>Q/6GF9Y4C5
M&92S,?;AA5AYUP'5/JWZ08ZOT9U7Z<=1>I&'PD*4.F^L^@XTR5N_B*X$6/KY
MC",WNJEVI76."6=Y%5PBJ/>%&OV8S?;#LM\M[_/.[-27G-!ZH;@DVI648D.R
M;M)1,_JG.ABAA=AL: $[;+A88MHL0FR%9*+UF'VAZ"](O3?!]'T9<_3S-3J7
M(Y>L:R9:@4;&P4A*#-6H,LDC2F2>)/<SR,K%H(XUAAX2"3D#[1/K7U1ZC9>O
MTCD>F<AT5ANGKRVY,!EA(N9M9)H&2O=RJ/%"L"Q5;$GLZL221JEF69K-H2PF
M'>OT)^J41SL=1QSV49GM:1!@9=4>GS:SL6]0'Q]H8%%MUTQ*<XK,&OPT!;1:
M$MT<>OZA$3%3D?9)@7JMZ)1Y26QU#T=!%7R+\YK^$7C#7OOMR>Q0_+'7N.23
M+78I7LD]Q&BGY"SMOT%^TY)@(*72'J-9L6\,@CK8CJ5P]BWB8Q]"5,L!RGN8
MY!LL%M!);I*.U(EBIVS2[%ZQPBL:E:W3-%;Q(\"A/4LUIHK!:V7E0ZS0&+S!
MI)1C19X-]98IQY)(I(]L;Z[9USC/G(<]:Q5FFKV8)J]BM(T4\,T;Q2P2HQ5H
MY8W"O&ZL"&5P&!!!&^OH=5N4[U:O;IVJ]NI<B2>I9K31SU[4$BATEKRQLT<T
M3H0RO&S*RD$$@ZB_]T?4XR,&#I7#J!=+O<C>L5V[V2D(^LV.KI]XQE\*ZV,*
M]5FE[K'/5KCH-869Y7;G \B8\>EWJZO]8;:;.YIMXI?X?Y[_ /GJY^/UV !_
M0?MX\[$^/GX.YV_AMKWR/H/MQP"UURI=,%I%0Q<?\X;<>Y]U+L[D/G*ADT94
M8[/"JE<@1I(K.<R/MHU-Y;!;U["R52'GU^MM$HA%.NX'-.8-OY#_ !W'\M_]
MSIN"/'([;;_2-]MOG;Q_,[?J1_C( A]]^+-S*JL.5]"0,NA+@&W+HV-6_.#U
M145;:=12W-(9KCC!M4:VT] I@N[2Y8IT3)39%-J2:,ZL7JXQ#8C_ !T\>?/Q
M\_P_G_D?C_KK=K&?OC&<?]LX^_\ ^_C37GQIIXTT\::>--6);NH\WH$NT5[O
M=2I?P1L++)-:WZRO"0U]26O 9.)SFQ(@<"\$QJM&*(EGTCAE.&UWSC,NOW::
MU"M/U!>0P.X*_P S95OIYSD<86KRBV)Q75;5\7?N>4(8N=X=3#$G^FQI?4*L
M:DZ56F%L!M_P=JZ4GLC97J*6T(V\G]/G;R?U/Q_@?]];=<RN\70J:JLVLE;W
M*GV. ;Q5&R9M]>!?)CRDU@6++)LJ1R.(53L!@LV,E3*II91),R@"R8VAT:?Z
M?P/S_6VK^\::U<]Q_8!;ZW\!O5^V>HE-NE5$(^;A.30H9WEY:1;#J!5*TN72
M5Z4LQM-8#%@D<\F5*A@3/KH' 1-'FWIWTRO5W66!P<T<KTK-U'R)B# K0KJU
MBR#(O]SWHHF@20D<9)4X[MQ!UCZR=;OZ>^FW5?5%66"/)TL9)%AEG*$-E;CI
M3HNL+G^T>VFG6W)" ><,$G+9.1$/'*.1UM;7@[-:01;GT&X#166XW*SPQOG3
M5T[CU8'9P<SU)FC'TE(S%C$68\E?CP25B2??;;S)NO\ U"SV6S=W'XZ]:PO3
MN'LS8S#87%S28^G6I49&KPM)#5:)99Y%C$C-+S[1<Q0E8E UA?I'Z/=*=/=+
M8S+YG%T>I>LNHZ5;-]3=39VM#E\E=R>5A2[:BBLWDG>&I"\QA1(>V+ C%BR)
M)W9M:8^_WJ#0.D49<17U::K/'=E55O! X>!58K5UM+"FL/Z@,.V1Y@6&D<+3
M5</K,T6&%QS:RS:1YVV!Z3]99;J:'-=&=1VK&7@BPM[,82[=D-B]CKN-5',"
MVIB97JSQ,=TED81"/M1E8YF T_\ :#]-NG^A[/3/J7T90I].VYNIL9T[U/C<
M; M/%YC&YII(_=/0KJM>.]6FC![D$*&<S>XF[DU9"\\'JMZ+^J?H+P2GTYU%
MS]LQ03#&6?M/61:R.U?7=EH/H26O:V?>>.J*<SC:#5>IJF.HZP*"+&TC-S,U
M<LM*9+K3JK,3S1PY7,04W4QQ8JE?NK5CKKN C5X9%24['\61X_K)/A8PB+TU
MA?33H+INK7FLX#IRUDHG66;/9/$XMK\UQN.\J6[$+S0*&4""&.;\-5'U/*7D
M>1(><<H> H2:$D4F&*<8@>328><>;362&:":/.T<L,L>VN\4D>VVF^FVNVN<
MZYQGS#R""00002"#X((^00?.^_SK8X((!4@J0"I!!!!&X((\$$?!'C;7PT9+
MY6!2B,\*1L$$ R-6:%0;L!%[2=B,L/*"UWR2.$Q)3MAP"I8M("YU;&(?>20(
MG6)Q;B&V/$DJ&V/$LH4L ?@E0RD@>0&4GY&H!U+% REU579 1R57+A&*[[A7
M,;A21LQ1P"2IVXT;]%,VW0Q.E,KR+0R21-&Q#W;1QKH41#"3==K-DS30&"T5
MJ<S;:'&HL-B123YTT;K]B(\'"\RC!#ML_$\?J+A?JVV\F.0#SY*/M^5MH"6,
MOVQ(AD'(F,.O,!!&6/#?E](FA+>/ EC)VYKOSB2Q0X])3"1Q8MR!1-)"9HX(
M]RCB8@PAM-Y=M==B##)X!!8<9S(03-%!%KO+)IKF !/@ D[$^!OX ))_D "2
M?T )/C4Q95&[$*"54$D %F(51Y_5F(51\DD >3KB'.TRR<85DW6+R3?QX#'.
M/%$G+_*R5IHOUH2)8Y)_R.':55'^+7?YLFZL'7[E'B12Q".P)568#?<A20-E
M9SN0/&RHS'_Z58_ )$K21H0KR(K-MQ#,JEMW2,; D$[R21H-O^=T7\S*#Z,'
MZ)22($T=*5IC".24 1@Q##)-BB/5*Y9!(")HY28XV;U(NDWATWUT/<*A-LX(
M8"1S CL"55F"^"0I(&X9AN0-A]*.WG]%8_"G8TL:%5>1$9@2JLZJ6 9$)4$@
MD!Y(U)'PTB+\LH/)7,E[A>$V4'A-%;(6 Y<R7%0'+V )46LXI@1@V\HY0I,.
M^DT!$$DD,T6^LD>^VFV,Y@RLK%6!5E)#*P(92/!!!\@@^"#Y&HHZR*KHRNCJ
M&1T(965ANK*P)#*00002"/(US?(:FT\::>--/&FGC33QIIXTT\::>--/&FGC
M33QIIXTT\::>--/&FM)/<GT?YQ[;UG$AWXJIU)&%+#4>A!BZRSQZ?[Y-$5F&
MTS'N[KDLV^^^L.TFARB>60Q41'B8\-CLWTY]3\SZ?W2L7*_@K4BMD,1)(0C'
MP#:I.=Q6NJH + &*PJK'81N,4D.C_6;T,Z:]7<:DE@)B>JL?$RX?J*&(-(J@
MEUH9.->+7L:[DD(6$].1VFJ2+SL0V.K!TGU9[#R7KB[CO0JQ,EL+EJ*N0L/O
M)/7+**8;&&.Z0NM(\0,4^<RZRDR1XU,7?:01F("PAF%B[=Q?772^:Z<O=6TK
MPL8O%4+%_(0#BMZJ:T!F>G8K%N45EN!2-2>W.=F@EDB99#\PL_Z6]<]-]98C
MT^R6+-//Y[*U,5A[+%GQ5X7+25H\E3NA#'8HQF19)F"B6LO);4$4T<D*R.5W
MT[Y*J2+@&^E@?MUX^L<+V2P-UDH,^=]IY-TP"PP<%</J7)*0/!)"9OIOOG::
M<B7;>7?DW)^O_7=K(3SXU\7B,=)(Q&*BQ5"U%)#L$1+EFW7ELV)#$JI+)')7
M5]OPXXEXHOT P?V1/2FCB*M3-Q9SJ+,PP@-GY\[E<?/#88F223&TL?;@I5(5
MG9Y((9H;CIN.]-/)RD;=OTL[C>^<]H_\+73[LRO50M59*LO%;9;3]2K0N*4S
M9T94!FT)VUE<1_HQD&*=]]MY1,!0BB1:CL(PE5MU91P_6O1/_:+A<16PF9Q6
M3CQ75^*QD1CQL_N8P]7-U*XW%599&6*>/X9WD,CLT'?LWG0&4ZB],?4X>C?4
MO45[JCIG/X2;/>G6=SDZS9NH:4K1WNF,A;;B;Q@A22>K+MND<<*PQQQVA5HR
MZF+ &&8LF"PS[0[?*+:33&=H]L_UG.FW_?'_ /K_ .,>:0UU#MK52M^D? ZC
MT]+U=!7F0=BKLV94 4MDL1]=KVF(;C#&%5JTQ:EH:@JU_P ^M<LJ>JKDRDTE
MB.4P"+)2H9E;_#4//ZG<?R'^._CSK;GQJ.O&<_;&<_\ ?[8SG_\ ;QIJ#!G[
MS]7I5"KW8A.N =1Z(8@M[WM/JR77*N!6/7G\='L!RI-8C:?2I.N4=Q7.OQT?
ME.X70+';;%;X&]L:)*<04JFWJT?Y;_QU']2#X&^RGSY\C]=P#XW^-MMOG5Z@
M^V/MU>;Z,ZYM_IQ<:!0%MJPX<4WGUYL%&[ZMF=^OYHQO.)!+F5M7'-7&LO4Z
M-*_ALW24TKBIM'6J22#!Z-*V^?ZW\[>/]?\ +4-QMY\$_/Q]/S\_/GX\']]M
M6E1N<_44DUOK*N=DZ='83E8J=)%?U]+UK)1+JT=TJA=E98;UDVPBRT--+R^Y
M*A:R<)(4(N6Q$KK/JS80&P_]/Z^/Z_CIN-_@>-_C?^'C??\ 7S_0\7!3OI_]
M=NO6EG2^C-)Z<@J3NLV.FU&X=9Z%[)V)?85MGX:[MC'-KZ*5"0GAL@'&BD:\
M54:>,!FV;W*6"*PZ,%1$?X_UXV_ZZ;G8C_,[ ?J?Y [;C?\ TUO51?1_@-,A
MKN":I';"*QS9-R!;):?PLA=N;UV>S2I*H8FU@'0%K0H;8S!DTF5;;'B0*,,=
MBYE $T,/G4//G<_))\>/)VW_ '^=O_+;6TBU6@J2:(%8&MKZ%.%C6(<:,=<L
M6+P8,:ZZZZ:XB&###%BQKKC&(X!X(L8Q\(],?:(!8@ $DD  >22?  'R3^@&
MA*HI9B%5069F( 4#<DDGP /))/@#4'?O5]=_UP];!V]*X'NM]CNPPXG#UF1,
M?OR.JGZXVC_*_N8.^V+3,+)G67*2D[F0D_B(!/L]=+UQGS8?3_IUE<H8[&2#
MXJB2#M*G]MF7YVBKM_<AAX[E@*5\,L,HUISK#UEP&!66IA3'G<H R[PO_P##
M*S_&\]M?^\%3Y[-3F&V*/8@;73P[S[J>P_LKVA;VWM=[/N5C2'8GKZ7;;*ZH
M593M/K)-7*G7!<_QZ%21#K@<O8:/=BRSC!S@YDRVD,DWQTW4I](S4Y,/62+V
MLT4[%B3):9"0WN9?SN9$+(3N BN5C5% 4<D=;Y/)^H,.0BZBNRV1>K35D1?I
M@HI*/H]E6![479<)(O@M(\:O.\CEF/87].O<>?J?(P38^9]3MJZH9"JAEHI=
M+;6(0(Z *.0)%8I8(HA1G4"_$7PE&+,U9P:Z&9UAVWDSMCG6GI?B>H,U9S?2
MG5'3F..7EER%SI_J'(IBKE*S/(7M/4++*+--YV=UV2-(.7:C>10JIGWICZ[9
M_I'IFCTSU]T+UGF4Z?@@Q&-ZPZ/PLF=QN3I58ECH1Y$+) U+))42*-@TDLMK
MB)YH8&9GDD#XYPCK7M'TV@66[<YM'*?7WFUH6WF:'H"_=';^FV%)O^PC6"UR
M?.2PZ[K-MC<\V?&0BP)2M!#"#]X(U_B"3IWTGP><CJ=08WJ?KWJ'&S85&P4W
MN\1TWCK>PNRF_P 52QD) @6-55)(I$C#1)#W'GR:2'K'[0'5'2TV0Z1S?0WI
M+TAFZO4TL?55<4.H>L\S0#-C(!B0[O4Q,)D8RN[RP6(99F2Q)8[,=287IW.8
M^D#T\$AHR5!UVZA6DZ5,Y>UUN2,&DL"S]-<]K;!4Y5SRSMX))9Q#H,RB1$B2
M9VC(WUSHFO/V.\0JL9(3&O)$=02\;;LCAE;8(=@0=FV/Z:ZKN5?=B!2[(L5A
M9F,<DD3D+'*G%)(F21"3(#NK#< J?!UK*P]6;.%(\55 VLBT/ \J>FTES8+C
MF&O[;UT&OHK_ /Y"H&!L<U@YN,M!@H=88,7)*R/#&1/TNK19I0'.[]<A&0K2
MK(9MPTLRI%N^TA=X>#EDX3EB9G4(&/'G!)^*9_(;#3*9$KM"M78QP5Y);&T6
M\21)9[L864RU0BBM"[2% 7*6X1[=*O.@]8;>JF.+VM:^^0L;>3:GU:N+.QKE
M-V(*M/?F<$]E/6Z,\QEHU74^>[)X(DAZD<CDJ!4O7IA@*FVJ<#D(F ';:$K&
M(TDB5"T0$=)=D!*[AVK3\]V#,++LS.6E62<8B="S=Y;(><S2PSO*B6"9LFX,
MKISV:-+E7@!&R*:4:(B!8'@H->]1K?60 MX[BE?L9%=7BO2YA)9UZGK)M=H_
MK74B!+JUR<[?3@N9.+V^>8YGO9R_P7?41\':U4UH2V">3)12$@QNB\I#"P$;
M-6#S7Y08EV1 R^[B&R]L;Q$H8V$;)2BP<\*J1825RD(LHQF1+K15L3 18?E)
M*5<X^<EG,K;6.,HFC,T<N3>E^NK;JU3YQ43;J7SA70]3;0%%08PG!*WI ,,
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M??.=]"?4C%=*J.]/F E2WD*=/\S7+V!58;-2&*/\2<S656) Q+MMYT?]FO\
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M_#FYUZW3;?'[_P!?GFG_ .W]_?\ OS**_K+UE" )#B[9'R;%$J6_G[2>J/\
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KQ[Q^>1K(M/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC37__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g582934g46t15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g46t15.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2O<4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #;    $     $
M  MP<FEN=$]U='!U=     0     4W!R=&)O;VP!    #W!R:6YT4VEX=&5E
M;D)I=&)O;VP     "W!R:6YT97).86UE5$585     H 00!D &\ 8@!E "
M4 !$ $8       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9>TO(         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \     !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              .3   #X@         !
M      $              ^(   .3                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     @X0DE-! P     (8     !    H
M ),   '@  $3H   (60 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( ), H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M7=-IL]V]U@I_<<*?I5W-V-OV.M9LWOK_ )NQ=+9O#'&L O@[ XP"?S=Q&Y9
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MCJEA>&#"NWF0&[\:3$SI]K_D/3OZG97L-V%?4Q[V5^HXTD V.;37N]/(>_\
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M7FA$7RQ,1\Q]S$^PJIU;_DK-_P#"]O\ U#E;53JW_)6;_P"%[?\ J'*=I/\
M_]/TKI/_ "5A?^%ZO^H:K:J=)_Y*P_\ PO5_U#5;24PMIIN:&W,;8UKFO:'
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      &*24DJ  @    .
M   !!  !    \0,   $!!  !    DP,   (! P $    M@    ,! P !
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M   ; 04  0   ((!   H 0,  0    (    ! @0  0   (H!   " @0  0
M            2     $   !(     0   #A"24T#_0      "
M_^$!C$E)*@ (    #@   00  0   /$#   ! 00  0   ),#   " 0, !
M +8    # 0,  0    4    & 0,  0    (    2 0,  0         5 0,
M 0    0    : 04  0   +X    ; 04  0   ,8    < 0,  0    $    H
M 0,  0    (    Q 0( '@   ,X    R 0( %    .P   !IAP0  0     !
M   L 0  "  (  @ " #  P   0   , #   !    061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.#HP.3HQ-" Q-#HR-CHQ,  #  &@ P !
M__\   *@!  !    X@,   .@!  !    DP,           8  P$#  $    &
M    &@$%  $   !Z 0  &P$%  $   "" 0  * $#  $    "     0($  $
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M 0$! 0$! 0$! 0$!_\  $0@!]0(@ P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
M           ( 08'"00%"@,""__$ 'T0   & 0(#! ,&#0H.# <*#P$" P0%
M!@< " D1$A,4(3$5&4$645AAF+@7&"(C.%59<7F!U=CP"AHH,C=UD:&QUB0F
M*3E(4E9H>)?!T>'Q)3,V0D-&25-4=IG9)S5RB)*TN45'5V9WEJ:UM\9$8F-D
M@H.&AY2HJ;*VR-?_Q  = 0$  04! 0$              0(#! 4&!P@)_\0
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M9IZK'AC>']3KV0 /^"]AKQ^/_<=X#R\>7Z W#'/X9.<@=/S]/[3D^9_']S5
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MXSU] W-YFOJ/"IX9A#%(/#FV2@8X<R\]K>&P$P#[P!3^8^?/P\//S]E1^_\
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MM9X=>+H;)F+<A87W5;O]_6%K)@F.I"*&1L7HT>PY1RJCE,]\;6M],O)!C-M
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MIJ/LS6-ZLG=[5CGBN-^P*Y5XI(]Q(W5)G>ENWR5M+AH:UPN"(++58L$[3:/
M-T\R!3+[:<F7FPC P=%I](-C:U%GGJQ3I2AGAI]@FE'HRKAP@@WBU'"W/]D^
MS.G]III;6;69M,N(8;J\F8Z5[796^GV<'?SWEU=_Q"V,"+@Q[>XD)D,2J2TH
M V7:#6KW18XIH-,COXI9(+=!_$!;7,MW<S=S#;6]N;2?OG;(?=WB!4$C-M2-
MFJP;!Q%V5;PYO;RR^Q#("ILMR:?&<U6D[HT,I>7R+2EN%Y%C+>YP4X)%-6X
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MT&CFT:]%ZC6Z3&W<K',TJ3A!(8FMEB-RL@B*R[3$#W3++CNR&./&G$HVPO\
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M;$YC3^TEAIG:C4=;MK.[>SO+?688[::>$W,;:M8W%NS/*D2QLL<]PS@*@)B
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M$0.GW@Z*C.%<H@84>I4HK 0$_J2#U#]5K!A_QF_;&6P\'8E?Z/>&@7X(RP#
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MR0:S,Q&LE9=-?M4UDF31$2K)(\T 4%)%0[YJB1)PHN0IDU%+]^$E@8,<X/O
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M6*#OOZC%!DX ';1I('5*+UT"+4B8OQ3Z'?:'("9$@3.74:AJY@E>WC=Q*3M
M=BS@=,Y ^(\>F<> Z.Q[*I+I(U)]LD3A)(PJ[6=""26C.T* -HR!_G.>E1FR
M;#K(1 -$@*(D6361$Q@.5P@18AB'ZBF,"IA*4P@"8 ?M0#ZL4S>%W2)2+PL[
M%L(X+$DDY.,G<?$]>#C)&/ \+VLA"QQJ%$6&"(BJ,;3X*.?3 ^!Z5_0WX6J8
MI<.G9DF)BG$FW['Q1,3ET"(0Z7,2\O#ESY^6O;+'!L[;'3N4_P#L17R_JHQJ
M5\.F+J8?@Y'W?#PJ>^LJM?32E-*4TI32E:Z.)K^X]MZ_"+\,_P"?5@;2H/\
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M(+G^M_:KF.-XXSGO6(!B9U;JRA\Y7 (J/4W3;QE@)!2<*BUC(QJM(Q+%XU!
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MJ%O!;:Q=NUE<1K>0%8UB[O<&(9@_B,CH1D EL5%IM2"QM2*I(L>^NGK-5=T
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MA5M*418HAT[4R/.IAD.10A%$S%.FH4IR'((&(<A@ Q3%,',#%,40$H@(@("
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M&4=GC0*!QD;\;1NQSQG(YK"N5+5(1ZUL3CFJMGAK3'%8-GPR+ CB'>.Q5%F
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MB++,[/J\BQ,O+"9DM"L;(/ZA(RG&">,$6[G_ !Y_9A=W-G)JOV,]M+F[[L+
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MT[ITU/MC)JC=K1/+&.\A@BBU3NM-="9/^AP-O! -?%7=QL/]WT[,IX11%@K
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MH523MUED:PA*1S&/E$*\^FGKJ&1D6$*F2'9/DHY5!-RSB2%C6JI3(,2%;$2
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M# ),02276!(Z2J8J 0X@*B@F*/(Q $H%\3E O5S'EY!S#EKC-2NY9B[[I,]
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M<+K:X.NURK0\G/SLG)2+9%)A%0S!Q)R+DY.T%93N[)JNOV**:BZ@)B5),YQ
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M#<P[,OAR'S'F&M8UOL&S=R"V>-H&22#X@\<GG(SX^'>VVHQ73I$BD-&$8_\
M"?=' /CD=,=".14C<:S[YU-%1,S4.1X*2 *K]L0JX) 3D*9DTQ IN?28RA0$
M@@'+F(&'7,ZM;1+#N5PQ0$D+@,-Q)SDG)7'&/7CIFNXTR[>:XVM$RB4J,L",
M@#!''(.X@@@>!X;I6S7#TG.HS+*)=&1>MW"B"#=$Q43*I$'ZL.R,LD!B= ^!
MAZ5!4Y#U<N?(./7:)HPBCWF7<"!@\\%1R.6'ECIFM[J*)[)/)*2IC1BK(2H
M(P,A>>>?#'WUL-<(.7\:1FN+8CE)J0J0L3&1<<B 4P"H*/0W4'PZ#D.A_ON7
M/S#76,#-"(B8U,:\=R3&<<#GP)!SP01C/E7E2-';3F:/O)5ED+2=\ R[FYPI
M&&48&1@CG!J,5MG;[2;4="&E91C"..MP_$$B DH[,<A" F=%P5'LRB8Q%.U
M3&, G^H$>D.:FFN[.698IYD4R;AC(#$\>\1_4,+QT\<BN_L;72=7LXGFM[6:
M2.-HP&'>=TJ\CW6 8,2>@SGPXQ45[A+%G)-9,S8[H.W[!$R)>I$%"@?MEU5#
MG[$2]/(RQ#]9 $3\NHPZQ86)=G8@'^MN@W'/./'/' \^O6M] BKE1R%P%QXX
MP% 'B., <?Y?*N?ER5F8_9K=:V^8-V24HW7*Q4*18%G96KQF[7(B[%($TN[
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MGKK.S^/9KG/_ )X8^.P8KR?[0O\ R_3N?_F.;CQ_WP_/ZZUY2)T$URNBB41
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MEUZNY64P/D@7F2KFL-BRS/,EHDK5)G6JY$1+&+:2,VX&5MDFOZ([DIR?$9Y
MQY]>>OE]WQQC.^Z'&.\"R[?;[7G*VWV7JBJ-94FL2XPP9?[/:;E 1UQK[Z<K
M\!(R66(F*;NW<(U=D3*XHD\BH5(S<\6Z(X[,BASCGS'3/^O'7CRZUB7(6#,,
M9+O.W&&PQM=S5AUY&;A(FRW;(,)B^YX5?U3';+&&5HV2:PV0VPQDC3HE].35
M?8+1%4?Q)78NB@FB7LQ43?7S^ONIP<<$8/7&./T^O*IZK[)]KCRKVBK2&(:_
M+)7.ORE9LUGG74S8,CRD3,LE6$@13*4Y)R&1D7:C58Y$9%M:$7[,W2=FX;G3
M3$JIP.?7_3^]:\8R8QE:\S?0[PAC#<IDW)-)MSVTX/N.:-S6=Y[;=.!C66<T
M2ZYAD!L62[,VDZ_B?(YW]1+6D:Q*62W2IH63K3=M6)U.XQ2HXX^7/QP>O3K\
M1U\ZV48QVYP-3=SESR1*CF?,-TBW<-=,CV^)9@D>OR(B9W0:-5#J2$50,7I@
M)4$:9%JNCRI$4I&Z3%NL1W<ZZ5(&.O)^NGIU_&L'86POAV/W6[IW##$V,V*]
M=4V\OZ^NSH=6;+0;\M*F'A7L.JC%$/&.RNTDG)7+(R"P.$DU@/VA"F"? ?7C
M^PJ .3P/#'3P'RJ<MABV\U!RT6YBH><2>Q[M#T18$$W,)(J*('*DTE456SPA
MV"Z@E3=<VCD01,<2H*B $-%55H?P3MAR76\E8_P[#;;MHE7R)M;R)6=PF2LC
MQ-]F7U?M;#=;8[TME:+I^/B[:H-"*6,ECM!]3V7N@BO<I)TC%Y"3DBUC)3MI
MS\?#!^O3U_:C!\@><XR?'Z)Z>>.IK?SJ*KJ(\7S^GPO/GR^E'Q5][G]&/,O/
M\?EI]?E]?C3Q^OKP\/OJ7&E*:4II2HDY&']F?M9#W\,;LO\ ZZVSZ5!ZK]_Y
M5+;2III2FE*:4II2FE*\67ZJ**!MP&USG_\  Y<0#E\=U3\Q\?9Y>'GKK>SP
MS;S\XQ.".G41C'7RZUY)]H9_\9Z:/'V*4D>&._QGP_/RZ\5Y3Y4@E.OT_4]2
M8 )>0#X<RAS#P\?$#>P/$>8:W5SQ 5R2>N?'KX\>/'^N!7,639V9Z@\?/'3&
M.?+/EQ748V5Z;%,1QA$IG+07*8B(!TBS6 IS@4P](G[)<>0?VO/F(\@Y^:=I
MX=\+2<[D;.#TP2>A \<C/)\37NGV=WG=7R0AMB31@.<Y((1V&,C^H-@CCP/A
MUNJSM3IO673U#U)G**ADRE%4_641,(% "AX#R*'L\>7AY\G92%HY #@#G:.0
M <#Q.?/[C]U>K:I"6FA*$G/#,W!)4AN,#'B,' .?3!KZ1TEV2A0*4AE#=F04
M5 $ ,!N0"/,!  \?VIA,', 'PYB&IFC!7R !)(()Z\8Z],??QUZU=@N=K^]@
MD@*BGJ<D ]!\>3_KEJN(I'255,DB<H%$W9*<C& XCX@ E4*<@B >'+GX!^V\
M1UH+UBLB("W!4Y\P3R.F#P/,? <YZW354DN H0Y#IU;G@[<YP#\1X5E>'<N4
MP3:H).$>W!-N" )D,!P/X!R.90.0#S HAXCS\P$?'7/W>%R[,HVC).WDG.X$
M<9'!SGT\:[;2)I2>XAW$RN$QD8VD 8P3SUZ8(\^*GOC#%]WBXQ55PQ:L(M9J
MB]3<S!V1620*$ #@0ZB;D"JB7M4P)S(H4_2;I$?#7 ZMJ-I<2(8G=W#,I*%M
MV 3Q_4"1SQUX/!KV[1M-N[.)HV"1HL:?U[-H)7KPI ..0>#SY\5FO&$D[A),
MP).VK1LJHLCVJ;1NY7$AB&( I'(45>8"3FF82EZNH * @'AI+P=XH!!+CH<G
M \#G.<<$\;?O\:VUN-H9?_D]V=O&2W@PZ$CCSP>F.IJ9U9M*3F;1;F79-Q%)
MN(*ON\/3.E5#@  =%)=)!(>@.1T"$$Q.8!R W/EJXPX?)*[>%)?) R1SMX)&
M1T)^'45%Y &B(7O&',C1IW:E5.<^]@D<G&1GPQQG&5+E8E%FJ$)Z+CTY94R
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MD66YJJ)&.8OBFF3I3 #%ZSF( F H".N ^TR0)I44;#<>_E)SCA0@"DYZGWR
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M0D8<'=TPQS@<].,? U_1XX52(-^'!LK1Z0)V>WG'1!(4"@4I@A4>HH 7ZD
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M659N7TC&0[.1>)R.2!YU!. ?O_*K"D=T6<FV_P!@-L<)#X=N^-WT.]L%V8U
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ML84,D#=_(K9P4 *GH"/$\' QGFO+)#"LF0Q#I"N0PD=( W13.H=0IQ(+=9$
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MU,W,5Z9^H<"G4*9R^BEF@  F 4P.J8W4 =B04@$2X3RVHFE(6:+;("?>>7)
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M@F/S_;F\/(>HP\O;[1'VCX!^,/'3)XYX/C\.N>F.>.OCCGK2J]H<? #FY?\
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MTDR-$SC(J4E$NWC%=%P>D9(.#G@C/C^&?$^F<>/D(QUK* )N3"/2181#P$
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MAX"O9,C4EM((QAK$S@K9!,5W3B*CIQL9B6U04$XDV+J)EHYZUE8Y%W&.4G)
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MI5/?Y<N?/GR\?/V_'X@'@'\H:GGGG..F<8X'7)^[/3J<4I[1\O;Y>?/R]_\
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MO?X/'^7SY:!@/$_@//XD?(5&QO+\J#Q.-FOLMV;_ +_TEN]G_+MY_P @^_\
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M;DS=JXP[71+R\TU]1M=D^W4K?2TL84N9=0FN+F"6>)H88K=XWC*PNF.^$Q?
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MVKTG2M*L[&_NM8TZ;3>T\?:$2:3!%,NJPK:PP?PVZ+W=H80C0L8Y2+F,)<S
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M&$O5G]01<LZJFLUF%[%+NGA:@@X+ *)NG3\\H5T<Q#UGM]92Z>EE<3:K,O\
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M59M;E3@P2@G/!1O D'P\""/NKF.=RFWQD@NZ>9JQ@U;-BB=PNXNL BBB0H@
MF444?%*0H"( (B( ',/?U9]AO 0OLMQN(R%[I\D'H0,9H+6Y.2()3CK[C<?*
MJUK<EM^N<HG"5+-6,++,+"H5&,A+K7Y)\J9),ZRI4VK1\JL<R:2:BAP*01*0
MAC#R !U:DAFA&98WC&0,NI7EB%4<XSN8@#S) %4M!.N-T4BY!(RI&0,Y(R.<
M8.<>1K*ZLY#()BLM*,$DBB4#**.T2$ 3CR* F,<  3"/(H"/,?9JT!GISG@8
M\:QPZ'.&!V_U8.<<XYQTY_MYUU$C?*5$-5'TI:Z_'LT2"HJZ>2K-NW33 HF$
MYUE5BIE+TE$>H3 '(!'4X)( !))P!CDGR \_2KJ1R28V([9Z;5)\SX#R!_ U
MYS<];0.%1D7=-O6S=DC?MBR&D]WVW6\8*M.(Y#(F*4H'&5FR+1<;4"W9GJJ3
MZ4)((WR2KF)\? <7*2)0=0J;E9TKVI"HW>XG SW4@"GG*-YD<^7.>?C]UPVU
MRK;3#*" 25[MLC']1/D .OYU?$'PH=E>5]J>T.F4K=)4\J36U.ZYER'6,_6^
MI81W U'+-FSH[L!LUNLK8MO\?:<;7%&Q2TX65:+B*,S5;-!PTO$3*+QJX!S:
M;,>=WN\ G/&%.,'T!XQYU:".QP%8G<5.!GW@H8K\0I#$=<$'I5TS_!JVO2.5
M<?9,A\TXS8VV*PU0,5W>)L6U;97>ZQ:J[C:TV&P05PQICZR8?6HN!;0HXM4Q
M!R;_ !K5F]>DHL(H7]?<ST82;6C=[@D#?RRP4.#[I=E+!01U8JI8#K@$] :%
M&&=RD8ZY'3!QSGR-9FVY\,S"NV+=O9MVF*MQ4M%WO(^2MQEISA5RL:P6MY<I
MF=;2-^JV.[,T2=E59K8/N(O9C'MS9=$^HQE)B!EDUX9YW5&KWFZ D#R&<8Z_
MO5)XQGCPYXR3T'/B? >-?._[/HNJ[YK=O^L^_>'K*MNAJCBV)IV0L<XMEF&.
ML0L104GL38DODU-,9.ADR/+D?S-GLL,Q"V2<DX;BL^<MHMJW RLH]Y2HYY((
MZ>>?(?+)JJ.-Y3B)&D;@812Q][(   ZD@\=21\*Q9M+X>^U+9GGK"F2'N]1O
M>5\-8]S;0=N-%L3?"](E6U/S=<$+U?7=_M]4BXRX9PE&DBNF,/,61RW:QJC]
MS*KL7DV_5DCD#2K*\8+K"JO,R@D1JVX(SD?TJQ5@N< D$#IQ7[//[A[J3#AM
MGN'#; K,5XYVJZ$^ #*3U%;E2YYPH:R1=.+EC'IK9-QKJ9AZV6V0HS<G$LB)
M*/))C& \%VZ8M4UD3N'**1TD2*IF4,4I@$9[M]K/L;8K*C/M.U7<$JC-T#,%
M8A2<G!XX-2;><*KF&0*ZLZ,4;#(O]3J<>\JYY894>)KG2F9L20<>XEIG)='B
M8MHX2:.9&1L\.S9(.EW"31%NJZ<.TT2+*NED6Z:9C@<ZRI$R@)C  SW4F=O=
MOG#-C:<[54LQZ=%4$D^ !)Z&J8XI93MBC>0],(I8]0/ >;*/B1YBOS&YHQ%,
M,6LE%9,HTE'ODS+,WS*S1#EJZ2(82&5071='353*<!**A#"7J#ESYZI*,K%&
M5@XZJ00PZ=1U'45)@F'!C?G./=/.,@_@01\:Z6W;C,"4".;R]XS)C6I13M)9
M=M)6&Y042P61;IBJLJF[>O44#)I)E$YC=?("ASY\M7HK2YFW]U!-)W>W?LC9
MMNY@B[L XRQ"CS) JD1R$A0C%F#,!@Y*H,L<=<*.2? 5Q*_N;VZVQ%-Q6,XX
MJL*"R#=RDM"WNN22:C=TJ9!LN4S.06 4EUR'124#ZDZI#)E$3%$ M-%(K%6C
M=65MA4JP(8#.T@C(;'..N.>E7#;7"QK*T,HC?^B0HVQN<>ZV,'GC@]:N&9S=
MAZNQJTS/9/HD/$MDS*N).2M$.S8-TR!U'46=KNR()$('B8QSE*7VB&JNXF)V
MB-\^6TY_#KXU0D4LAPD;N>.%4GKTZ#Q\*R>0Y5"%4(8IR'*4Y#E$!*8I@ 2F
M*(> E, @("'@(#SU:JW7ZTI32E4$0 !$1   .8B/@  'F(C[ #2E6 &6,7C$
M.[!]$2D^@F%N-0'LP-HA0C&EY+8DJ@:GN'PO0;)68+6NC6_09U DO3JJ<4#;
MOIRHBI6(=W.ZFE[/<2)98NM<MEP1D[W0L9UFJTM.!+-V&[9*LC.K56,"2M<Y
M6:I L5I)Z0\A.V6PQ$1'MDSF4='<';-G"E0YH_&(VU9$N6WVLU>F9H<P>>H#
M <D>_NJG"LZEBNP[H9*[PF!Z)D<REF&80L][F\>V*.2/6(JR0,6*]=>R$TG'
MV.-='4K:\DY;KF.5%=%8R?[<J2I%#$\1#ZL"&$2^("'CR\0$/9I2OMI2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2M='$U_<>
MV]?A%^&?\^K VE#^G3X_6?2J<)O[ ;"G[]9P^<'E72E;&-*5$[*62H^"R4-?
M<*R[YX%=<-&47'I)($9DG(MTO)RRCQX9&/*@S91B8N'CY13L!=HLHE->2<JL
MU\J)V(B@CMI&:63+W"C("1LAP 3U5F4!1@NS?YMN%Z2PL8VTWVPR*)%NE98F
M9U25H-Q1'9<[2P,C*3@+M&XJ&W58K[<7AA)5P:'L%9M$] .)->P-GD0WC)ZN
M14;(1K5^_M$:JS9R<%$PWIM!1W)2C-B*Y#.5V2+U%N_.VU+ZI91X7==RL)A$
M4C1G*OD))(Z[ R*K$*,*>-P!;!-;RRTG6+AKJ"24V*^R++W*W5PS[ F^)8E:
M9UEEE",R('(7"'$99-\;,L5N*RC6R6N(F99E$VE\DY1K-J!-U79^-DCK,(F2
M2CG+9L*:@N8HCN"4<$!1%MW9RBFV.51-*T;2"[N$N^[N[2Z0\QB9W1V1B1-W
M9D81_P"[/O+C"C"C#\]=I]Q/%9+:SS6\T;1%#<&%4F0-@>S3!@"P(N(Y"&QM
MD;<[;E$E96Q99G)JG7ZG%*HB\34>1 L53=W=L&9I R<8$BL#,O4BFW4*"2KP
M$S+,G+-JF"JJ)2#GRZC:))'!%N+#8C%MQ19N RKX8)VXQSGGD\C%.F-";N^N
M]QAB821!F=V6$0H4,8;)7.UI%C X828P,BLBNJ?(J2+R'M!CQ]=D80B:+@ZI
M8J19.45T3"LBYY$*8'"P'%UWI(R(,S.1.9+M"E'%+W#S3B]6/V64';ELA %Q
MM)! !&XDMY8P5.0:3?0>R6]SI5PSW-O.&D6$&578!F*[%&[ C*[57=[Z[<,I
MJ/EVNLKC&%D:+$KS%UGK:Q%CA^XN%(1XC%Q2\JFU?P#@LO)I2T\G$+=[;)SB
M 3"IU'7H]\Z9-#Q?.W=NUA8Q:?!--(MXR@SI-$TBQ]XTBAW#;E1$8K".3PHR
M'49Q+2V;5M434&CAMHK26:6XLGS&([IK:.(-"O"2]\=LLA9E8"7?DKN*J)C:
MO2=EQA>'-PNXWRCD.E86"+.9A&USF)M[WY^YL*TC&A,S31N=LD#A@H\1K:BK
M<IH2.2". "W+58UF,%E#*.[53*;I'WS;E=7E:60%N'?)8L2#MQ[O-7[^:[%K
M(-4+"W<31VK0R-&+41"/NHN[1UB'>("J(BE&0NL@Y5%R]D 7=4%_=YR"GK_+
MC&!(4W%[-^R:NW;UHZDFB31LF!$T7"*BO9NI!\Z7=&9E<**D(+4[=(-S96$5
MW>0^V/:6\+.J2WDS-,MFFT.S+"BDNVW.S:"7DW)N&"1HEO)9[:>UTO<EQ&KD
M8 A$[J V!--W80A"HVECM 5^-VVH,+;NK=FK.&/\/0-/L#.M3L#,Q64++#NV
M*\%CF:KLO(,I9]2+(G74HM[W=FDS1DB2RC9!5)RR;P;B0E7S0[ZTLNL:?J,E
MW=67\.TF*2/^&B]M2)=5A>1C#=SAIBT4-Q'L MVQ< [W>../ .QBTN&WLF@C
MG_BM_<7$O?31S3E;?W0K6ROW.^.[MI>\G,V3;2Q!$52K-)%C#(-[M=QLDO2L
M=2\=9J-8AE*A+0=FB&$Q5$4*Z1XK-I6LY7#Z3](3)2,).-<S(,;"DF1A*PQ4
MW$:Z:$Z#2;6'3WBUO4&OM2U%A#/8Z59W)MI((YY=T5["I8+((>[9X#N9"49)
MPA,53=6_\7W6)NK32-.CS%<75U';W0FE2)U:U=4+LL=P&*7&=K.KXC=F1D>X
M+Q-R'N/QM!-9E]CP[.58G$E?,G8JT[@H:6F6$HSLC8O?$4HN2:.8Y=T_;BJ"
M1D7 JJ@LF_3;;.>*S:\U>74%M]6MY[,3*MW=26=]#<WHA+WMI"@A2:>V=Y0D
M179(HR0R/SK?9V6&R6PN+JP]FNF59+15GM9+:R8K';W>Z1U:UE14:220%DDV
MX8.FXVK)9ZRAC^^JXOQLQ1G8YM(%DU85&N%"O0CQVV5*2)9NXA9JT-+)N5EH
MITM*3#IHL0BB1U!-T=%@:1V9L;"6]N-6U7VXN\5E90P]Y,0'(6X-F8Q*]JZJ
M6[Y$C49(W;E(JM8>U&L72&&VTB.P6%3-<LR['$BEC!'.I5(I X4!&)3_ #;-
MG R6ZS#D.=C:S:I"O0%0K1K/(,+O8\?7BK_[$M*R,<Z 4W35H\-$KF.L\;O8
M8)=@Y<*K@4YTVI579,Q]%MKF2[MFU/6)I?X9'<V.G36DUE/-=3DGN9A.ZS/$
MJH#'/"ICPZY*LH1M8HU&.*U=(M&BM8]2EM[VZAO>\B%O$N0ZM$IBWLX*302R
M *1D*ZDLN+K5E!S,5^NM9O)1N;EO[JRKUR/E9:T&K9TFKEI7I"P-SNRO$0-(
MG9OU7!I&.B7$<V[JX,LJB(U!+*R[O5(;,VNE642V,D-ZR7+7&HM.8#<VZ+*6
MN&B*F11;JQ?+_P"087*M=.>1?8.\-S?S2R7\<UE;B%+>S2/ONX:1%$<<4F\J
MQ<#:3$3M9BU8.L<BBEFBM4V2A*= ^Z<Y+&Y=Q36(DWDNT3*BJW]+G644?M8Z
M%7/VDH[:=DU5E"D?]@NA NUV5W4[K1K[3IK:UO\ 7[_4UDM[>WM)WN'@T]FF
M!:[, ]Z/VA,QVJ21F5(U;NU7)K>6::]93P2R0Z%:Z65EN+EK46T;WBB(8MY&
M;8DZPO\ S9]CLKN"[*>[45?T02S6I[9;P6:KD[;*XV;05=B: I*6*2D8%*4>
ME>HV"R,VY1<G%JJMVTJX>*)II&;LF:+1@R;H#M.Z%K%IG9^X]MAS.=3O+Z\1
M;>W"E7C@2WA9QAF92H411M(P=VWO(36H5_:7O-6CDM)6$8M;:SMU:24,9!)+
MW\[J"\9#;FQ+(%WX]P*%:UJ6TRJUR*=Y68R0!)VDRH%^<J66595AWCA=9-\U
MA8]N4 <1)2@9TC+-60J2+MX0?Z!!-Z"2]5_9)<Z:MM=ZDTZQR7&KV-K#%+'<
M/JDL\*=_=S/[MU"(81W'OQQ?S9"ONJ0+=O!W%^+YK2TA4K!87=U-+'<1^PI&
M[+%;0HSO;W$<LC&;8O>J44L%WY.5IO$U_P G[>YO"+^-;PE04N,;8H-A JN%
M8QA18V]4D63-:5=KHG?3XP[9=8008*D2(Y*F55,X%14HO)8+?5(=3D,QN!91
M17C3NFUKXP3F1+>*)?Y5ON"H,XR48CAF<:9;FTMM/DMK.6''MERUH\"LIBTX
M+(D2.TVUY)E#LX.S:&.#EMH,GH+%S2KP$6A 1L6@P0;IID8*,VRQR]V.H)5Q
M[8%!,8Q  I^T4, AR*!C"42#IFU19W8M,S,<D'O"0<\8!!X.?'PQEO,:*6YD
M=BQ) +$^]@GECU5B"V!QMY],#W3:%RQJC>:[.UDC"-C)&8CG[%LLB)2(@JKR
M^I6**B?8=L80ZRD X=2QPY)I 8 Q&FCWF4,V,KNW8R0!D<C.!D=<]!D^\<5D
M07LL6Y-V \;*H##:"2&!&<%>00O!Y?& N<=CBC#UU@IO&2#3&+>L,ZYE#&;U
MS>63Z@+"$9#LV[2TH21X6PN;2Y:2"ZJZ;)%6&,@FDL=-YW<B?7KDM2'>&5A(
MKB1ID95:5L,7#0L-\87" *S,7.W&03TK#GNYHFE#"=2XA"JP B4F:)GE[P7$
MBICWF(CC0L1_4S.RKMSM2S%^U45=HE10:%7!4Z*JG9 H;_AU2)<NI8O24Z8"
M7J(8X!XFY 6R@5=TS@'NMRJ>2,9SG'B<[>.>N*TS2--*D<09.\.Q@A.&W%<[
M@HSG R. 1Z_Y=16__/LWBG!MM=UJN.)Y\Z8/8<9!BJV;-J0F_8N^TL\V=53O
M*B34X-6T>U:H'57EGC)%4[<#<E;ENJRGO7GCA7&Y=V0\S%T5;>'9G^=(S9)9
ME"Q)(PW%0M=9HMJ_M4:/&[&.,L<*/Y9VL3)*'_ICCP  JLS.548W$UXXWX6R
MZWYY$1A#V"QW298-#@V;D6D)Z:GG*"1VB2O9@N7O[Y9-)1 IB&5^N%$H)CRU
M9CD6ZNH$$LFW+!!([%(PAR'*MDN\2Y/>,&"%AT8BNRU6XGTBWU,IW*1+$CWK
MK&A]QU,D\/>XS'!*>'A!1W"L,! *]SF)<%Q.W_#M(Q)WE.,0IE&@H:85;G((
MKRKU(2R;N/;"F"W2_GW,B];K&*H519H\+TB5$NM;=,)3/EY>ZD=P[\EB !L1
M=JXS'"!D+SD*PSN&?.[:ZEE,<O=)',P[P1;0$CDF8M(%)!SB1U569F]Q&0$X
MYD9C&)AV[R0G7HD;)Q\&@PAG+XA'#ADD\ PM)%5(Y%% [P:.!,$S&YG%%<!2
M(*RG:5H(@\17>($C'NDGC;[NX@D D#W?= /]0!QNK&FG)YD(##D%<L2[D[6&
MT%@%[O&#QR<#))K$U*+;C6NZ*6JSLI9)PZ3/&R31-!HFZ54,]("+5HBS9]"+
MU$R +IE R@G=-B'#M&BQS9\CP#N1 LR'<SEGW\Q@+EB,[0.64]!PQ/\ EVW'
M8R1,%"*YPF$QEWD([M Q!9BR\MXY*84-NQ&+.SJZY"9M'=>(A+1L))-UX9-2
M-;.6Q7A%SM"29RK-N9G(&34;I ;J!#M1ZTC%.*H9.Z*9&:9FVLNW:3@>]A2<
MYR6/F.0 =H&[%;*R9+1N[&W/#;B =R\9#JP)*X7!!X!Y8>-<>C1<2W083=VK
M<<YDFI3'6G7;=HO)5Y9=HW](I1KF5(H1B#9OV!CJ%,9JR**PI]F;O!3ZV!Y;
M:22.)F597"[59E$J@D(6"CG))"E1R?='-7[R1+D*D#94; B ;V4G871<YRP0
M+MSD(3N4#+;H9X3V\EC-S$U?8:Y-,CTIE8W$G*6E*P3CU6S33F->.(-U#MBR
M\M#QD:U2DX5J\DX63!M,OH!VB+9.-,1F3L[S44DL]AB%O-);B."T[F!XH(=R
MI-W\P2W:28F*;NT>!&@CF60N979VQ7EE]G"R,6=BV9%EGPJGO.Z2&%C-W(D3
MN%ED6=A.%=".[VBI09:ON$HRTT_#V6*FWO3V^SK"2J-<]'EF4DNA4RJCZ3;+
M/20QG$8BW=&,J8IE6Q$>A9-8S@6RVJ@M=2E]JU#3)3 +&+9=W2R]P8UD!PD+
M*#(6DR!A   X(=:MQ8: ERNPL>ZB/OEP5W/N7?M]U5.YF& %!9#N"M)1Y&Q3
M.'(WCX=JSK!^M)VW1;(%1$S J2/0V;L"@1J5-J(&$[<A%2F("@',X46..KB6
M4$$DAN68LP))))+.3^;?U9\B";(G#'!8%6QC'(;&%;:JXVGWLG !X]2:T=;\
M<M(9 4;8+K*D@-<A)<LGE>62?RC.+B5&C^-@:]4W\$Y6:L)8\X\F%A(1XFZ3
M9N4V,FU,9U'I'#JNSR"2=II5@)DBD6VB>.%YY1MEFGNH95,LL8MD@ >2- 6C
M>:+(5R1N1!-;H@'>E7'>2R*9! H&U8K:2)@D9:<NYBB=]W>I#(H9DP8J8TR'
M9-JR\E;L?-*2\L!HF,EK#!VIG/LGD%3[;*N'#L6,DU43:A ,IV)B9&02D&YW
MU8<-YB.<JH(N4T7.XU+3EU$16\<MT(XKFX2.2U]BECGFLTB$?=E26]H,,MPN
M(V$-VJVTT>YDE9*(9P 3-##L>%'>&5[J#N8YRQ:782(F@66*$L2@E@0SH6!(
MCDQENTWJ9LRDX:4"2?Q,/49TQT;%6ZN!5G2;M5FY3DD[ Y0<.8E]'R31Z\?Q
M\DU*T.[B5DY9N1@X2!8-=;Z?<:3/'*T+W;2)_+FNH-JF'>AAN;,LHF650BK(
MD@<1OOM)!(CE369(]T,,20)%/+LD6WD)E23:>\BN-C/"K'>^R2%XW>-EE5H"
M&(_H&Q/((J, /((]ERY#S\.[)^WV_?UQIZGXG\ZT9^OK)_,_&NPU%*:4KK9J
M'C+%#RU?FV2$E#3L:_AY>.=%ZVS^,DVJK)^R<$YAUH.FBZJ"I>8=2:A@Y^.E
M*\$6*MM>R6F<1"PU6KYMX;^#@P7OZ)4:1MSS?D/=+D_.4LZIF2*\_K\FR/*9
MJ:8RG+9:Y=4KZIQ[BIV2.K<Z9E!647\[#S+-&HY('!\L^&/P_O\ G0_7Q_7I
M7LVWL;2X?>AA4F'9J[2=%19WND9"92+>LU.^UZ3E:),%F8Z O^-[Y&R]*R/1
M9%R4HS5/L\>O'/%V[!^F9O(1K)RC32H.XXX,F-<9W#;[-1&?\Q2-2PU'[;E[
M?09EI3'D;EZZ[29_(-GP-;9*7+!I2]$9U"5R([;*4JBJQ=4>5VKTJNHL&+"#
M7](J5=. L!X-P'Q8-QL;@S#>+<-QUXV)[>;Y=&.+:#5J"SMMWE]R6ZE"5N%E
M;5:*BD9RSR2#-HB_GI,CF4=I-D".'2A44P*J/'[JVY:5--*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E:Z.)K^X]MZ_"+\,_P"?
M5@;2H/\ <?G5.$W]@-A3]^LX?.#RKI4UL8TI4"=PUKD(3+D$TAG)F\P[8PS4
M"Q\0P=/WL0LY<D?1:CUR@H9(\H+D6:"XB=2/2.LX8&0=G*8UB34]/M^]LYY-
M4FO)8':TL[0E+>.9U9$GE<1L&Q_6REMV8T V@EAZ1V;T*ZOM'@O$-C!9QZ@S
M75Q<L[2NEO)!,8D0..[CRH5V56#"1BRY49Q55Y+;["W*U2[6L%;9:;1P62VP
M+:*FG-A=UHAQ2CXQ^RBHV2-*DFI6;0173D$B,E631Z\2.H,4=0)MQ#'WWLP2
M>_@ASW%L^]A+,"%CN74':0@R20TD9*2<#<1D:Q<:F[VL+2K#9S;$-R517[I,
M-)<P.7C $<@V(F]96<[.[)V@]LE)5K(4NZO^2).&I[!)JG+-DG,G'.&+2L-B
ML(Y-NHE+I1S6(>+.Y)FR6<O%&)&JBZIDDTFQQ,[P9K*YA#ZGJDT.D=TT<<G_
M $Q'8BX]V-7WJ J%AAR$(+H.A<;,BWU9=.@M=(TBT.JF;OGBN)8)8X@\*FXN
M9&DV,SRI&P'=J6D;<-HRE??%K5=I+)VIM$E;5&0?1K5A-.S-&AR1AU%&L8[$
MQ3N"'#O 11#.2J@1 2E?ME#=B 'M6$,J3"9O99-.R\T5Y(,/)DG:X5L'#9;&
M1QE<X&*V&OWL$]B82)1?]R!/:P'>L9VQM(H"DJ^S: X$C[LS?UJ0IS7FJ+5M
MU6B)1E-O()&MR*#ILYAS,F*4^L@DXBSD4])$=':P#))5V[E':#4?2S!!,A4
M(1JNATF^,6MW'M@D-S;NL;S$XMLD.9@5V[V95VK'DK[Y&?>?/!:0##J,.X3
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M]?<&EP"I&< @'!)*<L2,D88CWN.#7!&TEU"L:$CAG4  $R L P !(X7>0=Q
M!X&*\PJIU;=?[A:IA]VKF:G)5^Y/VJQ0526<+.6Y3@L8HE19I%*9%,IA3333
M32*J!2B).Z6YCBMAD#;'&#M(!X106.?'=R=Q."<D@DXKT&!&VJ@ S(W4'.6<
MCG/AMR>,Y &,]"(V[A+Q,1%2D9*08-"Q<Z8M=B*\NHF[<F4"'>*-9%Z#98H
MW1Z7,F=9(3*G5;E1$IVAEBJ<HV=3N8TEVJBGOVV.K!8PZ@*K<^])E(P,@>]N
MR#MKH%D-I!(85!3:(??W!RS1LK.P!Z(K2297)]T8!'61FP>LS&VK;GG?.<I2
M/13K-1HW#^+9F;7<D0/72(RDO>K8[BS';.THGT>T$6"ZA47<S,,XJ"CU#K'
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M;+]XULFFW.I36L(U:9=,L5VSVD0&^]F#=Y'WLP7>JJW PY63H2BJN;G\:L;
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M)O!3J\R]'4)N-6W E#QLKC*Y+'^GHO &. /%<'(Y.*YZ>1F.T1/(Z*YV\D8
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M))))\]N1U4$11N..(9C;INV0[(TC<+&G%1,I)E%XL5^[9Q[>,B@<H.7!BQX
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MKF2F4?-2]$;3\?&1LC*1SMM .9^1@18-XJ,8HCZ4 TZY=03PR9V,HT6=R30
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MEER-"&)(2)5@[H$<BJ:042DQ(1!R<SE,^]ACV[8Y9+B\=4W&8Y5 %'^[4HB
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MK_7G#E QJ_J4E[*Y$]O.D.Y8S+<-#+;S,X5>^61&DBNK>1=LSSQ2ED5)5.&
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M-(QE#8SJ[R11@(H*[I5QD)E1A0W"NP<]6 ZCIC%8R*H$CDN2.$&>7QDDL%/
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MBN& (($@!!9203&N_*'<,L,MD6T\LCB***V23&XRR21J;=BI(,H*@X<*0'+
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M>OUJ-K+=9I&%,1H<Z0HH'*A_0Q$VR* I)JIHIKK%542.[4,[5<*]NX6 BA$
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MU; !)MYENI'1LJ8Y5)+*HW<SK%S;R)!<6IEB9-9N+&\BE"R+%;A8[BV==Q9
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M#?R3QP2 I/&.0/,\^)&83YWR"A42D9^DG2[?TB+]=$08E5*S8E4=E8D4*18
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M)-8:KN8J467OMLN[B'QI(R]P5K7IR2!-!]8X^OQ4%&14PN<J+-1C'F[V];K
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MC+NBR3W"N">].[&7&-KLH&UGK4"^MXI1-?=V;F::2SLX#$%5[D%&.P+$QC/
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M#+L4YILFE#QAV5NC^T[P0@O$D"R8H(!UL7BJ)W;@"\D#\7#I-Y<Z@9)DM8X
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MRLGWO@'P<?CT[OU^7[TJOZ]ML/W-R&^5D^_-RT[OU^7[TH/ZMML/A_4W(;Q
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7<RNA=@FZ%$&RHI@$YZ>G[T_;Y<U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g582934g55w46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g55w46.jpg
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MFZM034BRB(?9]"E)21<I,X^.86N%=O7KM<X)HMFK9!X=9==4X@1-),ACG,(
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MF+99]@79S$, EDJR,14V47'JR*]BDR)DBXA$I'3Q&1-B@-VMX3)T:$]%OTR
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M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2L.N=G\'F<_P X:O\
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M1K[BER:Y;QE&E>*1H=GH[D2XTO&:H"P:%@'#Y6=8+2;5O.IW!>,(X8)M4_\
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MF*4Q2F*4Q2F*4Q2F*4Q2F*5QU7C1%=LU6=-TG+SS0:-E5TDUW0H$\Q8&R)S
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MJ4KG3&NRK&5I=FP@B(UR5IREQUA.AE&DG;&,YS6FTUPPD3$MHM[?9K:^9[9
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M+:XXDD/,AU10IMD\QS!4A* I>HH&JIY([4U1& 1S+['U['@C'5V9(O(V^MM
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M5@- A)ME\.L.1(S\&0VF4+);KB_ 4'E+=[0XAAU\/KRTA2GG6]+ .-.5#0,
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MR]S=+NTP=11X2Y/$UR=/*#$=YUY3B=FW2XZ[(7=BK2AMP J4N\R A"4=4,
MX6'+5<$66. ]VJ5&CQ0RX IY@,L,PV^'@G6XZR2&T-\,PRXM:\X=E**AJ;Y4
MAB>&%0:[-XY7&)DDY6CZ/9;DLC-R_E5'4_<K5M.[-KU5DI-O$QL?6I.HT>4E
M;/9:XZ<G<2#&>^3KE@B!DY21>XEWY\Q+HPM&B1<%0FE!*-+;#,2.8SQ05J4Z
MAZ0A#33J1A*F^8%'!2@9VN%(J;A8I3;@=B6A-TD)4MPJ>E2;C+3,C!:6VT1W
M(L1QV0^PI1*T/<A2!D.+5G;G.UV-=I#2\G!2;.6AG2S.29K%4:KH#^>!_P!R
M)!(("55-4HBDJ@H4Z:Z9S)*$.0YBC4$@Y%4(!&#6T"HR4S+UN)D;!%_!I=TT
M(J]C^X3>4<1$"G[#"*C?U! *OZ18QEVGF>G6,95(XCF&XZ8]58#L?.N=/=?@
M<UVAU'X3(] ^T?1K= _[\P2]XLD><=[J<?\ =J\=\>WPZU:OX"L==*OH->8'
M:=HDZ;=G3B#<V2O6=[0]1@QL,%87\$JWB3:VJQWS)5*/*BJ_1D%"-# IZY%-
M S7\Y%<X@*?YU\3W*78[X\Y"=N$&X.6CAAMB?"N#L-3497#]N6^PIIE(6^AY
M8:4%%Q !9&0HD@?/UYFJMMP?4SVEF>[!M81(8?6RE+/860M*P@ N!:T).-8
MP-0) JL58:#=U-S<;+<Y UJEY&3&.B4&\3/K2;AN+<[A[/O/E46>AS.W#E4Q
M7,C *$=]AEFRSP15*ES/9(4BV.W2==)"KI,>?Y$7$:8J6ZA2>8N:Z+BB9$YA
M5E"WX12X-1:<=[VF+Y++L/W0FSGERY#CH::1&:E*6MO3WGG.U<]O*B<*6R <
M$I*N\!Z+.&R*K;5RK9=,Z*Z!J&DJDH42G34)I;5Q3D,4?<#$, E,'U& 0'W
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M"(VIJ+&:6,+;CLMK&0<*0VE*AD9!P0=P<'PJ5  F$"E 3&,( 4H (B(B/0
M ]Q$1]@ /<1S#6Q6:NEM*%AP:VZWM0-+B!%XB'7* EB@$ ,F]?)F#H,D(=#(
M-S!TC_910!>]I6>5*<;GKX>KZ_-6)2L[#I]-919?5E?DP )3 (=0$H@(#] @
M(?0/].",['<'8@^-*US[^X=5R6@I>RMXMC;6]:B)1Y"UYTUF6EK:Q[<JLC\F
M:W9:W(-3.VA# JA!,+' 6$\<"I&C1P1J (!X1QKZ)[7,AS)R8K-S%NAR7H4%
M;;[%Q0TV%O)M\&?!DLAQM/VQ$)FX0Y_(*DH;4EON'C[SPS#ELK=5&1+Y#;BF
M6U!Y,A",*7R&'XRVRI 5LT'VWM .E)"<"L?M'\.=>6J7D'M<91SZ.KQV+].R
M75O8[(W<JSSJ3F:^QC8=D[ID$Z<,*<>IR<F23^,("\F_(>QZ8D4:)\+P=Z*N
M'KE*DN6IIF3&@N1WC/O")\YMQ4Q<V5#98AMNVF$XXQ:C:9+XDHE(YTQ25LH"
M="8.T<(VQ2RMIAMSD*UHD3!(D \]:G6$I:0N*PLMQBPIP.AW!<"5#(56V+7U
M%8Z_@CP[5Z^E73R0=S$S,R0H>MF)E^)!>/UTVJ3=HV*)4T6[5DR;MV3!DW:L
MFB"3=N0@?3-DM#%FAF,T\]*=>?<ES)<DM\^7+>"0Z^X&D-M-Y"$(;99;;98:
M0AEI"&T)2/0XL=,9KEA2G%%16XZL)"W7%8RM6@)2-@$A*0 E*4I2 D"NUMUK
MA:/7)FV6-UZ*#@&"TC).@(=8Z;='ZDT$BG6765.)4D$4B&.LL<B28"<P!FS<
M[G#L]OF7.X.\B'!87(D.X*M+: 3A*$Y6M:CA"$)25+6I*4@DU?(?:BL.R'U:
M&F4*6M6E2L)2,G"4@J4>@  ))(K7[7N/FPN06U)?<^Y9"0A-83L,\B*GIY\8
MWQ,U3>A_B+>TLA0&/A7#@2-[ L5HHXFVTR#13UC%W&HJ$\0A\#WWCKB1_BWB
MU]<;AN;$D1K9PH^"9)M;VD1V[BT!R(SBRA%P);6[+:EADZVEL 5R+%HFW>YN
MW6Z.NMV]Q@L0[4K*'!'6-TRT#N)U*TOA(*W4.!'?;4C%9A:IT#J;2K=5+75-
MC8%PX;)-'LJ45GDS(H(G,H0K^4>J+O%P\PPG$GFE2$P$'RP A +ZIPUP5PSP
MBVI%@M4>$MQM+3T@:G9;R$**DI>E/*<>< )SWEX.$Y'=%=#;K/;;6%"##9C%
M8 6M )6O&XU+5E1&=\9Q\E7)G55)TQ2F*5B'SR_@F[=_J=4_V]JN>5>F[_)=
MQ7_Y%M_XU;:Y;C7_ !8NO^9&_KL:O,WGYR5\\4Q2F*4Q2F*4Q2L]M_T[3+.L
M[D9TBBP%4DM57O5$7 SD39+%*2%GC;Q5IU[8TY1"8G9..7092<6V49&BF3,S
M AB(+*JF4<*.O=./+1P@S;>+VK+8X-KD<,7SAB+!FQ;A<)+]QC7FVS7IXDHE
MS9,=:&I$9M3)C,M%E)2A:E%3BG>WOD2THC7=,.$Q&<MLZV-L/M2'W%R&YD9Y
M;X<#KSC92AQM)1RD)T; DY455Y6I/C<GI\S6>85<^S?DW84P<.*SMYQ*_'5/
MB?P4_P 4B]FQ].]03NC_ "' U?X8AVI_$6#[RW7J("VR?1VGA/E3F;8>)/<Z
M>G6Y;>*W)7;5=I[&>U1N(F+1S!EC0Y[F&.C">T,/Z7>9HQW.'A:=+[<;W1[.
M^-2H]T4[SSS.2>8W<$1-7P-)[/RT[:T*PK-E\&3W^,L"DS OBN:%\J(EA?X.
M+M$-7W\811@])%7>ZLI C-U8M90*3N5/+019MDQD79!27!-8J!ENB]"AOL><
MJ7">#EC]TXK%\A1KG$@/QM3#HBWF\,OAIVX<-PD.RC*A"8TS(=&E82L(*I#@
MLSFWR\RO5![2TB<RW):86WE"PU,F(<"%2+<P%NEU@/)2M8PH A),?-LNVZXX
MX7"N_E*D[$UV;8YO6]#@&LPX&O0VMJU)B]NUI8P .5FD2%QDGC" BFZK=%<L
M4>R'0,*:P'/H*XBNO#_H]NT$\12;@UQ)<9G#UC@MRW# B<.VV07;S<F(',6U
M&%VD/,0(J%MI7V8W!2#A>HX#<)-OL$MCW1<D)N,AZWPF$O*,=JWQW"N9)0QK
M4EKM;BFV6@4@\HOZ3A6:PASQ>N-IBE,4IBE,4IBE>O2A?\QJ7_FG7/U.SS]7
M+'_@6S_Z+M_]49KZF@_WE#_]+'_W2*EF2E;5,4IBE,4IBE,4IBE,4J@N5'\&
M_=_^C2V?JIQG#>DW_)[QG_JY=?ZHY4)Q)_@"\?Z.E?[I5>5S/S(KYJIBE,4I
MBE=K PDE99R&KD,W%W+S\K'0D4T*(%,ZDI5XBQ8MRF'V 5G2Z28"/L FZC[9
MM084BXS8=OAMEV7.E1X<5H$ N2)+J&66P3L-;BTIR=AG>LK#+DAYF.TG4Z^Z
MVRTG[IQU80A/QJ4!5L2V@MB#;K;6*%6[/M-I3IY_69*RTBI6&4A%9J(2*:6:
MH+MV2_0K58%4T#+"DH]0*B[11!)T@!NIE<"7\W6ZVVQ6^X\3LVB<_;9-QLUK
MG282ID1(,IIM:&E[-+U!!5I4\@(=0C2XC,F[8Y_:I,:%'D7),5]<9R1#BON,
MEYH9=0E24*^ <@%6DK&%!.%)S$*WJK9UR1DG%2UW=[.A#ODHR55@*M-RY(Z2
M64*DG'O3,&2_IWQE#E+Z17M7#N 3)@'OD3;N%^);NB0Y:N'[S<D1'DQI2H-L
MF2A'D+4$I8=++*^6\5$#E*PL9W2!6K'MEREAQ46!,D):6&G"Q&>=#;A( ;64
M(.E>2.X<*WZ59P\9K\TH;/8$V1:"B7])NMS;(/JY;U7) I5@8P*\-('9P+AI
M%/I;UQ9*->2#A"("/("CU^T.LB0_2^]O?6K&U?IH5"BOV:\7=MMZWW5;@]QY
M[$%<-]3,%QJ*]*YW:8[S[B(H83J>?:*T R7[79R829SV6&EPYDM*5L2BH=C?
M0RII90RI+:W0OF-K6I+6@=]:21FLGVJ-H1C2M/Y'75X8LKD[9L*DZ=U6;;H6
M5_)"4(YC!JJL2DE'DB!R&8-68K+O2'(HV35(<IAYM[A;B6,U;GI'#]Y9:O#K
M+%J<=MDQ"+B_)QV9F$I3($AV1J26&VM2W@0IM*@0:C5VNY-HCK<@3$(EJ0B*
MI49Y(D+<QRT,DH',4YD<M*<E8(*014]J7&?<]IM32H+4*V5F5D*M:+;'!9:K
M9(XK^,JT:J]<@T3^%*.%U7KT8^"8]B(I'F9J&9JJ)#(-S'G+5Z..,+G<VK4N
MQW2VR7[;<KI']T;9<& _'MD=3S@:3V93BU/.EB&QI04JERXC2E)YZ"=Z+P[=
MY,E$54*5'<<C293?:(TA 6W&;*U:1RRHE:^6RC P7GF4$CF))ZNG:,N]CLE#
M@9^+EZ RV:Z-&TBSVVO33"N3LNND(1+%J_.U(58DJ^.SCT734'1$5'[1PJ0&
M9S+EUK1P1>;A<;'!GQY5A9XD<,>RW*Z0);-OG2UH_<K#3Y; 4F4\6F$.M\P(
M+[3BD\HE8Q1++,D2(3#[;L%%Q46X<B4P\AAYTC[6A*].X<64MA20H K2HC0=
M55$_8NXQ\\C9!NHT?Q[MPQ>M50Z*MG;18[=RW5 !$ 4163.F< $>ABB'4<Y-
M]AV,^]&?0II^.ZXP\VK93;K2RVXA0\%(6DI/K%12T+:6MMQ)2MM2D+2>J5H)
M2I)]8((-<3,56TQ2F*4Q2O5KQL_@\Z+_ -$6NO\ 9*)S]0/1[_B%P3_JGP]_
MPF)7TSP__@*R_P"BK?\ U1JKKSL*EZ8I3%*ANPJ\A;:5::R[3.JUG*_+1JI$
MG(LUC>I9J)E!)R4Q!;G[C 8JWFI^68"F$0 !$(J^0&[I:+E;G0HHFPI,<Z%K
M;7AQI2>ZX@A2#J([VH8ZYVS6"2RB1'?86DJ0\RXVH Z3WDD;'P/D? X-=+IR
ML$J6L*1""*QG3> 9NY-5R^^)K+34J496<<'D 46!V+B6>O5@7(LHD<IRBD<R
M?:.:G"UN%KX>L\,ZBZU 96^I;QD*5)D#M,I1?*EETJDNNJUZU!6<A1&#6*WL
MF/!BM')4EE!<)7K*G5C6ZHKR0K+BE'4"0<['&*LS.@K<IBE,4K@2D7'S4>[B
MI5HB^CWR)D'35<O<FHF;W^KH8AR& #I*D$JB2A2*I'(H0I@==C2M>VU]42&O
M9 734%GU8?+"$?("'<HU4-U,$=("4 *1P0H#Y*W0J3Q,HG3 JI%D4L*DX]GU
MZUE2K.QZ_35C<=Z=5[1'V=6P0C&649O(U-L=V0QQ1(J@[,H4G0Q>@',0@C]/
MN4,N0 0<C.]462",'&U9&_DDUM_(Z&_U)_\ >9?@>0^059D^9^4T_))K;^1T
M-_J3_P"\Q@>0^04R?,_*:?DDUM_(Z&_U)_\ >8P/(?(*9/F?E-/R2:V_D=#?
MZD_^\Q@>0^04R?,_*:?DDUM_(Z&_U)_]YC \A\@ID^9^4T_))K;^1T-_J3_[
MS&!Y#Y!3)\S\II^236W\CH;_ %)_]YC \A\@ID^9^4U@+LF-9Q=]L\7%M4VK
M)K*J(-&B!1!-),"I]J:9?<>G4?8/<1$<PGJ?::RI^"/C^FLG=*Z5"&!K;K<U
M TN8"+P\.N0!"* 0 R;UZF8.@R0AT,@@8.D>'110/7=I6=Z4XW/7P'U^H]O2
MQ2L[#I]-919DJRF*4Q2N.Z2!9!1$P 8BQ#I* (B7J0Y#%, " "/N ].H=! !
M$0'J'0;'$I6A2%9PL%!QG.% @X(W!QG?;VU0^6,@['V?7Z^!I+CYKMIKBC.X
M=$KOS5[=:W)S/)8TTKZ%A,.*_6DO6&7<]",ZE"P#,&WF]S<[<Y%B)N/.('(\
M$6%NP69<-/,4I5SN;A+L@RE%EJ6["@CF*6X1HML:(V6]0Y:DJ04I4%)$;:8:
M8,5;* H R)&-;G,/+0\IJ.G5E7P(S3",9R-.#@Y%7KG8U)UB%R.C>1<G>M+I
M:?:QCJC-[*5ULI%Z:/,FNT(Z:D*G+M9$2^KATXT\BLBE'@J[+*D:N.PJS=D?
M/,>/(_'DB[\*?M43'7:6Y^KB!MY3&EY@O,)TRFWQ]MB-Q52U)0UJ<[2IM82%
M-MJ$!>4WI<FSBV)08J9A7<M1;'VD<L $+.HIP7#W 3J .Q":R[('0A Z"'0I
M0Z#](>P>P_SA]?\ /GIH &/'&V3U/M]O4^O>I^OUE:4Q2F*4Q2L0^>7\$W;O
M]3JG^WM5SRKTW?Y+N*__ "+;_P :MM<MQK_BQ=?\R-_78U>9O/SDKYXIBE9)
M/^+VPVXVEA%G962STJJ:\LUEIU>9SLK9&CK8[MBA&5AHQ9Q*P2-@B6TDRD)Y
M%NIZ-FW443;O';ENNB3T21Z-+\W[ILQE,W&Y6:UV"XW&T0&9TFXM.<0N,HC6
MUIEJ*OM$Z*W(9?G(0>4TVHAMUUQ"T)Z%SAN>GM*&RB1)AQH$B1$80\[(0JX*
M2&XZ4(:/,?:2M"WPGN(22$K6I) I^+USL*<=3K*%HEREWM7%4ME:1=7FY!U7
M3(G536"=;M&*JL2*2B"Z:H/R-Q3.BJ4W0R9P#DXW#U_F.368=CO$MVVE0N+4
M:V37W+>4%06)J&F%*BE!0L*#X;TE"@<%)Q%-V^>\IY#,&8ZN/D2$MQGEJ8(R
M"'DI02U@@@ZPG&#Y4K^N=@VQ@M*U6B7*S1C=XG'N)*OUB;F6"$@J!!28K/(Y
MBY;I/%043%-L=0JQP.02D$#%ZH/#U_NC"Y-LL=XN,9MX1W)$&VS9;"'U8TLK
M=CLN-I>5J3AM2@LZAA.XJC$"=*078T*7(;2H(4XQ&>=0%G&$%;:%)"CD823D
MY&U7$RXK[+DJ^A9H\T0\BE*AKNZ*JMR3ZYFT7LFPNZ[&(JF0@56Q7D,=DO+6
M,IG!&["%3.];N7HD.B7KF?1AQ'(@MW%@Q78J[5P_=UJ0F>LM1^(K@[;XZ%E$
M%38>AJ9<E7 %P-L0P7D..D*0)='#-Q<8$A!:6T8D"8HI#Y*6[A(5';2<,E.M
MDH4[(!4$H9!6E2\$" 7?2NS*%9)JMS%.LBIHB0MC1"79URP#"3K*ENW36>GX
M!ZZBVHR-?9D:G>KR9$B(M6)B.'H-@$0+ WK@WB.Q7&9;I=HN*S$?NC2);-OG
M]BFLV=UQN=.@O.1F^T0&0V7ER0D(;8*7'N6"0-&99[C!D/1W8DA7)<E(#J([
M_)?1#6I+S["U-IYC"0DK+@&$H(4O35>.(:8:MHIXZBI)LTG4UEH1TX8ND6TR
MBW=J,%U8I=1(J4@F@^169+':&6*F[24;'$JQ#$" <AS&FXKSL62VU.2M<)UQ
MAU#<Q+;JF%JBK4D)D)0^E3*RT5A+J5-DA8(J/4RZE+2U-.)2\"65*0H)="5%
M"BT2,. +!02@G"@4G<8KO)F@7RN'D4K#2;=!*0[%A)RR<S6YF+/%QLJZ*QBY
M"1(]9(&9,9)\<C-@[<@D@\='*W;J*+& @[LNPWRWF0F?9KM"5$98D2A+MTR,
M8T>2Z&8S\@/,H++,AXAIAUS2AUTAMM2E$"LSL&;'+@?ARF2TA#CH=CNMEMMU
M6AIQS6A.A#B^XA2L)6KNI).U3ICQ_P!J2=1=6N,J-@DEV%P=4V2J4?7;&\N$
M8[9UYC95I.1A6\0H=G#E82+4OJEU2*E64+WH%1.FL>;9X#XGDVEVZ1K3/D.,
M7=VSR+4Q;[@]=HSK5O9N2Y,B&W%4IF(&)#0YJU!6M0R@(*5JWD6*YN1%2FXK
M[BFY:HCD5$>0N6VI$=$A3KC*6B4,A"TC4H@Y(RD @F/#JZS+P5$EH=NO8I'8
M$C:HN(JL%$6%]8TG5378(O4U&I8<K5\=QZ\JJ",*\E%D$D5?B";)4"IFT#PS
M<EP;'+B-KN$B_2+I&BVN%$GOW%#MJ<80\E30B!MXN<\*0F&[)6A*%<]+*L).
MO[F22Q"=:2J0Y.<DM-166I"Y 5%4A*P4\K2LJU@I#*W%  \P(.U=2WUWL!W9
MEZ4UHMQ<W)J!C.:DWK$VM9FY2$35.9>!38FE40(FJDH85&I0*11,X]"G*(ZB
M.'[\[<5V=NR7=R[M@ERUHMLU=Q;  42N"EDR4 )4E1U-# 4#T(K$F!.5(,1,
M*6J6D95%3&>,A(P#DLA', P0=T]"#XU+6VB]F.J//WLE9EBL:U>H37<I"J0M
M@+8T['.MW"K9$(X(@R)$V[E-A%/4W#Q!^C+3T Q38K*2B(A*M\$<2.66=>Q;
M909MU[AV"3#5#GBXIN$UM:FTB.(A2$MN!B*\EQU#Z94V"REE:I**VDV6XJAO
MS1'="(\UF XR67^T=H>"BE(;Y6,)4$-K"EI6'7F4!!+@KYH::MYJWL:8D&RT
M#.:M+ O;51[!&RT/;48&?>HQB<\A'/6*0BSCY!Y&HR::YF[ANA)LWI$U6QE#
MIVHX0NQMW$,N0VN#.X9$%^YV6?'E0[HF#.>1&3.;COLH):CONQT24KY;C:)+
M+R4K;*BF@M$KL]P><26'K;R%R83[;K,H,/K#8?2VM RAMQ;8<!PI(<0O!221
M4N<K473%*]>E"_YC4O\ S3KGZG9Y^KEC_P "V?\ T7;_ .J,U]30?[RA_P#I
M8_\ ND5+,E*VJ8I3%*8I3%*8I3%*8I5!<J/X-^[_ /1I;/U4XSAO2;_D]XS_
M -7+K_5'*A.)/\ 7C_1TK_=*KRN9^9%?-5,4IBE,4JQ]/6IC1MLZSN<H4QHN
MJ7VI6&2 A!44"/B)Y@^>F2(4!,94K5!4R0  B*@%Z (^V=#PE<V++Q3PY>)0
M)C6R^6J?)P-2@Q%FLO/%(ZE26T**0-RH"I"TR40KI;I;O[W&G17W-LGEM/(6
ML@>82"1Z\5F>>Q:LH%,V#5[;L&P/2M>5"EQ@U],6JKR,O/0J-9.^A9PQ%I=%
M%6$>D630/*HN#KP$\)$5&R[YJY89[$JX<,V&SW^V76_3W0WZ3EW>$O@^YVV1
M+FPDVXO0YI2J6VA4)X*"#)2X5P)VE"FUO-N,UU_:+9!ASH\J<^L)XF5+8-HE
M1G'7V1'ULO$%U*2PL$)+H5J8>P"DK2I%=;#\L]?R]DAK7=8;8U9>U#>ELW%
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M;8'+Z+!10[47R" .T%V_F)&DK7";G2'FG%K0EN%.D@HTY*XL9Q]"3J!&E2D
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M86/O:I84K:PQKQ6F5&P33)DTA4I"P5N*<AY#%-:/7E6[Y/:<NSC:FTF\AX3
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M.% $9&^" ?.K%$0#Z?Y__#Z<Q9 ^,9\>@&:OK\@<HCT ?<?H]A#K_1U#W_\
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MX-:[W"%E^$8KNHCO8'=R<YQC;Q./(DG;.:ZV9\/:KE2>DA+9L.->"BN:/;S
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MY1!-T=DY GFI(F3N"5A6ES2IO"M1!Z#P"@3JWSX%0QUP.M2K;;8].GAZC_\
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MU;&'T+9U.R$%5H\RADU7LW8HA'L%JFZ<-8B==&X@">:EQ[("D!.R4Y()4.8
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M5E9U9'J\\DG-K.IE5ZNK+IDDCJ&>$*L&=-SN2$M(1<)R$L@)92F7(2EH!)0
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M_*)(1.:64F0ZI]Y65N.J6IU3BEJ*M2G%E2EJ.1E1))(ZFK'2DK5H3H0,)2G
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M.,;'&^V2?E%=X40$2B ]0$0Z"'N'TY-I4%#(W'@? ^L>JK:_2_\ [,V89/\
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M)-JQ+S)F$:2V2#5..6M22 I2ZLFFX>%7KGID^8/L/TXWQ5,;G;IC'EGK[/
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M]"WZ7F'ETF;:E2ZC<T).?6E73"678H+3,&BWH (5=^I(1KI,S523AY>>;M7
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M #IBI"1I+@;6A*6<9R=8; VQT*P<^L9VZ^)K<D*+SA<;YJ6ST1J.$D#<  ]
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M&? 'Q.?[<AVQB*(-E"F*<HMTE$S%, @<IB%.!@$.H"4P#U 0]A#H(>V8TH2
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M@!L1F0W&$5AD)882-MA@ '/J&W05K)W.<Y)R3GJ/KGY*VTY)5DJ/1?[]6?\
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M,@CE9)SN"!MBOMX1D6G);0O4JIY/FPB]'52 Y %4/7L[RV/Y2G8(D*)2"4X
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MTX). $ >>Y/AZJN2$ '0$@$Y.DYW^4UV\H_CX\P'?R+%@0P=>]Z[;-2B'O\
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M_P!.]?HO^P:4#:>.T '4+E:5GR"3&> ^/(5[ /D_'@_/BDV%M)$#=OJ UL)
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MD'4E"EO,Y2%9)(P!C.XSC)ZUTO"BED3DK.2A;(!\2G2L94-*0%9!!P,'&H
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M3\GY,UW[/62#8AR/;MLZ8.<H%,L^O,FW/UZ" F*E"%AFR1AZB(^4@4H>W0H
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M'?=9UXZ:^6I.K&3C.<>%<EI&Q[ # Q8,F0& "F!HU0; 8 ZB &!$A.H (B(
M/L'4<$D@Y)/>5U)/\$^=6O29,C!D2'WR,D<YUQW&>N-:E8SXXZUS<OK!3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
)I3%*8I3%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g582934g58p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g58p01.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1V@4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&2;
M=,         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/
M     0 ".$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             "(@  ! T          0
M               !              0-   "(@                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   "(@    !29VAT;&]N9P  ! T
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    #.$))300,     !/$
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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M[6&FS5ME9T<T]OZF]FRW^VEE[;"S&.IN)D?R!_.G^3['>G_UU28X,R7L)CU
M',![D>UX;_8;6DI$.FU!FSUKS$PXVN<[79^<_=_H_P#SY_I$.SIS*J7V>M?8
M6,>0++"X26N;]%W]9:"%E?T6[^H[\A24AJ.-]L<*G$V#=ZH)<0#[7<.]C>?S
M58L?L;H-Q.@"&3:<H!S0& .V.#B2=&?2;M&SW?RU#*L87-HW0Z\FIC?'3?:[
M_K=3?\])3##S,BZ]]=]0J8X"W%>UT[Z_HN%@(8YE];MK[&?S>R^K])9^E5C+
M_HMW_%N_(4/(V5.;:0?T;M\C]UPV6_YO\ZB9?]%N_P"+=^0I*?_1]/RZ[[<:
MRO'L%-SVEK+2-VTG\_;+/HJIU;(QL3IMC+[16UM8/J6&! <RN7VGV;G.>Q6<
M3,KRG7BMKV_9K30XO$!SFAKG.J_>K]^S^OO5A)3R]W7>ELQ :,_']=EN:]@;
M=4'2[[4:7-]0NK][G,]/U&>FJOU0ZYT_'JRJLSJK"P&NQAR[6M?N>TNO=OL+
M6_I'CUKJ&?T#+?DX/\SCTW7=DDDIBQ[+&->QP>QX#FN:9!!U#FD*A70RK+S[
M[Z2S'L=2=SW.L%CV-;^F93OMKI8S]#5[*:;/5HLM_P!$]:*22G OZIT;%ZNW
MULO'QI92=MMC:W0&YS&G9:YCU@?63JW0KQ5^NX=OLS6ZVU.^G:QVW4N^G_7_
M .MV?X'O4DE-7IW4,#-H!PLFG*%0:VPTV-LVDC< \UOLV_YRMIDZ2F(8P.+@
MT!SN3&I_UA ;CY!=:77.KW/EA9M)VZ?2WU>W]U*W/HJS\? =N-^4RVVN -NV
MDU-MW&?WLFI64E-7[-;5'HV.<YSAZK["-VT?N_HW_P!FO]'6ED4TNJ<;\@MJ
M$ESBYK -LG=ZC6M=6ZO;]-KE-V#@O<7OQZG.<9<XL:22>Y,*AE8/U=QV^G?C
MTTUMM.8\!@:PVO#Z'9%VP-9;:]KW?SF__P ]I*35W-](B[.:UWJ%@+7U.@[Q
M0RO<ZEGZ3U'UU[-G\]9Z2FRFRVMGIY)R,:X$NL+F&6.;[/1-57O:_=_I$"@=
M!RKF"AM=EK0YU9:#+1OKO?L_=;]HKHM_XRNM:---5%3*:6AE=8#6,;H !P D
MI%93<_):\/VU!I!B)W3V!8?^J43BFIK[*[";B/I6$08^BUSMCMK-Q_,5A[&6
M,+'M#V.$.:X2"/,%9V;3]7ZVOQ\RC'VN8765OJ:6E@W.=N]A;M_1/?\ V$E-
MBRW'K<*<C+:VW:'%CG5@P?9OV.;]!SD+&%-P?57E"W&>TBH,L:\D#VWZ[?S-
M[*_:]*NKHW4K?M#:ZK[:V>GO+=0R7?H_</H;VV>U&QNF=/Q'!^-CUTN:TL:6
M- AKG>K8UO[OJ6_I+/W[$E/_TO0.FYO4^H="Z;GU>B,C+QJ;[@\.#-UE;+7^
MGM)<WW.3CJME?4<?IN19B-R;F[G4^MMN< U[C9CXKV^I97NK_P"A=_HEC_5_
M*JR/JQ@X^70]^/BXN QGH[B]SW8]-^]^S9L8SU&+;QGX].,VVJA[F[ZZZVO^
MFP6"NO\ P[OH,W^[TW?\6DI:CJ];B'76XPH<#LLJM-FYP[?S;6?O_P"%>K&5
M9GM<UV*RI]42_P!1Q:=/-H=]+^JC^E7I[&Z<:#XH&7;EL<&TXXNK<#O?O#2W
M^RY)2XS\8Y(Q=Q%Q'&UVV8W^GZVWT?5V>_T?4]78C6^IZ;O2@V0=@=Q/\J%2
M_P */_#0_P#/2ONC:9XC6$E-&K(ZHRQGVJJH5O<&2QQW GOKN5]8& >F;Z1B
M/O+I8!ZV_@#3=N_._P",_P#/JO\ 3*FTNADQ=4RZV3.ZQT^I;_7?^<DI-ENZ
MDUP^QLJ>TCW>H2"#\D7&M==5O<T,=N<US0=PECG5Z.AG[O[J%E7YU3@,;&%[
M2-3Z@9!^#@L_]8<7VMOLH^R;K14PMVN<^W*8]M\M=ZC-K/\ T8DIV2UI() )
M'!\$UC/4;M)<W4&6F#H9B0I(%ME#[?LM@,[19)T:8/&[^S]%)2J:R:P7/>3K
MJ3YGP6=UEM_VKI>+5DW4,R\E]=QK(#BUN/E9#?>]C]OZ2ABT\< 4M X$Q]ZS
M^K_\I]#_ /#EG_MGG)*:_4.FY.+C^M3E]1RG[ZVFJNUD[7O;79;_ #/T:6.]
M5VW]Q4\6SJ56?@/LLS*F6]0OPS3DO8]MU#<;+R:,L-]&NRKU'8]3]G^#_FUU
M*R>M?\H]"_\ #[__ &RZBDIO>DX71ZKR'!SHD1)+?Y/YGT6J.95&+<X.)>UA
M<PN#70YHWUOAP_P=C6V-4V5ULR#LY<'%VI.I<#W2S3^IW_\ %O\ ^I*2G ;C
MY;>@T=2.9U'*O?138ZFE[-[G6!F_8UM/\O>GHIONZB_".1U2MDN]+*WM=6YK
M6UNWEWH;:GNL?=7Z5G^@_2?S]-:U^A?\B=/_ /"M/_GMBO)*?__3ZOZK8.31
MT'$S:KZJ79>#TX,<\.,"JEC;&.:Y_I;W[OT=C6?\9ZBUFTOONKJRK/5!8^PN
MJ+JVN<T8OIO_ $;_ ';=RN?9:+L2NBQ@](-;%8]K?:/:-K-OM;^ZJ6.#5978
MS$LJI]-XV^T07_9]C?<]KO\ !/24W\-SG8E#G$N<ZMA)/)):%#,OMJ#6LH=<
M+)#BR/:(Y.[:N.&)];_^>^%EU&_]@X]#*\FAN17L#Q2]KP[#;?[WMR',]_I+
MM,BWTZ2XL>[=#88-Q&[VSM'[J2FL/YT?^&O_ $2J7U9^LO1>NC,_966[+]"S
M=;O;8W:+=WHAOVAC/9^BL]C/H*RVX>H'>G;'K[_YJSZ/I>GN^A^^N,_Q2] Z
MST)W5&=6Q+,4Y?H>@7"0[T_M/J>^K>UFWU&?324]FP=4FHYCZ'-WLGT0X>[R
MW_FH=N7C8>&[)RKVXM+,.L.O>X,:TN)8S](_VM=O<W9_+4GX6#A75''Q[ Z0
MXO8'O&UIVP=7>[W?NK#^N>%F]3^JF7T_!QKK<JVC&8RO8YLNKNKMM;NL#6>R
MMFY)3OU=499@8V3@#]I4VM@7TO:]I+?8XE[?:[WM>UW\M!89JS206DUG0Q(_
M39?[NY4/J%BY?2/J=BX>?CV596(VYUM&WW>ZZ^YC:S_-V.?6[\QZO!S@W+'I
M6S8PAGZ-^I]7)?\ N_N6UI*=*NRTY=U;BTUM96Y@ AP+O4W[W;W;OH-V?HZU
M5LI8.K.ONIBEU+*_7>YNPO\ 4!KI],O^GO\ <U_IKC?JOT7JN#_C$ZQU?)P[
M:>GYC;VX]Y;(<;+J+&>QFZQF]K'O_2,7;6;Z^IBYUUOH^@6G&: YFXV,_3[6
M5NR/4_,_G/1]/\S\])3Q75/K[FX-N5CT5LV8UMM;7&/HUV/K_-=^ZUOYJT?V
M]]IQ^A=3RMM0&3:Y[6;G@?JF74PNV,L?_./:S_KBT3T'I5SK,I[)?:7N+RQQ
M'N<ZQSB[;[N5HTFC$IHJK#VX]33+R'0!$-#I_?W)*<VKZS8;GS9F5L8"=/3M
MD@_1^E6SWM_/2R^K=/ZCU3HM>%;ZSZLQ]CP&N$,^QY]>\[FM_/L8U;CLFIL;
MMPD@"6NU)X'T5!US775, <)<3)!:##7^WW0DIS^J=9Z?TI['2P.N%L1 !<QU
M?K[W?OM]3\Y5<3ZR8O5/MM%3V_HZG';J' P_Q'N:B]<Z7A]9MI9=Z@=C"R T
M.!]SJFN?M$;OYO\ 1O\ YM0Z)T3$Z0Z]^.'V6ENW: 9&FYC?^#WI*8]'^LG0
MZ^D8%;\^ECV8U(<USH<"*VR'-/T7M_<<KP^L_P!7O_+"C_/"NTY%9K !<XLA
MKH:XPX#W Z)'+I-1L9N>V"=S6F(')W&&I*?_U/4V;=HV1M@;8XCL@=0^Q?9O
MUV/1]2J.9]3U&?9MGI^_U?M/I>EL_P (OEY))3]-8O[&^W.^R^G]LV/G9SLW
MCUOY.W[1_P!-:"^54DE/TYU/]G3C_;9G>_T-N^=WI6^K_-?]U?7^E_Y\V(^#
M]F^Q8_V3^C>DST.?YO:/2^G[_H?OKY<224_52PC^P?VS9Z?K_M+>?5]+U_'#
MW>IL_0>CM^R?2_1^E]I_[M+YR224_52ROK%^Q?L3?VS/H[_T>SU-^Z#_ #?V
M;]-]#=OV_F?SGL7S4DDI^G\#[-^G^S>KL]03ZGJ;)V51]D];V_9MFS^C?J_J
M>K^?ZBCE>K]J;Z/T_2=NF-NW<S][\Y?,222GZ1=^U/M-&WT_V5]FO]>/3V[_
M -!]BV_R=GVGZ'Z+_2?X-$'VS[%3Z^_=Z??;/J;J_2]3U/9ZOTOI_H5\U))*
M?J.K^8Q_M>WUX;]+;/J;?=MCV[_I_P VB.]+U&;MOJ0?3F-T?G[/SOZR^6$D
ME/U0-F\Q&^!/C&NU)NR7;8F?='C ^E_97RNDDI^J&;(.R(DS'C/N_P"DF_1>
ME^;Z6WRV[8_S=J^6$DE/_]DX0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !BDE)*@ (
M#@   00  0   "@$   ! 00  0   %4"   " 0, !    +8    # 0,  0
M  4    & 0,  0    (    2 0,  0    $    5 0,  0    0    : 04
M 0   +X    ; 04  0   ,8    < 0,  0    $    H 0,  0    (    Q
M 0( '@   ,X    R 0( %    .P   !IAP0  0     !   L 0  "  (  @
M" #$)QD $"<  ,0G&0 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.#HP.#HS," Q,3HP,CHQ-P #  &@ P !    __\   *@!  !
M#00   .@!  !    (@(           8  P$#  $    &    &@$%  $   !Z
M 0  &P$%  $   "" 0  * $#  $    "     0($  $   "* 0   @($  $
M             $@    !    2     $    X0DE- _T       @
M /_A 8Q)22H "     X   $$  $    H!    0$$  $   !5 @   @$#  0
M  "V     P$#  $    %    !@$#  $    "    $@$#  $         %0$#
M  $    $    &@$%  $   "^    &P$%  $   #&    ' $#  $    !
M* $#  $    "    ,0$" !X   #.    ,@$" !0   #L    :8<$  $
M 0  + $   @ "  (  @ P ,   $   #  P   0   $%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,S @,3$Z,#(Z,3<  P !H ,  0
M /__   "H 0  0    T$   #H 0  0   "("           &  ,! P !
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ME#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.
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MLRMF+?3*[5].;GVN0*UP 1CB2Q5Q&IZ!=4C8\0A*8CYP47#<<4OUF4.(2I6
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MD^RNH^I>J"NZMW&30.@AS-6KTF57*=;K^=D&[I8AU4K(L54J*$L-I,32IXM
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M[5[9M.EM!%*^-V*!*EQ6Q;M2RP>S($D8T+,5D*)D/R3<]R+!Q#D87G"0KD\
MW6T;U^VGVE^%5KQKU./9M?Z<]H+\=6_MG;M"R'AEBV=_J_93>TRY Q7BBD3$
MQP:QD9@:1B,RTK?>E1%MLALFW"Y577]=)6Z[6 55ZR';:<)G#4QJ".A(?D-1
M&/;R7E)0E3\I]F.RC'I6Z\ZVTVE2UIQD/*3=UZC'E@8&5L>G(-68A7Q0 4@[
M!?(%B%K@ODZU'A18[SKSJC@V,_/&KPC#4J$TN2VO+./7X'@ZI^%7NW\2/7;\
ML.Q? D9P' <!P' <!P' <")ICH3T:L.W$[_/=-NK)O>R;0-NZ=T%M :I([63
M<PS\62(MN-A2ZH];,647)A0WQQS!;XG">B1G8TIM;#2DA_5/Z&='M>[73OBA
M=.>K=)W>DN<L"=Q5/06JZ[M%)ZS-3V+(:3?A%5B6G!8^P5)LFB."OO91HC.;
MFO/IEOX<#"_8BIUFO]L-8;OD]B2-)V8C2FQ=2T#3P73TG<1,_4+%::+:=@VY
MJGU&&2V 22+)U6H19!MIANKU^-*5')-KDE&'D!AXEUZV<>IEB[/>.?LW7IF^
M]ETBLZXV7:]M5YDQK'L!/TS8++67#QF(,#,SM5;;JLB7;J;7K8(KUFJ=:A11
M]8L6JK8'K@6.+#L*IXRM4FM+A:CB!LW07VSZ&O/7'L!77;52;M9]N:XO=])W
M^]/V^^#VRT*3;+1;SE]L,#8X9(4[&&;5N:'ZZ!+2Q4>IAG'7G1K3 C8%0VK3
M[45)ZS#;<NO:76&LQ^*Z_KT-MS<5'F5:QWT*3A#_ (D0!D15BLMHK@/WY0P;
M:KM8;&U(F(= PP0=YK4+3>ELAFF7C9=BN!+MKVKV&;I3[U&S%CP]F;5AVG:1
MFIKEUJ-*@# 3<2KV.6&GV-^.YZD; Y<Z;*4UZP=YVH_9QTG^E\*^KYV'X$EK
M/>J32E!47&WUFJ+LA1 2O(L9T8$4=,N-./MB1"24J-DD26RTX\B%#P])4VVM
M>&\I3G. ZVG;3UGL0="+T'85)NPHG.)#!Q*IVD)88$\B&:0\7@0Y8F;+8DS1
M;+C;I"*RM;T-M:%R$-I5C.0Q'H;[YG<?Z2 #T?Q5^M'^/T\"3' <!P' <!P'
M <!P' <"&7D6_ '[E_1FW3^0!W@3-X#@.!7+Y!NB8WO?C0-+M-KVQ2J#1K[:
M;1;[%I#=![2.R("9U&+!0JQQZOBY\H^'=*26XYJLNR1;+Z'HA;WIUT.W#D!X
MGIGXFM-]'-SS-QZPW=VKV-,+ZYLNNRH#L5O2S;K&L1CMAI5ACE:SFR8:S6)T
M9VI.12/N3;F#3$Z-B4IOX5'PX%J' <"H'O#\YAX</Q@=Q/JW3> \S/WF^G?[
MZ)X\O^OL-7,?^S/ M^X%05W^?=Z]?O7'9?ZSG7;@6^\!P' <!P' <!P' I@\
MAG>SN]U'VA78VO-'].OT/%JE@:F%WEVH[8_H>!3VQI]:M=K*5^6_-J9>OC![
M$"M)'!Y9$S%('3LU X>,D)0Y(;"3OC?[6[$[>Z.MFPMHM]>DVZK[@N&NY#W5
MW;;>]-.R8 856#@Q8/:,:/&'68I'AV5L?8UC&D11QR'-%NM1IT.9$8#TW;GM
M/9.O:9/VJ5@#8'*CHW<W9F\IL<HC%;FZQT5,H4*T52K.#?EC7FQN;!@N@2Q5
M$H$,;#S$$!TU<^-F,'6;\[GQ=4;HUMI\6!DM0#@NDW+:&V3U3O9JA:OJ.PKZ
MWKK7@LLNI!WV!]GV7:8YL4&)6PY5JO58P,@<-RR6&XX68&)/*$\VE/CX;]HC
M#N?)YU+S[/UT^T]1;UZ;];"/3ZWJ^E7J^MZ/1Z?D_P![@9(\C_WGM,_3<Z-?
M6DUAP+ N!7AWR_9YXZ_I_P!"_,9V"X%A_ @WW;\>O7SOZ(UL(WP]L^!G4UC,
MVFDF-4[.M.J[$-*GPCE>*^N=J<J&1?B2Q3SD9R(I]+2L+5ZV%8SG&0K3#_8R
MWC+KTZU$P#O:X(1O3[DF[SA/:_;0Z7<9+OO'M9%HD1"S+I]]WWN7[5THJ4XY
M[S(]96?;.>L%LG2WICHOH)H&M=:.N(<X"U54REC,!AMBL,^TE6IMJ+R3A=3Q
M@EG,M]MPA*>6RVO/JL-Y2VC]2G' ]-?^IO6S:=T(;&V'IBB6Z]EJU&IA2V&
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MZ-'/-46?.=GON.MGB%<DGX[><1HY-J,E+. EEY'_ +SVF?IN=&OK2:PX%@7
MKP[Y_L\\=?T_Z%^8SL%P+#^ X#@. X#@. X#@. X$">Y51E]D\1^H(%.T:18
MK!7Q>Y!_8VA#M5V$'H&RT*Y0)VMR]JJ6SI4^#;W[-9P\UD3454JS#; +!6G$
MY\&H<R48#&'C^ZPW3K=?MVP-]=G+AVE[&F &N&R=^.Z7TUH2LJU!&D7"51X]
M*H^DPHP%+9C6V=L ?83-FE3+>HK!;:<B#JT[6I!<+1> X$<ZI^%7NW\2/7;\
ML>QG^GR_^S@2,X#@. X'&FO>[0Y<CU7U>PC/O>K%95(DJ]DTM?JQXZ<*4^_G
MU?0TRE*E.N>JC&,Y5Z.! 78B3D?6&Y-B6B,<A27-76I'Q*SSDTAD9!+:[.@U
ML%P$9: 9TV@C71,N1GUW<L3K&U'%);@CXSCX<3QP=C)VZM)B*%;HDB'M;0U
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M,R%(9:F09;#(2(X#@. X$,_(M^ 1W+^C+NG]?\7YWT?K_)^OP)F<!P' ACY
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M72C6ZB2Y,F';NPRW)8N';PP:47#.X>2F(<&-2A,Q:'D1ICJV7<)"7W <!P'
M\3L%4W%:>:@.E&Y,R<,@)0(:PJ7*1.G,17869.4KR+C2VW5,2C"4Y6)86N>C
MT*8QG@0:\CTK9\W18;2>EZ8SL6X;:GSZH2K$QUAPB[KZ!5BJ+$<'RI3B5QS8
M,I+K!& 2>7&B*F-XBS2<'WYM;@8-Z\4,[T:W_/1>LQ4:T[=[1V,!!6"89=,6
M 5L&1LB6>T;4WH(IB>F=#L=0N%P /'"$MA%8CT2H"EX1&*O)%A<;P' <!P'
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MFK[,O6^_ZA>K7!WAV/%]9M-9%@A%A4#QL&X%:]8V3T3-QD5YVOU=$1E4BV,
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M?(<@-S,8-S0KSC@4O9O_ *5%Q\ZR?ZZ<#A53\*O=O^_I'KM^6/8S@2+X#@.
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M(A[!FVE^(JV0RPR(\V-8%0IB!+S+*77V%/*4K@3$\C_WGM,_3<Z-_6CUAP+
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M2=8D=KZ5H<?8]KZW6<9:Y5B)/V<![[",P*'N066"1IUA!J7'AFM5B8-A1E!
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M Z3#O4V.PS+MMJH%BDSL3(+ T:^-48E1(YH>P0"4OZ$K6?\ 7=V*_C5]DO\
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MV[V4O9ZV#A] KT*#4M["*V2<,![+47F-3HF6F*<D0)=ADR85QLJX8FK6.(7
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MQY\_V"W=H@CMZQ%((G!RB3(D6G4.U!!>NYH2J,%(&PHI4.4&30\>OAG*D>0
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M/8SE6<A,"'_L2+_Q=C_LD\#D<!P' <#4<\BO_I57A6^CUMO\G>S_  -N/@.
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M^8BIDN-L/PHS>64NP8N8SK*T.OONS8[+0==FYC345O%3+P9CDP9DM&+9@E2
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M9U3VE"M-E!C!P^RV25NV9MJP62U0O;";.;.S3->;'UV4)&1 Y&]^_&Q*7O\
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MC5#(UIV?;B=\OQEM4J1+]ZLUO,*63.S\*DJ93,F*R[B,TPQZ?4:3P,B\!P'
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M1$E.,+),M)QU/PE#$MWW=<QI/JHD.):6ZE:D)S@/EKSQ^8Y+D=;GV-MVI2F
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MX";N$L 0BWJOEJX>&2IL4$'8#8JZ3Z8DZL,PK)9*O;2,N<!<B;$<L(V%3H=
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LP!$":!93%8M!25&"YW@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g582934g61c22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g61c22.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1_D4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "$< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 %4')I;G0 .$))300E
M       0^*S$H2T?_KQ""!DS".HC_CA"24T$.@      _P   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     #
M $UD("!T>7!E     0       $--64T     26YT965N=6T     26YT90
M  !);6<@     $UP0FQB;V]L 0 X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #P     $  0/      0 !.$))300F       .
M             #^    X0DE- _(       H  /_______P  .$))300-
M   $    6CA"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]       $@ U     0 M
M!@       3A"24T#]P      '   _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              LP   <0          $
M                     0             '$    LP
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   LP     4F=H=&QO;F<
M  <0    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   +,     %)G:'1L;VYG   '$     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $     SA"24T$#      5
MO@    $   "@    /P   >   '8@   5H@ 8  '_V/_B#%A)0T-?4%)/1DE,
M10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-
M4T94     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M
M$6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M    %')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0
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M
M      !865H@        \U$  0    $6S%A96B
M6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M       DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C
M+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                 &1E<V,
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@                            !D97-C
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0                                  =FEE=P
M    $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %
M  !7'^=M96%S          $                        "CP    )S:6<@
M     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #<
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M.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_XD C0&1
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M]NR?SWU%]SF;OWTE/@U.,R_J=F)FO-;PVUK8()]:ICVXV-+_ *#+;JV8K/\
M1HM3.H_5_KN,Z&G.Q+*KFUT/;9+B6V>AOI+VO<_^9MI:NW^O7U0Z#F]3R,[I
M/6>G8V398[[=A9.2RL"V2+K&NW.=7;ZG\]18S^<_[:2^IOU-^K.!U&C,ZKUW
MIN;=58TXF)CY#"PW>W8YV][7VO;9_-5-K_\ 2:2G_]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$
M(@     !=DE)*@ (    #0   0,  0   +@(   ! 0,  0   )@#   " 0,
M 0    @    # 0,  0    4    & 0,  0    $    2 0,  0    $    5
M 0,  0    $    : 04  0   *H    ; 04  0   +(    H 0,  0    (
M   Q 0( '@   +H    R 0( %    -@   !IAP0  0   .P    8 0  P,8M
M ! G  # QBT $"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,3@Z,#DZ,30@,3$Z,C Z-#<  P !H ,  0   /__   "H 0  0   ! '   #
MH 0  0   ,P"           &  ,! P !    !@   !H!!0 !    9@$  !L!
M!0 !    ;@$  "@! P !     @    $"!  !    =@$   ("!  !
M      !(     0   $@    !    .$))30/]       (      $   #_X0%X
M24DJ  @    -   ! P !    N @   $! P !    F ,   (! P !    "
M  ,! P !    !0    8! P !     0   !(! P !         !4! P !
M 0   !H!!0 !    J@   !L!!0 !    L@   "@! P !     @   #$! @ >
M    N@   #(! @ 4    V    &F'!  !    [    !@!  #  P   0   , #
M   !    061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.3HQ
M-" Q,3HR,#HT-P #  &@ P !    __\   *@!  !    $ <   .@!  !
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M%R,D,E)5<94E0D5B@9&6H;'!T]09<M(S0T145H*2PM7_Q  4 0$
M            _\0 %!$!                     /_:  P# 0 "$0,1 #\
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MDE 7M]>_MKXO;XO;7Q>WO[>_M^?M[_G[>_ZO?\_; ^X# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8&QE &Y6,D8MY:VV9($L!UQKX?F-MF#N#K6W\6E)^-*7-
MJ1\25)^+6O?6]?E@6F7/1XXL'XL>(OCI2NU>0/+KOX.!2POCEY1\VLM7KO=J
MAJR 241;A3GWZE)46>@;I"R.XFU5N4IST3)#!1[K30A@C9.@YKG?I"^.W,T^
M.9<3=>O62U<*\G.B^7ENZ#T"R1-QOGD=W'JG+;3R6YVGMLX= LLR&C:O9FV!
M *C'U2/C68"# #%:!9*9+#]>+WI/<_\ $GJ,'9^7>3?EJYQ&BO6@CEGB-8.C
M5H_Q_P"<;MCLF\_&1HS%(#Z'8:W7'94EVD5RWWV>CJR\D9YI);@8:APX%7HZ
M<0%\0O&OQ7K/8N^4"Q>(-WM71_';R9H%EK5;[OSNXW*P7B7L18QR:J73)6&G
M8OH$]4I^M2]1,AYNN*&:+'^XCLR+81KE_HJ\<YK) SIOD-Y*]1M#7G;R?U Y
MJY=6LU.M-OMG8N4\N)Y<-$V*9'I<2AZHV((PB8D8^."C7XHKZ:)K#\+700XA
M@.Q>@^D;P3H\=WK<AT3M57N_8O,D#SKIO6.?VB'J72_'SOD5RZF<CCYCD4V/
M7B@41.JC4'0)&'ND3; ID:S6 21:?97&_;@W)_I4T&[^,]@\>^Y>3?EWWRRR
M_7*UWJO^1O1^JQ:NX<IZ_2!HH6CV[C)D!4X:C<Y:J:(GW K\927X.07+3ZK"
M',JFC-J"I7Q"\4B_%2G6: F_(COWDU9[A8TV.:Z%Y!V2M34\+IB* APZ_5XB
MEU.E5.JUD4<!)>XR)@6W39<R1E)$PPDG6V@JXP& P& P& P& P& P& P& P(
MO7_VE<OYF:_I>M8$HP& P& P& P& P& P& P+-<MZ$7IX]!1Y'3O?N/PGD7U
MSR:Z%U7H5Q[OU>!K,IUBK/\ 2Q-1477N<V(*&"34:_RZ$'C8SFXX@[A,+N-8
MD"23I%T@AT/SVGT8N;=LKW(@C?*ORWYY<Z'XK1_A1T_I?++K2*S:_)3QL"^%
MQVB]B;D:!/0SII1:Y(Q5FJ$;6)E#U@L"=ON-',-A!WC,>E=XLV.?[(JQ1$Y+
M\S[7X6\D\$K!QMV0;'IT/Q;C$A>#:>Y7905AFX VD9N[O,-S:["\\"Y"0LC'
M)%DQW2W@IL_^!OQJPTSN$%V7RB\OO(^Z=;\;+GXD5/JO=N@U"VW#A/"KTL1V
MQ5WE@<70J[5DSTT_&0ST_<[;!66RS?V4 <D] >S1C [HOGI.<7Z!0_/>@2?1
MNGAQGJ"\TXQS#IIH#M4T=3(CB7*@>2U^0HFR*X^.W)2T*"W)3&[ S-B[E%KV
M$.()\(V@^^4_I/<8\L)_L5@N?1NGUPKL_A/5_!N>9J[M42Q%\\JO7%=@#ML1
MJ6KDDXFYD3B]QA*S5EP?VKVTU$-F?Y3L.W.A^G_S3HW8O(GL\I<[R#/>2'A0
M+X.VJ+CUP&HB#YZ))]&E&[;7]$PSYJ;FI[I<NVM<D4=![:!CO:(TI)*B I!Z
MMZ&_!NGU7DE1C_(3RGY/&TOQ#YSX)]>1R6]5.L-^47C'S0!X*%H79Q3J/-,?
M/>3(V-HF?I":G*ZC;;8X=MY(!8C8(5'VCTQ^*6&<\RI4*SWBL@>9WA]1/"VT
MUV$<@-1'/.8\\IG2J-7I.@Z.AC#$6)J&Z9)Z<782IN,V[%17PQZ4)+24'41_
MHU\)D)&UR3G4.M-NVZ>].6?-0AVG?+&)]-9P-WD[(OQ5?:M,7I03>NAZ>4ZX
M[I:]5M<#OVWH-VYX'$]$]9<CU ;WS6!@:EPGQ.K'%>+6?[Q'2$WT_J-NL-VD
M[A?CX, XAR"'Y31+ 9S>LDSH(4Q*NWJTOBJ>B(Z*=2%W3 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$7K_
M .TKE_,S7]+UK E& P& P& P([9=G[$!8CR'!%F3$8*20RZPT0R$Z_[D*'61
M[M[>^%.M:1IMU2T[4C32_?>L#1^CM86M?22T?+MZ_P#NI@/8A.]?P^NB_A9]
M_P".U1F]_O\ [L!N?D!/RE:Y)LZU_G$Q>VIH77\5?"-MN1^'7Z_SCO?6L#?
MV.#D7/D"2@BR=;]MB..?3FIW_!09.FBD_P#2UK YK 8# 8# 8# 8# 8# 8#
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M[U^[>!QOX<(%_.(L$N!K7ZARG43 ?M^OV^7))=*2G^YHUKVU^KVP'S[:'O\
MQP43-,ZW[?, (>BC-I_C](;HH5:M_OU]Q9U^?Y8#5L 9_*5%E(/>ORVN4 =0
M+[_W2(OU4=[?O]]E)]M?GOVP.E^@6>7CYE+L'.J7%FLZ=94(^R2/MW6_=[3;
MJ?F)]M;6G7P:5_9]OU:P(?JUWM0^RTR$IL;6M[V_IGW:]M;]MJ^/Y/P_#K?Y
M;5[_  ZW^6]^^!+N>SUEGK&.,9*EOB,HV0^WO:4I5IM2=I2O:$IW\*M?%[Z]
M_P"U[>V];U[X%26 P& P& P& P& P& P& P& P& P& P."L[Q0]?EWPB$BEM
M@OJ')6XVTAES2?[+BG7O\6WI/Z_C7^2?UX&T_#2U:UO=CL_ZOW23.O\ P#U@
M/PRK_P#4=H_WFU_[/ _2:UO7Z[!9E?WJE$_]7]D9.O\ NP/NZW[_ /+UE_Z)
M7>O_  9U@?/PSK_7UF_WNO\ ]+ ^ZK2=?KG;*K_;+N?_ -6TX'W=;1O7MN;L
MG_1,D:W_ ->M:W@?G\,-_P"N[-_OPK :K+6O^6K-O^[<X7_Y;UO_ +\#]?AE
MG_7%D_WX;_\ 7@:+M1CR$;:+,F#65?K8.DGC6-[UO6]*VR3IUKXM>W]E7P_%
MKWW[;U[[P(//<F%DSV"0C/I!D-M,NL;3KW^6U^6M-[0C2$[^'>]:]DZ3K7PI
MTC7P_$H)HS2H<?>G&-EC$_ E"RPW_I"5Z2G2=^[["4O_  J]M>Z=NJU[>VM[
MWK6!K?A47_6UD_W_ "/_ *V _"@O^M;)_O\ D?\ UL#]ZJP?^LK#O^_=@E?S
M_O\ R)UK_JUK ^;JH6_S^Y6+_HL4OK_NT5K6!\_"@7^LK'_VCF/_ '>!]U50
M=?\ *%BW_?NQS7_D9K6!\W5 %?K/L7_:2;U_X':P/GX2C_\ \]8O^TLY_P"_
MP/NJG':__&V'?^VS3W_E(:P/OX3C=_K+L'_::?\ _P#1P.-3'[B+/!M GF[%
M-#F=&BGS)9ZG]L(#6,MAB0)?7[LK4O;C@R4[2E>M.J^!7ML)Q@,!@,!@,!@1
M>O\ [2N7\S-?TO6L"48# 8# 8' &6NL1\V)6CK%!B620CRY:/KI$J"U/'Q@*
MM)-D 8=;Z9$P(1>](()'&<997O2'%I5O6L"VKT/U4O%6$N$=7P[*19ZS'<MB
MN_S5[J\=JR1D!465E'&CSD.RTJ;KQP$(RF3D#9$0-N#6\D&6<C"D/_*#OKE_
MGWXS]4FJ'6XVZ_AJP]4CESO,82X:CHR0O=:>EMPD'8H9H&3E4!AVV29/:J4;
M87(2R3S$88<)![!^E)*"L@<D8MO;HI#!+6G2&-NCNMO-Z?$?<%*9VMM2DZ=&
M)9>'(;WOXV7VG&7-)<0I.@U\!@,!@,!@,!@=9W:@(LNA-Q^Q(Y;+CKCRTL)3
MIU2])UO:D-?+TM:_9/Q.*WM7LVC7YZ]O8.KWJ3:4VMO38CGT:"&4I>2K7TJ0
M4? E0^M?J^5MK6V]Z^#Y>];^)>];VKV"?U>HR%')*,2$Y.),U\"DQZQF7Q&T
MJVI/PM&$,Z(_)2M>R'4J_5_9W@3ANVPOQ);.>?AGE;]M,S8K\7[[_@A\I"!7
M??\ =MDAS6_W;P)"VZT\A+K+C;K:]>Z'&UI<0K6_U;2M.]I5K?\ '6]ZP-3
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M8VH=N+*0MI;[+;HORWU$,+2X6\PD/T**M<@EIIU!!A#;S"&S24LZ63(1Q4*
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M \>NUQT"5[N2@NWYUH.0;^0V%!TGTF$A>G05F@!Y:WUBJV*M6"N5KH>_F,,
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MB9D: NW9)8?D',X%MZ0D9>X-5:GV6KTLRTNEBC"SXL#51QSY";!5@9#N P&
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MBL$K.U[=U@) 80N+O#-=/B0[>"X,RV'/BG""(2$P-K JPP& P& P& P& P&
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M6FW/G?AN/VIW;J=L[:^YR7PMI9^3I6G-*^)2G-OJ2I.TITTC:=K6$EP& P&
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M# 8# 8# 8# 8# 8# 8# C]LJM<O-8L%,N$)&66JVJ'D("Q5^:$:/B)J&E17
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M)S-)3%6Z;?>%KC6SNA5"I7*R&03$LQT"NA5F1<(3(OV4"3?@Y(/5[CCFY./
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M&1>EOMJ3%Q%7)G;&U7A&VHID:)#:E#E0$>9*0D&3'UTW4,R%<V P& P& P&
MP& P& P& P& P& P&!$KY1*ATZFV;GU^K\7:J;<823KMDK\R(R;'2L/+AO '
MADCOH6A27A2'6_BUK2V]J^-M25ZUO08KGJE?HRG*O*/<'UOB]ON9O785$%6)
M&$MIT*WNR0"UAU."W&6"$'J<'2X7FT*Y&%(AF:I,!*J-23"000);FT2 4)<*
M_0^ HCI]-%ZAUNTUVB0?(NB/7&U4:?BI >[]C(ZC96.6QKE6DD:E-4 /FS-,
MM-]KKK\>Q)3P9%8 L1"2R9H4+MO(?T9[P[J=&H\+>=P(U[YP4!-UOH?&.=U6
MI3$ET&-F86>:Z[;3>H"=DL4]<R#8A(_X6)L2^1P@3YK-3Y[7V)$@5L+[/"/&
MGBGC;7V8#D% K5/^* A*],2L-#1D3)6,.OR=GFXW<RJ*$!$6D6:NMMD8\$00
M2*A=3Q<;!@1D,R%'"AWO@,!@,!@1>O\ [2N7\S-?TO6L"48# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# M&>NC1ZWT?TQ/)6E36WUSUF@8VM\U "B)"Q
MR<STNU2;%5J\'"5J.$D'YVQ2^YPT&N#ICCWX^=>CYZ,81,Q$:4.'D4_A6DW2
M2<C'KT)R(>J_=8[[!TP1]RP,%Q(CA1+)TC$0@&B+*;,L?;&VY*-@Q$#B)&-.
M:+'2P0'3$E*SEI=+EBI.6LMCV;L^3F'].DG(TE$6$(8Y(Z^>:5MUQ*!VM./)
M2/ID52%;<+=1H+_',?*KD=9]!;O'!:Y;(F;\A.B>H]3;\'S+J<#$WJVV"NE>
M/59A;7=XX&8C2()T-NU!2(,9*E$[FV$MN$J800XI"0JX\<OT;?K'"NRT[I/F
MW>*7%\;HD)TFS]/A^=27D/2IZH7NH^/-^[;480&\$<62/:ZX$=4'FKC=^)RU
MU&A3*[(5D$@Z:EZVF1"VIZOWCGXX^,OE[S^A4&9N%Z@YSQ.XET>W7:4ME^DI
M>\=5Z;RK5S>LY%CZ94JHJ.C5*GJQ-0];K$1-QJ(#<?#2;T#<G+/7($+2T7#V
M2YU-QN.%B$1//H^7D7S4I&C#W-R!3);R"7UO-$3$A\M7Q -HVK?T KZ4)WIE
MSX@K$\-:'=>@^8?CK7><QDQUJTV$RJ%1U5$$;';CK),2OPLUXAD@$J'!BQ[+
M(,'@H^WRH!0DT.(5&DG21D;H/:.Y/6[A3^:TFK7^V@WNY5^NQT38+?&5H.G
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MBN)<?BK!,LMNQC16I(])&H@H8!Q]4>2ZP<D0=_85T6SU=_*ZV3=@GR;O"ES
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MU8A).&LUUBQJ6=5E6T^#?L-3A&FR"(EJ#@+8)7"X403<M'.BCDQC(6Y>C3C
M%FE*E;H>2D3J79P:]]X1+M!3[]?JVBHTJ,<('W,5MUZ22@<@.=;C9)WYJ-&D
M$S&B%?/#M6N=J['X]6BI=*Y1:NC<-L<9;J;T/F$;NYG6((?5<>F=0=S? DHK
M<09)0EC8.-:D)$%(ZI"6/W#P(827DI"JIV^\D\C:!/PG6*_%0RJH[51++Y55
MZ/;FBY:3#;G]5V,D81RKN=#C2;3'E, .$,&#5R0G6B4S0,A-C0<LR%"E@H8
M(E2JU<G9\GJ(=@LU7M=4F(\2&CT)V6*_7CZW/.DL@D"2X;B!"XB4*T9J98?6
M,EUF1&0D(M5HVFFUZW2EL-)B#7(5]NL'K;*E")RV,2H"C (]KX&@@FDPI[.S
MRY4Q&V=N)+',^)Q(F!NJ7!RW2IRJ5 <NF4EC\*3,4)8+(,/%Q$L-%.S4J<89
M)G"O#/SGL85'A2B/D/LI$ #%):-_MOAH<^@8=\2>EIXZ8C6&(@],1,10!CH*
M["R/(["JIR_H2%.[GM"BZ]AVC&FF5_ 7MIM1*Q@N]>DWZ<?D-Y1^1%#Y/.U
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MRTM#R$#(6IEM+^PVE;=(GY"4BF*O R<C88.59;*ES&8QJ(>!95*DSL.:6;&
M"EB1T<\VD<M;S9"G'T)TZ24.RT'*0 A%AM-;HEFN@U9KR2Q8(B5?> E(BN5H
MXE<_)2#JQ)'8SFF"MZEB0V"WG5R6UMZ5]>WH9T-T)59]/VMBJ+GDC]*+=C*T
MTES[.S/E0TTI:AAV-%%?<V ) 0%,>P:0$8]-$!;%0X^-\>PNX^,)<_Y_^745
MS+RFYPQT66O5B$Y3 &S-GO4? ,=HL=;IG+X&>L_2J=+[<+)K,3%O=&%#:G @
MY=NON1I+TI"_)$V'<M\_1^_45X3Y,(X?4X5IZ9&N]>DJY,L- 6F'8HUUML;S
M:M=9?7'_ '<9RJNV67W#:)E8Z-L\*_%%S4I P(HSY00;JA>BMWJG^.0WF[Y+
M20W/O%X"U=&KELZCQ],'<NSC\[@KH1!25X(YQT2T42M3D+?+L8FBT^4B93ZV
M,;DEV.RCF1;->CK$'&R7BWX'>*C<E8K'?KO>H_I=;N)%/YO ]2@;==.:SU,C
MQNBTVJ=<L%!C:WSPP/L5<'CI@DFMV 2UU"1@&3F0Q14KJMT"YKX!_I(W'?&@
MR Y;/\SY_P ]KM>"C1)?O.O'N8M79IR#$<V)*UJ7)UVAN5DYJT("KLY(64K<
M'4:]I=@U&T@EZ*KT3.!DS^#GZ1;X<^45# D.ES]0Y1T1V^<UYXY78:ZCV*#/
MD.@T@BY&3XIUE I4G&U^AJBIZ'NSQD>6V!("P8$0=/3MKAX)07_*Q98*YUJO
M7"KR3$S6K7!Q-EKLN+IS0TK!3H \I$20VGD-.Z8.CRARF=.MMN?+=3\:$*]T
MZ#G,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"+
MU_\ :5R_F9K^EZU@2C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'DC>OQ*@S?
MG#TQ]5>[3S(RCSA,ST7DUMY17:(!S*U]"E79J!=JT_#WN;9ML!=H8XNQB6G[
M%4A)<EI98L:@6Q,%I"QD1JR<2MT1)0%BB&[$&"MSZR$)C;*V*_)!:WH<P*3C
M?H4.K$);T^.O4@R*[[+;*T4QI" J?\0O ?S*]0%RYQOBEP:P=:G:@RB1LFJW
M-T"F12U3;Y*&E&E7ZXU2&=*;V[H9$94Q'24QWYDLC-;04\&P\@/%/OWBT;<N
M6>544!R?L'#HJFBQ?'9(^D6:;E*OUI^7FG# YJFRUEA"T@Z(>E'UN2)<A%I/
M::4H)](Z1PI99G:?^&VPV:BN/L^CI=@F4&*)*'DH.5BPA0!"!I(PP<-V)DQ#
MRD$18HAYC,HMMR28^D$2D.+%+EAIIHVF&2L>0VF26-H)YP1^- $T6^\GZOZA
M[;*0X]K9;S^G$[;TIYW_ #T*7L*T^,6SJGBQW;D-WF(RD%U&K6Z+&L$1/6=Z
MT4F1IG1@G4ST#;C:X:5)UY;]4+FGV)>$8@^@U+:]VJO/!30L7)H#T<_(WUKN
M5^)?@3192X=[@>@^4?8>82=_JW0_'PBL=4HE7$MMEL4_4R6;9?':[5[M'\T9
MFZ13;-3-N-WAX"P1$JQ6P0)L:4:# D\I_5*\H/4,/MXW4;I!MTF+(ZE>QN56
M&S27X1G9?JLZ!)RL;2!K-+RJJN<"F/C9&MP$3+(?COM) \:TDIXTA06U*^?5
MW*-U<?Z^4 L:VZQ-4R @X8R:K0K*BB?Q6Z<;*:+DX,F)#7&"!S6G]+62X0P^
M20*X,^@-2I3=\^^L0MJLT]28#IX,9#GV*1@6M(E:Y%.I@&E*E) )LK==C6AR
M Y0P)]YE#(KS9C!JF5,8&C#=.EJ1<B;W!-:&LC<:#JN3<)+DLN0DS%.@A[GW
MTM/%B$D23D7\TV',:<B/HYS;0; K'VQ0H9E_HI^LIY:6?JW+^#S_ )L<OD>-
M<VJ_*[#-U3M<,G_"%V./MO0*'S2[46'LEA(>9HIG!.=/F6*&B*1,UJLDQ]7'
MF=UZSN6RPDPH>@-S+J//>S4N*Z-RNWPM\HDX_+CPELKA6CX*85!34A7I1V+D
M$)TQ(",3$4>(V<(IT(OZ?9 1! KC3[@3W 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8$7K_[2N7\S-?TO6L"48# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# \B_U[(GN$[ZH_F>/U*X3MPMDA8Z[3ZW7!Y*/C)$^NBQ
M4%*U*&AJRD1\A_FU<0.MRJ%ML,RLNH)@V4^DDI]YQ86-3H R' "A['1YF*GI
M3:;8%/RZCXV0<J+\:ZZ,EJ&-::9?CW%L*E$2.FUK(':^6 [MHI+R@O+?H]CK
M\SZKW@&RV-5F!J=W^>>?EMR[HEIGOQ'S.VCA!L09DG\4G&1.HHHELN.A6E1J
M3GDRI3?U +2PHI\G>2VZ\>2OEI8?'3GO=>@TJE=1Z1,]:L2>;RLV#0B%7JSG
M&S-@GJ&U/1U=K+!(A$C%RD\1$/?2A[=,2]]([O05L=+]'+R9X%X-QOFA:0>;
MTIBK\WX#WF0LK1'D&=?20?(N4F-<RHP\.?QL3D49:H&+B1YR_P @1?W*_5VY
M*O1,C/(N$[#5\X+/<E&LQ$I);N,Q]W<LU1(LNC:FC<JC\5SH;Y($7/OK?@VH
MYT&264'/Z#W),!O-$?3#2H^TMO!+N#5"Y66S:CJ00-5K*^8#&:O$]99*JPE2
M_$! FHF1-,"0J0%?D7ARZ^T6RE3"_O[8VV7'"QMJ"H3M'EEU08&U\ZJMPK-%
MIL#97X0?F=&@A-0ALW(U5ROV_K0!K4.)'1DQ. !M5=IZ-6Q(A1)Y8X;(^T&R
M$B%+0<$[^ 3+:]#!6\9Q)%* )_$[+$I5YY9D:=&24;70U"S9[#P6I"/*T:(3
M%NKE7'%*:/\ MI+P0:*K1<A+5R"@R 2IZ;F!HP5[9FA8_1)J@6P0RWI5D$0?
MY);[HYA!+VPO[&EI<TPU]22'*/,1R*NV--R]K>FX^3L4)%Q;(0!4%'C#(");
M0*07,,RH;I\T0>B2%3#-#MC[;)8<-,40(P'+P1=:"K34/,5U,5+6&Y12R;D\
M-J2:@:A#"+CYT!%>(4H@TQ^1*:E74J6*C:XU K/S'U:W%ASD"'"[B+*?#7\V
M+L3Y"J73XT)* B+9!2:DL2BK TV>X36XTP7ZQ<H@P@T=;\D$ $\T&"_]0'HP
M_HK/F#=+EQ*S</Z[UUJS5GFP\5S;BI3I$P] 2DG7["[,VN,.GKD=N<"Z*+OL
M5 HL14G@(5FP5:H1TM7(@YH(^<E@S"L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@1>O_ +2N7\S-?TO6L"48# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# \S;])\]/V^<V\OXSNE&AIN-I=V78%:Z;<BA(F<ZAT>RS
M3E_L]7KTX7>)IBT[JL1:BA881JJ<RC JS 2L,W7Y\ZOS=TM08IE\@NA3"(.P
MS\O.VP0J0=I]-E)B=>G";,-#%(%&:K6_B*4['"MEA"*80:^R,8M8PR_A]QV@
MDO+K]8N%=2BND1<G=^==(YQ:4(8F:+8Y"B7. F'2C8^<36INNC#O1$D) .R(
MNTZE(EEI[;J&WB@7W0&@OJ> 7K$0?@_XKR?/[G5+2=>!_)OI_D'SCHW.I?QX
MNURNUQN?-(&KN-]C1TNJ7MR#:CS(P%\;I4%&6.1E(Z=N-=D*R0\E@YP(%Y9^
MJC3NZ^*?3_%C<!>&9.0Y]Z?//W[2LX*=YF/)>'W/NKT/J$S# 52>6@2+NLQT
M*$L%5U]$0)]%7%-RP+4FS#MH"QH15IJ$@:1?2).O3<86\4RPS&V"&G), :*=
M)<?CYNJK0LZ,;5O1"]*E =ADMD)4I+C18KCX32O6VR2D\1:3:[*)(L$9,D-6
M*.D&*0"3^#HIHE#P"F(<J'W]L=8$1(1:6'P7G" !FV8EQ 9#8<:0_1X8N,U-
MECS4<71A[(U^#OIX2:1=R7G B(*=/."L+P[@!*36#=;TZQ(@#A'H9")D&E,!
MTVV$^]*MB!(?'=W((2'IUI#,@VX2ZG0^G=L*;7MUM>V]L(:0E3BO93+;>E^R
M0R >7>F'X)=-]/SK_FUT'SGZW1I3QIL%8Y5V>@5?P_9/'C^MWXR0CZ-!@3DK
MU2%G+*+)N#1F[/8BX0-<"<6?IN/>0(C;H62[Y.P)!59D>;1[U*'9H]2CYD,&
M8289+VL..T/:)E'T;B5!)D9!C1:(M]22&&W@WGFM$DZP-.8F[G9_Q5<[21&E
MDO203]@$EI-B*F)8R<+'/.*8A_JHZ9E_KB0QR94T-IWY&EH)<,0I[1*@V=)%
MY\$3)N="GK;$ '0TND,>C"QIASA[.HTB"08\?MP389<CMS[@PE8IT:N,5OVT
M0XPS@7^/T?;M$5P3S.CS":+Y8^0_-;%(UCH:N<^,TJR=:3+5R]1#]3OU_P"'
MEQ:)CH5,J%TG2(A$O&WJLB5N522S(&6B-EG8>0#UB(F28F8J,EQFRV1I6/#D
MAV3Q7P#FF#AFRFFS 24-DAEMMNI20*0VA\=[2V74)<0I.@Y# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# B]?_ &E<OYF:_I>M8$HP
M& P& P& P& P& P& P& P& P& P& P&!9E]:#TGH/U4.&PE6(Z-<:/:N6@W"
M5JD76X6HSX]Q(E%U>P;KS3-PDH".K=GDYJ@UR*@[ONP@"0D?(SX4P)(1,N6E
M@/*8[+X=>0G$^MWO@]QAB)27YT'T$^,#8M->D(XL*B2D[&2Q4 N-E[! RI@K
MPLI+-Q<#(23Q0CAY<:^M]U3V!3>1;9FQ5>-H(XD-$5\.Q%6SZ-D>14\5/2<>
M%!+<VHB0E"SR'!Q1DB@(5I>BEF)2VEC:DI#]6JFL4&?N%7NA4@/-58)@:OB!
M?0%-&RFY4!;C4RL<U:HP%R%=DCDLI=)DAW=@#/C-;(=6,$:D(DWYP4>F).B!
M)!IJ2%?F!/IG6Q#_ *<,L]XU>OBW#MG;WH=QW?P--:TKXDD$/+6$]OX#\-8V
M:[;0!JHR<U59<P&HMQI<4Y'HBV0FYN/0[*)&=,.AMF2;K#,\J,.EI(A'SXA:
M'1!0R2_'KT4I5[Q-\@O+B\C]3YM78BB] Y+Q>JVPNH6VY!]%N**!#U:H3=$:
MK\J:9+=/$O<N96G:/'E*A96:C9!BQBG13)A88\*J?2[K*;AEW>.Y Q5G9*&>
MA.I"/HGQS8L0@V1W*R41"A[?LC\R,F%&'DXR%82V.T*::(^.XAX.FY68G;2^
M=+F2DI9K']7HR2EW4NOF--CHC0 C')'6GBR4N*TT,RA3R-#J8&5K:UE+;P+[
M_C?Y4<:H7HN^HGR?5QBY+NG8/(OQ<L=;Y_V.-C+C/WE<$R2]TJSPT;)#OQ1H
M-?TZ\</)2Q>I,;;.Y5UIM_6F&@J\\0_T:/OD#W'QHNOEM;Z_3N-RMHJ\UV.N
M\]?[A5^@<X_$O-I_I-#A(F]S'&7N>VF0D9:(@ZK<);D%UOC?/IN0^SRQ8Q2F
MI ,+87JC>-'"_&[R/XU'U[J-U[;#]F\5>3>0MDNQ=HD3FGKAVJDFW* AZO8[
M?R[F,T'1Z[!RU*D:\'/5RR6R<A7FB[,=69^:.I=0"U[%P]ENE46+%A1.HJ@A
M3<R9)-ZT <O<BH4E[1Y#[R')$[X6&F8MH=*=J&8=3\*MH<VH*L_$*H72[^6O
MCI \]#F^KVFQ%5HF/IT,+],L"?EYLAEFLN#D".1 H:)\YB4#3L&3!,'G&!7H
M\R1/>C5![2?&JU>:;RRAU3I5LB[U>:_7(^*L=LA:T/4(R9,#;^4V^+7A"BQ(
M_3(J1Q'=B*&%,?'=/&C(A@IN*##LS 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MR,[#EF03%H"<D ]'K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8$7K_[2N7\S-?TO6L"48# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# Z2[YX[<A\F:&7SGLE/C[57B'AB1GG&VV)R%+&,%+^LKD\VW]TKQI'TB
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M:KCUGDQ8TDD=.VFR']CLB-/;'0%8. P& P& P& P& P& P& P& P& P& P&
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EX$_-VTE6UI;VY[?%MO2E*5I'O\.E*WO6O?>]X&I@,!@,!@?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g582934g62o26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g62o26.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1GV4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %X< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   "   <
M @4 ,D5Q=6EL;&EU;5]);&QU<W1R871I;VY-3T$M;6]D:69I960M2G5L>2!3
M,2!&:6=U<F5S.$))300E       0(H;/[PBK:FB=Z; <Y&!LDCA"24T$.@
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M965N=6T     26YT90    !);6<@     $UP0FQB;V]L 0 X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M 0 !.$))300F       .             #^    X0DE- _(       H  /__
M_____P  .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))300*       !   X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             "S@  !ND          0
M   !              ;I   "S@                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   "S@    !29VAT;&]N9P  !ND    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   LX     4F=H=&QO;F<   ;I     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    $.$))300,      [G     0   *    !!
M   !X   >>    [+ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" !! * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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MS?TE7\M2D@;L8B3L+\F^DLWIG7,7JN1DUX+76XV*=CLP1Z3[.754&=UNQO\
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M:[>ZE^YK&5UN>NSI=>=WK-:V/H[3,_']U<[T'J&!@8(]N3D6Y$6VWBET.):
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      8I)
M22H "     X   $#  $   !%.    0$#  $    X&    @$#  0   "V
M P$#  $    %    !@$#  $    %    $@$#  $    !    %0$#  $    $
M    &@$%  $   "^    &P$%  $   #&    ' $#  $    !    * $#  $
M   "    ,0$" !X   #.    ,@$" !0   #L    :8<$  $      0  + $
M  @ "  (  @ P,8M ! G  # QBT $"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,3@Z,#DZ,30@,3$Z,S Z,C(  P !H ,  0   /__   "
MH 0  0   .D&   #H 0  0   ,X"           &  ,! P !    !@   !H!
M!0 !    >@$  !L!!0 !    @@$  "@! P !     @    $"!  !    B@$
M  ("!  !              !(     0   $@    !    .$))30/]       (
M      $   #_X0&,24DJ  @    .   ! P !    13@   $! P !    .!@
M  (! P $    M@    ,! P !    !0    8! P !    !0   !(! P !
M     !4! P !    !    !H!!0 !    O@   !L!!0 !    Q@   !P! P !
M     0   "@! P !     @   #$! @ >    S@   #(! @ 4    [    &F'
M!  !      $  "P!   (  @ "  ( , #   !    P ,   $   !!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C Y.C$T(#$Q.C,P.C(R  ,
M : #  $   #__P   J $  $   #I!@   Z $  $   #. @          !@ #
M 0,  0    8    : 04  0   'H!   ; 04  0   ((!   H 0,  0    (
M   ! @0  0   (H!   " @0  0              P ,   $   #  P   0
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M 0$! ?_  !$( .8"-@,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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MCZPV=:*=<(77C=39TPWM:U&L:[(V$79[?)#'-%5>D&,W>L15Z']:T#,@@1!
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M-2=/>G#%NBJ'1EE/: ?Q$B",?Z>JA=IF;;F,/8[",%]_FQ(+DT_4E:5XW61
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M\3'/UJ[.Y^4!<-CE,"M-1WTZUC:U$\-:A=/.U(.,@-N;1J]ETWK:A8CI8&R
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M22$15 4>=)WCEGGEA@CJPR32R158GGDBK1/(S1UHY+,L]F2.!"L226)YIW5
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M D*<0&/(LC)=>2WAU?W/\+^-4\1?#[A/C5($K/G\1#9MUHF9H:^2@DDHY:O
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M:=-+FY2W:KM]<;#E).M# IMT>Y6;0&B*&D9YJB'1AA 28)^)FI]F:B8N;&D
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M+!0U8(<?1\A9M7([%_+U)9+QBGGJPP3I!$D>KGXX9/,W1PDV2N8^:/)8VUQ
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M%-$=\[!0[+[;C:=D [@'X]^X(/\ 4'8CY$;CWZ^C*.LB)(O-RR*KKS(\;<K
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M<W::6_7,R-MK.:3LNA7D(N1UOMNF>@>,F)L;0"LG5^PBAR<C&1MS!#FTHAI
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M01JTI2K*TL93C&>_;EDXFP53BGAOB#AF^Q6EQ%A,M@K;JH9TK9>A8Q\\B*2
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MD9HUL#I]\MH?#$<1)"C1X)J0B!Y E3@6&_6-?BRE^5I9*/128.ZP\A0WRV<
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M-YCJDA5,W.W3[KRAF9.9FV&WNNHZ'/[22'<;5"ZZZW*)6*(Q-%MQX6[M;-S
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M8AGV[E556D?T+D<NX+[C06$QT_%N>D-N5N5VDN7I1ZB(,H$4>_9>9F2&,?\
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M)895:.1@=?GI&\,O4]QZDW;T^;LG>?3)3A[.]!6G8%?@:93+KL&OVF.B(F)
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M]ULE#S> F\H<RG"VY.*D(ULU3S)B6B1GA"AL!-H-1[%#312U-1_0_K^O^?\
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MIQIIQIJP#KHZ+F>J.M"R%7,BX#8T''RP@,H6!$J;E0%@O'"1)9#D2Z<^^1.
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MBK*?4,IV(/R.N(]NQ]1KT.4Z:<::<::<::<::<::<::<::<::<::<::UYO$
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M0#9"Y?=>7M.--.--.--.--.--.--.--.--.--.--.--6A=3^X(VJQZZ6',2
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M+@:M!;*GY*><GK#C<=G.U]>0G-FC6U,"F[ZOF7&H,%N$CK(-"Q\$:;&).GZ
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M=KURKB>1:.-R,KV3!-2BCCBAD$%>M9EBBC$EHOSO)!C>D/#N/B+ [$=54O\
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M*?Z;Q:?%Z39U+2;77(_84=8[$3".UD*L3=@C?;)B]=!)@H%W%@AZV]=_?RY
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MV9PORY\Z?/A2$X56K%U5HP!&P9BQ+*RGLVZ@K[7-S'N%V'+V)[#4'O[A\?Z
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M"2+C#TJ<Q(+ (96RL MZ)0.^2VI2FI# I! BL>N\0RO)&:I9>ES;,Q9%)V=
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g582934g63c88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g582934g63c88.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1<24&AO=&]S:&]P(#,N,  X0DE-! 0
M     #$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   "   <
M @4 !5!R:6YT #A"24T$)0      $&L(6URE H%'FE =ZAKU+@4X0DE-!#H
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M=&5E;G5M     $EN=&4     26UG(     !-<$)L8F]O; $ .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#P
M  $  3A"24T$)@      #@             _@   .$))300-       $
M6CA"24T$&0      !    !XX0DE- _,       D           $ .$))300*
M       !   X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             "WP  !V@
M         0                         !              =H   "WP
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "WP
M  !29VAT;&]N9P  !V@    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    '
M.$))300,      Q%     0   *     ^   !X   =$    PI !@  ?_8_^T
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M;.CV-;']4O=_Z,0M3__1]0<]IO:R?<V9^8[(DCQ"!EXE64UK+JV6L:2=M@!
M,1N;(=[E1IZ1BBJAK:ZBTD[YJ8/4W-,BQOH-]/V_N>FDIUDED/Z+AFJUOI5
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !# %, -@    $ .$))300B      &*24DJ  @    .   ! P !    QP@
M  $! P !    W ,   (! P $    M@    ,! P !    !0    8! P !
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M   H 0,  0    (    ! @0  0   (H!   " @0  0              2
M  $   !(     0   #A"24T#_0      "      !    _^$!C$E)*@ (
M#@   0,  0   ,<(   ! 0,  0   -P#   " 0, !    +8    # 0,  0
M  4    & 0,  0    4    2 0,  0         5 0,  0    0    : 04
M 0   +X    ; 04  0   ,8    < 0,  0    $    H 0,  0    (    Q
M 0( '@   ,X    R 0( %    .P   !IAP0  0     !   L 0  "  (  @
M" #  P   0   , #   !    061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.#HP.3HQ-R Q,SHP,3HP.  #  &@ P !    __\   *@!  !
M: <   .@!  !    WP(           8  P$#  $    &    &@$%  $   !Z
M 0  &P$%  $   "" 0  * $#  $    "     0($  $   "* 0   @($  $
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M47-X87%T=;2X&"0E,S2S&3529Y&DL28G0U-4<H&%H?_$ !L! 0$! 0$! 0$
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M.Y:01=+_ '2-A$S$S4$PL^ X<]*+LN!B(@!4>EV09KQ<R\,;E$R[*]Q!B2'
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MJD_'.-D!FML$D"&@EH-@YH!]Z-G8J3CW7!50BX=HYLP1$P>LTS(+71TFD$&
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M^,EG+9N:YKV#M>[V>=DK);;Y;<AMQP\E,R4@\ID<>.CF6P8J&A1(J"BQ\.8
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MM_[Z-O)_N^7P7=/?Y/\ Z_WY[_E/\0K_ .7@?_\ ,Y./KA2O2YIN^I_K5?\
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M##MCA%(1X*<Q2[)\7O/J[]"V@6#N/2]I&[4ZU4F5I0;$9;ZW.5>1+!>(1*C
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MH..WK=T*D@M:!8@7,3)EU]=(+!%NJ>T5ID-L6M4K8&UXS9FQ]>QT_$T^ O\
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MA!;=I;$'%7^,J5JA9P*RTRWBRT60NK6(820B??AV&+29&643$-,S !E;EF$
MRPISK&#H@W <P!AU,N@$.'7!@7RU*;Z3QI]:G4>T'83F%P%UIU0PR"T]4P2-
M6/;49PA[&G;I$05#'3QTX5?0%M8.C]G1DS5JQ4[M3J:(=*#.V$N+O]W@[V>_
M=))1+8LD=6"H$:OU=T(9I"(,@O+Z677?*QH ],PZ7NDZD#]]B*L"03KB"V)/
M5+OKPW)>"&B1T0!LO%.C3G6Y/-9B8$YH^K+K66XRO6:J6>N-V6JLN6"O34(V
M]*.1DU&-+E8TD!+DC#NG#-2P*%/X47&N$#H.'PX*MYI+N5IR]A>Q[(ZS7-NV
M1T@1<;1?3:JQ[6O:XF0US7$!T$@$& =A._8J*4'I.?J-EZ?;.5U%/R#&DK]:
M;0BLRTE7+8T;$6:F;1K!HBKM-0X]RF[$8J^1,>?9ILKTMVI5>'B%H?F8[%DD
M.LF22UUVO:=3UJCWM,P#(S /-C5>WG'W.49)!$ M S,=: );3:S23N<6"2&-
M<6"UUZ&?">M?M#!_O8#VCF(.X^121O'F%0NT=.#LILKJ!O(.QZ29%;RK$U42
M*R?83X8:% LU9UK59*9AC83+DO6+.R#1SW)J3KLJ,WL/!=3'G1X=ZBQ<B3C(
M<KV1UYN6R6_Q>J#;+^\&:F>BXASY!J.!Z"JT%IMT<I@. S$%O6(V]'HNC,T9
M6W#6D78K$A U^M5Z!*N,++$PD'$Q!$JHJ$CE2;\: .&[(*CX]QD %1KC*B<A
M@LM!BY<\@9M#*$)QU=F<YSH/2<77DZF==O':N3<K0!(L +0-!&FS@JS;WTLU
MMW9VL;_!;>BJ,Y0@C0UOQA4,3(/Y*L%?G$$&1LLQ,5RU(CE0B3:H'/1S*:5=
MF8>^QI)Y,6["2'/([,XB1F;ED"XAE9H-QJ.=EKM6PYL%M1P75M1@: 0UT.S0
M38B6$MD&0#DAP'7!$D%C2MWZ;=>0^@M=&T O9\9<VU[ V/;HZ2*76XIX6-O%
MSF+4-&/,Q#(#!!0V91QV1/=:<>,DR37DN)%R,.QL@D-&6(!%A ZSB(    !
M  @1:RYEP)<2Z9@W/\H!V[2/T97UU)42*WGK1ZBQE_BJR6N=A9EN:C[(B%G
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M<*6K.,=U9[V2-"5(!U 72^!E/_9.M?N*+]EXD[SYE(&X>06%KVMZ+"0P$2%
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M.!L0&5"6$Y9$L&9ID=-F:6@V@N=]5=6"6.WEU-H=&8@G.Z"V#T79.D0"X$-
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MVK3<#+/V?$.+H_=F!AH?$D=!SJCH#R<@LZ256M!S-#707TQ! +P2:D-!B07
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MQ+Y3]L8VGTUATW;M@K^V;/5*]%7VZV"NF:YL"*G5XB$&V=4=.9IMA*EIHN:
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M%(SS.ND?/O\ %=!IK/R[O!6RY%4X1.$3A$X1.$3A$X1.$7B]U4]5W5!H_?\
ML'754-7/5VJ/4#J[>4]684CT/H[IU<,K^^]?C',0W=V<?V)!)+B) E;UF# L
MZ$#2*AAV&VM@ C=LXFWR]3N6"2"=2-?#RWG@(B57*=ZR>MDZ4I7D[#K.O)"W
MZGC>HG6\9?I_1^KZI<8_9>V+P_5Z+9R=C5M4K9:U2M5@4:KR4'09JN;$&GK
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MNMI;:'4?OBY7&?9B+&S(Q(T?<MISH]#5=9N.G8C7E8D$R)420IB.?":@]SC
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M0J6),&+7)F2.Z;Z"=ZRE-ZUNI/?%^AJG%$%5[7?47)D[PU/(8JT'XX+I2U?
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MVQ)WP*Y0PY]<K >MFVR :U5'(!S8$)//:Z^%K+MN?F,9%4J0-T&\"]X]OQ*
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M>,A%--,))D)@2)CT1@CUDER_.D[&?D-'E/R$R4:6]A;F%NY2O*>35(M'ZW*
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M]F;#I=0N-Q>A9*+AIO\ HG2G9*37!UV5DRTB.@1*)"8C5Q,)*3I8#1<B H(
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MG"DXS@D3JN;.,9QG&<=\9]6<9]>,XS\N,XX18<BO0!;0S)4'#DLA-Y9#:(C
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;3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
